<SEC-DOCUMENT>0001558370-23-002833.txt : 20230306
<SEC-HEADER>0001558370-23-002833.hdr.sgml : 20230306
<ACCEPTANCE-DATETIME>20230306071053
ACCESSION NUMBER:		0001558370-23-002833
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230306
DATE AS OF CHANGE:		20230306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Passage BIO, Inc.
		CENTRAL INDEX KEY:			0001787297
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				822729751
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39231
		FILM NUMBER:		23707538

	BUSINESS ADDRESS:	
		STREET 1:		ONE COMMERCE SQUARE
		STREET 2:		2005 MARKET STREET, 39TH FLOOR
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
		BUSINESS PHONE:		2678660312

	MAIL ADDRESS:	
		STREET 1:		ONE COMMERCE SQUARE
		STREET 2:		2005 MARKET STREET, 39TH FLOOR
		CITY:			PHILADELPHIA
		STATE:			PA
		ZIP:			19103
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>pasg-20221231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.0.4 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/6/2023 10:28:25 AM -->
      <!-- iXBRL Library version: 1.0.8405.27969 -->
      <!-- iXBRL Service Job ID: d54721b6-97a8-4041-b182-4e1aceca2421 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:pasg="http://www.passagebio.com/20221231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" xs:nil="true" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" name="us-gaap:CommitmentsAndContingencies" id="Hidden_xRI4qzn6Jku67ugFgR2TuA"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" xs:nil="true" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_85ZD75uU2k692pkPXiFulA"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:EntityCentralIndexKey" id="Tc_UOFjn3LqRU-nQ769eKzmFg_2_1">0001787297</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:CurrentFiscalYearEndDate" id="Tc_4VlxRFwzT0CbX4siJvq-cA_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:DocumentFiscalYearFocus" id="Tc_L6naryoywkaZxcXlK6MX-Q_4_1">2022</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:DocumentFiscalPeriodFocus" id="Tc_ZjAwFKZyMUC0CVz14hQfyQ_5_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:AmendmentFlag" id="Tc_9KuL6NmsW0aL558Cvv4cgg_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_vIrVM0Yz5kWZ5uqDROhiig">54614690</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_a4vZEQ-8k0exEPYJXuhf1w">54244996</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_mGa3yEM8z06MhUJxjwJeqA" name="pasg:ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" id="Hidden_pyhlfNmlOEC4x3JdtR4JSQ">P10Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="pasg-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_d5OcH9P0YU6Mqog4XpwvoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_wDFfPO_ZNUKxeG-q7TC3Rg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_yIzi3o8bAE2L3dxvXEqkRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_5_2021_To_3_5_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_SalesAgreementWithCowenAndCompanyLlcMember_LbBLENbq1kqwVJ5FMdSo8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:SalesAgreementWithCowenAndCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-05</xbrli:startDate><xbrli:endDate>2021-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_5_2021_To_3_5_2021_us-gaap_TypeOfArrangementAxis_pasg_SalesAgreementWithCowenAndCompanyLlcMember_c83rb3pHbUyDv5vHPbSVOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:SalesAgreementWithCowenAndCompanyLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-05</xbrli:startDate><xbrli:endDate>2021-03-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_illNEQwEHECIcckfPCTJRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PyRd_9rL4UqO5RO9ulICug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WTd6dzj7eEa_9Sk21SavjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7fu6Hq9yz0WPODQu1__Srw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mej-DQ41G0WhXJ-3c4uH-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rW0i_NK93UyCd57P6lJiTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_hM0jUdnMX0SstDzHGw84NQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_68O7F9-naUyJ7hFnufywEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7dx_D0t8AkeU7CcwmPSrnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_H3Kyaw9iDUKSzbJyfoPBBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TWUY5elwAUOM2vM1WL0RyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mB93yuXxFkmHu4pFLjXgug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hYpnLKF0Pkq_6zN2_OqwkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_XMou09J0cEirXcLwXtLPDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_ffSkQEILP0GGYx3Q6UsjsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2023_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_X3oAMRpPCkuZ5fd72D8-YA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityInducementPlan2021Member_R6lRMEzvCkuXk7SlC-tL4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityInducementPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_Ba8ei5M0iU212FOvifvfgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_IVEx45mF9UGGotpVBJv3wA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2SJMJY-9JE2TYYv1hxxQlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_pasg_AccruedExpensesAndOtherCurrentLiabilitiesMember_GPYjhSt04kqGmR--V5LGEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pasg:AccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_z_YtRBUDn0S9xCBNBKE8ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pasg:CatalentMarylandInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_oMHqSuMuOEyeN1Ln42FsEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_CJboIsPRPU2JiJLp82d18Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_c2lmnbj2xk-05fdWrtq5pA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_LaboratoryEquipmentMember_BrSr9bR8aE62mOH4GDhAjQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_2Hsg8LNvXEucBUm5ld8Thw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_618eVrMiP0KqpawEGChP-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_bJ5zjvxB5EGnQcqTp7xFSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_Wqhrge7I_kKR4RChMkdtEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_LaboratoryEquipmentMember_VlmbuSYC6USj3OTDddchPQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_ComputerHardwareAndSoftwareMember_JzsV16LRG0WCbPoDdOU4QA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_OVQG01q9_Eid2wbn4B4PpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_wweEz0CjaU-LuKc41hE1fg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_yGDjvEYReEuRzXheeim-wQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_S84Lz4H_jE-dgwqZQM7UOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_LaboratoryEquipmentMember_15fk6eyMukOdrAYC2-ThJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_ComputerHardwareAndSoftwareMember_kCoolnyGaUy4-vQysBpBNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_VKjaYfeOdEmdzPqOICqhlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Dy2fqtwSE0iMjVYx7LAqaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ft0vm0rTlEWzwuGEbsW4BQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_pasg_StateTaxAuthorityMember_csXMoMs05E-EaQFBpJ-dDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:StateTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_pasg_LocalTaxAuthoritiesMember_Ig7yZu-Op0CHDDSoRCT99A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:LocalTaxAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_mgIQoET8g0GzCQSgrV4mEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_pasg_StateTaxAuthorityMember_Af3k6h92bkmtwN0ci3mBEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:StateTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_pasg_LocalTaxAuthoritiesMember_NABkP1gdZkiCPP5SKrlohA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:LocalTaxAuthoritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_7zow5ahakk-p3Zr2YBVVfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5iXkDh6_nUWdtcuegYMTbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_YnP14VvzNEuqjHFsfp6GYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_4GJmz4SaeUW8G0iqOGx50A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_62A9Ji97c0e2uu5ff0EtfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ycWO8dyX_kC6uG93WKsSqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KknMkl4yeUm7mwrKVSBAMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember__Gr_-HqIS0e2m0hxthuJSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_BcQOcPP9S029dfsVqpuUWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_hKzkHH1vOE64CgLe9E8cBg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_PZny6jRjkUiFZ51MD_j8yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_9DDLbzIViEiYZ2wdZ2ebDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_EX8q_EtFJkmb7GR4fiSkgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_nU963VORek-l98BVpjXc2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_nzjfVFDIVUWSs3XTC4bDsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_xNnhYs_8xE25HkrTLSUCDg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_8rQIwJjX7U-HUdBs0mHPHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_U1C9pEJYU0mSIYjsXdwWXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_GIzjQ4m1DEOd0Y5zdqwlEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_SOu6oV8f4Uqc6G1TRruyZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_bskf0Lik9k62JRNH0Ahm_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_UcKqbx4Po0Ou91dnkxKM6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_tfIA7SpRCEeYVQ2vDETw2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_RLg8-oaulEugO9P5aol4lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember__szE3cOXwEaiDH4szkcG3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_oE0pMTTA8kyy9iM_moGuCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_zS-Tm2J2FUOYlB6qItnUOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_EKMTAzZhuUyVq0LA3FdSVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_mPnRzJMdn0WpI85X-EalUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_X6XgFKAqdUq2v933qg7wzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ddNrvr493EuYOz1vw-xceg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_m3qLi4_cEU60Ts_xTIoBAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qnM-OR-gAECiFX_LbmMPfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_btpJFa9_VkSBS3ixhn_iWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_C-o2Zgq5lkazNtHRBvQ8_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_pH7TkCz-oUyHvehAdIIrKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_zQffUCmMdE-_aOBnQ2S_vA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_LZ4JlGCAxUyPUIGpj_JLDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pasg:StockOptionsIncludingSharesSubjectToRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_IwGipl1FgE6Gk4DlC1uLiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_LFuw3TMIekuZBYlTISw11g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_qOjzooIZXUyOJbcVJeTNvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pasg:StockOptionsIncludingSharesSubjectToRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_fzK4cBH8fkuhwpQHwW1AZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_rKbIo3RACkur9OAM8iqIbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_gplgcbUrjEqXbb7bUxMbbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_aTuBNIMD5UOPhj-XOY8Bqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_weqi7Po-uUOAVerAuobXvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2022_1hJs1cU8B0yEBX43Mau-lg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForLaboratorySpaceMember_m3JiXizoFEGM-jTR8nDJpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tKy1_NMOUEmEHV1J-B4fuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FatF9mHr8kyTws1l1ujYjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_lvXskTRyzEmHGgFZuscuXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember__jemGaqshkeAAlBd2h-gkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityInducementPlan2021Member_NN2gJkl_wkeCgwEIqLXLgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityInducementPlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_mGa3yEM8z06MhUJxjwJeqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2022_mVsYEdTSSEuJbQ89GBbHMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_NhtNZVP74Ei9hd55TAwTew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_68a1wKllOU-ygbrbsjHfXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForOfficeSpaceMember_PnKu318m2kKf0m31ftbUUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForOfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForOfficeSpaceMember_ZrafZiQhmUuODBwDYCS8rQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForOfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForOfficeSpaceMember_Y66Drnyc1kO-defDYISTag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForOfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForLaboratorySpaceMember_olTE_Yzm10uPm2K7m0faAg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForLaboratorySpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_28_2020_To_2_28_2020_iDWURz96TU6yNVnGevdtWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-28</xbrli:startDate><xbrli:endDate>2020-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_2wbIkeBld021QObVHUyCCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_28_2020_To_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7S0-ZkqLP02l2ZtnRMvqNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-28</xbrli:startDate><xbrli:endDate>2020-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_e7qXKu9B8kaes7yJbBslkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_paHmp6CcHEeXKfzN77VxdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_V-j15wJiN0KMnb4hw5k1nA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_3_2020_To_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_X9L4Qp3mCEKi6Z_BUccfKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-03</xbrli:startDate><xbrli:endDate>2020-08-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_0J6NHzFpyUuN4ppDeH9zaQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_Qg9ksmS5wkuN_RKSudErVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2020_To_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_4KZiWVNG9E22l6ySZmuTUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pasg:CatalentMarylandInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2019_To_6_30_2019_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_2O0jJDglI0ukihnR8RMuWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">pasg:CatalentMarylandInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_Tz7eti2M40mA4VxFf-_HGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_z13QfKfPmkK_8C2JId34Bw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_HuyYaPjrf0-kSgqt367TIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_doDUoWoF-U6E9lX1OVWkNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_KS_iGfGyu0moP1TAVBgiKQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ZNLZ2q08tUyXeYUCJO4M5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_2_2023_niqzyjJXOUWALoPppfBlmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001787297</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_wlhC8WlTVEmcZqQ79zgOUA"><xbrli:measure>pasg:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_plan_r3kCEt0dLUCKcJ9iz91x7Q"><xbrli:measure>pasg:plan</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Option_5y2HNcjXj0iaLv1FEhwgXQ"><xbrli:measure>pasg:Option</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_lMTtBbJKdUumSSlUVKw17A"><xbrli:measure>pasg:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:6.9pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_9a2cf7e7_8447_4811_a3c0_a76f6b6fd16e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">WASHINGTON, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:DocumentType" id="Narr_svA_oXBkX0uORtQctT-N4Q"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:4pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_6f7d295c_3914_4643_90b0_87b473e19600"></a><a id="Tc_TgCbwKHaMEimdghgb2ghvg_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:4.88%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:95.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:4.88%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:DocumentAnnualReport" id="Tc_hfsDcjT3d0m1ii1q1gQlZg_1_0"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:95.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:14.4pt;margin:0pt;"><b style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-size:7pt;font-weight:bold;">For the fiscal&#160;year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:DocumentPeriodEndDate" id="Narr_q5QVpqYYFUqhlbxjCgHOcw"><b style="font-size:7pt;font-weight:bold;">December&#160;31, 2022</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><a id="_ba8fef0e_7520_4c63_8dff_1d31fc63aa48"></a><a id="Tc_ZObrDak2MEy_qMZCd8XjOg_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.5pt;padding-right:0.5pt;width:100%;"><tr><td style="vertical-align:top;width:4.88%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:95.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:4.88%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:DocumentTransitionReport" id="Tc_BGKRrgVehUS1Dc5UgupSew_1_0"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:95.11%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:14.4pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">Commission File Number </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:EntityFileNumber" id="Narr_3F89XQ3n2UyHGRo1fcz4uw"><b style="font-size:7pt;font-weight:bold;">001-39231</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:19pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:EntityRegistrantName" id="Narr_HGpg_gBiMU-feCw5-NE1MA"><b style="font-weight:bold;">PASSAGE BIO,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact Name of Registrant as Specified in Its Charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_db8939f0_41ca_46f2_af10_7bc8325e7911"></a><a id="Tc_yexqTYtJGkil8zmdB86FgQ_2_0"></a><a id="Tc_PKesrXKdLEG5CKkv_rnEiw_2_2"></a><a id="Tc_LsZkrTzCe0afB8hMjBHtLA_3_0"></a><a id="Tc_RB1i6IZp20CPTfFxkzze5g_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:48.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:EntityIncorporationStateCountryCode" id="Tc_KmJIA0-VR0C-Jy6Wwl6krQ_1_0"><b style="font-size:8pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:middle;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:EntityTaxIdentificationNumber" id="Tc_K6Gz2t5Kfk6WpUeWAeaFxA_1_2"><b style="font-size:9pt;font-weight:bold;">82-2729751</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction of</b></p></td><td style="vertical-align:middle;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p></td></tr><tr><td style="vertical-align:middle;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">incorporation or organization)</b></p></td><td style="vertical-align:middle;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_71689942_2921_4681_b41d_aa011eaa87ac"></a><a id="Tc_yItU1BXMh06ENkyoh5r8Pg_3_0"></a><a id="Tc_RwtuX7MycUSEczr3o_BQKg_4_0"></a><a id="Tc_3cnjG5Q0vE-vHxDnkj97yA_4_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:EntityAddressAddressLine1" id="Tc_e-9Zx5VON0GMiiNJbfzW4A_1_0"><b style="font-size:9pt;font-weight:bold;">One Commerce Square</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:EntityAddressAddressLine2" id="Tc_q_fTBI8KeUGzgnB2GkyVxw_2_0"><b style="font-size:9pt;font-weight:bold;">2005 Market Street, 39</b><sup style="font-size:6.75pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">th</sup><b style="font-size:9pt;font-weight:bold;">&#160;Floor</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:EntityAddressCityOrTown" id="Narr_63A7M2GSCkSyID9i2e5_1A"><b style="font-size:9pt;font-weight:bold;">Philadelphia</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:EntityAddressStateOrProvince" id="Narr_NqdwauVFwkqmBZP7y_2LEA"><b style="font-size:9pt;font-weight:bold;">PA</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:EntityAddressPostalZipCode" id="Tc_HJFhxUzYtEqYeS1V8iOzCQ_3_2"><b style="font-size:9pt;font-weight:bold;">19103</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:CityAreaCode" id="Narr_-2qvSztQqka4eAyNfHFp5g"><b style="font-size:9pt;font-weight:bold;">267</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:LocalPhoneNumber" id="Narr_LxsjsT1LFEqHoBYaPQhRtg"><b style="font-size:9pt;font-weight:bold;">866-0311</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><a id="_19cbd250_7596_407b_937a_2021e6942811"></a><a id="Tc_8NIku8TlrkmkCkTp-ynNrg_1_0"></a><a id="Tc_AfgFyZTQc0StT7BKZ1c_Tw_1_2"></a><a id="Tc_53FK-Yoi7UmXcwF8d2Mq9A_1_4"></a><a id="Tc_3zfylb2mKkWzt9RKixcWRQ_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:41.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:1pt 0pt 1pt 0pt;">Title of each class</p></td><td style="vertical-align:middle;width:0.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.78%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:1pt 0pt 1pt 0pt;">Trading Symbol</p></td><td style="vertical-align:middle;width:1.1%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:41.11%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:1pt 0pt 1pt 0pt;">Name of each exchange on which registered</p></td></tr><tr><td style="vertical-align:middle;width:39%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:Security12bTitle" id="Tc_qJvNqP1JU0KDJxKo_9SwUg_2_0"><span style="font-size:8pt;">Common stock</span></ix:nonNumeric></p></td><td style="vertical-align:middle;width:0.99%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.78%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:TradingSymbol" id="Tc_yF2V23I8cUKMulEw_dAB8g_2_2"><span style="font-size:8pt;">PASG</span></ix:nonNumeric></p></td><td style="vertical-align:middle;width:1.1%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:41.11%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:1pt 0pt 1pt 0pt;"><span style="font-size:8pt;">The </span><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:SecurityExchangeName" id="Narr_f8FfTjngAUqA3xNcFZXztA"><span style="font-size:8pt;">Nasdaq</span></ix:nonNumeric><span style="font-size:8pt;"> Stock Market LLC </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:1pt 0pt 1pt 0pt;">(Nasdaq Global Select Market)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">None</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. &#160;&#160;Yes&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;"> &#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_Xv2-QFL37Uyir2pFE33WtA"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act. &#160;&#160;Yes&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;"> &#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:EntityVoluntaryFilers" id="Narr_WiaCZcU5HUCV4fuwSZgp2A"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the issuer (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:EntityCurrentReportingStatus" id="Narr_8AIC-SndAEuEeTyttfnVAA"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span><span style="font-size:7pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:EntityInteractiveDataCurrent" id="Narr_VdxHmJTjD0KKpj1KubsOhQ"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span><span style="font-size:7pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_5ad02169_ca1e_4900_9c4b_67c9e1dacd3c"></a><a id="Tc_t70weSO2ZkmYUBYd170klw_1_0"></a><a id="Tc_5aZCVOoCfUKwLPLf1AH9Dw_1_1"></a><a id="Tc_NfqFHrRqqkWisbWYpyK15Q_1_4"></a><a id="Tc_AStppxEQkEmdzENPHQs1WA_1_5"></a><a id="Tc_veqhDIatyEiTP4ho8AYcog_2_1"></a><a id="Tc_KYhAuvSUVkO6VVXovny8oQ_2_4"></a><a id="Tc_ggJ3bWsyK0GwoTGzphy8rA_3_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:27.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:27.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;">Large&#160;accelerated&#160;filer</p></td><td style="vertical-align:top;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:14.4pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:14.4pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;">Accelerated&#160;filer</p></td><td style="vertical-align:top;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:27.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:EntityFilerCategory" id="Tc_IsjK74jxLU-A50-BBh0BPw_2_0"><span style="font-size:7pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:14.4pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:14.4pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;">Smaller&#160;reporting&#160;company</p></td><td style="vertical-align:top;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:EntitySmallBusiness" id="Tc_Hv5weFZwnEeXulSdmjzj0A_2_5"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:27.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;">     <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:38.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;text-indent:14.4pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:3.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:EntityEmergingGrowthCompany" id="Tc_c9tpE5nbEUiH5E8YhJQA7w_3_5"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:EntityExTransitionPeriod" id="Narr_xnGZP97E_ky4WvMkjconMg"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section&#160;404(b)&#160;of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:IcfrAuditorAttestationFlag" id="Narr_IKkYcF2NCkGTcF8_L-EFyg"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt 0pt 4pt 0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange&#160;Act). &#160;&#160;Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:EntityShellCompany" id="Narr_nRlf7I08qE6kjQIUWgCOEw"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric><span style="font-size:7pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt 0pt 4pt 0pt;">The aggregate market value of the common equity held by&#160;non-affiliates&#160;of the Registrant on June&#160;30, 2022 (the last business day of the Registrant&#8217;s second fiscal quarter), based upon the closing price of $2.36 of the Registrant&#8217;s common stock as reported on The Nasdaq Global Market, was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_6_30_2022_ZNLZ2q08tUyXeYUCJO4M5w" decimals="-5" name="dei:EntityPublicFloat" id="Narr_Vpw37YnP2kmPk1jQFmE37A">100.6</ix:nonFraction>&#160;million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt 0pt 4pt 0pt;">The number of shares of the registrant&#8217;s common stock outstanding as of March&#160;2, 2023, was <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_3_2_2023_niqzyjJXOUWALoPppfBlmA" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_xDVEqLPqTkiqqPps6emsnw">54,617,523</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:14.4pt;margin:0pt;">Portions of the Registrant&#8217;s Definitive Proxy Statement (&#8220;Proxy Statement&#8221;) relating to the 2023 Annual Meeting of Stockholders will be filed with the Commission within 120 days after the end of the Registrant&#8217;s 2022 fiscal year and is incorporated by reference into Part III of this Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e41fe5d6_ace1_40b3_9dfd_f280341089e2"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Passage Bio,&#160;Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">ANNUAL REPORT ON FORM&#160;10-K</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">TABLE OF CONTENTS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:2pt 0pt 2pt 0pt;">&#160;&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:2pt 0pt 2pt 0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;">&#160;&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:4.98%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#PARTI_128887"><b style="font-style:normal;font-weight:bold;">PART&#160;I</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item1Business_851218"><b style="font-style:normal;font-weight:bold;">ITEM&#160;1.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item1Business_851218"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item1ARiskFactors_934987"><b style="font-style:normal;font-weight:bold;">ITEM&#160;1A.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item1ARiskFactors_934987"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">39</p></td></tr><tr><td style="vertical-align:bottom;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item1BUnresolvedStaffComments_644817"><b style="font-style:normal;font-weight:bold;">ITEM&#160;1B.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item1BUnresolvedStaffComments_644817"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">90</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item2PropertiesandFacilities_24543"><b style="font-style:normal;font-weight:bold;">ITEM&#160;2.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item2PropertiesandFacilities_24543"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">91</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item3LegalProceedings_840413"><b style="font-style:normal;font-weight:bold;">ITEM&#160;3.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item3LegalProceedings_840413"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">92</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item4MineSafetyDisclosures_801065"><b style="font-style:normal;font-weight:bold;">ITEM&#160;4.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item4MineSafetyDisclosures_801065"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">93</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#PARTII_199413"><b style="font-style:normal;font-weight:bold;">PART&#160;II</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">94</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><b style="font-style:normal;font-weight:bold;">ITEM&#160;5.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item5MarketforRegistrantsCommonEquityRel"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">94</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item6SelectedFinancialData_184761"><b style="font-style:normal;font-weight:bold;">ITEM&#160;6.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item6SelectedFinancialData_184761"><span style="font-style:normal;font-weight:normal;">[Reserved]</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">94</p></td></tr><tr><td style="vertical-align:bottom;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><b style="font-style:normal;font-weight:bold;">ITEM&#160;7.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item7ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">95</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><b style="font-style:normal;font-weight:bold;">ITEM&#160;7A.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item7AQuantitativeandQualitativeDisclosu"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">105</p></td></tr><tr><td style="vertical-align:bottom;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item8FinancialStatementsandSupplementary"><b style="font-style:normal;font-weight:bold;">ITEM&#160;8.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item8FinancialStatementsandSupplementary"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">106</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><b style="font-style:normal;font-weight:bold;">ITEM&#160;9.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item9ChangesinandDisagreementswithAccoun"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">130</p></td></tr><tr><td style="vertical-align:bottom;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item9AControlsandProcedures_95933"><b style="font-style:normal;font-weight:bold;">ITEM&#160;9A.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item9AControlsandProcedures_95933"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">130</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item9BOtherInformation_661797"><b style="font-style:normal;font-weight:bold;">ITEM&#160;9B.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item9BOtherInformation_661797"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">132</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#item9c"><b style="font-style:normal;font-weight:bold;">ITEM 9C</b></a>.</p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#item9c"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">133</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#PARTIII_442551"><b style="font-style:normal;font-weight:bold;">PART&#160;III</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">134</p></td></tr><tr><td style="vertical-align:bottom;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><b style="font-style:normal;font-weight:bold;">ITEM&#160;10.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item10DirectorsExecutiveOfficersandCorpo"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers of the Registrant and Corporate Governance</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">134</p></td></tr><tr><td style="vertical-align:bottom;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item11ExecutiveCompensation_324480"><b style="font-style:normal;font-weight:bold;">ITEM&#160;11.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item11ExecutiveCompensation_324480"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">135</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><b style="font-style:normal;font-weight:bold;">ITEM&#160;12.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">136</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><b style="font-style:normal;font-weight:bold;">ITEM&#160;13.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item13CertainRelationshipsandRelatedTran"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">137</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item14PrincipalAccountantFeesandServices"><b style="font-style:normal;font-weight:bold;">ITEM&#160;14.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item14PrincipalAccountantFeesandServices"><span style="font-style:normal;font-weight:normal;">Principal Accounting Fees and Services</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">138</p></td></tr><tr><td style="vertical-align:bottom;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#PARTIV_315772"><b style="font-style:normal;font-weight:bold;">PART&#160;IV</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">139</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><b style="font-style:normal;font-weight:bold;">ITEM&#160;15.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item15ExhibitsandFinancialStatementSched"><span style="font-style:normal;font-weight:normal;">Exhibits and Financial Statement Schedules</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">139</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><a href="#Item16Form10KSummary_733791"><b style="font-style:normal;font-weight:bold;">ITEM&#160;16.</b></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#Item16Form10KSummary_733791"><span style="font-style:normal;font-weight:normal;">Form&#160;10-K Summary</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 0pt 0pt;">144</p></td></tr><tr><td style="vertical-align:top;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:79.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><a href="#SIGNATURES_809350"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:top;width:2.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">145</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_142cd8a6_1228_4b4d_9ca9_be944a75e2e7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CAUTIONARY NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This Annual Report on Form&#160;10-K contains forward-looking statements. All statements other than statements of historical facts contained in this Annual Report are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;aim,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. All statements other than statements of historical fact contained in this Annual Report, including without limitation statements regarding our plans to develop and commercialize our product candidates, the timing and results of our ongoing or planned preclinical studies and clinical trials, risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, the timing of and our ability to obtain and maintain regulatory approvals, the clinical utility of our product candidates, our commercialization, marketing and manufacturing capabilities and strategy, our expectations about the willingness of healthcare professionals to use our product candidates, the sufficiency of our cash and cash equivalents, general economic, industry and market conditions, including rising interest rates and inflation, our activities to evaluate and pursue strategic alternatives following our determination to discontinue the advancement of certain product candidates, and the plans and objectives of management for future operations and capital expenditures are forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The forward-looking statements in this Annual Report are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Annual Report and are subject to a number of known and unknown risks, uncertainties and assumptions, including those described under the sections in this Annual Report entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. We intend the forward-looking statements contained in this Annual Report to be covered by the safe harbor provisions for forward-looking statements contained in Section&#160;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-transform:uppercase;">Trademarks and Tradenames</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">&#8220;PASSAGE BIO&#8221; is a registered trademark, and the PASSAGE BIO mark, the Passage Bio logo and all product names are our common law trademarks. All other service marks, trademarks and tradenames appearing in this prospectus are the property of their respective owners. Solely for convenience, the trademarks and tradenames referred to in this prospectus appear without the &#174; and &#8482; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to these trademarks and tradenames.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 9pt;">Summary of Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 9pt;"><span style="font-weight:normal;">Our business is subject to a number of risks and uncertainties, including those immediately following this summary. Some of these risks are: </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are a clinical stage genetic medicines company with a history of operating losses, and we may not achieve or sustain profitability. We anticipate that we will continue to incur losses for the foreseeable future. Our limited operating history may make it difficult for you to evaluate our success to date and to assess our future viability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will need to raise additional funding before we can expect to become profitable from any potential future sales of our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are early in our development efforts. Our business is dependent on our ability to advance our current and future product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The disorders we seek to treat have low incidence and prevalence and it may be difficult to identify patients with these diseases, which may lead to delays in enrollment for our trials or slower commercial revenue if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Preclinical and clinical development involve a lengthy and expensive process with an uncertain outcome. We may incur additional expenses or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our current product candidates or any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Gene therapy is a novel technology, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our product candidates may cause undesirable and unforeseen side effects, which could delay or prevent their advancement into clinical trials or regulatory approval, limit the commercial potential or result in significant negative consequences;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We currently rely exclusively on our collaboration with Penn for our preclinical research and development, including for discovering, preclinically developing and conducting all IND-enabling studies for our clinical product candidates and our near-term future pipeline;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Gene therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in our development or commercialization programs or otherwise harm our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face significant competition in an environment of rapid technological change and the possibility that our competitors may achieve regulatory approval before us or develop therapies or technologies that are more advanced or effective than ours;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We currently rely and expect to continue to rely on third-party manufacturers to produce clinical supply of our product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to obtain and maintain patent protection or other necessary rights for our products and technology, or if the scope of the patent protection obtained is not sufficiently broad or our rights under licensed patents is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our products and technology may be adversely affected;</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_44627bc6_9efc_4668_9554_b607e5e0f383"></a><a id="_Hlk93564553"></a><a id="PARTI_128887"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><a id="Item1Business_851218"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1. &#160;&#160;&#160;<span style="font-style:italic;">Business</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Overview</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="letter-spacing:0.25pt;">We are a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system, or CNS, disorders with limited or no approved treatment options. Our vision is to fulfill the promise of gene therapy by developing groundbreaking therapies that transform the lives of patients with CNS diseases. The field of genetic medicine is rapidly expanding and we believe we have a differentiated approach to developing treatments for CNS disorders that enables us to select and advance product candidates with a higher probability of technical and regulatory success. We have entered into a strategic research collaboration with </span>the Trustees of the University of Pennsylvania&#8217;s, or Penn&#8217;s, Gene Therapy Program, or GTP<span style="letter-spacing:0.25pt;">, headed by Dr.&#160;James Wilson, a leader in the genetic medicines field. We also leverage our close working relationship with Penn&#8217;s Orphan Disease Center, or ODC, to develop historical and prospective comparable natural history patient profiles for comparison to participants in interventional trials. Through this collaboration we have assembled a strong portfolio of genetic medicine product candidates, for which we retain global rights, including our two lead clinical product candidates: PBGM01 for the treatment of GM1 </span>gangliosidosis, or GM1<span style="letter-spacing:0.25pt;">, and PBFT02 for the treatment of </span>frontotemporal dementia, or <span style="letter-spacing:0.25pt;">FTD; and two clinical stage product candidates for which, in order to reduce operating expenses, we have stopped further clinical development and are exploring strategic alternatives: PBKR03 for the treatment of Krabbe disease and </span>PBML04 for metachromatic leukodystrophy, or MLD. We have two programs in the research stage: PBAL05 for amyotrophic lateral sclerosis, or ALS, and an unnamed program for Huntington&#8217;s disease. We also have an exploratory research program for <span style="letter-spacing:0.25pt;">Temporal Lobe Epilepsy, or TLE.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We founded Passage Bio with the intent to build a differentiated CNS genetic medicines company delivering transformative therapies to patients by combining our team&#8217;s experience in rare and neurological disease development, manufacturing and commercialization with the pioneering research expertise of GTP in gene therapy. We are purposefully focusing on rare CNS disorders for which we believe our genetic medicine approach provides distinct technical advantages based on decades of research by GTP. GTP conducts rigorous preclinical studies to identify promising product candidates. Our collaboration provides us with access to cutting edge capabilities and innovation in the field of genetic medicine research, including capsid engineering and next-generation capsid libraries, vector engineering, transgene design and gene therapy modalities, animal disease models and related studies for lead-optimization of product candidates. Further, we believe our team&#8217;s deep clinical development experience in rare and neurological diseases will enable well planned clinical trials with the potential for efficient advancement to regulatory approval. In addition, we are engaging with key opinion leaders, practitioners and patient advocacy groups in the field of rare CNS disorders who provide strategic input and help inform our clinical development activities. We believe that our ability to execute on the above tenets provides us with product candidates that have an improved profile for clinical development and an enhanced probability of success.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="letter-spacing:0.25pt;">We are focused on developing and commercializing disease-modifying therapies that can have a transformative impact on patients&#8217; lives. Utilizing our rigorous selection process, we have assembled a strong portfolio of product candidates for rare, monogenic CNS disorders. Our first product candidate, PBGM01, utilizes a next-generation AAVhu68 capsid to deliver to the brain and peripheral tissues a functional </span><i style="font-style:italic;letter-spacing:0.25pt;">GLB1</i><span style="letter-spacing:0.25pt;"> gene encoding lysosomal beta-galactosidase, or &#946;-gal, for GM1. Our second product candidate, PBFT02, utilizes an AAV1 capsid to deliver to the brain a functional </span><i style="font-style:italic;letter-spacing:0.25pt;">GRN</i><span style="letter-spacing:0.25pt;"> gene encoding progranulin, or PGRN, for FTD caused by progranulin deficiency, or FTD-GRN. There are currently no approved disease-modifying therapies for these diseases. We believe our clinical product candidates have the potential to provide patients with significantly improved outcomes, given our chosen route of intra cisterna magna, or ICM, administration, </span>the potential for enhanced benefits due to cross-correction of neighboring cells by secreted gene products, and our rigorous capsid and transgene selection process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Our research collaboration with GTP provides us with access to one of the premier research institutions in the world for the discovery and preclinical development of genetic medicine product candidates and exclusive rights to product candidates for certain CNS disorders. As part of this collaboration, we have exclusive rights to all discovery work and IND-enabling research for product candidates in the CNS indications that we select. In </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:178.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="letter-spacing:0.25pt;">addition to our two lead clinical product candidates, we have two clinical product candidates for which, in order to reduce operating expenses, we have stopped further clinical development and are exploring strategic alternatives, two ongoing research programs, and eight remaining options available to us to license additional programs from GTP until August 2026. </span>We also have an exploratory research program with GTP in non-rare, non-monogenic, or large, CNS indications, currently focused on TLE, which can be expanded to other large, CNS diseases upon mutual agreement with GTP. <span style="letter-spacing:0.25pt;">Further, we have exclusive rights, subject to certain limitations, to technologies resulting from the discovery program for our products developed with GTP, such as novel capsids, toxicity reduction technologies, delivery, and formulation. We have global commercial rights to all of our current and future product candidates and believe that our approach to developing therapies for life-threatening diseases that are currently underserved presents an opportunity to efficiently advance our product candidates through clinical development, regulatory approval and ultimately to commercialization.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="letter-spacing:0.25pt;">We are led by pioneers and experts with decades of collective experience in genetic medicines and rare disease drug development, manufacturing and commercialization. Dr. Wilson, one of our scientific founders, is recognized as a world leader in research and development in the fields of genetic medicines and rare disease.</span><span style="color:#ff0000;letter-spacing:0.25pt;"> </span><span style="letter-spacing:0.25pt;">Dr. Wilson&#8217;s continuing relationship with our company helps guide our clinical and research programs. We have assembled a team whose members have extensive experience in successfully developing, manufacturing and commercializing genetic medicine and rare disease products.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Our pipeline</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We have assembled a strong portfolio of genetic medicine product candidates for rare, monogenic CNS disorders characterized by high unmet medical needs. We intend to further expand our portfolio with genetic medicine product candidates for other CNS disorders, as well as other treatment approaches as technology advances in the field. Our development programs consist of:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;"><img src="pasg-20221231x10k006.jpg" alt="Graphic" style="display:inline-block;height:178.45pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:485.3pt;" /></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 3pt 0pt;"><i style="font-style:italic;">*8 additional CNS pipeline license options remain; 3 license options were previously exercised, and rights were subsequently returned to the University of Pennsylvania.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 3pt 0pt;"><i style="font-style:italic;">&#8224; Program includes ongoing natural history study of infantile and juvenile GM1 gangliosidosis patients</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">PBGM01 for the treatment of GM1</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are currently developing PBGM01, which utilizes a proprietary, next-generation AAVhu68 capsid to deliver to the brain and peripheral tissues a functional <i style="font-style:italic;">GLB1</i> gene encoding &#946;-galactosidase (or &#946;-gal) for infantile GM1. Infantile GM1 is the most common and severe form of GM1, in which patients have mutations in the <i style="font-style:italic;">GLB1</i> gene that produce little or no residual &#946;-gal enzyme activity. &#946;-gal is an enzyme that catalyzes the first step in the natural degradation of GM1 ganglioside as well as other glycan substrates. Reduced &#946;-gal activity results in the accumulation of toxic levels of GM1 ganglioside in neurons throughout the brain, causing rapidly progressive neurodegeneration, with a life expectancy of two to ten years. Currently, there are no disease-modifying therapies approved for the treatment of GM1. Early onset infantile GM1 is characterized by onset in the first 6 months of life, while late onset infantile GM1 is characterized by onset between 6 and 24 months. We believe PBGM01 could provide patients with significantly improved outcomes. In </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">preclinical studies we observed meaningful transgene expression in both the CNS and in peripheral organs affected in GM1. We are conducting clinical trials using an ICM method of administration, which involves an injection at the craniocervical junction. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have an active Investigational New Drug application, or IND, from the U.S. Food and Drug Administration, or FDA, and approved clinical trial authorizations, or CTAs, in multiple countries for PBGM01, and we are actively proceeding with our Imagine-1 Trial, an international, multi-center, open-label, single-arm Phase 1/2 clinical trial of PBGM01 in patients with a diagnosis of early and late infantile GM1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have completed dosing of the initial four cohorts in our Imagine-1 Trial. This includes a total of eight patients, as follows: Cohort 1 for late infantile GM1 treated with low dose PBGM01, Cohort 2 for late infantile GM1 treated with high dose PBGM01, Cohort 3 for early infantile GM1 treated with low dose PBGM01, and Cohort 4 for early infantile GM1 treated with high dose PBGM01.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In December 2022 and February 2023, we reported interim safety and biomarker data for the first three cohorts of our Imagine-1 trial. The safety data showed that PBGM01 was well tolerated with no serious adverse events and no evidence of dorsal root ganglion toxicity or complications related to the ICM injection. We observed a dose-dependent increase in &#946;-gal activity in the cerebral spinal fluid, or CSF, coupled with a dose-dependent decrease in CSF levels of GM1 ganglioside. We also reported meaningful improvement in a subset of patients across developmental areas in assessments utilizing the Vineland II and Bayley III scales, performed by caregivers and trained healthcare providers, respectively. The data suggests that stage of disease may be a determinant in treatment outcomes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We expect to report initial safety and biomarker data from patients in Cohort 4 in the middle of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A key objective of the initial phase of the Imagine-1 trial is to determine the optimal dose for the confirmatory phase of the study. Based on the favorable safety profile of PBGM01 observed to date, the observed dose-response in key biomarkers, such as CSF <span style="font-family:'Symbol';">b</span>-gal activity and GM1 ganglioside levels, and that our preclinical studies showed no safety signals at doses higher than currently being evaluated in the ongoing clinical trial, we plan to treat additional patients in the Imagine-1 trial at higher doses of PBMG01 than the doses of PBGM01 administered to date in Cohorts 1 to 4. Following regulatory review, we expect to dose the first patient at a higher dose of PBGM01 in the second half of 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">The FDA has granted Orphan Drug Designation, or ODD, Rare Pediatric Disease Designation, or RPDD, and Fast Track Designation, to PBGM01 for the treatment of GM1. The European Commission has granted Orphan designation and Advanced Therapy Medicinal Product, or ATMP, designation for PBGM01. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">PBFT02 for the treatment of FTD-GRN</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:5pt 0pt 5pt 0pt;">We are currently developing PBFT02, which utilizes an AAV1 capsid to deliver a functional copy of the granulin gene, or GRN, encoding for human progranulin, or PGRN, for the treatment of frontotemporal dementia caused by progranulin deficiency, or FTD-GRN. FTD-GRN is an inheritable form of FTD in which patients have mutations in the <i style="font-style:italic;">GRN</i> gene, causing a deficiency in PGRN. PGRN is a complex and highly conserved protein thought to have multiple roles in cell homeostasis, neurodevelopment, and inflammation. Emerging evidence suggests that PGRN deficiency in FTD and other neurodegenerative disorders may contribute to lysosomal dysfunction. Currently, there are no disease-modifying therapies approved for the treatment of FTD-GRN. Based on findings in preclinical studies, we believe that PBFT02 may provide FTD-GRN patients with significantly improved outcomes. We selected the AAV1 capsid and ICM administration for PBFT02 because this approach led to extensive and robust expression of human PGRN throughout the brain and spinal cord of non-human primates, or NHPs, and due to the higher PGRN levels in CSF using AAV1 as compared with other serotypes tested. ICM administration of AAV1 to NHPs resulted in supraphysiologic CSF levels of human PGRN compared to levels in healthy human subjects&#8217; CSF, and in excess of levels achieved in NHPs with AAVhu68 or AAV5.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have an active IND from the FDA and approved CTAs in multiple countries for PBFT02, which allows us to proceed with our upliFT-D Trial, an international, multi-center, open-label, single-arm Phase 1/2 clinical trial of PBFT02 in patients with a diagnosis of early symptomatic FTD-GRN. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In August 2022, we dosed the first patient in our upliFT-D trial. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We expect to report initial safety and biomarker data from patients in Cohort 1 in the second half of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The FDA has granted ODD and Fast Track Designation to PBFT02 for the treatment of FTD-GRN and the European Commission granted Orphan designation for PBFT02. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Other Clinical Product Candidates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have two clinical product candidates, PBKR03 and PBML04, for which, in order to reduce operating expenses, we have stopped further clinical development and are exploring strategic alternatives for these assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PBKR03 utilizes a proprietary, next-generation AAVhu68 capsid to deliver to the brain and peripheral tissues a functional <i style="font-style:italic;">GALC</i> gene encoding the hydrolytic enzyme galactosylceramidase to treat Krabbe disease. Krabbe disease is an autosomal recessive lysosomal storage disease caused by mutations in the <i style="font-style:italic;">GALC</i> gene, which provides instructions for making an enzyme called galactosylceramidase, which breaks down certain fats, including galactosylceramide and psychosine. This results in the accumulation of galactolipids such as psychosine, resulting in widespread death of myelin-producing cells in the CNS and in the peripheral nervous system, or PNS. We have an active IND from the FDA and approved CTAs in multiple countries for PBKR03 to support our GALax-C Trial, an international, multi-center, open-label, single-arm Phase 1/2 clinical trial of PBKR03 in patients with a diagnosis of infantile Krabbe disease. In March 2022, we dosed the first patient in our GALax-C Trial. In November 2022, we announced plans to stop further clinical development of PBKR03 in order to reduce operating expenses, and are exploring strategic alternatives for this asset.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PBML04 utilizes a proprietary, next-generation AAVhu68 capsid to deliver to the brain and peripheral tissues a functional arylsulfatase A gene, or<i style="font-style:italic;"> ARSA</i>, encoding the ARSA enzyme to treat Metachromatic Leukodystrophy, or MLD. MLD is a rare, autosomal recessive lysosomal storage disease caused by mutations in the <i style="font-style:italic;">ARSA</i> gene, resulting in little or no functional activity of the ARSA enzyme, which is essential for the degradation of sphingolipid cerebroside-3-sulfate, or sulfatide. When the ARSA enzyme is lacking, sulfatides accumulate in lysosomal storage deposits in microglia, oligodendrocytes, and Schwann cells, leading to widespread demyelination. Our preclinical data in <i style="font-style:italic;">ARSA</i><span style="white-space:pre-wrap;">-/- mice and in NHPs support the ability of PBML04 administration into CSF to result in dose-dependent increases in brain and CSF levels of functional human ARSA enzyme, leading to improved biochemical, histopathological, behavioral, survival endpoints, and with no safety or toxicity signs up to the highest tested dose in NHPs. Preclinical findings were presented by GTP in 2021.  In April 2022, we submitted an IND for PBML04 to support clinical development in MLD. On May 20, 2022, the FDA cleared our IND application for PBML04, which supports PBML04-001, an international, multi-center, open-label, single-arm clinical trial of PBML04 in patients with a diagnosis of late onset infantile MLD. In November 2022, we </span>announced plans to stop further clinical development of PBML04 in order to reduce operating expenses, and are exploring strategic alternatives for this asset.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Research Programs</span><span style="letter-spacing:0.2pt;"> </span></p><a id="_Hlk92890436"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">We have two programs in preclinical research stages under our license agreement with Penn: PBAL05 for ALS and, an unnamed program for Huntington&#8217;s disease. PBAL05 is targeting patients with ALS who have a gain-of-function mutation in the </span><i style="font-style:italic;letter-spacing:0.25pt;">C9orf72</i><span style="letter-spacing:0.25pt;"> gene. Our unnamed program is focused on the treatment of Huntington&#8217;s disease, a repeat expansion disorder. Beyond this portfolio, through our research collaboration with GTP, we also have the option to license programs for eight additional new indications in CNS diseases along with certain rights and licenses to new gene therapy technologies developed by Penn, such as novel capsids, toxicity reduction technologies and delivery and formulation. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We also have an exploratory research program with GTP for larger non-monogenic indications, currently focused on TLE, which can be expanded to other large CNS diseases upon mutual agreement with GTP.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-weight:bold;letter-spacing:0.3pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-weight:bold;letter-spacing:0.3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Our Strategy</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We are a genetic medicines company focused on developing transformative therapies for CNS disorders with limited or no approved treatment options. Our vision is to fulfill the promise of gene therapy by developing groundbreaking therapies that transform the lives of patients with CNS diseases.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">To achieve our vision, we have assembled a world-class team whose members have decades of collective experience in genetic medicines and rare disease drug development and commercialization. We leverage this experience, to develop treatments that improve outcomes for patients with serious, life-threatening CNS diseases. Patients are considered every step of the way, in every decision we make.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Key elements of our strategy include:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Focus on underserved indications for which we can have a transformative impact on patients&#8217; lives.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> We believe that genetic medicine has the potential to have a transformative impact on CNS disorders, and on patients&#8217; lives, by providing them with a treatment for life-threatening diseases with limited or no approved treatment options.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Rapidly advance our clinical product candidates through clinical development and commercialization.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> We leverage our collaboration with GTP, as well as our internal capabilities, to select optimal product candidates for each indication based on extensive preclinical data, including animal data and disease-specific animal models and biomarkers, thus enhancing the probability of clinical success of our product candidates. Our goal is to select candidates that have the potential to address high unmet clinical needs and have transformative therapeutic effects for patients. If our clinical trials are successful, we plan to meet with regulatory authorities to discuss expedited regulatory approval strategies.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Advance and expand our pipeline by identifying and developing additional product candidates into the clinic.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> We believe our differentiated drug development approach as well as our internal and partnered research capabilities may allow us to address a broad range of CNS disorders, thus expanding our pipeline. Through our collaboration with GTP, we are continuing to develop additional genetic medicine product candidates targeting life-threatening CNS disorders. We have two lead clinical product candidates, two clinical product candidates for which we have stopped further clinical development in order to reduce operating expenses and are exploring strategic alternatives for these assets, and three additional programs advancing through the research or discovery stage. We also have the option to license eight additional CNS indications from GTP until May 2026.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Extend existing and establish new relationships with patients and patient advocacy groups.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> Patients are at the core of what we do. We have been engaging with them and with their advocacy groups since our inception and have acquired an intimate understanding of how we can positively impact their lives. These relationships deeply inform us as we develop and ultimately seek to commercialize our product candidates. Our relationship with Penn&#8217;s ODC, which is currently performing a natural history study for GM1 that we are funding, represents an example of our strategy, and has been helping us to engage effectively with patients. We have a collaboration with Invitae to facilitate genetic testing and support early identification of GM1 through Invitae&#8217;s Detect Lysosomal Storage Disorders, as well as provide clinical trial information to physicians and patients, and have partnered with InformedDNA to offer free genetic counseling and testing for adults who have been diagnosed with FTD.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Continue to develop proprietary manufacturing capabilities.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> We believe the quality, reliability and scalability of our genetic medicine manufacturing techniques and know-how will be a critical advantage to our long-term success. We have established robust in-house analytical and process development operations to support ongoing and future manufacturing</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">operations. We have also advanced our manufacturing and testing technology platforms; our in-house laboratory is equipped with state-of-the-art analytical capabilities, capable of assay development and validation, clinical product testing, and process and product development to support viral vector manufacturing. We also have the internal manufacturing </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">and quality expertise to oversee external manufacturing and supply chain operations provided by third party strategic relationships, such as Catalent Maryland, a unit of Catalent Biologics, Inc, or Catalent. We also have access to a manufacturing suite through Catalent where we have successfully produced GMP material for our clinical programs. This facility is capable of producing sufficient supplies to conduct our planned clinical trials and, supply initial commercial launch of our current clinical product candidates, if approved. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Selectively enter into new discovery relationships with premier research institutions and expand our existing collaboration.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> We will continue to foster our well-established relationship with Penn, and potentially enter into new collaborations to build or advance our pipeline. We will look to nurture our genetic medicine technology capabilities by keeping abreast of advances in next-generation capsid development, promoter selection, transgene design, gene silencing and gene editing, which will help us to engineer optimal product profiles to address life-threating CNS disorders characterized by high unmet medical needs.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Genetic Medicine Background</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Each person&#8217;s genetic material, or genome, consists of deoxyribonucleic acid, or DNA, in sequences of genetic code called genes. The DNA in the human genome contains approximately three billion nucleotide base pairs, and small changes, or mutations, routinely occur in the base pairs. A mutation in a single gene can alter the amount or activity of the protein expressed by the gene, causing deformities and disease. Currently, there are estimated to be over 10,000 diseases caused by a genetic abnormality in a single gene. These are also known as monogenic diseases. Based on research commissioned by us, we believe there are at least 790 rare monogenic CNS diseases, with few currently approved disease modifying treatments for any rare monogenic CNS diseases.</span><span style="letter-spacing:0.2pt;"> </span>In addition, gene therapy can also be applied to correct biological pathways that are not necessarily inherited or associated with one defective gene. This approach aims to reduce the expression of pathological proteins or increase the production of corrective biological targets. This is the basis for the programs that target non-hereditary conditions such as TLE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The development of molecular therapeutics to modulate human gene expression and correct disease-causing genetic defects had its advent several decades ago, and with advances in science and a deeper understanding of human genetics it has expanded to include a broader range of genetic medicines with the potential to modulate gene expression through additional molecular mechanisms.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">These transformative genetic medicines include gene therapy (delivery of an external gene to replace a defective gene), gene silencing (delivery of a DNA or ribonucleic acid, or RNA, based therapeutic that modulates the transcription or translation of an injurious gene product), gene editing (delivery of a DNA or RNA-based therapeutic that corrects the expression of targeted genes) and combinations of these therapeutic modalities. We believe that this expanded molecular biological tool-box will provide new therapeutics with the potential to deliver highly potent and safe interventions across a diverse set of CNS diseases, offering several advantages, including:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Potential to treat most diseases of genetic etiology.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> Theoretically, it should be possible to design and deliver a genetic medicine to correct the expression of any human protein whose presence, absence or activity causes disease.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Potential to target mechanisms that have not been effectively or safely modulated by traditional small molecule or protein-based therapeutics.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> The inherent specificity of genetic medicines for unique nucleic acid sequences can provide a high therapeutic index resulting from high potency and the potential to deliver adequate doses while avoiding off-target safety liabilities.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Efficient delivery of transformative therapeutics.</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> Because genetic medicines are designed to deliver a long-standing effect following a single administration, a single dose of these therapeutics has the potential to provide clinical benefits for many&#160;years.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Genetic medicines can be designed to mitigate challenges faced by other approaches in the development of therapeutics for the CNS. CNS disorders are among the most devastating in their impact on patients and their families. These disorders are generally life-threatening to patients. There is a significant need for genetic </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk94529398"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">medicines that can target these disorders. </span><span style="letter-spacing:0.25pt;">Our initial programs focus on rare, monogenic CNS disorders because they offer a compelling opportunity for the effective application of genetic medicines. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Our Approach</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">The field of genetic medicine is rapidly expanding and we believe we have developed a differentiated approach to developing treatments for CNS disorders that allows us to select and advance product candidates with a higher probability of technical and regulatory success. Our gene therapy product candidates use AAV, a small, non-pathogenic virus that is genetically engineered to function as a delivery vehicle, or vector. In our current clinical programs, the AAV is administered to a patient to introduce a healthy copy of a mutated gene, or the transgene, to the cells in a process referred to as transduction.</span> Our current approaches use AAVs to deliver either a (i) replacement non-mutant transgene, or (ii) a combination of a microRNA, known as miRNA, to reduce expression of a mutant transgene, and a replacement non-mutant transgene. <span style="letter-spacing:0.25pt;">The components of an AAV gene therapy vector include the therapeutic gene that makes up the DNA payload, or the transgene, the outer viral shell that encloses the DNA payload, or the capsid, and any promotors added to the vector to boost expression of the transgene. The AAV is often described by the serotype, or strain, of the vector. The core tenets of our approach include a rigorous process for selecting product candidates, mitigation of early development risk through relationships with leading researchers and academic institutions, and mitigation of clinical development risk through deep relationships with patient advocacy groups, key opinion leaders and practitioners. Together, these relationships allow us to directly benefit from decades of collective experience, the latest technologies and contemporary perspectives from patients and their experiences. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Rigorous Process for Selecting Product Candidates</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">In selecting our product candidates, we focus initially on optimizing transduction and expression of transgenes in the indication-specific target tissues. This involves prioritizing the following principles: selection of the route of administration to maximize transgene biodistribution; selection of capsid, transgene and promoter to optimize efficiency of transduction and expression; leveraging biological mechanisms such as cross-correction to maximize availability of transgene product to target cells; and the effective use of biomarkers to assess treatment effects on transduction, transgene expression and on disease pathophysiology.</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Optimal route of administration:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> Identifying the optimal route of administration for AAV gene therapy is critical to achieving safe and effective levels of transgene expression in the targeted location in the CNS. The optimal route of administration for CNS treatments should also leverage the immuno-privileged aspects of the CNS to reduce the potential effects of neutralizing antibodies, or NAbs, on AAV capsids, which are often faced by gene therapy product candidates. We evaluate preclinical studies and other data to decide the preferred route of administration on a program-by-program basis. For our existing clinical product candidates, we believe that ICM administration is the optimal route of administration as compared to other potential delivery mechanisms due to its diffuse delivery distribution, potential for improved biodistribution to the brain and spinal cord and transduction, and lower expected toxicity. Administration through ICM can also reduce the potential impact of NAbs as compared with intravenous administration. We believe that by using ICM we can achieve comparable protein expression at lower dosages than would be required by other administration routes.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Capsid, transgene, and promoter selection:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> For each of our programs, we conduct rigorous studies to select the capsid, transgene, and promoter to use for our product candidate. We identify the optimal AAV gene therapy for each of our indications depending on the target indication, our goal of CNS and/or PNS transduction, and the target brain regions and cell types. Typically, we compare multiple capsids in NHPs to identify the capsid best suited for each program.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Cross-correction:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> Our existing clinical product candidates exploit the cross-correction mechanism by which secreted gene product from transduced cells is taken up by non-transduced neurons. We believe this cross-correction mechanism can help overcome the limits of vector biodistribution and CNS transduction inefficiency that are characteristic of other genetic medicine approaches, and ultimately drive clinical benefit.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;letter-spacing:0.25pt;">Effective use of biomarkers:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> Our development program targets must have measurable, predictive biomarkers to inform early and efficient clinical development decisions. These include pharmacodynamic biomarkers to confirm achievement of target levels of transduction and gene expression, and disease activity and progression biomarkers to confirm downstream effects on the underlying disease pathophysiology.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Mitigation of Early Development Risk of Programs Prior to IND submission</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We have a strategic research collaboration with GTP, which is led by our co-founder and Chief Scientific Advisor, Dr.&#160;Wilson, and which we believe positions us at the forefront of gene therapy research. This collaboration provides us with access to differentiated discovery technology and expertise that informs the basis of our product candidate selection and subsequent development.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Our strategic research collaboration with GTP provides us with access until August 2026 to one of the premier gene therapy research institutes in the world for the discovery and preclinical development of gene therapy product candidates and exclusive rights to certain CNS disorders, including next-generation AAV capsid technology and vector engineering, and state-of-the art preclinical animal studies, including NHP models. Through GTP&#8217;s staff, we have access to cutting edge expertise and capabilities in gene therapy research and preclinical development.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Our collaboration with GTP allows us to choose programs that have been or will be validated through extensive testing in preclinical disease models, and once selected, to collaborate with GTP on further preclinical optimization of our product candidate, such as vector choice, transgene construct and route of administration. We believe this collaboration improves our probability of technical and regulatory success in developing product candidates that provide transformative clinical benefits.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Once we select a particular CNS indication for further development, GTP, with our close involvement and oversight, embarks on a rational discovery and development program to design product candidates that may provide improved clinical benefit. We usually evaluate transduction efficiency and biodistribution using multiple different capsids in NHPs to select the capsid best suited for the targeted indication. GTP also works to optimize the delivery method used for each product candidate by balancing delivery, efficacy, safety, host immunity and ease of administration. We believe the translational preclinical characterization provided by GTP, including the use of NHP models for vector screening and toxicology, reduces the early-stage development risk of our product candidates.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Mitigation of Clinical Development Risk through Our Relationship with Penn&#8217;s ODC</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We also have a strong relationship with Penn&#8217;s ODC. As part of our research collaboration with GTP, we have access to Penn&#8217;s ODC&#8217;s insights and capabilities in the study of rare diseases. We leverage our close working relationship with Penn&#8217;s ODC to develop historical and prospective external data for each disease for use in building comparable patient profiles of participants in interventional trials. Penn&#8217;s ODC is currently performing a natural history study for GM1 funded by us.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Our Product Candidates</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">GM1&#8212;PBGM01</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Overview of GM1</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">GM1 is a rare and often life-threatening monogenic recessive lysosomal storage disease that results in progressive damage to both the CNS and the peripheral tissues. The infantile form of the disease is characterized by onset in the first two years of life with symptoms including hypotonia (reduced muscle tone), progressive CNS dysfunction leading to deafness, blindness, enlarged liver and spleen, rigidity and progressive skeletal dysplasia that leads to restrictive lung disease and aspiration pneumonia. Early onset infantile GM1, or Type I, is characterized by onset in the first six&#160;months of life, while late onset infantile GM1, or Type IIa, is characterized by onset between six and 24&#160;months. The disease rapidly progresses, with a life expectancy of less than two years for early infantile GM1 and five to ten years for late infantile GM1.</span><span style="letter-spacing:0.2pt;"> </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">GM1 is caused by recessive mutations in the </span><i style="font-style:italic;letter-spacing:0.25pt;">GLB1</i><span style="letter-spacing:0.25pt;"> gene, which encodes lysosomal acid &#946;-gal, an enzyme that catalyzes the first step in the natural degradation of GM1 ganglioside as well as other glycan substrates. Reduced &#946;-gal activity results in the accumulation of toxic levels of GM1 ganglioside in neurons throughout the brain, causing rapidly progressing neurodegeneration. GM1 manifests as a continuum of clinical severity, ranging from infants with earlier onset and more severe and rapidly progressive disease to those with later juvenile or adult onset, slower progression and less severe manifestations.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The United States incidence of GM1 has been estimated to be approximately 1 in 100,000 live births, with infantile GM1 representing approximately 62.5% of such cases. No states include GM1 in mandatory infant screening. We engaged a third-party data-analytics firm to conduct an analysis of a variety of de-identified electronic medical records. </span>Based on this analysis, we estimate the incidence of infantile GM1 to be approximately 1.4 in 100,000 live births. <span style="letter-spacing:0.25pt;">Currently, there are no approved disease-modifying therapies available. Supportive treatment options include the use of feeding tubes or ventilators for infants with GM1.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Program selection</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We chose GM1 as one of our initial lead programs because it met our criteria for rare, monogenic CNS disorders in which we believe we can develop product candidates with a higher probability of technical and regulatory success that will substantially impact on the lives of severely underserved patients. </span>Several key factors supported the decision to focus on GM1 for AAV gene therapy, as described below.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Cross-correction</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">: Following treatment with PBGM01, we expect</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> that</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> newly synthesized</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> functional </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">&#946;-gal</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> will be secreted by transduced cells and provide a source of secreted proteins that could be taken up by surrounding non-transduced and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">other</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">wise enzyme-deficient</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cells. This cellular cross-correction could therefore lead to enzyme replacement</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> broad</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ly throughout the</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> CNS and peripheral organ</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">s</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Biomarkers</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">: There are known biomarkers in GM1 that are measurable and available to assist in drug development.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">&#946;</i><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">-gal activity.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"> Reduced &#946;-gal activity is a hallmark of GM1 and treatment with PBGM01 is expected to restore this activity. To this end, &#946;-gal activity is being measured in CSF and blood.  </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Pharmacodynamic biomarkers</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">. Reduced &#946;-gal activity results in the accumulation of GM1 ganglioside and other glycan substrates in neurons throughout the brain.  These substrates may be reduced following treatment with PBGM01 and are being measured in CSF, blood, and urine.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Disease progression biomarkers.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> Recent MRI studies of infants with GM1 have shown longitudinal changes in MRI in infants with GM1 consistent with progressive brain atrophy and ventricular enlargement, suggesting that brain MRI would be a useful biomarker to detect and help verify treatment effects on disease pathophysiology.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:8pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Preclinical validation:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> We used the </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">GLB1</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> knockout mouse disease model showing clinical, biological and histological manifestations of GM1 in preclinical studies. In these studies, we observed a robust dose-related improvement in both neurological status, enzyme activity, histologic lysosomal storage pathology and survival following treatment with PBGM01.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Product Candidate Development Strategy</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We have chosen the earliest and most severe form of GM1 for clinical development for several reasons. Within GM1, infantile GM1 represents the greatest medical need, as early onset GM1 infants often do not survive past two&#160;years, and thus are in immediate need of an effective therapy. We expect treatment-related efficacy to be measurable sooner after treatment in this more rapidly progressing form of GM1. Patients with onset forms of GM1 later than infantile, which we define as an onset later than 24 months, are caused by less severe reductions of &#946;-gal enzyme activity and generally demonstrate slower progression and more variable clinical courses, likely requiring larger and longer clinical trials and a broader control group. If our initial clinical trials in infantile GM1 are successful, we intend to explore expansion of the indication with trials in later onset forms of GM1.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Our Product Candidate</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We are developing PBGM01 to treat infantile GM1, with a single dose of PBGM01 by ICM administration. PBGM01 utilizes a next-generation AAVhu68 viral vector to deliver modified DNA encoding the &#946;-gal enzyme to a patient&#8217;s cells. The goal of this vector and delivery approach is to increase levels of the &#946;-gal enzyme in both the CNS and the peripheral tissues. We selected the AAVhu68 capsid and ICM route of administration due to the superior transduction observed in cells of the CNS and peripheral organs, which are both affected in GM1 disease patients. Based on prior capsid comparison studies, the AAVhu68 vector has the potential to provide corrective &#946;-gal enzyme to both the CNS and peripheral tissues, which we believe gives us the potential to treat both the CNS pathologies and the peripheral manifestations observed in GM1 disease.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We believe gene replacement with PBGM01 and consequent wide brain distribution and uptake of the &#946;-gal enzyme has the potential to greatly reduce the accumulation of GM1 gangliosides, reversing neuronal toxicity, thereby restoring developmental potential and improving the quality of life for treated patients. We will evaluate this clinically by assessing the prevention of further developmental regression and restoration of developmental trajectories, as measured by developmental milestones using accepted clinical scales and observer-reported outcomes.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Preclinical studies</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">The potential for efficacy of PBGM01 is supported by preclinical findings in GLB1 knockout (</span><i style="font-style:italic;letter-spacing:0.25pt;">GLB1-/-)</i><span style="letter-spacing:0.25pt;"> mice. This mouse line develops several characteristics that are reminiscent of the neurological presentation of GM1, including a rapid accumulation of GM1 ganglioside in the brain shortly after birth followed by progressive motor abnormalities and a shortened survival. Intracerebroventricular, or ICV, injection of PBGM01 in </span><i style="font-style:italic;letter-spacing:0.25pt;">GLB1-/-</i><span style="letter-spacing:0.25pt;"> mice resulted in persistent dose-dependent elevations in &#946;-gal activity in the brain, CSF, serum, and in peripheral organs. Increased &#946;-gal activity was associated with increased phenotypic and histopathological benefits in the </span><i style="font-style:italic;letter-spacing:0.25pt;">GLB1-/-</i><span style="letter-spacing:0.25pt;"> mice including the resolution of pre-existing brain lysosomal storage lesions as assessed by lysosomal associated membrane protein 1, or LAMP-1, immunohistochemistry, improved neurological phenotypes in assays of clinical deficits and animals&#8217; gait, and increased survival. Preclinical findings were published by GTP in 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">NHP Toxicology Study </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">A 120-day good laboratory practice, or GLP, compliant toxicology study conducted in NHPs assessed the safety, tolerability, biodistribution and excretion profile of PBGM01 following ICM administration of vehicle or one of three dose levels of PBGM01. PBGM01 vector distributed to the CSF and high levels of gene transfer were detected in the brain, spinal cord and dorsal root ganglia, or DRG. The quantity of vector genomes detected in CNS tissues was generally dose-dependent. PBGM01 also reached high levels in peripheral blood and liver. Measurement of transgene expression by &#946;-gal activity in CSF and serum was limited in NHPs by the nature of the assay, which could not distinguish between human and endogenous rhesus &#946;-gal. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">&#946;-gal activity in the CSF and serum was detectable in animals from all dose groups 14 days after PBGM01 administration. In the CSF, animals administered the two higher doses displayed dose-dependent increases in &#946;-gal activity to approximately two-fold and four-fold higher than the levels in vehicle-treated controls, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">There were no blood or CSF abnormalities related to PBGM01 administration except for asymptomatic, mild, and transient increases in CSF leukocytes in the majority of animals from all dose groups. PBGM01 was well-tolerated at all doses evaluated and no adverse effects were detected on body weight or clinical, neurological, or behavioral signs. PBGM01 vector DNA was detectable in urine and feces five days post-administration and was undetectable within 60 days. In response to a potential AAV platform risk reported in NHPs we assayed DRG and TRG toxicity after PBGM01 administration. Mild and transient degeneration of DRGs, TRGs, and associated sensory nerve axonopathy were observed in all dose groups; however, these findings were not linked with any clinical or neurological abnormalities in any animals up to 120 days post-dose.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">In summary, based on our preclinical studies, we believe that CSF delivery of PBGM01 has the potential to sufficiently increase &#946;-gal levels in both the CNS and in peripheral tissues to overcome intracellular &#946;-gal deficiency in GM1.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Clinical development</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Our clinical development plan is to start with trials in infantile GM1, and if successful, explore expansion of the indication with trials in later onset forms of GM1.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We initiated patient dosing in our Imagine-1 trial, a multi-center, open-label, single-arm Phase&#160;1/2 clinical trial of PBGM01 in patients with a diagnosis of early and late infantile GM1 in March 2021. Primary endpoints include safety and efficacy. Efficacy is being evaluated by the assessment of developmental milestones using accepted clinical scales and observer-reported outcomes. Secondary outcomes include serum and CSF &#946;-gal enzyme activity, GM1 ganglioside levels, and disease progression endpoints including evaluations using electroencephalogram, or EEG, and MRI.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">The<span style="letter-spacing:0.25pt;"> study</span> enrolled both<span style="letter-spacing:0.25pt;"> early and late infantile patients in separate, smaller cohorts. Part 1 of the study includes a total of four cohorts of two patients each, with separate dose-escalation cohorts for late onset infantile GM1 patients</span>, defined as<span style="letter-spacing:0.25pt;"> onset prior to </span>24<span style="letter-spacing:0.25pt;">&#160;months in age</span> and after 6 months in age,<span style="letter-spacing:0.25pt;"> and early onset infantile GM1</span>, defined as onset prior to 6 months of age<span style="letter-spacing:0.25pt;">. </span>The study is assessing<span style="letter-spacing:0.25pt;"> </span>an initial<span style="letter-spacing:0.25pt;"> </span>low <span style="letter-spacing:0.25pt;">dose </span>(3.3x10&#708;10 genome copies/gm brain weight) <span style="letter-spacing:0.25pt;">that exceeds the </span>minimum effective dose, or <span style="letter-spacing:0.25pt;">MED, as determined in our preclinical studies, and a 3-fold greater high dose</span> (1.1x10&#708;11 genome copies/gm brain weight).<span style="letter-spacing:0.25pt;"> Cohorts 1 and 2 </span>enrolled<span style="letter-spacing:0.25pt;"> patients diagnosed with late infantile GM1 and treated them with low dose and high dose PBGM01, respectively, while Cohorts 3 and 4 enrolled patients diagnosed with early infantile GM1 and treated them with low dose and high dose PBGM01, respectively. All patients are treated with an abbreviated course of low dose steroids. To better understand the clinical significance of the peripheral nerve findings in NHPs, we implemented clinical monitoring in our Imagine-1 trial, consisting of both nerve conduction studies and neurological exams focused on sensory and peripheral nerve function</span>.<span style="letter-spacing:0.25pt;"> There </span>is<span style="letter-spacing:0.25pt;"> a 60-day interval between </span>all <span style="letter-spacing:0.25pt;">subjects dosed within a cohort to allow review of biomarker and safety data before dosing the next subject. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Following the dose-escalation cohorts, each patient population will be enrolled into a confirmatory cohort. Patients will be evaluated over two years for safety and efficacy, followed by an additional 36 months of long-term follow up.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Clinical development results</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We completed dosing of the initial four cohorts in our Imagine-1 trial in November 2022. In December 2022 and February 2023, we reported interim safety and biomarker data for the first three cohorts of the trial. The results from the interim assessment are shown below and include clinical data from the first three cohorts with follow-up from three to eighteen months based on data as of December 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">PBGM01 was well tolerated, with a positive safety profile, no serious adverse events, or SAEs, and all treatment-related adverse events, or AEs, were mild to moderate in severity.  There were no clinically significant changes in liver function requiring intervention and no evidence of peripheral nerve toxicity as measured by nerve conduction studies and neurological exam. There was also a favorable immunological profile with no evidence of an immune response requiring changes to the immunosuppression regimen. As anticipated, moderate levels of Nabs developed to capsid in blood and low levels of NAbs to capsid were also detected in CSF. No antibodies were detected to the transgene product in either the CSF or serum. There were also no complications related to the ICM administration.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">The six patients enrolled in Cohorts 1 to 3 ranged from 6 to 31 months of age at the time of PBGM01 administration. Across the first three cohorts, PBGM01 administration resulted in a dose-dependent increase in CSF &#946;-gal </span>activity with the high dose resulting in a 3.6-5.2x increase in CSF &#946;-gal activity relative to baseline, well above levels observed in the Natural History Study being conducted by the University of Pennsylvania ODC. In patient 1, who was observed with the longest follow-up, increased CSF &#946;-gal activity was sustained for 12 months. Sustained &#946;-gal enzyme expression was also observed in blood.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:279.85pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.25pt;">GM1 Cohorts 1-3 Interim CSF </b><b style="font-family:'Symbol';font-weight:bold;letter-spacing:0.25pt;">b</b><b style="font-weight:bold;letter-spacing:0.25pt;">-gal Enzyme Activity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><img src="pasg-20221231x10k007.jpg" alt="Graphic" style="display:inline-block;height:279.85pt;width:321.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><i style="font-style:italic;">NHS patient value range based on preliminary data from University of Pennsylvania&#8217;s ODC Natural History Study (NHS) (NCT04041102); Value range (0.3-1.81 nmol/mL/3hr, or nanomole per milliliter per 3 hours)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">To assess pharmacodynamic activity in the CNS associated with </span><span style="font-family:'Symbol';">b</span><span style="letter-spacing:0.25pt;">-gal activity, GM1 gangliosides levels were measured in the CSF. GM1 gangliosides are hypothesized to mediate CNS manifestation of disease. PBGM01 administration resulted in a dose-dependent decrease in CSF GM1 ganglioside levels for patients in the high dose cohort, showing decreases of up to 75% at six months. GM1 ganglioside levels in the CSF were unchanged following the administration for patients in the low dose cohort.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Clinical assessments include the Bayley III and Vineland II scales, performed by trained healthcare providers and the patients caregivers, respectively. The scales assess the developmental age of the child across a broad range of clinical parameters. The patients treated with PBGM01 exhibited a broad range of developmental age at baseline, as assessed with the Bayley III, as well a wide range of developmental delay, which is determined by the patients chronological age minus their developmental age. Two patients, patients 1 and 5, exhibited developmental delay of 2 and 5.5 months, respectively, which we have characterized as mild-to-moderate delay. The remaining patients exhibited developmental delay ranging from 12 to 24 months, which we have characterized as marked delay.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:189pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="pasg-20221231x10k008.jpg" alt="Graphic" style="display:inline-block;height:117.1pt;width:474.4pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="pasg-20221231x10k009.jpg" alt="Graphic" style="display:inline-block;height:36pt;width:142.25pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Following treatment with PBGM01, we observed that patients with a lower developmental delay at dosing experienced a better clinical response to treatment, regardless of dosage level. On both the Bayley III and the Vineland II, the two patients with mild-to-moderate developmental delay at baseline show improvement in their developmental age over time, which contrasts with the plateau and subsequent regression generally expected based on the natural history of the disease. The remaining patients with more marked developmental delay show stabilization or limited improvement. Based on this data, we believe that milder developmental delay at the time of dosing may be a determinant in treatment outcomes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:0.25pt;">Cohorts 1 &#8211; 3 Interim Clinical Results: Vineland-II and Bayley-III</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="pasg-20221231x10k010.jpg" alt="Graphic" style="display:inline-block;height:188.65pt;left:0%;padding-bottom:0.35pt;position:relative;top:0pt;width:481.95pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-style:italic;letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">*The Vineland-II is caretaker-assessed.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">**The Bayley-III is based on direct observation by a neurodevelopmental specialist.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treatment effects on brain volume and white matter integrity are being assessed using a MRI severity score, a novel scoring metric, for GM1 patients based on baseline and follow-up brain MRI scans. The MRI severity score is based on cerebral and cerebellar atrophy, abnormalities in white matter, and signal abnormalities in the basal ganglia and hippocampi, where higher scores indicate more structural damage. In a natural history study with six late infantile GM1 patients, the MRI severity score increased in the majority of patients over the follow up period of six months to four years, implying progression of structural damage. In contrast, PBGM01 administration was associated with stabilization of the MRI severity score over the follow up period of six to twelve months. While the PBGM01 data is for a shorter period of time than the natural history study data, we believe the initial trend observed, if continued, may be an important indicator of biological activity.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:196.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8195;<span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:0.25pt;">Cohorts 1 &#8211; 3 Interim MRI Results: MRI Severity Score</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:0.25pt;"><img src="pasg-20221231x10k011.jpg" alt="Graphic" style="display:inline-block;height:196.4pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:440.05pt;" /></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Initial biomarker and safety data from Cohort 4 are expected to be reported in the middle of 2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A key objective of the initial phase of the Imagine-1 trial is to determine the optimal dose for the confirmatory phase of the study. Based on the favorable safety profile of PBGM01 to date, the observed dose-response in key biomarkers, such as CSF <span style="font-family:'Symbol';">b</span>-gal activity and GM1 ganglioside levels, and that our preclinical studies showed no safety signals at doses higher than currently being evaluated in the ongoing clinical trial, we plan to treat additional patients in the Imagine-1 trial at higher doses of PBGM01 than the doses of PBGM01 administered to date in cohorts 1 to 4. Following regulatory review, we expect to dose the first patient at a higher dose of PBGM01 in the second half of 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Based on the available data in the Imagine-1 trial to date, we believe that patients with more limited developmental delay at the time of enrollment may have better outcomes. As we consider our pivotal trial design and potential modifications to the ongoing trial, we are revising inclusion criteria to maximize the benefit-risk profile of PBGM01.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">As our clinical data matures, we are planning for continued interactions with regulatory authorities to align on design of the confirmatory study and appropriate pathway to submission of a Biologics License Application, or BLA, and regulatory approval for commercialization in the United States and internationally.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Natural History Data</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We are currently funding a GM1 natural history study being conducted by Penn&#8217;s ODC to collect prospective data on clinical disease progression in infantile and juvenile GM1. This data, supplemented with data from retrospective studies, will be used to construct natural history patient profiles for comparison to the profiles of treated participants in our planned Phase&#160;1/2 clinical trial.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Regulatory Designations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">The FDA has granted ODD, RPDD, and Fast Track Designation to PBGM01 for the treatment of GM1. The European Commission has granted Orphan designation and Advanced Therapy Medicinal Product, or ATMP, designation for PBGM01. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Clinical Supply</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Through our manufacturing partners, we have manufactured the PBGM01 clinical supply and have established a clinical supply chain to support our ongoing clinical trial activities. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">FTD&#8212;PBFT02</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Overview of FTD-GRN</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">FTD is one of the more common causes of early-onset dementia, occurring with a median age of 55 years. FTD presents as a rapidly progressive clinical syndrome and causes impairment in behavior, language, and executive function. Changes in personal and social conduct occur in early stages of the disease, including loss of inhibition, apathy, social withdrawal, hyperorality and ritualistic compulsive behaviors. These symptoms are severely disabling and may lead to misdiagnosis as a psychological or emotionally based problem, or, in the elderly, be mistaken for withdrawal or eccentricity. FTD progresses to immobility and loss of speech and expression. Survival averages eight&#160;years after onset of symptoms.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">In approximately 5% to 10% of individuals with FTD, the disease is caused by mutations in the granulin, or </span><i style="font-style:italic;letter-spacing:0.25pt;">GRN,</i><span style="letter-spacing:0.25pt;"> gene, causing a deficiency of progranulin. PGRN is a complex and highly conserved protein thought to have multiple roles in cell biology, development and inflammation. Emerging evidence suggests that PGRN&#8217;s pathogenic contribution to FTD and other neurodegenerative disorders relates to a critical role in lysosomal function.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">There are no disease modifying therapies approved for the treatment of FTD. Anti-depressants have been shown to manage some behavioral symptoms. We engaged a third-party data-analytics firm to conduct an analysis of a variety of de-identified electronic medical records. Based on this analysis, we estimate the prevalence of FTD in the United States to be approximately 62,000. The prevalence of FTD due to </span><i style="font-style:italic;letter-spacing:0.25pt;">GRN</i><span style="letter-spacing:0.25pt;"> mutation found in literature is 5% to 10%. Accordingly, we estimate the prevalence of FTD-GRN deficiency in the United States to be approximately 3,000 to 6,000.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Program selection</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We chose FTD-GRN as one of our initial lead programs because it meets our criteria for rare, monogenic CNS disorders in which we believe we can develop product candidates with a higher probability of technical and regulatory success:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Cross-correction:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> Following treatment with PBFT02, overexpressing PGRN in a subset of cells in the CNS could provide a source of secreted protein that could be taken up by surrounding cells, resulting in the potential for cross-correction and broad restoration of neuronal lysosomal function across the entire brain.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Biomarkers:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> There are known biomarkers in FTD-GRN that are measurable and available to assist in drug development.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Pharmacodynamic biomarkers.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> PGRN is a secreted protein that can be measured in the CSF and plasma, and it has been shown to be reduced in the CSF of human </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">GRN</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> mutation carriers.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Disease progression biomarkers.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> We expect to be able to use recent progress in the identification of clinical disease progression biomarkers for FTD, including CSF, neuroimaging and retinal biomarkers, to facilitate clinical development by enabling early detection of treatment effects on disease pathophysiology.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:8pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Preclinical Validation:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> In our preclinical studies in </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">GRN</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;"> knockout mice, or </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;letter-spacing:0.25pt;">GRN -/- </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">mice, ICV administration of PBFT02 resulted in increased levels of PGRN in the CNS and CSF, with resolution of lysosomal storage pathology. ICM administration in NHPs, which do not have the disease phenotype, resulted in robust increases in PGRN levels in CNS and CSF.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:189pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Our Product Candidate</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We are developing PBFT02 to treat patients affected with FTD-GRN with a single dose of PBFT02 by ICM administration. PBFT02 is a gene therapy that utilizes an AAV1 viral vector to deliver a modified DNA encoding the </span><i style="font-style:italic;letter-spacing:0.25pt;">GRN</i><span style="letter-spacing:0.25pt;"> gene to a patient&#8217;s cells. The goal of this vector and delivery approach is to provide higher than normal levels of PGRN to the CNS to overcome the progranulin deficiency in </span><i style="font-style:italic;letter-spacing:0.25pt;">GRN</i><span style="letter-spacing:0.25pt;"> mutation carriers, who have been observed to have reduced CSF PGRN levels ranging from 30% to 50% of the PGRN levels observed in normal, mutation non-carriers. We selected the AAV1 capsid and ICM administration route due to the widespread and robust expression of the human PGRN transgene observed throughout the brain and spinal cord in NHP studies. Following AAV1 administration in NHP levels of human PGRN in the CSF achieved supraphysiologic levels compared to those measured in healthy human CSF and exceeded</span> <span style="letter-spacing:0.25pt;">PGRN levels observed in NHPs that received AAV5 or AAVhu68 serotypes by greater than 5 times. </span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Preclinical studies</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">PBFT02 was selected as our development candidate following a study in adult NHPs which evaluated the expression of human PGRN protein in the CSF after ICM administration of four different vector constructs. The AAV1 vector construct produced supraphysiological levels of PGRN and greater than 5 times higher than the other vectors tested, as shown below. ICM AAV1 did not strongly transduce the liver or significantly elevate levels of circulating PGRN, which may reduce the potential for unknown peripheral effects of PGRN. Proof of concept findings were published by GTP in 2020. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comparison of Vector Serotypes:</b> <b style="font-weight:bold;">Production of Human PGRN-protein in CSF of NHPs following ICM-AAV administration.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><img src="pasg-20221231x10k012.jpg" alt="Graphic" style="display:inline-block;height:188.65pt;left:0%;padding-bottom:0.35pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk96012713"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The efficacy of the AAV1 vector was assayed in a dose-ranging study in <i style="font-style:italic;">GRN -/-</i> mice. PBFT02 was administered via ICV delivery to adult mice at an age when lipofuscin deposition (a marker of lysosomal dysfunction), lysosomal enzyme abnormalities, and neuroinflammation were present in brain regions involved in FTD-GRN pathophysiology. Human PGRN expression in the CSF increased in a dose-dependent manner following PBFT02 administration. Transgene expression led to improvements in histopathologic and enzymatic changes in key brain regions in the mice, including a reduction in the accumulation of lipofuscin and reduced neuroinflammation (as shown in below figure), and elevated lysosomal hexosaminidase activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:247.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="pasg-20221231x10k013.jpg" alt="Graphic" style="display:inline-block;height:247.1pt;left:0%;padding-bottom:0.4pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">NHP Toxicology Study </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_Hlk96589806"></a><a id="_Hlk96589261"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">A 90-day GLP compliant toxicology study conducted in NHPs assessed the safety, tolerability, biodistribution and excretion profile of PBFT02 following ICM administration at three dose levels. There were no blood or CSF abnormalities related to PBFT02 administration except for asymptomatic, mild, and transient increases in CSF leukocytes in the majority of animals</span><span style="letter-spacing:0.25pt;">. </span><span style="letter-spacing:0.25pt;">PBFT02 was well-tolerated at all doses evaluated and no adverse effects were detected on body weight or clinical, neurological, or behavioral signs. Vector distributed to the CSF and high levels of gene transfer were detected in the brain, spinal cord and DRG at Day 90. The quantity of vector genomes detected in CNS tissues was generally dose-dependent. PBFT02 also reached significant concentrations in the peripheral blood, liver and spleen. PBFT02 </span><span style="letter-spacing:0.25pt;">vector DNA was detectable in urine and feces 5&#160;days post-administration and was undetectable within 60&#160;days. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Human PGRN was detectable in CSF and serum in all animals by 7 to 14&#160;days after PBFT02 administration, peaking between Days 14 to 28. Responses were generally dose dependent and resulted in supraphysiologic PGRN levels after the 2 highest doses. Expression declined by Day 60, correlating with the appearance of antibodies against the human transgene product, which are not expected to develop in haploinsufficient patients with FTD-GRN. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Mild to minimal grade transient degeneration of DRGs and TRGs, and associated sensory nerve axonopathy, were observed in all PBFT02 dose groups. These histopathologic observations were not linked with any clinical or neurological abnormalities in any animals up to 90 days&#8217; post-dose. One PBFT02-treated animal exhibited a peripheral nerve conduction impairment in the median nerve, as detected by bilateral reductions in sensory nerve action potential, or SNAP, amplitudes on Day 28 and Day 90, that appeared to be treatment related as severe axon loss and endoneurial fibrosis were detected at necropsy. PBFT02-induced SNAP changes and sensory neuron degeneration were not associated with any clinical or neurological abnormalities in</span> <span style="letter-spacing:0.25pt;">any animals up to 90 days post-dose.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">In summary, our preclinical studies demonstrated that CSF delivery of PBFT02 has the potential to safely increase extracellular PGRN levels in the CNS up to supraphysiologic levels and has the potential to improve histopathologic and enzymatic changes in key brain regions associated with FTD.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Clinical development</i><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Our clinical development plan is to treat FTD-GRN with a single dose of PBFT02 via ICM administration, with our initial clinical trial focused on early symptomatic FTD patients who have the </span><i style="font-style:italic;letter-spacing:0.25pt;">GRN</i><span style="letter-spacing:0.25pt;"> mutation.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">&#8203;<span style="letter-spacing:0.25pt;">This trial is expected to be a two-cohort dose-escalation trial, with three subjects per cohort, and with a potential for a third higher-dose cohort,</span> if considered necessary based on the results of the first two cohorts<span style="letter-spacing:0.25pt;">. The planned starting dose </span>(3.3x10&#708;10 genome copies/gm brain weight) <span style="letter-spacing:0.25pt;">will exceed the MED in the </span><i style="font-style:italic;letter-spacing:0.25pt;">GRN</i><span style="letter-spacing:0.25pt;"> knockout mouse model, with planned escalation to a higher dose </span>(1.1x10&#708;11 genome copies/gm brain weight)<span style="letter-spacing:0.25pt;">. The primary endpoint of the trial is to assess safety and tolerability over 60 months.</span> <span style="letter-spacing:0.25pt;">To better understand the clinical significance of the peripheral nerve findings in NHPs, we implemented clinical monitoring in our uplift-D interventional trial, consisting of both nerve conduction studies and neurological exams focused on sensory and peripheral nerve function. Secondary endpoints are to assess change from baseline to 24 months on biomarkers, including CSF and plasma progranulin levels, biomarkers of neurodegeneration and disease progression, and on clinical outcomes as measured by the Clinical Dementia Rating, or CDR, for improving evaluation of patients with frontotemporal lobar degeneration, or FTLD, or CDR</span><sup style="font-size:7.5pt;letter-spacing:0.25pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="letter-spacing:0.25pt;">, plus NACC FTLD, and other neurocognitive assessments. Interim analyses are planned for certain biomarkers starting at one month post dosing and for clinical outcomes beginning at one year post dosing. The independent data monitoring committee, or IDMC, will review 30-day biomarker data and safety data for each subject in a cohort. All subjects will be followed for a total of five years to monitor safety and selected biomarker and efficacy measures. All subjects will be evaluated over two&#160;years for safety and efficacy, followed by an additional 36&#160;months of long-term follow up.</span><span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">A scientific advice meeting with MHRA was held in November&#160;2020, providing feedback on our proposed protocol. Feedback was also obtained from other regulatory agencies outside the United States.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.2pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">In August 2022, we dosed the first patient in our upliFT-D trial. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">We expect to report initial safety and biomarker data from patients in Cohort 1 in the second half of 2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Depending on the results from the initial cohorts, we plan to obtain input from regulatory agencies on the requirements to submit for regulatory approval for commercialization in the United States and internationally.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;letter-spacing:0.3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.3pt;">Regulatory designations and Clinical Trial Approvals</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have an active IND from the FDA and approved CTAs in multiple countries for PBFT02, which allows us to proceed with our upliFT-D Trial, an international, multi-center, open-label, single-arm Phase 1/2 clinical trial of PBFT02 in patients with a diagnosis of early symptomatic FTD-GRN. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">The FDA has granted ODD and Fast Track Designation to PBFT02 for the treatment of FTD-GRN and the European Commission granted Orphan designation for PBFT02. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Clinical Supply</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">Through our manufacturing partners, we have manufactured the PBFT02 clinical supply to support ongoing clinical trial activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Other Research Programs</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We have two additional programs in candidate selection or discovery stages of preclinical research, in collaboration with GTP. These include PBAL05 for ALS and our unnamed program for Huntington&#8217;s disease.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Overview of C9orf72 ALS - PBAL05</i><i style="font-style:italic;letter-spacing:0.25pt;"> </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C9orf72-mediated Amyotrophic Lateral Sclerosis, or C9orf72 <span style="letter-spacing:0.25pt;">ALS, is an adult-onset, rapidly progressing neurodegenerative disease characterized by dysfunction and death of upper and lower motor neurons leading to progressive weakness, loss of motor function, and death typically within three to five years of disease onset. Most cases of ALS are sporadic with an unknown etiology, but approximately 10% of patients have autosomal </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">dominantly inherited forms. We are focusing on C9orf72-mediated ALS, since mutations in the </span><i style="font-style:italic;letter-spacing:0.25pt;">C9orf72</i><span style="letter-spacing:0.25pt;"> gene are the most common mutation found in ALS patients including both familial (approximately 40% of familial ALS cases) and sporadic ALS cases (approximately 8% of sporadic ALS patients carry C9orf72 mutations), accounting for approximately 11% of all ALS cases. In 2021, the total number of prevalent C9orf72 ALS cases was estimated to be approximately 4,500 worldwide. In these cases, the disease is caused by a hexanucleotide repeat expansion in the first intron of C9orf72. The pathogenic mechanism of C9orf72 mutations is not yet proven, but three potential mechanisms predominate, which are toxic gain of function arising from deposition of transcribed atypical dipepetide repeat proteins, and/or deposition of mutant ribonucleic acid, or RNA, and/or loss of function of endogenous proteins.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Our approach is to use a single AAV vector to deliver a miRNA and a codon-optimized miRNA-resistant C9orf72 transgene combination, to both deplete normal and mutant mRNA within cells with the miRNA and to replace with functional wildtype human transgene. This program is currently at the discovery stage.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Unnamed Research Program</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">With GTP we have one additional specified research program, to develop a genetic medicine to treat Huntington&#8217;s disease. This program, initiated in 2021, is currently in the discovery stage. Beyond this portfolio, through our research collaboration with GTP, we also have the option to license programs for eight additional indications.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Exploratory Research Program</i><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We have an exploratory research program with GTP with the goal of developing genetic medicines for non-rare CNS disorders. The program is currently focused on treatment-resistant TLE, and can be expanded to other large CNS diseases upon mutual agreement with GTP.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Manufacturing</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Gene therapy manufacturing is a critical factor in the successful development and commercialization of novel genetic medicines, and to that end, we have established internal CMC capabilities to support our vector manufacturing and production platform and we have a relationship with Catalent, a contract development and manufacturing organization, or CDMO, for our initial manufacturing needs.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We utilize a production platform approach with HEK293 mammalian cells as the substrate, triple plasmid transient transfection and single-use fixed-bed iCELLis&#174; bioreactor system for the manufacture of our AAV product candidates. We are using a well-characterized production platform that has been used for both commercial and clinical AAV products and product candidates. We believe our approach will enable rapid development, control of product quality and regulatory compliance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;white-space:pre-wrap;">We have invested significantly in our internal laboratory capabilities and infrastructure to support the manufacturing of our clinical product candidates. Our in-house laboratory is equipped with state-of-the-art analytical and process development capabilities to support and enhance our viral vector manufacturing platform.  We have developed the internal technical and scientific capability along with the manufacturing and quality expertise to develop, transfer, and oversee vector production systems externally at commercial scale. We believe our capabilities provide a core strategic advantage and position us to be a leading drug development company to address CNS disorders. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">GTP currently provides us with the preclinical and toxicology research-grade vector supplies, while Catalent provides us with the cGMP AAV clinical supplies for our clinical trials. The production process for our two lead clinical stage product candidates, PBGM01 and PBFT02, and for the two clinical stage product candidates for which we have stopped clinical development, PBKR03 and PBML04, has been scaled up to GMP standards at Catalent&#8217;s facility. Clinical materials for these candidates have been manufactured.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We have a collaboration agreement with Catalent, or the Collaboration Agreement, </span>that gives us access to a cGMP manufacturing suite<span style="letter-spacing:0.25pt;">. Access to cGMP manufacturing capacity gives us the ability to meet production requirements for our current clinical product candidates supporting current and future clinical trials. We also have a development services and clinical supply agreement, or the Manufacturing and Supply Agreement, with Catalent to support clinical scale manufacturing for our gene therapy product candidates. </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We entered into a lease to support chemistry, manufacturing and controls laboratory operations for our gene therapy programs, which commenced in March 2021, in the Princeton West Innovation Campus. In 2021, we completed our build out of this new laboratory that is initially focused on state-of-the-art analytical capabilities, assay development and validation, and clinical product testing to support both viral vector manufacturing and clinical development.</span><span style="letter-spacing:0.2pt;"> Since then, we have been able to internalize all major CMC laboratory capabilities, including process development, which will enable late-stage development and commercialization of our gene therapies. We have advanced our manufacturing platform which can be leveraged across our clinical and pre-clinical pipeline through standardization of our manufacturing and analytical technologies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We believe that our manufacturing capabilities provide us with the advantages of better control of drug development timelines, improved control of vector supply for a portfolio of clinical assets and improved control of product quality through the improvements of the manufacturing platform.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We also anticipate that we will continue to make significant investments to further optimize our manufacturing capabilities and platforms to produce high-quality, cost-effective AAV vectors and we will continue to make investments in process and analytical sciences, internally or with third parties, to evaluate and develop manufacturing process improvements that may increase the productivity and efficiency of our manufacturing platform processes.</span><span style="letter-spacing:0.2pt;"> </span></p><a id="_Hlk92891219"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Competition</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The biotechnology and pharmaceutical industries, including the genetic medicines field, are characterized by rapidly changing technologies, competition and a strong emphasis on intellectual property. We are aware of several companies focused on developing gene therapies in various indications as well as several companies addressing methods for modifying genes and regulating gene expression. We may also face competition from large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions with genetic medicine and other therapeutic approaches.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We consider our most direct competitors with respect to PBGM01 for the treatment of GM1 to be Lysogene, S.A, or Lysogene, which is developing a gene therapy treatment administered via intracisternal magna for early and late infantile GM1. As of February 2022, Lysogene reported having dosed three patients and enrolled a fourth patient in the safety cohort. The National Institutes of Health is conducting a clinical trial for an IV gene therapy treatment for early and late infantile/juvenile GM1 and reported data from ten patients in October 2021. There are also preclinical enzyme replacement therapies in preclinical development. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We consider our most direct competitors with respect to PBFT02 for the treatment of FTD-GRN to be Alector, Inc. (partnered with GlaxoSmithKline), which is enrolling a Phase 3 clinical trial with a humanized anti-human sortilin monoclonal antibody for FTD-GRN, and Prevail Therapeutics Inc. (now part of Eli Lilly &amp; Co), which has initiated a Phase 1/2 clinical trial for a gene therapy treatment for FTD-GRN, and is expected to continue enrolling through 2023. Several other companies, including AviadoBio Ltd, Applied Genetic Technologies Corporation (recently acquired by Syncona Limited), and Orchard Therapeutics plc, are conducting preclinical research using gene therapy approaches to treat FTD-GRN patients. AviadoBio Ltd has reported the planned initiation of a phase 1/2 trial in 2023. Denali Therapeutics Inc. in partnership with Takeda Pharmaceutical Company Limited has a preclinical recombinant progranulin protein under evaluation in addition to their oral EIF2a modulator in a Phase 1 clinical trial. We are also aware of other therapeutic approaches in preclinical development that may target FTD-GRN patients.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Many of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical and other resources than we do, such as larger research and development, clinical, marketing and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of competitors. Our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any product candidates that we may develop. Competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market, if ever. Additionally, new or advanced technologies </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">developed by our competitors may render our current or future product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">License Agreement</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">University of Pennsylvania</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">We have a research, collaboration and licensing agreement, as amended, or the Penn Agreement, with Penn, for research and development collaborations and exclusive license rights to patents for certain products and technologies. Under the Penn Agreement, we have the obligation to fund certain research relating to the preclinical development of selected products in research programs as well as the new exploratory research program in non-rare and/or non-monogenic, or large, CNS indications, initially TLE. We also fund discovery research conducted by Penn through August 2026 and will receive exclusive rights, subject to certain limitations, to technologies resulting from the discovery program for products developed with GTP, such as novel capsids, toxicity reduction technologies and delivery and formulation improvements. Our discovery research funding commitment is $5.0 million a year for five years, with quarterly payments of $1.3 million through June 2026. Under the Penn Agreement we have eight remaining options available to us to commence additional licensed programs for CNS indications until August 2026. If we were to exercise any of these remaining options, we would owe Penn a non-refundable aggregate fee of $1.0&#160;million, with $0.5 million per product indication paid immediately and another $0.5 million fee owed upon a further developmental milestone.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.25pt;">The Penn Agreement requires that we make payments of up to (i) $16.5&#160;million per product candidate for rare, monogenic disorders in aggregate and (ii) $39.0 million per product candidate in the aggregate arising from the exploratory program for large CNS indications, currently TLE and such other mutually agreed upon large CNS indications. Each payment will be due upon the achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and no development milestone payments for subsequent indications. In addition, on a product-by-product basis, we are obligated to make up to $55.0&#160;million in sales milestone payments on each licensed product based on annual sales of the licensed product in excess of defined thresholds. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Upon successful commercialization of a product using the licensed technology, we are obligated to pay to Penn, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits on annual worldwide net sales of such licensed product. In addition, we are obligated to pay to Penn a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Penn Agreement. The agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i)&#160;the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such licensed product in such country, and (ii)&#160;the expiration of the royalty period. At any time after August&#160;2026, we may terminate the agreement in its entirety, or for a licensed product, for convenience upon 90&#160;</span><span style="letter-spacing:0.25pt;white-space:pre-wrap;">days&#8217; prior written notice to Penn. Penn may terminate the agreement on an indication-by-indication basis if we fail to meet any diligence event and fail to timely cure such breach, or the agreement in its entirety if we fail to pay the research funding, fail to comply with applicable laws, grant a security interest in any of the licensed patent rights, fail to achieve certain financing obligations, or make certain challenges to the licensed patent rights. Either party may terminate the agreement for the other party&#8217;s insolvency or material breach that is not cured within a specified period of time.  In addition, we will pay Penn a tiered transaction fee ranging from 1-2% of the net proceeds upon certain change of control events.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">The Penn Agreement includes an exploratory research collaboration to identify targets and early product candidates in such large CNS indications. The exploratory research program is focused on discovering targets and novel gene therapy candidates for large CNS diseases, currently focused on TLE, and that can be expanded to other large CNS diseases upon mutual agreement. The initial term of the exploratory research program is 3 years, or until August 2024, which term can be extended by mutual agreement. During such term we will have an exclusive right of first negotiation to include additional targets to the exploratory research program in the agreed upon large CNS indications. Under the exploratory research program, we will have the right to further develop and commercialize any gene therapy product candidates specific for those selected targets within TLE (and any future large CNS indications that are mutually agreed upon) that arise from the exploratory research programs on </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">substantially the same terms of the current Penn Agreement. </span>In November 2022, we agreed with GTP to not continue further advancement of our exploratory research program in AD.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Penn will notify us of any patented manufacturing methods developed by GTP during the specified research term, and we have the option to obtain a non-exclusive license under those patent rights controlled by Penn for our licensed products. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">On a CNS indication-by-indication basis, Penn has agreed that GTP will not collaborate with any commercial third party to develop another gene therapy product for the same indication during, or for one year following, its work for us on a given indication and licensed product. Under the licensed Penn patent rights, Penn retains the right to conduct (and to authorize non-commercial third parties to conduct) certain educational, research, clinical and patient care activities. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Under the Penn Agreement, we are obligated to use commercially reasonable efforts to develop, obtain regulatory approval for, and commercialize at least one licensed product for each of the licensed indications for prophylactic, diagnostic and therapeutic uses in humans. We may satisfy this obligation by achieving, for each licensed product, certain diligence events by a specified achievement date, which dates may be extended under certain circumstances. Pursuant to the agreement, Penn will be responsible for preclinical development activities, including all IND-enabling non-clinical studies and research grade manufacturing, and other collaborative activities set forth in the plan for the funded research, and we will be responsible for regulatory strategy and operations, clinical development, GMP manufacture and commercialization of all licensed products. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Intellectual Property</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Our commercial success depends in part on our ability to obtain and maintain proprietary and/or intellectual property protection in the United States and other countries for our current product candidates and future products, as well as our core technologies, including our manufacturing know-how. We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of our business by seeking, maintaining and defending our intellectual property, whether developed internally or licensed from third parties. We also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of gene therapy. Additionally, we intend to rely on regulatory protection afforded through rare drug designations, data exclusivity and market exclusivity as well as patent term extensions, where available.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;white-space:pre-wrap;">Currently, our patent protection consists of patent applications that we have in-licensed from Penn under the Penn Agreement for our product candidates in our licensed indications and a patent application that we filed and solely own related to a process for manufacturing our products.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The in-licensed patent applications are directed to new AAV capsids and certain defined variants, to recombinant AAV viruses, or rAAVs, capable of delivering certain genes into human cells to treat monogenic diseases of the CNS, to methods of treating those monogenic diseases with rAAV, as well as certain aspects of our manufacturing capabilities and related technologies. Our in-licensed patent portfolio currently includes:</span><span style="letter-spacing:0.2pt;"> </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">a patent family with applications pending in the United States and certain foreign jurisdictions with claims directed to rAAVs having an AAVhu68 capsid. We exclusively licensed the patent family for licensed products within our rare, monogenic field of use indications. Any patents that may issue from applications in this family are expected to expire on February&#160;27, 2038, absent any term adjustments or extensions;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">two patent families with claims directed to an rAAV containing a coding sequence of human &#946;-gal for use in treating GM1. The first patent family includes pending applications in fourteen jurisdictions, including the U.S., Argentina, Brazil, Canada, China, Europe, Israel, Japan, and Korea. Any patents that may issue from applications in this family are expected to expire on September&#160;30, 2039, absent any term adjustments or extensions. The second patent family includes applications pending in</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">sixteen jurisdictions, including the U.S., Argentina, Brazil, Canada, China, Europe, Israel, Japan, and Korea. Any patents that may issue from applications in this family are expected to expire on February&#160;1, 2041, absent any term adjustments or extensions;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8203;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:8pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">two patent families with claims directed to rAAV for use in treating FTD. The first patent family includes applications pending in fifteen jurisdictions, including the US, Argentina Brazil, Canada, China, Europe, Israel, Japan, and Korea. Any patents that may issue from applications in this family are expected to expire on February&#160;21, 2040, absent any term adjustments or extensions. The second patent family includes applications in Argentina and Taiwan and a pending PCT application. Any patents that may issue from applications in this family are expected to expire on August 26, 2041; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;letter-spacing:0.25pt;">one patent family with claims directed to rAAV for use in treating ALS. The patent family includes applications pending in Argentina and Taiwan and a pending PCT application. Any patents that may issue from applications in this family are expected to expire on January 10, 2043, absent any term adjustments or extensions.</span></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We also have options under the Penn Agreement to add additional intellectual property to our existing license, as described in the section &#8220;License Agreement&#8221;.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The term of individual patents may vary based on the countries in which they are obtained. Generally, patents issued from applications filed in the United States are effective for 20&#160;years from the earliest effective non-provisional filing date. In addition, in certain instances, a patent term can be extended to recapture a portion of the term effectively lost as a result of FDA regulatory review period. The restoration period cannot be longer than five&#160;years and the total patent term, including the restoration period, must not exceed 14&#160;years following FDA approval. The duration of patents outside of the United States varies in accordance with provisions of applicable local law, but typically is also 20&#160;years from the earliest effective national filing date.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">In addition to patents and patent applications that we license, we rely on trade secrets and know-how to develop and maintain our competitive position. For example, significant aspects of our AAV manufacturing capabilities and gene therapy technology are based upon trade secrets and know-how. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, and obtain and maintain control and/or ownership of certain technologies, in part, through confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and commercial partners. We also seek to preserve the integrity and confidentiality of our data, trade secrets and know-how, including by implementing measures intended to maintain the physical security of our premises and the physical and electronic security of our information technology systems.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Our ability to stop third parties from making, using, selling, offering to sell or importing our products may depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities. With respect to our licensed intellectual property, we cannot be sure that patents will issue with respect to any of the pending patent applications to which we license rights or with respect to any patent applications that we or our licensors may file in the future, nor can we be sure that any of our licensed patents or any patents that may be issued in the future to us or our licensors will be commercially useful in protecting our product candidates and methods of manufacturing the same. Moreover, we may be unable to obtain patent protection for certain of our product candidates generally, as well as with respect to certain indications. See the section entitled &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property&#8221; for a more comprehensive description of risks related to our intellectual property.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Government Regulation and Product Approval</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">FDA Approval Process</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Biological products used for the prevention, treatment, or cure of a disease or </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">condition of a human being are subject to regulation under the FDC Act, except the section of the FDC Act which governs the approval of New Drug Applications, or NDAs. Biological products, such as gene therapy products, are approved for marketing under provisions of the Public Health Service Act, or PHSA, via a BLA. However, the application process and requirements for approval of BLAs are very similar to those for NDAs. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as clinical hold, FDA refusal to file NDA/BLAs and to approve pending NDAs or BLAs, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Biological product development for a new product or certain changes to an approved product in the United States typically involves preclinical laboratory and animal tests, the submission to the FDA of an IND which must become effective before clinical testing may commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements typically takes many&#160;years and the actual time required may vary substantially based upon the type, complexity, and novelty of the product or disease.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Preclinical tests include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal studies to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including Good Laboratory Practices. The results of preclinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long-term preclinical tests, such as tests of reproductive toxicity and carcinogenicity in animals, may continue after the IND is submitted. A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin. Clinical trials involve the administration of the investigational biologic to subjects, including healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted: (i)&#160;in compliance with federal regulations; (ii)&#160;in compliance with Good Clinical Practice, or GCP, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors; as well as (iii)&#160;under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. subjects and subsequent protocol amendments must be submitted to the FDA as part of the IND.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The FDA may order the temporary or permanent discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA regulations or presents an unacceptable risk to the clinical trial subjects. The trial protocol and informed consent information for subjects in clinical trials must also be submitted to an institutional review board, or IRB, for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements, or may impose other conditions if it believes that the subjects are subject to unacceptable risk.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Clinical trials to support BLAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap. In Phase&#160;1, the initial introduction of the biologic into subjects, the product is tested to assess safety, dosage tolerance, metabolism, pharmacokinetics, pharmacological actions, side effects associated with drug exposure, and to obtain early evidence of a treatment effect if possible. Phase&#160;2 usually involves trials in a limited patient population to determine the effectiveness of the drug or biologic for a particular indication, determine optimal dose and regimen, and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase&#160;2 evaluations, generally Phase&#160;3 trials are undertaken to obtain additional information about clinical effects and confirm efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug or biologic and to provide adequate information for the labeling of the product. In most cases, the FDA requires two adequate and well-controlled Phase&#160;3 clinical trials to demonstrate the safety and efficacy of the drug or biologic. </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">In addition, the manufacturer of an investigational drug in a Phase&#160;2 or Phase&#160;3 clinical trial for a serious or life-threatening disease is required to make available, such as by posting on its website, its policy on evaluating and responding to requests for expanded access to such investigational drug.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">After completion of the required clinical testing, a BLA is prepared and submitted to the FDA. FDA approval of the BLA is required before marketing and distribution of the product may begin in the United States. The BLA must include the results of preclinical, clinical, and other testing and a compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture, and controls. The cost of preparing and submitting a BLA is substantial. The submission of most BLAs is additionally subject to a substantial application user fee. Under an approved BLA, the applicant is also subject to an annual program fee. These fees typically increase annually. A BLA for a drug that has been designated as an orphan drug is not subject to an application fee, unless the BLA includes an indication for other than a rare disease or condition. The FDA has 60&#160;days from its receipt of a BLA to determine whether the application will be accepted for filing based on the Agency&#8217;s determination that it is adequately organized and sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals to complete the review of BLAs. Most applications are classified as Standard Review products that are reviewed within ten&#160;months of the date the FDA accepts the BLA for filing; applications classified as Priority Review are reviewed within six&#160;months of the date the FDA accepts the BLA for filing. A BLA can be classified for Priority Review when the FDA determines the biologic product has the potential to treat a serious or life-threatening condition and, if approved, would be a significant improvement in safety or effectiveness compared to available therapies. The review process for both standard and priority reviews may be extended by the FDA for three or more additional&#160;months to consider certain late-submitted information, or information intended to clarify information already provided in the BLA submission.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The FDA may also refer applications for novel biologic products, or biologic products that present difficult questions of safety or efficacy, to be reviewed by an advisory committee&#8212;typically a panel that includes clinicians, statisticians and other experts&#8212;for review, evaluation, and a recommendation as to whether the BLA should be approved. The FDA is not bound by the recommendation of an advisory committee, but generally follows such recommendations. Before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the biologic product is manufactured. The FDA will not approve the product unless compliance with cGMPs is satisfactory and the BLA contains data that provide substantial evidence that the biologic is safe, pure, potent and effective in the claimed indication.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">After the FDA evaluates the BLA and completes any clinical and manufacturing site inspections, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the BLA submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application for approval. If, or when, those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six&#160;months depending on the type of information included. An approval letter authorizes commercial marketing and distribution of the biologic with specific prescribing information for specific indications. As a condition of BLA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the biologic outweigh the potential risks to patients. A REMS can include medication guides, communication plans for healthcare professionals, and elements to assure a product&#8217;s safe use, or ETASU. An ETASU can include, but is not limited to, special training or certification for prescribing or dispensing the product, dispensing the product only under certain circumstances, special monitoring, and the use of patient-specific registries. The requirement for a REMS can materially affect the potential market and profitability of the product. Moreover, the FDA may require substantial post-approval testing and surveillance to monitor the product&#8217;s safety or efficacy.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing. Changes to some of the conditions established in an approved BLA, including changes in indications, product labeling, manufacturing processes or facilities, require submission and FDA approval of a new BLA or BLA supplement before the change can be implemented. A BLA </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Additional Standard for Gene Therapy Products</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">In addition to the regulations discussed above, there are a number of additional standards that apply to clinical trials involving the use of gene therapy. FDA has issued various guidance documents regarding gene therapies, which outline additional factors that FDA will consider at each of the above stages of development and relate to, among other things: the proper preclinical assessment of gene therapies; the CMC information that should be included in an IND application; the proper design of tests to measure product potency in support of an IND or BLA application; and measures to observe delayed adverse effects in subjects who have been exposed to investigational gene therapies when the risk of such effects is high. For instance, FDA usually recommends that sponsors observe all surviving subjects who receive treatment using gene therapies that are based on adeno-associated virus vectors in clinical trials for potential gene therapy-related delayed adverse events for a minimum 5-year period. FDA does not require the long-term tracking to be complete prior to its review of the BLA.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Orphan Drug Designation</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Under the Orphan Drug Act, the FDA may grant Orphan Drug Designation to biological products intended to treat a rare disease or condition&#8212;generally a disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making a product available in the United States for such disease or condition will be recovered from sales of the product. Orphan Drug Designation must be requested before submitting a BLA. After the FDA grants Orphan Drug Designation, the identity of the biological product and its potential orphan disease use are disclosed publicly by the FDA. Orphan Drug Designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The first BLA applicant to receive FDA approval for a particular active moiety to treat a particular disease with FDA Orphan Drug Designation is entitled to a seven-year exclusive marketing period in the United States for that product in the approved indication. For large molecule drugs, including gene therapies, sameness is determined based on the principal molecular structural features of a product. As applied to gene therapies, the FDA has recently issued final guidance in which it stated it generally intends to consider certain key features, such as the transgenes expressed by the gene therapy and the vectors used to deliver the transgene, to be principal molecular structural features. With regard to vectors, the FDA generally intends to consider whether two vectors from the same viral class are the same or different on a case-by-case basis. The FDA does not intend to consider minor differences between transgenes and vectors to be different principal molecular structural features. When two gene therapy products express the same transgene and have or use the same vector, determining whether two gene therapies are the same drug may also depend on additional features of the final gene therapy product, such as regulatory elements and the cell type that is transduced (for genetically modified cells). In such cases, the FDA generally intends to determine whether two gene therapy products are different on a case-by-case basis. During the seven-year marketing exclusivity period, the FDA may not approve any other applications to market a biological product containing the same principal molecular structural features for the same indication, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. A product can be considered clinically superior if it is safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biological product for the same disease or condition, or the same biological product for a different disease or condition. Among the other benefits of Orphan Drug Designation are tax credits for certain research and a waiver of the BLA user fee.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Rare Pediatric Disease Priority Review Voucher Program</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Under the Rare Pediatric Disease Priority Review Voucher program, the FDA may award a priority review voucher to the sponsor of an approved marketing application for a product that treats or prevents a rare pediatric disease. The voucher entitles the sponsor to priority review of one subsequent marketing application. A voucher may be awarded only for an approved rare pediatric disease product application. A rare pediatric disease product application is an NDA or BLA for a product that treats or prevents a serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18&#160;years; in general, the disease must affect fewer than 200,000 such individuals in the U.S.; the NDA or BLA must be deemed </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">eligible for priority review; the NDA or BLA must not seek approval for a different adult indication (i.e., for a different disease/condition); the product must not contain an active ingredient that has been previously approved by the FDA; and the NDA or BLA must rely on clinical data derived from studies examining a pediatric population such that the approved product can be adequately labeled for the pediatric population. Before NDA or BLA approval, the FDA may designate a product in development as a product for a rare pediatric disease.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">To receive a rare pediatric disease priority review voucher, a sponsor must notify the FDA, upon submission of the NDA or BLA, of its intent to request a voucher. If the FDA determines that the NDA or BLA is a rare pediatric disease product application, and if the NDA or BLA is approved, the FDA will award the sponsor of the NDA or BLA a voucher upon approval of the NDA or BLA. The FDA may revoke a rare pediatric disease priority review voucher if the product for which it was awarded is not marketed in the U.S. within 365&#160;days of the product&#8217;s approval. The voucher, which is transferable to another sponsor, may be submitted with a subsequent NDA or BLA and entitles the holder to priority review of the accompanying NDA or BLA. The sponsor submitting the priority review voucher must notify the FDA of its intent to submit the voucher with the NDA or BLA at least 90&#160;days prior to submission of the NDA or BLA and must pay a priority review user fee in addition to any other required user fee. The FDA must take action on an NDA or BLA under priority review within six&#160;months of receipt of the NDA or BLA.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">On December 27, 2020, the Rare Pediatric Disease Priority Review Voucher program was reauthorized as part of the Consolidated Appropriations Act, 2021 allowing a product that is designated as a product for a rare pediatric disease prior to September 30, 2024 to be eligible to receive a rare pediatric disease priority review voucher upon approval of a qualifying NDA or BLA prior to September 30, 2026. It is unclear whether this program will continue to be reauthorized beyond the current sunset date in September 2024.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Fast Track Designation and Priority Review</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The FDA is required to facilitate the development, and expedite the review, of drugs that are intended for the treatment of a serious or life-threatening disease or condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. Fast track Designation may be granted for products that are intended to treat a serious or life-threatening disease or condition for which there is no effective treatment and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track Designation applies to both the product and the specific indication for which it is being studied. Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Priority review may be granted for products that are intended to treat a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application designated for priority review in an effort to facilitate the review.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Disclosure of Clinical Trial Information</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Sponsors of clinical trials of FDA-regulated products, including biological products, are required to register and disclose certain clinical trial information on the website www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators, and other aspects of a clinical trial are then made public as part of the registration. Sponsors are also obligated to disclose the results of their clinical trials after completion. Disclosure of the results of clinical trials can be delayed in certain circumstances for up to two&#160;years after the date of completion of the trial. Competitors may use this publicly available information to gain knowledge regarding the progress of clinical development programs as well as clinical trial design.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Pediatric Information</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Under the Pediatric Research Equity Act, or PREA, NDAs or BLAs or supplements to NDAs or BLAs must contain data to assess the safety and effectiveness of the biological product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the biological product is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA does not apply to any biological product with </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">orphan product designation except a product with a new active ingredient that is a molecularly targeted cancer product intended for the treatment of an adult cancer and directed at a molecular target determined by FDA to be substantially relevant to the growth or progression of a pediatric cancer.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Additional Controls for Biologics</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">To help reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately suspend biologics licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the introduction or spread of communicable diseases within the United States.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">After a BLA is approved, the product may also be subject to official lot release as a condition of approval. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the lot manufacturing history and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products, such as viral vaccines, before allowing the manufacturer to release the lots for distribution. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency, and effectiveness of biological products. As with drugs, after approval of a BLA, biologics manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic inspection after approval.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Biosimilars</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The Biologics Price Competition and Innovation Act of 2009, or BPCIA, creates an abbreviated approval pathway for biological products shown to be highly similar to or interchangeable with an FDA-licensed reference biological product. Biosimilarity sufficient to reference a prior FDA-approved product requires that there be no differences in conditions of use, route of administration, dosage form, and strength, and no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency. Biosimilarity must be shown through analytical trials, animal studies, and a clinical trial or trials, unless the Secretary of Health and Human Services waives a required element. A biosimilar product may be deemed interchangeable with a previously approved product if it meets the higher hurdle of demonstrating that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. The first biosimilar product was approved by the FDA in 2015, and the first interchangeable product was approved in 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">A reference biologic is granted 12&#160;years of exclusivity from the time of first licensure, or BLA approval, of the reference product, and no application for a biosimilar can be submitted for four&#160;years from the date of licensure of the reference product. The first biologic product submitted under the biosimilar abbreviated approval pathway that is determined to be interchangeable with the reference product has exclusivity against a finding of interchangeability for other biologics for the same condition of use for the lesser of (i)&#160;one year after first commercial marketing of the first interchangeable biosimilar, (ii)&#160;18&#160;months after the first interchangeable biosimilar is approved if there is no patent challenge, (iii)&#160;eighteen&#160;months after resolution of a lawsuit over the patents of the reference biologic in favor of the first interchangeable biosimilar applicant, or (iv)&#160;42&#160;months after the first interchangeable biosimilar&#8217;s application has been approved if a patent lawsuit is ongoing within the 42-month period.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Post-Approval Requirements</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Once a BLA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">promotional activities involving the Internet. Biologics may be marketed only for the approved indications and in accordance with the provisions of the approved labeling.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Adverse event reporting and submission of periodic safety summary reports are required following FDA approval of a BLA. The FDA also may require post-marketing testing, known as Phase&#160;4 testing, REMS, and surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control, biological product manufacture, packaging, and labeling procedures must continue to conform to cGMPs after approval. Biologic manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects a biologic product&#8217;s manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality-control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with required regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Other U.S. Healthcare Laws and Compliance Requirements</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">In the United States, biotechnology company activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, the Centers for Medicare &amp; Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General and the Office for Civil Rights), the U.S. Department of Justice, or DOJ, and individual U.S. Attorney offices within the DOJ, and state and local governments. The laws biotechnology companies may have to comply with include the anti-fraud and abuse provisions of the Social Security Act, the federal false claims laws, the privacy and security provisions of the Health Insurance Portability and Accountability Act, or HIPAA, and similar state laws, each as amended, as applicable.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering, recommending or arranging for the purchase, lease or order of any item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The Anti- Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and/or formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor. In addition, the statutory exceptions and regulatory safe harbors are subject to change.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Additionally, the intent standard under the Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, to a stricter standard such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. In addition, the ACA codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act (discussed below).</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Federal false claims laws, including the federal civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. In addition, manufacturers can be held liable under the civil False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies&#8217; marketing of the product for unapproved, and thus generally non-reimbursable, uses and purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">HIPAA created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Also, many states have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Data privacy and security regulations by both the federal government and the states in which business is conducted may also be applicable. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, imposes requirements relating to the privacy, security and transmission of individually identifiable health information. HIPAA requires covered entities to limit the use and disclosure of protected health information to specifically authorized situations, and requires covered entities to implement security measures to protect health information that they maintain in electronic form. Among other things, HITECH made HIPAA&#8217;s security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Additionally, the federal Physician Payments Sunshine Act within the ACA, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) report annually to CMS information related to certain payments or other transfers of value made or distributed to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), physician assistants, certain types of advanced practice nurses, and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Commercial distribution of products requires compliance with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. In addition, several states have enacted legislation requiring pharmaceutical and biotechnology companies to </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. Certain local jurisdictions also require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. Sales and marketing activities are also potentially subject to federal and state consumer protection and unfair competition laws.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Violation of any of the federal and state healthcare laws described above or any other governmental regulations may result in penalties, including without limitation, significant civil, criminal and/or administrative penalties, damages, fines, disgorgement, exclusion from participation in government programs, such as Medicare and Medicaid, imprisonment, injunctions, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government, refusal to enter into government contracts, oversight monitoring, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Coverage, Pricing and Reimbursement</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which regulatory approval is obtained. In the United States and markets in other countries, sales of any products for which regulatory approval is received for commercial sale will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such products. In the United States, third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved products for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. Expensive pharmaco-economic studies may need to be conducted in order to demonstrate the medical necessity and cost-effectiveness of product candidates, in addition to the costs required to obtain the FDA approvals. Product candidates may not be considered medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable the maintenance of price levels sufficient to realize an appropriate return on investment in product development.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Different pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">The marketability of any product candidates for which regulatory approval is received for commercial sale may suffer if the government and other third-party payors fail to provide coverage and adequate reimbursement. In addition, emphasis on managed care in the United States has increased and is expected to continue to increase the pressure on healthcare pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which regulatory approval is received, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.2pt;"> </span><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.25pt;">Healthcare Reform</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Healthcare reforms that have been adopted, and that may be adopted in the future, could result in further reductions in coverage and levels of reimbursement for pharmaceutical products, increases in rebates payable under U.S. government rebate programs and additional downward pressure on pharmaceutical product prices. Healthcare reform proposals recently culminated in the enactment of the Inflation Reduction Act, or IRA, which will eliminate, beginning in 2025, the coverage gap under Medicare Part D by significantly lowering the enrollee maximum out-of-pocket cost and requiring manufacturers to subsidize, through a newly established manufacturer discount program, 10% of Part D enrollees&#8217; prescription costs for brand drugs below the out-of-pocket maximum, and 20% once the out-of-pocket maximum has been reached. The IRA will also allow HHS to negotiate the selling price of certain drugs and biologics that CMS reimburses under Medicare Part B and Part D (excluding drugs and biologics that are designated and approved for only one rare disease or condition), although only high-expenditure single-source biologics that have been approved for at least 11 years (7 years for drugs) can be selected by CMS for negotiation, with the negotiated price taking effect two years after the selection year. The negotiated prices, which will first become effective in 2026, will be capped at a statutory ceiling price. Beginning in October 2022 for Medicare Part D and January 2023 for Medicare Part B, the IRA will also penalize drug manufacturers that increase prices of Medicare Part D and Part B drugs at a rate greater than the rate of inflation. It is unclear to what extent other statutory, regulatory, and administrative initiatives will be enacted and implemented in the future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Employees and Human Capital Resources</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">As of December&#160;31,&#160;2022, we had 85 full-time employees. From time to time, we also retain independent contractors to support our organization. Of these employees, 26 held Ph.D., Pharm.D. or M.D. degrees, and 57 were engaged in research, development and technical operations. All of our employees are based in the United States. None of our employees are represented by a labor union or covered by collective bargaining agreements, and we believe our relationship with our employees is good. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;letter-spacing:0.25pt;">Our Mission and Our Employees</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:4.9pt;margin:0pt;"><span style="font-size:4.9pt;letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">At Passage Bio, our mission is to discover and develop transformative therapies for CNS disorders with limited or no approved treatment options, while also building strong relationships with the communities we serve. We embrace collaboration, discipline and efficiency, while welcoming fresh ideas and stimulating personal development. We align our core values with our mission statement, which is outlined below:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.38;margin:0pt 3pt 0pt 0pt;"><span style="letter-spacing:0.25pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Put patients first</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We place the health and safety of our patients at the center of every decision we make</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We value the voice of our patient communities; we listen and we learn</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are driven to improve patients&#8217; lives; they are relying on us</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Committ to Excellence</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We apply leading-edge science and technology to develop gene therapies for our patients</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We strive to be the best in everything we do</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We embrace diversity and inclusion as essential to the success of our company</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have an unrelenting focus on quality</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Make and impact</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We act with a sense of urgency; patients are waiting</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are nimble and adaptable in driving toward our goals</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We approach every day with courage and tenacity</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Act with integrity</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We communicate openly, honestly and respectfully with each other</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We make decisions based on what&#8217;s right</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are accountable for our actions</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We care about our community and strive to be good citizens</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Suceed together</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We&#8217;re all part of the solution and help each other be successful</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We innovate by challenging the status quo, taking appropriate risk and encouraging diversity of thought</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We value and foster collaboration, both internally and with our external partners</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We work hard and find ways to make it fun</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Our Commitment to Diversity, Equity and Inclusion</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="page45"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">We are committed to creating and maintaining a diverse, equitable and inclusive workplace where all of our employees can thrive in an environment that values differences, provides equal opportunities and embraces different backgrounds and perspectives. We treat all individuals with respect and dignity and provide all of our employees with fair treatment based on merit. By embracing diversity and inclusion, we create an organization committed to working together to develop innovative solutions in support of our mission. </span>Our core values include a commitment to diversity, equity, and inclusion, and we have embraced them as integral parts of our business strategy.<span style="letter-spacing:0.25pt;"> </span></p><a id="page46"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Our Compensation and Benefits</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">We view our employees as one of our most valuable assets in serving our mission. We compete in the highly competitive biotechnology industry, and attracting, retaining and developing a diverse group of talented employees is crucial to our strategy and our ability to compete effectively. We are committed to the development and retention of our workforce to support our research, clinical operations, manufacturing and regulatory efforts. There currently is a shortage of skilled individuals with substantial experience discovering, developing and manufacturing genetic medicines, which is likely to continue. As a result, competition for these individuals is intense and the turnover rate can be high. We face substantial competition among numerous companies and academic institutions for individuals with these skills.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.45pt;margin:0pt 8pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">Given the highly competitive nature of our industry and the importance of recruitment and retention to our success, we strive to provide our employees with what we believe is a very competitive and comprehensive total rewards package of compensation, benefits and services. This package includes at or above-market pay, healthcare benefits for employees and family members, life insurance benefits, short and long-term disability benefits, generous paid time off benefits, parental leave, bereavement leave, flexible work schedules, a 5% employer match of employee contributions to our sponsored retirement plans, and an annual stipend for employees to spend on professional development. Additionally, we also offer every full-time employee the benefit of equity ownership in our Company through our equity plans.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.38;margin:0pt 3pt 0pt 0pt;"><span style="letter-spacing:0.25pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Facilities</b><span style="letter-spacing:0.25pt;"> </span></p><a id="_Hlk93564753"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">Our principal executive office is located in Philadelphia, Pennsylvania, where we lease a total of approximately 37,000 square feet of office space, </span>which commenced in February 2021 and will expire in December 2031, subject to our option to extend the term of the lease by up to two additional five-year terms<span style="letter-spacing:0.25pt;">.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We also lease approximately 62,000 square feet of laboratory space at the Princeton West Innovation Campus in Hopewell, New Jersey. This lease has a 15-year term from the lease commencement date of March 2021. We have the option to extend the term of the lease by up to two additional five-year terms.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;letter-spacing:0.3pt;">Legal Proceedings</b><span style="letter-spacing:0.25pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;margin:0pt;"><span style="letter-spacing:0.25pt;">From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Corporate Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;background:#ffffff;margin:0pt;">We were incorporated under the laws of the State of Delaware in July&#160;2017 under the name Passage Bio, Inc. Our principal executive office is located at Two Commerce Square, 2005 Market Street, 39th&#160;Floor, Philadelphia, PA, 19103, and our telephone number is (267) 866-0311. Our website address is www.passagebio.com. The information contained on, or that can be accessed through, our website is not part of, and is not incorporated by reference into, this prospectus. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;background:#ffffff;margin:0pt;"><b style="font-weight:bold;">Available Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:6pt;background:#ffffff;margin:0pt;">We file annual, quarterly and current reports, proxy statements and other documents with the Securities and Exchange Commission, or SEC, under the Securities Exchange Act of 1934, as amended, or Exchange Act. The SEC maintains an Internet website that contains reports, proxy and information statements, and other information regarding issuers, including us, that file electronically with the SEC. The public can obtain any documents that we file with the SEC at&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">www.sec.gov</span>. Copies of each of our filings with the SEC can also be viewed and downloaded free of charge at our website,&#160;https://investors.passagebio.com/<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">,</span>&#160;after the reports and amendments are electronically filed with or furnished to the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_873c769e_8460_4dfd_a49d_0c7830719eb6"></a><a id="Item1ARiskFactors_934987"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A.&#160;&#160;&#160;&#160;&#160;<span style="font-style:italic;">Risk Factors</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">RISK FACTORS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 9pt;"><i style="font-family:'Arial Narrow';font-style:italic;font-weight:normal;letter-spacing:0.25pt;">Investing in our common stock involves a high degree of risk. Before making your decision to invest in shares of our common stock, you should carefully consider the risks and uncertainties described below, together with the other information contained in this annual report, including our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221;. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. We cannot assure you that any of the events discussed below will not occur. These events could have a material and adverse impact on our business, financial condition, results of operations and prospects. If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Financial Position and Need for Additional Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are a clinical stage genetic medicines company with a history of operating losses, and we may not achieve or sustain profitability. We anticipate that we will continue to incur losses for the foreseeable future. Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are a clinical stage genetic medicines company with a limited operating history on which to base your investment decision. Biotechnology product development is a highly speculative undertaking and involves a substantial degree of risk. Our operations to date have been limited primarily to staffing our company, business planning, raising capital, entering into collaboration and vendor agreements for conducting preclinical research and clinical development activities for our product candidates, and performing clinical development activites and manufacturing clinical supply. All of our product candidates are in the clinical development stage, have been stopped from further clinical development in order to reduce operating expenditures, or are in the preclinical or discovery stage. We have no products approved for commercial sale and have not generated any revenue from commercial product sales, and we will continue to incur significant research and development and other expenses related to our clinical development and ongoing operations. We have funded our operations to date through proceeds from sales of our convertible preferred stock, and public offerings, and do not expect to receive revenue for many years, if ever.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have incurred net losses since our inception in 2017. We incurred net losses of $136.1 million and $185.4 million for the&#160;years ended December&#160;31, 2022 and 2021, respectively. As of December&#160;31, 2022, we had an accumulated deficit of $492.4 million. Substantially all of our operating losses have resulted from expenses incurred in connection with our research and development programs, acquiring the rights to our product candidates, and from general and administrative expenses associated with our operations. We expect to continue to incur significant expenses and operating losses over the next several&#160;years and for the foreseeable future as we intend to continue to conduct research and development, clinical testing, regulatory compliance activities, manufacturing activities, and, if any of our product candidates is approved, sales and marketing activities that, together with anticipated general and administrative expenses, will likely result in us incurring significant losses for the foreseeable future. Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect that it will be several&#160;years, if ever, before we have a commercialized product. We anticipate that our expenses will increase substantially if, and as, we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our product candidates advance from the preclinical or discovery stage to the clinical development stage;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our clinical product candidates advance into later stage clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire additional clinical, quality control, regulatory, manufacturing, scientific and administrative personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand our operational, financial and management systems and increase personnel, including personnel to support our clinical development, manufacturing and commercialization efforts and our operations as a public company;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand or build our internal manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand and protect our intellectual property portfolio; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur additional legal, accounting or other expenses in operating our business, including the additional costs associated with operating as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, as a new business, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. We are in the process of transitioning rapidly from a small start-up company with a focus on hiring employees, establishing key collaborations and financing to a more fully-integrated company that is capable of supporting clinical development, manufacturing and commercial activities. We may not be successful in such a transition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have never generated revenue from product sales and may never achieve or maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have no products approved for commercial sale and have not generated any revenue from commercial product sales. To become and remain profitable, we must develop and eventually commercialize product candidates with significant market potential, which will require us to be successful in a range of challenging activities. These activities can include completing preclinical studies and initiating and completing clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those products that are approved and satisfying any post marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate revenues that are significant or large enough to achieve profitability. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause you to lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We will need to raise additional funding before we can expect to become profitable from any potential future sales of our products. This additional financing may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit, or terminate our product development efforts or other operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We will require substantial future capital in order to complete planned and future preclinical and clinical development for our portfolio of product candidates and potentially commercialize these product candidates, if approved. If our product portfolio progresses into later stage clinical trials, or our current preclinical product candidates progress into the clinical trial stage, we expect our spending levels to significantly increase in connection with our continued clinical trial activites and production of our clinical product candidates supply. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant expenses related to product sales, medical affairs, marketing, manufacturing and distribution. Furthermore, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, reduce or eliminate certain of our licensing activities, our research and development programs or other operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our operations have consumed significant amounts of cash since inception. As of December&#160;31,&#160;2022, our cash, cash equivalents and marketable securities were $189.6 million. We expect that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into the first half of 2025. However, we have based this estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of factors currently unknown to us. As a result, we could deplete our capital resources sooner than we currently expect. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our future capital requirements will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, timing, progress and results of discovery, preclinical development, laboratory testing and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expenses of manufacturing our product candidates for clinical trials and in preparation for marketing approval and commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we enter into collaborations or other arrangements with additional third parties in order to further develop our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expenses of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expenses and fees associated with the discovery, acquisition or in-license of additional product candidates or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish collaborations on favorable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expenses required to scale up our clinical, regulatory and manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expenses of future commercialization activities, if any, including establishing sales, marketing, manufacturing and distribution capabilities, for any of our product candidates for which we receive marketing approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accordingly, we will need to continue to rely on additional financing to achieve our business objectives, which may not be available to us on acceptable terms, or at all. We may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. If adequate funds are not available to us on a timely basis or on terms acceptable to us, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for one or more product candidates or discovery stage programs or delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize any product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or securities convertible into equity, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures or declaring dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed or on terms acceptable to us, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Product Development and Regulatory Approval</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are early in our development efforts. Our business is dependent on our ability to advance our current and future product candidates through preclinical studies and clinical trials, obtain marketing approval and ultimately commercialize them. If we are unable, or experience significant delays in doing so, our business will be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are early in our clinical development efforts and our clinical product candidates are in early phase clinical trials. Additionally, we have a portfolio of programs that are in different stages of preclinical development and some may never advance to clinical stage development. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates, which may never occur. We currently generate no revenue from sales of any product and we may never be able to develop or commercialize a marketable product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Each of our programs and product candidates will require additional preclinical and/or clinical development, regulatory approval in multiple jurisdictions, obtaining manufacturing supply, capacity and expertise, building a commercial organization or successfully outsourcing commercialization, substantial investment and significant marketing efforts before we generate any revenue from product sales. Our product candidates must be authorized for marketing by the FDA, or certain other ex-U.S. regulatory agencies before we may commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The clinical and commercial success of our product candidates will depend on several factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timely and successful completion of preclinical studies, including toxicology studies, biodistribution studies, biocompatibility studies and minimally efficacious dose studies in animals, where applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effective INDs or comparable foreign applications that allow commencement of our planned clinical trials or future clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful enrollment and completion of clinical trials, including under the international current Good Clinical Practices, or cGCPs, and current Good Laboratory Practices, or GLPs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">positive results from our future clinical programs that support a finding of safety and effectiveness and an acceptable risk-benefit profile of our product candidates in the intended populations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of arrangements with third-party manufacturers or our own facilities for clinical supply and, where applicable, commercial manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment and maintenance of patent and trade secret protection or regulatory exclusivity for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">commercial launch of our product candidates, if approved, whether alone or in collaboration with others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of the benefits and use of our product candidates, including method of administration, if and when approved, by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effective competition with other therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment and maintenance of healthcare coverage and adequate reimbursement and patients&#8217; willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishment of a physician training system and network for administration of our product candidates by administration into the ICM;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enforcement and defense of intellectual property rights and claims; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintenance of a continued acceptable safety, tolerability and efficacy profile of our product candidates following approval.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we do not succeed in one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business. If we are unable to advance our product candidates to clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preclinical and clinical development involve a lengthy and expensive process with an uncertain outcome. We may incur additional expenses or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our current product candidates or any future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">All of our product candidates are in clinical or preclinical development and their risk of failure is high. We currently rely exclusively on GTP for our preclinical and IND-enabling studies. It is impossible to predict when or if any of our product candidates will receive regulatory approval. To obtain the requisite regulatory approvals to commercialize any product candidates, we must demonstrate through extensive preclinical studies and lengthy, complex and expensive clinical trials that our product candidates are safe and effective in humans. For example, our IND for PBGM01 for the treatment of GM1 was initially placed on clinical hold. Even though the FDA removed the clinical hold on the IND for PBGM01, other future product candidates may be subject to clinical holds in the future. Clinical testing can take many&#160;years to complete, and its outcome is inherently uncertain. We will rely on CROs for the clinical development of our clinical product candidates. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials or early cohorts of our clinical trials of our product candidates, including early biomarker data, may not be predictive of the results of later-stage clinical trials or later cohorts of our clinical trials. Early clinical trials and in particular initial cohorts of early clinical trials often enroll significantly fewer patients than later stage clinical trials or later cohorts of the same clinical trial and may not be as predictive as larger trials. We may be unable to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful or come to agreement on other aspects of clinical trial design. Moreover, a clinical trial can fail at any stage of testing. Differences in trial design between early-stage clinical trials and later-stage clinical trials make it difficult to extrapolate the results of earlier clinical trials to later clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in clinical trials have nonetheless failed to obtain marketing approval of their products. A number of companies in the biotechnology industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or to unfavorable safety profiles, notwithstanding promising results in earlier trials. There is typically a high rate of failure of product candidates proceeding through clinical trials. Most product candidates that commence clinical trials are never approved as products and there can be no assurance that any of our future clinical trials will ultimately be successful or support clinical development of our current or any of our future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We or our collaborators may experience delays in initiating or completing clinical trials. We or our collaborators also may experience numerous unforeseen events during, or as a result of, any future clinical trials that we could conduct that could delay or prevent our ability to receive marketing approval or commercialize our clinical product candidates or any future product candidates, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulators, such as the FDA, may place our clinical trials on clinical hold; for example, the FDA placed our trial of PBGM01 for the treatment of GM1 on clinical hold from July 2020 to December 2020;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">institutional review boards, or IRBs, the FDA or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective CROs the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trial sites deviating from trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">novel therapies, such as gene therapies with less well-characterized safety profiles, may require slower or more staggered early clinical trial enrollment to adequately assess safety data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials of any product candidates may fail to show safety or efficacy, produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional preclinical studies or clinical trials or we may decide to abandon product development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of subjects required for clinical trials of any product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or subjects may drop out of these clinical trials or fail to return for post-treatment follow up at a higher rate than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may elect to, or regulators, IRBs, or ethics committees may require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants in our trials are being exposed to unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the related expenses of clinical trials of any of our product candidates may be greater than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be inadequate to initiate or complete a given clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to manufacture sufficient quantities of our product candidates for use in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reports from clinical testing of other therapies may raise safety or efficacy concerns about our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure to establish an appropriate safety profile for a product candidate based on clinical or preclinical data for such product candidate as well as data emerging from other molecules in the same class as our product candidate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or ex-U.S. regulatory agencies may require us to submit additional data such as long-term toxicology studies, or impose other requirements before permitting us to initiate a clinical trial.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the number and location of clinical sites we enroll, the proximity of patients to clinical sites, the eligibility and exclusion criteria for the trial, the design of the clinical trial, the inability to obtain and maintain patient consents, the risk that enrolled participants will drop out before completion, competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs or therapeutic biologics that may be approved for the indications being investigated by us. Furthermore, we expect to rely on our collaborators, CROs and clinical trial sites to ensure the proper and timely conduct of our future clinical trials, including the patient enrollment process, and we have limited influence over their performance. Additionally, we could encounter delays if treating physicians encounter unresolved ethical issues associated with enrolling patients in future clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. For example, treating physicians with eligible patients for our FTD trial may instead elect to use alternative treatment approaches from our competitors, if such competitors are to receive regulatory approval in advance of our program, in lieu of enrolling in our clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs of the institutions in which such trials are being conducted, or the FDA or other regulatory authorities, or if a clinical trial is recommended for suspension or termination by the Independent Data Monitoring Committee for such trial. A suspension or termination may be imposed due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product or treatment, failure to establish or achieve clinically meaningful trial endpoints, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Clinical studies may also be delayed or terminated as a result of ambiguous or negative interim results. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Further, the FDA or other regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials, or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our product development expenses will increase if we experience delays in clinical testing or marketing approvals. We do not know whether any of our clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates and may allow our competitors to bring products to market before we do, potentially impairing our ability to successfully commercialize our product candidates and harming our business and results of operations. Any delays in our clinical development programs may harm our business, financial condition and results of operations significantly.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Success in early preclinical studies or clinical trials may not be indicative of results obtained in later preclinical studies and clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Conducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time of such testing may vary substantially according to the type, complexity and novelty of the program, and often can be several&#160;years or more per program. Delays associated with programs for which we are conducting preclinical testing and studies may cause us to incur additional operating expenses. We may experience unexpected or adverse results in our ongoing or future clinical trials. We will be required to demonstrate through adequately designed and executed clinical trials that our product candidates are safe and effective, with a favorable benefit-risk profile, for use in their target indications before we can seek regulatory approvals for their commercial sale. Our initial clinical trials have started with relatively small cohorts before expanding in size in subsequent cohorts. If safety issues arise in an early cohort, we may be delayed or prevented from subsequently expanding into larger trial cohorts. Earlier gene therapy clinical trials conducted by others also utilized adeno-associated viral, or AAV, vectors. However, these studies should not be relied upon as evidence that our planned clinical trials will succeed. Trial designs and results from previous trials are not necessarily predictive of our future clinical trial designs or results, and initial positive results we may observe may not be confirmed upon full analysis of the complete trial data. In addition, the positive results we have observed for our product candidates in preclinical animal models may not be predictive of our future clinical trials in humans. Our product candidates may also fail to show the desired safety and efficacy in later stages of clinical development even if they successfully advance through initial clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preliminary, topline or interim data from our clinical trials that we or our partners announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, we have made, and may continue to make, public preliminary, topline or interim data from our clinical trials, including preliminary biomarker data. Preliminary or topline data from clinical trials remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary or topline data that were previously made public. Interim data from clinical trials that we may complete are also subject to the risk that one or more of the clinical outcomes may materially change as subject enrollment continues and more data become available. As a result, preliminary, topline and interim data should be viewed with caution until the final data are available. Adverse differences between preliminary, topline or interim data and final data could significantly harm our reputation and business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we do not achieve our projected development goals in the time frames we announce and expect, the commercialization of our products may be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, we estimate the timing of the accomplishment of various scientific, clinical, regulatory, manufacturing and other product development goals, which we sometimes refer to as milestones. These milestones may include the commencement or completion of preclinical studies and clinical trials, the release of data from such studies and the submission of regulatory filings, including IND submissions. From time to time, we may publicly announce the expected timing of some of these milestones. All of these milestones are, and will be, based on a variety of assumptions. The actual timing of these milestones can vary significantly compared to our estimates, in some cases for reasons beyond our control. We may experience numerous unforeseen events during, or as a result of, any future clinical trials that we conduct that could delay or prevent our ability to receive marketing approval or commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Gene therapy is a novel technology, which makes it difficult to predict the time and cost of product candidate development and subsequently obtaining regulatory approval. Currently, only a limited number of gene therapy products have been approved in the United States and in foreign countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our current product candidates are based on gene therapy technology and our future success depends on the successful development of this novel therapeutic approach. The regulatory requirements that govern any novel gene therapy product candidates we develop are not entirely clear and are subject to change. The clinical study requirements of the FDA and ex-U.S. regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty and intended use and market of the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">potential products. The regulatory approval process for novel product candidates such as ours may be more expensive and take longer than for other, better known or extensively studied product candidates. Further, as we are developing novel treatments for diseases in which there is little clinical experience with new endpoints and methodologies, there is heightened risk that the FDA or comparable foreign regulatory bodies may not consider the clinical trial endpoints to provide clinically meaningful results, and the resulting clinical data and results may be more difficult to analyze. To date, only a limited number of gene therapy products have been approved in the United States and foreign countries, which makes it difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in the United States or other jurisdictions. Further, approvals by ex-U.S. regulatory agency may not be indicative of what the FDA may require for approval, or vice versa.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our product candidates may cause undesirable and unforeseen side effects, which could delay or prevent their advancement into clinical trials or regulatory approval, limit the commercial potential or result in significant negative consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">While new AAV vectors have been developed to reduce side effects previously reported in third-party gene therapy treatments, gene therapy is still a relatively new approach to disease treatment and additional adverse side effects could develop. There also is the potential risk of delayed adverse events following exposure to gene therapy products due to persistent biologic activity of the genetic material or other components of products used to carry the genetic material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For example, in our clinical study for PBKR03, for which, in order to reduce operating expenses, we have stopped further clinical development and are exploring strategic alternatives for this asset, a patient experienced a grade 4 serious adverse event of acute communicating hydrocephalus. Additional possible adverse side effects that could occur with treatment with gene therapy products include an immunologic reaction early after administration which, while not necessarily adverse to the patient&#8217;s health, could substantially limit the effectiveness of the treatment. For example, in previous third-party clinical trials involving AAV vectors for gene therapy, some subjects experienced the development of a T-cell immune response, whereby after the vector is within the target cells, the cellular immune response system triggers the removal of transduced cells by activated T-cells. Other recent clinical trials involving high doses of AAV vectors have also resulted in liver damage and death. Further, following administration of any AAV vector, patients are likely to develop NAbs specific to the vector administered. Other preclinical studies have suggested that high dosages of AAV administration may result in toxicity due to degeneration of the dorsal root ganglia. Preliminary results of our NHP toxicology studies for our PBGM01 and PBFT02 product candidates have demonstrated trigeminal ganglia and dorsal root ganglia toxicity. Based on these results, and if our vectors demonstrate a similar effect in other programs, we may decide or be required to perform additional preclinical studies or to halt or delay further clinical development of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to side effects caused by the product candidate, the administration process or related procedures also can cause adverse side effects. Each of our clinical product candidates are expected to utilize ICM administration. While this method of administration has been available for decades, its use for therapies is relatively new, no therapies are currently approved using ICM administration, and it may be perceived as having greater risk than more common methods of administration, such as intravenous injection. If any such adverse events occur, our clinical trials could be suspended or terminated. If we cannot demonstrate that any adverse events were not caused by the drug or administration process or related procedures, the FDA or ex-U.S. regulatory authorities could order us to cease further development of, or deny approval of, our product candidates for any or all targeted indications. Even if we are able to demonstrate that all future serious adverse events are not product related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to not initiate, delay, suspend or terminate any future clinical trial of any of our product candidates, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to develop other product candidates, and may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additionally, if any of our product candidates receives marketing approval, the FDA could require us to adopt a Risk Evaluation and Mitigation Strategies, or REMS, to ensure that the benefits of the product outweigh its risks, which may include, among other things, a Medication Guide outlining the risks of the product for distribution to patients and a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">communication plan to health care practitioners. Furthermore, if we or others later identify undesirable side effects caused by our product candidate, several potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may suspend or withdraw approvals of such product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require additional warnings in the labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to change the way a product candidate is administered or conduct additional clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any of these occurrences may harm our business, financial condition and prospects significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Adverse public perception of genetic medicines may negatively impact regulatory approval of, and/or demand for, our potential products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Regulatory approval of and/or demand for our potential products will depend in part on public acceptance of the use of genetic medicine for the prevention or treatment of human diseases. Public attitudes may be influenced by claims that genetic medicines are unsafe, unethical or immoral, and consequently, our products may not gain the acceptance of the public or the medical community. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There have been several significant adverse side effects reported in genetic medicine treatments in the past. For example, in 1999, there was public backlash against gene therapy following the death of a clinical trial subject in a gene therapy clinical trial that utilized an adenovirus vector. It was later discovered that adenoviruses could generate an extreme immune system reaction that can be life threatening. Dr.&#160;Wilson, our Chief Scientific Advisor, was a co-investigator of the 1999 trial while he was Director of the Institute for Human Gene Therapy of Penn. Serious adverse events in our clinical trials, or other clinical trials involving gene therapy by us or our competitors, even if not ultimately attributable to the relevant product candidates, and the resulting publicity, could result in increased government regulation, unfavorable public perception and potential regulatory delays in the clinical testing or approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">As an organization, we have limited experience designing and implementing clinical trials and we have never conducted pivotal clinical trials. Failure to adequately design a trial, or incorrect assumptions about the design of the trial, could adversely affect the ability to initiate the trial, enroll patients, complete the trial, or obtain regulatory approval on the basis of the trial results, as well as lead to increased or unexpected costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The design and implementation of clinical trials is a complex process. As an organization, we have limited experience designing and implementing clinical trials, and we may not successfully or cost effectively design and implement clinical trials that achieve our desired clinical endpoints efficiently, or at all. A clinical trial that is not well designed may delay or even prevent initiation of the trial, can lead to increased difficulty in enrolling patients, may make it more difficult to obtain regulatory approval for the product candidate on the basis of the study results, or, even if a product candidate is approved, could make it more difficult to commercialize the product successfully or obtain reimbursement from third-party payors. Additionally, a trial that is not well designed could be inefficient or more expensive than it otherwise would have been, or we may incorrectly estimate the related expenses to implement the clinical trial, which could lead to a shortfall in funding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The disorders we seek to treat have low incidence and prevalence, and it may be difficult to identify patients with these disorders, which may lead to delays in enrollment for our trials or slower commercial revenue if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Genetically defined disorders generally, and especially those for which our current product candidates are targeted, have low incidence and prevalence. For example, we estimate the incidence of GM1 in the United States is approximately 1 in 100,000 live births and that there are approximately 3,000 to 6,000 people in the United States with FTD-GRN. There is currently no mandatory screening for GM1. Without mandatory screening, it may be difficult for us to identify a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">sufficient number of eligible patients to conduct our clinical trials. These could be significant obstacles to the timely recruitment and enrollment of a sufficient number of eligible patients into our trials. Further, we expect to rely in part on our relationships with the Orphan Disease Center and other patient advocacy groups to assist in identifying eligible patients, and any deterioration of those relationships could impede our ability to successfully enroll patients. Patient enrollment may be affected by other factors including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the severity of the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">design of the study protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the eligibility criteria for the trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the perceived risks, benefits and convenience of administration of the product candidate being studied;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our efforts to facilitate timely enrollment in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of other clinical trials being conducted for the same indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patient referral practices of physicians; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proximity and availability of clinical trial sites to prospective patients.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our inability to enroll a sufficient number of patients with these diseases for our planned clinical trials would result in significant delays and could require us to not initiate or abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, our projections of both the number of people who have GM1, FTD, and our other product candidates, as well as the people with these diseases who have the potential to benefit from treatment with our product candidates, are based on estimates, including third-party analyses commissioned by us. The total addressable market opportunity for our product candidates will ultimately depend upon, among other things, the final approved product labeling for each of our product candidates, if our product candidates are approved for sale in our target indications, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients globally may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. Our products may potentially be dosed on a one-time basis, which means that patients who enroll in our clinical trials may not be eligible to receive our products on a commercial basis if they are approved, leading to lower revenue potential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if we complete the necessary clinical trials, we cannot predict when, or if, we will receive regulatory approval to commercialize a product candidate and the approval may be for a more narrow indication than we seek.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Prior to commercialization, our product candidates must be approved by the FDA pursuant to a BLA in the United States and by similar ex-U.S. regulatory authorities. The process of obtaining marketing approvals, both in the United States and abroad, is expensive and takes many&#160;years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not received approval to market any of our product candidates from regulatory authorities in any jurisdiction. Our company does not have experience in submitting and supporting the applications necessary to gain marketing approvals. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Approval of our product candidates may be delayed or refused for many reasons, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials, including the methods for collecting and analyzing data, the statistical analysis plan, and the lack of a concurrent control arm or a decision to use external or historical controls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may not agree that the efficacy endpoints used in our clinical trials are appropriate to establish clinical benefit in the intended populations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product candidates are safe and effective for any of their proposed indications;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">development of products for ultra rare diseases, and in particular pediatric diseases, may involve the use of natural history data as an external control.  We may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that the control arm(s) are adequate to establish the safety and/or effectiveness of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the FDA or comparable foreign regulatory authorities a durable response to our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate that our product candidates&#8217; clinical and other benefits outweigh their safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical programs or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the facilities of the third-party manufacturers with which we contract may not be adequate to support approval of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">even if our product candidates meet their safety and efficacy endpoints in clinical trials, the regulatory authorities may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory authority policy during the period of product development, clinical trials and the review process.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Regulatory authorities also may approve a product candidate for more limited indications than requested or they may impose significant limitations in the form of narrow indications, warnings or REMS.&#160;These regulatory authorities may require precautions or contra indications with respect to conditions of use or they may grant approval subject to the performance of costly post-marketing clinical trials. In addition, regulatory authorities may not approve the product labeling claims that are necessary or desirable for the successful commercialization of our product candidates. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates and materially and adversely affect our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Further, the regulatory authorities may require concurrent approval of a companion diagnostic device. For our product candidates, it may be necessary to use FDA-cleared or FDA-approved diagnostic tests to diagnose patients or to assure the safe and effective use of product candidates in trial subjects. The FDA refers to such tests as in vitro companion diagnostic devices. The FDA has issued guidance describing the agency&#8217;s current thinking about the development and regulation of in vitro companion diagnostic devices. The final guidance articulates a policy position that, when an in vitro diagnostic device is essential to the safe and effective use of a therapeutic product, the FDA generally will require approval or clearance of the diagnostic device at the same time that the FDA approves the therapeutic product. At this point, it is unclear how the FDA will apply this policy to our current or future gene therapy product candidates. Should the FDA deem genetic tests used for diagnosing patients for our therapies to be in vitro companion diagnostics requiring </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">FDA clearance or approval, we may face significant delays or obstacles in obtaining approval of a BLA for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The FDA and ex-U.S. regulatory agencies have demonstrated caution in their regulation of gene therapy treatments. Ethical and legal concerns about gene therapy and genetic testing may result in additional regulations or restrictions on the development and commercialization of our product candidates, which may be difficult to predict.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA and ex-U.S. regulatory agencies at both the federal and state level in the United States, U.S. congressional committees, and foreign governments, have expressed interest in further regulating the biotechnology industry, including gene therapy and genetic testing. Any such further regulation may delay or prevent commercialization of some or all of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Regulatory requirements in the United States and abroad governing gene therapy products have changed frequently and may continue to change in the future. In addition to the FDA, the Institutional Biosafety Committee and IRB of each institution at which we conduct our planned clinical trials, would need to review the proposed clinical trial to assess the safety of the trial. Within the FDA, the Office of Tissues and Advanced Therapies, within the Center for Biologics Evaluation and Research, or CBER, consolidates the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee advises CBER on its review. Adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of any of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">These regulatory review committees and advisory groups and the new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory and advisory groups and comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of such product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delays as a result of an increased or lengthier regulatory approval process or further restrictions on the development of our product candidates can be costly and could negatively impact our ability to complete clinical trials and commercialize our current and future product candidates in a timely manner, if at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several&#160;years, including for 35&#160;days beginning on December&#160;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop important activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed abroad and will limit our ability to realize their full market potential.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In order to eventually market any of our product candidates in any particular foreign jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a jurisdiction by jurisdiction basis regarding safety and efficacy. Approval by the FDA in the United States, if obtained, does not ensure approval by regulatory authorities in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">other countries or jurisdictions. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and costs for us and require additional preclinical studies or clinical trials which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. The foreign regulatory approval process involves all of the risks associated with FDA approval. In addition, gene therapy products are considered genetically modified organism, or GMO, products and are regulated as such in each country. Designation of the type of GMO product and subsequent handling and disposal requirements can vary across countries and is variable throughout the European Union. Addressing each specific country requirement and obtaining approval to commence a clinical trial in these countries could result in delays in starting, conducting, or completing a clinical trial. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets and expect to rely on third-party consultants. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of our products will be unrealized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be successful in our efforts to build a pipeline of additional product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our business model is centered on developing therapies for patients with CNS disorders by establishing focused selection criteria to select, develop and advance product candidates that we believe will have a high probability of technical and regulatory success through development into commercialization. We may not be able to continue to identify and develop new product candidates in addition to the pipeline of product candidates that we have established through our collaboration with Penn&#8217;s GTP. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development. For example, they may be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval and achieve market acceptance. If we do not successfully develop and commercialize product candidates based upon our approach, we will not be able to obtain product revenue in future periods, which likely would result in significant harm to our financial position and adversely affect our stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Reliance on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We currently rely exclusively on our collaboration with GTP and Penn for our preclinical research and development programs, including for discovering, preclinically developing and conducting all IND-enabling studies for our clinical product candidates and our near-term future pipeline. Failure or delay of Penn to fulfil all or part of its obligations to us under the agreement, a breakdown in collaboration between the parties or a complete or partial loss of this relationship would materially harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our collaboration with Penn is critical to our current preclinical pipeline. We entered into an amended and restated Research, Collaboration&#160;&amp; License Agreement in May 2020, as subsequently amended, or the Penn Agreement, with Penn&#8217;s GTP to discover and develop certain AAV vector based therapeutics, and the products developed under such collaboration currently represent all of our product pipeline and research programs. We currently rely exclusively on Penn&#8217;s GTP for all of our preclinical research and development capabilities, and in particular GTP under the direction of Dr.&#160;Wilson. Pursuant to the Penn Agreement, Penn&#8217;s GTP is responsible for discovery, preclinical development activities, including all IND-enabling non-clinical studies and research grade manufacturing, and other collaborative activities set forth in the plan for the funded research. Either party has the right in certain circumstances to terminate the collaboration pursuant to the terms of the Penn Agreement. If Penn&#8217;s GTP delays or fails to perform its obligations under the Penn Agreement, disagrees with our interpretation of the terms of the collaboration or our discovery plan or terminates our existing agreement, our pipeline of product candidates would be significantly adversely affected and our prospects will be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The term of the research funding portion of the Penn Agreement, under which we have the ability to acquire exclusive rights to additional gene therapy products for CNS indications, expires in August 2026. In addition, the discovery program, under which we have rights to new technologies for our product candidates is currently also set to expire in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">August&#160;2026. The term of the exploratory research program in large indications, initially TLE, expires in August 2024. If we seek to extend or alter the terms of our collaboration, we will need to negotiate a new or amended agreement, which may not be available to us on equally favorable terms, if at all. Penn has also entered into collaborations with third parties, including certain of our competitors, addressing targets and disease indications outside the scope of our collaboration. As a result, Penn may have competing interests with respect to their priorities and resources. We may have disagreements with Penn with respect to the interpretation of the Penn Agreement, use of resources or otherwise that could cause our relationship with Penn to deteriorate. As a result, Penn may reduce their focus on, and resources allocated to, our programs, potentially delaying or terminating our ability to advance product candidates through preclinical studies. Additionally, if Dr.&#160;Wilson were to leave Penn or to otherwise no longer be meaningfully involved with us, our preclinical research and development capabilities may be substantially reduced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Further, under the Penn Agreement, Penn is primarily responsible for prosecuting and maintaining our licensed intellectual property, and it may fail to properly prosecute, maintain or defend such intellectual property. In such event, if we are unable to otherwise maintain or defend such intellectual property, we could face the potential invalidation of the intellectual property or be subjected to litigation or arbitration, any of which would be time-consuming and expensive. To enforce the licensed intellectual property rights under the Penn Agreement, we will need to coordinate with Penn, which could slow down or hamper our ability to enforce our licensed intellectual property rights. In such event, we could face increased competition that could materially and adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We rely on third parties to conduct our preclinical studies and clinical trials and rely on them to perform other tasks for us. If these third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Although we have recruited a team that has experience with clinical trials, as a company we have limited experience in conducting clinical trials. Moreover, we currently rely exclusively on Penn for our discovery and preclinical research and will continue to rely upon medical institutions, clinical investigators, contract laboratories and other third parties, or our CROs, to conduct clinical trials for our product candidates. We expect to rely heavily on these parties for execution of preclinical and clinical trials for our product candidates and control only certain aspects of their activities. If these parties reduce the levels of efforts and resources to our product candidate activities, prioritize work with a competitor of ours or if a dispute were to arise between us and these parties, they may not meet our expected deadlines or provide us with sufficient materials for our regulatory filings. Nevertheless, we will be responsible for ensuring that each of our preclinical and clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards and our reliance on CROs will not relieve us of our regulatory responsibilities. For any violations of laws and regulations during the conduct of our preclinical studies and clinical trials, we could be subject to warning letters or enforcement action that may include civil penalties up to and including criminal prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We, Penn and our CROs will be required to comply with regulations, including cGCPs for conducting, monitoring, recording and reporting the results of preclinical and clinical trials to ensure that the data and results are scientifically credible and accurate and that the trial patients are adequately informed of the potential risks of participating in clinical trials and their rights are protected. These regulations are enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area and comparable foreign regulatory authorities for any drugs in clinical development. The FDA enforces cGCP regulations through periodic inspections of clinical trial sponsors, principal investigators, and trial sites. If we or our CROs fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, the FDA will determine that any of our future clinical trials will comply with cGCPs. In addition, our clinical trials must be conducted with product candidates produced in accordance with the requirements in cGMP regulations. Our failure or the failure of our CROs to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process and could also subject us to enforcement action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Although we currently design and intend to continue designing our planned clinical trials for our product candidates, for the foreseeable future CROs will conduct all of our planned clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, will be outside of our direct control. Our reliance on third </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">parties to conduct future preclinical studies and clinical trials will also result in less day-to-day control over the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, any preclinical studies or clinical trials with which such CROs are associated with may be extended, delayed or terminated. In such cases, we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates in the subject indication could be harmed, our costs could increase and our ability to generate revenue could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We rely on third parties to conduct our clinical trials. If those third parties do not perform as contractually required, fail to satisfy legal or regulatory requirements, miss expected deadlines or terminate the relationship, our development program could be delayed with potentially material and adverse effects on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We rely on third-party clinical investigators, CROs, clinical data management organizations and consultants to assist or provide the design, conduct, supervision and monitoring of clinical trials of our product candidates. Because we rely and intend to rely on these third parties and will not have the ability to conduct all clinical trials independently, we will have less control over the timing, quality and other aspects of clinical trials than we would have had we conducted them on our own. These investigators, CROs and consultants will not be our employees and we will have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties with which we may contract might not be diligent, careful or timely in conducting our clinical trials, resulting in the clinical trials being delayed or unsuccessful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we will be responsible for ensuring that each of our preclinical studies and clinical trials are conducted in accordance with the general investigational plan and protocols for the trial as well as applicable legal and regulatory requirements. The FDA generally requires preclinical studies to be conducted in accordance with GLPs and clinical trials to be conducted in accordance with cGCPs, including for designing, conducting, recording and reporting the results of preclinical studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control will not relieve us of these responsibilities and requirements. Any adverse development or delay in our preclinical studies or clinical trials as a result of our reliance on third parties could have a material and adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If any of our relationships with these third-party CROs or others terminate, we may not be able to enter into alternative arrangements or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO begins work. As a result, delays may occur, which can materially adversely impact our ability to meet our desired clinical development timelines.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may in the future enter into collaborations with other third parties for the discovery, development and commercialization of our product candidates. If any of our current or future collaborators cease development efforts under our collaboration agreements, or if any of those agreements are terminated, these collaborations may fail to lead to commercial products and we may never receive milestone payments or future royalties under these agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may in the future enter into third-party collaborations for research, development and commercialization of other therapeutic technologies or product candidates. Biotechnology companies are our likely future collaborators for any marketing, distribution, development, licensing or broader collaboration arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">With any future collaboration agreements, we expect to have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Moreover, our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our potential future collaborations involving our product candidates may pose the following risks to us:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on preclinical studies or clinical trial results, changes in the collaborators&#8217; strategic focus or available funding, or external factors such as an acquisition that diverts resources or creates competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation, indemnification obligations and potential liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaboration agreements may restrict our right to independently pursue new product candidates.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As a result of the foregoing, any future collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner or at all. If a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated. Any failure to successfully develop or commercialize our product candidates pursuant to our current or any future collaboration agreements could have a material and adverse effect on our business, financial condition, results of operations and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Moreover, to the extent that any of our existing or future collaborators were to terminate a collaboration agreement, we may be forced to independently develop our product candidates and research programs, including funding preclinical studies or clinical trials, assuming marketing and distribution costs and maintaining and defending intellectual property rights, or, in certain instances, abandon product candidates altogether, any of which could result in a change to our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be successful in finding additional collaborators for continuing development of certain of our product candidates or successfully commercializing or competing in the market for certain indications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may decide to pursue collaborations with additional pharmaceutical and biotechnology companies for the development and potential commercialization of some of our product candidates. In particular, we recently announced that we are looking for strategic partners for our MLD and Krabbe clinical programs. We face significant competition in seeking appropriate collaborators. Any new collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new collaboration if, for example, development or approval of a product candidate is delayed, sales of an approved product candidate do not meet expectations or the collaborator terminates the collaboration. In addition, a significant number of recent business combinations among large pharmaceutical companies has resulted in a reduced number of potential future collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. The terms of any additional collaborations or other arrangements that we may establish may not be favorable to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may have conflicts with our collaborators that could delay or prevent the development or commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We may have conflicts with our collaborators, including Penn, such as conflicts concerning the interpretation of preclinical or clinical data, the achievement of milestones, the interpretation of contractual obligations, payments for services, development obligations or the ownership of intellectual property developed during our collaboration. If any conflicts arise with any of our collaborators, including Penn, such collaborator may act in a manner that is adverse to our best interests. Any such disagreement could result in one or more of the following, each of which could delay or prevent the development or commercialization of our product candidates, and in turn prevent us from generating revenues: unwillingness on the part of a collaborator to pay us milestone payments or royalties we believe are due to us under a collaboration, which could require us to raise additional capital; uncertainty regarding ownership of intellectual property rights arising from our collaborative activities, which could prevent us from entering into additional collaborations; </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">unwillingness by the collaborator to cooperate in the development or manufacture of the product, including providing us with product data or materials; unwillingness on the part of a collaborator to keep us informed regarding the progress of its development and commercialization activities or to permit public disclosure of the results of those activities; initiating of litigation or alternative dispute resolution options by either party to resolve the dispute; or attempts by either party to terminate the relevant agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may in the future seek to engage in strategic transactions to acquire or in-license new products, product candidates or technologies. If we are unable to successfully complete, or realize the benefits from, such transactions it may adversely affect our ability to develop and commercialize product candidates, impact our cash position, increase our expenses and present significant distractions to our management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may consider strategic transactions, such as additional collaborations, acquisitions of companies, asset purchases, joint ventures and in-licensing of new products, product candidates or technologies that we believe will complement or augment our existing business. If we acquire assets with promising markets or technologies, we may not be able to realize the benefit of acquiring such assets if we are not able to successfully integrate them with our existing technologies. We may encounter numerous difficulties in developing, testing, manufacturing and marketing any new products resulting from a strategic acquisition that delay or prevent us from realizing their expected benefits or enhancing our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We cannot assure you that following any such strategic transaction, we will achieve the expected synergies to justify the transaction. For example, such transactions may require us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These transactions would entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the transaction or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and would have a material and adverse effect on our business, financial condition, results of operations and prospects. Conversely, any failure to enter any strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product candidates and have a negative impact on the competitiveness of any product candidate that reaches market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Manufacturing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Gene therapies are novel, complex and difficult to manufacture. We could experience manufacturing problems that result in delays in our development or commercialization programs or otherwise harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We currently rely on third parties to develop, manufacture and test clinical supplies of our product candidates, including the materials used to administer our product candidates. For our initial clinical trials, we rely on the manufacturing facility of Catalent Maryland (formerly Paragon Bioscience), or Catalent, for supply of our product candidates. We have limited experience as a company in developing manufacturing facilities. If or when we decide to construct our own manufacturing facility for long-term commercial market supply, we may face delays in building out a plant, constructing new facilities, transferring technology to the facilities or hiring experts to staff and operate the facilities and, accordingly, our production capacity could be limited. We have established internal testing operations supporting our preclinical and clinical manufacturing in addition to using external contract testing labs and established analytical development and process development capabilities to support our pipeline. The manufacturing processes used to produce our product candidates are complex, novel and have not been validated for commercial use. Many factors could cause production interruptions, including equipment malfunctions, facility contamination, raw material shortages or </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">contamination, natural disasters, disruption in utility services, human error or disruptions in the operations of our suppliers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our product candidates require processing steps that are more complex than those required for most small molecule drugs. Moreover, unlike small molecules, the physical and chemical properties of a biologic such as ours generally cannot be fully characterized. As a result, assays of the finished product may not be sufficient to ensure that the product is consistent from lot-to-lot or will perform in the intended manner. Accordingly, we employ multiple steps to control the manufacturing process to assure that the process works consistently and the product candidate is made strictly and consistently in compliance with the process. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, low lot yields, product recalls, product liability claims or insufficient inventory. As a result, we may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet the FDA or other applicable standards or specifications with consistent and acceptable production yields and costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, the FDA and ex-U.S. regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA or ex-U.S. regulatory authorities may require that we not distribute a lot until the agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures, low lot yields or product recalls. Lot failures, low lot yields or product recalls could cause us to delay product launches or clinical trials, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We, or our third-party collaborators, also may encounter problems hiring and retaining the experienced scientific, quality-control and manufacturing personnel needed to operate our manufacturing processes, which could result in delays in production or difficulties in maintaining compliance with applicable regulatory requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any problems in our, or our third-party collaborators&#8217;, manufacturing process or facilities could result in delays in our planned clinical trials and increased costs, and could make us a less attractive collaborator for potential partners, including larger biotechnology companies and academic research institutions, which could limit our access to additional attractive development programs. It could also require us to find alternative manufacturing processes, which may be unavailable to us on attractive terms, or at all. Problems in our manufacturing process could restrict our ability to meet potential future market demand for our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing, FDA notification or FDA approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">We currently rely and expect to continue to rely on third-party manufacturers to produce clinical supply of our product candidates, and we have not entered into binding agreements with any such manufacturers to support commercialization. The competition for gene therapy contract development, manufacturing and testing services is intense. Additionally, these manufacturers do not have experience producing our product candidates at commercial levels and may not achieve the necessary regulatory approvals or produce our product candidates at the quality, quantities, locations and timing needed to support commercialization.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">While we are in the process of establishing manufacturing capability for certain clinical manufacturing activities, we do not currently plan to independently manufacture most of the material for our planned clinical programs. We currently </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">rely, and expect to continue to rely, on third parties for the production of our preclinical study and planned clinical trial materials, including the materials used to administer our product candidates and, therefore, we can control only certain aspects of their activities. The competition for gene therapy contract development, manufacturing and testing is intense. Reliance on third-party manufacturers may expose us to different risks than if we were to manufacture product candidates ourselves, including but not limited to potential competition from other genetic biotechnology companies for the use of such third-party manufacturers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">While we have secured an agreement with Catalent to manufacture clinical supply of our product candidates, we have not yet secured manufacturing capabilities for commercial quantities of our product candidates. To date, while we have a collaboration agreement with Catalent for a dedicated clean room suite, we have only entered into agreements with such manufacturer to support our clinical studies. We may be unable to negotiate binding agreements with the manufacturers to support our potential commercialization activities at commercially reasonable terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Before any of our third-party manufacturers and suppliers can begin to commercially manufacture our product candidates, including the materials used to administer our product candidates, they must demonstrate to regulatory authorities that the planned chemistry, manufacturing and controls for our gene therapy product candidates meet certain requirements. Manufacturing of product candidates for clinical and commercial purposes must comply with the cGMP and applicable ex-U.S. regulatory requirements. The cGMP requirements govern quality control and documentation policies and procedures. Complying with cGMP and ex-U.S. regulatory requirements will require that we expend time, money and effort in production, recordkeeping and quality control to assure that our product candidates meet applicable specifications and other requirements. Our third-party manufacturers&#8217; also must demonstrate to the FDA and ex-U.S. regulators that they can make the product candidate in accordance with the cGMP requirements as part of a pre-approval inspection prior to FDA or similar ex-U.S. regulatory approval of the product candidate. Failure to pass a pre-approval inspection might significantly delay our ability to begin trials in the respective jurisdiction and FDA and ex-U.S. regulatory approval of our product candidates. If any of our third-party manufacturers fail to comply with these requirements, we would be subject to possible regulatory action, which could limit the jurisdictions in which we are permitted to sell our products. As a result, our business, financial condition and results of operations may be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, our third-party manufacturers may fail to comply with cGMP regulations or similar regulatory requirements outside the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even if our third-party manufacturers comply with applicable regulatory requirements, we cannot assure you that they will be able to successfully manufacture additional product candidates at a larger scale in a timely or economical manner, or at all. If they are unable to successfully increase our manufacturing scale or capacity, the development, testing, and clinical trials of our product candidates may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our third-party manufacturers and suppliers use biological materials and may use hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time-consuming or costly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our third-party manufacturers and suppliers may use hazardous materials, including chemicals and biological agents and compounds that could be dangerous to human health and safety or the environment. The operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state, and local laws and regulations govern the use, generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product development efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Any contamination in our third parties&#8217; manufacturing process, shortages of raw materials, labor or reagents or failure of any of our key suppliers to deliver necessary components of our platform could result in delays in our clinical development or marketing schedules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Given the nature of biologics manufacturing, there is a risk of contamination. Any contamination could materially adversely affect our or our third-party vendor&#8217;s ability to produce our gene therapies on schedule and could therefore harm our results of operations and cause reputational damage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The raw materials required in our third-party vendors manufacturing processes are derived from biological sources. We cannot assure that our third-party vendors have, or will be able to obtain on commercially reasonable terms, or at all, sufficient rights to these materials derived from biological sources. Such raw materials are difficult to procure and may also be subject to contamination or recall. A material shortage, contamination, recall, or restriction on the use of biologically derived substances in the manufacture of our product candidates could adversely impact or disrupt the clinical and commercial manufacturing of our product candidates, which could materially and adversely affect our operating results and development timelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We rely on third-party suppliers for the supply and manufacture of certain components of our technology. Should our ability to procure these material components from our suppliers be compromised, our ability to continuously operate would be impaired until an alternative supplier is sourced, qualified and tested, which could limit our ability to produce a clinical and commercial supply of our product candidates and harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We depend on third-party suppliers for materials used in the manufacture of our product candidates, and the loss of these third-party suppliers or their inability to supply us with adequate materials could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We rely on third-party suppliers for certain materials and components required for the production of our product candidates, including the materials used to administer our product candidates. Our dependence on these third-party suppliers and the challenges we may face in obtaining adequate supplies of materials involve several risks, including limited control over pricing, availability, and quality and delivery schedules. There is substantial demand and limited supply for certain of the raw materials used to manufacture gene therapy products. As a small company, our negotiation leverage is limited and we are likely to get lower priority than our competitors that are larger than we are. We cannot be certain that our suppliers will continue to provide us with the quantities of these raw materials that we require or satisfy our anticipated specifications and quality requirements. Any supply interruption in limited or sole sourced raw materials could materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and potential commercialization of our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Commercialization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We face significant competition in an environment of rapid technological change and the possibility that our competitors may achieve regulatory approval before us or develop therapies or technologies that are more advanced or effective than ours, which may harm our business and financial condition, and our ability to successfully market or commercialize our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries, including the genetic medicines field, are characterized by rapidly changing technologies, competition and a strong emphasis on intellectual property. We are aware of several companies focused on developing gene therapies in various indications as well as several companies addressing methods for modifying genes and regulating gene expression. We may also face competition from large and specialty pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">For the treatment of GM1, there are no approved disease-modifying therapies. We consider our most direct competitor with respect to PBGM01 for the treatment of GM1 to be Lysogene, S.A, or Lysogene. Lysogene is conducting a Phase 1/2 clinical trial for a gene therapy treatment administered via ICM for early and late infantile GM1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;">For the treatment of FTD, there are no approved disease-modifying therapies. We consider our most direct competitors with respect to PBFT02 for the treatment of FTD-GRN to be Alector, Inc. (partnered with GlaxoSmithKline), which is enrolling a Phase 3 clinical trial with a humanized anti-human sortilin monoclonal antibody for FTD-GRN, and Prevail Therapeutics Inc. (now part of Eli Lilly &amp; Co), which has initiated a Phase 1/2 clinical trial for a gene therapy treatment for FTD-GRN, and is expected to continue enrolling into 2023. Several other companies, including Applied Genetic Technologies Corporation (recently acquired by Syncona), Orchard Therapeutics plc, Sinfonia Biotherpeutics, QurAlis and Aviado Therapeutics, are conducting preclinical research using gene therapy approaches to treat FTD-GRN patients. <span style="letter-spacing:0.25pt;">AviadoBio Ltd has reported the planned initiation of a phase 1/2 trial in 2023. </span>Denali Therapeutics Inc. in partnership with Takeda Pharmaceutical Company Limited began recruitment of a Phase 1/2 clinical trial for their recombinant progranulin protein in addition to their oral EIF2a modulator already in a Phase 1 clinical trial. We are also aware of other therapeutic approaches in preclinical development that may target FTD-GRN patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Many of our potential competitors, alone or with their strategic partners, have substantially greater financial, technical, and other resources than we do, such as larger research and development, clinical, commercial and manufacturing organizations. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of competitors. Our commercial opportunity could be reduced or eliminated if competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any product candidates that we may develop. Competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market, if ever. Additionally, new or advanced technologies developed by our competitors may render our current or future product candidates uneconomical or obsolete, and we may not be successful in commercializing our product candidates against competitors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The commercial success of any of our product candidates will depend upon its degree of market acceptance by physicians, patients, third-party payors and others in the medical community.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Ethical, social and legal concerns about gene therapy could result in additional regulations restricting or prohibiting our products. Even with the requisite approvals from the FDA in the United States and other ex-U.S. regulatory authorities, the commercial success of our product candidates will depend, in part, on the acceptance of physicians, patients (which includes caregivers when applicable) and health care payors of gene therapy products in general, and our product candidates in particular, as medically necessary, cost-effective and safe. Any product that we commercialize may not gain acceptance by physicians, patients, health care payors and others in the medical community. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of gene therapy products and, in particular, our product candidates, if approved for commercial sale, will depend on several factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the efficacy, durability and safety of such product candidates as demonstrated in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential and perceived advantages of product candidates over alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of treatment relative to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the clinical indications for which the product candidate is approved by the FDA or ex-U.S. regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of physicians to order genetic testing for potential target patient populations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of potential patients to have genetic testing and counseling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of physicians to prescribe new therapies, including therapies using ICM administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to successfully train neurosurgeons and interventional radiologists in ICM administration of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and a therapy with ICM administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product labeling or product insert requirements of the FDA or ex-U.S. regulatory authorities, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">relative convenience and ease of administration;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing and distribution support;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of market introduction of competitive products and the perceptions of such competitive products compared to our products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">publicity concerning our products or competing products and treatments; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sufficient third-party payor coverage and adequate reimbursement and patients&#8217; willingness to pay out-of-pocket in the absence of such coverage and adequate reimbursement.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be fully known until after it is launched.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If in the future we are unable to establish U.S. or global sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if they are approved and we may not be able to generate any revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We currently do not have a sales team or marketing team for the sales, marketing, and distribution of any of our product candidates that may receive regulatory approval. In order to commercialize any product candidates after approval, we must build on a territory-by-territory basis sales, reimbursement, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. If our product candidates receive regulatory approval, we may decide to establish an internal sales team with technical expertise and supporting distribution capabilities to commercialize our product candidates, which will be expensive and time-consuming and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of any of our product candidates that we obtain approval to market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">With respect to the commercialization of all or certain of our product candidates, we may choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements when needed on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval or any such commercialization may experience delays or limitations. If we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay the pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to timely capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. The development of our clinical product candidates and ongoing research programs require significant resources. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Intellectual Property </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain and maintain patent protection or other necessary rights for our products and technology, or if the scope of the patent protection obtained is not sufficiently broad or our rights under licensed patents is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our products and technology may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our commercial success depends in part on our ability to obtain and maintain proprietary or intellectual property protection in the United States and other countries for our current product candidates and future products, as well as our core technologies, including our manufacturing know-how. We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of our business by seeking, maintaining and defending our intellectual property, whether developed internally or licensed from third parties. We also rely on trade secrets, know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of gene therapy. Additionally, for some of our product candidates, we intend to rely on regulatory protection afforded through rare drug designations, data exclusivity and market exclusivity as well as patent term extensions, where available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Currently, most of our intellectual property protection consists of patent applications that we have in-licensed from Penn under the Penn Agreement. The in-licensed patent applications are directed to certain new AAV capsids, to recombinant AAV viruses, or rAAV, capable of delivering certain genes into human cells to treat monogenic disorders of the CNS, to methods of treating those monogenic diseases with rAAV, as well as to certain aspects of our manufacturing capabilities and related technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We also have options under the Penn Agreement to add additional intellectual property to our existing license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our intellectual property further includes a patent application that we solely own that covers processes for manufacturing rAAV.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has in recent&#160;years been the subject of much litigation. The degree of patent protection we require to successfully compete in the marketplace may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our licensed patent applications will mature into issued patents, and cannot provide any assurances that any such patents, if issued, will include claims with a scope sufficient to protect our current and future product candidates or otherwise provide any competitive advantage. Additionally, patents can be enforced only in those jurisdictions in which the patent has issued. Furthermore, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally twenty&#160;years after its first nonprovisional U.S. filing. The natural expiration of a patent outside of the United States varies in accordance with provisions of applicable local law, but is generally 20&#160;years from the earliest local filing date. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Moreover, our exclusive license is subject to field restrictions and retained rights, which may adversely impact our competitive position. Our licensed patent portfolio may not provide us with adequate and continuing patent protection sufficient to exclude others from commercializing products similar to our product candidates, including biosimilar versions of such products. In addition, the patent portfolio licensed to us is, or may be, licensed to third parties outside our licensed field, and such third parties may have certain enforcement rights. Thus, patents licensed to us could be put at risk of being invalidated or interpreted narrowly in litigation filed by or against another licensee or in administrative proceedings brought by or against another licensee in response to such litigation or for other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other parties have developed technologies that may be related or competitive to our own and such parties may have filed or may file patent applications, or may have received or may receive patents, claiming inventions that may overlap or conflict with those claimed in our own patent applications or issued patents. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and in other jurisdictions </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether the inventors of our licensed patents and applications were the first to make the inventions claimed in those patents or pending patent applications, or that they were the first to file for patent protection of such inventions. Further, we cannot assure you that all of the potentially relevant prior art relating to our licensed patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application. As a result, the issuance, scope, validity and commercial value of our patent rights cannot be predicted with any certainty. Further, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, the patent prosecution process is expensive and time-consuming, and we or our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, the scope of the claims initially submitted for examination may be significantly narrowed by the time they issue, if at all. It is also possible that we or our licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We cannot provide any assurances that we will be able to pursue or obtain additional patent protection based on our research and development efforts, or that any such patents or other intellectual property we generate will provide any competitive advantage. Moreover, we do not have the right to control the preparation, filing and prosecution of patent applications, or to control the maintenance of the patents, covering technology that we license from third parties. Therefore, these patents and applications may not be filed, prosecuted or maintained in a manner consistent with the best interests of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even if we acquire patent protection that we expect should enable us to maintain competitive advantage, the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Third parties, including competitors, may challenge the inventorship, scope, validity, or enforceability thereof, which may result in such patents being narrowed, invalidated or held unenforceable. If issued, our licensed patents may be challenged in patent offices in the United States and international markets, or in court. For example, we may be subject to a third-party submission of prior art to the U.S. Patent and Trademark Office, or USPTO, challenging the validity of one or more claims of our licensed patents, once issued. Such submissions may also be made prior to a patent&#8217;s issuance, precluding the granting of a patent based on one of our pending licensed patent applications. We may become involved in opposition, reexamination, <i style="font-style:italic;">inter partes</i> review, post-grant review, derivation, interference, or similar proceedings in the United States or abroad challenging the claims of patents that we have licensed, once issued. Furthermore, patents that we have licensed may be challenged in court, once issued. Competitors may claim that they invented the inventions claimed in such patents or patent applications prior to the inventors of our licensed patents, or may have filed patent applications before the inventors of our licensed patents did. A competitor may also claim that we are infringing its patents and that we therefore cannot practice our technology as claimed under our licensed patent applications and patents, if issued. As a result, one or more claims of our licensed patents may be narrowed or invalidated. In litigation, a competitor could claim that our patents, if issued, are not valid for a number of reasons. If a court agrees, we would lose our rights to those challenged patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even if they are unchallenged, our licensed patents and pending patent applications, if issued, may not provide us with any meaningful protection or prevent competitors from designing around our patent claims to circumvent our licensed patents by developing similar or alternative technologies or therapeutics in a non-infringing manner. For example, even if we have a valid and enforceable patent, we may not be able to exclude others from practicing our invention if the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. Moreover, a third party may develop a competitive product that provides benefits similar to one or more of our product candidates but that uses a vector or an expression construct that falls outside the scope of our patent protection or license rights. If the patent protection provided by the patents and patent applications we hold or pursue with respect to our product candidates is not sufficiently broad to impede such competition, our ability to successfully commercialize our product candidates could be negatively affected, which would harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Similar risks would apply to any patents or patent applications that we may own or in-license in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition to patent protection, if any of our product candidates are approved by the FDA as a biological product under a BLA in the United States, we believe the product would qualify for a 12-year period of exclusivity. Other regulatory </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">exclusivities may be available, such as Orphan Drug exclusivity, with analogous data, marketing, and orphan exclusivities in various foreign countries. However, the scope of such regulatory exclusivities is subject to change, and may not provide us with adequate and continuing protection sufficient to exclude others from commercializing products similar to our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">All of our current product candidates and research programs are licensed from or based upon licenses from a third -party and are field limited to certain indications. If this license agreement is terminated or interpreted to narrow our rights, our ability to advance our current product candidates or develop new product candidates based on these technologies will be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We now depend on Penn, and will continue to depend on Penn and on licenses and sublicenses from other third parties, as well as potentially on other strategic relationships with third parties, for the research, development, manufacturing and commercialization of our current product candidates. If any of our licenses or relationships or any in-licenses on which our licenses are based are terminated or breached, we may:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lose our rights to develop and market our current product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lose patent or trade secret protection for our current product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">experience significant delays in the development or commercialization of our current product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not be able to obtain any other licenses on acceptable terms, if at all; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur liability for damages.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, even if not terminated or breached, our intellectual property licenses or sublicenses may be subject to disagreements over contract interpretation which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we experience any of the foregoing, it could have a materially adverse effect on our business and could force us to cease operations which could cause you to lose all of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we breach our license agreements it could have a material adverse effect on our commercialization efforts for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If we breach any of the agreements under which we license the use, development and commercialization rights to our product candidates or technology from third parties, we could lose license rights that are important to our business. Our current clinical product candidates and pipeline are and our anticipated near term pipeline will be, licensed from Penn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the Penn Agreement, we are subject to various obligations, including payment obligations, diligence obligations such as development and commercialization obligations, as well as potential royalty payments and other obligations. If we fail to comply with any of these obligations or otherwise breach our license agreements, our licensors may have the right to terminate the applicable license in whole or in part. Generally, the loss of any one of our current licenses, or any other license we may acquire in the future, could harm our business, prospects, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our right to sublicense patent and other intellectual property rights to third parties under collaborative development relationships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether and the extent to which inventors are able to contest the assignment of their rights to our licensors.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms or at all, we may be unable to successfully develop and commercialize the affected product candidates. In addition, if disputes arise as to ownership of licensed intellectual property, our ability to pursue or enforce the licensed patent rights may be jeopardized. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize our products could suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our strategy of obtaining rights to key technologies through in-licenses may not be successful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We seek to expand our product candidate pipeline in part by in-licensing the rights to key technologies. The future growth of our business will depend in part on our ability to in-license or otherwise acquire the rights to additional product candidates or technologies. We cannot assure you that we will be able to in-license or acquire the rights to any product candidates or technologies from third parties on acceptable terms or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The in-licensing and acquisition of these technologies is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire product candidates or technologies that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to license rights to us. Furthermore, we may be unable to identify suitable product candidates or technologies within our area of focus. If we are unable to successfully obtain rights to suitable product candidates or technologies, our business, financial condition and prospects could suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Third parties may initiate legal proceedings alleging claims of intellectual property infringement, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Our commercial success depends upon our ability and the ability of our collaborators to develop, manufacture, market and sell our product candidates and future products and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and frequent litigation regarding patents and other intellectual property rights. We may in the future become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates, future products and technology. Our competitors or other third parties may assert infringement or misappropriation claims against us, alleging that our therapeutics, manufacturing methods, formulations or administration methods are covered by their patents. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing product candidates. For example, a third party previously sent us a letter claiming that the use of our AAVhu68 capsid infringes certain patent claims to which the third party  has an exclusive license . While this matter has been resolved and we believe that we would have valid defenses to these and any other such claims; however, if any such claims were ultimately successful, we might require a license to continue to use and sell any product candidates using such AAV vector. Such licenses may not be available on commercially reasonable terms, or at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Further, we do not know which processes we will use for commercial manufacture of our future products, or which technologies owned or controlled by third parties may prove important or essential to those processes. Given the vast number of patents in our field of technology, we cannot be certain or guarantee that we do not or will not infringe existing patents or that we will not infringe patents that may be granted in the future. Many companies have filed, and continue to file, patent applications related to gene therapy and orphan diseases. Some of these patent applications have already been allowed or issued and others may issue in the future. Since this area is competitive and of strong interest to pharmaceutical and biotechnology companies, there will likely be additional patent applications filed and additional patents granted in the future, as well as additional research and development programs expected in the future. Furthermore, because patent applications can take many&#160;years to issue, may be confidential for 18&#160;months or more after filing and can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use, sale or importation of our product candidates or future products. If a </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">patent holder believes the manufacture, use, sale, offer for sale or importation of one of our product candidates or future products infringes its patent, the patent holder may sue us even if we have licensed other patent protection for our technology. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant product revenue and against whom our licensed patent portfolio may therefore have no deterrent effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">It is also possible that we have failed to identify relevant third-party patents or applications. For example, applications filed before November&#160;29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Moreover, it is difficult for industry participants, including us, to identify all third-party patent rights that may be relevant to our product candidates and technologies because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We may fail to identify relevant patents or patent applications or may identify pending patent applications of potential interest but incorrectly predict the likelihood that such patent applications may issue with claims of relevance to our technology. In addition, we may be unaware of one or more issued patents that would be infringed by the manufacture, sale, importation or use of a current or future product candidate, or we may incorrectly conclude that a third-party patent is invalid, unenforceable or not infringed by our activities. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, our future products or the manufacture or use of our future products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Third parties may assert infringement claims against us based on existing intellectual property rights and intellectual property rights that may be granted in the future. If we were to challenge the validity of an issued U.S. patent in court, such as an issued U.S. patent of potential relevance to some of our product candidates or future products or manufacture or methods of use, we would need to overcome a statutory presumption of validity that attaches to every U.S. patent. This means that in order to prevail, we would have to present clear and convincing evidence as to the invalidity of the patent&#8217;s claims. There is no assurance that a court would find in our favor on questions of infringement or validity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Patent and other types of intellectual property litigation can involve complex factual and legal questions, and their outcome is uncertain. If we are found, or believe there is a risk we may be found, to infringe a third-party&#8217;s intellectual property rights, we could be required or may choose to obtain a license from such third party to continue developing and marketing our products and technology. However, we may not be able to obtain any such license on commercially reasonable terms, or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. Without such a license, we could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our future products or force us to cease some of our business operations, which could materially harm our business. Alternatively, we may need to redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. If we lose a foreign patent lawsuit alleging our infringement of a competitor&#8217;s patents, we could be prevented from marketing our therapeutics in one or more foreign countries and/or be required to pay monetary damages for infringement or royalties in order to continue marketing. Claims that we have misappropriated the confidential information, trade secrets or other intellectual property of third parties could have a similar negative impact on our business. Any of these outcomes would have a materially adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Even if we are successful in these proceedings, we may incur substantial costs and divert management time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court, or redesign our future products or processes. Patent litigation is costly and time-consuming, and some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. We may not have sufficient resources to bring these actions to a successful conclusion. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts, adversely affect our ability to raise additional funds, and could limit our ability to continue our operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to the protection afforded by patents, we rely upon unpatented trade secret protection, unpatented know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our contractors, collaborators, scientific advisors, employees and consultants and invention assignment agreements with our consultants and employees. We may not be able to prevent the unauthorized disclosure or use of our technical know-how or other trade secrets by the parties to these agreements, however, despite the existence generally of confidentiality agreements and other contractual restrictions. Monitoring unauthorized uses and disclosures is difficult and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the contractors, collaborators, scientific advisors, employees and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation. As a result, we could lose our trade secrets. Enforcing a claim that a third-party illegally obtained and is using our trade secrets, like patent litigation, is expensive and time-consuming and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing or unwilling to protect trade secrets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our trade secrets could otherwise become known or be independently discovered by our competitors. Competitors could purchase our product candidates and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual property rights. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If our trade secrets are not adequately protected or sufficient to provide an advantage over our competitors, our competitive position could be adversely affected, as could our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating our trade secrets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees on issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime of the patent. While an unintentional lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in premature abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, we may not be able to stop a competitor from marketing drugs that are the same as or similar to our product candidates, which would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be able to protect our intellectual property rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. The requirements for patentability may differ in certain countries, particularly in developing countries. Moreover, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Further, licensing partners may not prosecute patents in certain jurisdictions in which we may obtain commercial rights, thereby precluding the possibility of later obtaining patent protection in these countries. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Most of our in-licensed patent families are pending in major pharmaceutical markets including the United States, Canada, Europe, Japan, Korea, and China, as well as other jurisdictions; we will not be able to enforce the patent in any jurisdictions in which the application has not been filed. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and we or our licensor may be unable to predict and may fail to seek patent protection in jurisdictions in which protection may ultimately be desired.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Competitors may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents, in addition to counterclaims asserting that our patents are invalid or unenforceable, or both. The outcome following legal assertions of invalidity and unenforceability is unpredictable. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our patent claims do not cover the invention. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties or other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for&#160;years before they are concluded. Even if we ultimately prevail </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in patent law in the United States and in ex-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Past or future patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. For example, in March&#160;2013, under the Leahy-Smith America Invents Act, or America Invents Act, the United States moved from a &#8220;first to invent&#8221; to a &#8220;first-inventor-to-file&#8221; patent system. Under a &#8220;first-inventor-to-file&#8221; system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to a patent on the invention regardless of whether another inventor had made the invention earlier. The America Invents Act includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted, redefine prior art and establish a new post-grant review system. The effects of these changes are currently unclear as the USPTO continues to promulgate new regulations and procedures in connection with the America Invents Act and many of the substantive changes to patent law, including the &#8220;first-inventor-to-file&#8221; provisions, only became effective in March&#160;2013. In addition, the courts have yet to address many of these provisions and the applicability of the act and new regulations on the specific patents discussed in this filing have not been determined and would need to be reviewed. However, the America Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. For example, in the case, <i style="font-style:italic;">Assoc. for Molecular Pathology v. Myriad Genetics,&#160;Inc.,</i> the U.S. Supreme Court held that certain claims to DNA molecules are not eligible for patent protection. We cannot predict how future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. Any similar adverse changes in the patent laws of other jurisdictions could also have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to claims asserting that our employees, consultants, advisors or collaborators have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of or other rights to what we regard as our own or licensed intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Many of our employees, consultants or advisors, and the employees, consultants or advisors of our licensors, are currently, or were previously, employed at or affiliated with universities, hospitals or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer. Moreover, some of our licensors, and our or our licensors&#8217; employees, consultants or advisors are or have been affiliated or have a contractual relationship with multiple institutions and companies including our competitors and may have or have had an obligation to them. Such institutions and companies could challenge our license rights or our licensors&#8217; intellectual property ownership rights. Litigation may be necessary to defend against these claims and we may be obligated to indemnify our employees, consultants, advisors or collaborators in certain instances. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting our product candidates might expire before or shortly after we or our partners commercialize those candidates. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we do not obtain patent term extension for any product candidates we may develop, our business may be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Depending upon the timing, duration and specifics of any FDA marketing approval of any product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Hatch-Waxman Amendments permit a patent extension term of up to five&#160;years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval, only one patent per product may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, even if we were to seek a patent term extension, it may not be granted because of, for example, the failure to exercise due diligence during the testing phase or regulatory review process, the failure to apply within applicable deadlines, the failure to apply prior to expiration of relevant patents, or any other failure to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and prospects could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Some of the intellectual property rights that we have in-licensed were generated through the use of U.S. government fundingand are thereforesubject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements, and a preference for U.S. based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with ex-U.S. manufacturers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Some of the intellectual property rights we have in-licensed were generated through the use of U.S. government funding and are therefore subject to certain federal regulations. As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act, and implementing regulations. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right to require us or our licensors to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i)&#160;adequate steps have not been taken to commercialize the invention; (ii)&#160;government action is necessary to meet public health or safety needs; or (iii)&#160;government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the intellectual property within specified time limits. These time limits have recently been changed by regulation, and may change in the future. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with ex-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The pricing, insurance coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our clinical product candidates target indications with small patient populations. In order for products that are designed to treat smaller patient populations to be commercially viable, the reimbursement for such products must be higher, on a relative basis, to account for the lack of volume. Accordingly, we will need to implement a coverage and reimbursement strategy for any approved product candidate that accounts for the smaller potential market size. If we are unable to establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We expect the cost of a single administration of gene therapy products, such as those we are developing, to be substantial when and if they achieve regulatory approval. Therefore, we expect that coverage and reimbursement by government and private payors will be essential for most patients to be able to afford these treatments. Accordingly, sales of any of our product candidates will depend substantially, both domestically and internationally, on the extent to which the costs of our product candidates will be paid by health maintenance, managed care, pharmacy benefit and similar healthcare management organizations, or will be reimbursed by government authorities, private health coverage insurers and other third-party payors. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a sufficient return on our investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about reimbursement for new products are typically made by the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, since CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare. Private payors tend to follow CMS to a substantial degree. However, one payor&#8217;s determination to provide coverage for a drug product does not assure that other payors will also provide coverage for the drug product. Further, a payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. It is difficult to predict what CMS will decide with respect to reimbursement for novel products such as ours since there is no body of established practices and precedents for these new products. Reimbursement agencies in Europe may be more conservative than CMS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the countries of the EU, the prices of medical products are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, the prices of products under such systems are substantially </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">lower than in the United States. Other countries allow companies to fix their own prices for products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Moreover, increasing efforts by governmental and third-party payors, in the United States and internationally, to cap or reduce healthcare costs may cause such organizations to limit both coverage and level of reimbursement for new products approved and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of certain third-party payors, such as health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products into the healthcare market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition to CMS and private payors, professional organizations such as the American Medical Association can influence decisions about reimbursement for new products by determining standards for care. In addition, many private payors contract with commercial vendors who sell software that provide guidelines that attempt to limit utilization of, and therefore reimbursement for, certain products deemed to provide limited benefit to existing alternatives. Such organizations may set guidelines that limit reimbursement or utilization of our product candidates. Even if favorable coverage and reimbursement status is attained for one or more products for which we or our collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fast Track Designation by the FDA may not lead to a faster development or regulatory review or approval process. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have obtained Fast Track Designation for PBGM01 for the treatment of GM1 gangliosidosis, for PBFT02 for the treatment of FTD-GRN and for PBKR03 for the treatment of Krabbe disease. We may seek Fast Track Designation for one or more of our other product candidates. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates the potential to address unmet medical needs for this condition, the product sponsor may apply for FDA Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may withdraw Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we decide to seek Orphan Drug Designation for some of our product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for supplemental market exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;">We have obtained Orphan Drug Designations for PBGM01 for the treatment of GM1 gangliosidosis, for PBFT02 for the treatment of FTD-GRN and for PBKR03 for the treatment of Krabbe disease. We have sought and may continue to seek Orphan Drug Designation for one or more of our other product candidates, and we may be unsuccessful. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as tax advantages and user-fee waivers. Opportunities for grant funding toward clinical trial costs may also be available for clinical trials of drugs for rare diseases, regardless of whether the drugs are designated for the orphan use. In addition, if a product that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;">market the same product for the same indication for seven&#160;years, except in limited circumstances. For large molecule drugs, including gene therapies, sameness is determined based on the principal molecular structural features of a product. As applied to gene therapies, the FDA has recently issued final guidance in which it stated it generally intends to consider certain key features, such as the transgenes expressed by the gene therapy and the vectors used to deliver the transgene, to be principal molecular structural features. With regard to vectors, the FDA generally intends to consider whether two vectors from the same viral class are the same or different on a case-by-case basis. The FDA does not intend to consider minor differences between transgenes and vectors to be different principal molecular structural features. When two gene therapy products express the same transgene and have or use the same vector, determining whether two gene therapies are the same drug may also depend on additional features of the final gene therapy product, such as regulatory elements and the cell type that is transduced (for genetically modified cells). In such cases, FDA generally intends to determine whether two gene therapy products are different on a case-by-case basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;">Although we have obtained Orphan Drug Designation for our clinical product candidates, and even if we obtain Orphan Drug Designation for additional product candidates in specific indications, we may not be the first to obtain marketing approval of these product candidates for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. If a competitor with a product that is determined by the FDA to be the same as one of our product candidates obtains marketing approval before us for the same indication we are pursuing and obtains orphan drug exclusivity, our product candidate may not be approved until the period of exclusivity ends unless we are able to demonstrate that our product candidate is clinically superior. Even after obtaining approval, we may be limited in our ability to market our product. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different principal molecular structural features can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same drug with the same principal molecular structural features for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. In addition, while we may seek Orphan Drug Designation for some of our product candidates, we may never receive such designations. Similarly, the European Commission may also designate a product as an orphan drug under certain circumstances, and we have received Orphan designation for PBGM01 and PBKR03 from the European Commission. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Rare Pediatric Disease designation by the FDA for any of our product candidates does not guarantee that the BLA for the product will qualify for a priority review voucher upon approval, and it does not lead to a faster development or regulatory review process, or increase the likelihood that our product candidates will receive marketing approval. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Under the Rare Pediatric Disease Priority Review Voucher program, upon the approval of a qualifying BLA for the treatment of a rare pediatric disease, the sponsor of such an application would be eligible for a rare pediatric disease priority review voucher that can be used to obtain priority review for a subsequent BLA or NDA. If a product candidate is designated before September 30, 2024, it is eligible to receive a voucher if it is approved before September 30, 2026. While we have obtained Rare Pediatric Disease Designation for PBGM01 for the treatment of GM1 gangliosidosis and PBKR03 for the treatment of Krabbe disease, it is uncertain whether either product candidate will be approved by September 30, 2026. If approval is not obtained by then, we would not be in a position to obtain a priority review voucher, unless Congress further reauthorizes the program beyond the current sunset date in September 2024. Additionally, designation of a drug for a rare pediatric disease does not guarantee that a BLA will meet the eligibility criteria for a rare pediatric disease priority review voucher at the time the application is approved. Finally, a Rare Pediatric Disease Designation does not lead to faster development or regulatory review of the product or increase the likelihood that it will receive marketing approval. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Any product candidate for which we obtain marketing approval will be subject to extensive post-marketing regulatory requirements and could be subject to post-marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our product candidates and the activities associated with their development and potential commercialization, including their testing, manufacture, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMPs, requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, including periodic inspections by the FDA and other regulatory authorities and requirements regarding the distribution of samples to physicians and recordkeeping.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of any approved product. The FDA closely regulates the post-approval marketing and promotion of drugs and biologics to ensure drugs and biologics are marketed only for the approved indications and in accordance with the provisions of the approved product labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding use of their products. If we promote our product candidates beyond their potentially approved indications, we may be subject to enforcement action for off-label promotion. Violations of the Federal Food, Drug, and Cosmetic Act relating to the promotion of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, later discovery of previously unknown adverse events or other problems with our product candidates, manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on such product candidates, manufacturers or manufacturing processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the labeling or marketing of a product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on product distribution or use;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">requirements to conduct post-marketing studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">warning or untitled letters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of any approved product from the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to approve pending applications or supplements to approved applications that we submit;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recall of product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, restitution or disgorgement of profits or revenues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension or withdrawal of marketing approvals;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal to permit the import or export of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Non-compliance with European requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our product candidates for which we intend to seek approval may face competition from biosimilars approved through an abbreviated regulatory pathway</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or the ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA. The BPCIA created an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as interchangeable based on its similarity to an existing reference product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12&#160;years after the original branded product is approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We believe that if any of our product candidates is approved as a biological product under a BLA, it should qualify for the 12-year period of exclusivity. However, there is a risk that the FDA will not consider any of our product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Additionally, this period of regulatory exclusivity does not apply to companies pursuing regulatory approval via their own traditional BLA, rather than via the abbreviated pathway. Moreover, an interchangeable biosimilar, once approved, may be substituted under existing law for any one of our reference products in a way that is similar to traditional generic substitution; any non-interchangeable biosimilar products may also be substituted by a health care provider but, under existing law, will not be automatically substituted at the pharmacy.  The extent of the impact of such substituion will depend on a number of marketplace and regulatory factors that are still developing. Finally, there has been public discussion of potentially decreasing the period of exclusivity from the current 12 years. If such a change were to be enacted, our product candidates, if approved, could have a shorter period of exclusivity than anticipated.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates and may affect the prices we may set. The full effect of recent United States healthcare reform and other changes in the healthcare industry, laws, and regulations and in healthcare spending is currently unknown, and the reform and other changes may adversely affect our business model.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any products for which we obtain marketing approval. The commercial potential for our products, if any, could be affected by changes in healthcare spending and policy in the United States and abroad.  New laws, regulations, or judicial decisions or new interpretations of existing laws, regulations, or decisions, related to healthcare availability, the method of delivery, or payment for healthcare products and services could adversely affect our business, operations, and financial condition, if and when we are able to obtain marketing approval and commercialize our products. For example, the ACA was enacted in 2010 with a goal, among others, of reducing the cost of healthcare and substantially changing the way healthcare is financed by both government and private insurers. The ACA, among other things, expanded manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program, imposed a significant annual, nondeductible fee on companies that manufacture or import certain branded prescription drug products, and enacted substantial provisions affecting compliance, which may affect our business practices with healthcare practitioners.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">There have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs in general and the cost of pharmaceuticals in particular. These initiatives recently culminated in the enactment of the Inflation Reduction Act, or IRA, in August 2022, which, among other things, will allow HHS to negotiate the selling price of certain drugs and biologics that CMS reimburses under Medicare Part B and Part D (excluding drugs and biologics that are designated and approved for only one rare disease or condition), although only high-expenditure single-source biologics that have been approved for at least 11 years (7 years for drugs) can be selected by CMS for negotiation, with the negotiated price taking effect two years after the selection year. The negotiated prices, which will first become effective in 2026, will be capped at a statutory ceiling price representing a significant discount from average prices to wholesalers and direct purchasers. Beginning in October 2022 for Medicare Part D and January 2023 for Medicare Part B, penalizes drug manufacturers that increase prices of Medicare Part D and Part B drugs at a rate greater than the rate of inflation. In addition, the law eliminates the &#8220;donut hole&#8221; under Medicare Part D beginning in 2025 by significantly lowering the beneficiary maximum out-of-pocket cost through a newly established manufacturer discount program. The IRA also extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025. The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. Manufacturers that fail to comply with the IRA may be subject to various penalties, including civil monetary penalties. These provisions will take effect progressively starting in 2023, although they may be subject to legal challenges. Thus, it is unclear how the IRA will be implemented but will likely have a significant impact on the pharmaceutical industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Further, at the U.S. state level, legislatures are increasingly enacting laws and implementing regulations designed to control pharmaceutical and biological product pricing, including price or reimbursement constraints, discount requirements, marketing cost disclosure and price increase transparency reporting, and programs designed to encourage importation from other countries and bulk purchasing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services or otherwise negatively impact our business model. Our operations and relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to penalties including criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Healthcare providers and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with providers, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any product candidates for which we obtain marketing approval.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Restrictions under applicable U.S. federal and state healthcare laws and regulations may include the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under federal healthcare programs such as Medicare and Medicaid;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal false claims laws, including the federal False Claims Act, imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health, or HITECH, Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, on certain types of people and entities with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Physician Payment Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), physician assistants, certain types of advanced practice nurses, and teaching hospitals, as well as certain ownership and investment interests held by physicians and their immediate family, which includes annual data collection and reporting obligations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. Other state laws require reporting of certain pricing information, including price increases. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of product candidates from government-funded healthcare programs, such as Medicare and Medicaid, disgorgement, oversight monitoring, contractual damages, reputational harm, diminished profits and future earnings, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government-funded healthcare programs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Employee Matters, Managing Growth and Other Risks Related to Our Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be required to expand our manufacturing, development and regulatory capabilities in the future, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may be required to expand our manufacturing, development and regulatory capabilities in the future, which could result in growth to the number of our employees and the scope of our operations, particularly in the areas of manufacturing and clinical strategy, and growing our capability to conduct clinical trials. We may not be able to effectively manage the expansion of our operations in the future or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are highly dependent on the research and development, clinical and business development expertise of our management, scientific and clinical team. We also benefit from the research expertise of Dr.&#160;Wilson, our Chief Scientific Advisor. Although we have entered into a consulting agreement with Dr.&#160;Wilson, he may terminate his relationship with us at any time. Although we have entered into employment letter agreements or employment agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and manufacturing strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Recruiting and retaining qualified scientific, clinical, manufacturing and, if needed, sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize drugs, particularly within the gene therapy space. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Failure to succeed in clinical trials may make it more challenging to recruit and retain qualified scientific personnel. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Further, the reductions in workforce announced in March 2022 and November 2022 may also make retention of our current personnel both more important and more challenging. These workforce reductions resulted in the loss of longer-term employees, the loss of institutional knowledge and expertise and the reallocation and combination of certain roles and responsibilities across the organization, all of which could adversely affect our operations. Given the complexity of our business, we must continue to implement and improve our managerial, operational and financial systems, manage our facilities and continue to recruit and retain qualified personnel. Given the complexity of our business, we must continue to implement and improve our managerial, operational and financial systems, manage our facilities and continue to recruit and retain qualified personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Further, we recently underwent a leadership transition, which may be viewed negatively by employees, investors and/or our strategic partners. Moreover, any attrition associated with this transition could significantly delay or prevent the achievement of product development and commercialization, and other business objectives, and adversely impact our stock price.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our internal computer systems, or those of our third-party collaborators or other contractors, may fail or suffer security breaches and cyber attacks, which could result in a material disruption of our development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We believe that we take reasonable steps that are designed to protect the security, integrity and confidentiality of the information we collect, use, store, and disclose, but inadvertent or unauthorized data access may occur despite our efforts. For example, our system protections may be ineffective or inadequate, or we could be impacted by software bugs or other technical malfunctions, as well as employee error or malfeasance. Additionally, privacy and data protection laws are evolving, and it is possible that these laws may be interpreted and applied in a manner that is inconsistent with our data handling safeguards and practices that could result in fines, lawsuits, and other penalties, and significant changes to our or our third-party partners business practices and products and service offerings. To the extent that the measures we or our third-party business partners have taken prove to be insufficient or inadequate, we may become subject to litigation, breach notification obligations, or regulatory or administrative sanctions, which could result in significant fines, penalties, damages, harm to our reputation or loss of patients. While we have not experienced any material losses as a result of any system failure, accident or security breach to date, we have been the subject of certain phishing attempts in the past. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. Additionally, a party who circumvents our security measures could, among other effects, appropriate patient information or other proprietary data, cause interruptions in our operations, or expose patients to hacks, viruses, and other disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, insurance coverage to compensate for any losses associated with such events may not be adequate to cover all potential losses. The development and maintenance of these systems, controls and processes is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become increasingly sophisticated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">To the extent that any disruption, security breach, or cyber-attack were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed. Depending on the nature of the information compromised, in the event of a data breach or other unauthorized access to our patient data, we may also have obligations to notify patients and regulators about the incident, and we may need to provide some form of remedy, such as a subscription to credit monitoring services, pay significant fines to one or more regulators, or pay compensation in connection with a class-action settlement (including under the new private right of action under the California Consumer Privacy Act of 2018, or the CCPA, which is expected to increase security breach litigation). Such breach notification laws continue to evolve and may be inconsistent from one jurisdiction to another. Complying with these obligations could cause us to incur substantial costs and could increase negative publicity surrounding any incident that compromises patient data. Additionally, the financial exposure from the events referenced above could either not be insured against or not be fully covered through any insurance that we may maintain, and there can be no assurance that the limitations of liability in any of our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages as a result of the events referenced above. Any of the foregoing could have an adverse effect on our business, reputation, operating results, and financial condition.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our ability to utilize our net operating loss carryforwards may be subject to limitation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">As of December 31, 2022, we had federal net operating loss, or NOL, carryforwards of $199.3 million. $0.3 million of the federal NOLs will begin to expire in 2037, if not used prior to that date, and the remainder will carryforward indefinitely. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">As of December 31, 2022, we had state NOL carryforwards of $199.3 million, which will begin to expire in 2037, and expire through 2042. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">As of December 31, 2022, we had local NOL carryforwards of $180.9 million, which will begin to expire in 2023, and expire through 2042. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any. Under legislative changes made by U.S. federal tax legislation, commonly referred to as the Tax Cuts and Jobs Act, or the TCJA, U.S. federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the ability to utilize such federal net operating losses to offset taxable income is limited to 80% of our taxable income before the deduction for such net operating loss carryovers. It is uncertain if and to what extent various states will conform to the TCJA.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the IRC, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes (such as research tax credits) to offset its post-change income and post-change liability may be limited. We have not undertaken a Section 382 study, and it is possible that we have previously undergone one or more ownership changes so that our use of net operating losses is subject to limitation. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">U.S. federal income tax reform and changes in other tax laws could adversely affect us.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tax laws are being re-examined and evaluated globally, and tax authorities are increasingly scrutinizing the tax positions of companies. Changes in tax laws and regulations in federal, state, local, and foreign jurisdictions could have material adverse impacts on our business, cash flows, operating results, or financial condition, and could materially affect our tax obligations and effective tax rate. For example, U.S. tax legislation enacted on December 22, 2017, informally titled the Tax Cuts and Jobs Act, or the Tax Cuts and Jobs Act, significantly reformed the Internal Revenue Code of 1986, as amended, or the Code. This legislation, among other things, included changes to U.S. federal tax rates, imposed significant additional limitations on the deductibility of interest and the use of net operating losses generated in tax years beginning after December 31, 2017 and allowed for the expensing of capital expenditures. The Tax Cuts and Jobs Act is unclear in many respects and could be subject to potential amendments and technical corrections, as well as interpretations and implementing regulations by the Treasury and the Internal Revenue Service, or IRS, any of which could lessen or increase certain adverse impacts of the legislation. In addition, in response to the COVID-19 pandemic, the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, was signed into law in March 2020, and subsequently in December 2020, the Continued Assistance for Unemployed Workers Act of 2020, or CARES Act II, was signed into law. The CARES Act and CARES Act II modify certain of the changes made by the Tax Cuts and Jobs Act. Changes in corporate tax rates, the realization of net deferred tax assets, and the deductibility of expenses under the Tax Cuts and Jobs Act, as amended by the CARES Act and CARES Act II, or future tax reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges in the current or future taxable years, and could increase our future U.S. tax expense. The foregoing items, as well as any other future changes in tax laws, could have a material adverse effect on our business, operating results and financial condition. In addition, it is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act, as amended by the CARES Act and CARES Act II, or any newly enacted federal tax legislation. Changes in tax laws or regulations in the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">various tax jurisdictions we are subject to that are applied adversely to us or our clients could increase the costs of our products and harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, we use our best judgment in attempting to quantify and reserve for our tax obligations. However, a challenge by a taxing authority, a limitation on our ability to utilize tax benefits such as carryforwards or tax credits, or a deviation from other tax-related assumptions could have a material adverse effect on our business, results of operations, or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the regulations of FDA and ex-U.S. regulators, provide accurate information to the FDA and ex-U.S. regulators, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidates that we may develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We will face an inherent risk of product liability exposure related to the testing of our product candidates in clinical trials and will face an even greater risk if we commercialize any of our product candidates. If we cannot successfully defend ourselves against claims that our product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for any product candidates that we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of investigations by regulators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant time and expenses to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of management and scientific resources from our business operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">loss of revenue; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize any product candidates that we may develop.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We currently hold limited product liability insurance coverage. We will need to purchase additional product liability insurance coverage as we expand our clinical trials, and if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. A successful product liability claim or series of claims brought against us, could decrease our cash and adversely affect our business and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations that can harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls, the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other partners from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States, to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other partners, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for holders of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our stock price has been and is likely to continue to be volatile. The stock market in general and the market for biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results of preclinical studies or clinical trials of our product candidates or those of our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated or serious safety concerns related to the use of any of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse regulatory decisions, including failure to receive regulatory approval for any of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of competitive drugs or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory or legal developments in the United States and other countries applicable to our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and growth of our prospective patient populations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments concerning our collaborators, our external manufacturers or in-house manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to obtain adequate product supply for any product candidate for preclinical studies, clinical trials or future commercial sale or inability to do so at acceptable prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the recruitment or departure of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of expenses related to any of our product candidates or clinical development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of our efforts to discover, develop, acquire or in-license additional product candidates or drugs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts or publications of research reports about us or our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations in our financial results or those of companies that are perceived to be similar to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the biotechnology sector;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our cash position or the announcement or expectation of additional financing efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ongoing COVID-19 pandemic could adversely impact our business, including our clinical trials and clinical trial operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry and market conditions, including rising interest rates and inflation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic uncertainty and capital markets disruptions, which has been substantially impacted by geopolitical instability due to the ongoing military conflict in Ukraine; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other factors, including those described in this &#8220;Risk Factors&#8221; section, many of which are beyond our control.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our executive officers, directors, principal stockholders and their affiliates exercise significant influence over our company, which will limit your ability to influence corporate matters and could delay or prevent a change in corporate control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, our executive officers, directors, beneficial owners of 5% or more of our capital stock and their respective affiliates beneficially owned shares representing a substantial portion of our capital stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">This group of stockholders has the ability to control us through this ownership position and may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid any cash dividends on our common stock and do not currently intend to do so for the foreseeable future. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will be limited to the appreciation of stock. Therefore, the success of an investment in shares of our common stock will depend upon any future appreciation in value of the stock. We cannot guarantee you that shares of our common stock will appreciate in value or even maintain the price at which our stockholders have purchased their shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we fail to establish and maintain proper and effective internal control over financial reporting in the future, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, investors&#8217; views of us and, as a result, the value of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to Section&#160;404 of the Sarbanes-Oxley Act, we are required to furnish a report by our management on our internal control over financial reporting within our Form 10-K. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that will need to be frequently evaluated. Section 404 of the Sarbanes-Oxley Act requires public companies to conduct an annual review and evaluation of their internal controls and attestations of the effectiveness of internal controls, however, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. Our failure to maintain the effectiveness of our internal controls in accordance with the requirements of the Sarbanes-Oxley Act could have a material adverse effect on our business.If we identify one or more material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. In addition, if we are not able to continue to meet these requirements, we may not be able to remain listed on The Nasdaq Stock Market LLC, or Nasdaq.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As we grow, we expect to hire additional personnel and may utilize external temporary resources to implement, document and modify policies and procedures to maintain effective internal controls. However, it is possible that we may identify deficiencies and weaknesses in our internal controls. If material weaknesses or deficiencies in our internal controls exist and go undetected or unremediated, our financial statements could contain material misstatements that, when discovered in the future, could cause us to fail to meet our future reporting obligations and cause the price of our common stock to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We will continue to incur increased costs as a result of operating as a public company and our management will continue to be required to devote substantial time to new compliance initiatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As a public company, particularly after we are no longer an &#8220;emerging growth company,&#8221; we will continue to incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act of 2002 and rules&#160;subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel will need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules&#160;and regulations will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. We are an &#8220;emerging growth company&#8221; and &#8220;smaller reporting company,&#8221; and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We will remain an emerging growth company until the earlier of (i)&#160;the last day of the fiscal&#160;year in which we have total annual gross revenue of $1.235 billion or more; (ii)&#160;December&#160;31, 2025; (iii)&#160;the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three&#160;years; or (iv)&#160;the date on which we are deemed to be a large accelerated filer under the rules&#160;of the SEC, which means the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the last business day of our most recently completed second fiscal quarter. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">being permitted to present only two&#160;years of audited financial statements in addition to any required unaudited interim financial statements with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure in this Form 10-K;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reduced disclosure obligations regarding executive compensation; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We may choose to take advantage of some, but not all, of the available exemptions. Even after we no longer qualify as an emerging growth company, we may still qualify as a smaller reporting company, which would allow us to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">elected to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will not be subject to the same adoption timelines for new or revised accounting standards as other public companies that are not emerging growth companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates is less than $700.0 million and our annual revenue is less than $100.0 million during the most recently completed fiscal&#160;year. We will continue to be a smaller reporting company if either (i)&#160;the market value of our stock held by non-affiliates is less than $250.0 million or (ii)&#160;our annual revenue is less than $100.0 million during the most recently completed fiscal&#160;year and the market value of our stock held by non-affiliates is less than $700.0 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal&#160;years of audited financial statements in our Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The exclusive forum provisions in our restated certificate of incorporation and amended and restated bylaws may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our restated certificate of incorporation, to the fullest extent permitted by law, provides that the Court of Chancery of the State of Delaware will be the exclusive forum for: any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, or the DGCL, our restated certificate of incorporation, or our restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. This exclusive forum provision does not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended, or the Exchange Act. It could apply, however, to a suit that falls within one or more of the categories enumerated in the exclusive forum provision and asserts claims under the Securities Act, inasmuch as Section&#160;22 of the Securities Act, creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rule&#160;and regulations thereunder. There is uncertainty as to whether a court would enforce such provision with respect to claims under the Securities Act, and our stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules&#160;and regulations thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2020,&#160;we amended and restated our restated bylaws to provide that the federal district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, or a Federal Forum Provision. Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While there can be no assurance that federal or state courts will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case, application of&#160;the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find the choice of forum provisions contained in our restated certificate of incorporation or amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, Section&#160;203 of the DGCL may discourage, delay or prevent a change in control of our company. Section&#160;203 imposes certain restrictions on mergers, business combinations and other transactions between us and holders of 15% or more of our common stock.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Provisions in our restated certificate of incorporation and our restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a classified board of directors so that not all members of our board are elected at one time;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">permit only the board of directors to establish the number of directors and fill vacancies on the board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">provide that directors may only be removed &#8220;for cause&#8221; and only with the approval of two-thirds of our stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">require super-majority voting to amend some provisions in our restated certificate of incorporation and restated bylaws;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">authorize the issuance of &#8220;blank check&#8221; preferred stock that our board could use to implement a stockholder rights plan, also known as a &#8220;poison pill&#8221;;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eliminate the ability of our stockholders to call special meetings of stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prohibit cumulative voting; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Moreover, we are governed by the provisions of Section&#160;203 of the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three&#160;years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any of these provisions of our charter documents or Delaware law could, under certain circumstances, depress the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">General Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to securities litigation, which could result in substantial expenses and could divert management attention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The market price of our common stock has been and may continue to be volatile. The stock market in general, and Nasdaq and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. We do not have any control over the analysts or the content and opinions included in </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">their reports. If one or more of the analysts covering our business downgrade their evaluations of our stock, the trading price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to a variety of privacy and data security laws, and our failure to comply with them could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We maintain a large quantity of sensitive information, including confidential business and personal information in connection with the operation of our business, and are subject to laws and regulations governing the privacy and security of such information. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the United States, there are numerous federal and state privacy and data security laws and regulations governing the collection, use, disclosure and protection of personal information, including federal and state health information privacy laws, federal and state security breach notification laws, and federal and state consumer protection laws. Each of these constantly evolving laws can be subject to varying interpretations. In addition, states are constantly adopting new laws or amending existing laws, requiring attention to frequently changing regulatory requirements with inconsistent or conflicting standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">California has enacted the CCPA, which became operative on January 1, 2020 and became enforceable by the California Attorney General on July 1, 2020. Additionally, in the California Privacy Rights Act, or CPRA, which expands upon the CCPA, became effective on January 1, 2023. The CCPA and CPRA require covered companies to, among other things, provide new disclosures to California users, and affords such users new privacy rights such as the ability to opt-out of certain sales of personal information and expanded rights to access and require deletion of their personal information, opt-out of certain personal information sharing, and receive detailed information about how their personal information is collected, used, and shared. The CCPA and CPRA provide for civil penalties for violations, as well as a private right of action for security breaches that may increase security breach litigation. Potential uncertainty surrounding the CCPA and CPRA may increase our compliance costs and potential liability, particularly in the event of a data breach, and could have a material adverse effect on our business, including how we use personal information, our financial condition, the results of our operations or prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Other states have passed similar laws, and a number of other states are actively considering bills with similar laws. To the extent multiple state-level laws are later introduced, it may require costly and difficult efforts to achieve compliance with such laws that could expose us to fines and penalties for non-compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In the European Economic Area, or the EEA, the General Data Protection Regulation or the GDPR, governs the collection, use, disclosure, transfer or other processing of personal data of European persons. Among other things, the GDPR imposes requirements regarding the security of personal data and notification of data processing obligations to the competent national data processing authorities, changes the lawful bases on which personal data can be processed, expands the definition of personal data and requires changes to informed consent practices, as well as more detailed notices for clinical trial subjects and investigators. In addition, the GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the EEA to the United States and other jurisdictions that the European Commission does not recognize as having &#8220;adequate&#8221; data protection laws (sometimes referred to as &#8220;third countries&#8221;), and imposes strict rules subject to substantial fines for breaches and violations (up to the greater of &#8364;20 million or 4% of our annual worldwide gross revenue). These obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other requirements or our practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, in the United Kingdom, or U.K., the Data Protection Act contains provisions, including its own derogations, for how GDPR is applied in the U.K. We have to continue to comply with the GDPR and also the U.K.&#8217;s Data Protection Act, with each regime having the ability to fine up to the greater of &#8364;20 million (&#163;17 million) or 4% of global turnover.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In 2020, the Court of Justice of the European Union, or CJEU, invalidated the European Union-United States, or E.U.-U.S., Privacy Shield (under which personal data could be transferred from the E.U. to U.S. entities that had self-certified under the Privacy Shield scheme), or Privacy Shield on the grounds that the Privacy Shield failed to offer adequate protections to E.U. personal data transferred to the United States. The Biden administration negotiated new privacy shield terms with EU regulators and signed an Executive Order in October 2022 directing the steps the United States will take to implement its commitments to the EU/US data privacy framework.  The new proposed Privacy Shield terms are subject to further review by EU regulators and member states.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In addition, while the CJEU upheld the adequacy of the standard contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism, and potential alternative to the Privacy Shield), it made clear that reliance on them alone may not necessarily be sufficient in all circumstances. Use of the standard contractual clauses must now be assessed on a case by case basis, taking into account the legal regime applicable in the destination country, in particular applicable surveillance laws and rights of individuals. The use of standard contractual clauses for the transfer of personal data specifically to the United States remains under review by a number of European data protection supervisory authorities, along with those of some other E.U. member states. German and Irish supervisory authorities have indicated, and enforced in recent rulings, that the standard contractual clauses alone provide inadequate protection for E.U.-U.S. data transfers. Further, on June 4, 2021 the European Commission finalized new versions of the Standard Contractual Clauses, with the Implementing Decision now in effect as of June 27, 2021. To comply with the Implementing Decision and the new Standard Contractual Clauses, we may need to implement additional safeguards to further enhance the security of data transferred out of the EEA, conduct data transfer impact assessments, and review existing agreements which could increase our compliance costs, expose us to further regulatory scrutiny and liability, and adversely affect our business. The new standard contractual clauses apply only to the transfer of data outside of the EEA and/or Switzerland and not the United Kingdom, though the U.K.&#8217;s Information Commissioner&#8217;s Officer launched a public consultation on its draft international data transfer agreement in August 2021, and subsequently issued a new international data transfer agreement and addendum which we are required to use under Article 46 of the UK GDPR when making restricted data transfers outside of the UK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations. Furthermore, the laws are not consistent, and compliance in the event of a widespread data breach is costly. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We generally seek to comply with industry standards and are subject to the terms of our privacy policies and privacy-related obligations to third parties. We strive to comply with all applicable laws, policies, legal obligations and industry codes of conduct relating to privacy and data protection to the extent possible. However, it is possible that these obligations may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other rules or our practices. Any failure or perceived failure by us, even if unfounded, to comply with applicable privacy and data security laws and regulations, our privacy policies, or our privacy-related obligations to users or other third parties, or any compromise of security that results in the unauthorized release or transfer of personal information or other sensitive data, may result in governmental enforcement actions, litigation, or public statements against us by consumer advocacy groups or others and could cause our users to lose trust in us, which would have an adverse effect on our reputation and business. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Any significant change to applicable laws, regulations or industry practices regarding the use or disclosure of our users&#8217; data, or regarding the manner in which the express or implied consent of users for the use and disclosure of such data is obtained &#8211; or in how these applicable laws, regulations or industry practices are interpreted and enforced by state, federal and international privacy regulators &#8211; could require us to modify our practices, possibly in a material manner, may subject us to regulatory enforcement actions and fines, and may limit our ability to operate using the data that was voluntarily shared with us.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. For example, the global financial crisis caused extreme volatility and disruptions in the capital and credit markets, and, in recent months, the global economy has been impacted by increasing interest rates and inflation. Likewise, the capital and credit markets may be adversely affected by the recent conflict between Russia and Ukraine, and the possibility of a wider European or global conflict, and global sanctions imposed in response thereto. A severe or prolonged economic downturn, such as the global financial crisis, could result in a variety of risks to our business, including, weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Natural disasters could severely disrupt our operations and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our manufacturing facilities, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. <span style="background:#ffffff;">In addition, the long-term effects of climate change on general economic conditions and the pharmaceutical industry in particular are unclear, and may heighten or intensify existing risk of natural disasters.&#160;</span>The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_509b353a_a9f4_4731_b75f_d66e29a935bb"></a><a id="Item1BUnresolvedStaffComments_644817"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1B.&#160;&#160;&#160;&#160;&#160;<span style="font-style:italic;">Unresolved Staff Comments</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">None</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_16e3743f_19b4_40e2_afbd_5feb515ecb51"></a><a id="Item2PropertiesandFacilities_24543"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;2.&#160;&#160;&#160;&#160;&#160;<span style="font-style:italic;">Properties and Facilities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="letter-spacing:0.25pt;">Our principal executive office is located in Philadelphia, Pennsylvania, where we lease a total of approximately 37,000 square feet of office space, </span>that we use for our administrative, research and development and other activities, which commenced in February 2021 and will expire in December 2031, subject to our option to extend the term of the lease by up to two additional five-year terms<span style="letter-spacing:0.25pt;">.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><span style="letter-spacing:0.25pt;">We also lease approximately 62,000 square feet of laboratory space at the Princeton West Innovation Campus in Hopewell, New Jersey. This lease has a 15-year term from the lease commencement date of March 2021. We have the option to extend the term of the lease by up to two additional five-year terms.</span><span style="letter-spacing:0.2pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_379da088_6a0a_452b_bd19_7ea9f083d029"></a><a id="Item3LegalProceedings_840413"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3.&#160;&#160;&#160;&#160;&#160;<span style="font-style:italic;">Legal Proceedings</span><span style="font-style:italic;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputational harm, and other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_00f766ad_a2b8_4311_87e4_1e76321bdbeb"></a><a id="Item4MineSafetyDisclosures_801065"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4.&#160;&#160;&#160;&#160;&#160;Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 18pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_50d755fc_de5e_4598_a304_1957ae794389"></a><a id="PARTII_199413"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="Item5MarketforRegistrantsCommonEquityRel"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:42.5pt;text-indent:-42.5pt;margin:0pt 0pt 12pt 0pt;">Item&#160;5.&#160;&#160;&#160;&#160;&#160;<span style="font-style:italic;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity</span><span style="font-style:italic;"> Securities</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Market Information for Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our common stock has been listed on The Nasdaq Global Market under the symbol &#8220;PASG&#8221; since February&#160;28, 2020. Prior to that there was no public trading market for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Holders of Record</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As of March&#160;2, 2023, there were approximately 24 stockholders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Dividend Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We currently intend to retain future earnings, if any, for use in operation of our business and to fund future growth. We have never declared or paid any cash dividends on our capital stock and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Unregistered Sales of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Use of Proceeds from Registered Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 18pt;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e7bdab2d_81ed_41b7_84b0_a0d39718ec4b"></a><a id="Item6SelectedFinancialData_184761"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;6.&#160;&#160;&#160;&#160;&#160;<span style="font-style:italic;">[Reserved]</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c351ff09_e792_4fa2_83a4_93fdb7e43098"></a><a id="Item7ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7.&#160;&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this Form 10-K. Some of the information contained in this discussion and analysis contains forward-looking statements that involve risks and uncertainties. You should review the section titled &#8220;Risk Factors&#8221; in this Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described below.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We are a clinical stage genetic medicines company focused on developing transformative therapies for CNS disorders. Our vision is to fulfill the promise of gene therapy by developing groundbreaking therapies that transform the lives of patients with CNS diseases. The field of genetic medicine is rapidly expanding and we believe we have a differentiated approach to developing treatments for CNS disorders that enables us to select and advance product candidates with a higher probability of technical and regulatory success. We have entered into a strategic research collaboration with the Trustees of the University of Pennsylvania&#8217;s, or Penn&#8217;s, Gene Therapy Program, or GTP, headed by Dr.&#160;James Wilson, a leader in the genetic medicines field. We also leverage our close working relationship with Penn&#8217;s Orphan Disease Center, or ODC, to develop historical and prospective comparable natural history patient profiles for comparison to participants in interventional trials. Through this collaboration we have assembled a deep portfolio of genetic medicine product candidates, for which we retain global rights, including our two lead clinical product candidates: PBGM01 for the treatment of GM1 gangliosidosis, or GM1, and PBFT02 for the treatment of frontotemporal dementia, or FTD, and two clinical stage product candidates for which, in order to reduce operating expenses, we have stopped further clinical development and are exploring strategic alternatives: PBKR03 for the treatment of Krabbe disease and PBML04 for metachromatic leukodystrophy, or MLD. We have two programs in the research stage: PBAL05 for amyotrophic lateral sclerosis, or ALS, and an unnamed program for Huntington&#8217;s disease. We also have an exploratory research program for Temporal Lobe Epilepsy, or TLE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We were incorporated in July&#160;2017 under the laws of the State of Delaware. Since inception, we have devoted substantially all of our resources to acquiring and developing product and technology rights, conducting research and development, organizing and staffing our company, business planning and raising capital. We have incurred recurring losses, the majority of which are attributable to research and development activities, and negative cash flows from operations. Historically, we have funded our operations through the sale of convertible preferred stock and public offerings of common stock. Our net losses were $136.1&#160;million and $185.4 million for the&#160;years ended December&#160;31, 2022 and 2021, respectively. As of December&#160;31,&#160;2022, we had an accumulated deficit of $492.4 million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates through all stages of development and clinical trials and, ultimately, seek regulatory approval. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Our net losses may fluctuate significantly from quarter to quarter and&#160;year to year, depending on the timing of our clinical trials and our expenditures on other research and development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We will need to raise substantial additional capital to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we plan to finance our operations through the sale of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. There are no assurances that we will be successful in obtaining an adequate level of financing as and when needed to finance our operations on terms acceptable to us or at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to secure adequate additional funding, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more product candidates or delay our pursuit of potential in-licenses or acquisitions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In March 2022, we announced a 13 percent reduction in workforce and plans to prioritize research and development programs to reduce operating expenses and to extend our cash runway. In November 2022, we announced a further 23 percent reduction in workforce and plans to prioritize research and development programs to reduce operating expenses and to extend our cash runway.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2022, we had cash, cash equivalents and marketable securities of $189.6 million. We expect our existing cash, cash equivalents and marketable securities, will enable us to fund our operating expenses and capital expenditure requirements into the first half of 2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financial Operations Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">University of Pennsylvania</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We have a research, collaboration and licensing agreement, as amended, or the Penn Agreement, with Penn, for research and development collaborations and exclusive license rights to patents for certain products and technologies.&#160;Under the Penn Agreement, we have the obligation to fund certain research relating to the preclinical development of selected products in research programs as well as the new exploratory research program in non-rare and/or non-monogenic, or large, CNS indications, currently in TLE. We also fund discovery research conducted by Penn through August 2026 and will receive exclusive rights, subject to certain limitations, to technologies resulting from the discovery program for products developed with GTP,&#160;such as novel capsids, toxicity reduction technologies and delivery and formulation improvements.&#160;Our discovery research funding commitment is $5.0 million a&#160;year for five&#160;years, with quarterly payments of $1.3 million through June 2026.&#160;Under&#160;the Penn Agreement we have eight remaining&#160;options available to us to commence additional licensed programs for CNS indications until August&#160;2026. If we were to exercise any of these remaining options, we would owe Penn a non-refundable aggregate fee of&#160;$1.0 million, with $0.5&#160;million per product indication paid immediately and another $0.5 million fee owed upon a further developmental milestone.</p><a id="_cp_text_2_21"></a><a id="_cp_text_1_22"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Penn Agreement requires that we make payments of up to (i) $16.5&#160;million per product candidate for rare, monogenic disorders in aggregate and (ii) $39.0 million per product candidate in the aggregate arising from the exploratory program for large CNS indications, currently TLE and such other mutually agreed upon large CNS indications. Each payment will be due upon the achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and no development milestone payments for subsequent indications. In addition, on a product-by-product basis, we are obligated to make up to $55.0&#160;million in sales milestone payments on each licensed product based on annual sales of the licensed product in excess of defined thresholds.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Upon successful commercialization of a product using the licensed technology, we are obligated to pay to Penn, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits on annual worldwide net sales of such licensed product. In addition, we are obligated to pay to Penn a&#160;percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Penn Agreement. In addition, we will pay Penn a tiered transaction fee ranging from 1-2% of the net proceeds upon certain change of control events.</p><a id="_cp_text_1_32"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Penn Agreement includes an exploratory research collaboration to identify targets and early product candidates in such large CNS indications. The exploratory research program is focused on discovering targets and novel gene therapy candidates for large CNS diseases, currently focused on TLE, and that can be expanded to other large CNS diseases upon mutual agreement. The initial term of the exploratory research program is 3 years, or until August 2024, which term can be extended by mutual agreement. During such term we will have an exclusive right of first negotiation to include additional targets to the exploratory research program in the agreed upon large CNS indications. Under the exploratory research program, we will have the right to further develop and commercialize any gene therapy product candidates specific for those selected targets within TLE (and any future large CNS indications that are mutually agreed upon) that arise from the exploratory research programs on substantially the same terms of the current Penn Agreement. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In November 2022, we agreed with GTP to not continue further advancement of our exploratory research program in AD.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Collaboration and Manufacturing and Supply Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Catalent</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June 2019, we entered into a collaboration agreement, or the Collaboration Agreement,&#160;with Catalent Maryland,&#160;Inc., or Catalent. As part of the Collaboration Agreement, we paid Catalent an upfront fee for the commissioning, qualification, validation and equipping of a dedicated clean room suite, or the Clean Room Suite. We will pay an annual fee for five years for the exclusive use of the Clean Room Suite, which commenced in November 2020 upon its validation. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2020, we entered into a development services and clinical supply agreement, or the Manufacturing and Supply Agreement, with Catalent to secure clinical scale manufacturing capacity for batches of active pharmaceutical ingredients for our gene therapy product candidates. The Manufacturing and Supply Agreement provides for a term of five&#160;years which period may be extended once, at our option, for an additional five&#160;year-period. The Collaboration Agreement <span style="background:#ffffff;">continues to be in effect pursuant to its terms</span>. <span style="background:#ffffff;">Under the terms of the Manufacturing and Supply Agreement, Catalent has agreed to manufacture batches of drug product for our gene therapy product candidates at the Clean Room Suite provided for in the Collaboration Agreement. There is a minimum annual purchase commitment owed to Catalent for five years beginning in November 2020, subject to certain inflationary adjustments. We have the right to terminate the Manufacturing and Supply Agreement for convenience or other reasons specified in the Manufacturing and Supply Agreement upon prior written notice. If we terminate the Manufacturing and Supply Agreement, we will be obligated to pay an early termination fee to Catalent.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">Under both the Collaboration Agreement and the Manufacturing and Supply Agreement, we have an annual minimum commitment of $10.6 million per year owed to Catalent for five years from November 2020, subject to certain inflationary adjustments.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Components of Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development and Acquired In-Process Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of costs incurred in connection with the development of our product candidates. These expenses include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred to conduct the necessary preclinical studies and clinical trials required to obtain regulatory approval, including payments to Penn for preclinical research and development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred in obtaining technology licenses related to technology that has not reached technological feasibility and has no alternative future use, which are classified as acquired In-process research and development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">personnel expenses, including salaries, benefits and share-based compensation expense for employees engaged in research and development functions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses related to funding research performed by third parties, including pursuant to agreements with clinical research organizations, or CROs, as well as investigative sites and consultants that conduct our preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">expenses incurred under agreements with contract manufacturing organizations, or CMOs, including  the cost of acquiring and manufacturing preclinical study and clinical trial materials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses and fees paid to consultants who assist with research and development activities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allocated expenses for facilities costs, including rent, utilities, depreciation and maintenance.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We track outsourced development expenses and other external research and development expenses to specific product candidates on a program-by-program basis, such as expenses incurred under our collaboration with Penn, fees paid to </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">CROs, CMOs and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. However, we do not track our internal research and development expenses on a program-by-program basis as they primarily relate to compensation and other expenses which are deployed across multiple projects under development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Expenses incurred in obtaining technology licenses are expensed as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development expenses than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Given our reductions in workforce and prioritization of research and development programs, in order to reduce operating expenses, we expect our research and development expenses to remain consistent or decrease in the near future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If our product candidate portfolio progresses into later-stage clinical trials, we expect that our research and development expenses will increase in the future to support our continued research and development activities and production of clinical supply. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of personnel expenses, including salaries, benefits and share-based compensation expense, for employees and consultants in executive, finance, accounting, legal, information technology, commercial, quality, regulatory, operations and human resource functions. General and administrative expenses also include corporate facility costs, including rent, utilities, depreciation and maintenance, legal expenses related to intellectual property and corporate matters, insurance expense, and expenses for accounting and consulting services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Given our recent reduction in workforce and prioritization of operating expenses, we expect our general and administrative expenses to remain consistent or decrease in the near future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If our product candidate portfolio progresses into later-stage clinical trials, we expect that our general and administrative expenses will increase in the future to support our continued research and development activities, potential commercialization efforts, and increased expenses of operating as a public company. These increases will likely include increased expenses related to the hiring of additional personnel and fees to outside consultants, lawyers and accountants, among other expenses. If any of our current or future product candidates obtain regulatory approval, we expect that we would incur significantly increased expenses associated with building a commercial sales and marketing team.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Interest Income, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Interest income, net consists of interest earned on our cash equivalents and marketable securities, offset by amortization of premium and discount on our marketable securities.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comparison of the&#160;Years Ended December&#160;31, 2022 and 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth our results of operations for the&#160;years ended December&#160;31, 2022 and 2021.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 86,053</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 117,673</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (31,620)</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Acquired in&#8209;process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,000)</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 49,341</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 60,056</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (10,715)</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (138,394)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (185,729)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 47,335</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,269</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 343</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,926</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (136,125)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (185,386)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 49,261</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses decreased by $31.6 million from $117.7 million for the&#160;year ended December&#160;31, 2021 to $86.1 million for the&#160;year ended December&#160;31, 2022. The decrease was primarily due to decreases of: $22.7&#160;million and $3.5 million in expenses for clinical manufacturing and clinical operations, respectively, which relates to the timing of our clinical manufacturing and operational activities to support our clinical trials; $9.6 million in research and development expenses with Penn; and, $3.0 million in personnel-related and share-based compensation expense. We expect that expenses associated with Penn will continue to vary from period to period based on the status of our preclinical pipeline and the timing of preclinical work performed. These decreases were partially offset by an increase of $3.6 million in professional services and an increase of $3.6 million in facility and other expenses, primarily due to depreciation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We track outsourced development, outsourced personnel expenses and other external research and development costs of specific programs. We do not track our internal research and development expenses on a program-by-program basis. Research and development expenses are summarized by program in the table below:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Program Specific Expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">PBGM01 (GM1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,055</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 16,871</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">PBFT02 (FTD&#8209;GRN)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,133</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,982</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">PBKR03 (Krabbe)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,527</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,022</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">PBML04 (MLD)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 5,949</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 12,542</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other Programs and Discovery</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,695</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 10,529</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Unallocated Internal Expenses</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Personnel-related (including share-based compensation)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 31,940</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 34,956</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,755</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 8,771</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 86,053</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.04%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 117,673</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Acquired In-Process Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Acquired in-process research and development expenses were $3.0 million for the&#160;year ended December&#160;31, 2022 compared to $8.0 million for the&#160;year ended December&#160;31, 2021. We incurred $3.0 million in fees related to the achievement of development milestones for dosing our first patients in PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe during the year ended December&#160;31,&#160;2022.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses decreased by $10.8 million from $60.1 million for the&#160;year ended December&#160;31, 2021 to $49.3 million for the&#160;year ended December&#160;31, 2022. The decrease was primarily due to decreases of $8.8 million in personnel-related and share-based compensation expense and a $4.4 million decrease in professional services and other expenses. These decreases were partially offset by an increase of $2.4 million in facility and other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Interest Income, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Interest income, net was $2.3 million and $0.3 million for the years ended December 31, 2022 and 2021, respectively. Interest income is primarily attributable to interest income earned on our cash, cash equivalents and marketable securities, partially offset by amortization of premium and discount on our marketable securities and fees paid to our external asset manager. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2022, we had $189.6 million in cash, cash equivalents and marketable securities and had an accumulated deficit of $492.4 million. We expect our existing cash, cash equivalents and marketable securities will enable us to fund our operating expense and capital expenditures into the first half of 2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Funding Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our primary use of cash is to fund operating expenses, most significantly research and development expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable, accrued expenses and prepaid expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, timing, progress and results of discovery, preclinical development, laboratory testing and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expenses of manufacturing our product candidates for clinical trials and in preparation for marketing approval and commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the extent to which we enter into collaborations or other arrangements with additional third parties in order to further develop our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expenses of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expenses and fees associated with the discovery, acquisition or in-license of additional product candidates or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish additional collaborations on favorable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expenses required to scale up our clinical, regulatory and manufacturing capabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expenses of future commercialization activities, if any, including establishing sales, marketing, manufacturing and distribution capabilities, for any of our product candidates for which we receive marketing approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We will need additional funds to meet operational needs and capital requirements for clinical trials, other research and development expenditures, and business development activities. We currently have no credit facility or committed sources of capital. Because of the numerous risks and uncertainties associated with the development and </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated clinical studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, existing stockholders&#8217; ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect existing stockholders&#8217; rights as common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates, or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, further reduce or terminate our research, product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On March 5, 2021, we entered into a Sales Agreement, or the Sales Agreement, with Cowen and Company, LLC, or Cowen, pursuant to which we may, but are not obligated to, offer and sell, from time to time, shares of our common stock with an aggregate offering price up to $125.0 million through Cowen, as sales agent. No sales of common stock have been made pursuant to this Sales Agreement to date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table shows a summary of our cash flows for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash provided by (used in) operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (118,210)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (126,879)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash provided by (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 25,199</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (45,814)</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash provided by (used in) financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (1,353)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 166,656</span></p></td></tr><tr><td style="vertical-align:bottom;width:75.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net increase (decrease) in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (94,364)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (6,037)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 11pt 0pt;">Net Cash Used in Operating Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">During the&#160;year ended December&#160;31,&#160;2022, we used $118.2 million of net cash in operating activities, primarily to fund our operations related to the development of our product candidates and related general and administrative support activities. Cash used in operating activities reflected our net loss of $136.1 million, which was partially offset by adjustments to reconcile net loss to net cash used in operating activities of $26.9 million related to acquired in-process research and development expense, share-based compensation, depreciation and amortization, amortization of premium and discount of marketable securities, net and amortization of operating lease ROU asset as well as a $9.0 million net decrease in cash flows resulting from changes in our operating assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">During the year ended December&#160;31,&#160;2021, we used $126.9 million of net cash in operating activities, primarily to fund our operations related to the development of our product candidates and related general and administrative support activities. Cash used in operating activities reflected our net loss of $185.4 million, which was partially offset by adjustments to reconcile net loss to net cash used in operating activities of $47.1 million related to acquired in-process research and development expense, share-based compensation, depreciation and amortization, amortization of premium and discount of marketable securities, net and changes in deferred rent as well as a $11.4 million net increase in cash flows resulting from changes in our operating assets and liabilities.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 11pt 0pt;">Net Cash From Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">During the&#160;year ended December&#160;31,&#160;2022, we purchased $157.8 million in marketable securities and had sales and maturities of $188.3 million in marketable securities. Additionally, we used $2.3 million for the purchase of property and equipment and we used $3.0 million to purchase technology rights from Penn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">During the&#160;year ended December&#160;31,&#160;2021, we purchased $202.5 million in marketable securities and had sales and maturities of $182.4 million in marketable securities. Additionally, we used $17.6 million for the purchase of property and equipment and we used $8.0 million to purchase technology rights from Penn.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 11pt 0pt;">Net Cash Used in Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">During the&#160;year ended December&#160;31,&#160;2022, we received $0.1 million from the exercise of stock options, received $0.3 million in proceeds from the issuance of common stock under the ESPP and paid $1.8 million for insurance premiums and insurance premium financing expenses under our short-term insurance premium financing arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">During the&#160;year ended December&#160;31,&#160;2021, financing activities provided $165.8 million from the sale of our common stock, we received $0.9 million from the issuance of common stock under our employee stock purchase plan, we received $0.3 million from the exercise of stock options, partially offset by payments for offering costs of $0.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Contractual obligations and other commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">We lease approximately 37,000 square feet of office space in Philadelphia, Pennsylvania. The lease will expire in&#160;December 2031. We have an option to extend the term of the lease by up to two additional five-year terms. The aggregate estimated rent payments due over the initial term of the lease is $11.8&#160;million, with rent payments that began in 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">We lease approximately 62,000 square feet of laboratory space in Hopewell, NJ. The lease will expire in March 2036. The aggregate estimated rent payments due over the initial term of the lease is approximately $40.3 million, with rent payments that began in 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">Under both the Collaboration Agreement and the Manufacturing and Supply Agreement with Catalent, we have an annual minimum commitment of $10.6 million per year owed to Catalent through November 2025, subject to certain inflationary adjustments. We have the right to terminate the Manufacturing and Supply Agreement for convenience or other reasons specified in the Manufacturing and Supply Agreement upon prior written notice. If we terminate the Manufacturing and Supply Agreement, we will be obligated to pay an early termination fee to Catalent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">Under the Penn Agreement, we agreed to fund discovery research conducted by Penn for five years, which began in May 2020. Our funding commitment is $5.0 million a year through June 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">The contractual obligations and commitments above are associated with contracts that are enforceable and legally binding and that specify all significant terms, including fixed or minimum services to be used, fixed, minimum or variable price provisions, and the approximate timing of the actions under the contracts. Payments due upon cancellation consisting only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation are not included in the preceding table as the amount and timing of such payments are not known.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 11pt 0pt;">The contractual obligations and commitments above do not include any potential milestone or royalty payments that we may be required to make under the Penn Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'Arial Narrow';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:13.0pt;margin:0pt;"><span style="font-family:'Arial Narrow';visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses and share-based compensation. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are described in more detail in Note&#160;3 to our annual financial statements included elsewhere in this Form 10-K, we believe the following accounting policy is the most critical to the judgments and estimates used in the preparation of our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Research and development costs are expensed as incurred and consist primarily of expenses incurred with Penn, contract research organizations, contract manufacturing organizations, internal analytical and testing activities, and employee-related expenses, including salaries, benefits, and share-based compensation. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">We make estimates of our external accrued research and development expenses, which primarily relates to</span> <span style="font-style:normal;font-weight:normal;">activities performed by our contract research organizations and contract manufacturing organizations, as of each balance sheet date in our financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to us at that time. We determine the estimates by reviewing contracts, vendor agreements and change orders,</span> <span style="font-style:normal;font-weight:normal;">invoicing to date, reviewing vendor provided supporting documentation and through discussions with our internal personnel and external service providers as to the progress to completion of services and the agreed-upon fee to be paid for such services. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Actual costs and estimates of progress to completion of our contract research organizations and contract manufacturing organizations are uncertain, subject to risks and may change depending upon a number of factors, including our enrollment levels and status of our clinical trials, and timing of our manufacturing activities. Such estimates are uncertain given the level of visibility we have towards the activities of our contract research organizations and contract manufacturing organizations. If the actual timing of the performance of services or the level of effort varies from the estimate, we will adjust the accrual and related expenses accordingly.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Recent Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">See Note&#160;3 to our financial statements found elsewhere in this Form 10-K for a description of recent accounting pronouncements applicable to our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">JOBS Act Accounting Election</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i)&#160;are no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We will remain an emerging growth company until the earliest of (1)&#160;the last day of our first fiscal&#160;<span style="white-space:pre-wrap;">year  (a)&#160;in which we have total annual gross revenues of at least $1.235 billion, or (b)&#160;in which we are deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the prior June&#160;30th, (2)&#160;the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period and (3)&#160;December&#160;31, 2025.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our stock held by non-affiliates is less than $700.0 million and our annual revenue is less than $100.0 million during the most recently completed fiscal&#160;year. We may continue to be a smaller reporting company if either (i)&#160;the market value of our stock held by non-affiliates is less than $250.0 million or (ii)&#160;our annual revenue is less than $100.0 million during the most recently completed fiscal&#160;year and the market value of our stock held by non-affiliates is less than $700.0 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal&#160;years of audited financial statements in our Annual Report on Form&#160;10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a4d1d934_94c5_47a3_93d6_7cd28ff4de78"></a><a id="Item7AQuantitativeandQualitativeDisclosu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;7A.&#160;&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures about Market Risk </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are exposed to market risks in the ordinary course of our business. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments are in marketable securities. Our marketable securities are subject to interest rate risk and could fall in value if market interest rates increase. However, we believe that our exposure to interest rate risk is not significant as the majority of our investments are short-term in duration and due to the low risk profile of our investments, a 10% change in interest rates would not have a material effect on the total market value of our investment portfolio. We have the ability to hold our marketable securities until maturity, and therefore we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a change in market interest rates on our investments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31,&#160;2022, we held $189.6&#160;million in cash, cash equivalents and marketable securities, all of which was denominated in U.S. dollar assets, and consisting primarily of cash accounts in banking institutions and investments in money market funds, certificates of deposit, commercial paper, corporate bonds and investments in U.S. and non-U.S. treasury securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are exposed to market risk related to changes in foreign currency exchange rates, as a result of entering into transactions denominated in currencies other than U.S. dollars. Due to the uncertain timing of expected payments in foreign currencies, we do not utilize any forward exchange contracts. All foreign transactions settle on the applicable spot exchange basis at the time such payments are made. For the&#160;year ended December&#160;31, 2022, a majority of our expenditures were denominated in U.S. dollars. A hypothetical 10% change in foreign exchange rates during any of the periods presented would not have had a material impact on our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Inflation may affect us by increasing our cost of labor, cost of external services, and cost of external goods and raw materials. We do not believe that inflation has had a material effect on our business, financial condition or results of operations for any period presented herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_de1a18aa_f221_4742_9379_21d681232284"></a><a id="Item8FinancialStatementsandSupplementary"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;8.&#160;&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PASSAGE BIO,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">INDEX TO AUDITED FINANCIAL STATEMENTS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:91.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><a href="#REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> <span style="font-size:9pt;">(</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:AuditorName" id="Narr_OT4_kkL8X0KlKDF3pdd59g"><span style="font-size:9pt;">KPMG LLP</span></ix:nonNumeric><span style="font-size:9pt;">, </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:AuditorLocation" id="Narr_fCYHzQ_EFEO8LagdrWmI8g"><span style="font-size:9pt;">Philadelphia, PA</span></ix:nonNumeric><span style="font-size:9pt;">, Auditor Firm ID:</span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="dei:AuditorFirmId" id="Narr_VpsdHOL3QEGXsDtEuR2HDA"><span style="font-size:9pt;">185</span></ix:nonNumeric><span style="font-size:9pt;">)</span></p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 2pt 0pt;">107</p></td></tr><tr><td style="vertical-align:bottom;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#BalanceSheets_463357"><span style="font-style:normal;font-weight:normal;">Balance Sheets</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">108</p></td></tr><tr><td style="vertical-align:bottom;width:91.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#StatementsofOperationsandComprehensiveLo"><span style="font-style:normal;font-weight:normal;">Statements of Operations and Comprehensive Loss</span></a></p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">109</p></td></tr><tr><td style="vertical-align:bottom;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#StatementsofConvertiblePreferredStockand"><span style="font-style:normal;font-weight:normal;">Statements of Stockholders&#8217; Equity </span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">110</p></td></tr><tr><td style="vertical-align:bottom;width:91.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><a href="#StatementsofCashFlows_152708"><span style="font-style:normal;font-weight:normal;">Statements of Cash Flows</span></a></p></td><td style="vertical-align:top;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 2pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 2pt 0pt;">111</p></td></tr><tr><td style="vertical-align:bottom;width:91.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><a href="#NotestoFinancialStatements_627885"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Financial Statements</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:2pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:2pt 0pt 0pt 0pt;">112</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_be4a46cd_2c6b_47d6_a4f0_8bdfa53ec739"></a><a id="REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 10pt 0pt;">To the Stockholders and Board of Directors<br />Passage Bio, Inc.:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;min-height:12.0pt;text-indent:0pt;"><i style="font-style:italic;">Opinion on the Financial Statements</i></div><div style="margin-top:5pt;"><a id="_0"></a><a id="_1"></a><a id="_2"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 10pt 0pt;">We have audited the accompanying balance sheets of Passage Bio, Inc.&#160;(the Company) as of December&#160;31,&#160;2022 and 2021, the related statements of operations and comprehensive loss, stockholders&#8217; equity, and cash flows for the years then ended, and the related notes (collectively, the financial statements).&#160;In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31,&#160;2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;min-height:12.0pt;text-indent:0pt;"><i style="font-style:italic;">Change in Accounting Principle</i></div><div style="margin-top:5pt;"><a id="_3"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 10pt 0pt;">As discussed in Notes 1 and 3 to the financial statements, the Company has changed its method of accounting for leases&#160;as of January 1, 2022 due to the adoption of Accounting Standards Update (ASU) No. 2016-02, <i style="font-style:italic;">Leases</i> <i style="font-style:italic;">(Topic 842)</i>.</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;min-height:12.0pt;text-indent:0pt;"><i style="font-style:italic;">Basis for Opinion</i></div><div style="margin-top:5pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 10pt 0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 10pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 10pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;text-align:center;margin:0pt 0pt 10pt 0pt;">/s/ KPMG LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 10pt 0pt;">We have served as the Company&#8217;s auditor since 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 10pt 0pt;">Philadelphia, Pennsylvania<br />March&#160;6,&#160;2023</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6ab9e6a7_f83d_4cce_bbcd_4a281d268a55"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio,&#160;Inc.</b></p><a id="BalanceSheets_463357"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Balance Sheets</b></p><a id="_25fb32fd_5435_41ad_9164_73be572e0ce8"></a><a id="Tc_tcBSOcYQSEi9LFic9G9j0w_1_2"></a><a id="Tc_yMjDwdFtIk-jArjDIclcAQ_2_0"></a><a id="Tc_z3y6dpGqEESrsCQlrQggHA_2_2"></a><a id="Tc_8uPNPL0fI0iyXyikQnQi7A_2_5"></a><a id="Tc_IfXSgGERG02yu6BYq7aU1w_3_0"></a><a id="Tc_mx9f2vJ4IkaBzcyzE7j3yw_4_0"></a><a id="Tc_NtA28ap4Zk63o6CK0jTJiQ_5_0"></a><a id="Tc_Oukvv9SHs0i5Kf-JJwOoHQ_5_2"></a><a id="Tc_W7tE4hKggESKFGXnSp8rZQ_5_5"></a><a id="Tc_5GUJjIGeSU2jwsEs1RLwZg_6_0"></a><a id="Tc_Lc4NBWBTAU28z4kM9t1R-Q_7_0"></a><a id="Tc_tIkHeFjvHkGiecmb-DlOGQ_8_0"></a><a id="Tc_D-G2MgLzdkCm8ILBEflCug_9_0"></a><a id="Tc_i_3Yt953KUeABMZJQV9TgA_10_0"></a><a id="Tc_plUn-Xmel0ikui_t9TnNiA_11_0"></a><a id="Tc_2yGqNx0pq0OQ2jU_qlH4mQ_11_6"></a><a id="Tc_i_BUon6yRUCQXkUevN8Djg_12_0"></a><a id="Tc_RaVTVw73MU-4RnPICq1p1g_13_0"></a><a id="Tc_9vWIam_EM0ipk_JrvyZrbQ_13_2"></a><a id="Tc_Rk70cYAYfUmBpaEpddVA0A_13_5"></a><a id="Tc_FtWxv_flSUeqtvuaLlkExQ_14_0"></a><a id="Tc_1YHX9SlU3UGYj3bkg6OrUg_15_0"></a><a id="Tc_CnY-qRmplkWSZe9KypJ22g_16_0"></a><a id="Tc_w-x_KlD3Tku9jlHWa2CEGA_16_2"></a><a id="Tc___-4uQXX0UGL06KXoT5Clw_16_5"></a><a id="Tc_PYdTpDnbS0O_xDqa4y6kyA_17_0"></a><a id="Tc_LDDHHq_bJkikM_R44rjhZQ_18_0"></a><a id="Tc_bozBYqMwbUyHP3Z5fEwiPQ_18_6"></a><a id="Tc_yOtS3ctj6kWj3PEQ1czDAw_19_0"></a><a id="Tc_IHcK_6DhRUqFcPsC30uK1g_20_0"></a><a id="Tc_vRQegu7cxE24p_UqIL-7CA_20_6"></a><a id="Tc_w6oed9I4ZEmuIHw1smN2sA_21_0"></a><a id="Tc_q1YNplDqCkiQr0jP1jpIlw_21_3"></a><a id="Tc_l3mqjs2tk0WaQCn6vLqzdA_22_0"></a><a id="Tc_GHRZu82lZU-t_oYM66Cq-w_24_0"></a><a id="Tc_Ana01FZwRESMdVpjo_GWyA_26_0"></a><a id="Tc_GICJKmFn2ECjBj0IKnYItQ_27_0"></a><a id="Tc_FEA8n530AkqdleQippKZFw_28_0"></a><a id="Tc_PsqLKEj1xkG9X43grpbwiQ_29_0"></a><a id="Tc_9GbiDSLtWESTwnNVdB3Eng_30_0"></a><a id="Tc_ULNTLxDn0EmX0_k6XoLbbQ_31_0"></a><a id="Tc_htU0KpQdLEeYaH5Oc7o5eA_32_0"></a><a id="Tc_W8ARv22M1UqSTRc2heg9KQ_32_2"></a><a id="Tc_tYprP0CTX0CDJihmd7pEBQ_32_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_HPY0ICBa0USWsKZ9nAfRlA_5_3">34,601</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_1Hj15ki3LkGHz_tFknFrpA_5_6">128,965</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_LCgJA8knc0OnwGLOMTWqPQ_6_3">155,009</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="Tc_T8iutxzID0SHzrg5TRHrtQ_6_6">186,808</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_lfZvKvaoB0KeJDC43G8VHA_7_3">926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_1LTFKmw-7UOGebbao0I_NQ_7_6">1,726</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaid research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="pasg:PrepaidResearchAndDevelopmentAssetCurrent" scale="3" id="Tc_27YVteqGFE-feVZ8r_MCcw_8_3">6,508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="pasg:PrepaidResearchAndDevelopmentAssetCurrent" scale="3" id="Tc_RyHrDgmKkk-93jDcJ0XT9w_8_6">7,567</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_pg6zsPXSaEKv4HZBcjl5XQ_9_3">197,044</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_-oQ6RTOq_EWbGPAB7oO5yw_9_6">325,066</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_utlk5-DoiEiiFhZ_Op0NKA_10_3">22,515</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_vEBfSSV_gU60XMuVRSWRhw_10_6">23,806</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right of use assets - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_sfXFqL7220S6wlFjz4Hqfw_11_3">19,723</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_zYKYkODp_0qxdz30huDUMw_12_3">4,267</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_Ptpdv6nkukC-I2Cdws6oQg_12_6">6,204</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_ZnubataPNEaa5JXofTztjg_13_3">243,549</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_FRA5lpmJIUqr0NncEUPHjA_13_6">355,076</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_TwLuRbnhDki4WcFwS5DSFg_16_3">4,065</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_Li-oqSQ3xk2rbz_AUjF2VA_16_6">9,448</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="pasg:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_Y1i74yuu2EiImkxlyKN8QQ_17_3">11,011</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="pasg:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_tvGOj8pGGkCcUimeA2nfuw_17_6">20,050</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_oZJqeUSJm0e1W9F3q0bZnQ_18_3">3,275</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_Zt2zfpGdKkqj18SBidFuJQ_19_3">18,351</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_zgObEMyz70OLFwwRWMmXpg_19_6">29,498</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease liabilities - noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_FTO6emVzaESL2rUD1r-y3Q_20_3">23,832</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred rent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" id="Tc_xswjchEA0UeC2U8wB_Vp-w_21_6">6,921</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_keN984gHR0iEvAC5ya8aQA_22_3">42,183</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_j1-wZlF0lUqDpUXp0c2uVQ_22_6">36,419</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments and Contingencies (note&#160;10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_mjCIo7Wtg0ySi8D0YZIaMA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_ToR_PorVa0GasJXTsv-_LQ">0.0001</ix:nonFraction></ix:nonFraction> par value: <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_eK7Bh-S3AkmeaB4rmY0Plg"><ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_V59K88fHq0uzwm4AMRbGNg">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_RgXCIiwx1k-Q4fqTRg8hgQ">54,614,690</ix:nonFraction> shares issued and <span style="-sec-ix-hidden:Hidden_vIrVM0Yz5kWZ5uqDROhiig;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span> at December&#160;31,&#160;2022 and <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_9LY3TFlj2UuTA4V7T2TtcQ">54,244,996</ix:nonFraction> shares <span style="-sec-ix-hidden:Hidden_a4vZEQ-8k0exEPYJXuhf1w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> and outstanding at December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_ILnX5nlG00C54dCbWGmXMg_27_3">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_kyGIdJhlokiH3GIP0gj-fw_27_6">5</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additional paid&#8209;in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_sKP5BWKYP0SXdElruaikQA_28_3">694,733</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_Hedi-rwQJ0i7A0WHYPuqJg_28_6">675,346</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accumulated other comprehensive income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_m8L839fEJESFf7pKLVEKow_29_3">966</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_y3d1Nx-PxkieJJsjYFE_LQ_29_6">413</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_1lnSQY7BFka-Aad1LuQswA_30_3">492,406</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_MgRpPwK4xEKCCRAHO6WZdA_30_6">356,281</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc__sCO_FL0FkGtiXunJrrrXg_31_3">201,366</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_pzgO3Ek4S0-kSxWzT4CHmg_31_6">318,657</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_owgZT1-ZikqESFTku-BD1Q_32_3">243,549</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_ghxKc58_3Em40vcSAJZjyg_32_6">355,076</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">See accompanying notes to financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d6540cc2_ec9b_415e_8ba7_6e8051f0a4e8"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">Passage Bio,&#160;Inc.</p><a id="StatementsofOperationsandComprehensiveLo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Statements of Operations and Comprehensive Loss</b></p><a id="_3565d96f_a090_49a4_b576_459ce462cbcf"></a><a id="_55c39055_083f_4482_b0c5_bfcebec7f2c3"></a><a id="Tc_JPEYbotb_0OiKA7XTYV6-Q_1_2"></a><a id="Tc_-HmKpIR1qUuzrklLDlzQqA_2_0"></a><a id="Tc_twlHv4f6QUuMySx-kJJMag_2_2"></a><a id="Tc_5P-NfnnrhkC7txyqj49tbg_2_5"></a><a id="Tc_6BMdV1gjDkS_6C7pdyuK_A_3_0"></a><a id="Tc_FwSj0P0X_0Go42i0IlmpcA_4_0"></a><a id="Tc_hSSZcW-YLE-rldNsnPzwpA_4_2"></a><a id="Tc_u_UKCWFrnkGz7KqlPKAIjQ_4_5"></a><a id="Tc_Cu5OUW2hcEapzOZYMyHD2Q_5_0"></a><a id="Tc_kzR0ERPw40aKOfjjDgxOyA_6_0"></a><a id="Tc_CdRus8qKFkmzNVOXP-devQ_7_0"></a><a id="Tc_t_zOvJ_H0kmCPrFJciY7Ww_8_0"></a><a id="Tc_I-_VS7m3vkOrP9woBXnPmQ_9_0"></a><a id="Tc_Pvn0YoY9OkuVX9JQYTBTFg_9_2"></a><a id="Tc_D0S5_OADQU6e8USuYJoiNQ_9_5"></a><a id="Tc_7w0eEuRHUk-2pK8AQRzqkA_10_0"></a><a id="Tc_DCCp4UQOMESawbvt-PGC_g_11_0"></a><a id="Tc_Cb06LByxv02OFWHN8qS_bw_11_2"></a><a id="Tc_QAIdxbhUskeygYlPNRZ5Jw_11_5"></a><a id="Tc_yq7bJgZ1m0mm2HUBmba3jQ_12_0"></a><a id="Tc_QJn2idJ1L0ej5UqO1E6zpQ_13_0"></a><a id="Tc_5h5J9yk2nEeUkCaXaG1Spw_14_0"></a><a id="Tc_YWBVZyxNvUW__ruA2JKquQ_14_2"></a><a id="Tc_hFihiw9pHUOWfkAeCL__tw_14_5"></a><a id="Tc_jJQSrZ-AWU-BR_DjOG0baQ_15_0"></a><a id="Tc_ImUH4_RG1E6RWZbyhT0rTA_16_0"></a><a id="Tc_Q02uSQ5L7ku4-BKzJ6RC7Q_16_2"></a><a id="Tc_-Uc3jFbHM0qOpfI-xIOLgg_16_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share and per share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_AMsP-CLk6kGqHAW6LpMTFg_4_3">86,053</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" id="Tc_GFDsoO0150KFG9bpvQtM4w_4_6">117,673</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Acquired in&#8209;process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_KHfc8TEmY0aB1xbPxMsWeA_5_3">3,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_AlGH-p4O2U2wnQpqYOjASg_5_6">8,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_rDgXiYDSNEm3Auxyvd8-mQ_6_3">49,341</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_jhZHrZc4-kGbpPqQz28kHg_6_6">60,056</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_oXRP6GAay0-G7nCQpIxMgQ_7_3">138,394</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_skDytPjYHEu25ohdFVjxcA_7_6">185,729</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Interest income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNet" scale="3" id="Tc_IsWVduXUw0SA5oj0E2On-g_8_3">2,269</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNet" scale="3" id="Tc_36xk3PMgF0auDLnvr0lwew_8_6">343</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc__z1vlNn7o0m-yQ0fuMeGyA_9_3">136,125</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Dae8OrLPMEmcOgk_fOa_wQ_9_6">185,386</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Per share information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share of common stock, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_MdQCTgzeEUC11o__Gyr-0w_11_3"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_MdQCTgzeEUC11o__Gyr-0w_11_3_2">2.50</ix:nonFraction></ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_V3M6KmIH5UCiFT0bPgn8oQ_11_6"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_V3M6KmIH5UCiFT0bPgn8oQ_11_6_2">3.48</ix:nonFraction></ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average common shares outstanding, basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_pRQJ54HPd06bJ3i_3rmZfA_12_3"><ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_pRQJ54HPd06bJ3i_3rmZfA_12_3_2">54,429,023</ix:nonFraction></ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_XH6KunGTMEyzZPRJtL2WDw_12_6"><ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_XH6KunGTMEyzZPRJtL2WDw_12_6_2">53,343,959</ix:nonFraction></ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ZW-DV_R2TE-MsaZav67Ymg_14_3">136,125</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_HLwDO37Gw0y34z4Euv61kQ_14_6">185,386</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized gain (loss) on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" sign="-" scale="3" id="Tc_4vs3WWQAxkaMajJiTCmHaQ_15_3">553</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" sign="-" scale="3" id="Tc_PRP9H0Bc1UOEy6o9Jaur_Q_15_6">401</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:59.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_grx9SwOEyUWGJgn8Xkqdhw_16_3">136,678</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_u9K4N4OzN0uN80NBukto4g_16_6">185,787</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">See accompanying notes to financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4ecfc549_6fe9_43df_8961_eb09c17ecc3b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio,&#160;Inc.</b></p><a id="StatementsofConvertiblePreferredStockand"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Statements of Stockholders&#8217; Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(in thousands, except share data)</b></p><a id="_3578a2fa_d9f9_4fa3_aa83_cec1e3cdf250"></a><a id="Tc_xcTuRWMV8EqgV0TqrzebMg_3_2"></a><a id="Tc_OTk2VvYbQE6MjvIzIO264Q_4_2"></a><a id="Tc_2q9tPM2JokK27m4aVNgNKw_4_7"></a><a id="Tc_Za-_W4A6BkCclRiFRUf0Lg_4_10"></a><a id="Tc_rZPOGKbfz0iCDSVJ-MdHVA_4_13"></a><a id="Tc_AhyKQ1Rj6Eqk948NK5lxwQ_5_0"></a><a id="Tc__WiFfUOUdEy_1UlhLZdknw_5_2"></a><a id="Tc_OloDo7QUgka8cLCsrIkeqw_5_4"></a><a id="Tc_QWi-9aJ4hUK9bjwI2fP9RQ_5_7"></a><a id="Tc_ramIbyDmgEGr9niLXPGI4Q_5_10"></a><a id="Tc_ZuME8NRq5kq9isIAfByPEw_5_13"></a><a id="Tc_mPOuM5X9jEuG2Z9UtRV5YQ_5_15"></a><a id="Tc_5xMPPPtv_kqbe61ukRvdug_6_0"></a><a id="Tc_hTyShysRU0Kkk1ZNMnBVlw_6_4"></a><a id="Tc_rfUaMEcotEeTIK-9bspoMQ_6_6"></a><a id="Tc_6MXF6eK5XkyJp4EMKAgN0A_6_9"></a><a id="Tc_bgRLJprDbEW9-26F_Y0yuA_6_12"></a><a id="Tc_TNYuSMySO0ymah8WkYvncA_6_15"></a><a id="Tc_MAVIXqxZpkivWpjGKyzsgQ_7_0"></a><a id="Tc_yn6v1pYdbUGO6ymXaRb1hw_7_5"></a><a id="Tc_cF3FjMhdLUWZgXnwyWTdOQ_7_10"></a><a id="Tc_IGrR1O3iUE-XFtJ9-N0PrQ_7_13"></a><a id="Tc_K7p2txWta0elUdtEnYqPPA_8_0"></a><a id="Tc_IL5QTgW0oka8xBBrzru6Bw_8_5"></a><a id="Tc_SEVWafRz5UyVax54Vmec5g_8_10"></a><a id="Tc_aN7pFGNxWUGDdjTa6qukVA_8_13"></a><a id="Tc_W4X-U56PGU-Vl1g9bNZhkg_9_0"></a><a id="Tc_5pgwDzT18kOxTEd9o1M-CQ_9_5"></a><a id="Tc_uloplai6h0u_eEkUj0xSCg_9_10"></a><a id="Tc_qVghnZjwXkmjqkHcCdX6aA_9_13"></a><a id="Tc_VmUf0wEkt0SA_9KNSF10Dw_10_0"></a><a id="Tc_Qn2tpygjAk27Sok_qAT-cQ_10_10"></a><a id="Tc_aYzORRbIFkeYaycY6jJ0Ig_10_13"></a><a id="Tc_DLpWgduFmEq9cFFexA9tCw_11_0"></a><a id="Tc_kUf_c0NU5USnasTGJbvzmg_11_2"></a><a id="Tc_gK4FwvA-vEGGwTvV5esb0Q_11_5"></a><a id="Tc_1Eeu2fCbjEayiapwp4N1Qw_11_7"></a><a id="Tc_u6Ir6QMmfU2zGoL6PwiZEw_11_13"></a><a id="Tc_4J0ayAAji0u-iuR4f3CcBg_12_0"></a><a id="Tc_K0h1kNfYlkGpuzfnzSv-hw_12_2"></a><a id="Tc_HeoimItXtUibnvKbw34H8A_12_5"></a><a id="Tc_-JSyZoW2tUK743zIdYSqmA_12_10"></a><a id="Tc_moFOrc4ZCkigTkbMamLsDA_12_13"></a><a id="Tc_8Bj-9w8HZ0KpqBIQUdOWog_13_0"></a><a id="Tc_Bs-YLk0M-kuOEtpb_xORbQ_13_2"></a><a id="Tc_x_joLhQzJkSU8SG-VDY5uA_13_5"></a><a id="Tc_zWgS74iR30OZ8Gg9U-jwXw_13_7"></a><a id="Tc_PkyAjPkiOE-xC7oy1rlbfA_13_10"></a><a id="Tc_EompaeeqS0iordKCaUEAUA_14_0"></a><a id="Tc_tO-JewiyvEGNvyp8-o0kRA_14_4"></a><a id="Tc_iiCCWimsYku2ForNoQBUpw_14_6"></a><a id="Tc_Bz_3GVAPKkytFR3X0bHuwQ_14_9"></a><a id="Tc_dnu3MK2EWU6qkYcUOe6vcA_14_12"></a><a id="Tc_2IsBA3fR8U2pUSmXS0dgRQ_14_15"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="15" style="vertical-align:bottom;white-space:nowrap;width:61.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stockholders&#8217; equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated&#160;other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands, except share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">paid</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">in&#160;capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">comprehensive&#160;income (loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hYpnLKF0Pkq_6zN2_OqwkA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_251biwtk4EShZ_RefLZcSQ_6_2">45,614,807</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hYpnLKF0Pkq_6zN2_OqwkA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_0aajLq00q0-h2mOmthireg_6_5">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7dx_D0t8AkeU7CcwmPSrnA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_5e94sseTJk6ifjCwAvsSgQ_6_7">475,617</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_H3Kyaw9iDUKSzbJyfoPBBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_kaBajKQOD020jRkYyg0p9A_6_10">12</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_68O7F9-naUyJ7hFnufywEw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Y_M8Y1GZR0mw1-WZ88lZdg_6_13">170,895</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2020_62A9Ji97c0e2uu5ff0EtfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_klfpxG3Mqka7IKcOd2uXZg_6_16">304,714</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of early exercise option awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FatF9mHr8kyTws1l1ujYjA" decimals="INF" format="ixt:numdotdecimal" name="pasg:StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" scale="0" id="Tc_KRxPjggpekCogikmuEjOFg_7_2">302,277</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tKy1_NMOUEmEHV1J-B4fuA" decimals="-3" format="ixt:numdotdecimal" name="pasg:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" scale="3" id="Tc_ktLvd9jGqUODmXGmAMLpJg_7_7">45</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="pasg:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" scale="3" id="Tc_So198YRpwEmhDuEoekpLcg_7_16">45</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of stock options and vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FatF9mHr8kyTws1l1ujYjA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_DPztbNsOgEqx9T0QvR9Q-g_8_2">186,787</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tKy1_NMOUEmEHV1J-B4fuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_kDOYbD3GckiodUnQ9Ou7qg_8_7">301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_wV4UiP_A1UGguqplIngdkQ_8_16">301</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of shares in connection with employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FatF9mHr8kyTws1l1ujYjA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_MZFOMtINskWuR4Mee6x5ZQ_9_2">91,125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tKy1_NMOUEmEHV1J-B4fuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_J_2zdg1d-UiQQgQmgnD3cQ_9_7">887</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_w1F7vPbzyE2E9D6EMu0JTA_9_16">887</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Sale of common stock, net of issuance costs of $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="pasg:StockIssuanceCosts" scale="3" id="Narr_3jInUu3E1UK_nUvuqctT1w">669</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FatF9mHr8kyTws1l1ujYjA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_VDH_ES3UdkmnwbOh1dUo1A_10_2">8,050,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FatF9mHr8kyTws1l1ujYjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_6eShocZ0o0akEWlXrwp0eA_10_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tKy1_NMOUEmEHV1J-B4fuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_QFAw2C1510GPVdNLnRbUyQ_10_7">165,805</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_Nj9OPQH--06PL0OagbWoKw_10_16">165,806</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized gain (loss) on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ft0vm0rTlEWzwuGEbsW4BQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" sign="-" scale="3" id="Tc_knPoybHxlEm0-zRCh070Jg_11_10">401</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" sign="-" scale="3" id="Tc_5xUkRq7_wE65AYIR9mT9Mg_11_16">401</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Share&#8209;based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tKy1_NMOUEmEHV1J-B4fuA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_bR1kvDqN2kW7v1f85ZlTBQ_12_7">32,691</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_va_mT1FW4UafeOdezV1PkQ_12_16">32,691</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_YnP14VvzNEuqjHFsfp6GYw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Nwj7s8Cap0qKeODR2r8flg_13_13">185,386</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_7IlfHzJ-Z02RbnNtimXHJA_13_16">185,386</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mB93yuXxFkmHu4pFLjXgug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_wZxFeUZ7Tk-yBC6c-CAzVQ_14_2">54,244,996</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mB93yuXxFkmHu4pFLjXgug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Iv9QTvrpg0yDj2GvJ6yz3w_14_5">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rW0i_NK93UyCd57P6lJiTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_vednNFSTcUqz9Jxi_wcERw_14_7">675,346</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_hM0jUdnMX0SstDzHGw84NQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_GmMPuvpSyUu_ea0JBPqE5w_14_10">413</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mej-DQ41G0WhXJ-3c4uH-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_SuO2sLIjyUO_tetZqVd9cg_14_13">356,281</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_TenSbsOSvkaMPKUVEeMO9A_14_16">318,657</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_48eb9e25_28dc_43cb_a19f_167dc11b009a"></a><a id="Tc_hKhZjheawkWvox2iIANQrw_3_2"></a><a id="Tc_Ei1-WDLLOU6qlQPySn6G7A_4_2"></a><a id="Tc_0AB8ssmogEWyACSznPO_lA_4_7"></a><a id="Tc_NpMzN2FFbEC64THo9Z_Z1w_4_10"></a><a id="Tc_JFi0gOTqjUiaHwXUEvloaQ_4_13"></a><a id="Tc_HrXa_iVAKEGRV5cx-cBNlQ_5_0"></a><a id="Tc_FJM5pxsP30eKKDwWSmOgZA_5_2"></a><a id="Tc_wYTQSP8o8kyHAWx6wmtTqA_5_4"></a><a id="Tc_DZmjxy9xjEGKX4In4ISaoQ_5_7"></a><a id="Tc_JYOiXyMv3ESEA0tT3j4VtA_5_10"></a><a id="Tc_LchWwfd_DkaJX4BgSyqyMQ_5_13"></a><a id="Tc_aYO956tB8Ui_M4_4EALheQ_5_15"></a><a id="Tc_ZJnob72TtEmuJEKMQe7yRg_6_0"></a><a id="Tc_yPN5qPQfKkK5szl1m0bp8g_6_4"></a><a id="Tc_rlfVGv0AOkuWffFXLCi2Cg_6_6"></a><a id="Tc_rAopIe4nqE6AL_Cib1Yg4g_6_9"></a><a id="Tc_o1VjG5tI502HAwpvXsxWZg_6_12"></a><a id="Tc_0ZUJ2JSiK0Gp1qu-SAAFtg_6_15"></a><a id="Tc_N-zETbGT9E24mfbJCawKcQ_7_0"></a><a id="Tc_VQcodsqmoU2tdxJL2GtBzw_7_5"></a><a id="Tc_bkUYE_ECpU2zgq2BTxSimw_7_10"></a><a id="Tc_cbo70DXOI0ONdqsPGxuWYA_7_13"></a><a id="Tc_ya6OR65FSEKQ2h_Kk-paOQ_8_0"></a><a id="Tc_1oP6gj0dEkWs4h60w_eWcw_8_5"></a><a id="Tc_JqXb07aHNk6HoUIEfAYxIQ_8_10"></a><a id="Tc__NOdjH1U5U66_DNlamKO2A_8_13"></a><a id="Tc_Pdjg1GUDs0O-Au0MNW75TQ_9_0"></a><a id="Tc_9XECoEI-SkOnA4hEeOfrxA_9_2"></a><a id="Tc_PyDTc6Ft70asge8B9GejVA_9_5"></a><a id="Tc_9FXG0TIVgUCX942wUQxVGA_9_7"></a><a id="Tc_7Hqp-Xo9AkmyJ8wSrRorIQ_9_13"></a><a id="Tc_kdfwSDN5ckSb3iHFbCzC-Q_10_0"></a><a id="Tc_dU_A1z-onESvPuKVSxNJuA_10_2"></a><a id="Tc_2rlTxVsx5U-itm9ievAQFg_10_5"></a><a id="Tc_fGXMALimMkadJWRO9AU46Q_10_10"></a><a id="Tc_VuVCsYhyokyzj-e1peYDCQ_10_13"></a><a id="Tc_RTlln1PqTE-O4WtkRTjpSA_11_0"></a><a id="Tc_MwDFeGOwJEO3Ji3AxdOC9Q_11_2"></a><a id="Tc_ZdIxvEMFU0aNIfBtN85GEg_11_5"></a><a id="Tc_9pP5289fx0WIZAz9Mxm-Ag_11_7"></a><a id="Tc_Ewy7n1A4Fkuy3kbGCQ7vrA_11_10"></a><a id="Tc_lZ72EC12gEq1JCGesUWPwQ_12_0"></a><a id="Tc_k7cwXh1TNk2ybHdpfX7zfg_12_4"></a><a id="Tc_bhnTlqk91Um6w1475nClNg_12_6"></a><a id="Tc_mxDeJe43QEuGGKRWBv0Hxw_12_9"></a><a id="Tc_OsHs9lY1t0yjPTGlKF-Xhw_12_12"></a><a id="Tc_80_7uR9ZEkqYoDFLFhLmeA_12_15"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.9%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:6.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="15" style="vertical-align:bottom;width:61.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="15" style="vertical-align:bottom;width:61.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217; equity </b></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:17.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated&#160;other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;margin:0pt;"><b style="font-weight:bold;">(in thousands, except share data)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">paid</b><b style="font-weight:bold;">&#8209;</b><b style="font-weight:bold;">in&#160;capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">comprehensive&#160;income (loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:7.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Balance at January 1, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mB93yuXxFkmHu4pFLjXgug" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_vQoW6vZdpUGq3j868bAARA_6_2">54,244,996</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mB93yuXxFkmHu4pFLjXgug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_E2p3CzLub0yL6qswoG2Luw_6_5">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rW0i_NK93UyCd57P6lJiTg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_LjfmAL1AuEGD1-tE10WIYg_6_7">675,346</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_hM0jUdnMX0SstDzHGw84NQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_g-BNLsULiE-Z1U0ZufVfAw_6_10">413</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mej-DQ41G0WhXJ-3c4uH-w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_cNJR0KyVUkit2tUtvWYjZg_6_13">356,281</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_eG4YwDCO0kKJfR5QDd4Stw_6_16">318,657</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Exercise of stock options and vesting of restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_illNEQwEHECIcckfPCTJRg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_S12byrm9iUq0YErQS0vcmA_7_2">165,223</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_weqi7Po-uUOAVerAuobXvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_4JF--l_6E0qmVMK42TnbQw_7_7">129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="Tc_D56gJbPiN0utoj5-ii9PBg_7_16">129</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Issuance of shares in connection with employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_illNEQwEHECIcckfPCTJRg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_cBuGnUMwx0eHwufBUbFVsQ_8_2">204,471</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_weqi7Po-uUOAVerAuobXvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_1Uxs_NbC7E6uwbwxrlIhLA_8_7">304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_kO1MqX_mUkiJwDvhx2PqgQ_8_16">304</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Unrealized gain (loss) on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Dy2fqtwSE0iMjVYx7LAqaQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" sign="-" scale="3" id="Tc_soVRS36uik270ThjPxbDJA_9_10">553</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" sign="-" scale="3" id="Tc_vmaZIXL5zUKJ3iS9nNwg_g_9_16">553</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Share&#8209;based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_weqi7Po-uUOAVerAuobXvg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_3gqXsVWK-U2L3kpQEUYwTg_10_7">18,954</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_P_SeW_S8U0q29z812R5iFw_10_16">18,954</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5iXkDh6_nUWdtcuegYMTbQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_6lMIM0F4QU6jGCweW0TZXw_11_13">136,125</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_lpLTVu0AYkSlScTkp0lkIw_11_16">136,125</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:36.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;"><b style="font-weight:bold;">Balance at December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TWUY5elwAUOM2vM1WL0RyA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_GjVlQzQIM0yRSn9j1fNBYA_12_2">54,614,690</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TWUY5elwAUOM2vM1WL0RyA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_tV_4D1poPkukaA8czDwybw_12_5">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WTd6dzj7eEa_9Sk21SavjA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_JUOqItYe4kiV6Z9JeGEkuw_12_7">694,733</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7fu6Hq9yz0WPODQu1__Srw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_P1hsndcT_kaMn3mvFAy_xw_12_10">966</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PyRd_9rL4UqO5RO9ulICug" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_NQ4Q-DhKEkCjoIQL8xiTpA_12_13">492,406</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_kVVNneGhPUyweIbOJuDtbA_12_16">201,366</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">See accompanying notes to financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f5c2c513_bf49_489b_bc52_faea6cd7648e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio,&#160;Inc.</b></p><a id="StatementsofCashFlows_152708"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Statements of Cash Flows</b></p><a id="_2267f59c_7543_4c93_8696_d5001f684adb"></a><a id="Tc_N72x4RrcpUS_cm-lEsDN3w_1_2"></a><a id="Tc_rK8UZxGyfUS9-FX2TbLW3A_2_2"></a><a id="Tc_t13Ej3fFWkabSGRQ6SPz_g_3_0"></a><a id="Tc_1icVqYz4QkKIgtLW1PseWg_3_2"></a><a id="Tc_O9pNL_gS-EmkgusUbL42wQ_3_5"></a><a id="Tc_6tIeSwin0EG5K6iwPZzUiw_4_0"></a><a id="Tc_KnbvRbC-aEOJMzUShndLuw_5_0"></a><a id="Tc_EcwnVAyRE0amcVgRhbzRJQ_5_2"></a><a id="Tc_myMV2DQ6_kSXLjtlMNmtPw_5_5"></a><a id="Tc_Nyu-lcs4sUu3l45HwwcwzA_6_0"></a><a id="Tc_A_ZWfKyyGE2Gr30okoCUnw_7_0"></a><a id="Tc_eyFEOvz9wU2rMwQwON5zqw_8_0"></a><a id="Tc_0MHWP-0FvkCAJQ6tmxDB8A_9_0"></a><a id="Tc_eVV7QFZgBkye84I2WM9L9Q_10_0"></a><a id="Tc_h5-Dbg9p0UOjjEUq0oIGZA_11_0"></a><a id="Tc_m7enj6NsLUi76Lgu9MMhzg_11_3"></a><a id="Tc_-Q0nJO7fjkmmoncVFuhV8A_12_0"></a><a id="Tc_mFX5AaDTLkeFcv8VrHrnHg_13_0"></a><a id="Tc_8b9e0ACO_UOcX8dEE8NMjA_14_0"></a><a id="Tc_zOJ7WZA_RU2SQDOX-Z7xyg_15_0"></a><a id="Tc_qajg13-LQEe6JDj-LVc-rA_15_6"></a><a id="Tc_tvl6Jic0qEmvUNOv4eP1vQ_16_0"></a><a id="Tc_Wn19-e02UkSnXL5039EwMA_17_0"></a><a id="Tc_cIF3H30LbE2R_JTc8NYmmg_18_0"></a><a id="Tc_iS9jtxkOLEuIgv6XDDWTmA_19_0"></a><a id="Tc_gMuVHRvV0E-EdWlWuyJTmw_20_0"></a><a id="Tc_W2vv49uNz0GjwrqB4BCyyA_21_0"></a><a id="Tc_Zw62F-dA_EqqTDMZ4sSA0Q_22_0"></a><a id="Tc_46dSUq5anUO23eAElfh1Dg_23_0"></a><a id="Tc_pwrlB2llpEiO5n9DPzRoUw_24_0"></a><a id="Tc_kza5YftT3EWJFoY3-bOXMA_25_0"></a><a id="Tc_MXqcTQrEZ0OF3XmMLNFVoQ_26_0"></a><a id="Tc_SadVaKDejkyYTFkUSedWwQ_26_3"></a><a id="Tc_BEglQPjnzUa8ee_8jviceA_27_0"></a><a id="Tc_2H5H6bYMnEi29wLtCTLJfg_27_3"></a><a id="Tc_0mRXTNwHAEqo5372SwbzQw_28_0"></a><a id="Tc_gEP7muvl80aghw-ToTsUXg_29_0"></a><a id="Tc_DhgVNsmsuEulv9LaqMj8Rw_30_0"></a><a id="Tc_ms_pNPHWJU6KPy-BBH0GNQ_30_6"></a><a id="Tc_xgGi2_BAK0KBtADPuZUcJQ_31_0"></a><a id="Tc_FHjtK04dWU6uLahnmjZNEA_32_0"></a><a id="Tc_5cD1yAbWBUGc2Uy_I15f4w_33_0"></a><a id="Tc_nkBzWuhDj0WZhqPH2oFzTQ_34_0"></a><a id="Tc_4hML-g7hVEKSj7XgIouZjQ_34_2"></a><a id="Tc_qie89B9By0Gnse6RV1Q2rg_34_5"></a><a id="Tc_EqRu9PxKtkOE0S3YWuNdjw_35_0"></a><a id="Tc_iKj-APZC-064I_w07KY8ag_36_0"></a><a id="Tc_XttgWcXwGUaJ_gpDq12PAA_36_2"></a><a id="Tc_UqdspxcXhEKrt3ygt91faA_36_5"></a><a id="Tc_p2SmmfX3nEakLUUNw3_U1A_37_0"></a><a id="Tc_MiffBh8r7UqGxiiWU-2o1A_37_2"></a><a id="Tc_xkUUMmXf1Uq-teNZ9cId3Q_37_3"></a><a id="Tc_QcyIqCQ_2EWQudr6IeLDNQ_37_5"></a><a id="Tc_QRVmjfGlvUyJFG2eLUNFEw_38_0"></a><a id="Tc_PjYI-LFocU-WjeOWFm7yyQ_38_2"></a><a id="Tc_95mU3EgJPEmY0OqeUihS_Q_38_5"></a><a id="Tc_eTBw0zBf9UCuGvrY6h5m_w_39_0"></a><a id="Tc_bsXO9w4hsEK6AcN3_i6f3w_39_2"></a><a id="Tc_LQgHJbDBtk-dak3SM5tWnQ_39_3"></a><a id="Tc_XhPwNXE5DUuNscrzyl2gZA_39_5"></a><a id="Tc_6TJdPhx1O06lrLDvDWUFyA_40_0"></a><a id="Tc_6Om2g_kl4k6eRlQmMzK0fA_40_2"></a><a id="Tc_jPAGcT5psUWD37X-5CRlkg_40_5"></a><a id="Tc_Wzef9rIhgUioE-EDNPSujw_40_6"></a><a id="Tc_JePYRid_AESXcmioDcPtXg_41_0"></a><a id="Tc_5h1RTW3zMEassST6S2EL_g_41_2"></a><a id="Tc_TGVL8SIhrEyqw-qDq0EWfA_41_5"></a><a id="Tc_JoTR3_tPh0GikBhTF-xN6g_41_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_sM0rynFA-U-QnAwUoeWdFA_5_3">136,125</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ZuIdxImy1EGSF5G5KH9H9Q_5_6">185,386</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Acquired in&#8209;process research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_fRVHCOyibkez4H7d-2CbfA_7_3">3,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" scale="3" id="Tc_inpf-oYSCE-P76XI9g3OTw_7_6">8,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_qlzSMntx_EquKeKgTmV1Vg_8_3">3,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="Tc_8X2gVXRsuEKElUQK5YbhbQ_8_6">1,543</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Share&#8209;based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_8jJ92_F2Bkexk_QkD6erJQ_9_3">18,954</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_rq0sMd_40Ee2SHle_aIZ4Q_9_6">32,691</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Amortization of premium and discount on marketable securities, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_g9YWezi7Q0Swvgp3tLN9CQ_10_3">773</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_eWLTfelOsUKFdwD-gYiUYA_10_6">2,778</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Deferred rent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="pasg:IncreaseDecreaseInDeferredRent" scale="3" id="Tc_yr1-b2AYTUuxrqpSyCYZmw_11_6">2,075</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Prepaid expenses and other current assets, and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_xKT85bZiVU2m0mBAMci36w_13_3">2,737</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_801rSOCfpkSGZVbi7phOog_13_6">1,842</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Prepaid research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment" sign="-" scale="3" id="Tc_4TAwyYx6bU66WRlRnLQpxw_14_3">1,059</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment" sign="-" scale="3" id="Tc_LLffgBXHKEWV8D2d_07JAg_14_6">3,394</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Right of use assets and operating lease liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="pasg:IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" sign="-" scale="3" id="Tc__eu-y0xDv069C06FMczVxA_15_3">463</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" sign="-" scale="3" id="Tc_maRXptlYskGz2Hv49WLWYg_16_3">5,412</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" id="Tc_V4t-hWszW0SWYB86Sjyvww_16_6">2,201</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="pasg:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" sign="-" scale="3" id="Tc_DtlLvj0dOUKD08VpG_RHcg_17_3">7,338</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="pasg:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_9Eq-dDIQVUudWksqmQjJJQ_17_6">3,983</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by (used in) operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_Z6DsLYekYEuZFCiTPNrV5Q_18_3">118,210</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_7h1eq61qik-UoPyWxv5CzA_18_6">126,879</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows provided by (used in) investing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Purchases of marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="Tc_HeMM2aW5CkuHlPDIiLSVCg_20_3">157,835</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="Tc_4bFOXPDy8EaW8bNhQjFfvg_20_6">202,546</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Sales or maturities of marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="Tc_hDcHo-b1LUi5CHID9lh2dQ_21_3">188,308</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="Tc_2rBlriRJikiKcMoEbUA_DQ_21_6">182,374</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Purchases of technology licenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_vsL2F_0dUEWYuiTthOD2Kw_22_3">3,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="3" id="Tc_3iPIuobWo0SbJhIa1AZr9A_22_6">8,000</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" scale="3" id="Tc_-eeQ0xzwo0O6qpalJRIdjQ_23_3">2,274</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMachineryAndEquipment" scale="3" id="Tc_V01F791h40i05sm_ro6pXg_23_6">17,642</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_c_xGx3Y2wESkfkKdRopoaA_24_3">25,199</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_hbMKa3bymEGAQuKCwrncvA_24_6">45,814</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows provided by (used in) financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Proceeds from issuance of common stock, net of offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_Pz1dSpu2BEKjSMRP1WlYYQ_26_6">165,806</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Payment of offering costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_OpRhlMjlDEupL-IOW3aayQ_27_6">338</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Proceeds from the exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_-2BnF55xqkSWCqvK1fCizQ_28_3">129</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_mqAB4C6dQEGjz1hV1r6KFQ_28_6">301</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Proceeds from the issuance of common stock under employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_rgu3iJAFRESGVlPeM_u0jQ_29_3">304</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_rJVZ9ynZcEKDfzeRZbyEjw_29_6">887</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Payments for insurance premium financing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="pasg:PaymentsForInsurancePremiumFinancing" scale="3" id="Tc_BDDjjHNEjEyKv-Zwb1ealg_30_3">1,786</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net cash provided by (used in) financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_Jtpw2ib9AEiV6LvXF5PKpA_31_3">1,353</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_X77nbYJafUmboBSFD04P0A_31_6">166,656</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net increase (decrease) in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_pY0Kdqx320aedCbbRRTSSw_32_3">94,364</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_gol8hjxs6UeSIuygmxJMAg_32_6">6,037</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents at beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_jcD1a0m2rkCauTYG0B0ELQ_33_3">128,965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2020_62A9Ji97c0e2uu5ff0EtfA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_YNecIB_zAkGBCu5KzXx_QA_33_6">135,002</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents at end of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_hb9smLyYhUyPq16bSCb6lw_34_3">34,601</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_NINg7Td4sUW8amcM8P5Qkw_34_6">128,965</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental disclosure of non&#8209;cash investing and financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Unrealized gain (loss) on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" sign="-" scale="3" id="Tc_SGHPc_ofREeOEk6EhoIjow_36_3">553</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" sign="-" scale="3" id="Tc_8LXcnulEcEG82QLpx-pOXA_36_6">401</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Property and equipment in deferred rent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="pasg:PropertyAndEquipmentInDeferredRent" scale="3" id="Tc_yukRypLR8k2ZEZRn14uzXA_37_6">2,769</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Property and equipment in accounts payable and accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="pasg:PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_yUEVg2wRxk-BP6QqFAPZcQ_38_3">114</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="pasg:PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_8s3llENqpkGw2VvBTn5Ccw_38_6">2,143</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Vesting of early exercise option awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="pasg:VestingOfEarlyExerciseOptionAwards" scale="3" id="Tc_-ObitvjlB0-N4Wp-S_9doA_39_6">45</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Right of use assets recognized upon the adoption of Topic 842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_mQUYu3IZYUa_VnzKJV5Thg_40_3">20,375</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:72.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Operating lease liabilities recognized upon the adoption of Topic 842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="pasg:OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" scale="3" id="Tc_ZpKy3aYX0EaG2LDT29DoaA_41_3">27,296</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-style:italic;">See accompanying notes to financial statements.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_77835525_ebc6_4429_bb96_5a6de4ebd037"></a><a id="NotestoFinancialStatements_627885"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio,&#160;Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes&#160;to Financial Statements</b></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:NatureOfOperations" id="Tb_U1u25cc8oUmpLmuzPktZXw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Passage Bio,&#160;Inc., or the Company, a Delaware corporation incorporated in July&#160;2017, is a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system, or CNS disorders, with limited or no approved treatment options. The Company has a strategic research collaboration with the Trustees of the University of Pennsylvania&#8217;s, or Penn, Gene Therapy Program, or GTP. Under this collaboration, GTP conducts discovery and preclinical activities enabling Investigational New Drug, or IND, applications and the Company conducts all clinical development, manufacturing, regulatory strategy, and commercialization activities under the agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Through this collaboration, the Company has assembled a portfolio of genetic medicine product candidates, including <ix:nonFraction unitRef="Unit_Standard_item_wlhC8WlTVEmcZqQ79zgOUA" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="INF" format="ixt-sec:numwordsen" name="pasg:NumberOfLeadClinicalProductCandidate" scale="0" id="Narr_OhsuLSTrG0Kqzf433wx61g">two</ix:nonFraction> lead clinical product candidates: PBGM01 for the treatment of GM1 gangliosidosis, or GM1, and PBFT02 for the treatment of frontotemporal dementia, or FTD. The Company also has a collaboration agreement and a development services and clinical supply agreement with Catalent Maryland,&#160;Inc., or Catalent, for clinical scale manufacturing requirements.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="pasg:RisksAndLiquidityTextBlock" id="Tb_98T5PQzQ7E6tpblSKk9Jhw" continuedAt="Tb_98T5PQzQ7E6tpblSKk9Jhw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Risks and Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred recurring losses and negative cash flows from operations since inception and had an accumulated deficit of $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="6" id="Narr_9XnLlxWqfkq3bOOkn5F0Rw">492.4</ix:nonFraction> million as of December&#160;31, 2022. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. Substantial additional capital will be needed by the Company to fund its operations and to develop its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2021, the Company closed a follow-on public offering in which the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_VKjaYfeOdEmdzPqOICqhlQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_AvguchULykS1qWstKH09hg">8,050,000</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA" contextRef="As_Of_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_XMou09J0cEirXcLwXtLPDg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_1ljSHZjiX0igplLr_oCC2A">22.00</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_VKjaYfeOdEmdzPqOICqhlQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="Narr_pQ9pyVN9k0OEFddlSt-1EQ">165.8</ix:nonFraction> million&#160;after deducting underwriting discounts, commissions and other offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company&#8217;s operations have consisted primarily of conducting preclinical studies, developing licensed technology,  conducting clinical trials and manufacturing clinical supply to support clinical trials. The Company faces risks associated with early-stage biotechnology companies whose product candidates are in development. Product candidates currently under development will require significant additional research and development efforts and establishing manufacturing capacity and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital for the Company to complete its research and development, achieve its research and development objectives, defend its intellectual property rights, and recruit and retain skilled personnel, and key members of management. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company plans to seek additional funding through public or private equity offerings, debt financings, other collaborations, strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding or prospects of funding are unfavorable, the Company could be required to further delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In March 2022 and November 2022, the Company reduced its workforce and prioritized research and development programs to reduce operating expenses and to extend its cash runway.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In accordance with Accounting Standards Update, or ASU, No. 2014-15<i style="font-style:italic;">, Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</i>, the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_98T5PQzQ7E6tpblSKk9Jhw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">within one year after the date that the financial statements are issued. As of the issuance date of these financial statements, the Company expects that its cash, cash equivalents and marketable debt securities will be sufficient to fund its forecasted operating expenses and capital expenditure requirements for at least the next twelve months from the issuance date of these financial statements.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_ta73gUbMwUmn0Wbo0MunWg" continuedAt="Tb_ta73gUbMwUmn0Wbo0MunWg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.&#160;Summary of Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="pasg:BasisOfPresentationPolicyTextBlock" id="Tb_fD5SItEXykeJAnxp8CsKkg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates promulgated by the Financial Accounting Standards Board, or FASB. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:UseOfEstimates" id="Tb_-qmI60vS50qlL6W7YRchTA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.3pt;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="letter-spacing:0.3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying financial statements in the period they are determined to be necessary.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_wJAjO7L_M0aFYsw_D79LuA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_ylzk2Hng7Em5w5yLx6kklA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash, cash equivalents, and marketable securities.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="pasg:SegmentPolicyPolicyTextBlock" id="Tb_morfPzgBTkiQBYbst2yfpQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment Information</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in <ix:nonFraction unitRef="Unit_Standard_segment_lMTtBbJKdUumSSlUVKw17A" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_c_iM5uf6yUS3gGyr9v_mYw">one</ix:nonFraction> segment.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_MmZ-8UmVOUmbcsVamFcaew" continuedAt="Tb_MmZ-8UmVOUmbcsVamFcaew_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly-liquid investments that have maturities of three&#160;months or less when acquired to be cash equivalents. Cash equivalents as of December&#160;31,&#160;2022 consisted of money market funds and commercial paper. Cash consists of cash deposits at banking institutions.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ta73gUbMwUmn0Wbo0MunWg_cont1" continuedAt="Tb_ta73gUbMwUmn0Wbo0MunWg_cont2"><ix:continuation id="Tb_MmZ-8UmVOUmbcsVamFcaew_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:MarketableSecuritiesPolicy" id="Tb_32KxGYtDAEeMuvnUZbVSdg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Marketable securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company classifies its marketable securities as available-for-sale, which include commercial paper, certificates of deposit, corporate debt securities, and United States, or U.S., government debt securities with original maturities of greater than three&#160;months. These securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other comprehensive income (loss) within stockholders&#8217; equity. Gains or losses on marketable securities sold are recognized as a component of other income, net in the statement of operations and comprehensive loss on the specific identification method. All marketable securities are available for use, as needed, to fund operations and therefore, the Company classifies all marketable securities as current assets within the balance sheet.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_7jzVn-XFfEKtWtN27mw4lw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and equipment consists of laboratory equipment, office equipment, computer hardware and software, furniture and leasehold improvements and are recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset by asset basis, which generally consists of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_c2lmnbj2xk-05fdWrtq5pA" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_Mbqdy00C40OyHwJPrZU6yw">three years</ix:nonNumeric> for computer hardware and software, <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_oMHqSuMuOEyeN1Ln42FsEQ" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_5WJpsaV7jEKmVwCggG-cSw">five years</ix:nonNumeric> for office equipment, <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_LaboratoryEquipmentMember_BrSr9bR8aE62mOH4GDhAjQ" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_TUTF97CVkE6Y1M0QXBN99Q">five years</ix:nonNumeric> for laboratory equipment and <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_CJboIsPRPU2JiJLp82d18Q" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_2NjPsTCIU0-wyDKhq6W2kw">seven years</ix:nonNumeric> for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. If circumstances require a long-lived asset to be tested for possible impairment, recoverability is measured by comparison of the carrying amount of the assets to estimated future undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset exceeds its estimated future cash flows, then impairment expense is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. For the years ended December 31, 2022, and 2021, <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="3" id="Narr_ZanLbkojKUe6z-1QAp5pTQ"><ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:AssetImpairmentCharges" scale="3" id="Narr_v1bF3y2dYE6O0h0nWtVyUg">no</ix:nonFraction></ix:nonFraction> impairment expenses were recognized.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_n2Z8zHSMYkGxniV7twWn-A" continuedAt="Tb_n2Z8zHSMYkGxniV7twWn-A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company measures share-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company&#8217;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or stock option awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company uses the Black-Scholes option pricing model to value its stock option awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Estimating the fair value of stock option awards requires the input of assumptions, including, the expected term of stock options and stock price volatility. The Company accounts for forfeitures for stock option awards as they occur. The assumptions used in estimating the fair value of share-based awards represent management&#39;s estimate and involve inherent uncertainties and the application of management&#39;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The expected term of the stock options is estimated using the &quot;simplified method,&quot; as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For stock price volatility, the Company uses a composite of comparable public company data as a basis for its expected volatility to calculate the fair value of option grants. The selection of comparable public company data requires the application of management&#8217;s judgement. </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ta73gUbMwUmn0Wbo0MunWg_cont2" continuedAt="Tb_ta73gUbMwUmn0Wbo0MunWg_cont3"><ix:continuation id="Tb_n2Z8zHSMYkGxniV7twWn-A_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for forfeitures for stock option awards as they occur.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_kD9ZjBRoHkuGRwwlqm22nQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred and consist primarily of expenses incurred with Penn, contract research organizations, contract manufacturing organizations, internal analytical and testing activities, and employee-related expenses, including salaries, benefits, and share-based compensation. Management makes estimates of the Company&#8217;s external accrued research and development expenses, which primarily relates to contract research organizations and contract manufacturing organizations, as of each balance sheet date in the Company&#8217;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at that time. The Company determines the estimates by reviewing contracts, vendor agreements and change orders, and through discussions with our internal clinical personnel and external service providers as to the progress to completion of services and the agreed-upon fee to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:InProcessResearchAndDevelopmentPolicy" id="Tb_x7mdNRn74k6zxYkQ6OEB3Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Acquired In-Process Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Fees paid to obtain research and development technology licenses are recognized as acquired in-process research and development expense if the research and development technology licensed has not reached technological feasibility and has no alternative future use. For the years ended December 31, 2022, and 2021, all fees paid to obtain technology licenses were recognized as acquired in-process research and development expense.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_GMBudi1t6UqEZ_OMj9hsWg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Income taxes are accounted for under the asset-and-liability method as required by FASB ASC Topic 740, <i style="font-style:italic;">Income Taxes</i> (ASC 740). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. Under ASC 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">FASB ASC Subtopic 740-10, Accounting for Uncertainty of Income Taxes, (ASC 740-10) defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company&#8217;s policy on statement of operations classification of interest and penalties related to income tax obligations is to include such items as part of total interest income, net.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_Qsup5OwXfEe9NkC1tBliCA" continuedAt="Tb_Qsup5OwXfEe9NkC1tBliCA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_SwKD_VBsp06-QBdpQPAFvg_1_2"></a><a id="Tc_K7HUZRdgQUGAOBB-8y2lmg_2_2"></a><a id="Tc_F1QWLSBOD0msaU-jJxZagA_2_4"></a><a id="Tc_ZM7yuxdiEUm1zzl4mKD-RQ_3_0"></a><a id="Tc_zXav6asLS0GsK230LMfe2w_4_0"></a><a id="Tc_sVBs2Dq5HEeVWnb8d4Bt5w_5_0"></a><ix:continuation id="Tb_ta73gUbMwUmn0Wbo0MunWg_cont3"><ix:continuation id="Tb_Qsup5OwXfEe9NkC1tBliCA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_e57BDM_QUEaJlGnUL32Q8Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:36.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_LZ4JlGCAxUyPUIGpj_JLDQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_aytSNXWX7kCftzrM2PVYAw_3_2">11,411,390</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_qOjzooIZXUyOJbcVJeTNvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_CeKuHjNIOEGGrrVRd4HcXA_3_4">9,416,998</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_pH7TkCz-oUyHvehAdIIrKA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_YWPFrhL_gEK_1vwUc5uSMw_4_2">1,229,166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_IwGipl1FgE6Gk4DlC1uLiw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_iBnx5gSpc02AlYFiYVSvrg_4_4">290,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_zQffUCmMdE-_aOBnQ2S_vA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_KTOtm09Ss0eMg8mr4o5G-A_5_2">26,680</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_LFuw3TMIekuZBYlTISw11g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_V0qqje0I9UakCiLoBql2Wg_5_4">33,753</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_b0gVByDShkahgdkuDD9BGw_6_2">12,667,236</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_Oq4qDl0zsU24W3mJn2EIkw_6_4">9,741,251</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_KD7LTCma_U2YKGcwdV4F5Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Adopted Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In February 2016, the FASB issued ASU No. 2016-02, <i style="font-style:italic;">Leases (Topic 842)</i>, or ASU 2016-02, which requires a lessee to record a right-of-use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. The Company adopted ASU 2016-02 on January 1, 2022 using the modified retrospective transition method and elected the following transition practical expedients: (i) to not reassess lease identification, lease classification and initial indirect costs related to those leases entered into prior to the adoption of Topic 842; and (ii) to not separate lease and non-lease components for the Company&#8217;s operating lease portfolio. The Company recorded an operating lease right-of-use asset and lease liability of $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_7zow5ahakk-p3Zr2YBVVfQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_xvhPYp-37ECvxaxTDXLx6Q">20.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_7zow5ahakk-p3Zr2YBVVfQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_QJctGMnvWUG2kULLxhDjmg">27.3</ix:nonFraction> million respectively, related to the adoption of the Topic 842. See note 9 for further details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2016, the FASB issued ASU No.&#160;2016-13, <i style="font-style:italic;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</i>, or ASU 2016-13, which replaces the incurred loss impairment methodology under current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 was subsequently updated by ASU No.&#160;2019-04, <i style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments</i>, to clarify that entities should include recoveries when estimating the allowance for credit losses. This guidance is effective for the Company starting in fiscal year 2023. The Company does not expect that the adoption of ASU 2016-13 will have a material impact on its financial statements.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_gEDhAdFNNU6raKVHCsnkVA_1_2"></a><a id="Tc_NwUZy4YtfE-WvMN4zzlbLg_2_0"></a><a id="Tc_e6E_qjlh0kCbTOaDO_IpaA_2_2"></a><a id="Tc_S1VRBolGMEy_qRn-ojwiTg_2_5"></a><a id="Tc_e8mSNd42_UKBcAoEM8S92w_2_8"></a><a id="Tc_jdVSgu_XCUW5D0nezIlS0A_2_11"></a><a id="Tc_F_zMjAKvr02W1nI0KF2ZLA_3_0"></a><a id="Tc_YCqR97_D_0SohemSs0tHqg_4_0"></a><a id="Tc_QwI1cIzn00q9sg7mqcTK4Q_4_2"></a><a id="Tc_19LvorlDZEOnTp_46wwH_g_4_5"></a><a id="Tc_RTxbYjNSt0erUDbuRIbuwA_4_6"></a><a id="Tc_OrJkjN8lgEmEjVkNBH7yVg_4_8"></a><a id="Tc_mLWMqcwDw0u-udaJNfc-6Q_4_9"></a><a id="Tc___Y237FQNEmn7y-n1qIkxQ_4_11"></a><a id="Tc_q1n1iU2z_E23abQDu_NgGA_5_0"></a><a id="Tc_gikTrHLALEuWntmPlonpwA_5_6"></a><a id="Tc_74HItT1cN0yVS88s5cyfxQ_5_9"></a><a id="Tc_6DCdKZ3EI0mL5yAP4D0YqA_6_0"></a><a id="Tc_9TtSs_ErqUC1mNoXy7Uayg_6_6"></a><a id="Tc_6I6V5Pzmxke2Ggp7ffFXnA_6_9"></a><a id="Tc_Yy_Kt9a8LkuINUmx-youWQ_7_0"></a><a id="Tc_Sn3rW3zio0yLW_9h2-PGeA_7_2"></a><a id="Tc_22pFoY9G20WopHfjApt6Xw_7_5"></a><a id="Tc_iRzZD9_U-UOqlpiJn2e9kA_7_6"></a><a id="Tc_c_H-vTW780ehGOXSH62Pig_7_8"></a><a id="Tc_dhLcJUTqZUOs2v3ZOXMaIg_7_9"></a><a id="Tc_FqOGEOxy-0S1f9BG46KSwA_7_11"></a><a id="Tc_1ikyavX-SkGW0-VYNHCL6w_9_0"></a><a id="Tc_JdAQ8sQ39U2OMM4oi-n8jg_10_0"></a><a id="Tc_MsB-prW8dkGQy-On78oOvQ_10_2"></a><a id="Tc_s8XFSDwSfEOxfExKNJTrNw_10_5"></a><a id="Tc_e6TbholST0CrdRWyJH-hUA_10_6"></a><a id="Tc_soUOjpDrdUazOnu6HSB99g_10_8"></a><a id="Tc_mS1YhXhCSEWIwUBQUok_Dg_10_9"></a><a id="Tc_VInOhdY8fUyn85vOVnQQfA_10_11"></a><a id="Tc_2Lf_H1qjSEqEH89KaD4MUA_11_0"></a><a id="Tc_4Gf5Co4mv0qtDSX5IWpf3g_11_6"></a><a id="Tc_Bim1d_fHn0y8gip4FDQ34Q_11_9"></a><a id="Tc_ssZtcDhP5Em-oP1VrivNEA_12_0"></a><a id="Tc_T2-xlA83tketmSiTppR9Ig_12_3"></a><a id="Tc_66ljIocHAEO5ezZKQuJzUA_12_6"></a><a id="Tc_B56SNeIrBEqWdo-r3-B8LQ_12_9"></a><a id="Tc_9f5UhbNcdUibxjcCGFU7kw_12_12"></a><a id="Tc_4vG8SnH3S0Cx4QOwL5fmng_13_0"></a><a id="Tc_yPLXyvDPlUOr1dBpM3Km0Q_13_2"></a><a id="Tc_jBRaPwo1TEa0mL2tn8lVEg_13_5"></a><a id="Tc_X7DFd8tzeUyvc55Ti13xpA_13_6"></a><a id="Tc_mNXSuCOziE-dq4PL-oT0hQ_13_8"></a><a id="Tc_NTmxHq6nZkWFR02MLRYNGw_13_9"></a><a id="Tc_O7neJQv6s0a4vB8tYDDtPw_13_11"></a><a id="Tc_FBeedNyA7UKBslSlsBw0Zg_1_0"></a><a id="Tc_Lso1q_0Gp0iXSLtoVE6kQA_1_2"></a><a id="Tc_oQYxJQdgYUS5tV332YVmFg_1_5"></a><a id="Tc_MKzocCUL3kKXlEM5W6OcEA_1_8"></a><a id="Tc_Cq0PyL-vc0m4RbQxBNBf8g_1_11"></a><a id="Tc_9354qswbD0exLQbeTQ1nkw_2_0"></a><a id="Tc_oNkNsNTjX0qxhVgiNG1INg_3_0"></a><a id="Tc_hNKAtE2Mc0OvSbGzcsH7Tw_3_2"></a><a id="Tc_38_ZskIj4022MduiTWLz6Q_3_5"></a><a id="Tc_ujcXArwqYku4bMceS8tBfQ_3_8"></a><a id="Tc_fLz9jJWQOEaFWnHxNsdhHQ_3_11"></a><a id="Tc_fyCSThmOB0ilrMYrv3N1zw_4_0"></a><a id="Tc_VCPz_Qaz_ESU_XmqQ__xgQ_5_0"></a><a id="Tc_hE7bIzQ01k6pzTwaQe8vag_6_0"></a><a id="Tc_pyOGt7DDqkurZgGoEZw4Nw_6_6"></a><a id="Tc_fh6IwLsmaEekWH9Sf9iJ0g_7_0"></a><a id="Tc_057CJnAyA0yS5vmQ63zq2A_7_2"></a><a id="Tc_n1tgOnD14EuyHhdwaTdxkg_7_5"></a><a id="Tc_gHpIWyAdT06AvB4VJhbJiA_7_8"></a><a id="Tc_rfLjP3NPgUiDKkHau9nqAg_7_11"></a><a id="Tc_ubA0TOrvUkGcoxIhJntPuQ_9_0"></a><a id="Tc_T_82ZMJdJkao74-g2F3TOw_10_0"></a><a id="Tc_aAEIk8yZS0yzLXMFgENiYQ_10_2"></a><a id="Tc_dyhobyM3BU-NZA4VKt-Uvw_10_5"></a><a id="Tc_UiFyLWbVZk-H6RUzdAavQg_10_6"></a><a id="Tc_O1KiIEKymESb_VOZ0U1hqQ_10_8"></a><a id="Tc_bPpPgKBlhE-vbKTYVYUJyA_10_9"></a><a id="Tc_pHNJ2bBGrk6IuJXbRXV3ZA_10_11"></a><a id="Tc_voXYAe0tFE6GThXdA5yvww_11_0"></a><a id="Tc_n7aAJo_v2UaRKYMUYXFY1A_12_0"></a><a id="Tc_dwLR21jhV0ODXdcMaFSUag_13_0"></a><a id="Tc_CCeex8jcuUa-nVdgSNu7Fg_13_6"></a><a id="Tc_GJ0yrIPtB06v9gBrGnIC1Q_14_0"></a><a id="Tc_cj0TLjY9z0KgYVhiUrbZqw_15_0"></a><a id="Tc_zgaQpRrMrUKiWsm-sK2T5A_15_2"></a><a id="Tc_CUXTWfz0m0iMFbmxaCtImg_15_5"></a><a id="Tc_KzqCGEdyf0uEJ9wGr99Dgw_15_8"></a><a id="Tc_BoEU5bU5lUaLAR2KIAU3Uw_15_11"></a><a id="Tc_O3zBME7DUkKtCDD10pdRww_1_0"></a><a id="Tc_7pS73DPwTEyYVQ9skz5BLw_1_2"></a><a id="Tc_unUbIs1VS0SGKLx7gdeDSA_1_5"></a><a id="Tc_ShevRAn_wki6xgide8xjzQ_2_0"></a><a id="Tc_uQFZwxoa5keBTaBBsrQziQ_2_2"></a><a id="Tc_Q3xUqO-MsE2zhzmNlYXoEQ_2_5"></a><a id="Tc_D935qpVt50KWq2pIfI7DDw_3_0"></a><a id="Tc_0RhuSDW4a060Z7oPM2Irsg_4_0"></a><a id="Tc_9Hzy7lVFkU6izm5VTyWGfg_4_2"></a><a id="Tc_IWKwURB8iUGP3k_C4Ioglw_4_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="Tb_mIv3l6maP0OclDp8N2HPpQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4.&#160;Cash, cash equivalents and marketable securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides details regarding the Company&#8217;s portfolio of cash and cash equivalents:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="Tb_NybnG4rtg0WByutnnM3CAQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Cash accounts in banking institutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_BcQOcPP9S029dfsVqpuUWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_j1S7DEKQ5UCQYSLiMB28Kg_4_3">7,532</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_BcQOcPP9S029dfsVqpuUWQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_x_XjrmXGlUmUTaphmAvokQ_4_12">7,532</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember__Gr_-HqIS0e2m0hxthuJSA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_MZ8s_4vtJEiwDoF7B3Ci7Q_5_3">24,578</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember__Gr_-HqIS0e2m0hxthuJSA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_M1cgavEpRUO-eLtBXMB_Cw_5_12">24,578</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_hKzkHH1vOE64CgLe9E8cBg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_g8zELqeh20-h6pShLL3jnA_6_3">2,491</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_hKzkHH1vOE64CgLe9E8cBg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_K9TEgG2ON0qVpRBjcBlLpw_6_12">2,491</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_MtJnt5H_6kuKXyIb4Ib9PQ_7_3">34,601</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_8jp9xSvYLUWnUV4sgRTn-A_7_12">34,601</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Cash accounts in banking institutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_EX8q_EtFJkmb7GR4fiSkgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_z8e3aEERN0uXggFVZ9tx3w_10_3">44,549</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_EX8q_EtFJkmb7GR4fiSkgA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_f9XgmqzDM0WzR--Vh-obJg_10_12">44,549</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_9DDLbzIViEiYZ2wdZ2ebDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_y8dzZfqws02CVojW39r8aA_11_3">84,416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_9DDLbzIViEiYZ2wdZ2ebDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_Lkwth17FYEi5a9VCS_5gdw_11_12">84,416</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="Tc_iR73GAoxekCGSLQhCtDvgA_13_3">128,965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_dv1X8PnAVkKltqp2vQVQCg_13_12">128,965</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides details regarding the Company&#8217;s portfolio of marketable securities:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="Tb_wiTq37h5eUajusVvIauYPw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.72120285%;padding-left:0pt;padding-right:0pt;width:101.44%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_EKMTAzZhuUyVq0LA3FdSVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_f5ApiKLXCkS589lm4NO1Mw_3_3">28,197</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_EKMTAzZhuUyVq0LA3FdSVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_n84NtLyz6U-CIeZFdCoR9Q_3_6">6</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_EKMTAzZhuUyVq0LA3FdSVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_ejs2Te4LK0y14bINq7-sRQ_3_9">92</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_EKMTAzZhuUyVq0LA3FdSVQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_NEBJ9QBQ-0i8AVvMlvYTUg_3_12">28,111</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_zS-Tm2J2FUOYlB6qItnUOQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_UbDAllr-VEyjye3_ccVpJw_4_3">58,572</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_zS-Tm2J2FUOYlB6qItnUOQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_B9kpDVdUV02HId1YgWP9VA_4_6">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_zS-Tm2J2FUOYlB6qItnUOQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_uZGv75UHYUK3Ue2gpdT68w_4_9">72</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_zS-Tm2J2FUOYlB6qItnUOQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_yMzLz0DOJUmXFflcGhdn8Q_4_12">58,512</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_oE0pMTTA8kyy9iM_moGuCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_PCAiKSvq1UO_cE66jb4Xng_5_3">67,206</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_oE0pMTTA8kyy9iM_moGuCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_Lw-YSHq2KUuYAe8-EgKY_w_5_6">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_oE0pMTTA8kyy9iM_moGuCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_XHUEVZEgdk2mFEMJy8pCiw_5_9">786</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_oE0pMTTA8kyy9iM_moGuCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_FpPUkZCAN0OceqTHMFjv9w_5_12">66,421</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_RLg8-oaulEugO9P5aol4lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_OgVG0WhGj0yz06X0q2INSg_6_3">2,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_RLg8-oaulEugO9P5aol4lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc__cRyAvslW0S1Sfy3GlHgnA_6_9">35</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_RLg8-oaulEugO9P5aol4lg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_Kf-GWWYjtkyIja4B6BPpeA_6_12">1,965</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_0QQsonojWUOVVQqtdZakfQ_7_3">155,975</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_VTarH4hhzUWvFmwuR1Hmuw_7_6">19</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_BC7Xmlb1BUOuAAOCyMfhoA_7_9">985</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_WlA-AHpVxUu0erZxemC3wA_7_12">155,009</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_tfIA7SpRCEeYVQ2vDETw2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_W9enkDyaNEWg-EprXaaosg_10_3">5,296</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_tfIA7SpRCEeYVQ2vDETw2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_AKoobUylWEy5uymWzHa69A_10_12">5,296</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ddNrvr493EuYOz1vw-xceg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_Sj0ja5jS3Eui5BQBG7iJ-A_11_3">26,503</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ddNrvr493EuYOz1vw-xceg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_CyCAbCbL0UWgWPFAOvL44A_11_6">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ddNrvr493EuYOz1vw-xceg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_8SjOmzQba0qzu68XzBzUVQ_11_9">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ddNrvr493EuYOz1vw-xceg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_7v9VbWbGakK_efoGuAM5_g_11_12">26,503</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_X6XgFKAqdUq2v933qg7wzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_MjKrOGwMj0CPkdAhmOPyaw_12_3">145,577</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_X6XgFKAqdUq2v933qg7wzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_ztvGhmmmeUWCWjXnD1yrSQ_12_6">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_X6XgFKAqdUq2v933qg7wzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_-uPDoyP3w0ilhJE_ZdraUw_12_9">418</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_X6XgFKAqdUq2v933qg7wzw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_JEgPGRJhLk2L_Nn95pSKeA_12_12">145,169</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember__szE3cOXwEaiDH4szkcG3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc__3dXEAezK0msy-qVgejpwg_13_3">1,996</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember__szE3cOXwEaiDH4szkcG3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_lnhIXn--skCNrR37mPAZIg_13_9">8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember__szE3cOXwEaiDH4szkcG3A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_Fvz6JpFnREuo_d-d7eyFBw_13_12">1,988</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Non-U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_mPnRzJMdn0WpI85X-EalUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_mLxw9KmRb0W4qhZpAluzIg_14_3">7,849</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_mPnRzJMdn0WpI85X-EalUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_q2dyb9t85065YHWtTw94oA_14_6">4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_mPnRzJMdn0WpI85X-EalUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_NOPoraitbUaZSje-YPUgag_14_9">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_mPnRzJMdn0WpI85X-EalUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_NGy59yYsb0KpnrvDKyWHpQ_14_12">7,852</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="Tc_Bvsu1y5lsEa22O9-t46wBQ_15_3">187,221</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_0mryIhWpRE61FYTxXbjeJQ_15_6">18</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_K018q8VZ_Uy37BuF8odH5A_15_9">431</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_ATVft1Iy00SlTKnL8xYgzQ_15_12">186,808</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">S</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The contractual maturities of our marketable securities as of December&#160;31,&#160;2022, are as follows:<b style="font-weight:bold;"> </b></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="Tb_6uA5CPm8wkWKmaipgliggQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:19.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:20.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due within one year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="3" id="Tc_QOxh7SHx706e05C5Kk6DWA_2_3">144,583</ix:nonFraction></p></td><td style="vertical-align:middle;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="Tc_B4CqORyxn0abHMeiz-MI5A_2_6">143,779</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due after one year through five years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="3" id="Tc_nfqRO73sukC47pO5ipHjDg_3_3">11,392</ix:nonFraction></p></td><td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="3" id="Tc_hhccZZEwa0yQnwZbNzR-TA_3_6">11,230</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" scale="3" id="Tc_dhL9Pw-_PkOQkErtxxcS0Q_4_3">155,975</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" scale="3" id="Tc_Zr2DQSYybUSnLVl2tB5sKQ_4_6">155,009</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_LgSmn0pbcEOpnf3jW_Ofxg" continuedAt="Tb_LgSmn0pbcEOpnf3jW_Ofxg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5.&#160;Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Fair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments be made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company&#8217;s financial instruments, including prepaid expense and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. The Company follows the provisions of FASB ASC Topic 820, <i style="font-style:italic;">Fair Value Measurement</i>, for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:31.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 1: </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:31.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 2: </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:31.5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 3: </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_yV7d6-QXXESEeO_tsOiFPg_1_2"></a><a id="Tc_uePu_CpYlEmsl0LIpe-4SQ_2_2"></a><a id="Tc_2klLkSojIUiHIvkvvZiMlw_3_2"></a><a id="Tc_vTWyFadnDkOylQXsv_yCxA_4_2"></a><a id="Tc_XNzpNqXN1069rIa03p-aDQ_4_5"></a><a id="Tc_m8rzCNw63kueh3RECVaLMg_5_3"></a><a id="Tc_h_A4NzpAkk-OpqCOu__2JQ_5_5"></a><a id="Tc_4zWQLgxRhkGtxjXuFyJDlg_5_8"></a><a id="Tc_JSdg7ZR3WEOiQTFK-HVrqw_6_2"></a><a id="Tc_-jzbTk2xiEa7SLubjr-2Ag_6_5"></a><a id="Tc_nbTLcjVDOUuN9PkC5IZDAw_6_9"></a><a id="Tc_m8TVzv44UESvtNFxz1Vleg_7_2"></a><a id="Tc_Ur3RocbaS0e2dRdVpZ_LNg_7_5"></a><a id="Tc_2ANN0f0TzUCPUwDOIanvrA_7_8"></a><a id="Tc_Ob9Pkzu_HEO0cNmhXwswIg_8_0"></a><a id="Tc_DaKod_jo40SvH1JCjOrdmg_8_2"></a><a id="Tc_Dvqdz_NPBEiBIdHkpH7w-A_8_5"></a><a id="Tc_Nj92ez7i-0SvgHPyIhrQeg_8_8"></a><a id="Tc_T-4AItKo_0eN4BqxkHfY0g_9_0"></a><a id="Tc_bFAgZY3KxUuO6nng-Rz_3w_10_0"></a><a id="Tc_JOgjRcPEZkuDebPnKqgQFg_11_0"></a><a id="Tc_tEQAoVQRUECTmpfNe7hKkQ_12_0"></a><a id="Tc_vs5UUnybj0a2lIFPEzpCtQ_12_2"></a><a id="Tc_p8fE0pw5V0WPoUtkXZxdvQ_12_5"></a><a id="Tc_JSJI7uJFNE-Uw2QAKwW_aA_12_6"></a><a id="Tc_P7YTgrmxZk2WGDl6XNxsXA_12_8"></a><a id="Tc_atITemv3Tkegqs9KDJ9v4g_12_9"></a><a id="Tc_Q5Z196th9kC0J1ZNaGP6Bw_13_0"></a><a id="Tc_w5cY3oWj906L1ethaWHHmg_13_3"></a><a id="Tc_1YrBpOtHJk-GSO5RgiCwHw_13_9"></a><a id="Tc_gl8d3nwbb0KKmEmoJ2nS_g_14_0"></a><a id="Tc_bLZVIWe34UeOpdT9AOse9w_14_9"></a><a id="Tc_BlbblwI2ZUS5MJPINYZD_g_16_0"></a><a id="Tc_o-7EYpULlki35bHwUtbRcQ_17_0"></a><a id="Tc_dCkAYN6m0UaCGBZgDxtj1w_17_3"></a><a id="Tc_-Jg25sv7KUqrbbFvCeJO7g_17_9"></a><a id="Tc_7QOX-vKGe0qB320bbWAzcw_18_0"></a><a id="Tc_8A2PN2eQUEqoHivTmZ5PAA_18_3"></a><a id="Tc_18Z1HFdg30GFM_4nK0TiOg_18_9"></a><a id="Tc_ikKIzK7S4ECNCJMwLag5JA_19_0"></a><a id="Tc_mrxBJRpvdEWsYmxJI9mkzQ_19_3"></a><a id="Tc_wUITqYv7fEiC2uwg1lWiOA_19_9"></a><a id="Tc_sScqyZ4Gi0iElK85kRlraA_20_0"></a><a id="Tc_71f8MZiq-E6zRD12vpH3zw_20_3"></a><a id="Tc_L3EJ76bBVUiQem7FG3LgQw_20_9"></a><a id="Tc_7BYAdViw2EWTVCCoWV4qtw_21_0"></a><a id="Tc_L1ecaksBKUamwwbFLsfosg_21_3"></a><a id="Tc_QHDwcAy6EEe1gLGYwjFZFA_21_9"></a><a id="Tc_T2J9y6ni_U-Xl4qsOpvoFg_23_0"></a><a id="Tc_g6ddvOi1ykapJcl51DY6_A_23_2"></a><a id="Tc_92Y4FFBOHEaY3WWKzlRewQ_23_5"></a><a id="Tc_5vJ8Ltwpc0iUtQYqceG2mw_23_8"></a><a id="Tc_Mv4_82r0OkmGaTJw1uVq8w_23_9"></a><a id="Tc_VkvbiYa6HEmGZG2CboGJNg_25_0"></a><a id="Tc_84cF7pNx80K_RyhSPe-ZOg_26_0"></a><a id="Tc_80ICwyMsBE-eob-s4BR-Eg_27_0"></a><a id="Tc_YQaSuBHPlUyWa2XEeYqx5g_28_0"></a><a id="Tc_zgFyNI4hCka5DaRp5ECmag_28_2"></a><a id="Tc_6NLouHlQUUi7YTfooX7aOg_28_5"></a><a id="Tc_S3KswvsSPUee1Ixs5GiQIQ_28_6"></a><a id="Tc_bPbNBqWQhUyg-usptre-IA_28_8"></a><a id="Tc_BPnZQV2g2U-xsNfdin1zWA_28_9"></a><a id="Tc_HYIeFzrflUSxfDnU8AZWJA_29_0"></a><a id="Tc_b0r5lb2SukW93k7BXLjVLg_29_3"></a><a id="Tc_S8DJfhOJDUaUWk2vsaedcw_29_6"></a><a id="Tc_CBVsnTGRq0K74U423d74nQ_29_9"></a><a id="Tc_T1pCJ5Cou06lnXPa4EKG3Q_30_0"></a><a id="Tc_EJjQpC6T10iRZegnYfbOAA_30_6"></a><a id="Tc_hE6g91hYeUCaFKNC_GMP0g_30_9"></a><a id="Tc_yIqgXj432USZpCenf4y0Ng_32_0"></a><a id="Tc_BN51U_AaXEe4PnQDeH4Lfw_33_0"></a><a id="Tc_m2_U-_vZHkqni5BRyg88Xw_33_3"></a><a id="Tc_qJaRsGjRykasLiQdvJ1qCA_33_9"></a><a id="Tc_5sQsFgBhnky3hog6Txv9Pg_34_0"></a><a id="Tc_Pe4XbCjaYkW3CHSyCXbHYA_34_3"></a><a id="Tc_ju7MiaBtB0akuJBmnHrIQA_34_9"></a><a id="Tc_VYR_7ds3MkurJTuAWeUlzQ_35_0"></a><a id="Tc_hxpUfmjvWUaYkzdXiEaXwA_35_3"></a><a id="Tc_G9KMIhtU5UC7NY0QR7Pg5A_35_9"></a><a id="Tc_UVjGDJyAL0-uWNanK6G4IA_36_0"></a><a id="Tc_jTaAgb_RZE-3PY0vYw6tvg_36_3"></a><a id="Tc_7uTamuBFsE2SWJSFRSWqTg_36_9"></a><a id="Tc_tjqvp6WDfEWCIF3WeJztLQ_37_0"></a><a id="Tc_Q6ex6BCR7k2IJBxd_B6gCg_37_3"></a><a id="Tc_14nQY0m7AEanpGKV2RMJyw_37_9"></a><a id="Tc_UZBti5YY8kONwPGG--vmGg_38_0"></a><a id="Tc_OecIlRdkmUK1Iwu-QMZl6Q_38_3"></a><a id="Tc_qMXarEoMGEKGkF618SCL0w_38_9"></a><a id="Tc_ehExB4yNI0Gcy80hKsU2NQ_40_0"></a><a id="Tc_kOCUCUa_BkmKg7YpvVtBEg_40_2"></a><a id="Tc_q7ULKwzzIkyDiUbjrRDf8Q_40_5"></a><a id="Tc_UmgSmhbTbU-AxNR3wH5CYA_40_8"></a><a id="Tc_TV7rNaZYe0yrKrEWtGiG3w_40_9"></a><ix:continuation id="Tb_LgSmn0pbcEOpnf3jW_Ofxg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following fair value hierarchy table presents information about the Company&#8217;s assets measured at fair value on a recurring basis. Included within cash and cash equivalents on the balance sheet, but excluded from the fair value hierarchy table, are cash deposits held at financial institutions:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="Tb_iUaF-uwpHEypyhFaJ6oGDA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">markets for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ycWO8dyX_kC6uG93WKsSqA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_eDSu8yUnvk-nu3-5o6uXuQ_12_3">24,578</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KknMkl4yeUm7mwrKVSBAMQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_46K-I3OYckqrtl8Ao0uS5w_13_6">2,491</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qnM-OR-gAECiFX_LbmMPfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_tTi6iSCJhUierBogPd2W8w_14_3">24,578</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_m3qLi4_cEU60Ts_xTIoBAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_1c9c51HbnkWMxPpjMcsN-w_14_6">2,491</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_8rQIwJjX7U-HUdBs0mHPHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_R5lgOQwEyUiZOq6A3SO5YA_17_6">28,111</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_xNnhYs_8xE25HkrTLSUCDg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_V1dkllVHzkeauuJh53aa8g_18_6">58,512</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_nzjfVFDIVUWSs3XTC4bDsA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_272w1uFGS0CtUd-jX-7roA_19_6">66,421</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_nU963VORek-l98BVpjXc2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_LCZu8JetN0ijvTY0zSc6iQ_20_6">1,965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_m3qLi4_cEU60Ts_xTIoBAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_IYeIkFuLZ0W0IzYS6hRRAg_21_6">155,009</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qnM-OR-gAECiFX_LbmMPfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_31LPwCJlX0e4KyMuBOGuvA_23_3">24,578</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_m3qLi4_cEU60Ts_xTIoBAA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_ZryHmRaRYU66FbJJLlQ-Sw_23_6">157,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_PZny6jRjkUiFZ51MD_j8yw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_1s_6vCMbwkqjICQc1hzUZQ_28_3">84,416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_C-o2Zgq5lkazNtHRBvQ8_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_DVI3_UVK6063lRiLGbvpzA_30_3">84,416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_UcKqbx4Po0Ou91dnkxKM6Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_RGCU4sMm7k6cF2BvGlPSng_33_6">5,296</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_bskf0Lik9k62JRNH0Ahm_w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_t6XO8GkLR02rlu-d5-EZ0g_34_6">26,503</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_SOu6oV8f4Uqc6G1TRruyZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_TrJNhvLVRkywL3Dgb5X6iQ_35_6">145,169</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_U1C9pEJYU0mSIYjsXdwWXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_u2Qqvhnj5UC-zOF6iqznAg_36_6">1,988</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Non-U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_GIzjQ4m1DEOd0Y5zdqwlEA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_HRl_l1f8dkm9IVh6KzTNIQ_37_6">7,852</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_btpJFa9_VkSBS3ixhn_iWw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="Tc_CzfrLgJVAEOkApuO1iNpgQ_38_6">186,808</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_C-o2Zgq5lkazNtHRBvQ8_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_CwoIpAHBnk2uE6Xz7LANAw_40_3">84,416</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_btpJFa9_VkSBS3ixhn_iWw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="Tc_JttsclLO70SL4U3Zw9bGhA_40_6">186,808</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_IajQ7ZHJKUSEi2pF-GrJJQ_1_0"></a><a id="Tc_JtUU7SO9oEml0zM-ruT4Pw_1_2"></a><a id="Tc_AT7hibO-G0Wq4k7bVP1CJg_1_4"></a><a id="Tc_O3gYFHRUBUOGyxcIL_IXUQ_2_0"></a><a id="Tc_N7jG6h62q0Sy7tzZfvQmGg_2_1"></a><a id="Tc_W3TpoJoXjkSYPEL6KtPhLg_2_4"></a><a id="Tc_dRfksi-cB0-9GXSxsEFp0w_3_0"></a><a id="Tc_oUCZme70jUCVvjw0sBy5Cg_4_0"></a><a id="Tc_VJLH14qvGkaQx47O5UsJgQ_5_0"></a><a id="Tc_YLu667vnekKWMWSRavGc7Q_6_0"></a><a id="Tc_rlgAJOV_90y5ojUnAjhStA_7_0"></a><a id="Tc_IntDAJWxOkaX7PB1BXlxbQ_8_0"></a><a id="Tc_ezi_pboxxUeavs-4mWqz6Q_9_0"></a><a id="Tc_aB4YKBg7MEikckOMFSIXwA_10_1"></a><a id="Tc_ESqP1w6Ei0i9KziaNEQS6g_10_4"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_H5VwR4SJZEetSkMMxfipSA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Property and Equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and Equipment, net, consist of the following: </p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="pasg:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" id="Tb_iPoshBSLa0-S1o7FGZFjVA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:101.08%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:18.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:middle;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:middle;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_LaboratoryEquipmentMember_VlmbuSYC6USj3OTDddchPQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_LkIoyMQOhECC3W3-gAMFfA_2_2">9,972</ix:nonFraction></p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_LaboratoryEquipmentMember_15fk6eyMukOdrAYC2-ThJg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_Do0af7RS5EWzMgOJQE4DIA_2_5">8,916</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office equipment</p></td><td style="vertical-align:middle;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_2Hsg8LNvXEucBUm5ld8Thw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_uBDYQFRN-UyNmIdLCl6m8A_3_2">601</ix:nonFraction></p></td><td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_OVQG01q9_Eid2wbn4B4PpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_oxgt5YuQcky5e_QPu4CI8Q_3_5">621</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer hardware and software</p></td><td style="vertical-align:middle;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_ComputerHardwareAndSoftwareMember_JzsV16LRG0WCbPoDdOU4QA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_8eurQUJ5rUGxZxvMjUvL8A_4_2">1,090</ix:nonFraction></p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_ComputerHardwareAndSoftwareMember_kCoolnyGaUy4-vQysBpBNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_QyC9gmG2JkGOgifbIdRTFg_4_5">1,028</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:middle;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_bJ5zjvxB5EGnQcqTp7xFSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_TL4JzvAHTkyKbsaTnzLQ2Q_5_2">1,208</ix:nonFraction></p></td><td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_yGDjvEYReEuRzXheeim-wQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_8Z6XTGU_90aP_LHwiZy-0w_5_5">1,487</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:middle;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_618eVrMiP0KqpawEGChP-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_3sIJSGqYtU2QdGPe-UgahA_6_2">13,506</ix:nonFraction></p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_wweEz0CjaU-LuKc41hE1fg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_eTtrlHjCpkmXa3qjrO-xow_6_5">13,409</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:middle;width:3.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_Wqhrge7I_kKR4RChMkdtEQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_St74M15f906lixs__H6IDg_7_2">1,291</ix:nonFraction></p></td><td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_S84Lz4H_jE-dgwqZQM7UOA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_oyWUL7pDQkOFRLHuTQue0w_7_5">822</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total property and equipment</p></td><td style="vertical-align:middle;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_l4hR0prNkEWbRtdyEKBlig_8_2">27,668</ix:nonFraction></p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_dMO6Te7Nlk68PW3N5bKfaQ_8_5">26,283</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_dNNdvqDAgEaix3CB5dNM3Q_9_2">5,153</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_AHST5i2wiE6RlaoPbPOEzw_9_5">2,477</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:18.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_2whFKk2R30WLlb6MqoJYow_10_2">22,515</ix:nonFraction></p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_ZUWJfVtFxEmd6j1-XbcbkQ_10_5">23,806</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation expense was $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="Narr_tV8hzmBa-kiOpWPJyTYV6w">3.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="Narr_ZIGQQrkb0EOpTi-CtdBejw">1.5</ix:nonFraction> million for the years ended December 31, 2022 and 2021, respectively.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_tM07aRYjKEeZC_WaTc2zJQ_1_0"></a><a id="Tc_vJ2o2nADtE2hG3qKWs979g_1_2"></a><a id="Tc_gGLbZ3SNJEyuzMyIEkwuwQ_1_5"></a><a id="Tc_DcrE55nn30mN6RrK75ZKhQ_2_0"></a><a id="Tc_KzJkhANhu0OtruCo-zMIkg_2_2"></a><a id="Tc_E9INj-OvwUGKUe8Yk1VmfQ_2_5"></a><a id="Tc_3bVkUzBq_UOV40lcTmr1gw_3_0"></a><a id="Tc_Ueo1LVWZ2UGYndaYms5HUQ_4_0"></a><a id="Tc_wNpKM65NQUenZcAHOulFaQ_5_0"></a><a id="Tc_rp8sG6jkO0m-42dqyxMHMg_6_0"></a><a id="Tc_GMEeL-5l10OgVJOiEW563g_6_3"></a><a id="Tc_1mCuMFiLkUWu9mhsMLwIWg_7_2"></a><a id="Tc_FK273PEIfk-Pji2-zeU-vg_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" id="Tb_GFFe2Tu5Uk6bIdA2CY0Jfg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7.&#160;Accrued Expenses and Other Current Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other current liabilities consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" id="Tb_i-PYfKwuX0KYtfhAT31HSQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5409012%;padding-left:0pt;padding-right:0pt;width:101.08%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_XMgUOhzDQEuvYYM8ByuPKw_2_3">602</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="Tc_PHzQa-XX3EeDkHEjIJ5B7g_2_6">877</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_xh4tAa4HKUG5QhFIIljhQw_3_3">8,446</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_8g-epVlfBkCN1MdCMglthw_3_6">10,014</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="pasg:AccruedResearchAndDevelopmentExpense" scale="3" id="Tc_fvkXn0BM2ESaYPhlgzVToQ_4_3">1,878</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="pasg:AccruedResearchAndDevelopmentExpense" scale="3" id="Tc_npvwdHZzXUSOfnQdh-4ZGQ_4_6">8,498</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="pasg:AccruedLiabilitiesPropertyAndEquipmentCurrent" scale="3" id="Tc_B3246E0feEOynBBthLJfeA_5_3">85</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="pasg:AccruedLiabilitiesPropertyAndEquipmentCurrent" scale="3" id="Tc_CCvY-BpGq0-VwB6zFeHXPQ_5_6">161</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_62z7ldT1x0-3rQ7OqH3DLg_6_6">500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="pasg:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_2mrd6B2cGkyrUvFKH4jBfQ_7_3">11,011</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="pasg:AccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_HyTZjnNsB0WXnBDyWvRVAA_7_6">20,050</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="Tb_I8l8WvPvkU24jIpMLf85SQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Severance </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In March 2022 and November 2022, the Company announced workforce reductions and that it has prioritized certain research and development programs to reduce operating expenses and to extend its cash runway. <span style="background:#ffffff;">In connection with these announcements, the Company reduced headcount by approximately&#160;</span><ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="As_Of_3_31_2022_NhtNZVP74Ei9hd55TAwTew" decimals="2" format="ixt:numdotdecimal" name="pasg:PercentReductionToOurWorkforce" scale="-2" id="Narr_AqJfC837TEqYrhjTEONmoQ">13</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="As_Of_11_30_2022_mVsYEdTSSEuJbQ89GBbHMg" decimals="2" format="ixt:numdotdecimal" name="pasg:PercentReductionToOurWorkforce" scale="-2" id="Narr_nNazXiUaokqIKJBMaC-I8A">23</ix:nonFraction>% in March 2022 and November 2022, respectively. <span style="background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In&#160;accordance with ASC 420,<i style="font-style:italic;">&#160;Exit and Disposal Activities,</i>&#160;the Company recorded severance and termination-related costs of $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_rKbIo3RACkur9OAM8iqIbA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SeveranceCosts1" scale="6" id="Narr_KisDaDMivES6uxyjBoO9CQ">3.8</ix:nonFraction> million in general and administrative expenses and $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_fzK4cBH8fkuhwpQHwW1AZA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SeveranceCosts1" scale="6" id="Narr_Zfb4cYvwqEi3Bw8f7MhT_A">2.3</ix:nonFraction> million in research and development expenses for the year ended December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_pasg_AccruedExpensesAndOtherCurrentLiabilitiesMember_GPYjhSt04kqGmR--V5LGEg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestructuringReserveCurrent" scale="6" id="Narr_gETmUQHnlk6WiltVVlzF0g">2.1</ix:nonFraction> million of severance and termination-related costs were unpaid and recognized in the balance sheet within Accrued expenses and other current liabilities.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_Wtcup82kPkqjbg-zc2CZeg" continuedAt="Tb_Wtcup82kPkqjbg-zc2CZeg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On January 1, 2022, the Company adopted ASU No. 2016-02, <i style="font-style:italic;">Leases</i>, using a modified retrospective approach and recorded operating lease right-of-use, or ROU, assets and operating lease liabilities of $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_7zow5ahakk-p3Zr2YBVVfQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="Narr_d_RHFoWfME-d8ZXcT0_jHQ">20.4</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_7zow5ahakk-p3Zr2YBVVfQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="Narr_ok3sEn6xzUa5hp4JGVHTDg">27.3</ix:nonFraction> million, respectively, related to the Company&#8217;s Lease Agreement and Laboratory Lease Agreement, or collectively, the Leases, which are each defined below. The Company elected the package of practical expedients available under ASU No. 2016-</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_Su5NRtGs6UW58bLspzIdNg_1_2"></a><a id="Tc_mDZCrZ5h7UCULjw8hbpGzQ_2_0"></a><a id="Tc_UsY4K3hUckmY-85YoYdnWA_2_2"></a><a id="Tc_y3zriB9CDEyuEizriZaldA_3_0"></a><a id="Tc_hIOb6uEBnEOXUt6CAIsdrw_3_2"></a><a id="Tc_KrYtoUpXMk6KYKhJ2BCDxw_4_0"></a><a id="Tc_EpFbdiyQIEWsVfNb6ixZQg_4_2"></a><a id="Tc_DI4w2r20oUGCLorOSeCKtw_5_0"></a><a id="Tc_6CsWruKo6kiupeZfNABtyg_6_0"></a><ix:continuation id="Tb_Wtcup82kPkqjbg-zc2CZeg_cont1" continuedAt="Tb_Wtcup82kPkqjbg-zc2CZeg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">02 and as such, did not reassess any of the Company&#8217;s existing or expired contracts or any other agreements that were previously concluded to not contain a lease for the following practical expedient guidance: (1) whether the arrangement is or contains a lease, (2) lease classification and (3) whether previously capitalized costs continue to qualify as initial direct costs. In addition, the Company applied the accounting policy election to not separate lease and non-lease components and the accounting policy election to not apply the recognition requirement under ASU No. 2016-02 to leases with a term of twelve months or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company was not required to record a cumulative effect adjustment upon adoption as the Company did not capitalize any material initial direct costs nor were any contracts reassessed leading to changes in the terms or contractual payments of historical arrangements that would impact expense recognition, however, the Company eliminated $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_1_1_2022_1hJs1cU8B0yEBX43Mau-lg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredRentCreditNoncurrent" scale="6" id="Narr_b8OFlYMMxkefmhT1raInnQ">3.2</ix:nonFraction> million of deferred rent liabilities and $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_1_1_2022_1hJs1cU8B0yEBX43Mau-lg" decimals="-5" format="ixt:numdotdecimal" name="pasg:TenantImprovementAllowancesLiability" scale="6" id="Narr_b1w_xlW-ykqQG_SrytZ_SA">3.8</ix:nonFraction> million of tenant improvement allowances as of January 1, 2022 related to the Leases as these liabilities are reflected in the operating lease ROU assets. The Company used incremental borrowing rates, or IBRs, of <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForOfficeSpaceMember_Y66Drnyc1kO-defDYISTag" decimals="3" format="ixt:numdotdecimal" name="pasg:LesseeOperatingLeaseIncrementalBorrowingRatePercentage" scale="-2" id="Narr_xL2yH2wVa0iHo9ccDJ7pWw">9.0</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForLaboratorySpaceMember_olTE_Yzm10uPm2K7m0faAg" decimals="3" format="ixt:numdotdecimal" name="pasg:LesseeOperatingLeaseIncrementalBorrowingRatePercentage" scale="-2" id="Narr_KBAhqGKweEiexf-WLTDWkQ">10.0</ix:nonFraction>% to discount the operating lease liabilities for the Lease Agreement and the Laboratory Lease Agreement, respectively. The Company&#8217;s IBRs were quoted by an unrelated third-party lender and reflect a collateralized borrowing with similar terms and amounts as the Leases. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is party to a lease agreement for office space, or the Lease Agreement, in Philadelphia, Pennsylvania. The Lease Agreement commenced in February 2021 and is expected to expire in December 2031. The Company has an option to extend the term of the Lease Agreement by up to <ix:nonFraction unitRef="Unit_Standard_item_wlhC8WlTVEmcZqQ79zgOUA" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForOfficeSpaceMember_ZrafZiQhmUuODBwDYCS8rQ" decimals="INF" format="ixt-sec:numwordsen" name="pasg:NewLeaseAgreementOperatingLeaseNumberOfExtensions" scale="0" id="Narr_7_zH39opJ0WtvlgZkgf1Eg">two</ix:nonFraction> <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForOfficeSpaceMember_PnKu318m2kKf0m31ftbUUQ" format="ixt-sec:durwordsen" name="pasg:NewLeaseAgreementOperatingLeaseRenewalTerm" id="Narr_D3sX_VUaKkSc8u5e3jiYwQ">five-year</ix:nonNumeric> terms. This option to extend was not recognized as part of the Company&#39;s measurement of the ROU asset and operating lease liability as of December&#160;31,&#160;2022. The landlord provided the Company with a tenant improvement allowance of $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForOfficeSpaceMember_ZrafZiQhmUuODBwDYCS8rQ" decimals="-5" format="ixt:numdotdecimal" name="pasg:TenantImprovementAllowanceReceivable" scale="6" id="Narr_d_cubb5Xr0yJkcEKQud8cw">2.8</ix:nonFraction> million, for which the related expenditures were paid directly by the landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is also party to a lease agreement for laboratory space, or the Laboratory Lease Agreement, in Hopewell, New Jersey. The laboratory is initially focused on state-of-the-art analytical capabilities, assay development and validation, and clinical product testing to support both viral vector manufacturing and clinical development. The Laboratory Lease Agreement commenced in March 2021 and is expected to expire in February 2036. The Company has an option to extend the term of the Laboratory Lease Agreement by up to <ix:nonFraction unitRef="Unit_Standard_item_wlhC8WlTVEmcZqQ79zgOUA" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForOfficeSpaceMember_ZrafZiQhmUuODBwDYCS8rQ" decimals="INF" format="ixt-sec:numwordsen" name="pasg:NewLeaseAgreementOperatingLeaseNumberOfExtensions" scale="0" id="Narr_Uiv-1vR5aEi7Gu8WXtGZiw">two</ix:nonFraction> <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForOfficeSpaceMember_PnKu318m2kKf0m31ftbUUQ" format="ixt-sec:durwordsen" name="pasg:NewLeaseAgreementOperatingLeaseRenewalTerm" id="Narr_iBbCNnvgzUK7Nq8di5bShA">five-year</ix:nonNumeric> terms. This option to extend was not recognized as part of the Company&#39;s measurement of the ROU asset and operating lease liability as of December&#160;31,&#160;2022. The landlord provided the Company with a tenant improvement allowance of $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForLaboratorySpaceMember_m3JiXizoFEGM-jTR8nDJpA" decimals="-5" format="ixt:numdotdecimal" name="pasg:TenantImprovementAllowanceReceivable" scale="6" id="Narr_n31UX1_bC02UyVGwxkiXVA">1.3</ix:nonFraction> million in connection with the Laboratory Lease Agreement, for which the related expenditures were paid by the Company and will be reimbursed by the landlord. As of December&#160;31,&#160;2022, $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_d5OcH9P0YU6Mqog4XpwvoA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TenantImprovements" scale="6" id="Narr_Pr_qyl7XAk2jCQvEwFGZPA">0.1</ix:nonFraction> million of reimbursements were unpaid by the landlord and recorded within other current assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the Company&#8217;s operating leases:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:LeaseCostTableTextBlock" id="Tb_R6fYZkeoeUadv-Iveokqjg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:65.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:24.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ in thousands)</b></p></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:middle;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:middle;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_W56INVoRIkOOcjDEFs1ilw_3_3">3,316</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of operating cash flows from operating leases</p></td><td style="vertical-align:middle;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:24.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePaymentsUse" scale="3" id="Tc_OyEY4lkKVEq4NF1tcSAI0Q_4_3">2,853</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate</p></td><td style="vertical-align:middle;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_kSXqbHpuVUS5IH9evC5z9A_5_3">9.7</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:middle;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (years)</p></td><td style="vertical-align:middle;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:24.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_1MNgGBP2K0GzSrl_iv30gw_6_3">12.2</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_y86L5ZDo6UmJ3yn5l3HAjg_1_0"></a><a id="Tc_4bA2XU8jeEq4wst-1bDzNQ_2_0"></a><a id="Tc_rlvCxkq1OECN37aNm_Yk9Q_2_2"></a><a id="Tc_Jc9f4xD3Y0ibN-wfdIOc-g_3_0"></a><a id="Tc_mUL5KYD6EUmVrIXKfFimVw_4_0"></a><a id="Tc_LGJ9Odo3qE65YvHLFF9fag_5_0"></a><a id="Tc_gGB6uB27pEu1TRw3cNBtiQ_6_0"></a><a id="Tc_7DDU5o7c8Em6-vQUeV0P6w_7_0"></a><a id="Tc_QCZR2dZJj02179OzvKN_8Q_8_0"></a><a id="Tc_w-ODKBcTxki-zlnREUt0Cw_9_0"></a><a id="Tc_p_qC4tD1KEWhIxGfDvgyGg_10_0"></a><a id="Tc_tWpeT_QQs0eRuTZ4XLA-AA_10_2"></a><ix:continuation id="Tb_Wtcup82kPkqjbg-zc2CZeg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes future minimum lease payments under the Company&#8217;s operating lease agreements:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Group_06Xd6Q3vcEafb_zt3okNdA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_AP1F5YgQFE2J5LTrK4rq0w_2_3">3,455</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_E3bEK__Y90q5d2zKFhxMiw_3_3">3,553</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_m-ZjksSYA0-qZDPt4Ey7aA_4_3">3,654</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_xEQ0IEnxyEumx9-eg3P7zg_5_3">3,757</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_z8L5-_W21k-fQFKxP6qjhA_6_3">3,864</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc_TVU4oZkbKUGAvKYtkBkxVw_7_3">29,679</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:middle;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_nH4HfXpNz0uVE0efGd0ETw_8_3">47,962</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_pxHT7HfLQU2isiIKlL9YyA_9_3">20,855</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liabilities</p></td><td style="vertical-align:middle;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_yQZQcj-aJU2YAcH9917idg_10_3">27,107</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_BMTiodvaZkyr0EfkBcYzPA" continuedAt="Tb_BMTiodvaZkyr0EfkBcYzPA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10.&#160;Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Amended and Restated Research, Collaboration and License Arrangement with Penn</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The Company has a research, collaboration and licensing agreement with Penn, as amended, or the Penn Agreement, for research and development collaborations and exclusive license rights to patents for certain products and technologies. Under the Penn Agreement, the Company has obligations to fund certain research relating to the preclinical development of selected products</span> <span style="font-weight:normal;">in research programs as well as the exploratory research program in non-rare and/or non-monogenic, or large CNS indications, currently TLE. In addition, the Company will fund discovery research conducted by Penn through August 3, 2026 and will receive exclusive rights, subject to certain limitations, to technologies resulting from the discovery research for the Company&#8217;s products developed with GTP, such as novel capsids, toxicity reduction technologies and delivery and formulation improvements. This funding commitment for the discovery research is </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_Tz7eti2M40mA4VxFf-_HGA" decimals="-5" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementAnnualFeePayable" scale="6" id="Narr_ehFkMrpSBkOC4iXShODsiA">5.0</ix:nonFraction></span><span style="font-weight:normal;"> million annually, paid in quarterly increments of </span><span style="font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_Tz7eti2M40mA4VxFf-_HGA" decimals="-5" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementQuarterlyFeePayable" scale="6" id="Narr_eyjlbewMr0mlgfGWQfRwkA">1.3</ix:nonFraction></span><span style="font-weight:normal;"> million through June 2026. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">The Penn Agreement includes an exploratory research program focused on discovering targets and novel gene therapy candidates for large CNS indications, currently focused on TLE, and can be expanded to other large CNS diseases upon mutual agreement. The initial term of the exploratory research program is until August 2024, which term can be extended by mutual agreement. During such term, the Company will have an exclusive right of first negotiation to include additional targets to the exploratory research program within the agreed upon large CNS indications. Under the exploratory research program, the Company will have the right to further develop and commercialize any gene therapy product candidates specific for those selected targets within TLE (and any future large CNS diseases that are mutually agreed upon) that may arise from the exploratory research programs on substantially the same terms of the current Penn Agreement.   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Under the Penn Agreement, the Company has <ix:nonFraction unitRef="Unit_Standard_Option_5y2HNcjXj0iaLv1FEhwgXQ" contextRef="As_Of_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_Tz7eti2M40mA4VxFf-_HGA" decimals="INF" format="ixt-sec:numwordsen" name="pasg:NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram" scale="0" id="Narr_RZcIS2w8UkCD_RBrsiyjsQ">eight</ix:nonFraction> remaining options available to commence additional licensed programs for CNS indications and has until August 3, 2026, to exercise these options.&#160;If the Company were to exercise any of these options, it would owe Penn a non-refundable upfront fee of $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_8_3_2020_To_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_X9L4Qp3mCEKi6Z_BUccfKQ" decimals="-5" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementUpfrontPaymentMade" scale="6" id="Narr_OR81fHPjuU-sUkHtlPlE3A">1.0</ix:nonFraction>&#160;million per product indication, with $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_Tz7eti2M40mA4VxFf-_HGA" decimals="-5" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementUpfrontFee" scale="6" id="Narr__1EyRSVWnkyAntz3fEei7w">0.5</ix:nonFraction> million due upfront and another $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_Tz7eti2M40mA4VxFf-_HGA" decimals="-5" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation" scale="6" id="Narr_NsaZwmt0f0uQatzw1Hnq4Q">0.5</ix:nonFraction> million fee owed upon a further developmental milestone. The Company has the obligation to fund certain research relating to the preclinical development of each licensed program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Penn Agreement requires that the Company make payments of up to (i) $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_z13QfKfPmkK_8C2JId34Bw" decimals="-5" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" scale="6" id="Narr_SsqKqqKSL0Gyd8JYjp9Wwg">16.5</ix:nonFraction>&#160;million per product candidate for rare, monogenic disorders in the aggregate and (ii) $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_HuyYaPjrf0-kSgqt367TIw" decimals="-5" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone" scale="6" id="Narr__3Eth1hgrkeMUMMIHeOVZw">39.0</ix:nonFraction> million per product candidate in the aggregate arising from the exploratory program for large CNS indications, currently for TLE. Each payment will be due upon the achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt-sec:numwordsen" name="pasg:DevelopmentMilestonePaymentsPayable" scale="3" id="Narr_4PCJqVVmmEOL7MqaQqxulg">no</ix:nonFraction> development milestone payments for subsequent indications. In addition, on a product-by-product basis, the Company is obligated to make up to $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_HuyYaPjrf0-kSgqt367TIw" decimals="-5" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementSalesMilestonePaymentsPayable" scale="6" id="Narr__0dROtyb0UK76faZzwFjhg">55.0</ix:nonFraction>&#160;million in sales milestone payments on each licensed product based on annual sales of the licensed product in excess of defined thresholds. </p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_BMTiodvaZkyr0EfkBcYzPA_cont1" continuedAt="Tb_BMTiodvaZkyr0EfkBcYzPA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Upon successful commercialization of a product using the licensed technology, the Company is obligated to pay to Penn, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits on annual worldwide net sales of such licensed product. In addition, the Company is obligated to pay to Penn a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Penn Agreement. The agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i)&#160;the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such licensed product in such country, and (ii)&#160;the expiration of the royalty period. In addition, the Company will pay a tiered transaction fee of <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_0J6NHzFpyUuN4ppDeH9zaQ" decimals="2" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementTieredTransactionFeePayablePercent" scale="-2" id="Narr_VPouL4DUiUu3MVVVIgzBiA">1</ix:nonFraction>-<ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_Qg9ksmS5wkuN_RKSudErVA" decimals="2" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementTieredTransactionFeePayablePercent" scale="-2" id="Narr_XK4Ay03tsUGTfdqGCGVTWA">2</ix:nonFraction>% of the net proceeds upon certain change of control events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">During the year ended December 31, 2022, the Company made payments under the Penn Agreement of </span><span style="letter-spacing:0.25pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_doDUoWoF-U6E9lX1OVWkNg" decimals="-5" format="ixt:numdotdecimal" name="pasg:AdditionalTechnologyLicenseFeePaid" scale="6" id="Narr_Z-l113Bn0kWYHl9sEkBw-g">3.0</ix:nonFraction></span><span style="letter-spacing:0.25pt;"> million related to the achievement of development milestones</span> <span style="letter-spacing:0.25pt;">for dosing our first patients in PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease, </span>which were recognized as in-process research and development expense<span style="letter-spacing:0.25pt;">. During the year ended December 31, 2021, the Company made payments under the Penn Agreement of </span>$<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_KS_iGfGyu0moP1TAVBgiKQ" decimals="-5" format="ixt:numdotdecimal" name="pasg:AdditionalTechnologyLicenseFeePaid" scale="6" id="Narr_IwkTdeYZukqir4twS1ggaw">1.5</ix:nonFraction> million related to the achievement of a development milestone, $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_KS_iGfGyu0moP1TAVBgiKQ" decimals="-5" format="ixt:numdotdecimal" name="pasg:CollaborationAgreementPaymentMadeOnOptionExercise" scale="6" id="Narr_o1k0q1nbD0y37dNt2EK2eg">1.5</ix:nonFraction> million related to option exercises under the Penn Agreement, and a $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_KS_iGfGyu0moP1TAVBgiKQ" decimals="-5" format="ixt:numdotdecimal" name="pasg:PaymentsForTechnologyLicenseFee" scale="6" id="Narr_BDBeSKjE8k-GxWBPd6_nmQ">5.0</ix:nonFraction> million payment related to the August 2021 amendment, which were recognized as in-process research and development expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Catalent Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2019, the Company entered into a collaboration agreement, or the Collaboration Agreement, with Catalent. As part of the Collaboration Agreement, the Company will pay an annual fee for <ix:nonNumeric contextRef="Duration_6_1_2019_To_6_30_2019_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_2O0jJDglI0ukihnR8RMuWw" format="ixt-sec:durwordsen" name="pasg:CollaborationAgreementAnnualFeePayableTerm" id="Narr_YouqQGfHsE2JbQsPSfseFg">five&#160;years</ix:nonNumeric> ending in 2025 for the use of the Clean Room&#160;Suite.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2020, the Company entered into a development services and clinical supply agreement, or the Manufacturing and Supply Agreement, with Catalent to secure clinical scale manufacturing capacity for batches of active pharmaceutical ingredients for the Company&#8217;s gene therapy product candidates. The Manufacturing and Supply Agreement confirms the terms contemplated by the Collaboration Agreement. The Collaboration Agreement continues to be in effect pursuant to its terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Manufacturing and Supply Agreement, Catalent has agreed to manufacture batches of drug product for the Company&#8217;s gene therapy product candidates at the Clean Room&#160;Suite&#160;at a Catalent facility provided for in the Collaboration Agreement. The Manufacturing and Supply Agreement provides for a term of <ix:nonNumeric contextRef="Duration_4_1_2020_To_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_4KZiWVNG9E22l6ySZmuTUg" format="ixt-sec:durwordsen" name="pasg:TermOfManufacturingAndSupplyAgreement" id="Narr_iHen0SSp1ECX5JYTYlQHAw">five&#160;years</ix:nonNumeric> which period may be extended once, at the Company&#8217;s option, for an additional <ix:nonNumeric contextRef="Duration_4_1_2020_To_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_4KZiWVNG9E22l6ySZmuTUg" format="ixt-sec:durwordsen" name="pasg:ManufacturingAndSupplyAgreementAdditionalExtensionTerm" id="Narr_XlIfJfQaFUmj9MSlWrJHyw">five-year</ix:nonNumeric> period. The Manufacturing and Supply Agreement also includes minimum annual purchase commitments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has the right to terminate the Manufacturing and Supply Agreement for convenience or other reasons specified in the Manufacturing and Supply Agreement upon prior written notice. If the Company terminates the Manufacturing and Supply Agreement, it will be obligated to pay an early termination fee to Catalent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under both the Collaboration Agreement and the Manufacturing and Supply Agreement, the Company has an annual minimum commitment of $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_z_YtRBUDn0S9xCBNBKE8ew" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted" scale="6" id="Narr__BhDroaTo0yLV8-vKo6dCA">10.6</ix:nonFraction> million per&#160;year owed to Catalent for <ix:nonNumeric contextRef="Duration_4_1_2020_To_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_4KZiWVNG9E22l6ySZmuTUg" format="ixt-sec:durwordsen" name="pasg:CollaborationAgreementPeriodForWhichAnnualFeeIsPayable" id="Narr_XMOreELbC0SftSQs7TFprg">five&#160;years</ix:nonNumeric> from the validation of the Clean Room, subject to certain inflationary adjustments. For the years ended December 31, 2022 and 2021, the Company paid amounts in excess of the minimum commitment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employment Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into employment agreements with key personnel providing for compensation and, in certain circumstances, severance and acceleration of vesting in stock-based compensation awards, as described in the respective employment agreements.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d21916af_f5ea_480c_b81a_71734a0cd173"></a><ix:continuation id="Tb_BMTiodvaZkyr0EfkBcYzPA_cont2"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_uclua8HSn0uyCVmrDUUf-g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2021, the Company closed a follow-on public offering in which the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_VKjaYfeOdEmdzPqOICqhlQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_TCly6uDhs0qcgembMJJLFw">8,050,000</ix:nonFraction> shares of its common stock, which included shares sold pursuant to an option granted to the underwriters to purchase additional shares, at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA" contextRef="As_Of_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_XMou09J0cEirXcLwXtLPDg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_rgQgFgfM9km5LQfsw6RlNg">22.00</ix:nonFraction> per share for net proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_VKjaYfeOdEmdzPqOICqhlQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="Narr_utguEKI6_ky5dRTWVkSjNQ">165.8</ix:nonFraction> million&#160;after deducting underwriting discounts, commissions and other offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On March 5, 2021, the Company entered into a Sales Agreement, or the Sales Agreement, with Cowen and Company, LLC, or Cowen, pursuant to which the Company may, but are not obligated to, offer and sell, from time to time, shares of the Company&#8217;s common stock with an aggregate offering price up to $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_3_5_2021_To_3_5_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_SalesAgreementWithCowenAndCompanyLlcMember_LbBLENbq1kqwVJ5FMdSo8g" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="Narr_1zHh8dG4OU2P25UHPxducA">125.0</ix:nonFraction> million through Cowen, as sales agent. <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_3_5_2021_To_3_5_2021_us-gaap_TypeOfArrangementAxis_pasg_SalesAgreementWithCowenAndCompanyLlcMember_c83rb3pHbUyDv5vHPbSVOA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_CzdGKh_02kSOcoRsMCHEoQ">No</ix:nonFraction> sales of common stock have been made pursuant to this Sales Agreement to date.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_Px5Gp_v24kK0TdUmUMMyMg" continuedAt="Tb_Px5Gp_v24kK0TdUmUMMyMg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Share-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has <ix:nonFraction unitRef="Unit_Standard_plan_r3kCEt0dLUCKcJ9iz91x7Q" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="INF" format="ixt-sec:numwordsen" name="pasg:NumberOfEquityIncentivePlans" scale="0" id="Narr_SsahnBf9DEayudufeUx5tw">three</ix:nonFraction> equity incentive plans: the 2018 Equity Incentive Plan, as amended, or the 2018 Plan, the 2020 Equity Incentive Plan, or the Incentive Plan, and the 2021 Equity Inducement Plan, or the Inducement Plan. New awards can only be granted under the Incentive Plan and the Inducement Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The total number of shares authorized under the Incentive Plan as of December&#160;31,&#160;2022 was <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_Ba8ei5M0iU212FOvifvfgw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_SeSGWSOaK0mOijwDlB0fyQ">10,370,926</ix:nonFraction>. Additionally, any awards previously issued under our 2018 Plan which were forfeited become available for issuance under the Incentive Plan. As of December&#160;31,&#160;2022, <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_Ba8ei5M0iU212FOvifvfgw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_HXpuufEUp0K4BsOEiKQdHQ">3,880,210</ix:nonFraction> shares were available for future grants under our Incentive Plan. The number of shares of the Company&#8217;s common stock that may be issued pursuant to rights granted under the Incentive Plan shall automatically increase on January&#160;1st of each&#160;year, commencing on January&#160;1, 2021 and continue for <span style="-sec-ix-hidden:Hidden_pyhlfNmlOEC4x3JdtR4JSQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten&#160;years</span></span>, in an amount equal to <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_mGa3yEM8z06MhUJxjwJeqA" decimals="2" format="ixt-sec:numwordsen" name="pasg:ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" scale="-2" id="Narr_craZfrqLnEOeYtgT9nrvjA">five</ix:nonFraction>&#160;percent of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31st of the preceding calendar&#160;year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such&#160;year. As a result, the number of shares reserved for issuance under the Incentive Plan increased by <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_e7qXKu9B8kaes7yJbBslkQ" decimals="INF" format="ixt:numdotdecimal" name="pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_hq9NrCVz-E2Y_iKh3Rnsbg">2,730,735</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_V-j15wJiN0KMnb4hw5k1nA" decimals="INF" format="ixt:numdotdecimal" name="pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_UwNMdgXcWU2YG5NHvyANZA">2,712,249</ix:nonFraction> shares in January 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Incentive Plan provides for the granting of common stock, incentive stock options, nonqualified stock options, restricted stock awards, and/or stock appreciation rights to employees, directors, and other persons, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options awarded to date under the Incentive Plan vest based on a requisite service period, generally over <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_mGa3yEM8z06MhUJxjwJeqA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_lz8XU_HMwEqdxVIXdj4Wwg">four-year</ix:nonNumeric> periods, and have a term of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_mGa3yEM8z06MhUJxjwJeqA" format="ixt-sec:durwordsen" name="pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" id="Narr_pfl24w71v0S_sltoKc2Qog">ten years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Inducement Plan was approved by the Company&#8217;s board of directors in July 2021. The total number of shares authorized under the Inducement Plan as of December&#160;31,&#160;2022 was <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityInducementPlan2021Member_R6lRMEzvCkuXk7SlC-tL4A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_ZaqasPb7AEaZrRX_UwFmsg">2,000,000</ix:nonFraction>, as a result of an increase to the shares authorized for issuance in February 2022. Of this amount, <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityInducementPlan2021Member_R6lRMEzvCkuXk7SlC-tL4A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_KBV_7DrwHUKUZtsGomPkCQ">384,167</ix:nonFraction> shares were available for future grants as of December&#160;31,&#160;2022. The Inducement Plan provides for the granting of nonqualified stock options and restricted stock awards to employees hired by the Company, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options awarded to date under the Inducement Plan vest based on requisite service period and have a term of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityInducementPlan2021Member_NN2gJkl_wkeCgwEIqLXLgQ" format="ixt-sec:durwordsen" name="pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" id="Narr_J3ouHxHqFk2Mvu3OPG9NOg">ten years</ix:nonNumeric>. The Company&#8217;s restricted stock units awarded to date under the Inducement Plan vest based on requisite service period and have a term based on each award agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_SYy0bnd98kSK74xelNkUxQ_1_2"></a><a id="Tc_UgpsT2smD0erFzekHzdLBQ_2_0"></a><a id="Tc_GuxC-GvRrkmwAqnqTd_9lQ_2_2"></a><a id="Tc_V5DqUpo5FUmOiTIgFR1N2A_2_5"></a><a id="Tc_uiYgNK_nxECRmTCrQ1JmFg_3_0"></a><a id="Tc_SaFLMCXyaECAXbHuQt30kA_3_2"></a><a id="Tc_YGjlT86er02D39DCibUEUw_3_5"></a><a id="Tc_ZwfmEv8AtkmIPPK48d4cqg_4_0"></a><a id="Tc_KnWiH_0Qm0e2STbQkKdapA_5_2"></a><a id="Tc_1H0RzpAzlEyqtteH3j6E0Q_5_5"></a><a id="Tc_px4J9D8Vs0K4_4fHVMdTPg_1_7"></a><a id="Tc__HDis7ydu0yOWktjYA2Pvw_2_4"></a><a id="Tc_VQy7ZNbIlEeizpklLxZ3EA_2_7"></a><a id="Tc_L4A_tKODcUWHFa70tMADOw_3_4"></a><a id="Tc_bZkoVTLRLEGlvdieQIx1tg_3_7"></a><a id="Tc_DWw2lk3Hnku4rjD_38gAKA_4_2"></a><a id="Tc_oT5kZFLqAk-Q_XFzWairBA_4_4"></a><a id="Tc_grHLY2DAeUGqTEvEuKemlw_4_7"></a><a id="Tc_XzRkdGKV1EaCNYu5kAJctg_5_2"></a><a id="Tc_ElJ_y3aBzk-RKrQrN_2G1A_5_4"></a><a id="Tc_hn4P-qL9WkiEx9wlZUCRxg_5_7"></a><a id="Tc_ccEagSJKTEmRRBBiBgEifQ_6_0"></a><a id="Tc_tfFD6-4DRU6qhys8Q_S_cw_6_4"></a><a id="Tc_t7k8T4Gg7ku28WbUGiyeRQ_7_0"></a><a id="Tc_ML7zr828F0alXIPgVpqcoQ_8_0"></a><a id="Tc_1dUhhdeC7E2hSijlEwLTMQ_9_0"></a><a id="Tc_dpEXm5tvq0yOvzop68PzqQ_10_0"></a><a id="Tc_QhdLESgebEiku1OeSHmbOw_10_4"></a><a id="Tc__ueye-unXkSBlH_IjF5syw_11_0"></a><a id="Tc_veaK4AB77EeM-dBAJOqf4w_11_4"></a><a id="Tc_lhKXQG5bSEaQpqVpy7RWHQ_12_0"></a><a id="Tc_RRmgHVy2pkeXrBwBi1tcbQ_12_4"></a><ix:continuation id="Tb_Px5Gp_v24kK0TdUmUMMyMg_cont1" continuedAt="Tb_Px5Gp_v24kK0TdUmUMMyMg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company recorded share-based compensation expense in the following expense categories in its accompanying statements of operations for the period presented:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_M6yI82Xr-0ax2ISSqjQVJA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:52.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_fzK4cBH8fkuhwpQHwW1AZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_4XuPDVcmA0ijodk1SGBz9A_3_3">8,278</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_lvXskTRyzEmHGgFZuscuXw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_xwwqN8VhdkSZeWaPl8iZvw_3_6">15,432</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_rKbIo3RACkur9OAM8iqIbA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_V4oyNyFYu0mTVth77HOgrA_4_3">10,676</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember__jemGaqshkeAAlBd2h-gkA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Snl2YtOvS0CuCnnvw9TcFw_4_6">17,259</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_RUHjXr5FCEKKellQpWiOvA_5_3">18,954</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_-lvP35Xnj0uKlgr3rYU_iQ_5_6">32,691</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December&#160;31,&#160;2022, the Company modified certain awards and recognized $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-5" format="ixt:numdotdecimal" name="pasg:ShareBasedCompensationArrangementExpensesDueToModifications" scale="6" id="Narr_AtuPxgju70aRArOx6ukmUA">0.4</ix:nonFraction> million related to the modifications, all of which was recognized in general &amp; administrative expense. The terms of such modifications included, on an awards-by-award basis, acceleration of the vesting period and extensions of the post-employment period to exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December&#160;31,&#160;2021, the Company modified certain awards and recognized $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-5" format="ixt:numdotdecimal" name="pasg:ShareBasedCompensationArrangementExpensesDueToModifications" scale="6" id="Narr_Kq4mnNpEA0CQF4pvKjKjgw">7.4</ix:nonFraction> million related to the modifications, $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_lvXskTRyzEmHGgFZuscuXw" decimals="-5" format="ixt:numdotdecimal" name="pasg:ShareBasedCompensationArrangementExpensesDueToModifications" scale="6" id="Narr_BqS4D2ewnk2xl0LgTIWJaA">6.1</ix:nonFraction> million of which was recognized in research and development expense and $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember__jemGaqshkeAAlBd2h-gkA" decimals="-5" format="ixt:numdotdecimal" name="pasg:ShareBasedCompensationArrangementExpensesDueToModifications" scale="6" id="Narr_nLPfaTlQ3U2aqx_HYEpEug">1.3</ix:nonFraction> million was recognized in general and administrative expense. The terms of such modifications included, on an awards-by-award basis, acceleration of the vesting period and extensions of the post-employment period to exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes stock option activity for the&#160;year ended December&#160;31,&#160;2022:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_ztPmsFEAr0qGsskacFcLEA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise&#160;price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per&#160;share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">term&#160;(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at January&#160;1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_XAfIjZze40CosK4oKZpCHA_6_2">9,416,998</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_sHKP1DNLaE6nQ9LJQ7uOrw_6_5">13.72</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_unacRbmoZ0-fxZAb95R05g_6_7"> 8.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="Tc_mZjeIJbF9USwrLyQX48aLw_7_2">6,609,441</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_XxYR2EgW3UWX9iCWOR20mQ_7_5">3.09</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_0pwo0nae8U2eFvf2DCYp5w_8_2">126,056</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_juiyUM_WgUyFWREDL5wMGw_8_5">1.02</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_TACj1n5l8EiS2kfvPfA3AA_9_2">4,488,993</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc__qBo21SNVEyBKyTVhNZkIw_9_5">10.41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_85DQiiJgHU6OFA8rIAAdFg_10_2">11,411,390</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_OjXyJYdDHU22M_jw6gK0Gg_10_5">9.01</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_oEYMLD_DTU6SjeBPbp7O9Q_10_7"> 7.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and Exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_Ou-z9EXWVU2dOeTABLe-tQ_11_2">6,074,955</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_BbhSdzFd_UKnlkVnnMlnjg_11_5">11.55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_OvHaHqEG6kaazHfUE641bQ_11_7"> 5.3</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested or expected to vest at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_KeS39jA2fEaePk5b1Kvy-A_12_2">11,411,390</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_ROMDk_bh5ker5I2gImSBAw_12_5">9.01</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_kT6Rq2wXLkSb_zhlxlH-rg_12_7"> 7.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant date fair value of options granted was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_1mvaf2FcSEyxyOshakaRAA">2.33</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_Ed2a4gGk20ixiBv5mb8gcg">12.75</ix:nonFraction> for the&#160;years ended December&#160;31, 2022 and 2021, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of options exercised was $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_I74GuAer-UewKnJ_WI4ghg">0.2</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_UVFYyJLlpUeVAtlNlhye0w">1.3</ix:nonFraction> million and during the year ended December 31, 2022 and 2021, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of options outstanding as of December 31, 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="Narr_0JD0lW9RZEOc6zQfSCCziw">0.1</ix:nonFraction> million and the aggregate intrinsic value of options exercisable as of December 31, 2022 was de minimus. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, the total unrecognized compensation expense related to unvested stock option awards was $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="Narr_b5ai8tpYrkOV1cvyrda67A">24.1</ix:nonFraction>&#160;million, which the Company expects to recognize over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_ba0siOFpckStYsfvTw9Lig">2.4</ix:nonNumeric>&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The 2018 Plan and 2020 Plan provide certain holders of stock options an election to early exercise prior to vesting. The Company has the right to repurchase early exercised options without transferring any appreciation in the value of the underlying shares to the employee if the employee terminates employment before the end of the original vesting period. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_PdTXKCTTX0mpBq_NZw2zYg_1_2"></a><a id="Tc_TD2y_3CEmkirvtZ5HErWrQ_2_2"></a><a id="Tc_YsFU76wNC0mU1aqdgZw08A_2_5"></a><a id="Tc_TbgpsDoFnUS-Z-Jnzt0Xzw_3_0"></a><a id="Tc_QHV2tEdK00q_Q5L6_ZCThg_3_3"></a><a id="Tc_ln3a-vbmpkeag8hO6WLJmw_3_6"></a><a id="Tc_4FdsU7t1YUGO9XT57zd-cQ_4_0"></a><a id="Tc_3PuP8VGtKEKnsVc2eqRP2A_4_3"></a><a id="Tc_SVmKiRe9HkCslTp0CT8yiA_4_6"></a><a id="Tc_T8OeXbGzgkGJgXSeCL9S7Q_5_0"></a><a id="Tc_UzDt6a5D4EOAo1ORp5CsQg_5_3"></a><a id="Tc_ESO0qGnIakKPTcgjChqedQ_5_6"></a><a id="Tc_2BNCN53s8EOcSmmwkOApgA_6_0"></a><a id="Tc_UyuZ9YZQOEWYsqX84HuIGg_1_6"></a><a id="Tc_w5bpFJ4ZxU25otyuU6K39A_2_3"></a><a id="Tc_o0nvNcwPWUGoYZvfdsT19A_2_6"></a><a id="Tc_UtdO5TeqyEO8ax6xW-f30A_3_0"></a><a id="Tc_M5_DqxYxv0y_qPQMxoXFmg_3_5"></a><a id="Tc_Ib5xrLViK0qixIaTEoFzpg_4_0"></a><a id="Tc_SVuBg9S75U6OYW9XsYPY1A_4_5"></a><a id="Tc_4LbaQ8UGnUGUzzWjMF1dYQ_5_0"></a><a id="Tc_cEr6skPSY0af7bgcoqnUOw_6_0"></a><a id="Tc_oyeelYRiRECnoSl6Iotv1g_6_5"></a><a id="Tc_B8UKd5VvIE-qm3wVkewG_w_7_0"></a><a id="Tc_SdHk8F0qv0qAj9V9IPQeQw_7_5"></a><ix:continuation id="Tb_Px5Gp_v24kK0TdUmUMMyMg_cont2" continuedAt="Tb_Px5Gp_v24kK0TdUmUMMyMg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The repurchase price is the lesser of the original exercise price or the then fair value of the Company&#8217;s common stock. As of December&#160;31,&#160;2022, <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="INF" format="ixt:numdotdecimal" name="pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise" scale="0" id="Narr_io2Mh3xjpkm-hFKRErrVBQ">113,932</ix:nonFraction> options to purchase common stock are unvested, but exercisable, under early exercise provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The fair value of each option was estimated on the date of grant using the weighted average assumptions in the table below:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_GvkbGCOHYEeM2Eyc7fJaug" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:50.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_7UAxGOP0ikyx80vfObTVIQ_3_2">92.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_E12zrwyIq0-4nfglR_J5tw_3_5">99.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk&#8209;free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_MxO_Nwxp10aNIkKOxtcYyQ_4_2">2.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_itmot3my0k22IkL6NZmktA_4_5">0.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_A8QyVPtMDECHMPMs9XXPxg_5_2"> 5.9</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_CXZ-GIYg9km7njj0ceO6KA_5_5"> 6.0</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_COt_l1E9zUaqXJHzPlB7rQ_6_2">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="3" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_nIc79rLcQkOJbny6ZoDaXA_6_5">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Stock Units </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company issues restricted stock units, or RSUs, to employees that vest over periods as determined by the board of directors. Any unvested shares are forfeited upon termination of services. The fair value price of the RSUs is equal to the fair market value of the Company&#8217;s common stock on the date of grant. Compensation expense is recognized on a straight-line basis over the vesting period of the RSUs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table summarizes activity related to RSU awards during the year ended December&#160;31,&#160;2022:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="Tb_mXTzMamlnEujgvfSNJp2IQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:23.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted average </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">grant date fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested balance at January 1, 2022</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_IVEx45mF9UGGotpVBJv3wA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_83ucZiz-10qeShpifXafiw_3_3">290,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA" contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_IVEx45mF9UGGotpVBJv3wA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_lS71s2WlhEqdY8nuDr93hQ_3_6">14.78</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2SJMJY-9JE2TYYv1hxxQlA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Tc_zxtPg80W0U6fgSJddPCY1w_4_3">1,171,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2SJMJY-9JE2TYYv1hxxQlA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_EG3K-mCC3UeLghdvvxIXMQ_4_6">1.97</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2SJMJY-9JE2TYYv1hxxQlA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Tc_xFAv4KpbpEqcupbFJn7MdQ_5_3">39,167</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2SJMJY-9JE2TYYv1hxxQlA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_vqH3hqNzaUSYcohbLgeiiw_5_6">15.06</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2SJMJY-9JE2TYYv1hxxQlA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="Tc_15JDK8BssU6D4pt5uIdB7Q_6_3">193,667</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2SJMJY-9JE2TYYv1hxxQlA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="Tc_xXhw9-ChKkuWvXlfJA7-lw_6_6">11.87</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_4GJmz4SaeUW8G0iqOGx50A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="Tc_5tXoDGSiakK8gFlJpk8-IQ_7_3">1,229,166</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_4GJmz4SaeUW8G0iqOGx50A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_QlRufJuQW0-FJn9vNa3Aag_7_6">2.98</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December&#160;31,&#160;2022, the total unrecognized expense related to all RSUs was $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_4GJmz4SaeUW8G0iqOGx50A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="Narr_L-H5cnxvqEKr2A1dqyqPBw">2.8</ix:nonFraction> million, which the Company expects to recognize over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2SJMJY-9JE2TYYv1hxxQlA" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="Narr_yYI8L9oLCkSQHTbDxy6wNg">1.8</ix:nonNumeric> years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employee Stock Purchase Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s 2020 Employee Stock Purchase Plan, or the ESPP, became effective on February 28, 2020. The ESPP authorizes the issuance of up to <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_2wbIkeBld021QObVHUyCCQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_YzWP21vpt0e4ohn_D8Lb_g">1,435,619</ix:nonFraction> shares of the Company&#8217;s common stock. Of this amount, <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_ffSkQEILP0GGYx3Q6UsjsQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_H9FySbUpjEGSHH-OzpuP0A">1,119,914</ix:nonFraction> were available for future grants as of December&#160;31,&#160;2022. The number of shares of the Company&#8217;s common stock that may be issued pursuant to rights granted under the ESPP shall automatically increase on January 1st of each year and continuing for <ix:nonNumeric contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7S0-ZkqLP02l2ZtnRMvqNw" format="ixt-sec:durwordsen" name="pasg:EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" id="Narr_6Buyu_AEt0aybnqJNC_biw">ten years</ix:nonNumeric>, in an amount equal to <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7S0-ZkqLP02l2ZtnRMvqNw" decimals="2" format="ixt-sec:numwordsen" name="pasg:EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" scale="-2" id="Narr_tfNStqdlLUW1LjMZuWaNGw">one</ix:nonFraction> percent of the total number of shares of the Company&#8217;s common stock outstanding on December 31st of the preceding calendar year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such year. As a result, on January 1, 2023, the number of shares reserved for issuance under the ESPP increased by <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_paHmp6CcHEeXKfzN77VxdQ" decimals="INF" format="ixt:numdotdecimal" name="pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_1YJLBvnWEkarTQWA02DW5A">546,147</ix:nonFraction> shares, resulting in a total of <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="As_Of_1_1_2023_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_X3oAMRpPCkuZ5fd72D8-YA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_-GTHgua29E-Ee7EMKX2DHQ">1,981,766</ix:nonFraction> shares authorized for issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Under the ESPP, eligible employees can purchase the Company&#8217;s common stock through accumulated payroll deductions at such times as are established by the compensation committee. Eligible employees may purchase the Company&#8217;s common stock at <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7S0-ZkqLP02l2ZtnRMvqNw" decimals="2" format="ixt:numdotdecimal" name="pasg:EmployeeStockPurchasePlanStockPurchasePricePercentage" scale="-2" id="Narr_RnciF8S6UkKiU3a1hD9yAA">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock on the first day of the offering period or on the last day of the offering period. The offering periods under the ESPP have a duration of </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Px5Gp_v24kK0TdUmUMMyMg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">six months, with periods ending in May and November of each calendar year. Eligible employees may contribute up to <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7S0-ZkqLP02l2ZtnRMvqNw" decimals="2" format="ixt:numdotdecimal" name="pasg:EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" scale="-2" id="Narr_gxnzaM8GrkeJx0Gs0yyPaQ">15</ix:nonFraction>% of their eligible compensation. Under the ESPP, a participant may not accrue rights to purchase more than $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_2wbIkeBld021QObVHUyCCQ" decimals="0" format="ixt:numdotdecimal" name="pasg:EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" scale="0" id="Narr_5SKeR088_ES4s9jKEoSMPA">25,000</ix:nonFraction> worth of the Company&#8217;s common stock for each calendar year in which such right is outstanding or purchase more than <ix:nonFraction unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw" contextRef="Duration_2_28_2020_To_2_28_2020_iDWURz96TU6yNVnGevdtWQ" decimals="INF" format="ixt:numdotdecimal" name="pasg:EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased" scale="0" id="Narr_PhUBHAAdWEOw4-5-h9tWPA">4,000</ix:nonFraction> shares of the Company&#8217;s common stock in any single offering period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In accordance with the guidance in ASC 718-50,<i style="font-style:italic;">&#160;Compensation&#160;&#8211; Stock Compensation</i>, the ability to purchase shares of the Company&#8217;s common stock at <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7S0-ZkqLP02l2ZtnRMvqNw" decimals="INF" format="ixt:numdotdecimal" name="pasg:EmployeeStockPurchasePlanStockPurchasePricePercentage" scale="-2" id="Narr_nzgqZsdHfk2v0h0MoZlhNw">85</ix:nonFraction>% of the lower of the price on the first day of the offering period or the last day of the offering period (i.e. the purchase date) represents an option and<b style="font-weight:bold;">, </b>therefore, the ESPP is a compensatory plan under this guidance. Accordingly, share-based compensation expense is determined based on the option&#8217;s grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the withholding period. The Company recognized share-based compensation expense of $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_gplgcbUrjEqXbb7bUxMbbA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_rHDZH-Nfgku34E_dYjYcEg">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_aTuBNIMD5UOPhj-XOY8Bqg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_qbc-Yco5yEaUA00MnaCUMA">0.4</ix:nonFraction> million during the years ended December&#160;31, 2022 and 2021, respectively, related to the ESPP.</p></ix:continuation><a id="Tc_ar71FCfBTkugzupjtFSYlw_1_2"></a><a id="Tc_3QD4a3U7wkCKr8Nu8eMOgg_2_0"></a><a id="Tc_zs7L5sKoGUOmo_rhLyBZzQ_2_2"></a><a id="Tc_WHJeIjV1QkWDAMyFmTMCVA_2_5"></a><a id="Tc_zqA-0ijnmkKxtfjlVzprvA_3_0"></a><a id="Tc_wtX_Mpp7g0uq6Io8qwwLtA_4_0"></a><a id="Tc_lmyj3osFkkaDtd3Bg-IURg_4_2"></a><a id="Tc_vyAaHonCBEyhuveBpZ8RQw_4_5"></a><a id="Tc_3dvJ9VHcBEWVzyCT9BaA8A_5_0"></a><a id="Tc_Wq2hKaWAVESpdSXnFkmzZw_6_0"></a><a id="Tc_BY3cpelGUEqiJPFUkvIDDQ_7_0"></a><a id="Tc_s7gbRBWRhE6AhXEsS0NlKg_8_0"></a><a id="Tc_8fb0D-3lP0GdQEn81bCwHQ_9_0"></a><a id="Tc_N7g7wx2MmkWDpy7YfEwF9A_10_0"></a><a id="Tc_Aszb6h-hSE2babFkuY6_3g_10_6"></a><a id="Tc_8tGw0I9KTUGLFV96needqw_11_0"></a><a id="Tc_keO0it18BEyfL20nd8rWjA_12_0"></a><a id="Tc_qc0g6hJWZkaF7seSPRHceA_13_0"></a><a id="Tc_Bxbp2KnJzEaYDvTaK8Fc4A_14_0"></a><a id="Tc_XV-lISZmh0mdj8HcHwzXHQ_15_0"></a><a id="Tc__c8UH7AF80GRNdMj1Z51sw_16_0"></a><a id="Tc_KnCmzdXgVUuMi2xCEpQ45A_17_0"></a><a id="Tc_xPpv7s8ZSkKaXAt3QuWM4g_18_0"></a><a id="Tc_ryI6T6bMZ0qGOrhGbAdvUg_18_2"></a><a id="Tc_kLvUUjFIV0K9L9aHF1Yf_Q_18_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_Rw3yMP-Urk6dPHv9iwQ0gw" continuedAt="Tb_Rw3yMP-Urk6dPHv9iwQ0gw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_RMCqefDzWkq7n9G5t_wk5A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">(in thousands) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_pYQGT4O8hkeSO1yxZramig_4_3">64,547</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_Zww8h2R0Q0CGDXg4p5_Rrw_4_6">42,351</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_nm7HjtYpsk-GtgHQ-G9tcA_5_3">32,068</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" id="Tc_gvHTsxIiI0y2uZKaVQtc-w_5_6">22,244</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Collaboration and license agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="pasg:DeferredTaxAssetsCollaborationAndLicenseAgreement" scale="3" id="Tc_5WUjxOfFhESdD8P8OlwWgw_6_3">4,504</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="pasg:DeferredTaxAssetsCollaborationAndLicenseAgreement" scale="3" id="Tc_BsSnKSrVeU2GkluucqI2-w_6_6">3,976</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="pasg:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="3" id="Tc_nj7YsQgDs0eF1X57kh09Sg_7_3">65,012</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="pasg:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="3" id="Tc_HjrwA8l5Gk2dJh6BFtaujQ_7_6">51,806</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_l9C0364JBEelNcfYIt89YQ_8_3">11,312</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_fAhGoWBehk6v320r7DrWOA_8_6">11,245</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="pasg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" scale="3" id="Tc_EzU7MlXs_EypwdLyu-46AQ_9_3">1,922</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="pasg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" scale="3" id="Tc_yaEPa4ALqk2j4ke0MA12xw_9_6">4,654</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="pasg:DeferredTaxAssetsOperatingLeaseLiabilities" scale="3" id="Tc_bqp1b91oXk6YDqCrsBKm5A_10_3">8,900</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">      Total gross deferred tax assets before valuation allowance</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_4c1D2_cV7kKL_OkUVgrIwQ_11_3">188,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_Dx931cizYEKES94IDej1Tw_11_6">136,276</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc__8RXCIenME69fVYOov2UKw_12_3">179,843</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_f3sw_8UXmEqVUWUMvo319w_12_6">135,053</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">      Net deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_vxfrxQ69lkWW3y_Satqg3Q_13_3">8,422</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_FtogY2c4bEebAmJN5m6XZw_13_6">1,223</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;">Right of use assets - operating leases </span><i style="font-style:italic;">(deferred rent for December 31, 2021)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="pasg:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" scale="3" id="Tc_iItmoUO870mKXNub51_cDg_15_3">7,609</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="pasg:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" scale="3" id="Tc_fEJC1K_4v0u6cKmIz3TkHA_15_6">876</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="Tc_Bk1qbe5cQUm5NEiCO3ptTQ_16_3">813</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="Tc_DmkZ3_t2w0WAarD4MDlIJw_16_6">347</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">      Total deferred tax liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="Tc_t0eeJD7onka3LZmlUqwqKA_17_3">8,422</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="Tc_NL0lBaHX_kGp3up-5IEDcA_17_6">1,223</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">      Net deferred taxes</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="Tc_h78TLZKA90y-EILg_Be_sw_18_3">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="Tc_iw81rVK8bkmeGl7lb6Q9bA_18_6">-</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more-likely-than-not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company&#8217;s net deferred tax assets as of December&#160;31, 2022 and 2021. The valuation allowance increased by $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_r2YwEMLht0O6x7rtRS1CGg">44.8</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_kQfu37Af6Eq9uigTLeWdCA">72.1</ix:nonFraction> million during the&#160;years ended December&#160;31, 2022 and 2021, respectively.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_8cTQ4ZtDlU-BwUvozAUYHQ_1_2"></a><a id="Tc_OaTQzXQKBkC0pFdNnybiuQ_2_2"></a><a id="Tc_UIr4mgAT9E2lUeiVLd039A_3_2"></a><a id="Tc_efC-164oTEa7zz99st6WVw_3_4"></a><a id="Tc_fsTmyxuDLEGOHeVuiseCgA_4_0"></a><a id="Tc_I9UeKpuHukuxBN_RxRBgWA_4_3"></a><a id="Tc_c8grbNa-rU62Z3MNZ4IOfg_4_5"></a><a id="Tc_kzjEemszPk25MIUZg8LyKA_5_0"></a><a id="Tc_pSTx3cKj10G6IVvx01YImw_6_0"></a><a id="Tc_G1-1elKzs0S26Wdj4Sr3Rg_7_0"></a><a id="Tc_nyT4dhP1rEC6Xmq1QvGbew_8_0"></a><a id="Tc_930JIscV5kezQNPp3mgF6A_9_3"></a><a id="Tc_l1ct9Q8hkEabFEfwHNMZPQ_9_5"></a><a id="Tc_zRg6tOt-dkORYSTDq4GOKw_1_2"></a><a id="Tc_RJOob5VzGk2OysSssx0hAg_2_0"></a><a id="Tc_D8GML_n_Ekqn4ED3s44YRw_2_2"></a><a id="Tc_Y9aiNgnAJkm87Sc0QRKVAA_2_5"></a><a id="Tc_JWkmrKlWL02raSH0fy4UAA_3_0"></a><a id="Tc_4U6BGogkdky8dTwSl_kD0A_3_2"></a><a id="Tc_vKM4cYOElUukLVtRtjNkdQ_3_5"></a><a id="Tc_WpTWyWze6kq5O_ycBwd4UA_4_0"></a><a id="Tc_4V4BSAOIoEqyHP7aLZdl8g_5_0"></a><a id="Tc_SSReX7WSh0KS7Nayu-Qq9g_6_0"></a><ix:continuation id="Tb_Rw3yMP-Urk6dPHv9iwQ0gw_cont1" continuedAt="Tb_Rw3yMP-Urk6dPHv9iwQ0gw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of the federal income tax rate to the Company&#8217;s effective tax rate is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_L3cMDrlxtUSWCHMxNkwshg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_i4bWzcnCmU-8x2k3KQ5KWQ_4_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_2SSiEw84ZU-abQ0qDJuzwQ_4_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_bcDaA_DjFkO6wD3un5VXGg_5_2">7.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_LabfdxvF0k-f4jWRw0jB3w_5_4">11.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="3" format="ixt:numdotdecimal" name="pasg:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" scale="-2" id="Tc_ylU-0FJv3k6oQREfWHT0mw_6_2">2.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="3" format="ixt:numdotdecimal" name="pasg:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" scale="-2" id="Tc_ki3_EcvgoEGFN3hjwTbcFg_6_4">1.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development and orphan tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="Tc__mUoIXsC6Em4rWl5aHw94g_7_2">6.9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" scale="-2" id="Tc_dc3T59JWKkmFpgHIEb_r3g_7_4">7.1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Tc_BKALwpjjzEuig4R7Y90D9Q_8_2">32.9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="Tc_Q22mW0MBGkGAXd2LPQnIRw_8_4">38.9</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_TWOE8d7eJEiPGxPuKjC54g_9_2">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA" contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA" decimals="3" format="ixt:zerodash" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Tc_IXBbaU5zPEadhuZ1xJT4cw_9_4">-</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes carryforwards of federal, state and local net operating losses, or NOL, and research and development and orphan drug tax credits:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="Tb_RYfx5ess60KteVD9yGIF-w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">(in thousands) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_68a1wKllOU-ygbrbsjHfXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Tc_m9uSToTGuECxftoX3v_FTw_3_3">199,233</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_mgIQoET8g0GzCQSgrV4mEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Tc_rdHNVxZ0JkC8yPWP6NSh7A_3_6">126,551</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_pasg_StateTaxAuthorityMember_csXMoMs05E-EaQFBpJ-dDw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Tc_-vx4c3rPqE2UmNjJD990SQ_4_3">199,230</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_pasg_StateTaxAuthorityMember_Af3k6h92bkmtwN0ci3mBEg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Tc_-7mwZXcLVE6sbxyH2M0-_A_4_6">126,547</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_pasg_LocalTaxAuthoritiesMember_Ig7yZu-Op0CHDDSoRCT99A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Tc_v5xorGLuMUmebr9u9Yh7ew_5_3">180,859</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_pasg_LocalTaxAuthoritiesMember_NABkP1gdZkiCPP5SKrlohA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="3" id="Tc_WWy71905Qk2M3MZBV4G-vg_5_6">116,301</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_wDFfPO_ZNUKxeG-q7TC3Rg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="Tc_3-_ws7zo2ki0ZPft85Ha7A_6_3">32,068</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2021_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_yIzi3o8bAE2L3dxvXEqkRg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="Tc_HJ55MAq1WUWT9AQnhGzG6Q_6_6">22,244</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For federal income tax purposes, $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_68a1wKllOU-ygbrbsjHfXA" decimals="-5" format="ixt:numdotdecimal" name="pasg:OperatingLossCarryforwardSubjectToExpiration" scale="6" id="Narr_gWlkp9KlU0K9rc9nQevgJQ">0.3</ix:nonFraction> million of NOL carryforwards expire in 2037. The remaining federal NOL carryforwards were generated subsequent to January 1, 2018, and therefore, are able to be carried forward indefinitely. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For state income tax purposes, NOL carryforwards begin expiring in 2037, and expire through 2042. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For local income tax purposes related to the city of Philadelphia, NOL carryforwards begin expiring in 2023, and expire through 2042. NOL carryforwards generated prior to 2023 expire after 3 years, whereas NOL carryforwards generated in 2023 expire after 20 years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company also had federal research and development and orphan drug tax credit carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-5" format="ixt:numdotdecimal" name="pasg:TaxCreditCarryForwardSubjectToExpiration" scale="6" id="Narr_qt-Mz9p3fUaDM1jMeWPlVQ">32.1</ix:nonFraction> million that will begin to expire in 2038, unless previously utilized. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50&#160;percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception. Certain state NOL carryforwards may also be limited, including Pennsylvania, which limits NOL utilization as a&#160;percentage of apportioned taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company will recognize interest and penalties related to uncertain tax positions as a component of interest income, net. As of December 31, 2022, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" scale="6" id="Narr_yoSj5eHEMEG9srXfZjicWA">no</ix:nonFraction> accrued interest or penalties related to uncertain tax positions and <ix:nonFraction unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw" contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="6" id="Narr_f725_u3bOUOHQ1hPnoZQLQ">no</ix:nonFraction> amounts have been recognized in the Company&#8217;s statement of operations. Tax years from 2019 and after remain subject to examination by the taxing jurisdictions. The NOL and tax credit carryforwards remain subject to review until utilized.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Passage Bio, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Notes to Financial Statements (cont.)</b></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Rw3yMP-Urk6dPHv9iwQ0gw_cont2"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw" name="us-gaap:SubsequentEventsTextBlock" id="Tb__96y-SsoJUezcIcnVs8v6Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14.&#160;Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None.</p></ix:nonNumeric><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7486221c_2a45_41ba_af4e_842b1307547d"></a><a id="Item9ChangesinandDisagreementswithAccoun"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9.&#160;&#160;&#160;&#160;&#160;<span style="font-style:italic;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_8acd639c_9f86_41da_9247_97c3d0e3a0b3"></a><a id="Item9AControlsandProcedures_95933"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9A.&#160;&#160;&#160;<span style="font-style:italic;">Controls and Procedures</span><span style="font-style:italic;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Conclusions Regarding the Effectiveness of Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">Under the supervision of and with the participation of our management, including our chief executive officer, who is our principal executive officer, and our chief financial officer, who is our principal financial officer, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as of December 31, 2022, the end of the period covered by this Annual Report. The term &#8220;disclosure controls and procedures,&#8221; as set forth in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the rules and forms promulgated by the SEC. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2022, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:17.5pt;background:#ffffff;margin:12pt 0pt 0pt 0pt;"><b style="font-weight:bold;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, our&#160;chief executive officer and chief financial officer&#160;and effected by our board of directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Our internal control over financial reporting includes those policies and procedures that:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:12pt 0pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:12pt 0pt 0pt 0pt;">&#8226;</p></td><td style="vertical-align:top;width:87.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:12pt 0pt 0pt 0pt;">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect our transactions and dispositions of our assets;</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:12pt 0pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:12pt 0pt 0pt 0pt;">&#8226;</p></td><td style="vertical-align:top;width:87.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:12pt 0pt 0pt 0pt;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:12pt 0pt 0pt 0pt;">&#160;</p></td><td style="vertical-align:top;white-space:nowrap;width:6.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:12pt 0pt 0pt 0pt;">&#8226;</p></td><td style="vertical-align:top;width:87.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:12pt 0pt 0pt 0pt;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:12pt 0pt 0pt 0pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Additionally, in designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">Our management, with the participation of our&#160;chief executive officer and chief financial officer, assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2022. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in its <i style="font-style:italic;">Internal Control &#8211; Integrated Framework (2013)</i>. Based on our assessment, our&#160;management has concluded that, as of December&#160;31, 2022, our internal control over financial reporting is effective based on those criteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:18pt;background:#ffffff;margin:0pt;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. For as long as we remain an &#8220;emerging growth company&#8221; as defined in Section&#160;2(a)&#160;of the Securities Act of 1933, or the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012, we intend to take advantage of the exemption permitting us not to comply with the requirement that our independent registered public accounting firm provide an attestation on the effectiveness of our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:12pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-indent:18pt;margin:0pt;">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule&#160;13a-15(d)&#160;and 15d-15(d)&#160;of the Exchange Act that occurred during the quarter ended December&#160;31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_47a4d301_69fd_45ad_814d_e589a3994aaf"></a><a id="Item9BOtherInformation_661797"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;9B.&#160;&#160;&#160;<span style="font-style:italic;">Other Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_24893056_9587_4475_925a_7655f2e559d3"></a><a id="item9c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Item 9C.     Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"></span>None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a8bdc168_85a7_4546_a7ec_b868c67fe56f"></a><a id="PARTIII_442551"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="Item10DirectorsExecutiveOfficersandCorpo"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item&#160;10.</b></span>&#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c249d278_58e3_4166_9699_59b3c214a22c"></a><a id="Item11ExecutiveCompensation_324480"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;11.&#160;&#160;&#160;&#160;Executive Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c145a944_b6fe_46a2_af9a_ae4949979341"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;12.&#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_914deeb6_7713_4190_8b95_81e15bf338a3"></a><a id="Item13CertainRelationshipsandRelatedTran"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;13.&#160;&#160;&#160;&#160;Certain Relationships and Related Transactions and Director Independence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_00a684e1_4075_4e8c_b7f6_f5e6cf9c6c48"></a><a id="Item14PrincipalAccountantFeesandServices"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;14.&#160;&#160;&#160;&#160;Principal Accountant Fees and Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The information required by this item is incorporated herein by reference to our Proxy Statement with respect to our 2023 Annual Meeting of Stockholders to be filed with the SEC within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b099648f_4560_4827_939b_5295c011175c"></a><a id="PARTIV_315772"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;IV</p><a id="Item15ExhibitsandFinancialStatementSched"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;15.&#160;&#160;&#160;&#160;<span style="font-style:italic;">Exhibits and Financial Statement Schedules</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Financial Statements:</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The financial statements required by Item&#160;15(a)&#160;are filed as part of this Annual Report on Form&#160;10-K under Item&#160;8 &#8220;Financial Statements and Supplementary Data.&#8221;</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18.35pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Financial Statement Schedules</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The financial statement schedules required by Item&#160;15(a)&#160;are omitted because they are not applicable, not required or the required information is included in the financial statements or notes thereto as filed in Item&#160;8 of this Annual Report on Form&#160;10-K.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Exhibits.</i></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:35.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">File&#160;No.</b></p></td><td style="vertical-align:top;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Filing</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:top;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Filed/</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Furnished</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Herewith</b></p></td></tr><tr><td style="vertical-align:top;width:10.16%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.21%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.17%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.02%;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.1</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000155837020006239/pasg-20200331ex3137f59e2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Restated Certificate of Incorporation, dated March 3, 2020.</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May 11, 2020</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">3.2</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000110465922124102/tm2231891d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Amended and Restated Bylaws, dated December 1, 2022.</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 2, 2022</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.1</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000104746920000894/a2240738zex-4_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Common Stock Certificate</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-236214</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 18, 2020</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.2</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000104746920000652/a2240560zex-4_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Amended and Restated Investors&#39; Rights Agreement, dated August&#160;21, 2019, by and among the Registrant and certain of its stockholders.</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-236214</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 3, 2020</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4.3</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000155837021002287/pasg-20201231ex43f0b5efe.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Registrant&#8217;s Securities</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 3, 2021</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.1<span style="background:#ffffff;">&#8224;&#708;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000155837020006239/pasg-20200331ex10109dea8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Development Services and Clinical Supply Agreement, dated April 13, 2020, by and between the Registrant and Catalent Maryland, Inc.</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May 11, 2020</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.2</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000155837020006239/pasg-20200331ex102f078db.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Lease, dated April 10, 2020, by and between the Registrant and Commerce Square Partners - Philadelphia Plaza, L.P.</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May 11, 2020</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.3</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000155837020006239/pasg-20200331ex103f31965.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">First Amendment to Lease, dated April 10, 2020, by and between the Registrant and Philadelphia Plaza &#8211; Phase II LP</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">May 11, 2020</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.4</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1787297/000104746920000652/a2240560zex-10_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnification Agreement between the Registrant and its directors and officers</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-236214</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 3, 2020</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.5</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000104746920000652/a2240560zex-10_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Amended and Restated 2018 Equity Incentive Plan, as amended, and forms of award agreements.</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-236214</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 3, 2020</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.6</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1787297/000104746920000894/a2240738zex-10_3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2020 Equity Incentive Plan of the Registrant, and forms of award agreements.</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-236214</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 18, 2020</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.7</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1787297/000104746920000894/a2240738zex-10_4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2020 Employee Stock Purchase Plan of the registrant</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-236214</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 18, 2020</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.8</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000104746920000894/a2240738zex-10_8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Employment Agreement dated February 14, 2020, by and between the Registrant and Bruce Goldsmith.</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-236214</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 18, 2020</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:middle;width:10.02%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.9</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1787297/000104746920000652/a2240560zex-10_11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consulting Agreement, dated January 8, 2019, as amended on January 31, 2020, by and between the Registrant and James Wilson, M.D., Ph.D.</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-236214</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 3, 2020</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.10<span style="background:#ffffff;">&#8224;&#708;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000155837020010495/pasg-20200630ex1049f486a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Sponsored Research, Collaboration and License Agreement, dated May 5, 2020, by and between the Registrant and The Trustees of the University of Pennsylvania</span></a>.</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">August 13, 2020</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.11<span style="background:#ffffff;">&#708;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000155837020013472/pasg-20200930ex101899b73.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 1, dated August 13, 2020, to the Amended and Restated Sponsored Research, Collaboration and License Agreement by and between the Registrant and the Trustees of the University of Pennsylvania</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 10, 2020</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.12<span style="background:#ffffff;">&#708;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000110465921005296/tm2038048d5_ex10-15.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 2, dated November 2, 2020, to the Amended and Restated Sponsored Research, Collaboration and License Agreement by and between the Registrant and the Trustees of the University of Pennsylvania</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-252213</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 19, 2021</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.13<span style="background:#ffffff;">&#8224;&#708;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000110465921005296/tm2038048d5_ex10-16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 3, dated December 9, 2020, to the Amended and Restated Sponsored Research, Collaboration and License Agreement by and between the Registrant and the Trustees of the University of Pennsylvania</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-1</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-252213</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">January 19, 2021</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.14&#708;</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000110465920137129/tm2038048d3_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease, dated December 15, 2020 by and between the Registrant and Hopewell Campus Owner, LLC</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">8-K</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">December 18, 2020</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.15</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0001787297/000155837021008991/tmb-20210719xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">2021 Equity Inducement Plan</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-8</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-258000</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">July 19, 2021</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.16&#8224;&#708;</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000155837022002719/pasg-20211231xex10d17.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 4, dated June 2, 2021, to the Amended and Restated Sponsored Research, Collaboration and License Agreement by and between the Registrant and the Trustees of the University of Pennsylvania</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 3, 2022</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:86.05pt;"><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.17</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0001787297/000155837021014460/pasg-20210930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 5, dated August 3, 2021, to the Amended and Restated Sponsored Research, Collaboration and License Agreement by and between the Registrant and the Trustees of the University of Pennsylvania</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 4, 2021</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.18&#8224;&#708;</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000155837022002719/pasg-20211231xex10d19.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 6, dated November 12, 2021, to the Amended and Restated Sponsored Research, Collaboration and License Agreement by and between the Registrant and the Trustees of the University of Pennsylvania</span></a> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 3, 2022</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.19&#8224;&#708;</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000155837022002719/pasg-20211231xex10d20.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment No. 7, dated December 3, 2021, to the Amended and Restated Sponsored Research, Collaboration and License Agreement by and between the Registrant and the Trustees of the University of Pennsylvania</span></a> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-K</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 3, 2022</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.20&#8224;&#708;</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000155837022012042/pasg-20220630xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Eighth Amendment to Amended and Restated Research, License &amp; Collaboration Agreement, dated May 11, 2022, by and between the Registrant and the Trustees of the University of Pennsylvania.</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">August 4, 2022</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.15pt;"><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.21+</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0001787297/000155837021014460/pasg-20210930xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated August 23, 2021 by and between the Registrant and Simona King.</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 4, 2021</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.22+&#8224;</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000155837022017285/pasg-20220930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, dated October 10, 2022 by and between the Registrant and William Chou.</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 10, 2022</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.23+&#8224;</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000155837022012042/pasg-20220630xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Transition and Separation Agreement, dated May 27, 2022 by and between the Registrant and Bruce Goldsmith.</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10-Q</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">001-39231</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">August 4, 2022</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.24+&#8224;</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pasg-20221231xex10d24.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement dated September 10, 2019, as amended on February 26</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">th</sup><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">, 2020, by and between the Registrant and Edgar B. (Chip) Cale.</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.25+&#8224;</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1787297/000104746920000894/a2240738zex-10_10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;white-space:pre-wrap;">Employment Agreement, dated July 22, 2019, as amended on February 14, 2022,  by and between the Registrant and Alexandros Fotopoulos.</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">S-1/A</p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">333-236214</p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">February 18, 2020</p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">10.26+&#8224;</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pasg-20221231xex10d26.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Transition and Separation Agreement, dated November 17, 2022, by and between the Registrant and Monika Toernsen.</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">23.1</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pasg-20221231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of KPMG LLP, an independent registered public accounting firm.</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">24.1</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Power_of_Attorney"><span style="font-style:normal;font-weight:normal;">Power of Attorney. Reference is made to the signature page hereto.</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.1</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pasg-20221231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">31.2</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pasg-20221231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.1*</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pasg-20221231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">32.2*</p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pasg-20221231xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">101.INS</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Instance Document</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">101.SCH</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Schema Document</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">101.CAL</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Calculation Linkbase Document.</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">101.DEF</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Definition Linkbase Document.</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">101.LAB</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Label Linkbase Document.</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">142</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="letter-spacing:0.25pt;">101.PRE</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">XBRL Taxonomy Extension Presentation Linkbase Document.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:10.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.0pt;margin:0pt;"><span style="letter-spacing:0.25pt;">104</span></p></td><td style="vertical-align:middle;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:35.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL).</p></td><td style="vertical-align:top;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:9.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">X</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-weight:normal;">+ </span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-weight:normal;">Indicates management contract or compensatory plan, contract or agreement.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-weight:normal;">&#8224; </span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-weight:normal;">Registrant has omitted portions of the exhibit as permitted under Item 601(b)(10) of Regulations S-K.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-weight:normal;">&#708; </span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"><span style="font-weight:normal;">Registrant has omitted schedules and exhibits pursuant to Item 601(a)(5) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of the omitted schedules and exhibits to the SEC upon request.</span></p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:22.5pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">*</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;">This certification is deemed not filed for purposes of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">143</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_42f38582_b4e0_4b04_aa67_9d0aaffd0f69"></a><a id="Item16Form10KSummary_733791"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;16.&#160;&#160;&#160;&#160;Form&#160;10-K Summary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Registrants may voluntarily include a summary of information required by Form&#160;10-K under Item&#160;16. We have elected not to include such summary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">144</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7b31f794_4b77_4819_8173_91995accf6ff"></a><a id="SIGNATURES_809350"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section&#160;13 or 15(d)&#160;the Securities Exchange Act of 1934, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PASSAGE BIO, INC.</p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 6, 2023</p></td><td style="vertical-align:bottom;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:42.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ William Chou, M.D.</p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:42.49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">William Chou, M.D.</p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:42.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer and Director</p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 6, 2023</p></td><td style="vertical-align:bottom;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:42.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Simona King</p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:42.49%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Simona King</p></td></tr><tr><td style="vertical-align:bottom;width:50.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:42.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">145</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_81b5450e_63c6_4d2f_a7b3_5f06844621f3"></a><a id="Power_of_Attorney"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">POWER OF ATTORNEY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each person whose individual signature appears below hereby authorizes and appoints William Chou, M.D., Simona King and Edgar B. Cale, and each of them, with full power of substitution and resubstitution, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form&#160;10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agents full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorney-in-fact and agents or his substitute or substitutes may lawfully do or cause to be done by virtue thereof. Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:29.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">/s/ William Chou, M.D.</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">President, Chief Executive&#160;Officer and Director</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:14.4pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March&#160;6,&#160;2023</p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">William Chou, M.D.</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:20.8pt;"><td style="vertical-align:bottom;width:29.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">/s/ Simona King</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Chief Financial Officer and Corporate Secretary</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March&#160;6,&#160;2023</p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Simona King</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><i style="font-style:italic;">(Principal Financial and Accounting Officer)</i></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:21.25pt;"><td style="vertical-align:bottom;width:29.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">/s/ Maxine Gowen, Ph.D.</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Director</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March&#160;6,&#160;2023</p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Maxine Gowen, Ph.D.</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:21.7pt;"><td style="vertical-align:bottom;width:29.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">/s/ Athena Countouriotis, M.D.</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Director</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March&#160;6,&#160;2023</p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Athena Countouriotis, M.D.</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:19.9pt;"><td style="vertical-align:bottom;width:29.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">/s/ Saqib Islam</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Director</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March&#160;6,&#160;2023</p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Saqib Islam</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">/s/ Sandip Kapadia</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Director</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March&#160;6,&#160;2023</p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Sandip Kapadia</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:21.7pt;"><td style="vertical-align:bottom;width:29.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">/s/ Michael Kamarck, Ph.D.</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Director</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March&#160;6,&#160;2023</p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Michael Kamarck, Ph.D.</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:22.15pt;"><td style="vertical-align:bottom;width:29.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">/s/ Derrell Porter, M.D.</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Director</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March&#160;6,&#160;2023</p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Derrell Porter, M.D.</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:22.15pt;"><td style="vertical-align:bottom;width:29.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">/s/ Tom Woiwode, Ph.D.</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Director</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">March&#160;6,&#160;2023</p></td></tr><tr><td style="vertical-align:bottom;width:29.33%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;">Tom Woiwode, Ph.D.</p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:42.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:14.4pt;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:20.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:6pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:216.6pt;"></span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">146</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>2
<FILENAME>pasg-20221231xex10d24.htm
<DESCRIPTION>EX-10.24
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/6/2023 10:28:23 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.13%;padding-right:10.78%;position:relative;"><div style="margin-top:30pt;min-height:32pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:48.35%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"></font><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 10.24</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0.05pt 0pt 0pt 0pt;"><b style="font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:3.95pt 130.5pt 0pt 133.8pt;"><font style="color:#231f20;margin-left:0pt;margin-right:0pt;margin-top:9.2pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-align:center;margin:3.95pt 130.5pt 0pt 133.8pt;"><b style="color:#231f20;font-weight:bold;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">EMPLOYMENT</b><b style="color:#231f20;font-weight:bold;letter-spacing:3.9pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="color:#231f20;font-weight:bold;letter-spacing:-0.1pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:13.8pt;text-align:justify;text-indent:36pt;margin:4.65pt 5.45pt 0pt 10pt;"><font style="color:#231f20;">THIS EMPLOYMENT AGREEMENT (this &#8220;Agreement&#8221;) is entered into effective as of September 10, 2019, by and between Passage BIO, Inc. (the &#8220;Company&#8221;), and Edgar Cale (the &#8220;Employee&#8221;) (collectively, the &#8220;Parties&#8221;). This Agreement amends, restates and supersedes any written or unwritten agreement or understanding between the Parties regarding the subject matter hereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:6pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:4.5pt 0pt 0pt 46pt;"><font style="color:#231f20;">The</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">Company</font><font style="color:#231f20;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;">and</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">Employee</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">agree</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">as</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;letter-spacing:-0.1pt;">follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:36pt;margin:0pt 5.95pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Definitions</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">The following terms used in this Agreement shall, unless otherwise clearly required by the context, have the meanings assigned to them in this </font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section 1.</u></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:71.95pt;margin:0pt 5.65pt 0pt 10pt;"><font style="color:#231f20;">&#8220;</font><font style="color:#231f20;font-style:italic;font-weight:bold;">Annual</font><font style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-style:italic;font-weight:bold;">Salary</font><font style="color:#231f20;">&#8221;</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">means</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">annual</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">salary</font><font style="color:#231f20;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;">payable</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">to</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">Employee,</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">initially</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">in</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">the amount of $360,000, less applicable deductions, and as may be changed from time to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 82pt;"><font style="color:#231f20;">&#8220;</font><font style="color:#231f20;font-style:italic;font-weight:bold;">Board</font><font style="color:#231f20;">&#8221;</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">means</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">the Board</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">Directors</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;letter-spacing:-0.1pt;">Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:0pt 5.6pt 0pt 10pt;"><font style="color:#231f20;">&#8220;</font><font style="color:#231f20;font-style:italic;font-weight:bold;">Cause</font><font style="color:#231f20;">&#8221;</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">means a good faith determination by</font><font style="color:#231f20;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;">the Board,</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">that any</font><font style="color:#231f20;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">following has occurred: (i) the Employee&#8217;s commission of, conviction of, or plea of nolo contendere to, a felony or an act constituting common law fraud, which has or is reasonably expected to have a material</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">adverse</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">effect</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">on</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">business</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">or</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">affairs</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">Company;</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">(ii) the Employee&#8217;s</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">willful</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">and repeated failure to perform in any material respect the Employee&#8217;s duties for the Company; (iii) the</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">Employee&#8217;s</font><font style="color:#231f20;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;">intentional</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">breach</font><font style="color:#231f20;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">Company</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">confidential</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">information</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">obligations,</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">invention assignment agreement, or any written Company policy that has been communicated to the Employee in advance of the Employee&#8217;s breach, (iv) the Employee&#8217;s intentional and material breach of this Agreement; provided, however, that prior to any</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">determination that &#8220;Cause&#8221; under this Agreement has occurred, the Board shall (A) provide to the Employee written notice specifying the particular event or actions giving rise to such determination and (B) solely in the event</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;">a</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">breach</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">subsection</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">(ii)</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">above,</font><font style="color:#231f20;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;">provide</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">Employee</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">an</font><font style="color:#231f20;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;">opportunity</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">to</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">be</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">heard</font><font style="color:#231f20;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;">within 30</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">days</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">such</font><font style="color:#231f20;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;">notice</font><font style="color:#231f20;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;">and</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">provide</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">Employee</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">with</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">30</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">days</font><font style="color:#231f20;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;">from</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">date</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">Employee</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">is</font><font style="color:#231f20;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;">heard to cure such event or actions giving rise to a determination of &#8220;Cause&#8221; under such subsection, if </font><font style="color:#231f20;letter-spacing:-0.1pt;">curable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:72pt;margin:4.5pt 5.7pt 0pt 10pt;"><font style="color:#231f20;">&#8220;</font><font style="color:#231f20;font-style:italic;font-weight:bold;">Change</font><font style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-style:italic;font-weight:bold;">of</font><font style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-style:italic;font-weight:bold;">Control</font><font style="color:#231f20;">&#8221;</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">means</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">(i)</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">a</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">sale,</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">conveyance,</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">exchange</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">or</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">transfer</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">(excluding any venture-backed or similar investments in the Company) in which any person or entity (other than</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">persons</font><font style="color:#231f20;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;">or</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">entities</font><font style="color:#231f20;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;">who</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">as</font><font style="color:#231f20;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">immediately</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">prior</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">to</font><font style="color:#231f20;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;">such</font><font style="color:#231f20;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;">sale,</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">conveyance,</font><font style="color:#231f20;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;">exchange</font><font style="color:#231f20;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;">or</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">transfer own more than fifty</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">percent (50%) of the total voting power of the then-outstanding securities in the Company) either directly</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">or indirectly</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">becomes the beneficial owner, directly</font><font style="color:#231f20;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;">or indirectly, of securities</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">Company</font><font style="color:#231f20;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;">representing</font><font style="color:#231f20;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;">more</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">than</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">fifty</font><font style="color:#231f20;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;">(50%)</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">percent</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">total</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">voting</font><font style="color:#231f20;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;">power</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">of all its then outstanding voting securities; (ii) a merger or consolidation of the Company in which its voting securities immediately prior to the merger or consolidation do not represent, or are not converted into securities that represent, a majority of the voting power of all voting securities of the surviving entity immediately after the merger or consolidation; (iii) a sale of substantially all of</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">assets</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">Company</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">or</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">a</font><font style="color:#231f20;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;">liquidation</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">or</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">dissolution</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">Company,</font><font style="color:#231f20;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;">provided</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">that,</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">in</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">each cases</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">(i)-(iii)</font><font style="color:#231f20;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">this</font><font style="color:#231f20;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;">definition,</font><font style="color:#231f20;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;">a</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">transaction</font><font style="color:#231f20;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;">or</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">series</font><font style="color:#231f20;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">transactions</font><font style="color:#231f20;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;">shall</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">only</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">constitute</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">a</font><font style="color:#231f20;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;">Change</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.13%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:79.08%;border-width:0;"><div style="max-width:100%;padding-left:10.13%;padding-right:10.78%;position:relative;"><div style="min-height:68pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:48.35%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"></font><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 10.24</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:3.7pt 0pt 0pt 10pt;"><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:2pt;"> </font><font style="color:#231f20;">Control</font><font style="color:#231f20;letter-spacing:2pt;"> </font><font style="color:#231f20;">if</font><font style="color:#231f20;letter-spacing:2pt;"> </font><font style="color:#231f20;">it</font><font style="color:#231f20;letter-spacing:2pt;"> </font><font style="color:#231f20;">also</font><font style="color:#231f20;letter-spacing:2pt;"> </font><font style="color:#231f20;">satisfies</font><font style="color:#231f20;letter-spacing:2pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:2pt;"> </font><font style="color:#231f20;">requirements</font><font style="color:#231f20;letter-spacing:2pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:2pt;"> </font><font style="color:#231f20;">a</font><font style="color:#231f20;letter-spacing:2pt;"> </font><font style="color:#231f20;">change</font><font style="color:#231f20;letter-spacing:2pt;"> </font><font style="color:#231f20;">in</font><font style="color:#231f20;letter-spacing:2pt;"> </font><font style="color:#231f20;">control</font><font style="color:#231f20;letter-spacing:2pt;"> </font><font style="color:#231f20;">under</font><font style="color:#231f20;letter-spacing:2pt;"> </font><font style="color:#231f20;">U.S.</font><font style="color:#231f20;letter-spacing:2pt;"> </font><font style="color:#231f20;">Treasury Regulation 1.409A-3(i)(5)(v), 1.409A-3(i)(5)(vi), or 1.409A-3(i)(5)(vii).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.05pt 0pt 0pt 82pt;"><font style="color:#231f20;">&#8220;</font><font style="color:#231f20;font-style:italic;font-weight:bold;">Code</font><font style="color:#231f20;">&#8221;</font><font style="color:#231f20;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;">means</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">Internal</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">Revenue</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">Code</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">1986,</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">as</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;letter-spacing:-0.1pt;">amended.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.05pt 0pt 0pt 82pt;"><font style="color:#231f20;font-size:12pt;">&#8220;</font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;">Vesting Commencement</font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;letter-spacing:0.05pt;"> </font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;">Date</font><font style="color:#231f20;font-size:12pt;">&#8221;</font><font style="color:#231f20;font-size:12pt;letter-spacing:0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">means</font><font style="color:#231f20;font-size:12pt;letter-spacing:0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">the date</font><font style="color:#231f20;font-size:12pt;letter-spacing:0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">used</font><font style="color:#231f20;font-size:12pt;letter-spacing:0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">to</font><font style="color:#231f20;font-size:12pt;letter-spacing:0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">measure the beginning </font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;">of</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 10pt;"><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">vesting</font><font style="color:#231f20;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;">period</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">for</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">Equity</font><font style="color:#231f20;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;">Award,</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">as</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">specified</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">in</font><font style="color:#231f20;letter-spacing:0.05pt;"> </font><u style="color:#231f20;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section</u><u style="color:#231f20;letter-spacing:-0.1pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> 3.3(b)</u><font style="color:#231f20;letter-spacing:-0.1pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.05pt 0pt 0pt 82pt;"><font style="color:#231f20;font-size:12pt;">&#8220;</font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;">Conflict</font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;">of</font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;">Interest</font><font style="color:#231f20;font-size:12pt;">&#8221;</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">has</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">meaning</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">set</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">forth</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">in </font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">4.3</u><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.05pt 0pt 0pt 82pt;"><font style="color:#231f20;font-size:12pt;">&#8220;</font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;">Date</font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;letter-spacing:3.75pt;"> </font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;">of</font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;letter-spacing:3.8pt;"> </font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;">Termination</font><font style="color:#231f20;font-size:12pt;">&#8221;</font><font style="color:#231f20;font-size:12pt;letter-spacing:3.65pt;"> </font><font style="color:#231f20;font-size:12pt;">means</font><font style="color:#231f20;font-size:12pt;letter-spacing:3.8pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:3.75pt;"> </font><font style="color:#231f20;font-size:12pt;">date</font><font style="color:#231f20;font-size:12pt;letter-spacing:3.8pt;"> </font><font style="color:#231f20;font-size:12pt;">that</font><font style="color:#231f20;font-size:12pt;letter-spacing:3.9pt;"> </font><font style="color:#231f20;font-size:12pt;">is</font><font style="color:#231f20;font-size:12pt;letter-spacing:3.95pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:3.8pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee&#8217;s</font><font style="color:#231f20;font-size:12pt;letter-spacing:3.8pt;"> </font><font style="color:#231f20;font-size:12pt;">last</font><font style="color:#231f20;font-size:12pt;letter-spacing:2.55pt;"> </font><font style="color:#231f20;font-size:12pt;">day</font><font style="color:#231f20;font-size:12pt;letter-spacing:3.7pt;"> </font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;">of</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 10pt;"><font style="color:#231f20;">employment</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">at</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;letter-spacing:-0.1pt;">Company.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 85pt;"><font style="color:#231f20;font-size:12pt;">&#8220;</font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;">Employment</font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;">Start</font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;">Date</font><font style="color:#231f20;font-size:12pt;">&#8221;</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">means</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">first</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">day</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee&#8217;s</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">employment</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;">with</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 10pt;"><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;">Company,</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">which</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">is</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">expected</font><font style="color:#231f20;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;">to</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">be</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">September</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">23,</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;letter-spacing:-0.1pt;">2019.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:71.95pt;margin:0pt 5.75pt 0pt 10pt;"><font style="color:#231f20;">&#8220;</font><font style="color:#231f20;font-style:italic;font-weight:bold;">Good</font><font style="color:#231f20;font-style:italic;font-weight:bold;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-style:italic;font-weight:bold;">Reason</font><font style="color:#231f20;">&#8221;</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">means</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">any</font><font style="color:#231f20;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">following</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">taken without the</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">Employee&#8217;s written consent</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">and</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">provided (a)</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">Company</font><font style="color:#231f20;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;">receives,</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">within</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">ninety</font><font style="color:#231f20;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;">(90)</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">days following</font><font style="color:#231f20;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;">the initial</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">date on</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">which</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">Employee</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">knows</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">occurrence</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">any</font><font style="color:#231f20;letter-spacing:-0.85pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">events</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">set</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">forth</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">in</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">clauses</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">(i)</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">through</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:0.05pt;text-align:justify;text-indent:-0.05pt;margin:0pt 5.6pt 0pt 9.95pt;"><font style="color:#231f20;">(iv) below, written notice from the Employee specifying the specific basis for the Employee&#8217;s belief that the Employee is entitled to terminate employment for Good Reason, (b) the Company fails</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">to</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">cure</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">event</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">constituting</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">Good</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">Reason</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">within</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">thirty</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">(30)</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">days</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">after</font><font style="color:#231f20;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;">receipt</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">such</font><font style="color:#231f20;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;">written notice thereof, and (c) the Employee terminates employment within thirty (30) days following expiration</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">such</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">cure</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">period:</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">(i)</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">a</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">material</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">reduction</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">Employee&#8217;s</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">responsibilities,</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">authority or duties to a level materially less than the responsibilities, authorities or duties the Employee occupied</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">or</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">possessed,</font><font style="color:#231f20;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;">on</font><font style="color:#231f20;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">date</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">immediately</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">preceding</font><font style="color:#231f20;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;">such</font><font style="color:#231f20;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;">reduction;</font><font style="color:#231f20;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;">(ii)</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">a</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">material</font><font style="color:#231f20;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;">reduction in</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">Employee&#8217;s</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">Annual</font><font style="color:#231f20;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;">Salary;</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">(iii)</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">Company&#8217;s</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">requiring</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">Employee&#8217;s</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">to</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">be</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">based</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">at</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">any office or location more than thirty (30) miles from 2 Commerce Square, Philadelphia, Pennsylvania; or (iv) the Company&#8217;s material breach of any provision of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;text-indent:71.95pt;margin:0pt 5.7pt 0pt 10pt;"><font style="color:#231f20;">&#8220;</font><font style="color:#231f20;font-style:italic;font-weight:bold;">Omnibus Plan</font><font style="color:#231f20;">&#8221; means the Company&#8217;s shareholder approved incentive plan or plans, which may include long-term equity-based compensation plans, short-term performance- based</font><font style="color:#231f20;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;">compensation</font><font style="color:#231f20;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;">plans</font><font style="color:#231f20;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;">and</font><font style="color:#231f20;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;">any</font><font style="color:#231f20;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;">other</font><font style="color:#231f20;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;">similar</font><font style="color:#231f20;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;">plans,</font><font style="color:#231f20;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;">as</font><font style="color:#231f20;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;">such</font><font style="color:#231f20;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;">may</font><font style="color:#231f20;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;">be</font><font style="color:#231f20;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;">in</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">effect</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">from</font><font style="color:#231f20;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;">time</font><font style="color:#231f20;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;">to time.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.7pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">2.</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Title and Duties</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">The Employee shall serve as General Counsel of the Company. The</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">will</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">have</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">duties</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">and</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">responsibilities</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">that</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">are</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">customary</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">for</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee&#8217;s</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">position, and</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">shall</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">initially</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">report</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">to</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">Chief</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">Executive</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">Officer</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">(&#8220;</font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;">CEO</font><font style="color:#231f20;font-size:12pt;">&#8221;)</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">Company.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">The</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee will devote all reasonable efforts and all of the Employee&#8217;s business time to the Company.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:45.95pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">3.</td><td style="padding:0pt;"><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Compensation</u><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">and</u><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Benefits</u><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 5.85pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">3.1</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Annual Salary</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">The Annual Salary</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">will be payable in accordance with the payroll policies of the Company in effect from time to time, less any deductions required to be withheld by applicable law and less any voluntary deductions made by the Employee.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 5.8pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">3.2</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Incentive Compensation</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">The Employee shall be eligible to receive </font><font style="color:#101111;font-size:12pt;">an annual performance bonus, with a target amount equal to </font><font style="color:#231f20;font-size:12pt;">35</font><font style="color:#101111;font-size:12pt;">% of the Annual Salary, based upon</font></div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="height:15.3pt;left:47.54%;max-width:52.46%;position:absolute;top:639.55pt;width:28pt;z-index:-9223372036603117568;"><div style="height:15.3pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:28pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;width:100%;margin:0.5pt 0pt 0pt 1pt;"><font style="color:#231f20;">-</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">2</font><font style="color:#231f20;"> </font><font style="color:#231f20;letter-spacing:-0.5pt;">-</font></p></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.13%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:79.08%;border-width:0;"><div style="max-width:100%;padding-left:10.13%;padding-right:10.78%;position:relative;"><div style="min-height:68pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:48.35%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"></font><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 10.24</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:3.7pt 5.7pt 0pt 10pt;"><font style="color:#101111;">the achievement of performance objectives established by the Board or CEO and subject to the terms of</font><font style="color:#101111;letter-spacing:-0.05pt;"> </font><font style="color:#101111;">the</font><font style="color:#101111;letter-spacing:-0.05pt;"> </font><font style="color:#101111;">applicable</font><font style="color:#101111;letter-spacing:-0.05pt;"> </font><font style="color:#101111;">bonus plan(s).</font><font style="color:#101111;letter-spacing:2pt;"> </font><font style="color:#101111;">Bonus payouts, if</font><font style="color:#101111;letter-spacing:-0.05pt;"> </font><font style="color:#101111;">any,</font><font style="color:#101111;letter-spacing:-0.1pt;"> </font><font style="color:#101111;">will</font><font style="color:#101111;letter-spacing:-0.05pt;"> </font><font style="color:#101111;">be paid no later</font><font style="color:#101111;letter-spacing:-0.05pt;"> </font><font style="color:#101111;">than</font><font style="color:#101111;letter-spacing:-0.05pt;"> </font><font style="color:#101111;">March 15 of the year following the calendar year to which the bonus is applicable, and will be pro-rated based, as applicable, on hire date and/or on approved leaves of absence.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 5.8pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">3.3</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Equity-Based Compensation</u><font style="color:#231f20;font-size:12pt;">: The Employee shall receive a stock option (the &#8220;</font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;">Equity Award</font><font style="color:#231f20;font-size:12pt;">&#8221;) to purchase 810,543 shares of common stock of the Company at a strike price no less than the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">fair market value</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">per</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">share as determined</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">by</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">the Board.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">The Equity</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">Award shall have the following features:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:107.95pt;margin:0pt 5.9pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.15pt;text-indent:0pt;white-space:nowrap;">(a)</font><font style="color:#231f20;font-size:12pt;">The Employee shall have the right to exercise the Equity Award early, subject to entering into a</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">restricted stock</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">agreement as</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">directed</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">by</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">the Company; provided, however,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">that</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">stock</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">acquired</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">by</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">exercise</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">Equity</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">Award</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">that</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">is</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">not</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">vested</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">shall</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">be</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">subject to the same vesting schedule that applied to the Equity Award, so that on termination of employment, any stock that has not become vested may be repurchased, at the Company&#8217;s discretion,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">on</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">payment</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">lesser</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">(A)</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">amount</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">paid</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">by</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">for</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">such</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">stock,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">or</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">(B) the then fair market value of such stock.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:107.95pt;margin:0pt 5.85pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">(b)</font><font style="color:#231f20;font-size:12pt;">The Equity Award shall become vested as to 25% on the one-year anniversary of the Vesting Commencement Date, and shall thereafter become vested in 36 equal monthly installments (so as to be fully vested on the fourth anniversary of the Vesting Commencement Date), subject to the Employee&#8217;s continuous service as required by the Equity Award and restricted stock agreement.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">The Vesting Commencement Date for the Equity</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">Award will be the Employment Start Date.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 5.75pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">3.4</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Participation</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">in</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Employee</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Benefit</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Plans</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">The</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">may</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">participate</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">in any</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">group</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">life,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">hospitalization</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">or</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">disability</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">insurance</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">plan,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">health</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">program,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">retirement</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">plan,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">similar benefit</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">plan</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">or</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">other</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">so</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">called</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">&#8220;fringe</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">benefits&#8221;</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">Company</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">for</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">which</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">is</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">eligible. The Employee&#8217;s participation in any such plans shall be on the terms and conditions set forth in the governing plan documents as they may be in effect from time to time.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 5.8pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">3.5</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">General Business Expenses</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">The Company shall pay or reimburse the Employee for all business expenses reasonably and necessarily incurred by the Employee in the performance of the Employee&#8217;s duties under this Agreement, consistent with the Company&#8217;s business expense reimbursement policy, as in effect from time to time.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 5.75pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">3.6</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company Policies</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">The Employee understands and agrees to abide by Company&#8217;s insider trading policy, code of conduct, and any</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">other policies and programs adopted by the Company regulating the behavior of its employees, as such policies and programs may</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">be amended from time to time.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:45.95pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">4.</td><td style="padding:0pt;"><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Protection</u><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">of</u><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Company</u><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Trade</u><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Secrets</u><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">and</u><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Proprietary</u><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Information</u><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 5.85pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">4.1</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">EIACNA</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:1.85pt;"> </font><font style="color:#231f20;font-size:12pt;">As</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">an</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">employee</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">Company,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">will</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">have</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">access to certain confidential information of the Company and the Employee may, during the course of the Employee&#8217;s employment, develop certain information or inventions that will be the property of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">Company.</font><font style="color:#231f20;font-size:12pt;letter-spacing:1.7pt;"> </font><font style="color:#231f20;font-size:12pt;">To</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">protect</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">Company&#8217;s</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">interests,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">as</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">a</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">condition</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">employment,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee</font></div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="height:15.3pt;left:47.54%;max-width:52.46%;position:absolute;top:639.55pt;width:28pt;z-index:-9223372036603117568;"><div style="height:15.3pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:28pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;width:100%;margin:0.5pt 0pt 0pt 1pt;"><font style="color:#231f20;">-</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">3</font><font style="color:#231f20;"> </font><font style="color:#231f20;letter-spacing:-0.5pt;">-</font></p></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.13%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:79.08%;border-width:0;"><div style="max-width:100%;padding-left:10.13%;padding-right:10.78%;position:relative;"><div style="min-height:68pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:48.35%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"></font><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 10.24</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:3.7pt 0pt 0pt 10pt;"><font style="color:#231f20;">must</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">sign</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">and</font><font style="color:#231f20;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;">abide</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">by</font><font style="color:#231f20;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">Company&#8217;s</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">standard</font><font style="color:#231f20;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;">Employee</font><font style="color:#231f20;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;">Invention</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">Assignment,</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">Confidentiality, and Non-Competition Agreement (the &#8220;</font><font style="color:#231f20;font-style:italic;font-weight:bold;">EIACNA</font><font style="color:#231f20;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 5.8pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">4.2</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">No</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Breach</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">of</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Obligations</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">to</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Prior</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Employers</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:1.7pt;"> </font><font style="color:#231f20;font-size:12pt;">The</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">Company</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">hereby</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">directs the Employee not to bring with the Employee any confidential or proprietary material of any former employer or to violate any other obligations the Employee may have to any former employer.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">The Employee represents that by signing of this Agreement and the Company&#8217;s EIACNA and</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">the Employee&#8217;s commencement</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">of employment with</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">Company</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">will</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">not</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">violate any agreement currently in place between the Employee and current or past employers.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 5.65pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">4.3</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Conflicts of Interest</u><i style="color:#231f20;font-size:12pt;font-style:italic;">.</i><i style="color:#231f20;font-size:12pt;font-style:italic;letter-spacing:2pt;"> </i><font style="color:#231f20;font-size:12pt;">The Employee agrees that during the Employee&#8217;s employment</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">with</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">Company</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">will</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">not</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">engage,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">either</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">directly</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">or</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">indirectly,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">in</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">any activity which might adversely affect the Company or its affiliates (a &#8220;</font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;">Conflict of Interest</font><font style="color:#231f20;font-size:12pt;">&#8221;), including ownership of a material interest in any supplier, contractor, distributor, subcontractor, customer or other entity with which the Company does business or acceptance of any material payment, service, loan, gift, trip, entertainment, or other favor from a supplier, contractor, distributor, subcontractor, customer or other entity with which the Company does business, and that the Employee will promptly inform the Board as to each offer received by the Employee to engage in any such activity. The Employee further agrees to disclose to the Company any other facts</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">which</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">becomes</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">aware</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">which</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">might</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">in</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee&#8217;s</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">good</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">faith</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">judgment reasonably be expected to involve or give rise to a Conflict of Interest or potential Conflict of </font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;">Interest.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:45.95pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">5.</td><td style="padding:0pt;"><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Termination</u><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:85.55pt;margin:0pt 5.95pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:22.5pt;text-indent:0pt;white-space:nowrap;">5.1</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Accrued Payments</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">In general, on termination of the Employee&#8217;s employment for any reason, the following amounts will be paid to the Employee, or the Employee&#8217;s estate, as the case may be:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:107.95pt;margin:0pt 5.55pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">(a)</font><font style="color:#231f20;font-size:12pt;">All</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">accrued</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">but</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">unpaid</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">Annual</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">Salary,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">payable</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">in</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">next</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">regularly scheduled pay period following the Employee&#8217;s Date of Termination or such earlier date as may be required by law;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.5pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:107.95pt;margin:0pt 5.65pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.15pt;text-indent:0pt;white-space:nowrap;">(b)</font><font style="color:#231f20;font-size:12pt;">Accrued but unused vacation time, to the extent payment is either required by law or provided for in the Company&#8217;s vacation or paid-time-off policy, as such may be in effect from time to time;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:107.95pt;margin:0pt 5.7pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.15pt;text-indent:0pt;white-space:nowrap;">(c)</font><font style="color:#231f20;font-size:12pt;">Any amounts payable to the Employee under the terms of any employee benefit plans in which the Employee was a participant;</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:107.95pt;margin:0pt 5.9pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.15pt;text-indent:0pt;white-space:nowrap;">(d)</font><font style="color:#231f20;font-size:12pt;">Reimbursement of any of the Employee&#8217;s business expenses not previously reimbursed, to the extent provided for under the Company&#8217;s business expense reimbursement policy; and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:107.95pt;margin:0pt 5.9pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.15pt;text-indent:0pt;white-space:nowrap;">(e)</font><font style="color:#231f20;font-size:12pt;">Payment of any amounts that are determined to be due under the terms of the Omnibus Plan, or any grants or awards made thereunder.</font></div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:11pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="height:15.3pt;left:47.54%;max-width:52.46%;position:absolute;top:639.55pt;width:28pt;z-index:-9223372036603117568;"><div style="height:15.3pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:28pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;width:100%;margin:0.5pt 0pt 0pt 1pt;"><font style="color:#231f20;">-</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">4</font><font style="color:#231f20;"> </font><font style="color:#231f20;letter-spacing:-0.5pt;">-</font></p></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.13%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:79.08%;border-width:0;"><div style="max-width:100%;padding-left:10.13%;padding-right:10.78%;position:relative;"><div style="min-height:68pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:48.35%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"></font><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 10.24</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="margin-top:3.7pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72.1pt;margin:0pt 5.8pt 0pt 5.45pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:40.5pt;text-indent:0pt;white-space:nowrap;">5.2</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Termination</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">for</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Cause</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">The</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">Company</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">has the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">right,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">at</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">any</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">time</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">during</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">the Employee&#8217;s employment, subject to all of the provisions hereof, exercisable by serving notice, effective on or after the date of service of such notice as specified therein, to terminate the Employee&#8217;s employment under this Agreement and discharge the Employee for Cause. A termination of employment will be effective on the date set forth in such notice of termination.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:85.55pt;margin:0pt 5.65pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:22.5pt;text-indent:0pt;white-space:nowrap;">5.3</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Termination</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">without</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Cause</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:1.95pt;"> </font><font style="color:#231f20;font-size:12pt;">The</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">Company</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">has</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">right,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">at</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">any</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">time</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">during the Employee&#8217;s employment, to terminate the Employee&#8217;s employment without Cause by providing the Employee with notice.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:85.55pt;margin:0pt 5.8pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:22.5pt;text-indent:0pt;white-space:nowrap;">5.4</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Termination without Cause or Resignation for Good Reason</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">In the event the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">Company</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">terminates</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee&#8217;s</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">employment</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">without</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">Cause</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">or</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">resigns</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">from employment with the Company for Good Reason, </font><font style="color:#323031;font-size:12pt;">then subject to the Employee&#8217;s satisfaction of the Severance Conditions (defined below), the Employee will be entitled to the following separation benefits:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.5pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:107.95pt;margin:0pt 5.8pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.15pt;text-indent:0pt;white-space:nowrap;">(a)</font><font style="color:#231f20;font-size:12pt;">Severance.</font><font style="color:#231f20;font-size:12pt;letter-spacing:0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">Should</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">termination</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">occur</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">during</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">first</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">twelve</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">(12) months of employment, the Employee will be entitled to a lump sum payment equal to the Employee&#8217;s Annual Salary for an additional nine (9) months after the Date of Termination (the &#8220;</font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;">Severance</font><font style="color:#231f20;font-size:12pt;">&#8221;).</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">Should</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">termination</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">occur</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">after</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">first</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">twelve</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">(12)</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">months</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">employment,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">the lump sum Severance payment will</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">be increased from nine</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">(9)</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">months of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">Annual Salary</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">to twelve</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 0pt 10pt;"><font style="color:#231f20;">(12)</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">months of</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">Annual </font><font style="color:#231f20;letter-spacing:-0.1pt;">Salary.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:107.95pt;margin:0pt 5.7pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.15pt;text-indent:0pt;white-space:nowrap;">(b)</font><font style="color:#333133;font-size:12pt;">COBRA.</font><font style="color:#333133;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">Consistent</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">with</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">terms</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">COBRA</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">and</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">Company&#8217;s health</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">insurance</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">plan,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">Company</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">shall</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">provide</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">a</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">taxable</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">lump</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">sum</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">payment</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">equal to</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">12</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">months</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">monthly</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">COBRA</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">premium</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">would</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">be</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">required</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">to</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">pay</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">to</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">continue the group health coverage in effect on the Date of Termination (which monthly amount shall be based on the premium for the first month of COBRA coverage), which payment shall be made regardless of whether the Employee elects COBRA continuation coverage (the &#8220;</font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;">COBRA </font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;letter-spacing:-0.1pt;">Payment</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;">&#8221;).</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.5pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:107.95pt;margin:0pt 5.8pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.15pt;text-indent:0pt;white-space:nowrap;">(c)</font><font style="color:#231f20;font-size:12pt;">the Employee will be entitled to receive the Severance and the COBRA Payments referenced in Section 5.4 and on the terms of Section 5.4 within thirty (30) calendar days of the Date of Termination provided the Employee has satisfied the following &#8220;</font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;">Severance</font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;">Conditions</font><font style="color:#231f20;font-size:12pt;">&#8221;:</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">(1)</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">has</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">resigned</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">from</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">all</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">officer</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">and</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">director</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">positions</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">the Employee may</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">have held with the Company, if</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">requested</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">by</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">Company; (2)</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee has returned all material Company property in the Employee&#8217;s possession; (3) the Employee has materially complied with the Employee&#8217;s obligations under the EIACNA and continues to materially comply with such obligations; and (4) the Employee has executed a general release of all known and unknown claims that the Employee may have against the Company or persons affiliated with the Company on the Company&#8217;s standard form approved by the Company (the &#8220;</font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;">Release</font><font style="color:#231f20;font-size:12pt;">&#8221;) and the Release becomes effective and irrevocable.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:85.55pt;margin:0pt 5.7pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:22.5pt;text-indent:0pt;white-space:nowrap;">5.5</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Termination without Cause or Resignation for Good Reason within 2</u><font style="color:#231f20;font-size:12pt;"> </font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">months</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">prior</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">to</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">or</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">12</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">months</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">following</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">a</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Change</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">of</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Control</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:1.95pt;"> </font><font style="color:#231f20;font-size:12pt;">In</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">event</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">Company</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">terminates the Employee&#8217;s employment without Cause or the Employee resigns from employment with the</font></div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:11pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="height:15.3pt;left:47.54%;max-width:52.46%;position:absolute;top:639.55pt;width:28pt;z-index:-9223372036603117568;"><div style="height:15.3pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:28pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;width:100%;margin:0.5pt 0pt 0pt 1pt;"><font style="color:#231f20;">-</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">5</font><font style="color:#231f20;"> </font><font style="color:#231f20;letter-spacing:-0.5pt;">-</font></p></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.13%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:79.08%;border-width:0;"><div style="max-width:100%;padding-left:10.13%;padding-right:10.78%;position:relative;"><div style="min-height:68pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:48.35%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"></font><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 10.24</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:3.7pt 5.95pt 0pt 10pt;"><font style="color:#231f20;">Company for Good Reason, in each case within two (2) months prior to or twelve (12) months following a Change of Control, </font><font style="color:#323031;">then subject to the Employee&#8217;s satisfaction of the Severance Conditions (defined above), the Employee will be entitled to the </font><font style="color:#231f20;">Severance and the COBRA Payments</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">referenced</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">in</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">Section</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">5.4,</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">and 100%</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">then</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">unvested</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">portion of</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">Equity</font><font style="color:#231f20;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;">Awards will be accelerated and become vested.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:45.95pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">6.</td><td style="padding:0pt;"><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Tax </u><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Matters</u><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:85.55pt;margin:0pt 6pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:22.5pt;text-indent:0pt;white-space:nowrap;">6.1</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Withholding,</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Taxes,</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Deductions</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">All</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">forms</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">compensation</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">referred</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">to</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law as referenced in this Agreement.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:85.55pt;margin:0pt 5.8pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:22.5pt;text-indent:0pt;white-space:nowrap;">6.2</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Code Section 409A</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">The following provisions shall apply in connection with compliance with Code Section 409A:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:107.95pt;margin:0pt 5.75pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.15pt;text-indent:0pt;white-space:nowrap;">(a)</font><font style="color:#231f20;font-size:12pt;">The intent of the Parties is that payments and benefits under the Agreement that are</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">not exempt from Section 409A</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">Code shall be in compliance</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">with Code Section 409A (and regulations and guidance promulgated by the IRS and/or Treasury related to Code Section 409A) (together &#8220;</font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;">Code Section 409A</font><font style="color:#231f20;font-size:12pt;">&#8221;) to the maximum extent permitted, and the Agreement shall be interpreted to be in compliance therewith.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:107.95pt;margin:0pt 5.9pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.15pt;text-indent:0pt;white-space:nowrap;">(b)</font><font style="color:#231f20;font-size:12pt;">A</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">termination</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">employment</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">shall</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">not</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">be</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">deemed</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">to</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">have</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">occurred for purposes of any provision of this Agreement providing for the payment of any amounts or taxable benefits subject to Code Section 409A upon or following a termination of employment unless</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">such</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">termination</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">is</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">also</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">a</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">&#8220;separation</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">from</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">service&#8221;</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">within</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">meaning</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">Section</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">409A</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">of the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">Code,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">and</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">for</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">purposes</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">any</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">such</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">provision</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">this</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">Agreement,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">references</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">to</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">a</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">&#8220;termination,&#8221; &#8220;termination of employment,&#8221; &#8220;termination of the Term,&#8221; or like terms shall mean &#8220;separation from service.&#8221;</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">The determination of whether and when a separation from service has occurred shall be made in a manner consistent with, and based on the presumptions set forth in, U.S. Treasury Regulation Section 1.409A-1(h) or any successor provision thereto.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:107.95pt;margin:0pt 5.85pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.15pt;text-indent:0pt;white-space:nowrap;">(c)</font><font style="color:#231f20;font-size:12pt;">It is intended that each installment, if any, of any payments and benefits</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">provided</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">hereunder</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">to</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">which</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">Code</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">Section</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">409A</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">is</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">applicable</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">shall</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">be</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">treated</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">as</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">a</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">separate &#8220;payment&#8221;</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">for</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">purposes</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">Code</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">Section</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">409A.</font><font style="color:#231f20;font-size:12pt;letter-spacing:1.65pt;"> </font><font style="color:#231f20;font-size:12pt;">Neither</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">Company</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">nor</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">shall</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A of the Code.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:107.95pt;margin:0pt 5.8pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.15pt;text-indent:0pt;white-space:nowrap;">(d)</font><font style="color:#231f20;font-size:12pt;">In the event, as of the date of the Employee&#8217;s &#8220;separation from service,&#8221; the Employee is a &#8220;specified employee&#8221; (within the meaning of that term under Code Section 409A(a)(2)(B)), then with regard to any payment or the provision of any benefit that is subject</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">to</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">Code</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">Section</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">409A</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">(whether</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">under</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">this</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">Agreement,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">or</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">pursuant</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">to</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">any</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">other</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">agreement with, or plan, program, payroll practice of, the Company) and is due upon or as a result of the Employee&#8217;s</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">separation</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">from</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">service,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">such</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">payment</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">or</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">benefit</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">shall</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">not</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">be</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">made</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">or</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">provided,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">to</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">the extent making or providing such payment or benefit would result in additional taxes or interest under</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">Section</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">409A</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">Code,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">until</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">date</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">which</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">is</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">earlier</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">(A)</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">expiration</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">six (6)-month period measured from the date of such &#8220;separation from service,&#8221; and (B) the date of</font></div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:11pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="height:15.3pt;left:47.54%;max-width:52.46%;position:absolute;top:639.55pt;width:28pt;z-index:-9223372036603117568;"><div style="height:15.3pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:28pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;width:100%;margin:0.5pt 0pt 0pt 1pt;"><font style="color:#231f20;">-</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">6</font><font style="color:#231f20;"> </font><font style="color:#231f20;letter-spacing:-0.5pt;">-</font></p></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.13%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:79.08%;border-width:0;"><div style="max-width:100%;padding-left:10.13%;padding-right:10.78%;position:relative;"><div style="min-height:68pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:48.35%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"></font><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 10.24</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:3.7pt 0pt 0pt 10pt;"><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">Employee&#8217;s</font><font style="color:#231f20;letter-spacing:0.1pt;"> </font><font style="color:#231f20;">death</font><font style="color:#231f20;letter-spacing:0.1pt;"> </font><font style="color:#231f20;">and shall then</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">be</font><font style="color:#231f20;letter-spacing:0.05pt;"> </font><font style="color:#231f20;">paid</font><font style="color:#231f20;letter-spacing:0.15pt;"> </font><font style="color:#231f20;">in a</font><font style="color:#231f20;letter-spacing:0.05pt;"> </font><font style="color:#231f20;">single sum</font><font style="color:#231f20;letter-spacing:0.15pt;"> </font><font style="color:#231f20;">as</font><font style="color:#231f20;letter-spacing:0.05pt;"> </font><font style="color:#231f20;">soon</font><font style="color:#231f20;letter-spacing:0.1pt;"> </font><font style="color:#231f20;">as</font><font style="color:#231f20;letter-spacing:0.05pt;"> </font><font style="color:#231f20;">practicable on</font><font style="color:#231f20;letter-spacing:0.1pt;"> </font><font style="color:#231f20;">or</font><font style="color:#231f20;letter-spacing:0.1pt;"> </font><font style="color:#231f20;">after </font><font style="color:#231f20;letter-spacing:-0.25pt;">the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 10pt;"><font style="color:#231f20;">date</font><font style="color:#231f20;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;">such</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">payment</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">is</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">permitted to</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">be</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">made</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">under this</font><font style="color:#231f20;letter-spacing:-0.1pt;"> paragraph.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:107.95pt;margin:0pt 5.75pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.15pt;text-indent:0pt;white-space:nowrap;">(e)</font><font style="color:#231f20;font-size:12pt;">All reimbursements and in-kind benefits provided under this Agreement or otherwise to the Employee, to the extent such payments or benefits are subject to Code Section 409A, shall be made or provided in accordance with the requirements of Section 409A of the Code and specifically, consistent with Treasury Regulation Section 1.409A- </font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;">3(i)(1)(iv).</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:4.5pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:85.55pt;margin:0pt 5.65pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:22.5pt;text-indent:0pt;white-space:nowrap;">6.3</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Certain Excise Taxes</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">Notwithstanding anything to the contrary in this Agreement, if the Employee is a &#8220;disqualified individual&#8221; (as defined in Section 280G(c) of the Code), and the payments and benefits provided for in this Agreement, together with any other payments and benefits which the Employee has the right to receive from the Company or any of its affiliates, would constitute a &#8220;parachute payment&#8221; (as defined in Section 280G(b)(2) of the Code), then the payments and benefits provided for in this Agreement shall be either (a) reduced (but not below zero) so that the present value of such total amounts and benefits received by the Employee from the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">Company</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">and its affiliates will be one dollar</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">($1.00)</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">less than</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">three times the Employee&#8217;s</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">&#8220;base</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">amount&#8221;</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">(as</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">defined</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">in</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">Section</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">280G(b)(3)</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">Code)</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">and</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">so</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">that</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">no</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">portion of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">such</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">amounts</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">and</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">benefits</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">received</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">by</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">shall</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">be</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">subject</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">to</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">excise</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">tax</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">imposed by</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">Section</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">4999</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">Code</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">or</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">(b)</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">paid</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">in</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">full,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">whichever</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">produces</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">better</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">net</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">after-tax</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">position to the Employee (taking into account any applicable excise tax under Section 4999 of the Code and any other applicable taxes, and as determined by the Company and its advisors in their sole discretion).</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">Nothing in this </font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Section 6.3</u><font style="color:#231f20;font-size:12pt;"> shall require the Company to be responsible for, or have any</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">liability</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">or</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">obligation</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">with</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">respect</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">to,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee&#8217;s</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">excise</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">tax</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">liabilities</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">under</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">Section</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">4999 of the Code.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:35.95pt;margin:0pt 5.8pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">7.</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Indemnification</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">The</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">Company</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">will</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">agree</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">to</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">indemnify</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">with</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">respect to</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">activities</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">in</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">connection</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">with</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee&#8217;s</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">employment</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">hereunder</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">on</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">terms</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">and</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">conditions set forth in its standard Indemnification Agreement for officers and directors.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">The parties shall execute the Indemnification Agreement upon or shortly following the Employment Start Date.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:45.95pt;"></td><td style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;">8.</td><td style="padding:0pt;"><u style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</u><font style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 5.8pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">8.1</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">At Will Employment</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">Employment with the Company is for no specific period of time and, at all times, is &#8220;at will&#8221; in nature, which means the employment relationship can be terminated by either of the Employee or the Company for any reason, at any time.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">Any statements or representations to the contrary (and, indeed, any statements contradicting any provision in this Agreement) are superseded by this Agreement.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">Further, the Employee&#8217;s participation</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">in</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">any</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">stock</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">option</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">or</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">benefit</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">program</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">is</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">not</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">to</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">be</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">regarded</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">as</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">assuring</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee of continuing employment for any particular period of time.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 5.95pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">8.2</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Notices</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">Any notice or other communication required or permitted hereunder shall be in writing and shall be delivered via email, as follows:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 10pt;"><font style="color:#231f20;">if</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">to</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">Company,</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;letter-spacing:-0.25pt;">to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:4.5pt 0pt 0pt 154.05pt;"><font style="color:#231f20;">Jill</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">Thompson</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;">Quigley, [*]</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:9pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="height:15.3pt;left:47.54%;max-width:52.46%;position:absolute;top:639.55pt;width:28pt;z-index:-9223372036603117568;"><div style="height:15.3pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:28pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;width:100%;margin:0.5pt 0pt 0pt 1pt;"><font style="color:#231f20;">-</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">7</font><font style="color:#231f20;"> </font><font style="color:#231f20;letter-spacing:-0.5pt;">-</font></p></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.13%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:79.08%;border-width:0;"><div style="max-width:100%;padding-left:10.13%;padding-right:10.78%;position:relative;"><div style="min-height:68pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:48.35%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"></font><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 10.24</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:3.7pt 0pt 0pt 10pt;"><font style="color:#231f20;">if</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">to</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">Employee, </font><font style="color:#231f20;letter-spacing:-0.25pt;">to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0.05pt 130.5pt 0pt 122.35pt;"><font style="color:#231f20;">Edgar</font><font style="color:#231f20;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;">Cale</font>,<font style="letter-spacing:-0.25pt;"> </font><font style="letter-spacing:-0.1pt;text-decoration-color:#3953a4;">[*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:4.5pt 0pt 0pt 10pt;"><font style="color:#231f20;">Any</font><font style="color:#231f20;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;">party</font><font style="color:#231f20;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;">may</font><font style="color:#231f20;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;">change</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">its</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">address</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">for</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">notice</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">hereunder</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">by</font><font style="color:#231f20;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;">notice</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">to</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">other</font><font style="color:#231f20;letter-spacing:0.1pt;"> </font><font style="color:#231f20;">party</font><font style="color:#231f20;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;letter-spacing:-0.1pt;">hereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 5.7pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">8.3</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Entire</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">This</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">Agreement</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">contains</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">entire</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">agreement</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">between the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">parties</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">with</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">respect</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">to</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">subject</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">matter</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">hereof</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">and</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">supersedes</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">all</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">prior</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">agreements</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">(including but not limited to prior employment agreements and incentive plans and agreements), written or oral,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">with</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">respect</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">thereto,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">however,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">terms</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">any</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">benefit</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">plans</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">shall</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">remain</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">in</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">force</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">and</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">effect.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:76.55pt;margin:0pt 5.9pt 0pt 5.45pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.05pt;text-indent:0pt;white-space:nowrap;">8.4</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Background Check</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">Employment under this Agreement is conditioned upon satisfactory verification of criminal, education, driving and/or employment background.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 5.85pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">8.5</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Waivers</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">and</u><u style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Amendments</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">This</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">Agreement</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">may</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">be</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">amended,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">superseded, canceled, renewed or extended, and the terms and conditions hereof may be waived, only by a written instrument signed by the parties or, in the case of a waiver, by the party waiving compliance.</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">No</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">delay</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">on</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">part</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">any</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">party</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">in</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">exercising</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">any</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">right,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">power</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">or</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">privilege</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">hereunder shall operate as a waiver thereof nor shall any waiver on the part of any party of any such right, power or privilege hereunder, nor any single or partial exercise of any right, power or privilege hereunder,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">preclude</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">any</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">other or</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">further exercise</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">thereof</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">or</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">exercise</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">of any</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">other</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">right, power or privilege hereunder.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 5.8pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">8.6</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania (without giving effect to the choice of law provisions thereof).</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 5.75pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">8.7</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Assignment</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">This Agreement, and any rights and obligations hereunder, may not be assigned by the Employee and may be assigned by the Company only to a successor by</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">merger</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">or</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">purchasers</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">substantially</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">all</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">assets</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">Company</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">or</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">its</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">affiliates;</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">provided, however,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">that</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">this</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">Agreement</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">shall</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">inure</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">to</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">benefit</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">and</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">may</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">be</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">enforced</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">by</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">Employee&#8217;s heirs and legal representatives.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 6pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">8.8</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">This Agreement may be executed in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 5.85pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">8.9</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Headings</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">The</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">headings</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">in</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">this</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">Agreement</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">are</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">for</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">reference</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">purposes</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">only and shall not in any way affect the meaning or interpretation of this Agreement.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 6pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">8.10</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">No Presumption against Interest</u><font style="color:#231f20;font-size:12pt;">. This Agreement has been negotiated, drafted, edited and reviewed by the respective parties, and therefore, no provision of this Agreement shall be construed against any party as being drafted by said party.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72.1pt;margin:0pt 5.7pt 0pt 5.45pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:40.5pt;text-indent:0pt;white-space:nowrap;">8.11</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">No Duty to Mitigate</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">The Employee shall not be required to mitigate damages with respect to the termination of the Employee&#8217;s employment under this Agreement by seeking</font><font style="color:#231f20;font-size:12pt;letter-spacing:1.75pt;"> </font><font style="color:#231f20;font-size:12pt;">other</font><font style="color:#231f20;font-size:12pt;letter-spacing:1.8pt;"> </font><font style="color:#231f20;font-size:12pt;">employment</font><font style="color:#231f20;font-size:12pt;letter-spacing:1.85pt;"> </font><font style="color:#231f20;font-size:12pt;">or</font><font style="color:#231f20;font-size:12pt;letter-spacing:1.8pt;"> </font><font style="color:#231f20;font-size:12pt;">otherwise,</font><font style="color:#231f20;font-size:12pt;letter-spacing:1.85pt;"> </font><font style="color:#231f20;font-size:12pt;">and</font><font style="color:#231f20;font-size:12pt;letter-spacing:1.85pt;"> </font><font style="color:#231f20;font-size:12pt;">there</font><font style="color:#231f20;font-size:12pt;letter-spacing:1.75pt;"> </font><font style="color:#231f20;font-size:12pt;">shall</font><font style="color:#231f20;font-size:12pt;letter-spacing:1.85pt;"> </font><font style="color:#231f20;font-size:12pt;">be</font><font style="color:#231f20;font-size:12pt;letter-spacing:1.85pt;"> </font><font style="color:#231f20;font-size:12pt;">no</font><font style="color:#231f20;font-size:12pt;letter-spacing:1.85pt;"> </font><font style="color:#231f20;font-size:12pt;">offset</font><font style="color:#231f20;font-size:12pt;letter-spacing:1.9pt;"> </font><font style="color:#231f20;font-size:12pt;">against</font><font style="color:#231f20;font-size:12pt;letter-spacing:1.85pt;"> </font><font style="color:#231f20;font-size:12pt;">amounts</font><font style="color:#231f20;font-size:12pt;letter-spacing:1.85pt;"> </font><font style="color:#231f20;font-size:12pt;">due</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font></div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:11pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="height:15.3pt;left:47.54%;max-width:52.46%;position:absolute;top:639.55pt;width:28pt;z-index:-9223372036603117568;"><div style="height:15.3pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:28pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;width:100%;margin:0.5pt 0pt 0pt 1pt;"><font style="color:#231f20;">-</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">8</font><font style="color:#231f20;"> </font><font style="color:#231f20;letter-spacing:-0.5pt;">-</font></p></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.13%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:79.08%;border-width:0;"><div style="max-width:100%;padding-left:10.13%;padding-right:10.78%;position:relative;"><div style="min-height:68pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:48.35%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"></font><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 10.24</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:3.7pt 5.9pt 0pt 5.45pt;"><font style="color:#231f20;">Employee under this Agreement on account of subsequent employment except as specifically provided in this Agreement. Additionally, amounts owed to the Employee under this Agreement shall</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">not</font><font style="color:#231f20;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;">be</font><font style="color:#231f20;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;">offset</font><font style="color:#231f20;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;">by</font><font style="color:#231f20;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;">any</font><font style="color:#231f20;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;">claims</font><font style="color:#231f20;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">Company</font><font style="color:#231f20;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;">may</font><font style="color:#231f20;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;">have</font><font style="color:#231f20;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;">against</font><font style="color:#231f20;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;">Employee,</font><font style="color:#231f20;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;">and</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">the</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">Company&#8217;s obligation to make the payments provided for in this Agreement, and otherwise to perform its obligations hereunder, shall not be affected by any other circumstances, including, without limitation, any counterclaim, recoupment, defense or other right which the Company may have against the Employee or others.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="margin-top:0.05pt;"></div><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-indent:72pt;margin:0pt 5.75pt 0pt 0pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:50.45pt;text-indent:0pt;white-space:nowrap;">8.12</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Dispute Resolution</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">If any dispute arises out of or relates to this Agreement, or the breach thereof, the Employee and the Company</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">agree to promptly negotiate in good</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">faith</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">to</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">resolve</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">such</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">dispute.</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">If</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">dispute</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">cannot</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">be</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">settled</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">by</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">parties</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.75pt;"> </font><font style="color:#231f20;font-size:12pt;">through</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.7pt;"> </font><font style="color:#231f20;font-size:12pt;">negotiation, the Employee and the Company agree to try</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">in good faith to settle the dispute by</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;font-size:12pt;">mediation under the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">then-current</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">employment</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">mediation</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">rules</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">American</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">Arbitration</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">Association</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.6pt;"> </font><font style="color:#231f20;font-size:12pt;">(&#8220;</font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;">AAA</font><font style="color:#231f20;font-size:12pt;">&#8221;) before</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">resorting</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">to</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">arbitration</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">or</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">any</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">other</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">dispute</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">resolution</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">procedure. If</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">parties</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">are</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">unable</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">to settle the dispute by mediation as provided in the preceding sentence within 30 days of a written demand for mediation, any Arbitrable Claims (as defined herein) shall be resolved by binding arbitration before one (1) arbitrator in accordance with the AAA&#8217;s</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">then-current rules for the resolution of employment disputes (currently the Employment Arbitration Rules and Mediation </font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;">Procedures,</font><font style="color:#231f20;font-size:12pt;"> </font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;">which</font><font style="color:#231f20;font-size:12pt;"> </font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;">may</font><font style="color:#231f20;font-size:12pt;"> </font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;">be</font><font style="color:#231f20;font-size:12pt;"> </font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.1pt;">accessed</font><font style="color:#231f20;font-size:12pt;"> </font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;">at </font><u style="color:#3953a4;font-size:12pt;text-decoration-color:#3953a4;text-decoration-line:underline;text-decoration-style:solid;">https://www.adr.org</u><u style="color:#3953a4;font-size:12pt;text-decoration-color:#3953a4;text-decoration-line:underline;text-decoration-style:solid;">/</u><u style="color:#3953a4;font-size:12pt;text-decoration-color:#3953a4;text-decoration-line:underline;text-decoration-style:solid;">sites/defa</u><u style="color:#3953a4;font-size:12pt;text-decoration-color:#3953a4;text-decoration-line:underline;text-decoration-style:solid;">u</u><u style="color:#3953a4;font-size:12pt;text-decoration-color:#3953a4;text-decoration-line:underline;text-decoration-style:solid;">lt/files/Emplo</u><u style="color:#3953a4;font-size:12pt;text-decoration-color:#3953a4;text-decoration-line:underline;text-decoration-style:solid;">ymen</u><u style="color:#3953a4;font-size:12pt;text-decoration-color:#3953a4;text-decoration-line:underline;text-decoration-style:solid;">tRules_Web2119.pdf</u><font style="color:#231f20;font-size:12pt;">). The arbitration shall be held in Philadelphia County, Pennsylvania, or such other location to which the parties mutually agree. The arbitrator shall among other things determine the validity, scope, interpretation and enforceability of this arbitration clause. The award shall be a reasoned award and rendered within 30</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">days</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">conclusion</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">arbitration</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">hearing.</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">The</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">decision</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">arbitrator</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">shall</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">be</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">final</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;font-size:12pt;">and binding and judgment upon the award rendered may be entered in any court having jurisdiction thereof. &#8220;</font><font style="color:#231f20;font-size:12pt;font-style:italic;font-weight:bold;">Arbitrable Claims</font><font style="color:#231f20;font-size:12pt;">&#8221; refers to any claim, controversy or dispute arising out of or relating to the Employee&#8217;s employment with the Company and the termination thereof, including, but not limited to, claims arising from or related to this Agreement or the breach thereof, or claims for unpaid</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">wages,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">wrongful</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">termination,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">torts,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">stock</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">or</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">stock</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">options</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">or</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;font-size:12pt;">other</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">ownership</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;font-size:12pt;">interest</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">in</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.2pt;"> </font><font style="color:#231f20;font-size:12pt;">the Company, and/or discrimination (including harassment) based upon any federal, state, or local ordinance,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;font-size:12pt;">statute,</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">regulation</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">or</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">constitutional</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.5pt;"> </font><font style="color:#231f20;font-size:12pt;">provision.</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;font-size:12pt;">Notwithstanding</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.55pt;"> </font><font style="color:#231f20;font-size:12pt;">foregoing</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.65pt;"> </font><font style="color:#231f20;font-size:12pt;">provisions of this Section 8.12, either party may seek injunctive relief from a court of competent jurisdiction located</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">in Philadelphia County, Pennsylvania, in the</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">event of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">a</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">breach or</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">threatened breach</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">of any covenant contained in the EIACNA.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10.5pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:72.1pt;margin:0pt 5.9pt 0pt 5.45pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:40.5pt;text-indent:0pt;white-space:nowrap;">8.13</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Attorney Fees</u><font style="color:#231f20;font-size:12pt;">. The Company will reimburse you for up to $5,000.00 for your reasonable attorney fees in reviewing and negotiating</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;font-size:12pt;">this</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">Agreement, upon receipt of</font><font style="color:#231f20;font-size:12pt;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;font-size:12pt;">one or more letters from counsel that you have incurred at least the amount sought, and with payment to be made within 10 days after receipt of the letter.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:justify;text-indent:71.95pt;margin:0pt 5.8pt 0pt 10pt;"><font style="color:#231f20;display:inline-block;font-size:12pt;min-width:36.1pt;text-indent:0pt;white-space:nowrap;">8.14</font><u style="color:#231f20;font-size:12pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Authorization to Work</u><font style="color:#231f20;font-size:12pt;">.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">Because of employer regulations adopted in the Immigration Reform and Control Act of 1986, within three (3) business days of the Employment Start Date, the Employee must present documentation demonstrating that the Employee has authorization to work in the United States.</font><font style="color:#231f20;font-size:12pt;letter-spacing:2pt;"> </font><font style="color:#231f20;font-size:12pt;">The obligations set forth in this Agreement are contingent upon satisfaction of this requirement.</font></div><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:justify;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:11pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="height:15.3pt;left:47.54%;max-width:52.46%;position:absolute;top:639.55pt;width:28pt;z-index:-9223372036603117568;"><div style="height:15.3pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:28pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;width:100%;margin:0.5pt 0pt 0pt 1pt;"><font style="color:#231f20;">-</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">9</font><font style="color:#231f20;"> </font><font style="color:#231f20;letter-spacing:-0.5pt;">-</font></p></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.13%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:79.08%;border-width:0;"><div style="max-width:100%;padding-left:10.13%;padding-right:10.78%;position:relative;"><div style="min-height:91pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:48.35%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"></font><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 10.24</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:6.5pt 130.5pt 0pt 134.45pt;"><font style="color:#231f20;">[Remainder</font><font style="color:#231f20;letter-spacing:-0.3pt;"> </font><font style="color:#231f20;">of</font><font style="color:#231f20;letter-spacing:-0.35pt;"> </font><font style="color:#231f20;">Page</font><font style="color:#231f20;letter-spacing:-0.1pt;"> </font><font style="color:#231f20;">Intentionally</font><font style="color:#231f20;letter-spacing:-0.4pt;"> </font><font style="color:#231f20;">Left</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;letter-spacing:-0.1pt;">Blank]</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;text-align:center;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:11pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><div style="height:15.3pt;left:47.54%;max-width:52.46%;position:absolute;top:616.55pt;width:28pt;z-index:-9223372036603117568;"><div style="height:15.3pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:28pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;width:100%;margin:0.5pt 0pt 0pt 1pt;"><font style="color:#231f20;">-</font><font style="color:#231f20;letter-spacing:-0.05pt;"> </font><font style="color:#231f20;">10</font><font style="color:#231f20;"> </font><font style="color:#231f20;letter-spacing:-0.5pt;">-</font></p></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.13%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:79.08%;border-width:0;"><div style="max-width:100%;padding-left:10.13%;padding-right:10.78%;position:relative;"><div style="min-height:68pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:48.35%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"></font><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 10.24</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;min-height:21.85pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:35.95pt;margin:3.79pt 0pt 0pt 10pt;"><font style="color:#231f20;">IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first above written.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:13pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:9.19pt 0pt 0pt 15.4pt;"><b style="color:#231f20;font-weight:bold;letter-spacing:-0.1pt;">EMPLOYEE:</b><font style="display:inline-block;width:160.08pt;"></font><b style="color:#231f20;font-weight:bold;letter-spacing:-0.1pt;">COMPANY:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.5pt 0pt 0pt 0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 247.25pt;"><font style="color:#231f20;">Passage</font><font style="color:#231f20;letter-spacing:-0.45pt;"> </font><font style="color:#231f20;">BIO,</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;letter-spacing:-0.2pt;">Inc.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="height:0pt;position:relative;width:100%;"><div style="height:21pt;left:3.61%;max-width:96.39%;position:absolute;top:0.85pt;width:126.75pt;z-index:251664384;"><div style="height:21pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:126.75pt;"><div style="height:calc(100% - 7.18pt);left:0pt;position:relative;text-indent:0pt;top:0pt;padding:3.59pt 7.19pt 3.59pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;width:100%;margin:0pt;"><font style="font-size:12pt;">/s/ Edgar Cale</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.1pt 0pt 0pt 0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p><div style="position:relative;white-space:nowrap;"><div style="display:inline-block;padding-right:11.51%;vertical-align:top;white-space:normal;width:24.88%;"><div style="height:0pt;position:relative;width:100%;"><div style="left:3.18%;max-width:87.21%;position:absolute;top:7.6pt;width:180pt;z-index:251658240;"><div style="left:0pt;padding-bottom:0pt;position:relative;width:180pt;"><img src="pasg-20221231xex10d24003.jpg" alt="Graphic" style="width:180pt;"></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:7.84pt 0pt 0pt 15.4pt;"><font style="color:#231f20;">Edgar</font><font style="color:#231f20;letter-spacing:-0.25pt;"> </font><font style="color:#231f20;letter-spacing:-0.2pt;">Cale</font></p></div><div style="display:inline-block;padding-left:11.51%;vertical-align:top;white-space:normal;width:52.1%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;border-bottom:1px solid #000000;margin:0pt;"><font style="color:#231f20;letter-spacing:-0.25pt;">By: </font><font style="font-size:12pt;">/s/ Jill Quigley</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 117.15pt 0pt 15.4pt;"><font style="color:#231f20;letter-spacing:-0.1pt;">Name: </font><font style="color:#231f20;">Jill</font><font style="color:#231f20;letter-spacing:-0.15pt;"> </font><font style="color:#231f20;letter-spacing:-0.1pt;">Quigley</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.05pt 54.15pt 0pt 15.4pt;"><font style="color:#231f20;letter-spacing:-0.1pt;">Title: Chief Executive Officer</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.55pt 0pt 0pt 0pt;"><font style="font-size:6.5pt;visibility:hidden;">&#8203;</font></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p><div style="position:relative;white-space:nowrap;"><div style="display:inline-block;padding-right:0.24%;vertical-align:top;white-space:normal;width:47.43%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.3pt 0pt 0pt 15.4pt;"><font style="color:#231f20;letter-spacing:-0.1pt;">Date:</font><u style="color:#231f20;letter-spacing:-0.1pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">  9/8/2019</u><u style="color:#231f20;text-decoration-color:#221e1f;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">                                     </u></p></div><div style="display:inline-block;padding-left:0.24%;vertical-align:top;white-space:normal;width:52.1%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0.05pt 0pt 0pt 0pt;"><font style="font-size:12.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 15.4pt;"><font style="color:#231f20;letter-spacing:-0.1pt;">Date: </font><u style="color:#231f20;letter-spacing:-0.1pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">9/10/2019</u><u style="color:#231f20;text-decoration-color:#221e1f;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;">                                                 </u><u style="color:#231f20;text-decoration-color:#221e1f;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:13.45pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><font style="font-size:0pt;visibility:hidden;">&#8203;</font></p></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.13%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:79.08%;border-width:0;"><div style="max-width:100%;padding-left:10.13%;padding-right:10.78%;position:relative;"><div style="min-height:68pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:48.35%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"></font><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 10.24</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:0pt 162.8pt 0pt 160.79pt;">AMENDMENT TO EMPLOYMENT<b style="font-weight:bold;letter-spacing:-0.7pt;"> </b>AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;line-height:1.28;padding-left:0.1pt;text-align:center;text-indent:-0.1pt;margin:3.84pt 162.8pt 0pt 160.79pt;"><font style="margin-left:0pt;margin-right:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;text-align:justify;text-indent:35.95pt;margin:0pt 6.7pt 0pt 5pt;">This Amendment (the &#8220;<b style="font-weight:bold;">Amendment</b>&#8221;) to the Employment Agreement dated September 10, 2019 (the &#8220;<b style="font-weight:bold;">Employment Agreement</b>&#8221;), by and between Passage BIO, Inc. (the &#8220;<b style="font-weight:bold;">Company</b>&#8221;) and Edgar Cale (the &#8220;<b style="font-weight:bold;">Employee</b>&#8221;) will become effective on the day immediately prior to the first date on which the Registration Statement on Form S-1 for the initial public offering of the Company&#8217;s common stock is declared effective by the United States Securities and Exchange Commission.<font style="letter-spacing:2pt;"> </font>All capitalized terms not otherwise defined herein shall have the same meanings as set forth in the Employment Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 183.55pt 0pt 181.8pt;"><u style="letter-spacing:-0.1pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RECITALS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:8.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;text-align:justify;text-indent:35.95pt;margin:4.55pt 6.9pt 0pt 5pt;"><b style="font-weight:bold;">WHEREAS</b>,the Company and the Employee desire to amend certain terms of the Employment Agreement with respect to the treatment of the Employee&#8217;s equity awards upon certain terminations of service in the manner reflected herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;text-align:justify;text-indent:35.95pt;margin:0.05pt 7pt 0pt 5pt;"><b style="font-weight:bold;">NOW,</b><b style="font-weight:bold;letter-spacing:-0.05pt;"> </b><b style="font-weight:bold;">THEREFORE</b>,<font style="letter-spacing:-0.05pt;"> </font>in<font style="letter-spacing:-0.3pt;"> </font>consideration<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>mutual<font style="letter-spacing:-0.1pt;"> </font>covenants<font style="letter-spacing:-0.05pt;"> </font>contained<font style="letter-spacing:-0.05pt;"> </font>herein<font style="letter-spacing:-0.2pt;"> </font>and<font style="letter-spacing:-0.05pt;"> </font>other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-top:7.84pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.65pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">to</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.6pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Employment</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.4pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">:</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-1.15pt;"> </b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Section</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">5.5</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Employment</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Agreement</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">is</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.55pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">amended</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and restated in its entirety as follows:</font></td><td style="width:6.9pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.05pt 0pt 0pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;text-align:justify;margin:0pt 6.65pt 0pt 59pt;">&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Termination without Cause or Resignation for Good Reason within 2 months prior to, or 12</u> <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">months following a Change in Control</u>. In the event of a termination of employment resulting from (i) a termination by the Company of the Employee&#8217;s employment for any reason other than Cause, death or disability (as defined in Section 22(e)(3) of the Code) or (ii) the Employee&#8217;s voluntary resignation of employment for Good Reason, in each case within 2 months prior to, or 12 months following a Change in Control, then subject to the Employee&#8217;s satisfaction of the Severance Conditions (defined above), the Employee will be entitled to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:59pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the payments and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">benefits</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">referenced in Section 5.4; provided that &#8220;Severance&#8221;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">shall also be</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">deemed</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">include</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">100%</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Employee&#8217;s</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">then-current</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">target</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">bonus</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">for</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">year</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">which such termination of employment occurs; and</font></td><td style="width:6.8pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:59pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">each of the Employee&#8217;s then-outstanding unvested options to purchase shares of the Company common stock as well as any and all other stock-based awards granted to the </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">Employee,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">including</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">but not limited</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">to</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">stock</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">bonus awards, restricted stock,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">restricted stock </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">units</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">stock</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">appreciation</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">rights</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Awards</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;)</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">shall</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">accelerate</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.65pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">become</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">fully</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.7pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">vested</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.6pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and, if</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">applicable,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">exercisable</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">forfeiture</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">restrictions</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">thereon</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">shall</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">lapse,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">effective</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">as of the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">date</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">such</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">termination</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">service;</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</i><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><i style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:italic;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</i><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">that</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">grant</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">agreement</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.4pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">for</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the purpose</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">any</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Award</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">that</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">would</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">otherwise</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">vest</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">upon</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">satisfaction</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.15pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">performance</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">metrics or factors other than the continuation of the Employee&#8217;s employment with the Company </font></td><td style="width:6.7pt;"></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.13%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:79.08%;border-width:0;"><div style="max-width:100%;padding-left:10.13%;padding-right:10.78%;position:relative;"><div style="min-height:68pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:48.35%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"></font><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 10.24</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:59pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">(the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;">Performance-Based Awards</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">&#8221;) may provide for alternative treatment in lieu of the foregoing and, absent any such treatment in the grant agreement, the vesting acceleration provided for herein shall be deemed to have been met based on the achievement of the Performance-Based Award at the greater of &#8220;at target&#8221; or, if determinable, actual </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">performance.</font></td><td style="width:6.7pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;text-align:justify;margin:3.59pt 6.7pt 0pt 59pt;">Notwithstanding<font style="letter-spacing:-0.2pt;"> </font>anything<font style="letter-spacing:-0.2pt;"> </font>to<font style="letter-spacing:-0.05pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>contrary<font style="letter-spacing:-0.2pt;"> </font>herein<font style="letter-spacing:-0.05pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>in<font style="letter-spacing:-0.05pt;"> </font>any<font style="letter-spacing:-0.2pt;"> </font>equity<font style="letter-spacing:-0.2pt;"> </font>plan<font style="letter-spacing:-0.05pt;"> </font>or<font style="letter-spacing:-0.05pt;"> </font>any<font style="letter-spacing:-0.15pt;"> </font>applicable<font style="letter-spacing:-0.05pt;"> </font>award agreement<font style="letter-spacing:-0.3pt;"> </font>pursuant<font style="letter-spacing:-0.3pt;"> </font>to<font style="letter-spacing:-0.35pt;"> </font>Awards<font style="letter-spacing:-0.3pt;"> </font>granted<font style="letter-spacing:-0.35pt;"> </font>thereunder,<font style="letter-spacing:-0.35pt;"> </font>if<font style="letter-spacing:-0.45pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>successor<font style="letter-spacing:-0.3pt;"> </font>or<font style="letter-spacing:-0.3pt;"> </font>acquiring<font style="letter-spacing:-0.5pt;"> </font>corporation<font style="letter-spacing:-0.5pt;"> </font>(if any)<font style="letter-spacing:-0.5pt;"> </font>of<font style="letter-spacing:-0.6pt;"> </font>the<font style="letter-spacing:-0.5pt;"> </font>Company<font style="letter-spacing:-0.65pt;"> </font>refuses<font style="letter-spacing:-0.5pt;"> </font>to<font style="letter-spacing:-0.55pt;"> </font>assume,<font style="letter-spacing:-0.5pt;"> </font>convert,<font style="letter-spacing:-0.65pt;"> </font>replace<font style="letter-spacing:-0.5pt;"> </font>or<font style="letter-spacing:-0.6pt;"> </font>substitute<font style="letter-spacing:-0.6pt;"> </font>the<font style="letter-spacing:-0.65pt;"> </font>Employee&#8217;s<font style="letter-spacing:-0.65pt;"> </font>unvested Awards<font style="letter-spacing:-0.45pt;"> </font>in<font style="letter-spacing:-0.35pt;"> </font>connection<font style="letter-spacing:-0.35pt;"> </font>with<font style="letter-spacing:-0.5pt;"> </font>a<font style="letter-spacing:-0.25pt;"> </font>Change<font style="letter-spacing:-0.35pt;"> </font>in<font style="letter-spacing:-0.5pt;"> </font>Control,<font style="letter-spacing:-0.35pt;"> </font>each<font style="letter-spacing:-0.35pt;"> </font>of<font style="letter-spacing:-0.3pt;"> </font>the<font style="letter-spacing:-0.35pt;"> </font>Employee&#8217;s<font style="letter-spacing:-0.35pt;"> </font>unvested<font style="letter-spacing:-0.5pt;"> </font>Awards<font style="letter-spacing:-0.45pt;"> </font>that are not assumed, converted, replaced or substituted, shall accelerate and become fully vested and if applicable, exercisable, effective immediately prior to the Change in Control.<font style="letter-spacing:2pt;"> </font>With respect to Performance-Based Awards, the grant agreement may provide for alternative treatment in lieu of the foregoing and, absent any such treatment in the grant agreement, the vesting acceleration provided for herein shall be deemed to have been met based on the achievement of<font style="letter-spacing:-0.15pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>Performance-Based<font style="letter-spacing:-0.05pt;"> </font>Award<font style="letter-spacing:-0.15pt;"> </font>at<font style="letter-spacing:-0.1pt;"> </font>the<font style="letter-spacing:-0.05pt;"> </font>greater<font style="letter-spacing:-0.15pt;"> </font>of<font style="letter-spacing:-0.15pt;"> </font>&#8220;at<font style="letter-spacing:-0.1pt;"> </font>target&#8221;<font style="letter-spacing:-0.15pt;"> </font>or,<font style="letter-spacing:-0.2pt;"> </font>if<font style="letter-spacing:-0.15pt;"> </font>determinable, actual performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Other Amendment</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Except as expressly set forth above, all of the terms and conditions of the Employment Agreement remain in full force and effect, including but not limited to provisions regarding the at-will nature of Employee&#8217;s services to the Company.</font></td><td style="width:6.9pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.44pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing</b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;letter-spacing:-0.1pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Law</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">This</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Amendment</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">shall</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.05pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">be</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">governed</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.2pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">by</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.25pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">and</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">construed in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">accordance</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">with</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">the</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">law</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of the Commonwealth of Pennsylvania without regard to conflicts of law principles thereof.</font></td><td style="width:6.75pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.34pt 0pt 0pt 0pt;"><font style="font-size:11.5pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.28;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:5pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</b><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">.</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:1.85pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">This</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Amendment</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">may</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">be</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">executed</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">in</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.5pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">two</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">or</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">more</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">counterparts,</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">each</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.35pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">of</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.3pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">which</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">shall</font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;letter-spacing:-0.45pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">be deemed an original and such counterparts together shall constitute one and the same instrument.</font></td><td style="width:6.9pt;"></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.15pt 0pt 0pt 0pt;"><font style="font-size:13.5pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 183.6pt 0pt 181.8pt;">(<i style="font-style:italic;">Signature</i><i style="font-style:italic;letter-spacing:-0.25pt;"> </i><i style="font-style:italic;">Pages</i><i style="font-style:italic;letter-spacing:-0.2pt;"> </i><i style="font-style:italic;letter-spacing:-0.1pt;">Follow</i><font style="letter-spacing:-0.1pt;">)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.13%;margin-right:10.78%;margin-top:30pt;page-break-after:always;width:79.08%;border-width:0;"><div style="max-width:100%;padding-left:10.13%;padding-right:10.78%;position:relative;"><div style="min-height:68pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="display:inline-block;width:48.35%;">&#9;</font></font><font style="display:block;height:1px;left:0pt;position:absolute;width:100%;z-index:0;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"></font><font style="margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT 10.24</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;min-height:43.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.27;margin:0pt;"><font style="font-size:12pt;">I</font>N<font style="letter-spacing:2pt;"> </font><font style="font-size:12pt;">W</font>ITNESS<font style="letter-spacing:2pt;"> </font><font style="font-size:12pt;">W</font>HEREOF<font style="font-size:12pt;">,</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">each</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">of</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">parties</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">has</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">executed</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">this</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">Amendment</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">to</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">the</font><font style="font-size:12pt;letter-spacing:2pt;"> </font><font style="font-size:12pt;">Employment</font><font style="font-size:12pt;letter-spacing:4pt;"> </font><font style="font-size:12pt;">Agreement as of the day and year first above written.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0.3pt 0pt 0pt 0pt;"><font style="font-size:14pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:9.19pt 0pt 0pt 15.4pt;">PASSAGE<b style="font-weight:bold;letter-spacing:-0.35pt;"> </b>BIO,<b style="font-weight:bold;letter-spacing:-0.3pt;"> </b><b style="font-weight:bold;letter-spacing:-0.2pt;">INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><div style="height:0pt;position:relative;width:100%;"><div style="height:21pt;left:10.07%;max-width:89.93%;position:absolute;top:5.85pt;width:126.75pt;z-index:251666432;"><div style="height:21pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:126.75pt;"><div style="height:calc(100% - 7.18pt);left:0pt;position:relative;text-indent:0pt;top:0pt;padding:3.59pt 7.19pt 3.59pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;width:100%;margin:0pt;"><font style="font-size:12pt;">/s/ Jill Quigley</font></p></div></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.4pt 0pt 0pt 0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin:0pt 287.15pt 0pt 23pt;">By: <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:169.75pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u> Name:<font style="letter-spacing:2pt;"> </font>Jill Quigley</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:12.55pt;margin:0pt 0pt 0pt 23pt;"><font style="display:inline-block;text-indent:0pt;width:34.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:-0.1pt;">Title:</font></font>Chief<font style="letter-spacing:-0.2pt;"> </font>Operating<font style="letter-spacing:-0.35pt;"> </font><font style="letter-spacing:-0.1pt;">Officer</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0.05pt 0pt 0pt 275.05pt;"><font style="letter-spacing:-0.1pt;margin-left:0pt;margin-top:9.2pt;visibility:hidden;">&#8203;</font></p><div style="height:40.5pt;left:0pt;margin-left:auto;position:relative;top:0pt;width:207pt;z-index:-9223372036603113472;"><div style="height:40.15pt;left:0pt;padding-bottom:0.35pt;position:relative;top:0pt;width:205.95pt;"><div style="height:40.15pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:205.95pt;"><div style="height:100%;left:0pt;position:relative;text-indent:0pt;top:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;width:100%;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;width:100%;margin:0.25pt 0pt 0pt 0pt;"><font style="font-size:9.5pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;width:100%;margin:0pt;">Name:<font style="letter-spacing:2.5pt;"> </font>Edgar<font style="letter-spacing:-0.1pt;"> </font><font style="letter-spacing:-0.2pt;">Cale</font></p></div></div></div></div><div style="height:0pt;position:relative;width:100%;"><div style="height:21pt;left:57.64%;max-width:42.36%;position:absolute;top:19.5pt;width:126.75pt;z-index:251668480;"><div style="height:21pt;left:0pt;padding-bottom:0pt;position:relative;top:0pt;width:126.75pt;"><div style="height:calc(100% - 7.18pt);left:0pt;position:relative;text-indent:0pt;top:0pt;padding:3.59pt 7.19pt 3.59pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;width:100%;margin:0pt;"><font style="font-size:12pt;">/s/ Edgar Cale</font></p></div></div></div></div><div style="height:0pt;position:relative;width:100%;"><div style="height:1.45pt;left:57.57%;max-width:42.43%;position:absolute;top:42.05pt;width:200.9pt;z-index:251660288;"><div style="height:1.45pt;left:0pt;padding-bottom:0pt;position:relative;width:200.9pt;"><img src="pasg-20221231xex10d24007.jpg" alt="Graphic" style="height:1.45pt;width:200.9pt;"></div></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0.05pt 0pt 0pt 275.05pt;"><b style="font-size:12pt;font-weight:bold;letter-spacing:-0.1pt;">EMPLOYEE</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0.07;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.13%;margin-right:10.78%;margin-top:30pt;page-break-after:avoid;width:79.08%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.26
<SEQUENCE>3
<FILENAME>pasg-20221231xex10d26.htm
<DESCRIPTION>EX-10.26
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/6/2023 10:28:23 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">EXHIBIT 10.26</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">November 17, 2022</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">VIA E-MAIL</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Monika Maria Toernsen</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">[*]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Re: Terms of Transition and Separation of Employment</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Dear Maria:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">This letter confirms the agreement (&#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Agreement</font><font style="font-size:11pt;">&#8221;) between you and Passage Bio, Inc. (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Company</font><font style="font-size:11pt;">&#8221;) concerning the terms of your transition and separation from your employment with the Company. If you agree to the terms outlined herein, please sign and return this Agreement to me in the timeframe outlined below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">Separation of Employment: As we have discussed, and as a result of a reduction in force, your role with the Company has been eliminated and your employment with the Company will end. The Company has discussed with you the terms under which it is willing to continue your employment through the Transition Period, as described further below.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">Separation Date and Transition Period: Your last day of employment with the Company will be December 31, 2022 (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Separation Date</font><font style="font-size:11pt;">&#8221;). Between now and the Separation Date (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Transition Period</font><font style="font-size:11pt;">&#8221;), you are expected to perform the responsibilities and duties of your position as directed by the CEO, to facilitate a smooth and effective transitioning of your duties, responsibilities, and knowledge relative to your position, and to provide such other services as the Company may reasonably request of you (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Transition Services</font><font style="font-size:11pt;">&#8221;). During the Transition Period, you will continue to receive your regular base salary and to be eligible to participate in benefits the Company customarily offers to its employees, including Company-sponsored health care coverage and equity vesting to the fullest extent allowed by the applicable governing policies, agreements, or plans.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">Separation Benefits: At the end of the Transition Period, and in exchange for your agreement to the general release and waiver of claims and covenant not to sue set forth in Exhibit A (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Release</font><font style="font-size:11pt;">&#8221;), to be signed no earlier than the Separation Date, and your other promises and obligations outlined herein, the Company agrees to provide you with the following separation benefits: (1) a lump sum payment in the total gross amount of four hundred thirty nine thousand eight hundred seventy five dollars ($439,875), less applicable state and federal payroll deductions, which is equal to twelve (12) months of your base salary (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Severance</font><font style="font-size:11pt;">&#8221;); (2) a lump sum payment in the total gross amount of one hundred fifty eight thousand three hundred fifty five dollars ($158,355), less applicable state and federal payroll deductions, which is equal to your target bonus for the 2022 calendar year after applying a 90% multiplier reflecting both Company and individual performance for 2022 (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">2022 Bonus</font><font style="font-size:11pt;white-space:pre-wrap;">&#8221;); (3) a lump sum payment in the total gross amount of twelve thousand one hundred ten dollars and one cent ($12,110.04), less applicable state and federal payroll deductions, which is equal to 12 months of the monthly  COBRA premium you be would be required to pay to continue the group health coverage in effect on the Separation Date (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">COBRA Payment</font><font style="font-size:11pt;">&#8221;); and (4) the Company agrees to extend your post-employment deadline to exercise any unexercised vested options to purchase shares of</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;">the Company&#8217;s common stock to the twelve (12) month anniversary of the Separation Date ((1)-(4) collectively, the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Separation Benefits</font><font style="font-size:11pt;">&#8221;). You expressly agree and acknowledge that the Separation Benefits fully satisfy any and all severance obligations the Company may owe to you under the Employment Agreement that you entered into with the Company, dated July 18, 2021, or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">Final Pay: On the Separation Date, the Company will pay you for all wages, salary, transportation and commuting allowance, bonuses, commissions, reimbursable expenses previously submitted by you, accrued vacation (if applicable and up to a maximum amount of 160 hours) and any similar payments due you from the Company as of your termination of employment. By signing below, you acknowledge that the Company does not owe you any other amounts, except as otherwise may become payable under this Agreement and the Release.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">Return of Company Property: You hereby warrant to the Company that, on or before the Separation Date (or sooner if requested by the Company), you will return to the Company all property or data of the Company of any type whatsoever that has been in your possession or control.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">6.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">Post-Employment Obligations: You hereby acknowledge that: (a) you continue to be bound by the attached Employee Invention Assignment, Confidentiality, and Non-Competition Agreement (Exhibit B hereto) (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Restrictive Covenant Agreement</font><font style="font-size:11pt;">&#8221;); (b) as a result of your employment with the Company, you have had access to the Company&#8217;s proprietary and/or confidential information, and you will continue to hold all such information in strictest confidence and not make use of it on behalf of anyone; and (c) you must, and by your signature below confirm that you shall, deliver to the Company, no later than the Separation Date, all documents and data of any nature containing or pertaining to such information, and not take with you, or otherwise retain in any respect, any such documents or data or any reproduction thereof.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">7.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">Arbitration: Except for any claim for injunctive relief arising out of a breach of a party&#8217;s obligations to protect the other&#8217;s proprietary information, the parties agree to arbitrate, in Philadelphia, Pennsylvania through JAMS, any and all disputes or claims arising out of or related to the validity, enforceability, interpretation, performance or breach of this Agreement, whether sounding in tort, contract, statutory violation or otherwise, or involving the construction or application or any of the terms, provisions, or conditions of this Agreement. Any arbitration may be initiated by a written demand to the other party. The arbitrator&#8217;s decision shall be final, binding, and conclusive. The parties further agree that this Agreement is intended to be strictly construed to provide for arbitration as the sole and exclusive means for resolution of all disputes hereunder to the fullest extent permitted by law. The parties expressly waive any entitlement to have such controversies decided by a court or a jury.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">8.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">Attorneys&#8217; Fees: If any action is brought to enforce the terms of this Agreement, the prevailing party will be entitled to recover its reasonable attorneys&#8217; fees, costs and expenses from the other party, in addition to any other relief to which the prevailing party may be entitled.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">9.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">Mutual Non-disparagement: You agree that you will not, directly or indirectly, disparage or make negative remarks regarding the Company or its current executive officers, directors, and employees, including, but not limited to, any statement posted on social media (including online company review sites) or otherwise on the Internet, whether or not made anonymously or with attribution. The Company agrees that its current executive officers, for so long as they are employed by or providing services to the Company, will not, directly or indirectly, disparage or</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;">make negative remarks regarding you, including, but not limited to, any statement posted on social media or otherwise on the Internet, whether or not made anonymously or with attribution. Nothing in this section shall prohibit you or the Company (including its executive officers) from providing truthful information in response to a subpoena or other legal process.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">10.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">Complete and Voluntary Agreement: This Agreement, together with all exhibits attached hereto and any agreements between you and the Company concerning your equity interests in the Company, constitute the entire agreement between you and the Company with respect to the subject matter hereof and supersedes all prior negotiations and agreements, whether written or oral, relating to such subject matter. You acknowledge that neither the Company nor its agents or attorneys have made any promise, representation or warranty whatsoever, either express or implied, written or oral, which is not contained in this Agreement for the purpose of inducing you to execute the Agreement, and you acknowledge that you have executed this Agreement in reliance only upon such promises, representations and warranties as are contained herein, and that you are executing this Agreement voluntarily, free of any duress or coercion.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">11.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">Severability: The provisions of this Agreement are severable, and if any part of it is found to be invalid or unenforceable, the other parts shall remain fully valid and enforceable. Specifically, should a court, arbitrator, or government agency conclude that a particular claim may not be released as a matter of law, it is the intention of the parties that the general release, the waiver of unknown claims and the covenant not to sue above shall otherwise remain effective to release any and all other claims provided that the Company timely provides you with all payments and other consideration described in this Agreement.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">12.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">Modification; Counterparts; Electronic/PDF Signatures: It is expressly agreed that this Agreement may not be altered, amended, modified, or otherwise changed in any respect except by another written agreement that specifically refers to this Agreement, executed by authorized representatives of each of the parties to this Agreement. This Agreement may be executed in any number of counterparts, each of which shall constitute an original and all of which together shall constitute one and the same instrument. Execution of an electronic or PDF copy shall have the same force and effect as execution of an original, and a copy of a signature will be equally admissible in any legal proceeding as if an original.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">13.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">Governing Law: This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:18pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">14.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">Effective Date: This Agreement is effective on the date it is signed by both parties (the &#8220;</font><font style="font-size:11pt;font-style:italic;font-weight:bold;">Effective Date</font><font style="font-size:11pt;">&#8221;).</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">If you agree to abide by the terms outlined in this Agreement, please sign and return it to me by Monday, November 21, 2022. I wish you the best in your future endeavors.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-size:11pt;font-style:italic;">[Remainder of page left blank intentionally; signature page follows]</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;"><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Sincerely,</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">PASSAGE BIO, INC.</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">By: /s/ Will Chou</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Will Chou, MD</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Chief Executive Officer</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">READ, UNDERSTOOD AND AGREED</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Monika Toernsen</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Monika Maria Toernsen</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Date: </font></p></td><td style="vertical-align:top;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">11/18/2022</font></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">EXHIBIT A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">RELEASE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">[*]</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>pasg-20221231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/6/2023 10:28:22 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><font style="font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-height:12.0pt;margin:0pt 0pt 10pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';">We consent to the incorporation by reference in the registration statements (Nos. 333-236734, 333-253922, 333-258000, and 333-263252) on Form S-8 and the registration statement (No. 333-253955) on Form S-3 of our report dated March 6, 2023, with respect to the financial statements of Passage Bio, Inc. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">/s/ KPMG LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Philadelphia, Pennsylvania</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">March 6, 2023</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>pasg-20221231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/6/2023 10:28:22 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THE SECURITIES EXCHANGE ACT OF 1934,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">I, William Chou, certify that:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this Annual Report on Form 10-K of Passage Bio, Inc.;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></td></tr></table><div style="margin-top:8pt;"></div><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td colspan="2" style="vertical-align:bottom;width:48.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 6, 2023</p></td><td colspan="2" style="vertical-align:bottom;width:49.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ William Chou</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:49.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">William Chou</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:49.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Chief Executive Officer</i></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:49.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>pasg-20221231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/6/2023 10:28:43 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) OF</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">THE SECURITIES EXCHANGE ACT OF 1934,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">I, Simona King, certify that:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">I have reviewed this Annual Report on Form 10-K of Passage Bio, Inc.;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </font></td></tr></table><div style="margin-top:8pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:47.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 6, 2023</p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Simona King</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Simona King</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Chief Financial Officer</i></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Financial Officer and Principal Accounting Officer)</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>pasg-20221231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/6/2023 10:28:44 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">I, William Chou, Chief Executive Officer of Passage Bio, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Annual Report on Form&#160;10-K&#160;of the Company for the fiscal year ended December 31, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:48.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:3.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March 6, 2023&#160;</p></td><td colspan="2" style="vertical-align:top;width:51.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;/s/ William Chou</p></td></tr><tr><td style="vertical-align:top;width:48.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:51.92%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">William Chou</p></td></tr><tr><td style="vertical-align:top;width:48.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:top;width:51.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Chief Executive Officer</i></p></td></tr><tr><td style="vertical-align:top;width:48.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td><td colspan="2" style="vertical-align:top;width:51.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>pasg-20221231xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/6/2023 10:28:45 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">I, Simona King, Chief Financial Officer of Passage Bio, Inc. (the &#8220;Company&#8221;), do hereby certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the Annual Report on Form&#160;10-K&#160;of the Company for the fiscal year ended December 31, 2022 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 10pt 0pt;">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:48.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dated: March 6, 2023</p></td><td colspan="2" style="vertical-align:top;width:50.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Simona King</p></td></tr><tr><td style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:50.84%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Simona King</p></td></tr><tr><td style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Chief Financial Officer</i></p></td></tr><tr><td style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Financial Officer and</i></p></td></tr><tr><td style="vertical-align:top;width:49.15%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:50.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">Principal Accounting Officer)</i></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>pasg-20221231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pasg-20221231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %E \L# 2(  A$! Q$!_\0
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M)H_X7=X/_P"@M_Y+R_\ Q-?+%%']KU>R#^UZO\J/J?\ X7=X/_Z"W_DO+_\
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M,1:S$@#V"5@+^UA\,">?$1_\ KC_ .-U\^LH8$$ @\$'H?:O$/%VAG0-;F@
M(@?]Y$3W4_X8(KT\%F#Q$G&:U/F,[XGQV70C5HP3CUN?>7_#6'PP'_,QG_P"
MN/\ XW1_PUA\,?\ H8__ "2N/_C=?GGQBC/M7L<WD?&_\1%S#_GW'\3]#/\
MAK#X8_\ 0Q_^2-Q_\;H_X:P^&/\ T,?_ ))7'_QNOSSS["C/L*.;R#_B(N8?
M\^X_C_F?H9_PUA\,/^AB/_@%<?\ QNC_ (:P^&/_ $,?_DE<?_&Z_/,<^E&?
MI1SKL"\1,P_Y]Q_'_,_0S_AK#X8_]#'_ .25Q_\ &Z/^&L/AC_T,?_DC<?\
MQNOSSS[4<>E'-Y!_Q$7,/^?<?Q_S/T,_X:P^&/\ T,?_ ))7'_QNC_AJ_P"&
M/_0QG_P"N/\ XW7YZ8!]*" #THYUV#_B(F8?\^X_B?H7_P -7?##_H8C_P"
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M ,%EY_\ &:/^&[O@?_T.H_\ !9>?_&:_(?;QG-)1H'^LV)_E1^O/_#=WP/\
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M=]&U>UNKF\OKG5(Q_9\%O<Z?>:+=V$:W09B[EKF>4S2<D-)%^[(V_,3C'N%
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M[=UC=;M'CW BW VE#RREB?N<AAD^\$4FGC5-->>>R.B^7$#%\A<2>41EE W
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ML["\M;"QL-*BEVRRB-)#O(+#EMK-D@#CMQ5J*:/H</@\-5PRE.=IN_X'E_\
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MH#,"-HP2:T=%;IG4\M@]545CYF&,\\#UK;\-^#M:\6&^_LC39[X6-NUU<M&
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M?^#BW_\ BZ/^%T_#_P#Z'GPU_P"#BW_^+IV%='8"/ QUI=O&*X[_ (73\/\
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M_P#\718+H[+GVHY]JXW_ (73\/\ _H>?#7_@XM__ (NC_A=/P_\ ^AY\-?\
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M@@XP:6:62XF>661II)&+/)(Q+,2<DDGZFO:_^&:C_P!##_Y)'_XNE_X9J/\
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MJ)U*:LO-'PBS%B2>I.<TG;I7V]_P[1;_ **$/_!-_P#;Z/\ AVDP_P":A_\
ME'_^WUY?U6JNA]&N%\S_ )/Q1\08/I1@^E?;_P#P[2;_ **'_P"4?_[?1_P[
M2;_HH?\ Y1__ +?1]6J]A_ZKYG_)^*/B')]#2G![<U]N_P##M)O^BA_^4?\
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MOH^K5>Q/^J^9_P GXH^(,'TI<&OM[_AVDW_10_\ RC__ &^C_AVB_P#T4/\
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M_P#?I?\ "C^R;'_GSM_^_2_X5,+A&&0<BC[3'C.X8]0:!61#_9-C_P ^=O\
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MYU]<)"F?]YB!2%*48*\G9&OBC%<#_P +_P#AG_T4#PQ_X.+?_P"+I?\ A?\
M\-/^B@>&/_!Q;_\ Q=*Z[G/]:P__ #\7WH[W%&!Z5P/_  O_ .&G_10/#'_@
MXM__ (NC_A?_ ,-/^B@>&/\ P<6__P 71=!]:H?SK[T=]@>@HP/2N!_X7_\
M#3_HH'AC_P '%O\ _%T?\+_^&G_10/#'_@XM_P#XNBZ#ZU0_G7WH[[ ]*,5P
M/_"__AG_ -% \,?^#BW_ /BZ4?'[X:$@#X@>&"3V&L6__P 71==P^M4/YU]Z
M.]Q1BN('QR^'9Z>.?#G_ (-8/_BZ/^%X_#S_ *'GPY_X-8/_ (NBZ[C^M4/Y
MU]Z.WP*,#T%<1_PO'X>?]#SX<_\ !K!_\71_PO'X>?\ 0\^'/_!K!_\ %T77
M</K-#^=?>CM\#THQ7$?\+Q^'G_0\^'/_  :P?_%T?\+Q^'G_ $//AS_P:P?_
M !=%UW#ZS0_G7WH[? ]!1@>E<1_PO'X>?]#SX<_\&L'_ ,71_P +Q^'G_0\^
M'/\ P:P?_%T77</K-#^=?>CM]HSG%&!Z5Q'_  O'X>?]#SX<_P#!K!_\71_P
MO'X>?]#QX<_\&L'_ ,71=!]9H?SK[T=O@>E&*XC_ (7E\//^AX\.?^#6#_XN
MC_A>7P\_Z'CPY_X-8/\ XNBZ#ZS0_G7WG;XHQ7$?\+R^'G_0\>'/_!K!_P#%
MT?\ "\OAYW\<^'!_W%8/_BZ+H/K-#^=?>=OBC%<5'\;?A],<)XW\.N?1=5@/
M_L]2_P#"XO O_0XZ#_X,H?\ XJBZ']9H_P Z^\[#%&*X_P#X7%X%_P"AQT'_
M ,&4/_Q5'_"XO O_ $..@_\ @RA_^*HNA?6:/\Z^\[#%&*X__A<7@7_H<=!_
M\&4/_P 51_PN+P+_ -#CH/\ X,H?_BJ+H/K-'^=?>CL,48KC_P#A<7@7_H<=
M!_\ !E#_ /%4?\+B\"_]#CH/_@RA_P#BJ+H/K-'^=?>=ABC%<?\ \+B\"_\
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MH^W6W_/Q%_WV* )L48J'[=;?\_$7_?8H^W6W_/Q%_P!]B@"; HP/2H?MMO\
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M (8$^%?_ #PU7_P./^%'U2IW#_5+,/YE]Y^:''H/RHX]!^5?I?\ \,"?"O\
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M_ T?_$T?\._OA=Z:S_X&C_XFCZI4[A_JEF7\R^\_-;%&*_2G_AW]\+O36?\
MP-'_ ,31_P ._OA=Z:S_ .!H_P#B:/JE3N'^J69?S+[S\UL48K]*/^'?WPO_
M .HS_P"!H_\ B:1O^"?OPO8<'61[B]'_ ,34_5*G<7^J69?S+[S\V,>] ..U
M?I+_ ,.^/AC_ ,]=;_\  Q?_ (BD_P"'?'PQ_P">VM_^!B__ !%'U6H+_5/,
MOYE]Y^;>_P! *3>?05^DO_#OCX8_\]M;_P# Q?\ XBC_ (=\?#'_ )[:W_X&
M+_\ $4?5:@?ZIYGW7WGYM;S[4;SZ"OTE_P"'?'PQ_P">VM_^!B__ !%'_#OC
MX8_\]M;_ / Q?_B*/JM0/]4\S[K[S\VMY]!2[^/2OTD_X=\?#'_GMK?_ (&+
M_P#$4#_@GU\,1QYVM_\ @8O_ ,12^JU1_P"JF9+JOO\ ^ ?.G[ ^/^%JZZ1V
MT5__ $?#7W?WKC?A3^RMX-^#VO7&K:"^HO=W-LUJXNK@.NPLK< *.<J.:]6&
M@6N/XQ_P+_ZU>E1@Z<.5GZ3DF"JX#"*E6>ISGXFC\371_P!@6OJ__?7_ -:C
M^P+7U?\ [Z_^M6Y[YSGXF@'%='_8%KZO_P!]?_6I1X?M3W?_ +Z_^M0!SF>E
M.7DUT/\ 8%KC^/\ [ZI1H=KG^/\ .@#G@*DK>_L.V'9_SH_L2W])/SH P@,4
MZMS^Q;?_ *:?G1_8UOZ/^= &*.M.'4UL_P!D0#^_^=']D0_[?YT 9 '>O#O#
M7'[87C'_ +%JV_\ 1BU]$'2H5'\>/J*X[3_A)IVG_%#5/&Z75P]_?V$>GR0-
MCRU1&# CC.>*Z*-2,.;FZHX,71E5Y.7H[GAOP6^&7AGQ;XQ^+6I:UHUIJMPW
MB*:S!NXPX2,1HQVYZ$EN2/0>E8'P"^%_AGQ)\$/%5WK&EPZI>"XOK..YNQYD
MD,,(*Q)&QY0*!QC'-?2O@3X66'@2Z\27%M=3W+:YJ;ZG*LN (W954JN.V%[^
MM4O /P:TWX?^#-1\.6EY<W-M>W%S</--M#*9OO 8';M7=+%K6S[?@>3'+FN5
MN*^U?Y['B?A?QCH]O^R=X*D\6:5/XI^W?9[*VTM/F>[G$Q6%.2!_"O7CC&#G
M%<]JT=]IGQM^%,[_  YM_A\TFH30B:UNK:1KJ,Q?,C+">@]_6O=#^SCH3_";
M2? LE]?>1I3K-9:E"XCN89E<ND@(& 03658?LS*/&'A_Q)K?C77O$>I:)*9;
M7[<T8C4$$%=JJ!SW/4X'-7#$45S/U[]3*K@\3)0BEM;73I^)S_@_PIH_C[X^
M_%"Z\26%OJT^EM965C%>H)4MX6AWL55N!N8GGK\OUJG^SQH.F>$/B[\:=.TE
M$M--M[FR*11\I$#'(S*/0 D\=L4?&Y/!GA3XIC4[GQ/XB^'VO7EDJRZM86Y:
MTOD!($;$JREU^G (YR*L?LD>"'L-2^(&OH-2FT36;N%;"[U@-]IO5C5O,G8,
M <.SG''3V JG-.C*5W9I:$TX\N*A3:5TVV^NQPWPIU,#X@>&],FT"3P:\MQ)
M='6]4-S)-KTA9BPC=L*N_P"\5<]\*.*[+7_!&C>-/VR%CUJPAU&WM/"D<\<%
MPH>/?]H=02IX. 37K=I\/;OP_K5L+"\%YH)F\Q].OU\S[.>H>%SRI![?EBKD
M?PPLD^*TGCI;F<WSZ4NE&VX\L()"X;USDUY]&M&#E)*S:M\SZ''4)UE3@Y\\
M8M6OO;S]#RSP+HMEX%_:'\>Z5H-FECI]QH=GJ/V*W&V+[1OD7*J. 2%':O%O
MA=X.U_XB?"+4)%^'6D>)[C79;MY_$-YJB)=-,SNN_P"9"R%3C ![5]A6GPWL
M[+XD:CXR6YF:\OM/BTY[<@>6J1NS!AWR=QKS_4/V9(XKO5E\.>,]?\)Z/JL[
MSW6E:;(GDEW)WF/<I,6<GA"/Y8[8XJ&O>RU]#P:N7U7:RTN]-.I>\-Z=\2O#
M7PH\*:?8PZ1>^)K6W2#4#JUQ(4PJX!5HP=QX'6J/Q7D\5S?LY^.CXNM]*MM0
M^P2A%TF21XO+VCJ7 .<YX^E>N^'/#\'AS1+'2X9)YX;2!($DNI3+(P48!9CR
MQ]ZI>/\ P=!X]\':OX>NII+:VU*W:W>:$#>@/<9XS7!&JG-.W6YZ[PTO9-)N
M]K6OIM8R?@/S\%? 7_8!L/\ TG2N\K"\%>&XO!WA/1M!@D::WTRSALHY)/O,
ML:! 3COA:W:QFU*3:.RC%PIQC+=(****@V"BBB@!,@4M1RPK,A5L[3Z$C^55
M_P"RX/1_^_C?XT 7**I_V7!Z/_W\;_&C^RX/1_\ OXW^- %RBJ?]EP>C_P#?
MQO\ &C^RX/1_^_C?XT 7**I_V7!Z/_W\;_&C^RX/1_\ OXW^- %RBJ?]EP>C
M_P#?QO\ &C^RX/1_^_C?XT 7**I_V7!Z/_W\;_&C^RX/1_\ OXW^- %RBJ?]
MEP>C_P#?QO\ &C^RX/1_^_C?XT 7**I_V7!Z/_W\;_&C^RX/1_\ OXW^- %R
MBJ?]EP>C_P#?QO\ &C^RX/1_^_C?XT 7**I_V7!Z/_W\;_&C^RX/1_\ OXW^
M- %RBJ?]EP>C_P#?QO\ &C^RX/1_^_C?XT 7**I_V7!Z/_W\;_&C^RX/1_\
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MT?\ [^-_C0!;VBC;53^RX/1_^_C?XT?V7!Z/_P!_&_QH M;:7:*J?V7!Z/\
M]_&_QH_LN#T?_OXW^- %O;2;157^RX/1_P#OXW^-']EP>C_]_&_QH M%?2DV
MU6_LN#T?_OXW^-']EP>C_P#?QO\ &@"UM^M&WZU5_LN#T?\ [^-_C1_9<'H_
M_?QO\: +6WZT;?K57^RX/1_^_C?XT?V7!Z/_ -_&_P : +6WZT;?K57^RX/1
M_P#OXW^-']EP>C_]_&_QH M;?K1M^M5?[+@]'_[^-_C1_9<'H_\ W\;_ !H
MM;?K1M^M5?[+@]'_ ._C?XT?V7!Z/_W\;_&@"UM^M&WZU5_LN#T?_OXW^-']
MEP>C_P#?QO\ &@"UM^M&WZU5_LN#T?\ [^-_C1_9<'H__?QO\: +.RC::K?V
M7!Z/_P!_&_QH_LN#T?\ [^-_C0!:"TFSWJM_9<'H_P#W\;_&C^RX/1_^_C?X
MTK 6MI]:3:?6JW]EP>C_ /?QO\:/[+@]'_[^-_C18"SL/K2[3ZU5_LN#T?\
M[^-_C1_9<'H__?QO\:+ 6=I]:-M5O[+@]'_[^-_C1_9<'H__ '\;_&BPBT <
MTH&*J?V7!Z/_ -_&_P :/[+@]'_[^-_C3&7**I_V7!Z/_P!_&_QH_LN#T?\
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M1_PLCQ=_T-&M?^#&;_XJCZY'L'^NE'_GT_O/V;\U?[U'FK_>K\9/^%D>+O\
MH:-:_P#!C-_\51_PLCQ=_P!#1K7_ (,9O_BJ/KD>P?ZZ4?\ GT_O/V:\U/[X
M_.@2I_?'YU^,O_"Q_%W_ $-&M?\ @QF_^*H_X6/XN'_,T:U_X,9O_BJ?UR'8
MG_72C_SZ?WG[.><OJ/SH\U/[P_.OQG_X6AXQ_P"AJUK _P"HA+_\51_PM#QE
M_P!#5K/_ (,)O_BJ7UR/8K_72C_SZ?WG[,>:G]X?G1YJ?WA^=?C/_P +/\9?
M]#5K/_@PE_\ BJ/^%G^,O^AJUG_P82__ !5/ZY'L'^NE#_GT_O/V8\U/[P_.
MCS4_O#\Z_&?_ (6?XR_Z&K6?_!A+_P#%4?\ "S_&7_0U:S_X,)?_ (JCZY'L
M'^NE#_GT_O/V8\U/[P_.CS4_O#\Z_&?_ (6?XR_Z&K6?_!A+_P#%4?\ "S_&
M7_0U:S_X,)?_ (JE]<CV#_72A_SZ?WG[,>:G]X?G2>:O]X?G7XT?\+/\9?\
M0U:S_P"#"7_XJC_A:'C'_H:M9_\  ^;_ .*H^N1[!_KI0_Y]/[S]E_-7^\/S
MH\U?[R_G7XT?\+/\8_\ 0UZU_P"!\O\ \51_PL_QC_T->M_^!\O_ ,51]<CV
M#_72A_SZ?WG[+^:O]X?G1YJ_WA7XT?\ "SO&/_0UZW_X,)?_ (J@?$_QD/\
MF:];_P#!A+_\53^MQ["_UUH?\^G]Y^RWG+_>%'G+_>%?C8GQ4\9H<CQ7K0/_
M %_R_P#Q5/'Q:\:X_P"1LUK_ ,#I?\:7UR/8?^NE#_GT_P #]D?.7^\*/-7^
M\*_&[_A;7C7_ *&W6O\ P.E_QH_X6UXU_P"AMUK_ ,#I?\:/KD>P?ZZT/^?3
M_ _9'SE_O"CSE_O"OQN_X6UXU_Z&W6O_  .E_P :/^%M>-?^AMUK_P #I?\
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MC_A<?CG_ *&_6O\ P.D_QI_7(=@_USP__/I_@?L;O'J*-X]17XY?\+C\<_\
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M ..4?\.UO^I\/_@M'_QRON' HP*/84NP?ZM99_SZ_/\ S/A[_AVM_P!3X?\
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M\J\_Y^(O^_)_^*H\J\_Y^(O^_)_^*JW10!4\J\_Y^(O^_)_^*H\J\_Y^(O\
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MM44 </>QW O;C,L9_>-SY9]?]ZH=D_\ SUC_ .^#_C5V_P#^/VX_ZZ-_.H*
M(=D__/6/_O@_XT;)_P#GK'_WP?\ &IJ* (=D_P#SUC_[X/\ C1LG_P">L?\
MWP?\:FHH AV3_P#/6/\ [X/^-&R?_GK'_P!\'_&IJ* (=D__ #UC_P"^#_C1
MLG_YZ1_]\'_XJIJ* .AT:*Z_LV'$\8'/_+(GN?\ :JYY5U_S\1?]^?\ [*H]
M%_Y!D/X_S-6V()/>@"OY=W_S\1?]^3_\51Y=W_S\0_\ ?D__ !56>E)D4K@5
M_+N_^?B'_OR?_BJ7RKS_ )^(O^_)_P#BJGS1NH @\J\_Y^(O^_)_^*H\J\_Y
M^(O^_)_^*JQN]Z-WO3 K^5=][B+_ +\G_P"*H\JZ_P"?B+_OS_\ 95/N'K2$
MT 0^5=]KB+_OS_\ 94>5>?\ /Q%_WY/_ ,54Z-Q_]:G \4 5O*O/^?B+_OR?
M_BJ/*O/^?B+_ +\G_P"*JUFC- %7RKS_ )^(O^_)_P#BJ/*O/^?B+_OR?_BJ
MM9HS0!5\J\_Y^(O^_)_^*H\J\_Y^(O\ OR?_ (JK6:,T 5?*O/\ GXB_[\G_
M .*H\J\_Y^(O^_)_^*JUFC- %7RKS_GXB_[\G_XJCRKS_GXB_P"_)_\ BJM9
MHS0!5\J\_P"?B+_OR?\ XJCRKS_GXB_[\G_XJK6:,T 5?*O/^?B+_OR?_BJ/
M*O/^?B+_ +\G_P"*JUFC- %7RKS_ )^(O^_)_P#BJ/*O/^?B+_OR?_BJM9HS
M0!5\J\_Y^(O^_)_^*H\J\_Y^(O\ OR?_ (JK6:,T 5?*O/\ GXB_[\G_ .*H
M\J\_Y^(O^_)_^*JUFC- %7RKS_GXB_[\G_XJCRKS_GXB_P"_)_\ BJM9HS0!
M5\J\_P"?B+_OR?\ XJCRKS_GXB_[\G_XJK6:,T 5?*O/^?B+_OR?_BJ/*O/^
M?B+_ +\G_P"*JUFC- %7RKS_ )^(O^_)_P#BJ/*O/^?B+_OR?_BJM9HS0!5\
MJ\_Y^(O^_)_^*H\J\_Y^(O\ OR?_ (JK6:,T 5?*O/\ GXB_[\G_ .*H\J\_
MY^(O^_)_^*JUFC- %7RKS_GXB_[\G_XJCRKS_GXB_P"_)_\ BJM9HS0!5\J\
M_P"?B+_OR?\ XJCRKS_GXB_[\G_XJK6:,T 5?*O/^?B+_OR?_BJ/*O/^?B+_
M +\G_P"*JUFC- %7RKS_ )^(O^_)_P#BJ/*O/^?B+_OR?_BJM9HS0!5\J\_Y
M^(O^_)_^*H\J\_Y^(O\ OR?_ (JK6:,T 5?*O/\ GXB_[\G_ .*H\J\_Y^(O
M^_)_^*JUFC- %7RKS_GXB_[\G_XJCRKS_GXB_P"_)_\ BJM9HS0!5\J\_P"?
MB+_OR?\ XJCRKS_GXB_[\G_XJK6:,T 5?*O/^?B+_OR?_BJ/*O/^?B+_ +\G
M_P"*JUFC- %7RKS_ )^(O^_)_P#BJ/*O/^?B+_OR?_BJM9HS0!5\J\_Y^(O^
M_)_^*H\J\_Y^(O\ OR?_ (JK6:,T 5?*O/\ GXB_[\G_ .*H\J\_Y^(O^_)_
M^*JUFC- %7RKS_GXB_[\G_XJCRKS_GXB_P"_)_\ BJM9HS0!5\J\_P"?B+_O
MR?\ XJCRKS_GXB_[\G_XJK6:,T 10+,H/FN'/;:FW^IJ:DS2T %%%% !1110
M 4444 <=\8_'[_"OX4^+O&*60U%]"TNXU$6C2>6)C'&7V%L'&<8S@U\PR?M^
MZOI_@[Q%?ZCX/T6'5=,M=(OX_LWB#SM/,-_.L2B:?R08G0-N92AP!Z8)^F_C
M)X#;XI_"SQ;X-6^&F'7=+N-.%X8O-\@RH4W[,KNQG.,BO+_%G[)VD7GP$M_A
MYX5&C>$KR-].N)=5M-%0QW4]K)%)YDL*,F\R&/G+D_,>30!F^$?VOY_$?P4\
M6>-'\/V,^HZ-JIT6TM])U475EJMTSI'%]GN-BDHSR*,E/7 -7(OVL+AOAU\/
M?$$GAR*+4O$7BZV\(:EIOVS(TZX>Z:WE(?9\^QE) (7/M7.R_L3OXL2:#QGX
MHAU>QU77X=>UW3])TUM+M[TP6Q@@BB$4V^$ X=CN9F95Y&*K7?[#L^@Z/<:-
MX+\81^'M%M?%]CXQT6ROM/EU :?<P*/,1G>X#RI(R1MR1C#==V0 =5\;/VJ=
M4^&/B;Q+9:-X1A\0Z7X1TRWU?Q'=RZA]GD@AF=@JP1[&\QPJLY#%1C'.3BG^
M%_VHKWQ5\?M8\ V]OX3MM.TV\2U+W?B+9JMTC6L<XE@L_*/F)F4+G?V8]JR?
M''[)WB?X@WFK7-[\0;:U/BG2+?2/%B6NA!5OXX7<JUOF8FW8HY0Y,G'(Q71^
M(/V=M7\4?%+P[XAU3Q-I\GAWP]JBZMIVEVVAQP7BR*A1(WNP_P \:@GC8"<+
MD]Z />4;>,TZF1_=I] !2,VT<TM9OB&UO;_1KZVT^[6POI8)(X+MH_,$,A4A
M7VY&[!(.,C..M 'F?@;]H*T\6>,_&.CW=B-,L='CDNK"^\QI/[1MH9I;>YE5
M N1Y<T)4@9R'0C[U/A_:G^'$\/G)K%\81;1WV\Z'?@&U?.VY&8.8/E(,P_=J
M>&8$BN5T;]D;1/"4/AN;P]K.K6VH:7IUQI=Q/J6I7E_%<V\\!254AFG,<&Z4
M1R_NU RF,=,;D_P >;PY-I0UQ0TG@E/!_G?9#P54C[1C?[_<S_P*@#M?^%P>
M%?+D<ZH%$>K?V(X:WE!%WMW[,;,[2GSB3[A7YMV.:YJ^_::\%0^'-=U:RGU'
M4AI>GR:DL,.D7BF^@4[?-M6:$"XBW;<RP[T565F8*<UR-S\"KKQ%\;]2N;^2
MX7PDGA](FCV!4N-2EA>T:=&Y.Y+92O\ VU7TK<T_X#ZI<Z5:Z9XA\2V^H6NF
M^'KKP[IK6.G?9I$BGC2)YIB9'#OLBCP%"+G<<<@* =#I'Q_\)ZJ=#A,FIVM_
MJUF+^*QGT6]26&#>4,LRF$&*,,,&23:F"ISAU)A3]I+X?MIFKZD^N2VUAI=@
MVJS3W>G74 ELU.&N+??$OVF(<?O(=Z_,O/S+F#2_@U<RO*VN:O!>O<>&!X:N
M!96K6ZE-S_O5W2.5.U@,9/(SG' \Q^-'P \4:Q\'?$,,^I1^*=8TOP;?Z!H5
MCIFG_9GF,Z1!FE)D;?(PMX@ H10=QQR, ':_$#]I;1=,\&WVK^';E;B[TS6-
M)L;Z#5-.NH&CM[R\AA,RQNL;NK1O(8Y$W(Q7@M@BNFC^-VC:H?#DFCSH]KJ.
MMR:)<)J=O=65S;S);33E##)"'5]L.<2B-2IR&.5#<QK_ , M6\8WM_J>O>);
M:?5[BXT4QR6>FF&%+;3[X7@0H96)DD<R ON 4,N%X.;>J_L_IK7B.[U*XU@_
M9[GQ/_PD#VRV^&V'2GT\PAM_!._S-^/;;WH [?P7\4_#OQ$:[&@W=Q=I;JLG
MG26,\$,\;%@LD$DB*L\9*-B2(LO3GD9X_P .?'_3;7P#9Z_XL=[.2>ZOXG;3
M--NKF*&*WNY81++Y:R>4FV-2SR$+DGD=!O\ PF\#ZY\//#5AX=U#6[36-,TF
MR@T_3S!8&VF$42E%:5O,8.Y0(#M5!D$XYP/+O%_[*%SXE\)+H/\ PD&G3V_V
M/4[0#5='-W% UW=M<?:(8_.4),@;8'.3@<;<D$ ] B_:'\,Q^)_&.D7\>I:;
M%X96-[G4;C3+H6L@9 PV2>5L+$L%502TA/R!JGF_:&\#6VE1ZA/JEW;I)J']
ME"TFTF\2]%V8FE6!K4PB97:-=R*4&_*[<EESSWC+X!3^+)O%43:O:)I^NBQN
M/(NM.\\Q75IL,9<-)LEA;RU#Q,OS D;N:FTWX"0V5QX<N8D\/Z//I6OC6IH_
M#^AK8Q7(%I+;*A42,2W[W=O8MP,8'8 ZD_&/PS<>(8_#\=S=QZO/'(UNEUIM
MU#!,Z1^8\2SO&(FD5<EH@^]<-E05.,?X?_&F"^^!'A#Q]XL>+3Y=8TZQN)H[
M"VED#W%P$"Q00KOD<L[A50;F)(')KE;?]FF['Q5MO&%SK]I>_9]8O]566?3"
MVHNEQ;R0K:M<F7_4PB0!$" !4 (S\QZ73/@RVE_ ;0/AU)/I>KKIFG6M@\VK
M:<9[:Y\E5&\PB12IRNY2'RK!2#D4 =!=_&7PO97.E6\MU>FXU*%;B*&'2KN1
MXHF;:'G58B;==V5S-L&0PZ@XY/0?VA-,L]#OKWQ0[0WB:YK.G6MEHVG75[/)
M;V5Y+!YIA@663 1(R[X"!G'W=RBCP=\&O$/@6[TRZT[Q<E[<II<.DWTNKVDE
MU)-'%-+)&T;M-N4@3,F9#)D!223DG NOV6H'UR#6OM&BZQ?17FLRFV\0Z*M]
M:&&_OC=[1&9%*R1L%42!OF&[*C(P >B?\+W\$OKKZ3'K0GN(M/3599[>VFEM
M8;1XWD2=[A4,21LL;D,S@$X R2 8K;X^>#;K2=0U 7][##8"%IH+G2+R"Z(F
M;;"8[=X1+*)&^53&C!B"!DBL0_ "T>#QQ:F\AM-/\2Z!9:$MMI]DMNEF+>.=
M-Z*IV@'SP0@  V8YS4-_\$-2\2KJ]SXBU'1-;U&]TRWT@1S:0XLA;QR-(V^+
MSRS.S-]Y77:5!7!Z@&OJ'QWT/2-9F^WW,=GH<6B)J[330727@+7/D",VYASD
MOM0)GS2YVB/-=[X>\06GB?2H-1L?/%M,"4%S;26\HP2"'CD571@0058 @CD5
MXUIO[.=[:01_;O$%MXCF701HDD?B"Q>^BF47AN,R"28NZ@$1J&<N-JDN37HW
MPH\%W/P[\":;X?N=6GUJ2T,N+JX9V(5I7=8P9'=]B*PC7<[':BY)H [&BBB@
M#CK[_C^N/^NC?SKS>'Q]K_B37=:M_#.C65SIFC7)LKB]U&\:'SYU"M(D*I&^
M0@;:6; W CL:]'OQF]N/^NC?SKSKPUX#U_PAJFJ+IVNV3:'?:E<:F;:XT]GN
M(WF.]T$HE"E=Y)^YG!VY/!H YOP_\?)M2UO0)+_2K33O#.O_ -H&QOFO<S11
MVH)::="H5$8(YX8E?ESU..B@^/?@>;2]3U!]7ELK;3HX)K@ZAI]S:L(IGV0R
MJLL:EXW;@.H*GGG@URM_^S79:Y'X@NKTZ)I^KZEIL^G0SZ#HRVD<0F97DDD4
MNS2.S*H)+8QD?Q,3HW/P1N]<U=]9UW6;6[U26ZTUI?LM@8X!;6<K31PHC2,0
M6E8LSDGH..* &S?&>X\2_$S2?"GA>&> OIS:I=SZSX=U&-3&6Q%&&98Q#OVR
M_O'W %-NTMQ5[PG\0O%7B;Q!XKTN/2-&F31/+MA>VU_*89+QL&2')BS^[4J6
M(S@L%P"#B'PMX?US6?%/Q(\2HKZ%=ZK';Z5HTU];EWBAMXGQ,8B0<&>>8A<@
MD*#W%.U;X/:A:_"[3O!7A37H]"MD;&I7<UL\DU^CDM/\Z2HT;S.S,\@.[YFV
MX)R #H/A9XZN?B!H-]>W5G!9RVFI76G%K68S03>3(4,D;D E20>W4$=J[*LC
MPEHA\-^'+#2_*L+=+2(0I#I=J;:V11PJI&6;: ,<9/ZUKT %%%% '4Z,<:7#
M^/\ ,UXG\2/C9J=IKEUINC".VCMF,;W#H'9G!YP#P #D=*]KTC_D%0_C_,UX
MU\0_@CJ&JZW<ZGHTD3BY<R26\IVD,>I!Z')^F*\W'>W]G^XW/-QWM_9_N=SB
M/^%T>,.VK?\ DO%_\31_PNGQC_T%_P#R7B_^)JS_ ,**\7?\^</_ '_6E_X4
M5XN'_+G#_P!_UKY[EQ_F?.\N._O%7_A=/C'_ *"__DO%_P#$T?\ "Z?&/_07
M_P#)>+_XFK#? SQ<.EC$?I.G^-)_PH[Q?_T#X_\ O^G^-*V/[2#_ &[S(/\
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MT?\ >;9%^F#7112"6-77HPR*YZW\/S.P\W;&G?G)KH8T$:*B\ # H ?1110
M4444 %%%% !144\CI&3'&)''\);:/SJO]IO/^?6'_O\ G_XF@"[15+[3>?\
M/K#_ -_S_P#$T?:;S_GUA_[_ )_^)H NT52^TWG_ #ZP_P#?\_\ Q-'VF\_Y
M]8?^_P"?_B: +M%4OM-Y_P ^L/\ W_/_ ,31]IO/^?6'_O\ G_XF@"[15+[3
M>?\ /K#_ -_S_P#$T?:;S_GUA_[_ )_^)H NT52^TWG_ #ZP_P#?\_\ Q-'V
MF\_Y]8?^_P"?_B: +M%4OM-Y_P ^L/\ W_/_ ,31]IO/^?6'_O\ G_XF@"[1
M5+[3>?\ /K#_ -_S_P#$T?:;S_GUA_[_ )_^)H NT52^TWG_ #ZP_P#?\_\
MQ-'VF\_Y]8?^_P"?_B: +M%4OM-Y_P ^L/\ W_/_ ,31]IO/^?6'_O\ G_XF
M@"[15+[3>?\ /K#_ -_S_P#$T?:;S_GUA_[_ )_^)H NT52^TWG_ #ZP_P#?
M\_\ Q-'VF\_Y]8?^_P"?_B: +M%4OM-Y_P ^L/\ W_/_ ,31]IO/^?6'_O\
MG_XF@"[15+[3>?\ /K#_ -_S_P#$T?:;S_GUA_[_ )_^)H NT52^TWG_ #ZP
M_P#?\_\ Q-'VF\_Y]8?^_P"?_B: +M%4OM-Y_P ^L/\ W_/_ ,32^?>_\^D7
M_?\ _P#L: .:O_\ C]N/^NC?SJ"FWLET;V?-O'GS&_Y:GU_W:A\RZ_Y]T_[^
M_P#UJ +%%5_,NO\ GW3_ +^__6H\RZ_Y]T_[^_\ UJ +%%5_,NO^?=/^_O\
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M +M%4OM-Y_SZP_\ ?\__ !-'VF\_Y]8?^_Y_^)H NT52^TWG_/K#_P!_S_\
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M_G_XF@"[15+[3>?\^L/_ '_/_P 31]IO/^?6'_O^?_B: +M%4OM-Y_SZP_\
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MU_.C'U_.J_\ :-K_ ,_$?_?8H_M&U_Y^(_\ OL4 6,?7\Z,?7\ZK_P!HVO\
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MQ'_WV*/[1M?^?B/_ +[% %C'U_.C'U_.J_\ :-K_ ,_$?_?8H_M&U_Y^(_\
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MQ0!8Q]?SHQ]?SJO_ &C:_P#/Q'_WV*/[1M?^?B/_ +[% %C'U_.C'U_.J_\
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M9G\#_M^V/B"TMM6UWP%JGAGPY?>'M0U_3]1>^AN7NUL@/M4:Q)@K@Y"LQ&[
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MKV^FW4T9VND+LI]"%)!J[45Q;I=020R#*.I5@/0C!_G0!\S?#3X\Z_XM\&?
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MD*' )[M@9)P*ZBR\$Z5I^J>(-0@BDCNM=:-[YUF92Y2(1*5P05PB@<8YYZT
M<C\&_BV?BGX.N-;N-.MM)F@;$UA#>FYEMOW:OY5PK1QM%.H.&C*X!^ZS@YKR
M#6/C1XLUCQ/9:[]@F\.Z%/X(UO6=,6TU07+7 1K8PR30M%Y<<P4Y Q*H$A&X
M\@_0/A'X;:/X.DU2:V:[O;S4V0WEYJ-RUQ-,$38BEF[*N0![D]37-VG[.W@^
MS,@VZE-"=+NM%B@GU"5X[>SN"ADAC4G"C]VF#U   .* .<A_:'@T/6I-/UJU
MAL["RT7^UI;R]O?+O;M$MEGED@M_*"31J#M9DDW!L_N\<U6\-_M,7&K^'M:U
M/4?"ITE+33X=1M99KN1;:199-B1332P1B.8%D+)&)N&_=F1L*?0+WX,^&]4N
M[62_6\U"TM8_+ATV[NWEM$S T!/E$XR8W93V.X\9.:K?\**\-R>%I?#T\VK7
M>EG[/Y$5QJ4KFT\B198#"2<H4=$(/7Y0"2.* /.#^U9.GA2#5)O"\%M<QZU<
MZ/J$EWJ;P:=:&*-9 _VJ2W5AYBR1A!+%$"Q(9D #'H;C]H9T^)LGANT\-7%_
MI5OJL6BW&HVYG::.X=5/F")8#'Y"F1 SM,K##'9@9.[_ ,,^>%QH6I:0+G6_
ML>J7%Q<:B#JTY:]:=$282DM\RLL2C';D+@,0=G3?A/H>BZ_+JFG/J&GB:59Y
MK&UO9$M)9518P[1 X)VJ@/8[1D&@#LEQ@8&!2T@&!BEH **** "BBB@ HHHH
M XZ^_P"/Z?/_ #T;^9K@KSX1Z%?:!<:/.;J6RN-977IE,HS+.+D7.UN.8]Z*
M-O\ =7&>]=[?_P#'[<?]=&_G7C6I?%+4M(\,_&#Q%-+$UAX:DFM],A2,??BL
MXW.2/O%IGVX/3:* /1H?"UE!XMN_$:F4ZC<V45@V7_=B*-Y'7"^I,K9/?"^G
M*:!X4L_#M]K5U:F9[C5[PWMRTS!OGV)'A0!PH5% 'M7F\?QV.B74VD:EI-]J
M%UHTNE:=K&IQF*.);N\6':J(6!8@S(S #@-TZ9I:O\:I?%&M>$(=$M[NR\/W
M^MSQ'6G>/R[NWM$E:XPF2X0M%C<0,@9R,KD VO%W[.'A7QPNKVNK7.JRZ'JV
MH#5KO1H;H16\EX$55FW(HF!'EHVP2;-R@[>M>F:=9?V=IUK:":6Y\B)8O.FV
M[Y-H W-M &3U. !D].U>0> /CS%J46EV6IK<7-W-H\>OW=[=+!9&&TF$KQL(
M3(2ZHJ!6*;L$C)R>)O%'Q/U;6?!.FW=CI5]X<?6]2TZWTZYG>)I)HIIP6.U2
MQ0^2KDA@, ]<@T >PYS17E%O^T-I=S#9Z@=(U#^P-2M;V[TS5(PL@O8[9#(S
M)&#O = 2F1\PQTR*I:I^TWH&B^'M&U&^@AM)=9$DMA'+JMH(9X$C5VE$_F;,
M?.$"YW%@0%(^:@#V,G%+7@_Q&_:&O8?AKXBO?#?AO51J]MH4=Y(MV(X)-.N;
MF,_98I(W8,TFX@E5!(X[D"O:M$M;BRT:PM[RX:\O(;>..:Y?EI7"@,QX')()
M_&@#MM(S_94./?\ F:^5OBA'>Q^.M7^W;O,:9C'NR,QY^3'MC^M?5.C?\@N'
M\?YFJNM>%-)\1*HU&QANRG"M(H) ^M>?C<,\53Y$[,\_&X9XJGR)V/C?!HP?
M>OK$?";PF/\ F#P_K1_PJ;PG_P! >']:\3^R)_S(\/\ LBI_,CY.Q2'BOK$_
M"7PD>NCQ?F:;_P *B\)?] :'\V_QI?V14_F0_P"R:G\R/E"BOJ__ (5%X2_Z
M \/YM_C1_P *B\)_] >+_OIO\:/[)J?S(/[(GW1\H$XHX]Q7U<?A!X1/71X_
M^^F_QI/^%/\ A'_H#Q_]]M_C1_9%3^9!_9-3^9&1X4P/#&D_]>D7_H K5R/6
MNCM_#=A:V\<,492*-0J+N. !T%2#0K3^ZW_?1KZFG'D@HOHCZBG'D@H]D<OF
MC-=3_85I_<;_ +Z-']A6G]QO^^C5EG+9HS74_P!A6G]QO^^C1_85I_<;_OHT
M <MFC-=3_85I_<;_ +Z-']A6G]QO^^C0!RV:,UU/]A6G]QO^^C1_85I_<;_O
MHT <MFC-=3_85I_<;_OHT?V%:?W&_P"^C0!RV:,UU/\ 85I_<;_OHT?V%:?W
M&_[Z- '+9HS74_V%:?W&_P"^C1_85I_<;_OHT <MFC-=3_85I_<;_OHT?V%:
M?W&_[Z- '+9HS74_V%:?W&_[Z-']A6G]QO\ OHT <MFC-=3_ &%:?W&_[Z-'
M]A6G]QO^^C0!RV:,UU/]A6G]QO\ OHT?V%:?W&_[Z- '+9HS74_V%:?W&_[Z
M-']A6G]QO^^C0!RV:,UU/]A6G]QO^^C1_85I_<;_ +Z- '+9HS74_P!A6G]Q
MO^^C1_85I_<;_OHT <MFC-=3_85I_<;_ +Z-']A6G]QO^^C0!RV:,UU/]A6G
M]QO^^C1_85I_<;_OHT <MFC-=3_85I_<;_OHT?V%:?W&_P"^C0!RV:,UU/\
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M1:5_T$K/_O\ I_C0!HT5G?\ "1:5_P!!*S_[_I_C1_PD6E?]!*S_ ._Z?XT
M:-%9W_"1:5_T$K/_ +_I_C1_PD6E?]!*S_[_ *?XT :&T9S@9H"A1@ "L_\
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MOZYXA30[P7EJ-3D@Q\MO) D;+'$BLJK*YSC<6P69L5W']JV7_/Y;_P#?U?\
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MW]M>J6M[B*=5."8G# ?E5B@ HHHH **** "BBB@!-HS1BEHH 3%&*,T9 [T
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M"UBC%5?[5M?^>RT?VK:_\]EH L[1G-.JO#>PSMA)58^@/-6* "BBB@ HHHH
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M;CEE(PQX')]!Z4^W\/Z?:QQ1PV-K%%%$8(TCA50D9QE  .%.!QTX% 'S#?\
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M(GF,<#ZDYJV-$LC_ ,L3_P!]M_C7U%*'LZ:B^A]12A[.FHOH<M174_V'9?\
M/$_]]M_C1_8=E_SQ/_?;?XUJ:G+45U/]AV7_ #Q/_?;?XT?V'9?\\3_WVW^-
M '+45U/]AV7_ #Q/_?;?XT?V'9?\\3_WVW^- '+45U/]AV7_ #Q/_?;?XT?V
M'9?\\3_WVW^- '+45U/]AV7_ #Q/_?;?XT?V'9?\\3_WVW^- '+45U/]AV7_
M #Q/_?;?XT?V'9?\\3_WVW^- '+45U/]AV7_ #Q/_?;?XT?V'9?\\3_WVW^-
M '+45U/]AV7_ #Q/_?;?XT?V'9?\\3_WVW^- '+45U/]AV7_ #Q/_?;?XT?V
M'9?\\3_WVW^- '+45U/]AV7_ #Q/_?;?XT?V'9?\\3_WVW^- '+45U/]AV7_
M #Q/_?;?XT?V'9?\\3_WVW^- '+45U/]AV7_ #Q/_?;?XT?V'9?\\3_WVW^-
M '+45U/]AV7_ #Q/_?;?XT?V'9?\\3_WVW^- '+45U/]AV7_ #Q/_?;?XT?V
M'9?\\3_WVW^- '+45U/]AV7_ #Q/_?;?XT?V'9?\\3_WVW^- '+45U/]AV7_
M #Q/_?;?XT?V'9?\\3_WVW^- '+45U/]AV7_ #Q/_?;?XT?V'9?\\3_WVW^-
M '+45U/]AV7_ #Q/_?;?XT?V'9?\\3_WVW^- '+45U/]AV7_ #Q/_?;?XT?V
M'9?\\3_WVW^- '+45U/]AV7_ #Q/_?;?XT?V'9?\\3_WVW^- '+45U/]AV7_
M #Q/_?;?XT?V'9?\\3_WVW^- '+45U/]AV7_ #Q/_?;?XT?V'9?\\3_WVW^-
M '+45U/]AV7_ #Q/_?;?XT?V'9?\\3_WVW^- '+45U/]AV7_ #Q/_?;?XT?V
M'9?\\3_WVW^- '+45U/]AV7_ #Q/_?;?XT?V'9?\\3_WVW^- '+45U/]AV7_
M #Q/_?;?XT?V'9?\\3_WVW^- '+45U/]AV7_ #Q/_?;?XT?V'9?\\3_WVW^-
M '+45U/]AV7_ #Q/_?;?XT?V'9?\\3_WVW^- '+45U/]AV7_ #Q/_?;?XT?V
M'9?\\3_WVW^- '+45U/]AV7_ #Q/_?;?XT?V'9?\\3_WVW^- '+45U/]AV7_
M #Q/_?;?XT?V'9?\\3_WVW^- '+45U/]AV7_ #Q/_?;?XT?V)9?\\?\ Q]O\
M: .70LK KG/;%=E;%S!&7^_M&?K44&FVUNVY(@&]3R?UJR* %HHHH **** "
MD[TM)0 &DW5Y!^U-XGU;PA\)[K4=&OY].O5NH4$]NVU@I;!&?>OB[_AH'XC?
M]#CJG_?ZNJEAIUES1.>I6C3=F?IAFES[U^9W_#07Q&_Z'#5#_P!MJ/\ AH'X
MB_\ 0WZI_P!_JW^HU.Y'UB+Z'Z8_C1^-?F=_PT%\1?\ H;]4_P"_U'_#07Q%
M_P"AOU3_ +_4?4:G=!]8CV/TQ_&C\:_,[_AH+XB_]#?JG_?ZC_AH+XB_]#?J
MG_?ZCZC4[H/K$>Q^F/XT?C7YG?\ #07Q%_Z&_5/^_P!1_P -!?$7_H;]4_[_
M %'U&IW0?6(]C],?QH_&OS._X:"^(O\ T-^J?]_J/^&@OB+_ -#?JG_?ZCZC
M4[H/K$>Q^F/XT?C7YG?\-!?$7_H;]4_[_4?\-!?$7_H;]4_[_4?4:G=!]8CV
M/TQ_&C\:_,[_ (:"^(O_ $-^J?\ ?ZC_ (:"^(O_ $-^J?\ ?ZCZC4[H/K$>
MQ^F/XT?C7YG?\-!?$7_H;]4_[_4?\-!?$7_H;]4_[_4?4:G=!]8CV/TQ_&C\
M:_,[_AH+XB_]#?JG_?ZC_AH+XB_]#?JG_?ZCZC4[H/K$>Q^F/XT?C7YG?\-!
M?$7_ *&_5/\ O]1_PT%\1?\ H;]4_P"_U'U&IW0?6(]C],?QH_&OS._X:"^(
MO_0WZI_W^H_X:"^(O_0WZI_W^H^HU.Z#ZQ'L?IC^-'XU^9W_  T%\1?^AOU3
M_O\ 4?\ #07Q%_Z&_5/^_P!1]1J=T'UB/8_3'\:/QK\SO^&@OB+_ -#?JG_?
MZC_AH+XB_P#0WZI_W^H^HU.Z#ZQ'L?IC^-'XU^9W_#07Q%_Z&_5/^_U'_#07
MQ%_Z&_5/^_U'U&IW0?6(]C],?QH_&OS._P"&@OB+_P!#?JG_ '^I/^&@?B-_
MT.&J?]_O_K4?4:G=!]8CV/T"OO\ C]N/^NC?SJ"OS]?XY>/I&+-XKU$L3DGS
M*3_A=_CW_H:]1_[^#_"J^HR[A]9CV/T#HK\_/^%W^/?^AKU'_OX/\*/^%W^/
M?^AKU'_OX/\ "G]1E_,'UF/9GZ!T5^?G_"[_ ![_ -#7J/\ W\'^%'_"[_'O
M_0UZC_W\'^%'U&7\P?68]F?H'17Y^?\ "[_'O_0UZC_W\'^%'_"[_'O_ $->
MH_\ ?P?X4?49?S!]9CV9^@=%?GY_PN_Q[_T->H_]_!_A1_PO#Q[_ -#5J/\
MW]_^M2>!E_,'UF/8_2S1O^0;#^/\S5W (ZU^9J?'SXAQ($3Q=JBJ.BB;C^5+
M_P - ?$7_H<-4_[_ %3]1J=T'UB/8_3#'O1^-?FA_P -!?$7_H;]4_[_ %'_
M  T%\1?^AOU3_O\ 4?4:G=!]8CV/TOQ2@>]?F?\ \-!?$7_H;]4_[_4?\-!?
M$7_H;]4_[_4?4:G=!]8CV/TP_&E_&OS._P"&@OB+_P!#?JG_ '^H_P"&@OB+
M_P!#?JG_ '^H^HU.Z#ZQ'L?IC^-'XU^9W_#07Q%_Z&_5/^_U'_#07Q%_Z&_5
M/^_U'U&IW0?6(]C],?QH_&OS._X:"^(O_0WZI_W^H_X:"^(O_0WZI_W^H^HU
M.Z#ZQ'L?IC^-'XU^9W_#07Q%_P"AOU3_ +_4?\-!?$7_ *&_5/\ O]1]1J=T
M'UB/8_3'\:/QK\SO^&@OB+_T-^J?]_J/^&@OB+_T-^J?]_J/J-3N@^L1['Z8
M_C1^-?F=_P -!?$7_H;]4_[_ %'_  T%\1?^AOU3_O\ 4?4:G=!]8CV/TQ_&
MC\:_,[_AH+XB_P#0WZI_W^H_X:"^(O\ T-^J?]_J/J-3N@^L1['Z8_C1^-?F
M=_PT%\1?^AOU3_O]1_PT%\1?^AOU3_O]1]1J=T'UB/8_3'\:/QK\SO\ AH+X
MB_\ 0WZI_P!_J/\ AH+XB_\ 0WZI_P!_J/J-3N@^L1['Z8_C1^-?F=_PT%\1
M?^AOU3_O]1_PT%\1?^AOU3_O]1]1J=T'UB/8_3'\:/QK\SO^&@OB+_T-^J?]
M_J/^&@OB+_T-^J?]_J/J-3N@^L1['Z8_C1^-?F=_PT%\1?\ H;]4_P"_U'_#
M07Q%_P"AOU3_ +_4?4:G=!]8CV/TQ_&C\:_,[_AH+XB_]#?JG_?ZC_AH+XB_
M]#?JG_?ZCZC4[H/K$>Q^F/XT?C7YG?\ #07Q%_Z&_5/^_P!1_P -!?$7_H;]
M4_[_ %'U&IW0?6(]C],?QH_&OS._X:"^(O\ T-^J?]_J/^&@OB+_ -#?JG_?
MZCZC4[H/K$>Q^F/XT?C7YG?\-!?$7_H;]4_[_4?\-!?$7_H;]4_[_4?4:G=!
M]8CV/TQ_&C\:_,[_ (:"^(O_ $-^J?\ ?ZC_ (:"^(O_ $-^J?\ ?ZCZC4[H
M/K$>Q^F/XT?C7YG?\-!?$7_H;]4_[_4?\-!?$7_H;]4_[_4?4:G=!]8CV/TQ
M_&C\:_,[_AH+XB_]#?JG_?ZC_AH+XB_]#?JG_?ZCZC4[H/K$>Q^F/XT?C7YG
M?\-!?$7_ *&_5/\ O]1_PT%\1?\ H;]4_P"_U'U&IW0?6(]C],?QH_&OS._X
M:"^(O_0WZI_W^H_X:"^(O_0WZI_W^H^HU.Z#ZQ'L?IC^-'XU^9W_  T%\1?^
MAOU3_O\ 4?\ #07Q%_Z&_5/^_P!1]1J=T'UB/8_3'\:/QK\SO^&@OB+_ -#?
MJG_?ZC_AH+XB_P#0WZI_W^H^HU.Z#ZQ'L?IC^-'XU^9W_#07Q%_Z&_5/^_U'
M_#07Q%_Z&_5/^_U'U&IW0?6(]C],?QH_&OS._P"&@OB+_P!#?JG_ '^H_P"&
M@OB+_P!#?JG_ '^I?4:G=!]8CV/TQ_&C\:_,[_AH+XB_]#?JG_?ZC_AH+XB_
M]#?JG_?ZG]1J=T'UB/8_3'\:/QK\SO\ AH+XB_\ 0WZI_P!_J/\ AH+XB_\
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M/V1_B@?^8!%_X'P?_%U^AQB4G/?UI=HKHI8B=%6B83I*;NS\\?\ AD;XH_\
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M&P__ !=?<N:,T?7J@?5H'PU_PR_\1?\ H"Q?^!L/_P 71_PR_P#$7_H"Q?\
M@;#_ /%U]RYHS1]>J!]6@?#7_#+_ ,1?^@+%_P"!L/\ \71_PR_\1?\ H"Q?
M^!L/_P 77W+FC-'UZH'U:!\-?\,O_$7_ * L7_@;#_\ %T?\,P?$7_H"Q?\
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M#X/_ (NC_AD;XH_] "'_ ,#X/_BZ_0[:*-HH^O5A_5H'YX_\,C?%'_H 0_\
M@?!_\71_PR-\4?\ H 0_^!\'_P 77Z';11M%'UZL'U:!^>/_  R-\4?^@!#_
M .!\'_Q='_#(WQ1_Z $/_@?!_P#%U^AVT4;11]>K!]6@?GC_ ,,C?%'_ * $
M/_@?!_\ %T?\,C?%'_H 0_\ @?!_\77Z';11M%'UZL'U:!^>/_#(WQ1_Z $/
M_@?!_P#%T?\ #(WQ1_Z $/\ X'P?_%U^AVT4;?:G]=K"^K0/SQ_X9&^*/_0
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M-\4?^@!#_P"!\'_Q='_#(WQ1_P"@!#_X'P?_ !=?H=M%&T4?7JP_JT#\\?\
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M!_\ %T?\,B_%'_H 1?\ @?!_\773?\-S>.O^@/X>_P# :?\ ^/4?\-S>.O\
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M#^'O_ :?_P"/4^;%]D.U'S.9_P"&1?BC_P! "+_P/@_^+H_X9%^*/_0 B_\
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M&'P-_P!#9I'_ (&)_C7Y?Y_VO\_G1G_:_P _G1]07\P?67V/T_\ ^%Q>!O\
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M=NE0?VK9?\_EO_W]6C^U;+_G\M_^_JT 6@,4M5/[5LO^?RW_ ._JT?VK9?\
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M[%']H6O_ #\P_P#?8H L457_ +0M?^?F'_OL4?VA:_\ /S#_ -]B@"Q15?\
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M_P#?U:/:U/YF')'L>4_\,E?##_H7F_\  V?_ .+H_P"&2OAA_P!"\W_@9/\
M_%UZM_:ME_S^6_\ W]6C^U;+_G\M_P#OZM'M:G\S#DCV/*?^&2OAA_T+S?\
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MH_M6R_Y_+?\ [^K1[6I_,PY(]CR7_AD3X7?] "7_ ,&%Q_\ %T?\,B?"[_H
M2_\ @PN/_BZ]:_M6R_Y_+?\ [^K1_:ME_P _EO\ ]_5H]K4_F8<D>QY+_P ,
MB?"[_H 2_P#@PN/_ (NC_AD/X7?] "7_ ,#[C_XNO6O[5LO^?RW_ ._JT?VK
M9?\ /Y;_ /?U:/:S_F8N2/8X;P/\ O!7PYU274-!TR2TNI8C [M=2R90E6QA
MF(ZJ.:[<:/:C_EG_ ./&G?VK9?\ /Y;_ /?U:/[5LO\ G\M_^_JUFVV[LM))
M60W^Q[4_\LS_ -]'_&D_L6T_YYG_ +Z-/_M6R_Y_+?\ [^K1_:ME_P _EO\
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M]2_\-R^ O^@7XA_\!H/_ (]1["K_ "L/:P[GT317ST/VX/ '&;'75^MK%_\
M':7_ (;@^'__ #YZ[_X"Q_\ QVCV%7^5A[6'<^A**^>_^&X/A_\ \^>N_P#@
M+'_\=H_X;A^'_P#SYZ[_ . L?_QRE[&I_*P]K#N?0E%?/?\ PW!\/_\ GSUW
M_P !8_\ X[1_PW!\/_\ GSUW_P !8_\ X[1[&I_*P]K#N?0E%?/?_#</P_\
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M'_AMCX>?\\]8_P# 1?\ XNC_ (;8^'G_ #SUC_P$7_XNCV-3^5ASQ[GOU%>
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M5/\ P#_^RH_X;2^'7]_5/_ /_P"RI>QJ?RL7M(]SWFBO!O\ AM+X=?W]4_\
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M4[. !QCI6=_PK/27^(.G^,&67^T=.TJ32+.W&P6]M"\BO(44*"&;9&N<XVH
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MY)(/SFOJJ_\ ^/RX[_O&X/U-8Z>'-)CTJWTM=+LUTVW*&&S6W00Q%&#(53&
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M_ "+_"C^T%_*'U9GY:T8K]2?^%6>#_\ H5]&_P# "+_"C_A5O@__ *%;1O\
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M62XT^)V_,KFJY^#7@$?\R5X?_P#!9#_\3112YY=Q<L>PG_"F_ /_ $)/A_\
M\%L/_P 31_PIOP#_ -"3X?\ _!;#_P#$T44<\NY7)'L'_"F_ /\ T)/A_P#\
M%L/_ ,31_P *;\ _]"3X?_\ !;#_ /$T44<\NX^2/8/^%-^ ?^A)\/\ _@MA
M_P#B:/\ A3?@'_H2?#__ (+8?_B:**.>7<.2/8/^%-^ ?^A)\/\ _@MA_P#B
M:/\ A3?@'_H2?#__ (+8?_B:**.>7<.2/8/^%-^ ?^A)\/\ _@MA_P#B:/\
MA3?@'_H2?#__ (+8?_B:**.>7<.2/8/^%-^ ?^A)\/\ _@MA_P#B:/\ A3?@
M'_H2?#__ (+8?_B:**.>7<.2/8/^%-^ ?^A)\/\ _@MA_P#B:4?!GP"?^9*\
M/_\ @LA_^)HHHYY=R'"/8%^#G@-&RO@O0 0>"--A_P#B:Z;3M+M-*@6"RMH;
>2!>%C@C"*/P%%%'/)Z-D\J1> Q2T45104444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>pasg-20221231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pasg-20221231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (P H,# 2(  A$! Q$!_\0
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MU%%% !129I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(/\ "O6OV=_VK;#]H+7=8TRU\.WFBRZ=;1W+/<W$<H<,Y4 ;>G(K\M*^OO\
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M\]A^1_PJYBC%&@:E/^V;/_GL/R/^%']LV?\ SV'Y'_"KF*,4:!J4_P"V;/\
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M/!J,[226SA4E?)9E(Z$]R,?J*[*F%E3ASW/:Q.65,-1]M*5^YZ)15'^V;/\
MY[#\C_A1_;-G_P ]A^1_PKCLSQ;HO451_MFS_P">P_(_X4?VS9_\]A^1_P *
M+,+HO451_MFS_P">P_(_X4?VS9_\]A^1_P *+,+HO451_MFS_P">P_(_X4?V
MS9_\]A^1_P *+,+HO451_MFS_P">P_(_X4?VS9_\]A^1_P *+,+HO451_MFS
M_P">P_(_X4?VS9_\]A^1_P *+,+HO451_MFS_P">P_(_X4?VS9_\]A^1_P *
M+,+HO451_MFS_P">P_(_X4?VS9_\]A^1_P *+,+HO451_MFS_P">P_(_X4?V
MS9_\]A^1_P *+,+HO451_MFS_P">P_(_X4?VS9_\]A^1_P *+,+HO451_MFS
M_P">P_(_X4?VS9_\]A^1_P *+,+HO451_MFS_P">P_(_X4?VS9_\]A^1_P *
M+,+HO451_MFS_P">P_(_X4?VS9_\]A^1_P *+,+HO451_MFS_P">P_(_X4?V
MS9_\]A^1_P *+,+HO451_MFS_P">P_(_X4?VS9_\]A^1_P *+,+HO451_MFS
M_P">P_(_X4?VS9_\]A^1_P *+,+HO451_MFS_P">P_(_X4?VS9_\]A^1_P *
M+,+HO451_MFS_P">P_(_X4?VS9_\]A^1_P *+,+HO451_MFS_P">P_(_X4?V
MS9_\]A^1_P *+,+HO451_MFS_P">P_(_X4?VS9_\]A^1_P *+,+HO451_MFS
M_P">P_(_X4?VS9_\]A^1_P *+,+HO451_MFS_P">P_(_X4?VS9_\]A^1_P *
M+,+HO451_MFS_P">P_(_X4?VS9_\]A^1_P *+,+HO451_MFS_P">P_(_X4?V
MS9_\]A^1_P *+,+HO451_MFS_P">P_(_X4?VS9_\]A^1_P *+,+HO451_MFS
M_P">P_(_X4?VS9_\]A^1_P *+,+HO451_MFS_P">P_(_X4?VS9_\]A^1_P *
M+,+HO451_MFS_P">P_(_X4HUBT) $PS]#_A19A=%VBBBD,**** /PPT;_D$V
MG_7,5<JGHW_()M/^N8JY7S;W/Y>J_P 27JPJWI>D7VMW:VNG65SJ%RPR(;6%
MI7(]=J@FJE?3'P(N/$\'P@C;X="<:\/%$0\0MIBAKT6&Q/(Q_%Y.[S=VWOUX
MS50CS.QV8'"K%U>23=K7T5V_1?UI=GS?-IUW;/<I+:S1/;-LG5XV!B;.,/D?
M*<\8-5Z^L_&GA'6O"MY^T;K_ (@L)]-\-ZN9K2P>\7RQ?7;7JO 8@>7VA7;<
M!C!ZU\FMU-$X\CL5CL&\'*,6]7?=6V;2^^UQ*^OO^";7_)1/&?\ V";;_P!'
MO7R#7U]_P3:_Y*)XS_[!-M_Z/>ML-_%1ZW#/_(UI?/\ )GZ"T445[A^^A7 _
M';7-5\-_"S6M0T*XEMM;B-N+%HK?SR\[7$:QQE"Z J[,$.7088DLH&1WU>%?
MM/Z'JOB2#1=/TOP=8^+=T%[//!J<UXD$J11JWV0?9_E$LV<(TN5'EMP20* /
M0?AAJGC;5=,NW\;Z+9Z+>K,!!%93"17CVC+'#O@YR.M)XN^$NC>.-62ZUBXU
M2ZLLPO+HYU"46%PT3;XS) #M;#!21T;:NX&N6_9^T?6?#*>)-%UBTMUDM;BW
MD2]L[:YMXIO,MT=HPL\TN3&3L+*^#QD!@U>O4 )CBO#?AT2?VN_C,"20/#?A
M?&3_ +>JU[G7AGPY_P"3O/C-_P!BWX7_ /0]5H ]RQ1BEHH 3%,GF6W@DE;.
MU%+''H!FI*R/$QM)]*FL;F_33S>1M"DC. >G.,]>.M5%7=BX1YI),^)OBW\:
MT\"ZG;^9ID=W>Z@);IK:&3REMU+?*.AR.2.Q^7/M79?LX?M;>%[;PQJ-OXTO
M;3P]>?;B;<Q12N)8V4$9*JW*D8R<9R..M4?B!^Q'JWQ(\6W.O6'C/3I-*NEB
M^S,T+.5B" '!4[2,Y(P><]J]D\ _LG^ O"/@FWT#4](M?$LRRM<37^H0#S'D
M8 ';CE%PH 4'MW/-?25ZV"=!0;;?ENOOT/T?'8W)I8*-&3<I.U^6Z:_\"5M-
MCO/!GQ6\'_$.62+PYXBT_5YXT\QX+:<&15SC<4."!D@9QWKHX-0M;F:6&&YB
MEEB)5T20,R$=B >*XKP-\"? OPUUVXUCPWX?ATO49X?(>:.61\(2"5 9B%R0
M,X'85Y)XG_80\):UK-[JFG^(-=TBYNIGG8)*DBJ[$L<9 ;&3W.?>O&4,-*;7
M.XKI=7_)GQT:675:LE[64(65FXIN_6]F?3'&*!@]Z\GU?X2>)K#X+67@[PMX
MWO;'6;,KMUN\RTLJAV8HQ&2H^8 8R0% YYKB? '@+]H+PSXRTD:SXXTG7/#2
MSJ;Y)5W2-%_$%S$&#>AW=<9R*F-"$HN2J+2^]U?\.I$,%2J0G..(BK-V3NFT
MNJTZ]KGT=BC%>#?%_P"(7QH\(^,YD\)^!;+Q%X8$,9BG!+S.^,OD*X*X.0!M
M/ !SSQT'PN^+7BGQ'X)\0ZUXP\#7_AJYTD.ZVJ*S/>*L98^4C -NXQCH21@]
M:3PTU!5$TUZJ_P!Q,LNK1H+$)Q:=MI)O7NKWO^1ZSBC%?,.E_M_^!II/+U/1
MM>TI\X.^".0#\G!_2O;/%GQC\&^!;+2KK7]>MM+AU5/,LS.&!E7"G. "0,,O
M7'6B>%KTVHR@[L*^5XW#RC"I2:<MM+WMO:QV6*,5R_A+XH^$?'DSP^'_ !'I
MNKSHN]H;6Y5Y%7IDKUQTYQWKIA-&SE0ZEAU /(KGE&47:2L>?.G.E+EG%I^>
M@[%&*,\49![U)F&*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10
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MF]%Z8MTHE9"RD;/,8#)93G  (KP<\FJJ;[6-\UM[5/D<)6U3OW=M6W?2UVM
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M3_M-/^>5Q_WX;_"C^TT_YY7'_?AO\*N44!J4_P"TT_YY7'_?AO\ "@:DA/\
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M+U!CR3=64<A/XLIK.\<?"CPG\1M#M=(\0:);W^GVA!MX1NB\G"[?D*$%1CC
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M<@(W9KU.N)^,^A:WXF^&FM:;X=9_[7G6(1)'J#V!E42HTD7VA 7B#H'0NGS
M,2O.* ,/X!P:7!H6I#2X?#,,1N07'AC3Y;.(G8/OK)R6]QVKHM>^$OA3Q/XB
MBUK5-)6]O4:%RLL\OD.\1S$SP[_+=D."K,I((!!X&(?A9HL^BZ7>1S^''\-E
MY@PA?5WU'S/E W;V)V^F/QKM<T +7AGPY/\ QEY\9O\ L6_"_P#Z'JM>YUX9
M\.?^3O/C-_V+?A?_ -#U6@#W.N!^+?Q&/@#13/$\4<WER3/),NY8HT7);&1G
MGI]*[TG%>4^*_!GASXP^(Y+<>(%N%L'MSJ&FP@,7C#%U0D]$<J02 <X89'..
MB@H<]ZGPH]# QI>U4\0O<CJ]+G7_  RU?6-?\ Z#JGB"UBLM9O+..>ZAA4JJ
MLPR."20<8R,G!R.U=12 8&*6L9/F;:5CCJ24YN25DWMV\@HHHJ3,**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKG\E_P#BJMXHQ0!4_M!_^?*Y_)?_ (JC^T'_ .?*Y_)?_BJMXHQ0!4_M!_\
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M,I'UQVK2G7A4=HGHY?GN"S*HZ-"3YM[-6/3:***W/H@HHHH _##1O^03:?\
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M_)?_ (JC^T)/^?*Y_)?_ (JBP7+E%4_[0D_Y\KG\E_\ BJ/[0D_Y\KG\E_\
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MSI,?[YH \6_X7+\<?^C?#_X6UA_\11_PN7XX_P#1OA_\+:P_^(KZ HH ^?\
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M_P#"VT__ .(H_P"%R_''_HWP_P#A;6'_ ,17OX&*6@#Y_P#^%R_''_HWP_\
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MNO/7RY9%Y[,:UJ /G_\ X7+\<?\ HWP_^%M8?_$4?\+E^./_ $;X?_"VL/\
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M (6UA_\ $4?\+E^./_1OA_\ "VL/_B*^@** /G__ (7+\<?^C?#_ .%M8?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*0=*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1_\ P4K_ /%T?6J9/^MV6=Y?<?J!17Y?_P##>'Q?_P"@KH__ (*5_P#BZ/\
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ML+?$?PY\'OA'X6F;P^=0\)_$S_A*;W[+=NMN;'>3^ZRF=V.B'VYK[_&HV:@
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M,1&#55=_Z[G1G"Y:L8\K22>]KZR;>S:5F[6O=6U"ON'_ ()F?=^)/_733?\
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M_/8?]\G_  H_MBT_Y[#_ +Y/^%%F%T7:*I?VQ:?\]A_WR?\ "C^V+3_GL/\
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M18:]INJKNLM0M;L>L$RO_(URN,H[HZ%)/9E[%&*,BC-24&*,4M% "8HQ2T4
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MT3_2O_(O_P 73)?V,/@M, '^'^F\=-CS+_)Z]KHHYI=PY5V/$?\ ABGX)_\
M0@6'_@1/_P#'*/\ ABGX)_\ 0@6'_@1/_P#'*]NHHYI=PY5V/#I?V)?@E+&R
M'P#9*",96YN 1^/F54_X84^"'_0CP_\ @;<?_'*]\I,T^>7<.5=CP3_AA3X(
M?]"/#_X&W'_QRC_AA3X(?]"/#_X&W'_QRO>\T9HYY=PY5V/GAOV O@<S$_\
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M^8U[#YGCR?\ Y9VEO_WS_B:/[*\<7)^?5+:'_=Q_1:X.>?62_#_(Z^6/1/\
MKYGCO_"F_C##\T/Q3NY&/&)([C&/Q4TA^&'QRM^(/B0) >IDCEX_.(U['_PB
M/BF?_7>(RG_7,M_@*4?#K4IO^/CQ)=O[#=_5J/:+K)?=_P  .1]$_O/&6\#_
M +05O\J>/K-HQT:2)L_K;FH'TK]H.UY;QEI+;.S!!N_. 5[:/A3 _P#KM4NY
M?7H/\:GC^$VC+R\EU(?>0#^E'M8=;?\ @(<D_/[SP.36OCY9_,WB709#TV,T
M']4%5Y/'?QYMO^8EH%SGW@X_05]'1?#+08^MM))_O2M_2K<7@+08NFFQG_>9
MC_,TO;TOY?P0>SJ=_P 3YC'Q1^/$/RE-"E/][]U_1A6A:_%3XVN%\Q/#,>.I
MD1CG_OEJ^EHO"FC0_=TRU_&('^=6X])LH?\ 5V=O'_NQ*/Z4G7I?R#5*I_,?
M/EE\3OBU(X,G_"*X[JMM<N/T<5T.G^/_ (DR']_;Z),#VM]-N1_.4U[4D2)]
MU57Z#%.Q6;K0?V$6J<_YCS"'QMXU6,&;18Y&/>.PF _]#-077Q*\4P@K_P (
M_<[AU\K3+A_Z8KU>BH]K'^1%>SE_,>#7WQE\40*S?\(]X@P.IB\.W! _$K7.
M:C\??%4"ECX=\6;3P"NC%!GZD5].4F*T5>"^PB'2D_M,^0;_ /:(\5HV/^$9
M\5<\C=&8LC\%K//[0NI,VV]\->)PW<>:?ZK7V=CZ_G1M'O\ G6BQ45]@GV#_
M )CXT'[0.AMS=>'/%+?WCO3CUZBIHOVA_ 4)S/X;\3B/^\S0_P#UJ^Q2H((/
M(/8U$UI"XPT4;#T*@T?6E_+^(>P??\#Y-MOVF/A;&?W_ (;\1#TR(SG_ ,BB
MM2V_:C^$2KD^']80^DENK'_T::^F7TJSDQNM(&QZQ*?Z5#)X<TF5MSZ99NWJ
MUNA/\JAUX/=/[RE2DNJ^X\ M_P!JOX1QA2NE7B$_WM.0D?\ CQJ75_VL?AD^
MBZA%8BX6Z>WD6$?V?L!?:=HSVR<<U[@_@CP[(27T'3&+=2;.,Y_\=KG_ !E\
M+/#VH^$-;M;#POHYOYK&>.VVV,*GS3&P3#;>#NQSVI*I2;5T_O&X3MNON/D#
M_AI6P_Z %W_X$I_\37T7^S-\2(?''AC5[N/3[FT2&]$6P_O23Y:G.5'O7RI_
MPRK\4O\ H57_ / RW_\ CE?4W[)?PX\1?#;P?K%GXCTXZ;<W%_YT<9E20LGE
MJ,Y1B.H-=V)E3=)\K3^9RT(R4[M'M']II_SQN/\ OPW^%']II_SQN/\ OPW^
M%7**\8]$I_VFG_/&X_[\-_A1_::?\\;C_OPW^%7** *?]II_SQN/^_#?X4?V
MFG_/&X_[\-_A5RB@"G_::?\ /&X_[\-_A1_::?\ /&X_[\-_A5RB@"G_ &FG
M_/&X_P"_#?X4?VFG_/&X_P"_#?X5<HH I_VFG_/&X_[\-_A1_::?\\;C_OPW
M^%7** *?]II_SQN/^_#?X4?VFG_/&X_[\-_A5RB@"G_::?\ /&X_[\-_A1_:
M:?\ /&X_[\-_A5RB@"G_ &FG_/&X_P"_#?X5D>+--M/&/AV^T:[%]#:WD?E2
MM!$0Y3()7)!X(&#[$UT=<_\ $#7[OPKX*UK6;&V2\N;"U>Y6"1BJN$&YAD<]
M ::WT$]M3D]>^%&@^(/$&NZO,^K0SZS:06=S%"F(PD<BN2H*'!<1QHQ[J@Q@
M\UMZCX<CN];O]9M;[5-/U.ZMX+59X;=7\J.)Y'VJKH1\QD.[.>BXQBN3N_C+
M>W=YJ"Z9#IL=A;QWE^FH7DSB)K*U\M'D^7N\S2*IZ!8RW.0#FZ+\2M7U+QQH
M\\L BDOK;3+"33_M#F&"6:">\N6 XRR1)$ 2!U[9Q5V9G>)NZY\/#+X6M-$T
MJZO8A-K4>JZE?SQGSY6$OGNX 0H6,BQ_+M"[1CM@O?X66!FAO(]5UZWUCSKF
M:XU.)%$TYGC2.0<Q[4PL487: 5"#'?.'_P +SUC6;2T70=!-_>W-O/J$0CBE
MFBD@^TR0VJ;T&$:81EM[D(@!/S5W/B/Q3K$'BKP_H&E6EF;F_M[B\NY;J1B+
M6*(Q#(5<%RS2!1R.A/;%'O(?NLP)/A%HG]F_V=#<ZQ;V+:'#H$D21@E[>,L5
M.XH2&.]MQ!PV>1P*D3X6Z5%-XD\FYU*"WUR.Z2>.*RA5XS<9,A67RO,/)8@,
MQ STX&,&3XYZK':Q:K]@TYM+N](U#6X+?SW%S';6X B9^-I,K.G3&W)'S$9&
MA!\5?$45Y<:/>Z581Z[+<V%G;K%,[0Q37$$DTB2$@%O*2)FRN-V5'RYS3]X7
MNFOJOPXTG4A?M'-JEG+=?8 CQ1 B$6;[X5560@KNR6#9!SVK0^)E\K?#3Q4A
M2X)_LB[&YH2,_N'YZ5PJ_''7;ZSAMM/T>"_U69K^2.2RBGN()(;:;R$("+D&
M:0'!8A5 )+'C/??$*:>X^$OB.6Z@^R7+Z)<M+ '#^6YMV++N'7!R,]\5G--+
M4RK-.E.W9_D?C:3G'T%)2MU_ 4E?,'\RA7WG^P;X8T'QA\&O$&F^(=$M-=LS
MKK$07UFMQ$";>$9PP(!]Z^#*_0__ ()Q?\DF\1_]AMO_ $GAKKPG\5'V/"?_
M "-(^C_(^I=%T'3?#>GQV&DZ?:Z98Q_<MK.%8HU^BJ !5^BBO:/W0**** /P
MPT;_ )!-I_US%7*IZ-_R";3_ *YBKE?-O<_EZK_$EZL****1F%%%% !7W#_P
M3,^[\2?^NFF_^@7%?#U?</\ P3,^[\2?^NFF_P#H%Q75A?XJ/K^%/^1K#TE^
M3/N*BBBO;/W8**** "DSS0>!7S9XO\?^)X+KQCXLM=>N[5?#/C'3O#UOX?18
MC:W5O(]DDOF J7,C_;'96##;MCP,;MP![E\04$G@_4@W38I_$.I%>&'K7O\
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MUI/_ ,L* /<J*\-_X:1\2?\ 1 ?BA_WZTG_Y84?\-(^)/^B _%#_ +]:3_\
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M10 F.,=JY_0? 6B^&O$?B;7-/M##J7B.YAN]2E,C,)98K>.W0A2<+B.)!A<
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M37OB;HVH^'-+TC5_#DEJFG6!OFD#>?:B9%N9E4@-DC=Y:L%R0"^,D ]!\">
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MY&[&?:@#HZ*** $Q1BEHH 3%&*6B@!,48I:* $Q2T44 %%%% !1110 4444
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M8<Y^88H ]HHKG-.^)'A/5]7U32K'Q/HUYJ>E*7O[*WOXGFM%!P3*@;* 8/+
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M:=0\.ZUI^O6 D,1NM,NDN(MXQE=R$C(R./>M>@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>pasg-20221231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pasg-20221231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #K [4# 2(  A$! Q$!_\0
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MC10%R]_;^I_]!&[_ ._[?XT?V_J?_01N_P#O^W^-4:OQ>']5N+ WT6EW\MB
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M-.O-/:3)07=M)"7QUQN S^% :CO[?U/_ *"-W_W_ &_QH_M_4_\ H(W?_?\
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M[?U/_H(W?_?]O\:KWEE/I]W/:W,+P7$#M'+$XPR,#@@^X-0X/I0!>_M_4_\
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M.E_=1VDEJMS.MK*P>2!96$;L.A9<X)'8D5!51CRDSES!1115D!1110 4444
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M3+8V]EJU_9VY;<8;:[DC0GUVJP&?>DM_$&JV<,<-OJE];PQR>:D<5U(BH_\
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M?X4?V+J/_0.O/_ :3_"OUUWM_>;\Z-[?WF_.CVOD'L?,_(K^Q=1_Z!UY_P"
MTG^%']BZC_T#KS_P&D_PK]==[?WF_.C>W]YOSH]KY!['S/R*_L74?^@=>?\
M@-)_A1_8NH_] Z\_\!I/\*_77>W]YOSHWM_>;\Z/:^0>Q\S\BO[%U'_H'7G_
M (#2?X4?V+J/_0.O/_ :3_"OUUWM_>;\Z-[?WF_.CVOD'L?,_(K^Q=1_Z!UY
M_P" TG^%']BZC_T#KS_P&D_PK]==[?WF_.C>W]YOSH]KY!['S/R*_L74?^@=
M>?\ @-)_A1_8NH_] Z\_\!I/\*_77>W]YOSHWM_>;\Z/:^0>Q\S\BO[%U'_H
M'7G_ (#2?X4?V+J/_0.O/_ :3_"OUUWM_>;\Z-[?WF_.CVOD'L?,_(K^Q=1_
MZ!UY_P" TG^%']BZC_T#KS_P&D_PK]==[?WF_.C>W]YOSH]KY!['S/R*_L74
M?^@=>?\ @-)_A1_8NH_] Z\_\!I/\*_77>W]YOSHWM_>;\Z/:^0>Q\S\BO[%
MU'_H'7G_ (#2?X4?V+J/_0.O/_ :3_"OUUWM_>;\Z-[?WF_.CVOD'L?,_(K^
MQ=1_Z!UY_P" TG^%']BZC_T#KS_P&D_PK]==[?WF_.C>W]YOSH]KY!['S/R*
M_L74?^@=>?\ @-)_A1_8VH?] ^\_\!G_ ,*_77>W]YOSJ"9VW_>;\ZYZ^*]C
M'FM<B=/D5[GY(_V-J'_0/O/_  &?_"C^QM0_Z!]Y_P" S_X5^M6]O[S?G1O;
M^\WYUP_VF_Y/Q_X!@?DK_8VH?] ^\_\  9_\*/[&U#_H'WG_ (#/_A7ZU;V_
MO-^=&]O[S?G1_:;_ )/Q_P" !^2O]C:A_P! ^\_\!G_PH_L;4/\ H'WG_@,_
M^%?K5O;^\WYT;V_O-^=']IO^3\?^ !^2O]C:A_T#[S_P&?\ PH_L;4/^@?>?
M^ S_ .%?K5O;^\WYT;V_O-^=']IO^3\?^ !^2O\ 8VH?] ^\_P# 9_\ "C^Q
MM0_Z!]Y_X#/_ (5^M6]O[S?G1O;^\WYT?VF_Y/Q_X 'Y*_V-J'_0/O/_  &?
M_"C^QM0_Z!]Y_P" S_X5^M6]O[S?G1O;^\WYT?VF_P"3\?\ @ ?DK_8VH?\
M0/O/_ 9_\*/[&U#_ *!]Y_X#/_A7ZU;V_O-^=&]O[S?G1_:;_D_'_@ ?DK_8
MVH?] ^\_\!G_ ,*/[%U'_H'7G_@-)_A7ZUAVR/F;\ZM;V_O-^===#%NLG[MK
M&T(<Y^17]BZC_P! Z\_\!I/\*/[%U'_H'7G_ (#2?X5^NN]O[S?G1O;^\WYU
MU^U\C3V/F?D5_8NH_P#0.O/_  &D_P */[%U'_H'7G_@-)_A7ZZ[V_O-^=&]
MO[S?G1[7R#V/F?D5_8NH_P#0.O/_  &D_P */[%U'_H'7G_@-)_A7ZZ[V_O-
M^=&]O[S?G1[7R#V/F?D5_8NH_P#0.O/_  &D_P */[%U'_H'7G_@-)_A7ZZ[
MV_O-^=&]O[S?G1[7R#V/F?D5_8NH_P#0.O/_  &D_P */[%U'_H'7G_@-)_A
M7ZZ[V_O-^=&]O[S?G1[7R#V/F?D5_8NH_P#0.O/_  &D_P */[%U'_H'7G_@
M-)_A7ZZ[V_O-^=&]O[S?G1[7R#V/F?D5_8NH_P#0.O/_  &D_P */[%U'_H'
M7G_@-)_A7ZZ[V_O-^=&]O[S?G1[7R#V/F?FK\&K>:P_M<7,$UN6\DJ)8F7/^
MLZ9%%?87QS8G7].R2?\ 1/7_ *:-14-W=PY>70[C]GKCX+>$_P#KU?\ ]'25
M'K'[1/P^\/\ B74]#U+79+&\TNYBLK^>;3[D6=I-*JM''+=>7Y*%@ZXW./O"
MI/V>N?@KX4_Z]7_]'25XOXT\!>/+ZY_:%\,:=X(OKZ'XAW<$>FZU-<VT>FPP
MFPBMY)IB9?,!1E8A1&2Q48QG-<4MV>A'X4?2^C>(H=;U#6;2&TU"W?2KA;:6
M6\LWABF8H'#0NW$J88#>O&<CJ*UB"O48^O%?'7B[X,^/;:/Q=I=OX/A\4:1J
M7B2W<7-[#!>2FUCTB*W6YAMY;B.,DSH58R-E 2ZJ2 :\4\06%SI'BKP=H/Q(
MLVNI- T3PU!J-K/-#=ZK%,MS(S1V4<DRF4/^[68PK-E!R01BIN4?IAM.,X.*
M-K?W3^5?'MI^S_XWT[Q!:ZUH^E3:-XCG\4^)6N-6%TN8]/N()A:%L.?W7FF-
M@@&5/) .36%I7[/7BFY\,7]JW@SQ#X3LG\+V6F:O9Z;>VD]SK6KQW*2/>!'G
M\N=,*V\RLC2K(5Q1<#[)'B*%O%+:"+/4?M(L_MOVK[&_V39OV[//QM\SOLZX
MYZ5JD8KXSF^"7COQ!H[1:_X4O-)AE\'#2WM?"+6R>7,NI^<D:P23>7S$ SP[
M]F"R!NE?1OP'TK7=#^%6AV/B31[#0-5@$JOI^FQK%#$GF,8_W:NZQL5P61&*
MJ20#@4 =_1113$%%%% !1110 4444 %%%% !1110 4444 %%%% $%]_QZO6-
M6S??\>KUC5Y>*^->AY^)^)!1117&<H50L->L=4U+4;"UG\V[TZ18KJ,*P\MF
M4,HR1@Y!!XS5\UY2O_"0:'XV\>I!X1U+4X=9*2V5ZK0K9.5M@FV5_-$B L,9
M"GK^--*XTKGI6JZQ8Z';)<:A=16<#RI LDQPID8X5?J3Q5S'^-?*%I\(/$>H
M:+XF_M#P&GV-[K3+Z#0TL[6W29XF_P!($47VB12Q7C>[*7[UUF@_"O5?^%NR
M:WJ.GZ]:A=1^UV%U9Q6 MH;3R]J6TDA;ST51\IA7*D@$>M6XI=2W%=SU7Q7\
M6?"W@J_>RU;49([F*$7$Z6UE/=?9HCG$DQB1A$G!^9\# )Z5U-G=0ZC:0W5K
M*EQ;3()(Y8CN5U(R"".H(KRG4(/$W@OQ?XXN+'PE>^*+7Q((Y;2>PN+=%BD$
M A,5QYLB%$!&0RA_E)XSQ7#7?[/^HII%U'<:2NJZKIGAS3;72+Q9N([V*1FD
M,.6&U@,?,0..,XR*.5=Q<J[GTICG'?T[U3OM9L=,N;&WN[N*WFOY##:I(V#,
MX4L57U(4$_A7S]X@^&_B^YO_ !]%H>BSVS:Q:L[:M?BV2[>3S4+06]RLA:2)
MXQ( LRJ$)"Y()Q7T[X,C3X_#>HCP=K&JP6>O_:YM*U2TTV*2WC:W\LR00Q.(
ME02!'89W$@L 32Y5W'RKN?2M% Z#M14&84444 30?=/UJ6HH/NGZU+7T6&_A
M1.^G\*"BBBN@LJ:MJEKH>E7NI7LOD65G!)<SR[2=D:*69L#DX )P.:EL[J*_
MLX+N!O,MYXTFC?!&58 J>>F01UK%^(>F76M_#_Q1IUE$9[V\TF[MH(@0"\CP
M.JKD\#)('->0^-[/Q)XU^'OAO21\-KUUM8Q:W<6MV=K<RQ,MH%22&#[6L;@O
ME3([93[P4YR$V.Q[C'K-C-K,^DI=Q/J<$*7,MH#^\2-V94<CT)1@/]TU;=UC
M0N[!4 )+,<  =3FOEX_"#Q:ND2M%X>EC\7ZE\/[+21X@$D!EM-0A5UGCEF+[
MP\D;*BR*&!QR0!FNX\ ?"F2U^'?CC1[2#6] .OVS6\5MK-O96R6\AMVBWQ0V
M9**"2-S=7*YHN.QV_AOXQ^$/%VKVVFZ7JKS7-VCR6;2V<\,-\J#+M;RR(J3
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MV"Q])SZS8VNJVFF37<4>H7<;S06S-AY43:'91W WKGZBKM?//A3X0KX;\5>
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M#_P=V/\ \71_;?CO_HF&H?\ @[L?_BZ+!<ZNBN4_MOQW_P!$PU#_ ,'=C_\
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MKJ590RG@AAD&@ *    .PKB?^$T\6?\ 1.;_ /\ !Q9?_%T?\)IXL_Z)S?\
M_@XLO_BZ+!<[;%&*XG_A-/%G_1.;_P#\'%E_\71_PFGBS_HG-_\ ^#BR_P#B
MZ+!<[:EKB/\ A-/%G_1.;_\ \'%E_P#%T?\ ":>+/^B<W_\ X.++_P"+HL%S
MMZ*XC_A-/%G_ $3F_P#_  <67_Q='_":>+/^B<W_ /X.++_XNBP7.WHKB/\
MA-/%G_1.;_\ \'%E_P#%T?\ ":>+/^B<W_\ X.++_P"+HL%SMZ*XC_A-/%G_
M $3F_P#_  <67_Q='_":>+/^B<W_ /X.++_XNBP7.WHKB/\ A-/%G_1.;_\
M\'%E_P#%T?\ ":>+/^B<W_\ X.++_P"+HL%SML"C%<3_ ,)IXL_Z)S?_ /@X
MLO\ XNC_ (33Q9_T3F__ /!Q9?\ Q=%@N=M17$_\)IXL_P"B<W__ (.++_XN
MC_A-/%G_ $3F_P#_  <67_Q=%@N=O28KB?\ A-/%G_1.;_\ \'%E_P#%T?\
M":>+/^B<W_\ X.++_P"+HL%SML4M<1_PFGBS_HG-_P#^#BR_^+H_X33Q9_T3
MF_\ _!Q9?_%T6"YV]%<1_P )IXL_Z)S?_P#@XLO_ (NC_A-/%G_1.;__ ,'%
ME_\ %T6"YV]5YOOUR'_":>+/^B<W_P#X.++_ .+J&7QGXK+_ /).K\?]Q>R_
M^+KAQD6Z?S,:KO$[*BN*_P"$R\5_]$[O_P#P;V7_ ,71_P )EXK_ .B=W_\
MX-[+_P"+KQ>1^7WK_,XSM:,9KBO^$R\5_P#1.[__ ,&]E_\ %T?\)EXK_P"B
M=W__ (-[+_XNCD?E]Z_S [7 HKBO^$R\5_\ 1.[_ /\ !O9?_%T?\)EXK_Z)
MW?\ _@WLO_BZ.1^7WK_,#LU14SM55!.3M &3W/UIV*XK_A,O%?\ T3N__P#!
MO9?_ !='_"9>*_\ HG=__P"#>R_^+HY'Y?>O\P.UHQ7%?\)EXK_Z)W?_ /@W
MLO\ XNC_ (3+Q7_T3N__ /!O9?\ Q='(_+[U_F!VM%<5_P )EXK_ .B=W_\
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MJE=O.<5TFC:Q9>(=*M-3TVYCO;"ZC$L-Q$<JZGOZ^V#R""#0!=HHHH$%%%%
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M+\-CQ&FA'4L:D\@A"FWF\KS2-PB,VSRQ)CG86W>U=/0 4444""BBB@ HHHH
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M]3CTG5M4U74WMY9K@QI)*EM&D+@^4LBY,C*&8X'3-:/[+PS\!/!X_P"G1O\
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M8K_9^ISV2.95B(<L=I1OOJ@<*=I-','*>H>1\2_^AZTC_P )S_[HH\CXE_\
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M+_(#B?\ A'O'O_0ZZ7_X3P_^/T?\(]X]_P"AUTO_ ,)X?_'Z[:BCG?9?<O\
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M^E_^$Z/_ (_7<447"QP__".^/O\ H=]+_P#"='_Q^C_A'?'W_0[Z7_X3H_\
MC]=Q11<+'#_\([X^_P"AWTO_ ,)T?_'Z/^$=\??]#OI?_A.C_P"/UW%%%PL<
M/_PCOC[_ *'?2_\ PG1_\?H_X1WQ]_T.^E_^$Z/_ (_7<447"QP__".^/O\
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M5 K6HHIB"BBB@""^_P"/5ZQJV;[_ (]7K&KR\5\:]#S\3\2"BBBN,Y0HHHH
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M,$OV:U+$^3'O53@9/R@9P *]4_X4JW_0]^,?_!A%_P#&J/\ A2K?]#WXQ_\
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M/_0Z^+/_  /B_P#C5'_"OKG_ *'7Q9_X'Q?_ !JN3ECW.4Z[(]11D>HKD?\
MA7US_P!#KXL_\#XO_C5'_"OKG_H=?%G_ ('Q?_&J.6/<#KLCU%&1ZBN1_P"%
M?7/_ $.OBS_P/B_^-4?\*^N?^AU\6?\ @?%_\:HY8]P.NR/449'J*Y'_ (5]
M<_\ 0Z^+/_ ^+_XU1_PKZY_Z'7Q9_P"!\7_QJCECW Z[(]11D>HKD?\ A7US
M_P!#KXL_\#XO_C5'_"OKG_H=?%G_ ('Q?_&J.6/<#KLCU%&1ZBN1_P"%?7/_
M $.OBS_P/B_^-4?\*^N?^AU\6?\ @?%_\:HY8]P.NR/449'J*Y'_ (5]<_\
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M[<_]#MXM_P# ^+_XS0%V=?D>HHR/45R'_"O;G_H=O%O_ ('Q?_&:/^%>W/\
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M[<_]#MXM_P# ^+_XS1_PKVY_Z';Q;_X'Q?\ QF@+LZ_(]11D>HKD/^%>W/\
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M:[N6&((0LD;[MSX&Q0"<G) &1'XEM_'-W\(+9;+[1'XS:&T-R=,>&&7=O0W
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M2IRV[C-<LI--ZG7&*Y5H?7/_  I[PC_T#;G_ ,&U[_\ 'Z/^%/>$O^@;<_\
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M%.[YS@'N!1S/N'*NQ]0?\*>\)?\ 0-N?_!M>_P#Q^C_A3WA+_H&W/_@VO?\
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M_A37@[_H$2_^#*\_^/4?\*:\'?\ 0(E_\&5Y_P#'J[6BB["R['%?\*:\'?\
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M;[]<.,E)4]'U,:J2B<3_ ,*=\(?] J7_ ,&-W_\ 'J/^%.^$/^@5+_X,;O\
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M_P#@QN__ (]1_P *=\(?] J7_P &-W_\>KLZ*/:3_F?W@<9_PIWPA_T"I?\
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M'N=J@"IJ** (+[_CU>L:MF^_X]7K&KR\5\:]#S\3\2"BBBN,Y0HHHH ****
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MP)_T->G?]]/_ /$T?\+H\"?]#7IW_?3_ /Q->W;1[_G1M'O^=%UV"S[GB/\
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M_P";_P#Q-'_"X?!/_0SZ?^;_ /Q->_[1[_G1M'O^='M5V#V;[G@'_"X?!/\
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1THK[,V_7\Z*?M?(CV-^I_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>pasg-20221231x10k009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pasg-20221231x10k009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !( 1T# 2(  A$! Q$!_\0
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MQ/XH7_@EM=>(-1\6SZQXAN?"FGWG]LVY-O.#(;<[6D61BS@,5:3(+')(&<4
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MZNIY;FYET"QDDFF<N\C&!"69CR23U)K:G651VL;4<0ZD^1QMI?>_Z(H?#O\
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M8LR1 IA%+$DA< DDUT=OX4T2T@U6&#1["&'597GU"..V15O)'4([R@#]XS*
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M)X4US1-5BGT;1Y+'2=4T^2U\.Z8;2 RW<UM()E5G;YE^S#);.XD'C&*]BHH
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M]M9/C);<D4]TQXP/W/)(X^BZ* $Z4M%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5\LZ5I5UXIU#Q/>WOB3Q*DJ^(M5MDCM=9FAB2**[D2-513@ *
M /PKZFKYJ\#]/%'_ &-.M?\ I=+6M&*E4M)7T_R//Q2O**?G^@?\(./^AE\6
M_P#A07'^-'_"#C_H9?%O_A07'^-=)FC-=_L:?\J.;V<>QS$O@D)$[#Q+XMR%
M)'_%07'I]:]?^!NIW>L?!;P+J%_<RWE[<Z%933W$S;GE=H$+,Q[DDDDUPD_^
MHE_W&_D:[+]GL9^ OP\'_4O6'_I.E<=>$8-<JMO^AM02C5LNS_-&)X&_:*TK
MQ5XV^(WAZ_LI-"/A"5V-W=2J8KRVCR)9TQT"."K \C*G^(5D> OVM?"WB+X>
MMXK\1QR>#H3J5W8):Z@=\I6'#&5@@.U=C(S9X7=R:YOQ=^R?JWB:]N9HO$,%
M@-1\37]SJ8B1B;K0KT0FYL<XX=FMXOFZ ;O6H_%G[-GCF]TK7-.T;Q-9VVGZ
MQK&MZA<V0N;BT5EO/+^SLTD2[V,.UP8@55_,Y;Y17.>F>E^.?VA_"7A:UUNV
MLM5M-5\0V.C3:S#I<,A)FB6UDN(V+*"%1UB;#G@]LGBGQ_M$>"[71([S4M9M
M[6Z46\=Q:1;YGBN)8!/Y("J2S+&=Q &0N"0 :Y#PQ^SKJV@>$/'&DMJ=B]QK
MWA#3O#D$J(P6.6VL9K8N_'*%I0P R<9XS7$K^QWKNB1^'K?3=1TO4]+\.W,\
M^FZ??W-W;-MNXD%XCW$/[PE9HP\;G<2DCQL/E5J /1_C%^U9X,^&/@V75+35
MM/UG5)M,35-/L8[@A;J%V"Q-YBA@JN<A2?O$$#.#7I?CGQ_H'PWT%M8\1ZE#
MIEAYJ0+)+DF21CA410"68\X4 G@U\[>)_P!E/Q0WASQ!X=\+7?AK1]$\2Z%I
M^FW]O+%<,+&2UWX%L.=T;A\?.05.6^;=@>R_&/P#K?C"+PMJ7ANYL(=>\-ZN
MNJVL6J!_LMQF":W>-R@+*=D[%6 .&4<8)H YSPE^U+X1U?P;)XCU?4+32[&7
M6=3TVQ:*5I_M4-I.\9G4*N=NU0S'&$W $UIVO[0.A1ZQXS74I[:TT70YM/BM
M=1BE,POOM5JLZ%%523][ "[L@9KR>;]DOQ&?[)U2YO-#UO68+O79+NTEFO+&
MTDCU*\6Z)C:$[U9&0*58,K*>H(!KH;G]G;Q7HUGJ\?A76=/T2"\N='(T^SEG
MM8VL[.P%L]J)E5I(5+*K*R9;:@4D;B: /5-.^-O@?5M.FO[3Q+83V<.D'7I)
MDD^5;(,Z-,3_ '5:*13W!4@@&NQLKR+4+."Z@;?!/&LB-@C*L,@X/L:^1M4_
M9C\0:5X;^$WA99_MMTVI:EI_B:^LXY7@DT:YN9-0GC>1_F#-)%;Q@N26,DG7
M)KZ_48% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %>677[/&@S:CJ%W!J_B&P^W7<U]+!9ZH\<0EE<R2%5QQEF)Q112,YTX5/B
M5R/_ (9VTC_H9/%7_@X?_"C_ (9VTC_H9/%7_@X?_"BB@S^KTOY0/[.NCD$'
MQ'XJ(/!']L/_ (5Z'X7\.67@_P -:5H6G*R:?IMK%9VZNVYA'&H503W. .:*
M*"X4H0=XJQJ4444S4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
:HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>pasg-20221231x10k010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pasg-20221231x10k010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %Z \0# 2(  A$! Q$!_\0
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M(2Y0I=LP8A8&SB4C8V0N<8YKTN@ HHHH **** "BBB@ HHHH **** "BBB@
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M^Y? /[/_ (!^&'PUN? /AGP_'IGA2Y$HFL%GE?S/,&')D9BY)'&=W:J?AO\
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M>2377^'OV7/!</P1\%?#CQ!ID>L:9X;CMI8U262%3=1'>90493S(6;!XYY%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%8WBWQ;IW@G19=4U,W/V9&5 EG9RW<SLQPJI%$K.Y)[ &@#9HKR]_
MVD_ A\+Z1KUM?:CJ-KJM]-IEM;:?HUY<7GVJ(2&:%[9(C+&Z"*3<'0;=O->A
M:)J\.OZ19ZC;Q7,,%U$LJ1WEM);3*",@/%(%=&]58 CN* +U%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %<QXO^)_@[X>^7_PE/BS0_#7F#*?VQJ4-IO&2./,89Z'\JZ>O
M!_BW90_#77SJWA?X567B;6=?@N_,O[?23<3R:D3"MJEQ,H)BMV#2L\CG:HBP
M,$@$ ]C\.>*M%\8:<NH:#J]AK=@QPMUIUREQ$3Z!T)'ZUX3XXUO5_&O[0>A:
M-K/@[Q1%X-\,:A!>6-W:Z69K;4]19"$GDF#_ +NWMQ(3@C+2<G"Q@/U_P&\(
MK91ZOK6K>$=#T/Q:+N?3+K5=%TIM.35(8Y 4G\IB6P3D#<S9VDJQ5A7K>T9S
M@9]<4 ?-W@C2-=TOXWV<'A'1?&_A_P ,_;]2N_$T7B2=7TJ;S?-=39AI'.]K
MEUD!BVJ$+[N2HKZ$URRNM2T:^M;'4)-)O9X'CAOH8TD>W<@A9 K@JQ4\X8$'
M'(JZ  <XYI: /%/@_J'C"U^)OCWP;XB\8S^*X='L]+O;6_N=.M;693<_:@Z$
M0HJ,H^SH0=N>6Y/&/7_LMQ_S^/\ ]^T_PKRGX?\ _)S7Q9_[ OA[_P!"U&O8
MJ!6*?V6X_P"?Q_\ OVG^%'V6X_Y_'_[]I_A5RBF%BG]EN/\ G\?_ +]I_A1]
MEN/^?Q_^_:?X5<HH"Q3^RW'_ #^/_P!^T_PH^RW'_/X__?M/\*N44!8I_9;C
M_G\?_OVG^%'V6X_Y_'_[]I_A5RB@+%/[+<?\_C_]^T_PH^RW'_/X_P#W[3_"
MKE% 6*?V6X_Y_'_[]I_A1]EN/^?Q_P#OVG^%7** L4_LMQ_S^/\ ]^T_PH^R
MW'_/X_\ W[3_  JY10%BG]EN/^?Q_P#OVG^%'V6X_P"?Q_\ OVG^%7** L4_
MLMQ_S^/_ -^T_P */LMQ_P _C_\ ?M/\*N44!8I_9;C_ )_'_P"_:?X4?9;C
M_G\?_OVG^%7*SM<UZT\/VGVBZ8X)PJ(,LQ]J5[";45=DOV6X_P"?Q_\ OVG^
M%'V6X_Y_'_[]I_A6)IGQ#TC4$<R2-:,O.V8=?IC.:2;Q_8L^RTAN;Y^PBCP/
MUY_2ES(R]M3M?F-S[+<?\_C_ /?M/\*RM<UV#P\J&[U"7>_W8XXE+$>O2JO]
MK^(]0S]ETJ.S0_QW+\C\./Y5R_B[PMKUQ(EY<8OW(VL+9<[/PP*ER=M$8U:T
ME&].+9V^C:I%KUN9;34'8*<,K1*&7ZC%:'V6X_Y_'_[]I_A7 >$O!^M0PRW"
MW3Z4SX 1DR6'N.U=";#Q5;CY-1M+D#M(F#_*A2=M4.G5FXISB_Z^9O?9;C_G
M\?\ []I_A1]EN/\ G\?_ +]I_A6#]N\56X^?3[2Y'_3-\'^= \5:K /](\/W
M''>)MW]*KF-/:Q6Z:^3-[[+<?\_C_P#?M/\ "C[+<?\ /X__ '[3_"L)?']M
M&<7-C>VY_P!J/_Z]6(?'NBS'!N6C/^W&P_I1S(:JTW]HU?LMQ_S^/_W[3_"C
M[+<?\_C_ /?M/\*KP^)M*G/R:A;_ / G _G6/=_$K2K6^, $TJ X::-05_#G
MFCF2&ZE.*NY'0?9;C_G\?_OVG^%'V6X_Y_'_ ._:?X5/;W$=W DT3!XW&Y6'
M<5+3N:Z,I_9;C_G\?_OVG^%'V6X_Y_'_ ._:?X5<HIA8I_9;C_G\?_OVG^%'
MV6X_Y_'_ ._:?X5<HH"Q3^RW'_/X_P#W[3_"C[+<?\_C_P#?M/\ "KE% 6*?
MV6X_Y_'_ ._:?X4?9;C_ )_'_P"_:?X5<HH"Q3^RW'_/X_\ W[3_  H^RW'_
M #^/_P!^T_PJY10%BG]EN/\ G\?_ +]I_A1]EN/^?Q_^_:?X5<HH"Q3^RW'_
M #^/_P!^T_PH^RW'_/X__?M/\*N44!8:@*H 3N(')(ZTZBBD,**** "BBB@
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M6X_Y_'_[]I_A1]EN/^?Q_P#OVG^%7** L4_LMQ_S^/\ ]^T_PH^RW'_/X_\
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MJ5/[4M/^?F+_ +ZH_M2T_P"?F+_OJK=%&@:E3^U+3_GYB_[ZH_M2T_Y^8O\
MOJK=%&@:E3^U+3_GYB_[ZH_M2T_Y^8O^^JMT4:!J5/[4M/\ GYB_[ZH_M2T_
MY^8O^^JMT4:!J5/[4M/^?F+_ +ZH_M2T_P"?F+_OJK=%&@:E3^U+3_GYB_[Z
MH_M2T_Y^8O\ OJK=%&@:E3^U+3_GYB_[ZH_M2T_Y^8O^^JMT4:!J5/[4M/\
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M99>L%@X.+T5]%IUV?7JCY; Y%BXYB\=C9J2WMJ]7ZKIT9T5%5=]Y_P \8/\
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M%D%,;DC<C.!R17T1\5+?PO=> ]5B\9W-G:^&VC NWU"\^RV[#<-JR/N4;6;
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MO_B:+!<M455WWG_/&#_OZW_Q-&^\_P">,'_?UO\ XFBP7+5%5=]Y_P \8/\
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M/^_K?_$T;[S_ )XP?]_6_P#B:+!<M455WWG_ #Q@_P"_K?\ Q-&^\_YXP?\
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MB2"-8XU"(HP% P *5$6)%1%"JHP !@ 4ZFE8N$.75ZL****9H%%%% !1110
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M( !Z!17CWAK]I'3_ !'XNTO3QX<U>T\.ZU?W.E:/XGF,!M+^Z@\SS$5%D,J
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M.:)@\4BAT8=P1D&I*\K5:,^@5FKHI_V5:_\ //\ \>/^-']E6O\ SS_\>/\
MC5RBB["R*?\ 95K_ ,\__'C_ (T?V5:_\\__ !X_XU<HHNPLBG_95K_SS_\
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M ,>/^-7**+L+(I_V5:_\\_\ QX_XT?V5:_\ //\ \>/^-7**+L+(I_V5:_\
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M+1QZY\#I/K!O7_MU]5Y;^IU1Q=;+WR8_6'2HEI_V^OLOSV]#Z<_LJU_YY_\
MCQ_QH_LJU_YY_P#CQ_QINC:W8>(=,M]1TR\AO[&X4/%<6[AT<'N"*NUX3O%V
M>Y[Z<9*ZV*G]E6O_ #S_ /'C_C1_95K_ ,\__'C_ (U<HI78[(I_V5:_\\__
M !X_XT?V5:_\\_\ QX_XU<HHNPLB""RAMV+1IM)XSDFIZ**0PHHHH *\._:/
M757U7P@)I/&L?@??=?VPW@(7'V_S]J?9=_V;_2/(_P!?N\KG=Y>[Y<U[C7R+
M^UAI'A?P!X@T74C9%+K7+MKB]O-5\6ZK96[*LUO&\%ND-RB"=EG:11PH6"0X
M.. #V?\ 9QD\22_#MF\1+K2QC4+I=*/B48U0Z>)/]'-T#\WF8S]_Y]NS?\VZ
MO4Z\I_9QU+1=0\&ZM'X=B/\ 8=GKE]9VEV-2GU!+Q(Y,>:DTSNS#.5.&*[D;
M'%>K4 %%)D9QFEH \=^'_P#R<U\6?^P+X>_]"U&O8J\=^'__ "<U\6?^P+X>
M_P#0M1KV*@ HHHH **** "BBB@ HHHH **** "BBB@!DTJPQ/(WW44L?H*^0
M/%'[8'B6/Q5<?V3:6,>D02E$AGB+O*H.,LV1C/MT]Z^P'02(RL,JPP1ZU\W^
M)OV-K/5O%$U]8:\UAIMQ*97M6M][IDY(5MP&/3(X]Z^KR"KE=.=3^TE?32Z;
M7GMU['Y]Q?0SVO2HK))--/WK-)]+:NVF]T>B>%OBS?\ Q"^'EWKGAWPY<2ZI
M"!''9WK"*.9\<[),X91SZ?A53X>:3\1'O)KCQ!;Z9HT,C;Q%:7#2.,_PE?F4
M_7=7HGA?PY9^$?#]CH]@I6TLXA$FXY)]2?<G)_&M6O+J8VE!U*>&I)1D]&[M
MI=%O;\#WZ&78BHJ%7&5Y.I&.JC91;ZNUK^6ZVV/G3Q?\&-+N?$UW/K6JZOX@
M,CF58KVY(CCR<@*%[#IU'TKE)/V8-/\ $WB*T72+TZ78YS=12,7(4?\ ///?
MZG%?27B3PG_;,RW$,BQ3 ;6#CAA^%2>&O"XT1GEED$L[#'RCA17N4\^Q%&@G
M3JOFM:W3[MCY^OPGE^*K.-7#IQ;O?KW^+XOE<Y:Y\$>)/ WP_ATCP+J2W-[;
MR[U;7&\TLG]P$  >W'Y5YIXS_:.\;^ ]%>TU[P=%IFN2-M@NS)OM9 .K  Y/
MT#5]*5P'Q@^$5A\6]"CL[BX>QN[=_,M[I%W;#C!!7C(/UKS\OQV&E72S&FI1
M;NY6?-^#U7E9G;G&4XV&%E+)JTH3C'EC"ZY6EVYD[.VS36MKGE?P(_:9U'QC
MXE70O$ZVB27 /V:[A7RLO_<89P<]L5]("5&=D#J749*@\C\*\/\ A-^RWI?@
M'51JNK7B:[?QG-NIAV10G^]@DY;^5=!XU_9V\.>,M=N-;-YJFEZK.07GL;K:
M"0,9P0<?ABNC,_[)Q&-?U:3A3MNHW5_)732_JQQY%_K%A,L7UZFJM7FV<[2Y
M?-I23=]M=MV>I9I:\[\2> _%*^%=)TSPMXPGTVZL>'NKZ(3O<C_;8@_RH\(6
MWQ(T71]7/B*YTK7[V-,V"V@,1D;'1SM4#\OQKQ?JD'3=2%:+UM;5/>U]5;SW
MT/J/[0JQK*C4P\TK7YE9QVNUH^:_3X=7L>B45\W^-?VBO'?@W0Y1JW@(Z->R
M'RX;Z28R6X;Z 8)]MU<U\%/VF/$^L^.++1_$,\6HVE_)Y2NL"QO"QZ$;0,CV
M->O'AS'2P\\2N7ECVDG>V]K77XH^;GQKE-/&4\%+G4YV6L'&S>B3YK/[DT?6
MM%)2U\N?>A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5E>*O[5_X1G5O["\K^V_LDWV'SQ^[^T;&\K=[;]N?
M:M6N%^,GA'1O$W@J^N=9T[4M6328)K^&RTO4KFRFF=(V(0-!(C$MC !R,D<4
M >$_!-O$L?Q"\)I8M\4Y)GM9SXP_X3D7']GH_E_)Y!F'E>;YV-HM#Y>PMGHM
M?6%?%/[-GBCPO/XY\-):_P!GWWB.XU&_M"ND>+=4U&**U2U659_*N+AP5!<1
M,SJ!O9=N#Q7VM0 44A('4XI: /%?VR_^3:O'/_7K%_Z415[-#_JEKQG]LO\
MY-J\<_\ 7K%_Z415[-#_ *I: )**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH SO$-[/IN@ZC=VT
M7G7$%O))''_>8*2!7Y&ZQ\9?'-]XRF\03>)-4AU<3%PZ7+KY1S]U5S@*.F,8
MK]@B,C!YKRK4?V6OA?JOBP^([GPG:OJ1D\UL22+"[YSN:(-L)S[5]7D6:X7+
M?:?6*?-S+2UG\M>C/D<_RG%9G[+ZM5Y>5ZW;7STZH\J^%O[,:?%/2M'\:_%3
MQ!JOC#4+R%;B+3+J0Q6T /(&U3SQV&T<]*^FM"\.Z7X7TV+3](T^VTRQB&$M
M[6)8T7\!5^.-(8UCC4(B *JJ,  = !3J\7%XZMC)>_+W>D=DO1+0]S!X"A@H
M_NX^\]Y;MONV]0HHHKSCT@HHHH **** "J&NZ#IWB;2KC3=5LH-0L+A=DMO<
M('1Q[@U?HIIN+NGJ)I25FKH^ OV@M/UW]D/58X?AUXIU#3-$U]7=M,E594MF
M!Y,;,#@^^,^YJA^S]^VQXJT'4KBP\81ZKXTL'C+Q&SA62[A8=?3<OU/%?9_Q
M@^"OAOXV^'TTOQ##*/)8R6]W;.$F@;H2I((Y[@@BN>^"7[,/A'X&37-WI!N[
M_5+A?+>^OW4NJ?W5"@!1Z]S7W4,XR^KE[AC*7/6[V2;[/F6NWS]3X&>39C2S
M%3P=7DH]KMI=UR[:OY'&)^W?X$C'^FZ)XIT\]_/TU>/RDJ=?V\_A0T$C_;]1
M215)6*33W!8@<+D9 STKZ'>-9!AE##T(S65J_A#1=>L[BUO]+M+F&>-HW$D"
MDE2,'G&1Q7SZKY:W[U"2])_YQ/HGA\S2]W$1?K#_ "D? [_\%#/&_P#PEWVM
M-,TO^P!+C^SC$WF&//\ SUW9W8[XQ[5]]^%O$-OXL\.:;K%J"+>^@2XC#=0&
M&<5\CS?\$X]-?Q>;E/%DJ>'3+YALOLG^D!<Y\L2;L>V['X5]@Z/I-MH6EVFG
M648BM+6)88D'95&!7I9Y5RJI&E_9RL^NC7WWW9YF0TLVI3J_VD[KIJGKUM;9
M%RBBBODC[ **** "O"_VIK-]3TO0[*VM_%%]?W,DL=O::-8V%U83,=F!>K?C
M[,%SC8697SNV$G(/NE?(O[;FJ:!J>K^';"+4]*O_ !/I"&\&AWVFWU^($>>"
M1+S-G;SM;R@VS(DCIRLLH4@T >]_ R/QE!\.=/A\<V&@Z9K<+/$+7PZ3]FBA
M4XC4K]U9 !AE0E0?NDBN^->6?LWVQF^'DFO-K6E:Z?$FHW6MF;0G=[&+SG_U
M4+. S!=OS%E4ERY*KT'J9&10!\W_  \FUGP'\9$LO'*^+AJ'B75]5BT6]E\0
M_;='GC#S7$,7V4/^X9;9/ERA&8V&X$C/T'KFJC0]%OM1:UNKY;2!YS;6,)FG
MEV@G;&@Y9CC  ZFN0\/? SP5X7\8/XHL-(?^W/WHBN+J^N+E;;S3F7R(Y9&2
M#=W\I5R..G%=[UH ^=O@;XZ3QG\>_BMJB:%K^C*VE:#%]EUO37L[CY3J'S>6
MQSM.>#W(/I7OO]H_].]Q_P!^C7E'P_4#]IGXLX '_$E\/?\ H6HU[%BF(J?V
MC_T[W'_?HT?VC_T[W'_?HU;Q1B@-2I_:/_3O<?\ ?HT?VC_T[W'_ 'Z-6\48
MH#4J?VC_ -.]Q_WZ-']H_P#3O<?]^C5O%1S7$-OCS9$CSTWL!F@-B#^T?^G>
MX_[]&C^T?^G>X_[]&IHKN"9ML<T;MZ*P)J7% +4J?VC_ -.]Q_WZ-']H_P#3
MO<?]^C5O%(64'!(% %7^T?\ IWN/^_1H_M'_ *=[C_OT:M JW0@T,RH"6( '
M<T 5?[1_Z=[C_OT:/[1'_/O<?]^C4%UXCTVTSONHV(_AC^8_I7GM]?//>SR1
MRR!&<E>2.*[J&$E6O?0\G%YC3PUK>\_)GI/]HC_GWN/^_1H_M'_IWN/^_1KG
M?#/B.SM;!8+J9DEW$[G!(_.NFM[VVNQF&:.4?[# UA5HRI2::T[G7A\33Q$%
M*,E=]+D?]H_].]Q_WZ-']H_].]Q_WZ-6^*;O3U'YU@=96_M'_IWN/^_1H_M'
M_IWN/^_1JWP:,4 5/[1_Z=[C_OT:/[1_Z=[C_OT:MXHQ0&I4_M'_ *=[C_OT
M:/[1_P"G>X_[]&K>*,4!J<?\0?"&E_$CPW/H^J6MVL3D,DL4>'C<=&%>=_#'
M]F_1/AWXB369;J_UB[AR;=9+41I$?7 )R?QKW3%&*]&CF6+H4)8:E4:A+=?U
M^AXF)R3+\7BX8ZO14JL-GZ;>3MTNG8J?V@/^?>X_[]&C^T?^G>X_[]&K>*,5
MYQ[>I4_M'_IWN/\ OT:/[1_Z=[C_ +]&K>*,4!J5/[1_Z=[C_OT:/[1_Z=[C
M_OT:MXHQ0&I4_M'_ *=[C_OT:/[1_P"G>X_[]&K>*,4!J5/[1_Z=[C_OT:/[
M1_Z=[C_OT:MXHQ0&I4_M'_IWN/\ OT:/[1_Z=[C_ +]&K>*,4!J5/[1_Z=[C
M_OT:/[1_Z=[C_OT:MXHQ0&I4_M'_ *=[C_OT:/[1_P"G>X_[]&K>*,4!J5/[
M1_Z=[C_OT:/[1_Z=[C_OT:MXHQ0&I4_M'_IWN/\ OT:/[1_Z=[C_ +]&K>*,
M4!J5/[1_Z=[C_OT:/[1'_/O<?]^C5O%&* U$1MZ!L$9&<$8(IU%%(84444 %
M%%% !6?X@*#0M1,ANPGV:3<=/#&XQL.?*V_-O_NXYSC%:%<C\6]:T70?AOXB
MN/$&O+X8TN2REMI-5+8:W,JF-63')?<PVJ.2V .30!X1^SYI_C>U^)$E]I^D
M>7X&ODD^VZGXRL]/M/$,\BCY0OV+F0!OO?:E609]>OU+7Q!^RCI\>H?$.STJ
MVO\ PMHUCHEY=ZY!I6FZ;J&G7EV)H%MMRVUW;P[(<Y=RIERY0$C&3]OT >0_
MM$>&?%_B2U\*KX836;FSMM3>75K30=<_LFZFMS;RJH$VY<@2M&Q7<,X]JZ?X
M*^+=*\;?#'0=5T5]5>P>%H -<D,EZKQ.T4BS.6;<ZNC MN;)&02.:O>/?AGX
M?^)=G;6VO6]W+';.SQ/9:C<V4JEAAAYD$B-@CJI.#@<<5J^&?#&E>#- L-$T
M/3[?2])L(5@MK.U0)'$@Z "@#Y[_ &W?B+'IGPF\4>%SX=\27;WEG PU6STF
M273X=UPG$DX.U"-O.>F1ZU]%I?;%V^1<''<1&O(OVRU'_#-7CDX&?LL7/_;Q
M%7LT(_=+0!7_ +1_Z=[C_OT:/[1_Z=[C_OT:MXHQ3%J5/[1_Z=[C_OT:/[1_
MZ=[C_OT:MXHQ0&I4_M'_ *=[C_OT:/[1_P"G>X_[]&K>*,4!J5/[1_Z=[C_O
MT:/[1_Z=[C_OT:MXHQ0&I4_M'_IWN/\ OT:/[1_Z=[C_ +]&K>*,4!J5/[1_
MZ=[C_OT:/[1_Z=[C_OT:MXHQ0&IS7BKQ#-8V*K;I+#+(V-[IC ]O>N;T3Q3>
M6=\GG7$D\#-AUD.[CU%=YJ^D0:S:&";(YRKKU4^M8^F>!;6RN/-GE-UC[J,N
M%_'UKU:%;#QH.,UJ>37HXB5=2@]#:_M$$9%O<$>HB-']H_\ 3O<?]^C535O#
MRZE,DR7,UK,B[5:)N,?2E,>I:=I86-EU&Z5NLGRY7_&N#DBTK2U[;?CL>ASS
M3?-'3OO^&Y:_M'_IWN/^_1H_M'_IWN/^_1K*7Q1)!:W$EYI\UM)$N<-]UCG
M -8=KX^N_M0\^&)H">50$$#V-;PP=6:;2V\S"6,I0:3>_D=C_:/_ $[W'_?H
MT?VC_P!.]Q_WZ-68W66-77E6&0?:G8KB.TJ?VC_T[W'_ 'Z-']H_].]Q_P!^
MC5O%&* U*G]H_P#3O<?]^C1_:/\ T[W'_?HU;Q1B@-2I_:/_ $[W'_?HT?VC
M_P!.]Q_WZ-6\48H#4J?VC_T[W'_?HT?VC_T[W'_?HU;Q1B@-2I_:/_3O<?\
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M;PYK*^)Y]*EU;5=:O-7DBT7S?LD/GL&*)Y@#?>#,20,LY/>O2J\\^!46HQ>
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M,@C!!K._X1S3?^?.+\J]##XU4T_:*_I8\;&96ZSC[)V2[MO[MR71O^07:_\
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M_P#@DT3_ .0J /8J*^:_&'@;XQZ+XO\ "&G:7\8?%FH:9J=Q-'J-X/#NCO\
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M_P!2^-WBRPU&ZLX9[FU.@Z*GDRM&K.FUK+(PQ(P>1CFM;_A3OQ%_Z+SXK_\
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M#V*BOFSXG^!OC'X4TC3;CP_\8?%FM7,^I6]K/"/#VCR^7 [$2282S!&T<Y/
M[UV ^#WQ%(_Y+SXK_P#!)HG_ ,A4 >QT5X[_ ,*=^(O_ $7GQ7_X)-$_^0JY
M/PIX!^+^L>+/%^GZE\9/%ECINF74,.G79\/:.GVR-H%=VW-9X;#EERN!Q@\T
M ?1U%<%X$\!>*_#&J2W.N?$O6_&-LT>Q;/4=.TZW1&S]\-;V\;9]B<>U=[0
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M*"Q&3[5\W?L;O#!KGCZV\[PYJ=X6L9)M5\#A5T*4>4RJD2*,),N"7^9LADZ
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M/KMMJ5A+<V2X7Q3.!(-@M#@G;@Y/!& W(KEI1H-QXCDM=M@?C0/B!YJ@HO\
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MM\,OBC\)?"O['.F7&L_\(SXCTG3=6O+&RT82VLT7VN2_N1:P .?+C+*P(9R
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MI=IJ&J3:5I5Q<VFFB= 0\\B*PB0DG&XDX&3QS0![#>6%MJ$8CNK>*X0'(65
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MN^(;ZYO[>;P9:Z1INHV%Y9V\LMQ=/=/*H147+.S%%"H%#9)!YZ 'M2J$4*H
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M7L=% 'Q5\5?V8?$7A+7;5?"EOJ?B+PG)>W5^+-99[FYM)IH@CH[&_MY98Y"
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MKZZEMX&OW\/-HL>EZ5 '2R9;E989AF1QG$:EHRS\L?G/4_2A&>M+0!X/X_\
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M_I6E10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 53FUBPMY&CEO;>.1>"K2J"/PS5RLB
MX\*:3=SO-+91M(YW,V2,G\Z3OT(ES?9(=7\9:9I-H9OM,=RV<+' X9B?SX'O
M4>B>.-,UB%G:9;.1#@QW#A3]0>]5M9^'NFZA9^7:QBRG!RLBY8?0@GI4>A?#
MFQTZ!Q>A;Z9CU(*A1Z 9J/>N<U\1S[*QT UW36( U"U)/0"9?\:\2^+?[2&I
M?#/QWJ.FQZ/I%]I&EVFGW-RLVJF#4;DW4\L02U@\LK*R^5G:6!8L ,5["/!N
MC @BPCR/=O\ &N?A^$FD?\+5U#QS=06=]J$UC:65J)[*-I++R6G8O'*<L-WG
MX(&/N#KVM7ZG3'G^U8K>&_B9JFL?%OQ#X0OO#ITJTT^QBO;2]DNUDDNU:1HR
MQC4$1KE>,L6/.0O%6-)^)\=WXM\<:5>6@M;/PS':RM=(S2M*LL;N?D"Y&-F,
M#).:H:9\,_$=G\9[_P ;7'BBPN-,NK%=._L>/1FCD2)69T/VC[0<L&8Y/EX(
MXP.M8WB;X'^)-4\4>,K_ $?QTN@:?XIM(;:ZB@TLM>6YCC= \%R)UV'Y\\H<
M8ZTRR/Q!^U/X6TDZ*+/3]>U.2^UI-%GM4T:[BNK*5X_,#2P/$) "N"/E&X'@
M\&NQTWXR>%-6\6_\(Y;7\SZB9I+5':SF6VDGC3?)"DY3RVD5024#$C!XX./+
MM$_91NO#]O-/8^*K.TU@ZW::W!+;Z*5M(W@B\HH86N&=@ZEB29<ACG)Z5O>"
M?V;+/P5\2+KQ)#<Z3>64M_<ZE%%<:*IOX)YP=^V[\W 3<SD#R]V&*[L4 :>N
M?M":%X/\9Z[HOB%9+&&S>Q@LY;6":[FO)[E9V$2Q11LV?W'&,YSVK"O_ -I&
MVU3X@>#-(\.;IM#U6PNM5O=2N-'O9-L,$@C:)=J@12!RP;S/NE=I7+"M[6/@
M2FK?$T>,/[;>%Q>65W]C%L"/]'BN(]N_=_%]HSG'&WOGC+T[]G%M,@=;?Q9>
MVLYL=7LTNK.$131&^NEN/,1MQPT97:/7KQ0!L/\ M*> H-/>ZGU'4+5EO8].
M-G<:->QW9GD4M$@MVB$IW@':=N#V-44_:7\.:CXN\/:)I5GJFH1:WI]U>PZB
MFFW(A@:"01O'-^ZS&0Q(;=@IMY'(KG? O[*1\(ZK#J,WB6&XG35++4V2STPV
M\;FWB>/:=TTC$OOW,Y8G/;TV-(_9WNO#^M:9J.G^*0KV\NJ"YCGTX2">"]F\
MUHU(D!1E(4!_F! .5YX '^$OVA+6]&KWFN/96^DVEAIMU!<:<EQ.UQ)=&4!(
MT*"1R3&H51&&))XKTGP=XTTCQYI!U'1KAY[=)7MY4FA>&6&53AHY(W 9&''!
M Z@]"*\<NOV2[2Z\(SZ-)X@\Z3[/I26\T^GK)&DMBTC([Q;_ )U<R89,C@<-
MSD>H_"[P"GPY\+C2@-+\UIWN)7TC3180.[8Y$6]SG  )+L3CK0!U]%%% &?K
M?B#2_#-@]]J^HVFEV2$!KB]G6&,$] 68@5S/_"[_ (=_]#YX:_\ !M!_\76M
MXV\!>'_B+HQTKQ'I<.JZ>7$GDS9 ##H0001^=>?_ /#(OPB_Z$FR_P"_T_\
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MAMM*;[9;R):PP )<K<+\C?9U++L!*LZAER&#++5[^T]X8CU3PE:6.GZ[J/\
M;NK7&C2"/1KM)M/GAMVF99X6BWH<!.& ^5]_*J375Z#\8_"GB3Q0V@6&H2R7
MY-PL+26DT=O=- VR=8)F01RF-N&",<$'T.///#'[,EYX3@L9]/\ $]G:ZI:^
M*)?$B-!HNVT EL_LDMNL/G%@/+W$.9"0Q!.[&#H?"[]FVS^&'C*75;>XTF]L
M8YKR>R#Z*JZC;FXD:1E:[\T[E&]U&(U)4@,3CD OW_[1.A>&_%?B/1M?CGLC
M8ZG%I>GBRMI[V>_E:R6[95BBC9@P4OQSD+G/:L-OVEK36/BGHFCZ&PG\*R^'
MW\17>K-I5[-YT)8K&D3(H6-@5;<'!).$"AC72+\#8U^*$OC'^V7W/JIU3[']
MF& 3IOV'9OW>G[S./;'>N5TK]E=]&\/W6GVGC34+*XE\.S:"E_90"&:(O=/<
M><I#Y!!?;M!&0,[@3P =;/\ M(>!;72X+V>]U.&2;4'TI+"31+U;[[6L/G^2
M;;RO-#&+YQE<$$$=:R$_:>\/:IXL@T71[:]O8+OP])K]MK)LK@66Q6*[9&$1
M,>"#NSRI&W&X@54\ _LSCP9J]MJ3:[;/+%KLNMFWT_3/LL&7T\V7E*IE=@,'
M?N+,2<@]<U'H/[,L_AO^SDLO%9,4>D:AHU\LVG!C<17-PTZLA$@\MD=L<[@P
M'12<@ N^$?VB;.]BUVZU]K:"SM'TV*Q_LN&XN9;V2ZM4F"1Q[/,D)9R% 0':
M,D#G'J'A/Q9I?C?0X=6T>X-S92L\>7C>)T='*.CHX#(ZLK*58 @@@UXC?_LA
MVEYX>-B?$"37D5SIEY:RWFFB:!)+.T6VQ+#Y@\Q)$#9 92-W!R,UZ]\-O!,7
MP^\(VFBQKIZM$TDDK:78"RMW=W+,RPAGVYSSEF)/)))H ZBBBB@#,U_Q-I'A
M2Q^V:UJMEI%H6">??7"0IN/0;F(&:YS_ (7?\._^A\\-?^#:#_XNM'QW\./#
M7Q,TN+3O$^D0:O9Q2B:.*8L-C@$;@5((."1U[UPG_#(OPB_Z$FR_[_3_ /QR
MO2H+ N'^T.?-Y)6_%H\S$/'J?^SQ@X_WG*_X)G$^)/V]/ &@>-_[#B@O=3L(
MY!%-K%F4:!3W*C.74=R/PS7KT?QS^'4L:NOCOPWM8 C.JP _D6XKYP\2_P#!
M.S2M2\<->Z5XB.E^&Y91(^G&W,DL0[HCEL8]"1D>]>R1?L@_"**)$_X0NT?:
M -SSS$GW/S]:]K%PR)0I^QG.]M;+\[VU]-#P\'4SZ4ZGMX0M?2[?X6OIZV9L
M^/\ XV:3H/PO\1^+/#-]I'BAM)@+^7!J*F'?V$DB;M@]\&N6T'XX>+O$^A>*
M%TOP_P"&[K6O#EY]GO+E==D.ER)Y/F[HYUMRY<#"E"@VD@DX-;6J_LT^#1\/
M/$?A/P[IMMX<MM=B$5U+%$9]P'3<KM\PP3QG'-3_ !1^"T_C#P79>%_"^JZ?
MX,T5+D2WEA%I EMKR$<F!DCEA*HS8W;3\PR#UKYFM[)3?L6^7I??\#ZFC[5T
MU[9+FZVO;\;$-U\<G3X*:#X_BT1HVU1+-_[.N)]IC\]U7[X7Y@-V0<#<,=,U
MT_B7XL^'?".O6FDZI+>P7%RZ1K.FFW,EJCN=L:/<+&8T9CP S DUE>._A=J?
MCKX6Q>%YM<L[#5(S ZZE:Z7BW5XI ZXMO-X7Y0-OF?C7#>)/V9]=\;>*++6_
M$/CBVU"X@N;2Y,::,ZI"8)"^VV5KEA"),@.2')VC!'2L38W_  C^TYX9\1^&
MKK6+NQUG2!%JDVE16D^E7+SW4L;,/W*+'NDX0D[0=O\ %BMSQC\8['1OA>/&
MNB(FMV,C1B)69H=VZ01L#E=RE3D%2,@@@XKA-9_97DU?2OL3^([.X6SUR?6M
M+6_T83Q0><'\V*=!,OG [VPP,97CK79ZG\%H-2^$EOX(2[M-,2/8S3Z9IRP0
M[ED\PE( Y"@G/&X]<DDT 9][^T_X(:WUM-,O+W4;_3H+N00II=T$N)+?/FQ1
M.8]LCJ1RJ$G'.,54\ _M#V%SX.\+ZAXODFL-1UV.*96MM!U"&TMQ*1Y22R2(
M1&23@,[*&Z@8-.7]G1!;:7#_ ,)!(18S:I*#]E'S_;5D!'W^-GF?CCMFL+Q7
M^RE-XGN?#^_Q<WV+2K.PM4M[JP,_EFUQ\\'[Y5B,F!ORKG@8(QR =5-^TYX%
M<ZM%87=_J5YI\5TWDPZ7=!9Y+<$S112&+9(ZXR54DXYQBN;U?]IIY_!NF:_H
MVFQP&^TJ/4DT_6(;F"Y4-+&A^4QJI0>9][<"3@@$<ULV_P"SK%%%I,3:_*Z6
M%YJ5V<6P!D%VCJ5^]QL\S(/.<=!69-^S-=:EH.F:?J7BT7,UAI"Z/'<0:8(@
MT2S1R(Q7S3\P$84\X.<X'2@#T&+XQ^%)O%X\-+J$O]I&=K17-I,+9IPNXPBX
MV>49 I!V!L^U=K7BWAS]FVS\-?$^[\407&DW-E/?OJ:V]WHJR7L$[* ?+NS+
M\JY&0/+W#D;J]IH **** *TNI6D#E)+J&-QU5I "*S]5\46FG1(\;I=%CC;%
M("15BX\/Z?=3-++:HTC<ELD9_6J&H>#;*ZC58 +1@<EE!;/MR:[*?U>ZYVSS
M:SQG++V27EW_ !5A^E>+;746D$FVTV]#+(.:TAJUBQ %Y;DGH!*O^-8^G>"K
M2T+FX878/0,I7'Y&KZ^&-,5@1:)D<]3_ (TZBPW,^1NW]=R:+QW(O:*-_7_)
M6/'?C'^T1J?PP\97&G6^DZ->:=8Z=%J-T;_5FM;J</,(Q';1^4RN_.<%AGI6
MA9?'B^F^,NF^#)--T:6#48'F2*QUCSM4LD5 PDN[7RP(D;.T?.2".]=5<_"#
M1]0^*@\;7\-I?W45@EE:PW-DDC6Q5]WF1R-DJ3TX ^M8E[\%]5U[XG:1XHUK
MQ/!>6&C7,EUI]E:Z0EO<JSKMV2W(D/F(!_"$7/<FN(]0S]=^.&H6GQO;P);-
MX5LHXH;>8MK6LO;7EUYF25MX!&0Y&/[U;]W^T)X'TU-9>_U&]TY-)A%S</>Z
M5=P!H2_E^9%OB'G)O^7,>X9JIJGPCUQOBG?>+M(\2Z?8V]_;P6]S97FB_:90
M(P1F*83IL)![JV/>N&T_]D66&^U6YO/&!O9[VT6S^U-IQ^TR 7(G#SRM,QE?
MC;D!!C&!0!U_A_\ :"TW5?B%-HMRKV.FW*6JZ7-<V5Q!--+*A?9(KJ/+X!(W
M!<UK>)?C/IUE\.T\6Z''_;-C)>16D9DWP*^Z81,P++D@$G'&#CK7%_'+X#ZC
MXJT?Q?J&AW=Q+X@U6.R2P6$)&UE-"0OG!V8 _*SDC\LUVVK?!ZVU/X6Z5X,@
MNQIT%E]E831Q;P3"ZN?E)'WBI_.@##U']J7P0=(UZXTBZO=4O--LKJZC@72[
MM4N6@!$B1.8MLA5L;@A)4'/2F^!OV@M/F\,^&9O%TTUEJNM+&ZO;Z#J%O:0F
M7_51R22H1&QZ#>R[NH&"*K_\,UQ_V/I=A_PD4N+&VU.W#_9!\_VQ<9QOXV?K
M[5E^*_V6)_$^N:)=OXN<V>FI8JEM=6!G,1ML<P'S@L0DQEOD8YZ'M0!T=W^U
M#X%%CK4NG75_JESIMK=7(@BTNZ5;EK<?O8XI&BVNRG&X*3@')XK%U7]I-YO#
MNF:MI&G)#]NLK2\6QU>"YM[I%ENEA)*-&HV@$X.[)(^Z1S5U/V;(#I>DV$GB
M"9HK$:HK,ML 9!>+M./F.TIVZY]JKO\ LWWNHV&FQ:IXL2ZNK+3K;3EGM],$
M*ND-T)T8KYK<D *>??VH [NU^,GA2[\7#PU'J$AU-IGM58VDPMWG09>%9RGE
MM(HZH&R.?0UVU>+^%?V;[3PI\3+KQ-!<Z3=6<U_-J4<-SHJO?032_>V7?F\+
MDG \O=@XW5[10 4444 %%%% !1110 4444 %%%>&>+_CMX_T#Q+J.G:=\'-8
MUBQMIFCBOX[K:LZCHZ@1, #]?KSQ0<6*QE'!14ZU[/32,I?^DIGN1('4XH!!
MZ'-?!?[3'[1_Q0&F:($\-ZY\,@9I"9UNVS=?*/ESY:].OXUE_LS_ +1_Q0.I
MZT&TK7?B8/)C_P!':[;_ $7YC\WW&Z].U3<^9?%6#6*^K<LK=^5]K_#;F_#\
M#]":3.*^>;;]HKXDRW$:2? S6TC9@&87AX&>O,(KF/BKX=\7^._C[K-CX8BU
M&UU*VT?1IK;5U\026EOHS-<71E=[57Q<%E3!78P;:%) .:H^CPF.H8V_L;Z=
MXRC_ .E)7^1]6YYHSS7S/X'$W@#X_P 5KJ%Q8^)7\6WVIM9:C8:]=SS62(K2
MF.:T=VA"*$\O<F-K;1CYC1:P7&I?M1^,+N\MX[W3](33I([BY\2W5L;(F*5C
MY=D@,<P) )W$9QWQ0>@?3-%?(D7[57C.ZM]<73?[$U$RVNG7^C7UUILMI"T5
MS>+;Y:/[0\CIM8,KGRF.#\GI<O?BGK'P9^(WC+6-;N[.^T>&\TVUUZ]%N\21
M![681RQJ9&\I?.\L%26X8\T ?5]%>$^-O%'B:X^"G@C6-98:1K]_K&C2W<%B
MSPK$);R(F$_,2<(P1@3@D-Q@XKR[Q9\;OB'KGPQU$7VH:%8MX@\-ZO?6,NFV
M,RR6)M9?+^9FG_>;T/4!-K=-PH ^QNM+7R;HOQ;U/X77_@KP=HDVB76D6DNF
MZ5J5I::-);K#+=C(83/=?*V#NV+')GG<R[N*/B+X\?$F^\#7,DNI:%ILNN:+
MJ]UIT^F6,RS6#V<K*K,S3D2;E!S@+M;&,B@#Z_S2U\?>*/%.JWDWAVSU/4;?
M5+YK/P]=3:K:--")V>_C!'E><\8&.I W$YR<'%>@?##XV^-?'GQ(DMGT2U3P
MO_:-_ITA"QQRVOV<L$DWFY+RERO*>2N X.<#D ^@:*** "BN<\>>)-3\+:"]
M[I.@7'B.[#A19VS[&P>^<'@>P-<UX!^)7B?Q5J4]MJ_@'4/#L,<1D6XGFW*[
M#^'E5Y/XUVPP=:I1=>-N5?WHI_<W?\#RZN98>CB8X2?-SRV]V37_ ($ERKYL
M]'S2U\0^*/VB_'T/Q#N&2[ETZ*WNC$NDE%*!0V-K#')/K[\5]'>+OBEXJT"7
M3TTSX?7^OI<6L<\D\$VQ8W89*8",<CWQ7LXKA_%X7V2DXMS5U[R5K6ZNRZ]S
MYK <89=C_;N,9I4FD_=;O>]FE'F?3JE8]0I,YKQOXC^+]:UK]G?Q=JUWH]]X
M5U1+&8+;-<E)EP!AED&TKG/7@BO&8[_Q?\+?A=J,MRFN>'=-\3"VMK&!;VZU
MZ?2U$!-Q=F5!(8R_&U<E01G()KYVI3E2FZ<MUYI_BM#[.C6AB*<:M/:2NKII
M_<[-?-'V52U\L^&?&DVI?L-VNKVFL:E)=0V0B.HW4LR7)*W&W<TCX<G&,MWY
MK>^-'[0NI>!/$%E:>'KS3=0CM4MI=1LY+%I3Y<T@12;GST6/.3@*DK$CD"LS
M8^B**^3;/XQ^._!FC^(3<:W:>([V\\9R:-9YT\%M.C.TC<K72AQ@X5"T?.>3
MG%=YXF\9>*=8_9FU[5]<MAH.OQQM&6L9U4X690LBF.1_++#JN\D<C- 'NU)U
MKY9D^-_CYHB);K0HM*OKZ_T.T$-G,;N%X;?>D[2F;:QSU4*/7-<9X.^+.M?!
MSX6^%[;2;W1;_46MH]7U>"/19%,ZSSA/,DF:[ 1B2?F D8G^ "@#[:I,U\QZ
MG\;_ !\VI7&;C0;?1[S6+[0;2."RF-W"T<.])VD,VUB#U0*/J*\\UCQMXAOO
MA%X977M:M_$.IWV@W<\FJ0F:!UVS( I43LC'U9@3Z;: /N"BOF[P[\<?&NK?
M$G^PM,T2WFT+3;ZWTNZ21(UD,;1!FN/.:Y4@],((6W#/-?2- !1110 45AWN
MN7]M=21Q:/-/&IP) W#?I57Q1K=W9Z5;O%&UM)-]XG!*>U=,</.3BM-?-'-+
M$0BI/73R9TU%</X3\0WTT\T,I>\ C+J"<MD=LUMVFNW]Q<QQR:--"C'!D+\+
M^E74PM2G)QTT\R*>*IU(J6NOD;F:,\U\K?&;0/%/C/X]WFE>&HM2-_!H]E-:
MZE#K\EC;Z4QN&WS- KXFW*"-NQL]#@<U1^'GC?4#\:!>>)K=]5N[OQ#=Z#:3
MIXHF6:R$2G:#IBJL0C(4DN2S98'O7&=A]<45X9-X_3PE\4OBK=ZCK*VMCIFE
MV=S&EY(\D,/[DDL(E.3D]0HR:\MU+XW_ !"\416UC%XAL/#]U8>*-/MWU Z2
M8%N;:XMVE"20_;'VCZR M\I*J>* /L6BOGKPA\;O&_BCXK3Z5#H]K)X<M=8N
M-'NB8XXI(EB4XN/,-SN8LP_U0A^ZP.XXR<WQ[\0/%?AKXWZMIWAV^M%GU&;2
M=.C75Q+/;6RR1W#/(L2.OS?NQT(SW- 'TO17QU/XVUOQSXY\&:[XHU/0H;'P
MW9:[<WD3Z;-);M/9RK&;E%$VY#C! PY4;@,[N-72_P!I+Q[J<MSH]L-%.IOK
M.GV=KJ%]I<ML@M[J!Y=S6ZW4C;ALRN77<",JM 'UA25\N^'OB9X[\5?$?P5'
M=^)M*T^U0:Y8:G906#K#J$MI/''O0-/E&8'('SE/F^]GCD/#?Q@U+P7IFI^)
M;"R6>]NM"T"&.$R23PV[3S2(9#YLNY@,_P 4@R< L* /M*BO/_@QXK\3^*_#
MEY+XJT^&ROK:\DMXI81&@N8@?DD,233")B#@H7/(KT"@ HHHH **** "BBB@
M HHHH **** "BDKP;Q#\??B'I6NW]E9?!;6=0M+>=XHKM;L@3*#@. (F&#UX
M)H.'%8VC@DI5KZ]HRE_Z2F>\D@=3B@$'H<U^?_[3G[1_Q0$GAX+HFN?#!2)_
ME6[;_3/N<YV+]S\?OU+^S'^T?\4##XB#Z!KGQ/ :WP6O&_T+B3_8;[_X?<J;
MGS7^M6#^M?5N65N_*^U_AMS?AY[:GWY29YKP?PU\>_B%K'B#3K&^^#&LZ99W
M,Z12WK79*P*QP7(,2C ZGD=*XC7_  _XL\9?M-^*HO#_ /:,,NE:CH$PUS^W
MY8;73[41B6Z@^Q!BLYFC#I@IC,@)8%!5'TN%QM'&Q<J-[+O&4?\ TI(^K\YH
MSSBOFCX.L_@#XTMH-]-8^);KQ1#JVIVNN:9KUW>-#;QW:N([BVE9HXQB=$5X
M\#,17 S4>C2-#^T#\4?$&J0P2:;H.HHT>I77B:[1K)%TBVD*+IR QNF69B<@
MY=C@D4'<?3E%?)FB_M*^/-9M]0LK1]"GU"74/#R:??W>E2VT7V;5)9$W-;BZ
MD<[5CWH6=&;< R+C)+WXQ:O\$/$_CC5]6DM-3T5O$+V.HRK$\;"\_L6TDM3$
M-[!$EEC:+8=WS31_-UR ?6=%>&_$K6_$MAX5^$D^L7"V'B"YU[35U2+3W>*%
MI6B=I8@-Q)CW C:2<X%>*^._C-\1O%GP4U:UU;4] LKGQ!X'C\1V\^DV,Z?9
M$:6&*:!BT^9-R3##C9M.>&&#0!]N45\RP_%_4_A]\0O#O@C2#H]YX=M;^/PW
M=P6.C26D=K<_8S<?NY6N3R/D/E+$ZA'YDW=.*\2?';XGZO\ "+4KFXUK0M'U
M'5O!,GBBQO-(L9D;3_+FA1XR7G/F;EF!#C;L(/#"@#[.S2U\J^./$-\?B=IE
MC>75O?W-IJ_AAY+^P,L273227F[$1E=$7Y!@+R<G<S8&.I^"'QN\:_$OQ7%)
M>:);P^&+P7RA@D44MB\$YC1"WVEWF+!6W_NH]C8'3J ?0-%%% !17+?$/Q5J
MWA'1H[O1_#=SXGN7E$9M;63847!^8G!..,<#O7!Z3\9_&]]J5M;W/PIU6T@E
MD5'G^T$^6"?O<Q@<?45Z5'+Z^(I^UIVMYRBG]S:9XN*SC"8.LL/5<N;3:$Y+
M7S46OQ/9,TM?$WC[]H7QYIWQ,U);;4)+*VL;QX(M.$:^6R*V!N!&6+#G/OQ7
MLT/QT\>R0QN/A'JCAE!W"X8 \=<>57KU^',;0A3G>+YE?XDK?^!-7^5SYO"<
M:Y9BZM6E::=-V^"4K[Z^XI6VZV/<NE&:\.^./BK6=5_9D\4ZK-I5_P"'-5:R
M<?8ENS#.IR!A95*E">QX(KRSQ5<^*_A?\/-<TC4I==\*:7XEO'%DEO<W>M7&
MA6:0$S'[5&LC(\K#"#<0A8'=U ^9J0=.;A+=?/\ %:'W-*K&O3C5ALU=737X
M.S7S/L2EKYAN?&]QJ/['?@;7+75KU)Y;;25EOI)989F/F1+(6=\.<\Y)^]UR
M0<UM?%/]H'5/"OQ!LM-T"[T_4-/@N[&TU&V.GLYB-U(41C=&X15;@E42.3.T
M[BM0:GT)17R'X>^-/Q \+^#;>&;6;3Q1J^K^*K[2H+DV )L8XVE8*R-=(')"
M!5!=,9_BKO\ XC>,?$NH_LVQZUJL1\/^())(5G2QN0 I%P%RK1R, &4 [0[8
MR02<4 >^TE?*MW\:?B'K&GW45Q?>'[2SUE-;L[ VEC-Y]FUHLI25W,V)-PC(
M*@+@X(/:L+P_\6M7^#'@WP+HND3:-?JEEIESK%K!HTL0/VPC$C3M=81VY/"R
MEB"2%Z4 ?9%)FOEIOC;\1-4AF$M]H%C::M)K.GZ>;2PF,]F]JDC1S.[38<G9
M@J%7'4'M7*>)_%NM7_PY\-IK.KV^N:E<^%(+Z75;4RPLS&YMQM*"9D)^8Y8C
M<3W49% 'VC17S[X8^-_C7Q/\6;K3+70[8^&[769=(N4D6..6%40,)_-:YW,Q
M+?ZL0=.0QKZ!H 6BBB@ HK$OM<O[:Z>.+2)KB-3Q(&P&_2JOB;6[NSTB"2*)
MK:6;ALX)3VKICAYR<5IKYHYI8B$5)ZZ>3.EHKAO"?B&^FN9896>[787 8Y;(
M[9K<M=>U">Y2.31IH48X+E_N^_2KJ86I3DXZ:>?^9%/%4ZD5+77R-S-&>:^5
M_C?H7BCQE\=I=)\-0ZC)?QZ'!-:W\'B"2P@TN3[1\T[Q*_[[*@C;L;/0X%9W
M@;QMJ*_&DW?B>!]7NI?$,OA^UF3Q/-'-9[(QM/\ 9BJ(C&<%BY+-R#BN,[#Z
MZHKP^?QVOA;XN?$JXU#6%M;#3M&M+F..[E=X8CL8EA$#D].=HR:\HU3XY_$#
MQ39+9P>(M/T&XLO$.F+_ &E_9)@%Q:W,;.$>'[6^U>G5P6&,JIH ^QZ*^>?#
M'QO\<>(OBO/H\&CVD_A^SU=](NV,<<4BJB9^T"1KG<23TB$)X/WCC-9_Q%^(
M'BKPO\;-3LO#M[:"XOAI=A''JWFS6MN)3)OD$2.OS?*.A&>YH ^E:6OCN[\9
M:]X\\=>#-2\3ZGH4=EX<&M27L;:9,]O+-:8'VA$$Y9#CD#YRO.,YK3T[]I;Q
MWJ37NF6O]B27[ZEIT%E?WNERVT?V>Z1FW-;K<R,2 H*DNA(ZJ* /K&DS7RYH
MWQ+\>>)_B)X,M[KQ-I.G00SZSIVI6L%@ZPZB]LR ,H:?*$@\#+[3GKGCDM!^
M+^H^"[/5?$]E8K/>2Z#ID4=N99)H8&ENG3>?-EW,!G^*09.!N H ^T:*\]^"
M_BSQ1XKT&^?Q5I\-G=VUV\,,\(CC^TQ#[LC1)--Y;=BI<UZ%0 4444 %%%%
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M?^VLCO/ 'AO4-<36+G0["?5$((NY+=3)D=#G'4>M;_'I^E8G_"&Z7_SRG_\
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M33]/^")3K36D8M?XG_\ (E[3M'L]*#"VA$9;J>23^)J[Q6)_PANE_P#/*?\
M\"IO_BZ/^$-TO_GE/_X%3?\ Q=*7LY.\I-OT_P""./MXJT812_Q/_P"1-)--
MLX]0DODM(%O9(Q$]R(@)&0'(4MC) )/'O6?#X,\/V_B.;Q!%H6FQ:],GER:H
MEG&+IT_NM*%W$<#@FF_\(;I?_/*?_P "IO\ XNC_ (0W2_\ GE/_ .!4W_Q=
M*U+^9_=_P2N;$?R1_P# G_\ (E?5OAKX0U_6TUG4_"NBZCJZ+L74+O3H9;A5
MQC D92P&"1C/>HH?A9X+MM)NM*B\(:#%IETZO<62:9 (9F7E2Z!-K$8&"1Q5
MW_A#=+_YY3_^!4W_ ,71_P (;I?_ #RG_P# J;_XNBU+^9_=_P $.;$?R1_\
M"?\ \B,C\ ^&(O$2Z^GAS24UU4$2ZHMC$+H)C&T2[=V, #&>U7)_#6D75_\
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M_P#X%3?_ !=*/!NE!E)@D?:0P#W$K#(.1D%L&G%44TVV_E_P2)/$N+48I/\
MQ/\ ^1-F-MZ!L8R,TZD P,#I2USG:%%%% !1110 4444 %%%% '/Z'XIM[JT
MF-]>6D%S'<SPM'YJJ0$E=5R">NT"K_\ ;VE_]!"T_P"_Z?XTVY\,Z1>3O-/I
M=E-*YRTDENC,3[DBH_\ A$-#_P"@-I__ ("1_P#Q-3J<Z55*VC.>\9^$/ /Q
M#:T/B2QT76C:;A ;PH_E[L;L<\9VC\J=X,\)^ OAX+L>&[+1M%%WL\_[&R)Y
MFW.W=SSC<WYFM_\ X1#0_P#H#:?_ . D?_Q-8GB(^#_"MQI$.I:;8P-JEVMC
M;$6*LIE8$@,0OR@XQD\9('>C5;G-*E&$_;RC%2[]>V]OD=#_ &]I?_00M/\
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M$5N8Q,S)"?++D!-P R,DC&:=QNK)*[<?O)KC0O UUXA&O3Z=X?FUQ< :G)!
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MM.T:STH-]FA$9;J<DD_B:N\5B?\ "&Z7_P \I_\ P*F_^+H_X0W2_P#GE/\
M^!4W_P 73DZ<W>4FWZ?\$(^W@K1A%+_$_P#Y$TETVS34'OUM(%OGC$37(B'F
ML@.0I;&<9YQTK/C\&>'XO$C^(4T+34U^1/*?5%LXQ=,G]TR[=Q'MFF_\(;I?
M_/*?_P "IO\ XNC_ (0W2_\ GE/_ .!4W_Q=3:E_,_N_X)7-B/Y(_P#@3_\
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MVHJ6KVT>IV-%%%<)ZH4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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G\W*KA1114&@4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>pasg-20221231x10k011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pasg-20221231x10k011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &) W$# 2(  A$! Q$!_\0
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M1^UUXWU[PKX^_9XMM%UB]TJUUCQU;6>H0VLS1K=V[1MF*0 _,I_NGBN/T/\
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M7M*'EMQ4N3ES0![G1110 4444 %%%% !1110 4444 %%%% !1110 45\J_\
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M_"/]J?Q+=^"?A]X+^'?A3^W_ !+<>%9_%-Z?$^NR2"WLDNI($!N"A:61Y$8
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M_P!F7]I[5OAIX5T?_A-;+R=!\0^,?$-K?:K>7S2-I5Q&YE2$DC!3 =0<CD#
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M1"[E\R3YW+G+8&>2>U=C10!XM%^R/\/XO@?IWPJ\G43X;TVY^V6,XO"MY:W
MF:998YE (=78D''YUY;\8/V)%D^'DMAX(ENM>UV^UVTUC7+_ ,2ZS*NHZJL
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M>FW>D1^&X_M.F6EA9(NJ1S/<37MS+;()"P7!C#3RY.1@1>QP ?;=%?&6L_M
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MSQ3Q,V1QB2%6XZ\B@#N**BMHF@MHHWD,SH@5I&&"Y Y)^M2T %%%% !1110
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M **** "BBL3Q;I6LZOIJPZ'K:Z#=B0,URUFMSE<'*[2R@=N?:JBE*23=O/\
MX:Y$FXQ;2OY?\/9&T2%!)( '4FHK6]M[Y"]O/'.@."T;!AGTXKP_XJ?"WXH:
M]\/==T^P^(2W]U/;,BVJ:4EJ9O5!*)"5R,C.*\D_9/\ @/\ %GP:NNR7>LR^
M"[6?8JV]S:K=F9P3E@A<!>#U[_A7N4\NP\\+.N\3%.+6FNOX7^Y,\.IF6(AB
MH4%AI.,D[NZT_&WWM'VC6%X?\=^&_%=Y>6FBZ]INK75DQ2YALKI)7A8$J0X4
MDJ<@CGN*Q_"_A;QAI6K+<:QXUCURQ"D-:#24MR3V.\.2,?2O#]"^#WBCPSX$
MO=>NX+C4];7[796>C:8)-/GAMIM1>5V>>*0R2-L(8%-AQP.3FO&J0C!VC)2]
M+_JD>U3G*<;RBX^3M^C9]-7^K66EQ2R7EW#;)%$\[M*X7;&O+.<]AW-6(9DN
M(DEB=9(W4,KJ<A@>A%?'6F_#SQU+H.E:IJFG>*)=?BTOQ)IUBZ:E=&2VWW4C
M6'FYERP\H( TFYCA-Q)&:W=3\&_$^[\<>(KN76/$%HR0 :3%91S/;/;_ -GH
MOE,PN!$LGVCSB6:$R D$/C:!D:GU-/<Q6L8>:5(D+!=SL ,DX ^I) K+\1>,
MM!\(BU.N:U8:.+I_*@^W7*0^:_'RKN(R>1P/6OF_6OA'XE7P7K>DW(\4ZU8*
MOAW5TCEUBYENI+N.=C?K%)YH<?(D9\M2%#$%0#S7??M!I?ZQX,TWPKI_A?4]
M2L?$%N]CJ&HPVOVJ;3K(HHD&&)8RN#M7)X(+-G;@@'M?6BJVFJB:=:K'&\,8
MB4+'+]]1@8!]Q5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y+XJ?
M\B3>?]=(?_1JUUM<E\4_^1*O/^ND/_HU: .KC_U:_04ZFQ_<7Z"G4 %%%% !
M1110!7U"_M]*LI[R[F2WM8$,DDLAPJ*.22:^0O ?_!3'X<>-OVB-4^'2SBUT
MM0D&FZY(<175R"PD3V'W=I[X/M7UUJL5I-IEVE^D<EB8F\]9@"A3'S9SVQ7P
M]^S?^P#X"/Q8U'XR7-@ATV^N)+G0] =/W5H/-?;*P/7*A"!V)/M0!]UJP8 @
MY!Y!I:0 *  , =J6@ HHHH *P;T9N)ATR3TK>K"N_P#CZE_WC0!Y]\*?A+:?
M"B'78[75]2U8:MJ$FH.=1E#^46_@3C@<5Y5=?#[Q=IVLZW-HEE/:GQ3J5SI>
MH7*_*UM;.R%;P<]5C\\ \_,4KZ0JEINLV>K12RVLZR)%*\#GIAU.&'/I5*3W
M \&TWX4ZVATG3=,DO_"T%KK6K/#>6,,;&"%U"PG;(C+L.!VR<<$5T'PI\+:G
MI%YX'6XT272ETO1+S3[M3DHLXGC!8,225D*-(ISR&%>H^*?$MGX0\.:GK=^S
M"RT^VDNIO+&6V(I8X'<X%6+'6;349;N."8,]I(L4P/&QBBN!_P!\NI_&GS-@
M>/\ B32]<LO'U]<>"+35[#4=2NMVJI=V^=-G A$8N%=A\L@5(P-IYVC*GK7*
M>%_ ?C4Z1J=TVIZDFL6]BDWV%].G@CGO8IDE5C+)/()"=KH=@4,LG/0"OI;>
MN0-PR>V:AL]1M;^)Y+:XCGC1VC9D8$!E)# ^X((HY@/G37O"_C?5(M$U.[^V
MV=GJ0O;N^L19SWCVMQ(\?D*8HIHV^6-7 .2%.<C)!&IJ?P]\03>%_'TTDFK:
MGK*^&!9Z5.[R1F:<V3HS+%N($A<@'J<XYKW[<,9R,>M()$/1AZ=:.8#PG5?A
MY>-XK\?3VEI=V&JZAIUI=:;JHWB 3PJ6VNV=HRZH"#U4FNO^#FH7GB?P;?>,
M-1MYU?Q)(U_!8.<F*U"!($ SC+(@<^\IKT6>.*YCD@E"R)(I5XVYR",$$4VV
MBM[.VB@@6.&")1&D:8"HH&  .PQ2;N@/G8:+XGT^PO-(\,V?B$>"((H"UA?P
MF&[@ G7S+>U?Y7>,Q;^#D@@!6YP+VNZ%<SW:'^PO%,OAU]*>/2;6*:;S;:],
MTA9I0&WJ"AAV%^%"L.,U] %@!DD >M0+J-JU\UF+B,W2QK,T(8;@A) ;'H2K
M<^QI\P'A<W@+QE-X>\;7HFO%\7C3+>WTR=KAS'YGV.-93&H8*6+[QN_O <\5
MI^"/A=#XK\)>(-'\4M=W^E7[!5L[G3YK(6Y\HHS1B6:5B?F)W9QNY R,U[0'
M5NC _0T%U&/F'/3GK2YF!S5CH>EZ'KVF6ECI=S;I;V<B02P%A:PH7!*%0=NX
MGD<9 Z5YU\1O >IZIXO\4ZY8V^H?;8M/TM=-EM9G16D2XF,F%4@,0K#.0>&]
MZ]CL=1M=2MQ/:W$=Q"69 \;!AE258?@01^%3%U'\0_.A-H#Y=^(,7B2W<Z7,
MERK:AXAU.Z2&61E#VP@4(X"NI(5FR.<9 X]-,^!IO$EAJ.MZ,NJW*IX.TR+1
M[N.26%I;F.:]9LJ&Y=0\9PV<;_<U[5X[N/#]KI4-WKUE%?6Z7$<*;HA(5>1@
MHQZ<D9KHX88;.!(HD2&% %5% 55'8 4^;0#Y]7PIXTO/B3)>7VI7]G(NHK<6
M[PZ;/*DEIM_U)F$XB12-P(,>0>>3@UZ)\*/#5SX9^&D(O4OQK,\#2W?G2M).
M9.<8W$@'& !TZ5UGAKQ-9>*M'AU*R9A;2LZKY@VG*L5/'U!K4+J#@L ?3-)O
MH!\XZ)H?B"RTW2[/5-(US4/#5G=,MS-;BYBNK_\ = 1RR0%RXPP.[:<,2&P,
M<7=4\.Z]-JURJZ9XC_M5IM.;1+Q[EVBM;9(X?.29E;;OW"??NR6W#KQ7T"9$
M !W#![YH+JI + $]B:?,!\_ZUX"\3Q>"[^\L6OX]7N_$UY)>B4S7#-I_V^8Q
MK'"LB'88_+;:I7()]:B;PYXDTNR\*3P'6-?NK66Y9;&XLKFT@9);A64%O-9H
M6B5<*9"X*L1@9)KZ&#*6QD9],TM', 4445 !6OI7_'L?]XUD5KZ5_P >Q_WC
M0!<HHHH **** "BBB@#Q_P#:JEL(?A%>O>SW,,JW%N]LML\BEY%E0X(3[PP&
M.#QQ7D7Q)U"X\0_'[1];TR!KK3D_L,P))')]KNT6:64R6#@;4CQ*%F#\N(R/
MEP"?KVB@"GJXOVTJ[&EM;IJ)B;[,UT&,0DQ\N\+SMSC..:\O_9P75%TCQL-:
M>U?5!XKU#[0UD&$);]W]T-SCIUKURO,O@=U^('_8W:A_[3H ]-HHHH ****
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MR,Q)GU=QVKB?VS?BU;^"/"D6E-9WFI6YC;5=6@L(C(XL86&5('022%$)]"U
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M<#@ GH#0!T%O;Q6EO%!!&L4,2A$C08"J!@ #T J2BB@ HHHH **** "BBB@
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MFG6$&E6%O96L8BM[>-8HT48"J!@"@#SOX,?LY^!?@&-;/@[1HM-?5[IKJYD
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MH;QQ"Y34]0@L@P; 42'[U+J_C_1="UF#3+VXDAN9G2-&,#F+>Y 12X&T$D@
M$]Q6;XR\#WVNZ!H5IIU[#;7NDW5O=1RW"%D<Q=B!SS7*>(/@QK7BGQ#!JFI:
MY;RD7-E=-&$EVPM RL4B7?M <KDDJ3DGVPE8#H-(^-?AS4],U2_E>YLH;"_;
M3V\^VD5I90Y4+&,9<D@\+DUI:M\1=/B^&^N^+M+8:A;:;8W-WY?*$M#&S%&!
MY4Y7&".*Y#6O@=/K&G7ED^IPF%-=.O6"O$PVRL) \<NU@2I$C $$$<'G&*Z!
M?AD@^%FO>$XS:V4FK6=U;O+:QL$5YHV0OAF)8C.<D\XIZ 6C\7/#,.KQ:5<:
M@(M19H8GC\MRL<DH!C5GQM!;( R>:YCPI\<;34H_$FI:IYUKI=EJ<VGVZ)83
MEPL1*EV.WOM8G^[QFM&\^$9NX-93[<H.H7VG7@;9]S[*\38_X%Y?ZUEZW\$+
MW4;"6V@UH1Q3:K?ZA+;R"012"Y=F 8(RDE-W&3@T>Z!U.I_%_P )Z1>6]M<:
MH/,GM8;U#%$[J()698Y"R@@*2C#)_K67+\:M,F?Q+!:0S"XT.]CLYFNHGCB<
MMY)R'VX_Y;# ZG&>G-9]E\#VM/#=SI9U)',WAS3]!$GEG@VSS-YG_ O.Z?[-
M3W_PAO;K_A)[9-4A73M:N[6_*-"?,CFB2!#SG!4K;CMU;VH]T#0L?BQ86-MJ
M4NN3"W:/5[K3[:&"-I))5B/4(H).!R2!@5T-[X[T+3_"L7B2?4(UT63R@MV,
ME3YDBQIT]6=1[9K@_$/P*_M:[AOX[V%[R#4;Z\2*X5_*>.Y*ET.Q@P(,:$'V
M(QSD7_'?@*]3X2V?AS08H(KN#4--DC^SPDQ1!+^"5Y A;)"A68@MS@\\T: ;
MD7Q8\.3Z;+>Q7-Q(D4QMY(DM)3-&X ;#1[=PX(/([UG3_&G0FUJ'3;,S7;7.
MCG6;>[2%S;O%@%27 P 0<Y[5S][\$]7U&>YU&YUV%]3O;S[1=PI'+':R*(A&
MB[4<,=N"W)P2?858T3X*7GA_3/#MG;:M"RZ?X;;P[<F2$_O4VKAUY^4Y7H<\
M&BT0.D3XM>'[6VTK^T+U(+J]M(+LI$K2)$DO",S 85200"V,X-/C^+OA>;6)
M=,BOWDO(YIK8JL$A4S1!C)&&Q@N C':#G S7&/\ L]0IJ]E?+<6EW_Q+;+3[
MN*]CD96^S;MKH%<#D-@ALCY0?6NCB^%/EKIB_;%Q9^(KK7#A/O"83CR_P\_K
M_LT>Z!K^!_B)8>/O!X\0:=%/%;E7.RZB:(@KGU'(XZBF^'OB3I&NR:59K/NU
M*^M(KORH$=XT#Q[QE\8&1DC.,TWP+X+N_"?@QO#]Q>Q7<48ECMY8XRI$;$D!
MN3DC<>E<]H_P@N](UKPE=PZE!;QZ):0VTTEM&Z37BQP&+RY/FVLF2&&X$C:
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M%=\#FO;J* (;**:&S@CN)A<3I&JR3!-@=@.6VY.,GG&:FHHH **** "BBB@
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M;M8:/)J+-]HB&\M(L /1"P&2?[HQ7Z35E^&/#UGX3\/:?H]A$L-I90K#&BC
MP!C_ .O6?\0/&EOX%\.3:A(AN+IR(;.T3[]S.W"1J/4G\ADT <U\3O$.H:QJ
M%OX%\-SF#6-13?>WR\_V?9YP\G^^PRJ#U.>U=OX<\/6/A31+/2=-A%O96L8C
MC0<G [D]R>I-<Y\,?!=QX9TZXU#5Y%N?$FJN+C4+@<@-VB7_ &4' _/O7:T
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MN9;>0O@NQ!'V?'4YWGD8Y[RI=N@!6OI7_'L?]XUD5KZ5_P >Q_WC2 N4444
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M@#I:\R^!W7X@?]C=J'_M.O3:\R^!W7X@?]C=J'_M.@#TVBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ IK.J#+$*/<TZHKBUBNT"31K(H.<,,TU:^HG>V@VZO8;2UDN)'
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M!XJU10 @    P!7)_%3_ )$F\_ZZ0_\ HU*ZVN2^*?\ R)5Y_P!=(?\ T:M
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M"NC2M;M)IEHS03M<PDQ+E)6.6<>C$\DTV\T?0]8E@U6ZM+.[DM@6BNY$5C&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K%\9;Y/"VJ6\,L,-W=6TEO;&X.$,SH50'ZDBMJN)^+NF:/J7A$'6M:
M_P"$>@MKJ*XAU+<%\F96^0\\'GL: /'OV5M7U5-8N?"\MK#I\>@)J,6HQ>=;
MM)--)>*UJ=L1R=D(=68]W Y.:^EZ\>^%&A?#VW\0Z6_A/7K74[[2M)N+-T@D
M5Y)EFFADEGE8<LQ>->3W<^M>PT %<OXP^)OA?P!-:1>(-:M=+DNFVQ"=\9Y
MR?09(Y/%=17Q[^U6FJ>"/&_B?7H]*L_&-EXF\+MH,.AR3K]I2X.\)Y<9Y8.7
MYQS\OM0!]@1R+*BNC!T89# Y!%<I\5/^1)O/^ND/_HU:K?!+PSJO@SX/>"=!
MUR<W.LZ;H]I:WDK-N+3)$H?GOR#S5/XN6NK/H<\L-Y"FFAX-\#1Y=CYJYP:
M/0(_]6OT%97BWQ%;^$O#.J:S=L$M[&W>=B?]D9Q6HA C4]!BOBG]IS]MKX=V
M?Q;\.?"2[U>(Z;/>+-X@U!&S%"L9WI;DC^^RA6] : /G_P#;R^._BOX2?"?0
M?"FF:=<6VIZ]>1>(]:U;&45V?S(H#CH<JN0>RU]0?\$X_$NO?$KX9:W\0/%6
MG75OKWB&^$CWEPNU9XD0*GEC^X,'\Z\-_:0_:5^&FC^";OPSXKM;7Q!X@^($
MS7,\1(9=)AV%;5RW\)7Y#@=B:_0+X7:=HVD?#OPY8^'YX+G1K:QABMIK8@HZ
M!0 PQZ]: .IHHHH **** "BBB@ HHHH *PKO_CZE_P!XUNUA7?\ Q]2_[QH
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MC_980!OI.E>E>,?'FO>%_"%[=S:4]M-91P,]_(R&&0F1%DPH.X##,>1VI<K
M[:^\,:3J:3)=Z=;W"S,C.)(P=Q484_4#@5D6OPXTJT\2)JL:;88K-[*'3PBB
M"-'8-)A<<[B!G/I7G&O_ !DOW\02V.G:GI]O9-XGBT5;Z7YHTC;3I+@G.<$^
M8@ ^M;$'Q+U;_A1GC'Q.Q@FU+1;74F@N(U_=7!MT<I(!Z$J/R-%F!Z%8^$-$
MTVW\BUTNUMXO,6;;'$ -Z_=;ZCMZ5->^'=+U*.[2ZL(+A+LJ9Q(@/F%1A2?I
MVKPW5_C3XCT9KJUMIK+73*+)H[ZS $=L9V8%6).. HQDCKS6QX=\<^-M9UW0
M-'NOLFGO<37;23Y64RP1>6RGY"0&.\@C/;-.S ],M_!NG1>,Y/$ZKNOVTZ/3
M$Z;8X5D>0A?J6&?]T59UKP_HNHS17VJ6-I/);#Y)[E%.P9SC)[9[5XEH?Q(U
M>/0M!L+:^M-&66QU/47O+\EUD:&[*+$I)ZX;<>>G2N>\?_%#6?&_P^\1"YN+
M/0XX+&Q+Z;<*?.N3.B.S+GMEMH]U.:.5W ^FE@M-.>>X"16[7#J99.%WMPBY
M/<] /PJ@_A+09+JZE;2[-I[L?OV,2[I.0>?Q /X"N6^*TAFU?X=:=)_QY7WB
M2-;A>S"*TNKB,'_MK!$?^ BO/? 'B>Z;X@6EQJ:0WFH:EK=]I^U;I_/M4C61
ME)BSM";8U&<=7'/-)+2X'N\FBV$MW]J>TB:XWK)YI7YMR@A3GU 9A^)JC=^"
M= O[6WMKG1[.>"W#"*.2$$(&Y8#ZFO-/BK\0_$_AO5?$S:/+:)::%I$>J-%/
M&29SO8,F>P(7K535?B;XGT#6K_P]>75E]H^V6$:ZJ8RL5O'<+*3N&>QA(!_V
MA3Y6![)%HMA!]HV6<*BX54F&P8D55VJ#Z@#BJMIX5T72H%6WTZVMHHI!<#:@
M 5P" WX GZ9KQ[2OB9XN\1ZQ::%9W-E%*+[4K,ZIY1:*Z2W2)TDC'UD*'W1J
MI:%XWUWQ;K=[/?:K';6-[X+@OUTO: KRL;I)"A/)(V(3[$4<K ]\LK2U@@?[
M+'&L4[&5O+ PY;DM[YJIIOA;1]&%P+'3+6U%QQ*(H@-X]#[<GCWKQ/POXP\7
M:#X6328YK&[NH_#>FZC9,P$2QAY?*="6."=BY7)'S<5Z?X7\6WFO?#^VUBPA
M.JWK97RF'D[V5RK=>!C!^N*330&U+X1T6?2[;3GTNU:QMAB"#RQMB_W1VJ[:
M:;9V,K-;6\4$AC2(^6H!V)G8OT&3CZUD>'M9UN_DN/[5T7^S(XTW(RS"0N>X
MP*\=^%WBG4=:^-[7>J6NMV%YJFC3S-87MM+%#:HL\8B0 _+D+G+#JS$9QBBU
MP/<;WPYI>I7C75U803W+1>0TKH"QCR3M)],D\>YIUUX>TR]%P+BP@F%Q$D,N
M^,'>B%BBGV4LQ'IDUY5K/Q7UW2/&6K>%1;)/JUI.^I1!4/[W2A 9%?Z^:KP?
M4 ]ZPM#^,7BR31;K4M2BMX+"XM()+>Y1HW:.XDF2,1;%<G!#_>;&"IS1RL#W
MG3M,M=(M$MK*WCMK=,XCC7 'K4TLT<"AI'6-2P4%C@9)P!^)('XUX7X=^*7B
MKQ5<^%],ADM;.YOM1U.SN;AU#X2V *D;21D].#CFJGC7QGJ6K>!?BC8ZO-#'
MJ.CZ7/JU@+8!EC: O);R!P3\P>%#M.#D4^5@?05:^E?\>Q_WC6-$Q:-&(P2
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MN'^KLH 53_OMM\A_WJ /F#]H?_@GEX&^,?[27A>S\.PC0+*TLEO/$4=M]QH
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M5VB@"N-.M5*D6\0VR&880<.>K?7D\TR^TFRU/R_M=I#<^6=R>:@;:?;-6Z*
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M&O+_ -GO3+71K'QU96,"6MI#XLU!8X8QA5'[O@5ZO7F7P.Z_$#_L;M0_]IT
M>FT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M ./J7_>-;M85W_Q]2_[QH AHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'J%E;W41S%/&LJ'V(R/YT 3T444 %%%% !1110 4444 %%%% !1110 4444
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M,&A7L?6ES*]C)UX*:AU.UHK/_M;_ *=I_P#OFC^UO^G:?_OFG<UYD:%%9_\
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M0HK/_M;_ *=I_P#OFC^UO^G:?_OFBY?,C0HK/_M;_IVG_P"^:/[6_P"G:?\
M[YHN',C0HK/_ +6_Z=I_^^:/[6_Z=I_^^:+AS(T**S_[6_Z=I_\ OFC^UO\
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M2KY.*]NHH ^3X_"?Q%_X2'P]H%_.XEUS1VU'4T@DP+66Q9UB&5XW3"XM5;&
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M>^M]$M$E@D^]$?*7Y#[J,*?I7H#HLB,K*&5A@J1D$4H&!@=* %HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *AM[2"U#""&.$,=S>6H7)]3BIJ* "BBB@ HHHH **** "
MBBB@ HHHH @>QMI+A;AK>)IU^[*4!8?0]:GHHH *\^^/T-Q_PIOQC>6=[<Z?
M>Z?I-W?6\]J^UUDC@=T_#('%>@U#>6D.H6D]K<Q+/;SHT4L3C*NI&"".X(-
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MKQKVY=CDO(55?R"HH'TH UJAMK."S5E@@C@#')$:!<GUXJ:B@ HHHH ****
M"BBB@ HHHH **** *8T;3U5U%C;!7^^!"N&^O'-6(+>*UB$<,20QCHD:A0/P
M%244 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW-M/Y6E17B27:),49XA:W28XZ_O9(#C_ &<]J] HI7 \$U/X8>.H_ U\EA-
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>pasg-20221231x10k012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pasg-20221231x10k012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %Z \L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ JG-K-A;RM'+>V\<B\%7F4$?4$U;/0U^8G[342-\>
M?&1**3]K3DJ/^>,==6'H>WDXWL<U>M[&*E:Y^EO]OZ;_ -!"U_[_ *?XT?V_
MIO\ T$+7_O\ I_C7Y!^3'_SS3_OD4>3'_P \T_[Y%=_]GK^;\/\ @G%]>?\
M+^)^OG]OZ;_T$+7_ +_I_C1_;^F_]!"U_P"_Z?XU^0?DQ_\ /-/^^11Y,?\
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M_F_#_@A]>?\ +^)^OG]OZ;_T$+7_ +_I_C1_;^F_]!"U_P"_Z?XU^0?DQ_\
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MB?KY_;^F_P#00M?^_P"G^-']OZ;_ -!"U_[_ *?XU^0?DQ_\\T_[Y%'DQ_\
M/-/^^11_9Z_F_#_@A]>?\OXGZ^?V_IO_ $$+7_O^G^-']OZ;_P!!"U_[_I_C
M7Y!^3'_SS3_OD4>3'_SS3_OD4?V>OYOP_P""'UY_R_B?KY_;^F_]!"U_[_I_
MC1_;^F_]!"U_[_I_C7Y!^3'_ ,\T_P"^11Y,?_/-/^^11_9Z_F_#_@A]>?\
M+^)^OG]OZ;_T$+7_ +_I_C1_;^F_]!"U_P"_Z?XU^0?DQ_\ /-/^^11Y,?\
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MS96MEH^DW)5YKV[6"VMDXVAI9#U/IR:[K1?'_@/Q!I/PUO\ 6?$TV@WWA/\
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MZM\4_!^J_%7Q["/$MO:V/B+P_%I]IKQW&**4+R'(&5![^A%8>G^-M,\"^&_
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MI!T%+7RI],%%%% !1110 4444 %%%% !1110 AZ&OS&_:9_Y+QXR_P"OM/\
MT3'7Z<GH:_,;]IG_ )+QXR_Z^T_]$QUZF7_Q'Z'G8[X%ZGF-%%%>X>*%%%%
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MW_)>/#GUE_\ 0#6-;^'+T-:7\2/J?I2.@I:0=!2U\J?3!1110 4444 %%%%
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M_P"&3/BQ_P!"E)_X&VW_ ,<H_P"&3/BQ_P!"E)_X&VW_ ,<HO0Y>6ZMZ]_\
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M ,%<_P#\11_PJKQK_P!"?X@_\%<__P 11SQ[ARR['+T5U'_"JO&O_0G^(/\
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MT2*UO5NO$.O#5+5W1=B1;P<.=V0V!T (]ZX?_A57C7_H3_$'_@KG_P#B*/\
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M*Y__ (BC_A57C7_H3_$'_@KG_P#B*TBX0BHI[&<N><G)K5G+T5U'_"JO&O\
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MQ2T5D:B8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4
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M_P DP3_L)7__ *525ZG6M7^)+U,J7P+T"BBBLC4**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRSQ1_R<'X'_[!U]_(
M5ZG7EGBC_DX/P/\ ]@Z^_D*UI[OT?Y&539>J_,]3HHHK(U"BBB@ HHHH ***
M* "BBB@ HHHH 0]#7EGP>_Y'7XI_]A]/_22&O4ST->6?![_D=?BG_P!A]/\
MTDAK6'PR_KJC*7Q1_KH>J4445D:A1110 4444 %%%% #)8UFC:-QN1@5(]0:
MY>\^%GA:_72UGTB-UTU0ELOF2 *N0=K -\ZY .'R,BNKHHV Y[3/ &@:-X@N
MM;L].2'4[G/F3!W(YQN*J254G R5 SCG->5?&3_DOGP>Z_\ 'W=?^BJ]VKPG
MXR_\E\^#W_7U=?\ HJKCN)GNHZ"EI!T%+4#"BBB@ HHHH **** "BBB@ HHH
MH *0G S7->-OB+H7@"S6;5KL)-+\L%I$/,GG;LJ(.2?TKAO['\:?%[Y]8>;P
M5X5?IIML_P#I]TG_ $U<?ZL'^Z.:YYUE%\D5>7;_ #['#5Q<82]E37-/LNGJ
M]DO7Y)G@OB3]IWX@:=XAU2UM]3LQ!!=21Q@V,9PH8@<]Z^IO!_Q0\-^(='L'
M7Q)I5Q?/ AFC2ZC#!]HW#;G(YS7G\G['?@:21G%UK2 G.U;M,#VYCS7H%Q\&
M_!-[8P6MWX9TR[6)%C$DMHGF, ,9+  D^]>;A:6-IRDZC3OW;/G<MPN;X>=2
M5>:DGLG)O[NWW'8131SH'C=9$/1E.0?RIV17BWB_X2?"[P/9&_N[F?PI'_"]
MEJD\#,?15#')]@*X[1-#\=^)M1B?P-KWBK2_#XZZCXIG219!ZQ1,F\CW.*ZI
M8F=.7+*%WV3N_P D>I4S"K0FJ<Z7-+M"7,_6S4;+S>AM^)_VN=*\/^-I-'AT
M>2]TZWF\B>_6< YS@E4QR![D5[U:74=[:PW$1W12H)$/J",BOS:U[0]4CUW4
M$FMKNZE6XD#S"U<"0[CEL =^M>^^&?%VN_#^.QM+?5KWP[*\:%-%\9J9+&?@
M?ZB\7[F?[K=*\K"YC4<Y>V6GY?UZW[7/F<LS_$3JU/K:O&^FRMY=$_OOVN?5
MU%>6:1\>;"UG@L_&&FW'A"]FP(Y[DB6RG]X[A?E(^N*].MKJ&]@2:WFCGA<9
M62-@RL/4$=:^@IU85?@?]>A]S1Q-+$)^SE>VZZKU3U7S):***U.D**** (KF
MYBM+>6>9Q'#$I=W;HJ@9)/X5S?@?XF^'?B*EVV@Z@+S[*^R53&R$>APP&0?6
ML_QG\'="\=ZD][J4^J)(\8B9+74988RH_P!A3C]*X_0?V4_"FAI.!J&MR-*Q
M.Z._:W(7LO[O;G'J:XYRQ*FN2*Y?7_@?YGDUJF/59*E3BX:WO+7RZ:?B>TT5
M5TO3HM(TZVLH&D:&!!&AE<NY ]6/)/O5JNM>9ZJO;4**2BF,6BBB@ HHHH *
M*** /+/V@_\ D!>%O^QET_\ ]#:O4ATKRW]H/_D!>%O^QET__P!#:O4ATK67
MP1^9G'XW\A:***R- I&Z4M(W2@#RW]FO_DF"?]A*_P#_ $JDKU.O+/V:_P#D
MF"?]A*__ /2J2O4ZUJ_Q)>IE2^!>@4445D:A1110 4444 %%%% %<S-]O$6?
MD\O=CWS5BJA_Y"J_]<3_ .A5;IB04444AA1110!7L)6GLXI'.69<DBK%5-*_
MY!\'^[5N@2"BBB@85!<2M'+;JIX=]K?3:3_2IZJWG^OL_P#KJ?\ T%J:$RU1
M112&%%%% !4%K*TK3ACG9)M'TP/\:GJK9??NO^NI_P#010(M4444#"BBB@"O
M?2M!;.Z'##'7ZU8JIJ?_ !Y2?A_.K=,74****0PHHHH KK,QOGC)^0(& ]\U
M8JHG_(3E_P"N:_S-6Z8D%%%%(84V0E8V(Z@$TZF3?ZI_]TT -M9&EMHG;EF4
M$U+4%C_QY0?[@_E4] D%%%% PHHHH *\L\4?\G!^!_\ L'7W\A7J=>6>*/\
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MO+/V:_\ DF"?]A*__P#2J2O4ZUJ_Q)>IE2^!>@4445D:A1110 4444 %%%%
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M$J_?V]#FO20 H  P!3:L*XM>$_&7_DOGP>_Z^KK_ -%5[M7A/QE_Y+Y\'O\
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MV$[']5SVKVH=!64:BE*4>W_#GH5L'*AAZ.(;NJB;7E:3CK]PM%%%:' %%%%
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M05V]DMSR"]_;B^%]A\3SX(EOK[[8MQ]D?4A;#[$DV<;"^[=UXR%QGO7OX8,
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M4ED4#L'8=ZZ&B@#EK?X7>$K6U-O%X>T]8?*D@"^2#MC=E9D'HI,:' Z;%QC
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MSVJ/1/AWXTT#QY<ZNVN^&?&OC_[ K36VHSNEW8(1C,!Y11GOM&:]?\#? _\
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M* ,=*6B@"C-#'/JBB1%D A) 90>]3?V?;?\ /O%_W['^%,/_ "%5_P"N)_\
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MM-Y*I&?(@RB["PSE\' KZ"/PVF^&GPIN?#OPJLM,TK48XBMJ]^6,9D/WI96
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M)6W>9D-MQP,',N?V:X)M*;2H=?N++39-)_LVX%JCI+=,,%))")-A"$?*%56
M)7?MXJW;H2O,]3'BFQN]!;5]*?\ MVU(S%_9;+,93G&%.X+G/J0!W(I/"/BN
MP\;>'K/6=,:1K.Z4E?.C,;J02K*0>X((].."1S7-Z%\,1H'@K4-&@?3[B[OY
MFN+J6^MI[NWN'; 8R1S3N[9"@<R=JU?AKX(7X=>#+#0$OI-02U,A661=H4-(
MSB-%R=D:;MJ+D[551DXI: <S\:OBVOP@ATS4&TLZK]L9K?RQ-Y6S W9S@YKR
MS_AMN/\ Z%"3_P #Q_\ &Z[O]I#X8ZS\4=/T:RT3[-Y]K*\TGVF7RQM*[1@X
M/.:\*_X9%\>_]0K_ ,##_P#$5\]C:F.C6:H)\NG1'PF:XC.:>*E'!)\FEK13
MZ:ZM=SNO^&VX_P#H4)/_  /'_P ;H_X;;C_Z%"3_ ,#Q_P#&ZX7_ (9%\>_]
M0K_P,/\ \11_PR+X]_ZA7_@8?_B*X?;9IV?W+_(\CZWQ'_++_P !C_D=U_PV
MW'_T*$G_ ('C_P"-T?\ #;<?_0H2?^!X_P#C=<+_ ,,B^/?^H5_X&'_XBC_A
MD7Q[_P!0K_P,/_Q%'MLT[/[E_D'UOB/^67_@,?\ ([6U_;4CMK>.+_A$7;:,
M9^WCG_QRI?\ AMN/_H4)/_ \?_&ZX*']DKQW/$LB_P!E;6&1_IA_^(I__#(O
MCW_J%?\ @8?_ (BCVV:=G]R_R#ZWQ'_++_P&/^1W7_#;<?\ T*$G_@>/_C='
M_#;<?_0H2?\ @>/_ (W7"_\ #(OCW_J%?^!A_P#B*/\ AD7Q[_U"O_ P_P#Q
M%'MLT[/[E_D'UOB/^67_ (#'_([K_AMN/_H4)/\ P/'_ ,;J*;]M6.5X6_X1
M%QY;;O\ C_'/!']SWKBO^&1?'O\ U"O_  ,/_P 13'_9*\>1LBG^RLN=H_TP
M]<$_W/:CVV:=G]R_R#ZWQ'_++_P&/^1WO_#;<?\ T*$G_@>/_C='_#;<?_0H
M2?\ @>/_ (W7"_\ #(OCW_J%?^!A_P#B*/\ AD7Q[_U"O_ P_P#Q%'MLT[/[
ME_D'UOB/^67_ (#'_([K_AMN/_H4)/\ P/'_ ,;H_P"&VX_^A0D_\#Q_\;KA
M?^&1?'O_ %"O_ P__$4?\,B^/?\ J%?^!A_^(H]MFG9_<O\ (/K?$?\ ++_P
M&/\ D=U_PVW'_P!"A)_X'C_XW44'[:L<)E/_  B+G>^[_C_'' ']SVKBO^&1
M?'O_ %"O_ P__$4R/]DKQY(7 _LKY&VG_3#UQG^Y[T>VS3L_N7^0?6^(_P"6
M7_@*_P CO?\ AMN/_H4)/_ \?_&Z/^&VX_\ H4'_ / \?_&ZX7_AD7Q[_P!0
MK_P,/_Q%'_#(OCW_ *A7_@8?_B*/;9IV?W+_ "#ZWQ'_ "R_\!C_ )'V?HVH
M_P!KZ18WWE^5]I@CFV9SMW*&QGOUJY6=X=L9=,\/Z99S;?.M[6*%]IR-RH <
M'ZBM&OK(WLKGZA"[BN;<J:G_ ,>4GX?SJW534_\ CRD_#^=6ZOH5U"BBBD,*
M*** *B?\A.7_ *YK_,U;JHG_ "$Y?^N:_P S5NFQ(****0PIDW^J?_=-/IDW
M^J?_ '30!'8_\>4'^X/Y5/4%C_QY0?[@_E4] EL%%%% PHHHH *\L\4?\G!^
M!_\ L'7W\A7J=>6>*/\ DX/P/_V#K[^0K6GN_1_D95-EZK\SU.BBBLC4****
M "BBB@ HHHH **** "BBB@!#T->6?![_ )'7XI_]A]/_ $DAKU,]#7EGP>_Y
M'7XI_P#8?3_TDAK6'PR_KJC*7Q1_KH>J4445D:A1110 4444 %8/C/PUIWBO
M2H['4;FXLT\^.2*:TNFMY5E5@4VNI!!SCI6]7&_%.SNY_#UO=64FG1S:?>07
MN=5NC;6Y$;AB&D"MMZ=<&CJ@&>$?A5IW@S4FO++5M>N"[.[P7NK33PN[#!9D
M8D$^]=K7E'PKU?7++7+S0-1?PO)()9KV>/3=;>XNH1(VY086A7Y>1SN'4<5Z
MO52OU)5NAQ-MX4N;?XB:MJ,%LMG97>FK"+F+:"9MY).!R3C!R?SKQ#3O ^I_
M"WXZ^!T\4^+=1^(;ZI]IAL6U*,+_ &?(%W>8F7;J,CC!YKZEKPGXR_\ )?/@
M]_U]77_HJJB^@-=3W4=*6D'04M9E!7/^/]=C\,^"]:U.4;EM[61]N<9.T\9K
MH*\7_:SUX:1\*9[8'#W\Z0?AG+?H*Y\14]E1G/LCAQU9T,-4J+=)V]>GXGQ0
M=:ELK];N)//GTRUEN8HR<[KR<^5 /KN;-9/QK%FVNZ1H=W97 \,>&M/'A_3Y
MX9?*LI-99 T[2RD\*&8ELGG!%-T#7$L+Y-6EC\\03/JOE'GS3"/+M8_^!3.I
MQ_LU]0_LY^-O \/@'4/"7C-O#EOIEK<DR7WB&]@ U>^8[[J18I< JCL$W GI
M7TG#E.679;#$\CDY-O31V>B^:2^Z3/<SF@L&\/DZ=OJU.$'_ ([<]3_R>37R
M-G]AZ*/1M%\5^']-\0W?BOP]I=U!'::I(X>V:8QYN$@?N@?&,<5Z[XP^.'AC
MP=XQTCPI+)=:IXEU-PL>EZ5 ;B:).\LH!_=QC^\?PS7-_#7X[>"O%/C^?P#X
M L([[3-+M3-=:EI*Q1Z?;'.%C0*1OR>Z @>M=OX0^%7A;P)K&M:KHVDQ6NIZ
MQ.;B]O&+233,>Q=B2%]%' ]*RQ4HRQ$ZF(@TVDTM/O?;OMKY;GE0344H,ZLJ
M&(..1T-.HHKR#<**** "BBB@ HHHH *0\TM% 'R=??"SXB?#/QEXR;PEX!T+
MQ?'XDEFDL_$=S?1VUQIHF&)(Y0R[G0'D!#S7T-\*_!C?#[X>Z%X><P-+86JQ
M2M;)MC+]6*CL,DUU=%=U?&3Q$%&27F]=;*ROK^5C.--1=T%%%%<)H%%%% !1
M110!YG\1=<^*5CJTEOX.\-:'J6G-"-MYJ&IM!(LA'/[O800#[\UY=\._'7[1
M&HP:C->^&?#^J+%</;*MW=?82CH<-@*K;@3WXKZ=I ,5QSP\I3YO:->6G^1]
M+ALXHX?#.A+!TI-V]YJ5]//FZ^5BEHLM_<:3:2:G;Q6NH-&IGA@DWHCXY"MQ
MD>]7<4M%=:T1\Y)\TFTK"8%&*6BF2%%%% !1110 4444 >6?M!_\@+PM_P!C
M+I__ *&U>I#I7EO[0?\ R O"W_8RZ?\ ^AM7J0Z5K+X(_,SC\;^0M%%%9&@4
MC=*6D;I0!Y;^S7_R3!/^PE?_ /I5)7J=>6?LU_\ ),$_["5__P"E4E>IUK5_
MB2]3*E\"] HHHK(U"BBB@ HHHH **** *A_Y"J_]<3_Z%5NJA_Y"J_\ 7$_^
MA5:S38D+129HS2&+129HS0!5TK_D'P?[M6ZJ:41_9T'/\-6LT"6PM%)FC- Q
M:JWG^OL_^NI_]!:K.:JWA'GV?_74_P#H+4T)ENBDS1FD,6BDS1F@!:JV7W[K
M_KJ?_015G-5K(C?=<_\ +4_^@B@1:HI,T9H&+129HS0!5U/_ (\I/P_G5NJF
MID?8I.?3^=6LBGT%U%HI,T9I#%HI,T9H JI_R$Y?^N:_S-6ZJ(1_:<O/_+-?
MYFK6:;$A:*3-+2&%,F_U3_[II],F_P!4_P#NF@".Q_X\H/\ <'\JGJ"Q_P"/
M*#_<'\JGH$M@HHHH&%%%% !7EGBC_DX/P/\ ]@Z^_D*]3KRSQ1_R<'X'_P"P
M=??R%:T]WZ/\C*ILO5?F>IT445D:A1110 4444 %%%% !1110 4444 (>AKR
MSX/?\CK\4_\ L/I_Z20UZF>AKRSX/?\ (Z_%/_L/I_Z20UK#X9?UU1E+XH_U
MT/5****R-0HHHH **** "N/^*6EOJ/A?S4FT^(V5Q#>;=5E\JUD\MPVV1L':
M#CK@X]#785RWQ&T"[U_08ULH(;RYM;J&[6SN6VQW'EN&\MC@@9QU(P#C-'5
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MCBOT>O6HX.K[&FY.$(J*4=-;-7OMIMZGD5Z\\;5GB:S7/.3D[^;N>0_LLS>
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M^')_*OJ+_AD'P%_U%?\ P,_^QJ&W_9'\!RM,#_:OR/M'^F=L _W?>C^S\?\
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MYD6_TPV307&\AX8_D4.@&#GYC_M&O7,48Q33L2%+112 **** "BBB@ HHHH
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M@R.I&0P(Z@@YS0(GHHHH&%%%0WM[!IUI-=74T=O;0H7DEE8*J*.223T% "+
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M /!Q-_\ $T<H7/=Z*\(_X2?]H3_H2_!?_@XF_P#B:F^'OQ8^(%W\65\&>-=
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M<O9Q/!=1NLDZ%@\2D'EU*ME1R-IR.*G77K%]<?1UGW:BD N7A52=L9;:"3C
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M$C@ D$#E?"G[-6FIX62P\4WEQJUTD5[!$(I\16B7%V;@M"=BL'R(N6+8*87
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M6@N9;OR_^6LRQJS?A&JJ/P45?H8!1112 **** "BBB@ HHHH **** "BBB@
MHHHH **** "O+/%'_)P?@?\ [!U]_(5ZG7EGBC_DX/P/_P!@Z^_D*UI[OT?Y
M&539>J_,]3HHHK(U"BBB@ HHHH **** "BBB@ HHHH 0]#7EGP>_Y'7XI_\
M8?3_ -)(:]3/0UX+X?\ '+?#CQ[\0H]1\,>*+M+_ %=+FWGTW1)[F&2/[-$F
M0ZC'52/PK:FG)22_K4QFTG%L][HKRO\ X:"T_P#Z$_QQ_P"$S<_X4?\ #06G
M_P#0G^./_"9N?\*7LI]BO:0[GJE%>5_\-!:?_P!"?XX_\)FY_P */^&@M/\
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M (3-S_A1[*?8/:0[GJE%>5_\-!:?_P!"?XX_\)FY_P */^&@M/\ ^A/\<?\
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MS<_X4?\ #06G_P#0G^./_"9N?\*S]E/L:>TAW/5**\K_ .&@M/\ ^A/\<?\
MA,W/^%'_  T%I_\ T)_CC_PF;G_"CV4^P>TAW/5**\K_ .&@M/\ ^A/\<?\
MA,W/^%'_  T%I_\ T)_CC_PF;G_"CV4^P>TAW/5**\K_ .&@M/\ ^A/\<?\
MA,W/^%'_  T%I_\ T)_CC_PF;G_"CV4^P>TAW/5**\K_ .&@M/\ ^A/\<?\
MA,W/^%'_  T%I_\ T)_CC_PF;G_"CV4^P>TAW/5**\K_ .&@M/\ ^A/\<?\
MA,W/^%'_  T%I_\ T)_CC_PF;G_"CV4^P>TAW/5**\K_ .&@M/\ ^A/\<?\
MA,W/^%'_  T%I_\ T)_CC_PF;G_"CV4^P>TAW/5**\K_ .&@M/\ ^A/\<?\
MA,W/^%'_  T%I_\ T)_CC_PF;G_"CV4^P>TAW/5**\K_ .&@M/\ ^A/\<?\
MA,W/^%'_  T%I_\ T)_CC_PF;G_"CV4^P>TAW/5**\K_ .&@M/\ ^A/\<?\
MA,W/^%'_  T%I_\ T)_CC_PF;G_"CV4^P>TAW/5**\K_ .&@M/\ ^A/\<?\
MA,W/^%'_  T%I_\ T)_CC_PF;G_"CV4^P>TAW/5**\K_ .&@M/\ ^A/\<?\
MA,W/^%'_  T%I_\ T)_CC_PF;G_"CV4^P>TAW/5**\K_ .&@M/\ ^A/\<?\
MA,W/^%'_  T%I_\ T)_CC_PF;G_"CV4^P>TAW/5**\K_ .&@M/\ ^A/\<?\
MA,W/^%'_  T%I_\ T)_CC_PF;G_"CV4^P>TAW/5**\K_ .&@M/\ ^A/\<?\
MA,W/^%'_  T%I_\ T)_CC_PF;G_"CV4^P>TAW/5**\K_ .&@M/\ ^A/\<?\
MA,W/^%'_  T%I_\ T)_CC_PF;G_"CV4^P>TAW/5**\K_ .&@M/\ ^A/\<?\
MA,W/^%'_  T%I_\ T)_CC_PF;G_"CV4^P>TAW/5**\K_ .&@M/\ ^A/\<?\
MA,W/^%'_  T%I_\ T)_CC_PF;G_"CV4^P>TAW/5**\K_ .&@M/\ ^A/\<?\
MA,W/^%'_  T%I_\ T)_CC_PF;G_"CV4^P>TAW/5**\K_ .&@M/\ ^A/\<?\
MA,W/^%'_  T%I_\ T)_CC_PF;G_"CV4^P>TAW/5**\K_ .&@M/\ ^A/\<?\
MA,W/^%'_  T%I_\ T)_CC_PF;G_"CV4^P>TAW/5**\K_ .&@M/\ ^A/\<?\
MA,W/^%'_  T%I_\ T)_CC_PF;G_"CV4^P>TAW/5**\K_ .&@M/\ ^A/\<?\
MA,W/^%'_  T%I_\ T)_CC_PF;G_"CV4^P>TAW/5**\K_ .&@M/\ ^A/\<?\
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MEHH 3%&*6B@!,48I:* $Q2T44 %%%% !1110 F*,4M% "8HQ2T4 )BC%+10
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MC6$=RUT;UI4MU#&<C!E)Q]_'&[K4D_A;1KF/4$ETVTD34<?;%>)2+C P-_\
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M<],]Z[.7Q[HL.N0Z6]XHDEL6U%9\CR/)5@I;S,[>K"HSXBT+7M1OK:2(7?\
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M."HQZTUI;^NK_4;U;_KM^AXYI.M?$6[U29)+S5;*[9;X:F+C3B]I9!2?LK0
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&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>pasg-20221231x10k013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pasg-20221231x10k013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'O \L# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO^A#'_@V_P#M-'_#PEO^A#'_ (-O_M-?'M%'U2A_+^+#ZU6[_D?87_#PEO\
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M#;_[37Q[11]4H?R_BP^M5N_Y'V%_P\);_H0Q_P"#;_[31_P\);_H0Q_X-O\
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MD**"".HHP<9QQ0 4444 %%%% !1110 5[U^Q-_R7*V_Z\;C^0KP6O>OV)O\
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M_A\,=0TH6<MK,@7.[:6)#'Y3TX..M3.K"F[294*<I_"CPNBO4/!/P)N?$/A
M^+=?U_3_  =X7,ABAOM15I'N&_Z9Q+@MR#WYP< U0\7?"[2]%M-,OM!\;Z1X
MJL;V[6S)M4>&>!ST+PO\P7W_ ,:?M(\W+?47LY<O-T//J*^B-0_9-TZS\61^
M$Q\2M,'BJ:$30:;<:;-'Y@() \S<5Y /J>.E8/PL_9>U?XD:IXJTVXU>VT&^
M\/W"VDT<T)F$DIW# 8,,#*]><YZ5G[>G9N_YE^PJ)VL>*YHKT7P7\%M0\5ZI
MXRTZYO%TB\\,V4UW<1RPF0R-&2"@P1C.WKSUZ5Q7AW3X]8\0:58S,RQ7=W#
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MS;:'J&H"=[+3[R]BA8AY+>W>14_WBH('XT^=<SC\Q<CY>;Y%&BBBK(#-%%%
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MOB>V\5'Q+'KU^-?.<ZB92TIR,$9.>,=L8]J=XN^)/BGQ[/;S>(=>O=6DM_\
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M*9^7&?RKP*3XI>+I/%I\4'Q#?+X@*",ZA&X20J!@*=H (P!P1BE\8_%7Q?\
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M]M;I?RKNQ;E=F0W';!Z9Z5>\,?%7PE8_M&>.O$$^N6L6BW]G)';7AW;)6**
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M]>,'_H-?H;7YY?MM?\EQN/\ KQ@_]!KT,#_%^1P8W^'\SP2BBBOH#PPHHHH
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M_@LG_P#B*/\ A7WBK_H5]<_\%D__ ,11S+N'*^Q@45O_ /"OO%7_ $*^N?\
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M5_T*^N?^"R?_ .(H_P"%?>*O^A7US_P63_\ Q%',NX<K[&!16_\ \*^\5?\
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MNE>-O .E^,IM&A%O97\]W);2K& ,*^P'>.!Z XZ9YKQ_R9/^>;_]\FCR9/\
MGF__ 'R:/8P73\_0/:S[GIOA_P"-R^&]$\?Z99^&K*TM/%:!!#:2F**P4!@
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MY.E\:_\ 8O:=_P"C9:VI[2]/U1C4WCZ_H>S4445B;!1110 4444 %>,^+_\
MDZ3X?_\ 8"U3_P!"AKV:O&?%_P#R=)\/_P#L!:I_Z%#6U+=^C_(QJ[+U7YGL
MU%%%8FP4444 %%%% !1110 4444 ,ED6&-G;[JC)Q7R\G_!1OX3O;W]XMIXQ
MDTJPGDM[K58O"]W)9PM&</NE52 !WKZ<O_\ CQG_ -P_RK\9/AIX@AC^!OQ#
MTJ?]IZV^'4,VK:L'\#R6,#M=@G_GID2@2_=^7TXH _8SPGXMTCQSX9TSQ!H5
M]'J6CZE MS:7<.=LL;#((R,CZ'D=ZUL\5^3E]\4/#OQ,\%? _P -W_A:;PU(
MOAFXNX] U;QI-X=\.PVR.\<=RTJ+YTTK>665=W0Y.=V3QWAOQ-K'C?X"_#)-
M0^(&GZLMCKVL6\/@_P 1>(KS3[77(5\HQ@:@&4 Q;CL65UR''T(!^RF>*XGX
MN_&'PY\$?"8\1^*);B'3#=0V>ZVMVF?S)7"(-HYQDCFORKG^-&LZ_P# KPCX
M;TJ#7='\'IX[DTOQ$NM^,W:Q.$#1VD>K1H3':DAN?FQ@'<=U3ZA=ZPO[/GQ.
MTQ_$NEZQX5M/&6AG2]+TWQ%-K:Z.S70$D NI8UWH=H(P3]WZD@'ZK:%\3-,\
M0>/-?\)V]IJD6HZ+'%)<3W%A)':R!P"/*F(VR$9Y"GBNMSFOS6^.GBC6K?X@
M_MB0PZSJ$$=EX:L7M$CNY +=BBY:,9PA^F*M>'O"5[\$?CA\#;SPSX@\1:EJ
M7C3P1J=YK"ZMJ\]V+ZYCL4EC;:[$+AWX"@ !5]\@'Z/YYI:_'_\ 91\0>)+_
M ,:_"3Q#8>)=*7QGJ>M2KK37_CNYN[W5H69A-;RZ88BL!5>5)8#ISR,?K^.E
M "T444 %%%% !1110 4444 %%%% "=*^<O&__!0'X-?#OQCKGAK7-;U.VU'1
M)A!J#Q:)=S06[$ C=*D94#!'.:^C3TK\^?AG\6/ /PW^,_[6$7CGQ+H^C6]W
MJ,.RTU.Y16N5^RX(2,\R=0, 'K0!]Z>&O$NF>+] T_6]'NTO]+OX%N+:YBSM
MDC895AGG\ZTLU^3U_)=6OP!^"?A6]G\00WU[8:KJMEI,7BA?#U@MF'9HYKFY
M(+DHK!EB4'<#6QX/^./B3X1_!?X'_%;5]<U;5=,N[+4O#FIR27<MPCLQD-K*
MY.=S*R@!L9((H _4.]O8-.LY[JYD6&W@1I))&Z*H&23^ KQCX6?MF?"7XR^*
M;KP_X7\2O=:G##)<JES83VZSPIG?)$\B!9%&#RI[5C_L\>"=9T[]D2QL?&FK
MW4FLZMI5Q?:C>WLCS/";A6?N2<*K#BOBGX57FJZQ\6?A/H5CXB\(>)K3P_X3
MUNTLKOPG++)+);>4X26Z5U7R68X CQU!- 'WG\+OVP?A7\8O'%QX2\+^(I+S
M6XQ*T<,]C/ ERL9Q(T+N@60+CG::]IK\P?V;->TCQ#\2/V3M,T2[M[O5]'T+
M5DU6WMG#2VA#MO64#E23S@]:_3T=!0 M%%% !1110 4444 %%%% !1110 5Y
M!XI_Y.:\$_\ 8%O?_0A7K]>0>*?^3FO!/_8%O?\ T(5M2W?H_P C*ILO5?F>
MOT445B:A1110 4444 %%%% !1110 4444 %>.^&O^3G_ !E_V!;+^;5[%7CO
MAK_DY_QE_P!@6R_FU;4]I>GZHRGO'U/8J***Q-0HHHH **** "BBB@ KS+X\
M?M#>$_V=/#NGZSXM_M!K6_O%L+>/3+-KF629A\JA%Y.>GUKTVOA;_@K/)Y/P
MI^'\G]I#1MGBVT;^T6 (M<?\M<'@[/O8/I0![Q\//VP_ /Q!\:VGA%H?$/A7
MQ)?1F6QT[Q5H=QIDEXHSN,1E4!\8/ .>*]PS7Y2Z;\2+?2OVM/A5J#?%^U_:
M-Q:7<;/!8K%/H*")G:6(6YV,Q (^<'\,BLGPI\5;*_\ C=\,/%W@^\71WU_Q
M0]I=7>J>.IM2U[4("S*RW=D,0P19P%7&1P >* /UPSS1FOR)\)?$9/ WQXL_
M$.LZE;^/#?\ C)K"#7-!\97=EKD9DF*B&ZTR4_/"N0"HB48QACGG,U;XG^-]
M0\:>.->UG4]-TKXHZ;XL6PTS4]4\9W%G=V">:JI:Q:1'$RS0NI*DX(.XD]*
M/TFOOVJ?!UK>^/+*VLO$&K7_ (+N(K;5+32])ENIB\A^7RD3)D'') XKUO3[
MY-1L;>Z2.6))HUD"3(4=01G#*>0?:OR:^-&O:KHVA_M@:A::A/I^JKJFDEKB
MRG:)U8M\V&7!'?TKU'7_  DGQ3^*?QHLM=UO7'T[1OA[I>J6UC::S<6T*W8L
MG=9F6-QN(*YP>#DD@T ?HYFEK\9;/XN^-/&FF? W1?&^I_\ "0^";SP[<SM!
MX@\62Z!:7UW%/*@::^0%FDC15PK>QZGG]$?V"]?\0>(OV=M'N=>U>'70ES<0
MV-]%=271>U65A$K321HTA4#;O*_-MSDYS0!]$T444 %%%% !1110 4444 %%
M%% !1110 5XC^UM\?=7_ &=_AUI6O:%X=M_%&J:CK=KHT&GW-V;96>?<%.\*
M<?,H'/'/7BO;J^5_^"B6DZMJ7PD\(3Z3H>JZ^^F^,]*U&XM-&LGN[@01,[.P
MC0$G _4B@"+X>?M=>/;+XQ>'?A[\8OA0WP]N_$ZRC0]5LM634+2YEC7>\3,H
M&UL>YY(XYS7LQ_:/^%H\>'P4?B#X<7Q8+C[)_8YU*(7/GYQY6S/W\\;>N>,5
M\U:WKWB;]JO]H?X,ZAX>^'GBOPYX.\#WUUJNK:UXMTMM+W2/%LCAACD.^0Y
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MHHHK$V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?ASXB^'K+1;OR;"^NO%VK(E]%DJ74F?YOF#<C QBO7/^&#OAD!C[;XWQZ?\
M"9ZI_P#'Z ."^ O[+7P)^,O@-?$5Y\#[3PV[74T*VMX\X9D5CL< R9 9=IY'
M?C(YKT;_ (8"_9]_Z)AI/_?<_P#\<JL?V#?AB>MYXW/_ '.>J?\ Q^@?L&?#
M$_\ +YXV_P#"TU3_ ./T 6O^& OV??\ HF&D_P#?<_\ \<H_X8#_ &??^B8Z
M3_WW/_\ '*K?\,%_#'_G\\;?^%IJG_Q^C_A@OX8_\_GC;_PM-4_^/T 6?^&
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M"V7\VKV*O'?#7_)S_C+_ + ME_-JVI[2]/U1E/>/J>Q4445B:A1110 4444
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MUFTDZ=,;J0Q ^4P$YY=AN#+&,CC(!]IYI:_-C1O%?B,^"M*DE\0>*Y/"1O\
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M?L3_ !!\'VUM))?:#=W'AVWL;+28TNYE748[?5)+TO.3%^Y9EDV# ?##/0T
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MW_\ D:@_LS7>#_Q>7XH_^#JW_P#D:O;** (+"U-C96]N9Y;DQ1K&9IV#228
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MA;?^.;WP_(GQ TG2--UV"4Q^;H5V\]I=(.DJ!U#QY_N-DCU-=E0 F!1BEI*
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M;KG_ &'I?_1:5]_T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAT)'(H _+3P9\<O%%QH(NM9^(?B1? *WEI%J&N7.J3Q/#J!TYWEMS<9#HHN
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M ?I7V[X7_P"1;TO_ *]8O_0!7EO[9/\ R:Y\3?\ L!W'\A7J7A?_ )%O2_\
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MB^-NM:U>+\3?"GA/0-(%L'M9] U2:ZE>7</E974 +MR<^M 'L=%%% !1110
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MCQ/XJL-+T^^L]4:QCCTF.1(R@C5LD.['.6/>OJ.OSY_X(N?\FY^)O^QAD_\
M1,=?H-0 4E1W4AAMI9 54JI;+' &!W-?G=XA_:=^(VE7T.@77C<V5]?ZF]S+
MKFGWFFZA81V1CNWMX8'2 ")V:%$99"['!PP)- 'Z*GO7E7P8_P"1R^+'_8RC
M_P!([>O"OV>OC_XX\<^(]&U+7-8N-1N+\&&Y\*6L-LGDHNE170E12%<,\KD
MN^W# <8KV']G'6I_$6K?$_4+G1M0T":;Q)EM/U01"XB_T2W'S"-W3GKPQZT
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M _F6G_UK_6F4^?\ UK_6F4 ?6'_!+;_D]OP#_N7_ /Z1S5^_%?@/_P $MO\
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M@A\/?#7PV^'GB?2?!'A_3/$3>'[*0ZK::;%'<EI+5/,;S N[+9.3GG)KW2@
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MI:0=*6@ HHHH *_"#_@K-_R>)K/_ &#;/_T%J_=^OP@_X*S?\GB:S_V#;/\
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M .G1*]^R#7QKH'P#\9^%]7UW5-+^.WC&TOM<N%N]1F&EZ2QGE5 @8@VQ ^4
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M?A)H"6\?S2,GBAF8+GD@?9^37AM9GB;_ )%_4/\ KD?YBL9Y)A8Q;5_O_P"
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MF9^,8B(^I%?/?C3]NZ7Q3X/UW1H_AMJ$$FHV$]HLKZQ:E4,D;("<=ANKIO\
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M)_[ M[_Z$*VI;OT?Y&539>J_,]?HHHK$U"BBB@ HHHH **** "BBB@ HHHH
M*\=\-?\ )S_C+_L"V7\VKV*O'?#7_)S_ (R_[ ME_-JVI[2]/U1E/>/J>Q44
M45B:F1XOO+?3_">M75U9-J=K!9322V2+N:X0(2T8'<L 1CWK\>-8UKX3:II<
M&HZ3\+_!FEVVGVRZSJUG>>/+F&YO8Y)3BP@4,3*RA1NA8 *W &.O[$>+-?C\
M*>%]8UJ6)IHM-LYKQXU."XC0N0/<XK\V'^'/C>3PI_PU _A?X2O8,@UW_A%F
M\+I]H^REP=WVO&?M&TYW$=: /TF\(W5O?>%='N+6T-C;2VD3Q6K#!B4H"$_
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M_P#;Y_Y,^^*'_8,'_HV.@#^=AOO&DI6^\:2@#V;]C3_DZ;X8_P#8<M_YU_2
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M?2'A'"?L2?\ (M_%[_LHFN?^AI7RC\*_^1"TO_MM_P"CGKZN_8D_Y%OXO?\
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MZ;QWQKT%'6OW-_X)L_\ )HG@W_MO_P"C#7X9#K7[F_\ !-G_ )-$\&_]M_\
MT8:Y_%3_ '7"_P"*7Y(>!^*1]04445_.1[ 4444 %>0>*?\ DYKP3_V!;W_T
M(5Z_7D'BG_DYKP3_ -@6]_\ 0A6U+=^C_(RJ;+U7YGK]%%%8FH4444 %%%%
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M?\G2^-?^Q>T[_P!&RUM3VEZ?JC&IO'U_0]FHHHK$V"BBB@ HHHH *\9\7_\
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M:H5^X\O_  1\^ LTK223^+7D8EF9M60DD]2?W5<==?\ !'_X8CXHV44*:\?
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ML&!+GR8M-N;@>6V=IW1HP[=,UXE=?\%D/@/!<RQ1V?BZYC1BJS1:9$%< _>
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M^UP?<7_EJOI]:\__ .&6_@Y_T2OP;_X(K;_XBI?^&9OA)_T3/PG_ .":W_\
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M::XF>/R9QC!.TC<.!P>.*@\.? ;P7X5^*GB+XBZ;I1A\6:_%'#?WIG=@ZIT
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M&?%__)TGP_\ ^P%JG_H4-;4MWZ/\C&KLO5?F>S4445B;!1110 4444 %%%%
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MZW0 5P/Q=^,.C_"73+-KZ/4;[4M2:6*PT_2-.EO[J9DC,DCB&/YBB*-S'CC
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MW7<DH!CCE!!PY60%5&?M.RLK?3K9;>U@CMX%R5CA0(HR<G ''4T 2H@C154
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MI;OT?Y&539>J_,]?HHHK$U"BBB@ HHHH **** "BBB@ HHHH *\=\-?\G/\
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MG['VA?$GXEW7CJ+QUX^\&Z]=64=A.WA+7!8)+$C%E# 1DGECU- 'O5%?-/\
MPQ!'_P!%X^-__A:-_P#&J/\ AB"/_HO'QO\ _"T;_P"-4 ?2U%?-/_#$$?\
MT7CXW_\ A:-_\:H_X8@C_P"B\?&__P +1O\ XU0!]+45\T_\,01_]%X^-_\
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M %%%% !1110 4444 %%%% !7D'BG_DYKP3_V!;W_ -"%>OUY!XI_Y.:\$_\
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M'^(M"_M9-4AFM8G"-)"/.Q).K!(Q(0Z[2Y)&T, :=G?E_KK_ ),5U:_]=/\
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M?29;N6"18!"9K1DF0!F51\L@901GVKV:/Q'92^(9]%477VZ&!;EB;.80[&)
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MNUBR@Y'H?44[R(PZOL7>HVAL#('I4Q?+;Y_K_G^ VKW_ *[?Y?B?*OQ,\%>
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M444 %%%% !1110 5XSX6_P"3I?&O_8O:=_Z-EKV:O&?"W_)TOC7_ +%[3O\
MT;+6U/:7I^J,:F\?7]#V:BBBL38**** "BBB@ KQGQ?_ ,G2?#__ + 6J?\
MH4->S5X;\7#KWA[XT^#O%.F>$]6\46-EI=]:SII2H61Y6CVY+L!T4UO1UDUY
M/\C&KHD_-?F>Y45XU_POGQ)_T1WQI_WQ;?\ QVC_ (7SXD_Z([XT_P"^+;_X
M[2]C/^F@]K'^DSV6BO&O^%\^)/\ HCOC3_OBV_\ CM'_  OGQ)_T1WQI_P!\
M6W_QVCV,_P"F@]K'^DSV6BO&O^%\^)/^B.^-/^^+;_X[1_POGQ)_T1WQI_WQ
M;?\ QVCV,_Z:#VL?Z3/9:*\:_P"%\^)/^B.^-/\ OBV_^.T?\+Y\2?\ 1'?&
MG_?%M_\ ':/8S_IH/:Q_I,]EHKQK_A?/B3_HCOC3_OBV_P#CM'_"^?$G_1'?
M&G_?%M_\=H]C/^F@]K'^DSV6BO&O^%\^)/\ HCOC3_OBV_\ CM'_  OGQ)_T
M1WQI_P!\6W_QVCV,_P"F@]K'^DSV6BO&O^%\^)/^B.^-/^^+;_X[1_POGQ)_
MT1WQI_WQ;?\ QVCV,_Z:#VL?Z3/9:*\:_P"%\^)/^B.^-/\ OBV_^.T?\+Y\
M2?\ 1'?&G_?%M_\ ':/8S_IH/:Q_I,]EHKQK_A?/B3_HCOC3_OBV_P#CM'_"
M^?$G_1'?&G_?%M_\=H]C/^F@]K'^DSV6BO&O^%\^)/\ HCOC3_OBV_\ CM'_
M  OGQ)_T1WQI_P!\6W_QVCV,_P"F@]K'^DSV6BO&O^%\^)/^B.^-/^^+;_X[
M1_POGQ)_T1WQI_WQ;?\ QVCV,_Z:#VL?Z3/9:*\:_P"%\^)/^B.^-/\ OBV_
M^.T?\+Y\2?\ 1'?&G_?%M_\ ':/8S_IH/:Q_I,]EHKQK_A?/B3_HCOC3_OBV
M_P#CM'_"^?$G_1'?&G_?%M_\=H]C/^F@]K'^DSV6BO&O^%\^)/\ HCOC3_OB
MV_\ CM'_  OGQ)_T1WQI_P!\6W_QVCV,_P"F@]K'^DSV6BO&O^%\^)/^B.^-
M/^^+;_X[1_POGQ)_T1WQI_WQ;?\ QVCV,_Z:#VL?Z3/9:*\:_P"%\^)/^B.^
M-/\ OBV_^.T?\+Y\2?\ 1'?&G_?%M_\ ':/8S_IH/:Q_I,]EHKQK_A?/B3_H
MCOC3_OBV_P#CM'_"^?$G_1'?&G_?%M_\=H]C/^F@]K'^DSV6BO&O^%\^)/\
MHCOC3_OBV_\ CM'_  OGQ)_T1WQI_P!\6W_QVCV,_P"F@]K'^DSV6BO&O^%\
M^)/^B.^-/^^+;_X[1_POGQ)_T1WQI_WQ;?\ QVCV,_Z:#VL?Z3/9:*\:_P"%
M\^)/^B.^-/\ OBV_^.T?\+Y\2?\ 1'?&G_?%M_\ ':/8S_IH/:Q_I,]EHKQK
M_A?/B3_HCOC3_OBV_P#CM'_"^?$G_1'?&G_?%M_\=H]C/^F@]K'^DSV6BO&O
M^%\^)/\ HCOC3_OBV_\ CM'_  OGQ)_T1WQI_P!\6W_QVCV,_P"F@]K'^DSV
M6BO&O^%\^)/^B.^-/^^+;_X[1_POGQ)_T1WQI_WQ;?\ QVCV,_Z:#VL?Z3/9
M:*\:_P"%\^)/^B.^-/\ OBV_^.T?\+Y\2?\ 1'?&G_?%M_\ ':/8S_IH/:Q_
MI,]EKR#Q3_R<UX)_[ M[_P"A"H?^%\^)/^B.^-/^^+;_ ..UD^']6\1^/OCM
MX>UV[\#:[X8T[3]-N;>2;54B"LSD$8*.U:0IRA=OL^J(E-2LEW70][HHHKE.
MD**** "BBB@ HHHH **** "BBB@ KQWPU_R<_P",O^P+9?S:O8J\"\1:IXB\
M!?'?7]>M/ VN^)].O],M;>.;2EBVJR9+9+NOK6])7YEY?Y&-1VY7YGOM(>*\
M;_X7SXD_Z([XT_[XMO\ X[1_POGQ)_T1WQI_WQ;?_':7L9_TT'M8_P!)F;\.
MOVL](^(O[0_C+X36_AG6['4/#:;Y-4NH0+>;!P<=U!_A)^\*]WKQ=?CGXA65
MI!\&O&0D;AF$=KD_4^;3_P#A?/B3_HCOC3_OBV_^.T>QG9+KZH/:QN_\F,^,
MWC+Q'>_$3PA\-O"VL_\ ",WNNP7-_>ZTEND\]O:P[05@60,GF,SCYG5@ .AK
ME/B;I?Q \':9X,\+K\5-:F?6_$<=D-?BL+&/4H[;R)',;'R3"YW*/F$2\<8[
MUC?%?6O%7C[4]"\0:)\/O'7A/Q?H1E^P:I'9V=U$4D $D,\+3+YD;;5. RD$
M9!%<GXJ?XO\ BK0=%DN=*\63>+]+U9-5@U*X\-V9L(BL;1^4EHMXK!2&)RTS
M-GOVH5&6EUUUU7?U[?KW*]K"_P GT>]GY=SN-8^*OBS]G7Q%XAT#Q-XED\>Z
M<GAR?7M)U'4K2*"]C>%MCPSF!$CD4ED(945N2,'BJ7PD^*FLZQ>ZKYGCWQ/J
MWB^]T>:[T[0_%'A@:+H]Q*J;@]F[V\<C1J2H.97X.3ZUSVGZ3XHUP^(-0^(/
M@CQWXP\0:SI;:.;NTT^ST^VL;8Y)6VA$[E26.XL[N20.PQ6:OA[Q[XFC\GQY
MX>\=^)+>STVYTK2AIVCV6G/:QS(J/+*WVF3S9MJJ,@(G!^3DT>QGU[=UY_CM
M_GU$JL+_ #[/R_X/7Y=#J/V<?BQXA\9?$NSLH_B%JOBU'TZ6XU_2=>TVULUL
M;@, @L6BC0RIG>"0TJ8"G?DU]*>%_$VIZMX2&K:QX>N?#E\%D9],NIXY9$"D
MXR\9*\@9_&OE#P=%\2;+Q7X<U;Q=X9\6>([;PQ%)%HUIIOAZSTUD#H$)N'%U
M)YAVJ.$"+GDKTQZ9X:^+/CVQ\)_V9X@^'GC3Q#J;+(DFI+86=KO#$X_=)-@8
M! ]\4YTI\ONVOZKS\Q1JPYM;_<_Z_+T,[2?VQ-7U:V\.7D?PD\1_V?XF5XM#
MG6]M";NZ4$F-D+@Q1D D2MP0#\O0'K]._:$U36/AOJFN6?@2\;Q)I-_)IFI:
M!<:K:0+9SQG#E[MW$7E],.,D[A\M>2>'K7Q%H6@?##3/^%<^-I_^$)G:<2_8
M[5?MF8GCQCSSL^_GOTKE_&W@'Q'XLL-:C3P#XJ\^]\23>(H[;5M$L]0TYFD3
M9Y-Q:M<J)U )(.Y<'G%-T9:I?+5=U^E_N^]JK&Z_R?G_ ,#[SV>+]KJ*\\":
M-K-CX-U#4M;O]<?PZ^AV5];2M'>*DA^6=6,3Q_N_O@XP<]L5S"?&C4/"/QZ\
M0#4]&O9/%&K>']*33_!MO?K,[71:8R*K@^6%0<O+C  '4X!X+P)X!UWP-I.A
M6,/P]\6-'IGBB3Q+LL]%L;*!B\<B&!(8Y]D2@R9&,\#&.];7C_0-:\<^.=8\
M6CX=>.M*UN6VLUTF]MK6U,VEW-N9")0WG_.KB0J\9P&7(SR"&Z+33_5=E^MQ
MJK"S5^G9[\WIVL=C\0OV[_"GP[\<S^'[V#3G&F31VVL,_B.Q@NK:9MN5@M)'
M6:Y"EADJHZ' ;%>@Z3\=-2\2_%G4_!VB^"+^_P!/TF:!-1U][V&*WA26W69"
MJ-\\C?, 5 XX.><5X)';?$S2/%U[JF@>&?$VF6&KW2W^K6=UX8L;R1KC"B1K
M65KH>2'*Y*NLF"3CM7>^#?%_B3PEXX\9^(O^%7>-;MO$=Q;SF V]JGD>5;I#
MC/G?-G9NZ#&<4E1EUM]ZWT_#>WXDNK#6WY/_ "_KH>D?$OXRZIX7\3V_A;PE
MX,O?'/B9K4:A<6D%[!90VML7**TDTQQN9E8*@!)VG.!7@?QJ^+6L?&75/A%I
MNB>#=5U+PSKE_<_VIIO_  D(TBX^TVX97MI3&P;]RP+G:VUB .:U_B#K?Q"U
MCQM%XP\%^#?&'A'7WLETV]^VZ/::E:W5NKLZ$Q_:8V61"[X8-C#<J<"L_0-(
MUCPW=?#^:U^'/CVX?PO=WU_<375M:-+J4]TI\V1BLP"$L2V ".<"B%&6CE^:
M[_UYW&ZT-;?D^WYW^5CZ/^)?C75?ASX.2_T?PQ+XCN(]J&W?5+>RBA4#[TMQ
M.P"CH,X8DGIWKS^S_:J@UWP/H=_H/A2]UGQ;K%[<Z;;>&X;ZWXN+8D7!:[W&
M'RDQ_K 3NW+@<\>>_'Z7Q)\;=.T2-/AAXFL[C2;IKB.VUK1K/5M-N=R;")[5
MKA Y Y4[AM.>N:XKP]\/_%G@GPCHMIX9\'>+]'\2:'JE[J6G:FF@V LU6Z8F
M6![*.X1/+QMP$9""HP>H*5&3OS?FO(3JQ5N7\GY_\ ]=U?X[_%:W^,?@3P]%
M\,#;6&KZ9/<:A:7.NV8EA=)8E=U89W+&')P/]8'&,;2*VO!OQY2'QM)HE[;Z
MQ=VVH^*M3T./4-0GMS%9SP*'2%!'&A\MU639N+,-A#,<BO,]0U+XH7^O^"/$
MC>&_%K^)]"2>VOKN3P_9FWO[:9T:2-(1=#R6'EJ%?<^!G(:L[7= \3ZKX(\7
MZ/:^!/'&G:OJ_B*7Q+INLQ6%JSZ7=-('0A#<8DVC<IY&0QX%.-*26J77JOYE
MY]KV_$/:1=]>W1]GY=[7_P SV74_VC-5F\':AXB\.>!Y-<LH=6N=-@GN-;M-
M/MI8X)/+,[33D!0SA@J@,3MSQFN#U?\ :M\9^(_$WPDN/ 7@@:QX?\4Q7ANX
M;K5+:"430D+)$&.X?NB"VY25<-@=,UPOCOP!J_B?PMX%T;3_ (9>(XXO"ULU
MHMOXA\/V.L6-TKA \K6SW"*)\IE9,G&YL@YIF@>"?%_@SPK\.]/\-^#_ !CI
M^J>#+R[E@O9]$LI(+B"Y8F6(VZW"!"!@*58!2/ND<4U1:>O?NOZ\^_8'5B]O
MU_KR['IGB/\ ;T\&^'?B7)X:D33YK&UU%='O+L>(;!;V*[,@CPFGF3SY8P[
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M-/\ OBV_^.U4Z+YGR[>J(C57*N;?T9[+17C7_"^?$G_1'?&G_?%M_P#':/\
MA?/B3_HCOC3_ +XMO_CM1[&?]-%>UC_29[+17C7_  OGQ)_T1WQI_P!\6W_Q
MVC_A?/B3_HCOC3_OBV_^.T>QG_30>UC_ $F>RT5XU_POGQ)_T1WQI_WQ;?\
MQVC_ (7SXD_Z([XT_P"^+;_X[1[&?]-![6/])GLM%>-?\+Y\2?\ 1'?&G_?%
MM_\ ':/^%\^)/^B.^-/^^+;_ ..T>QG_ $T'M8_TF>RT5XU_POGQ)_T1WQI_
MWQ;?_':/^%\^)/\ HCOC3_OBV_\ CM'L9_TT'M8_TF>RT5XU_P +Y\2?]$=\
M:?\ ?%M_\=H_X7SXD_Z([XT_[XMO_CM'L9_TT'M8_P!)GLM>,^%O^3I?&O\
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JH 3:/04;1Z"EHH 3:/04;1Z"EHH 3:/04  =!BEHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>pasg-20221231xex10d24003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pasg-20221231xex10d24003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ! 6@# 2(  A$! Q$!_\0
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>pasg-20221231xex10d24007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pasg-20221231xex10d24007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  % 90# 2(  A$! Q$!_\0
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M[XO/_EA110 ?\,"_&'_H[;QQ_P!\7G_RPH_X8%^,/_1VWCC_ +XO/_EA110
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M[XO/_EA110 ?\,"_&'_H[;QQ_P!\7G_RPH_X8%^,/_1VWCC_ +XO/_EA110
M?\,"_&'_ *.V\<?]\7G_ ,L*/^&!?C#_ -';>./^^+S_ .6%%% !_P ,"_&'
M_H[;QQ_WQ>?_ "PH_P"&!?C#_P!';>./^^+S_P"6%%% !_PP+\8?^CMO''_?
M%Y_\L*/^&!?C#_T=MXX_[XO/_EA110 ?\,"_&'_H[;QQ_P!\7G_RPH_X8%^,
M/_1VWCC_ +XO/_EA110!](_LW?L]>-/ACX&OM+U[XPZ]XYO)M1DN4U'45F$D
5:&*)1$-]Q(< HS=0,N>.Y*** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>19
<FILENAME>pasg-20221231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/6/2023 10:28:39 AM-->
<!--Modified on: 3/6/2023 10:28:39 AM-->
<xsd:schema targetNamespace="http://www.passagebio.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:pasg="http://www.passagebio.com/20221231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:attributeFormDefault="unqualified" xmlns:srt="http://fasb.org/srt/2022" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>00100 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" id="StatementStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>00400 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails" id="DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails">
        <link:definition>40402 - Disclosure - Cash, cash equivalents and marketable securities - Portfolio of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails" id="DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails">
        <link:definition>40403 - Disclosure - Cash, cash equivalents and marketable securities (Contractual Final Maturities of Marketable Securities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" id="DisclosureFairValueOfFinancialInstrumentsDetails">
        <link:definition>40501 - Disclosure - Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetDetails">
        <link:definition>40601 - Disclosure - Property and Equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>40701 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureLeasesDetailss" id="DisclosureLeasesDetailss">
        <link:definition>40801 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureLeasesDetails" id="DisclosureLeasesDetails">
        <link:definition>40901 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails">
        <link:definition>41301 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails" id="DisclosureIncomeTaxesEffectiveTaxRateDetails">
        <link:definition>41302 - Disclosure - Income Taxes - Effective tax rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity" id="StatementStatementsOfStockholdersEquity">
        <link:definition>00300 - Statement - Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/StatementStatementsOfStockholdersEquityParenthetical" id="StatementStatementsOfStockholdersEquityParenthetical">
        <link:definition>00305 - Statement - Statements of Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails" id="DisclosureRisksAndLiquidityDetails">
        <link:definition>40201 - Disclosure - Risks and Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>40301 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails" id="DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails">
        <link:definition>40401 - Disclosure - Cash, cash equivalents and marketable securities - Portfolio of Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureSeveranceDetails" id="DisclosureSeveranceDetails">
        <link:definition>40801 - Disclosure - Severance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails" id="DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails">
        <link:definition>41001 - Disclosure - Commitments and Contingencies - Collaboration Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureCommonStockDetails" id="DisclosureCommonStockDetails">
        <link:definition>41101 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails" id="DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails">
        <link:definition>41201 - Disclosure - Share-Based Compensation - Equity Incentive Plan &amp; ESPP (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" id="DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>41202 - Disclosure - Share-Based Compensation - Share-based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails" id="DisclosureShareBasedCompensationRestrictedStockUnitsDetails">
        <link:definition>41205 - Disclosure - Share-Based Compensation - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails" id="DisclosureIncomeTaxesNetOperatingLossesDetails">
        <link:definition>41303 - Disclosure - Income Taxes - Net operating losses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureNatureOfOperations" id="DisclosureNatureOfOperations">
        <link:definition>10101 - Disclosure - Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureRisksAndLiquidity" id="DisclosureRisksAndLiquidity">
        <link:definition>10201 - Disclosure - Risks and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10301 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecurities" id="DisclosureCashCashEquivalentsAndMarketableSecurities">
        <link:definition>10401 - Disclosure - Cash, cash equivalents and marketable securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstruments" id="DisclosureFairValueOfFinancialInstruments">
        <link:definition>10501 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>10601 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" id="DisclosureAccruedExpensesAndOtherCurrentLiabilities">
        <link:definition>10701 - Disclosure - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureSeverance" id="DisclosureSeverance">
        <link:definition>10801 - Disclosure - Severance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>10901 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11001 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureCommonStock" id="DisclosureCommonStock">
        <link:definition>11101 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
        <link:definition>11201 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11301 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11401 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20302 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30303 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesTables" id="DisclosureCashCashEquivalentsAndMarketableSecuritiesTables">
        <link:definition>30403 - Disclosure - Cash, cash equivalents and marketable securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsTables" id="DisclosureFairValueOfFinancialInstrumentsTables">
        <link:definition>30503 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>30603 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables">
        <link:definition>30703 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>30903 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationTables" id="DisclosureShareBasedCompensationTables">
        <link:definition>31203 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31303 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureNatureOfOperationsDetails" id="DisclosureNatureOfOperationsDetails">
        <link:definition>40101 - Disclosure - Nature of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureLeasesOperatingLeaseCostDetails" id="DisclosureLeasesOperatingLeaseCostDetails">
        <link:definition>40902 - Disclosure - Leases - Operating lease cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" id="DisclosureShareBasedCompensationStockOptionActivityDetails">
        <link:definition>41203 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails" id="DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails">
        <link:definition>41204 - Disclosure - Share-Based Compensation - Assumptions Used in Determining Fair Value &amp; Early exercise of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="pasg-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pasg-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pasg-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pasg-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xsd:element id="pasg_AccruedExpensesAndOtherCurrentLiabilities" name="AccruedExpensesAndOtherCurrentLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="pasg_IncreaseDecreaseInDeferredRent" name="IncreaseDecreaseInDeferredRent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment" name="IncreaseDecreaseInPrepaidResearchAndDevelopment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="pasg_VestingOfEarlyExerciseOptionAwards" name="VestingOfEarlyExerciseOptionAwards" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="pasg_PrepaidResearchAndDevelopmentAssetCurrent" name="PrepaidResearchAndDevelopmentAssetCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="pasg_RisksAndLiquidityAbstract" name="RisksAndLiquidityAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_RisksAndLiquidityTextBlock" name="RisksAndLiquidityTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" name="AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_BasisOfPresentationPolicyTextBlock" name="BasisOfPresentationPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" name="ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_RisksAndLiquidityTable" name="RisksAndLiquidityTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" name="StockOptionsIncludingSharesSubjectToRepurchaseMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_AccruedResearchAndDevelopmentExpense" name="AccruedResearchAndDevelopmentExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="pasg_CollaborationAgreementUpfrontPaymentMade" name="CollaborationAgreementUpfrontPaymentMade" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="pasg_CollaborationAgreementAnnualFeePayable" name="CollaborationAgreementAnnualFeePayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable" name="CollaborationAgreementPeriodForWhichAnnualFeeIsPayable" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" name="EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" name="EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" name="EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" name="EmployeeStockPurchasePlanStockPurchasePricePercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_RisksAndLiquidityLineItems" name="RisksAndLiquidityLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_StockIssuanceCosts" name="StockIssuanceCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="pasg_TermOfManufacturingAndSupplyAgreement" name="TermOfManufacturingAndSupplyAgreement" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm" name="ManufacturingAndSupplyAgreementAdditionalExtensionTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" name="NewLeaseAgreementOperatingLeaseRenewalTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" name="NewLeaseAgreementOperatingLeaseNumberOfExtensions" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="pasg_TenantImprovementAllowanceReceivable" name="TenantImprovementAllowanceReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" name="ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_ShareBasedCompensationArrangementExpensesDueToModifications" name="ShareBasedCompensationArrangementExpensesDueToModifications" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" name="EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_NumberOfEquityIncentivePlans" name="NumberOfEquityIncentivePlans" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" name="ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_CollaborationAgreementQuarterlyFeePayable" name="CollaborationAgreementQuarterlyFeePayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" name="StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" name="StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" name="AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" name="IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" name="CashCashEquivalentsAndMarketableSecuritiesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_CatalentMarylandInc.Member" name="CatalentMarylandInc.Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement" name="DeferredTaxAssetsCollaborationAndLicenseAgreement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" name="EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_StateTaxAuthorityMember" name="StateTaxAuthorityMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_LocalTaxAuthoritiesMember" name="LocalTaxAuthoritiesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_TaxCreditCarryForwardSubjectToExpiration" name="TaxCreditCarryForwardSubjectToExpiration" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="pasg_SegmentPolicyPolicyTextBlock" name="SegmentPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_PropertyAndEquipmentInDeferredRent" name="PropertyAndEquipmentInDeferredRent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram" name="NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" />
  <xsd:element id="pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation" name="CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="pasg_CollaborationAgreementAnnualFeePayableTerm" name="CollaborationAgreementAnnualFeePayableTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased" name="EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment" name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="pasg_DevelopmentMilestonePaymentsPayable" name="DevelopmentMilestonePaymentsPayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="pasg_CollaborationAgreementSalesMilestonePaymentsPayable" name="CollaborationAgreementSalesMilestonePaymentsPayable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="pasg_PaymentsForTechnologyLicenseFee" name="PaymentsForTechnologyLicenseFee" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" name="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_OperatingLeasesForOfficeSpaceMember" name="OperatingLeasesForOfficeSpaceMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_OperatingLeasesForLaboratorySpaceMember" name="OperatingLeasesForLaboratorySpaceMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_EquityIncentivePlan2020Member" name="EquityIncentivePlan2020Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_EquityInducementPlan2021Member" name="EquityInducementPlan2021Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" name="PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent" name="AccruedLiabilitiesPropertyAndEquipmentCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="pasg_AdditionalTechnologyLicenseFeePaid" name="AdditionalTechnologyLicenseFeePaid" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="pasg_CollaborationAgreementTieredTransactionFeePayablePercent" name="CollaborationAgreementTieredTransactionFeePayablePercent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="pasg_CollaborationAgreementPaymentMadeOnOptionExercise" name="CollaborationAgreementPaymentMadeOnOptionExercise" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element name="ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" id="pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LaboratoryEquipmentMember" id="pasg_LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ComputerHardwareAndSoftwareMember" id="pasg_ComputerHardwareAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" id="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone" id="pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SalesAgreementWithCowenAndCompanyLlcMember" id="pasg_SalesAgreementWithCowenAndCompanyLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise" id="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="TenantImprovementAllowancesLiability" id="pasg_TenantImprovementAllowancesLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LesseeOperatingLeaseIncrementalBorrowingRatePercentage" id="pasg_LesseeOperatingLeaseIncrementalBorrowingRatePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" id="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" id="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CollaborationAgreementUpfrontFee" id="pasg_CollaborationAgreementUpfrontFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" id="pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PaymentsForInsurancePremiumFinancing" id="pasg_PaymentsForInsurancePremiumFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="PercentReductionToOurWorkforce" id="pasg_PercentReductionToOurWorkforce" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfLeadClinicalProductCandidate" id="pasg_NumberOfLeadClinicalProductCandidate" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AccruedExpensesAndOtherCurrentLiabilitiesMember" id="pasg_AccruedExpensesAndOtherCurrentLiabilitiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DeferredTaxAssetsOperatingLeaseLiabilities" id="pasg_DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" id="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="OperatingLossCarryforwardSubjectToExpiration" id="pasg_OperatingLossCarryforwardSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>20
<FILENAME>pasg-20221231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/6/2023 10:28:39 AM-->
<!--Modified on: 3/6/2023 10:28:39 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#StatementBalanceSheets" roleURI="http://www.passagebio.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.passagebio.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails" roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails" roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsDetails" roleURI="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureLeasesDetailss" roleURI="http://www.passagebio.com/role/DisclosureLeasesDetailss" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureLeasesDetails" roleURI="http://www.passagebio.com/role/DisclosureLeasesDetails" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxesDetails" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureIncomeTaxesEffectiveTaxRateDetails" roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails" />
  <calculationLink xlink:role="http://www.passagebio.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638136953177604614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638136953177604614" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638136953177604614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638136953177604614" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638136953177604614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638136953177604614" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638136953177604614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638136953177604614" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638136953177604614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638136953177604614" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638136953177604614" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_PrepaidResearchAndDevelopmentAssetCurrent" xlink:label="pasg_PrepaidResearchAndDevelopmentAssetCurrent_638136953177604614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638136953177604614" xlink:to="pasg_PrepaidResearchAndDevelopmentAssetCurrent_638136953177604614" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_638136953177604614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638136953177604614" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_638136953177604614" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638136953177604614" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638136953177604614" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638136953177604614" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638136953177614593" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638136953177614593" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638136953177614593" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638136953177614593" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638136953177614593" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638136953177614593" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638136953177614593" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638136953177614593" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638136953177614593" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638136953177614593" xlink:to="us-gaap_AdditionalPaidInCapital_638136953177614593" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638136953177614593" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638136953177614593" xlink:to="us-gaap_CommonStockValue_638136953177614593" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638136953177614593" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638136953177614593" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638136953177624592" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638136953177614593" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638136953177624592" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_638136953177624592" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638136953177614593" xlink:to="us-gaap_DeferredRentCreditNoncurrent_638136953177624592" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638136953177624592" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638136953177614593" xlink:to="us-gaap_LiabilitiesCurrent_638136953177624592" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilities_638136953177624592" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638136953177624592" xlink:to="pasg_AccruedExpensesAndOtherCurrentLiabilities_638136953177624592" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638136953177624592" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638136953177624592" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638136953177624592" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638136953177624592" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638136953177624592" xlink:to="us-gaap_AccountsPayableCurrent_638136953177624592" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Statements of Operations and Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638136953177634809" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638136953177634809" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet_638136953177634809" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638136953177634809" xlink:to="us-gaap_InvestmentIncomeNet_638136953177634809" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638136953177634809" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638136953177634809" xlink:to="us-gaap_OperatingIncomeLoss_638136953177634809" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638136953177634809" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638136953177634809" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638136953177634809" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638136953177634809" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638136953177634809" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638136953177634809" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638136953177634809" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638136953177634809" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638136953177634809" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_638136953177634809" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_638136953177634809" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.passagebio.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638136953177644595" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638136953177644595" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638136953177644595" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638136953177644595" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638136953177644595" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_638136953177644595" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638136953177644595" xlink:to="us-gaap_ProceedsFromStockPlans_638136953177644595" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638136953177644595" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638136953177644595" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638136953177644595" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638136953177644595" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638136953177644595" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638136953177644595" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_PaymentsForInsurancePremiumFinancing" xlink:label="pasg_PaymentsForInsurancePremiumFinancing_638136953177644595" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638136953177644595" xlink:to="pasg_PaymentsForInsurancePremiumFinancing_638136953177644595" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638136953177654601" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638136953177654601" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_638136953177654601" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638136953177654601" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_638136953177654601" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638136953177654601" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638136953177654601" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638136953177654601" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_638136953177654601" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638136953177654601" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_638136953177654601" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638136953177654601" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638136953177654601" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638136953177654601" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638136953177654601" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638136953177654601" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_638136953177654601" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638136953177654601" xlink:to="pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_638136953177654601" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities_638136953177654601" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638136953177654601" xlink:to="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities_638136953177654601" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_638136953177664588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638136953177654601" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_638136953177664588" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638136953177664588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638136953177654601" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638136953177664588" order="4" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:label="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_638136953177664588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638136953177654601" xlink:to="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_638136953177664588" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_IncreaseDecreaseInDeferredRent" xlink:label="pasg_IncreaseDecreaseInDeferredRent_638136953177664588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638136953177654601" xlink:to="pasg_IncreaseDecreaseInDeferredRent_638136953177664588" order="6" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638136953177664588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638136953177654601" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638136953177664588" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638136953177664588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638136953177654601" xlink:to="us-gaap_ShareBasedCompensation_638136953177664588" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638136953177664588" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638136953177654601" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638136953177664588" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638136953177674584" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638136953177654601" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638136953177674584" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638136953177674584" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638136953177654601" xlink:to="us-gaap_NetIncomeLoss_638136953177674584" order="11" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Cash, cash equivalents and marketable securities - Portfolio of Marketable Securities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638136953177674584" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638136953177674584" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638136953177674584" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638136953177674584" order="2" use="optional" weight="1" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638136953177674584" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638136953177674584" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Cash, cash equivalents and marketable securities (Contractual Final Maturities of Marketable Securities) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_638136953177684595" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_638136953177684595" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_638136953177684595" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_638136953177684595" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_638136953177684595" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_638136953177684595" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_638136953177684595" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_638136953177684595" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Fair Value of Financial Instruments (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638136953177684595" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638136953177684595" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638136953177684595" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638136953177684595" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and Equipment, net (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638136953177694594" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638136953177694594" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638136953177694594" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638136953177694594" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638136953177694594" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638136953177694594" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638136953177694594" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638136953177694594" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_AccruedResearchAndDevelopmentExpense" xlink:label="pasg_AccruedResearchAndDevelopmentExpense_638136953177694594" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="pasg_AccruedResearchAndDevelopmentExpense_638136953177694594" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent" xlink:label="pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent_638136953177694594" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent_638136953177694594" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638136953177704606" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="us-gaap_OtherLiabilitiesCurrent_638136953177704606" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.passagebio.com/role/DisclosureLeasesDetailss" xlink:type="extended" xlink:title="40801 - Disclosure - Leases (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638136953177704606" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638136953177704606" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638136953177704606" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_OperatingLeaseLiability_638136953177704606" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.passagebio.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Leases (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638136953177704606" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638136953177704606" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638136953177704606" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638136953177704606" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638136953177704606" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638136953177704606" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638136953177714592" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638136953177714592" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638136953177714592" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638136953177714592" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638136953177714592" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638136953177714592" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.passagebio.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Income Taxes (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638136953177714592" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638136953177714592" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638136953177714592" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet_638136953177714592" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638136953177714592" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_638136953177714592" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet_638136953177714592" xlink:to="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_638136953177714592" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638136953177714592" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_638136953177714592" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638136953177714592" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638136953177714592" xlink:to="us-gaap_DeferredTaxAssetsGross_638136953177714592" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="pasg_DeferredTaxAssetsOperatingLeaseLiabilities_638136953177724593" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638136953177714592" xlink:to="pasg_DeferredTaxAssetsOperatingLeaseLiabilities_638136953177724593" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:label="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_638136953177724593" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638136953177714592" xlink:to="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_638136953177724593" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638136953177724593" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638136953177714592" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638136953177724593" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_638136953177724593" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638136953177714592" xlink:to="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_638136953177724593" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement" xlink:label="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_638136953177724593" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638136953177714592" xlink:to="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_638136953177724593" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638136953177724593" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638136953177714592" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638136953177724593" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638136953177734598" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638136953177714592" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638136953177734598" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638136953177734598" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638136953177714592" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638136953177734598" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Income Taxes - Effective tax rate (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637456100089205502" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638136953177734598" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637456100089205502" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638136953177734598" order="1" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638136953177734598" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637456100089205502" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638136953177734598" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638136953177734598" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637456100089205502" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638136953177734598" order="3" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638136953177734598" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637456100089205502" xlink:to="pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638136953177734598" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638136953177734598" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations_637456100089205502" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638136953177734598" order="5" use="optional" weight="-1" priority="3" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>21
<FILENAME>pasg-20221231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/6/2023 10:28:39 AM-->
<!--Modified on: 3/6/2023 10:28:39 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureRisksAndLiquidityDetails" roleURI="http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails" roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails" roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsDetails" roleURI="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureSeveranceDetails" roleURI="http://www.passagebio.com/role/DisclosureSeveranceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureLeasesDetails" roleURI="http://www.passagebio.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails" roleURI="http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureCommonStockDetails" roleURI="http://www.passagebio.com/role/DisclosureCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails" roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureShareBasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureIncomeTaxesNetOperatingLossesDetails" roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.passagebio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="pasg-20221231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.passagebio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1" xlink:title="us-gaap_CashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Statements of Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:label="pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:label="pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Risks and Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_RisksAndLiquidityTable" xlink:label="pasg_RisksAndLiquidityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="pasg_RisksAndLiquidityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_RisksAndLiquidityLineItems" xlink:label="pasg_RisksAndLiquidityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="pasg_RisksAndLiquidityLineItems" xlink:to="pasg_RisksAndLiquidityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="pasg_RisksAndLiquidityLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="pasg_RisksAndLiquidityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="pasg_RisksAndLiquidityLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="pasg_RisksAndLiquidityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_LaboratoryEquipmentMember" xlink:label="pasg_LaboratoryEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pasg_LaboratoryEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:label="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AssetImpairmentCharges" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Cash, cash equivalents and marketable securities - Portfolio of Cash and Cash Equivalents (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DemandDepositsMember" xlink:label="us-gaap_DemandDepositsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_DemandDepositsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Cash, cash equivalents and marketable securities - Portfolio of Marketable Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ForeignGovernmentDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Fair Value of Financial Instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CertificatesOfDepositMember" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_ForeignGovernmentDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and Equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_LaboratoryEquipmentMember" xlink:label="pasg_LaboratoryEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pasg_LaboratoryEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ComputerHardwareAndSoftwareMember" xlink:label="pasg_ComputerHardwareAndSoftwareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pasg_ComputerHardwareAndSoftwareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureSeveranceDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Severance (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="pasg_AccruedExpensesAndOtherCurrentLiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_PercentReductionToOurWorkforce" xlink:label="pasg_PercentReductionToOurWorkforce" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="pasg_PercentReductionToOurWorkforce" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_SeveranceCosts1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringReserveCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_OperatingLeasesForOfficeSpaceMember" xlink:label="pasg_OperatingLeasesForOfficeSpaceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pasg_OperatingLeasesForOfficeSpaceMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_OperatingLeasesForLaboratorySpaceMember" xlink:label="pasg_OperatingLeasesForLaboratorySpaceMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="pasg_OperatingLeasesForLaboratorySpaceMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_BalanceSheetLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="us-gaap_OtherCurrentAssetsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherCurrentAssetsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:label="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:label="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_TenantImprovementAllowanceReceivable" xlink:label="pasg_TenantImprovementAllowanceReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pasg_TenantImprovementAllowanceReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_DeferredRentCreditNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_TenantImprovements" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_TenantImprovementAllowancesLiability" xlink:label="pasg_TenantImprovementAllowancesLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pasg_TenantImprovementAllowancesLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_LesseeOperatingLeaseIncrementalBorrowingRatePercentage" xlink:label="pasg_LesseeOperatingLeaseIncrementalBorrowingRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="pasg_LesseeOperatingLeaseIncrementalBorrowingRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Commitments and Contingencies - Collaboration Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:label="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CatalentMarylandInc.Member" xlink:label="pasg_CatalentMarylandInc.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="pasg_CatalentMarylandInc.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementAnnualFeePayable" xlink:label="pasg_CollaborationAgreementAnnualFeePayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementAnnualFeePayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementQuarterlyFeePayable" xlink:label="pasg_CollaborationAgreementQuarterlyFeePayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementQuarterlyFeePayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram" xlink:label="pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementUpfrontPaymentMade" xlink:label="pasg_CollaborationAgreementUpfrontPaymentMade" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementUpfrontPaymentMade" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation" xlink:label="pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementUpfrontFee" xlink:label="pasg_CollaborationAgreementUpfrontFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementUpfrontFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_DevelopmentMilestonePaymentsPayable" xlink:label="pasg_DevelopmentMilestonePaymentsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_DevelopmentMilestonePaymentsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementTieredTransactionFeePayablePercent" xlink:label="pasg_CollaborationAgreementTieredTransactionFeePayablePercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementTieredTransactionFeePayablePercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_PaymentsForTechnologyLicenseFee" xlink:label="pasg_PaymentsForTechnologyLicenseFee" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_PaymentsForTechnologyLicenseFee" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_AdditionalTechnologyLicenseFeePaid" xlink:label="pasg_AdditionalTechnologyLicenseFeePaid" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_AdditionalTechnologyLicenseFeePaid" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementAnnualFeePayableTerm" xlink:label="pasg_CollaborationAgreementAnnualFeePayableTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementAnnualFeePayableTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable" xlink:label="pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_TermOfManufacturingAndSupplyAgreement" xlink:label="pasg_TermOfManufacturingAndSupplyAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_TermOfManufacturingAndSupplyAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm" xlink:label="pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementPaymentMadeOnOptionExercise" xlink:label="pasg_CollaborationAgreementPaymentMadeOnOptionExercise" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementPaymentMadeOnOptionExercise" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementSalesMilestonePaymentsPayable" xlink:label="pasg_CollaborationAgreementSalesMilestonePaymentsPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="pasg_CollaborationAgreementSalesMilestonePaymentsPayable" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureCommonStockDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_SalesAgreementWithCowenAndCompanyLlcMember" xlink:label="pasg_SalesAgreementWithCowenAndCompanyLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="pasg_SalesAgreementWithCowenAndCompanyLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Share-Based Compensation - Equity Incentive Plan &amp; ESPP (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EquityIncentivePlan2020Member" xlink:label="pasg_EquityIncentivePlan2020Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="pasg_EquityIncentivePlan2020Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EquityInducementPlan2021Member" xlink:label="pasg_EquityInducementPlan2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="pasg_EquityInducementPlan2021Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EmployeeStockPurchasePlanMember" xlink:label="pasg_EmployeeStockPurchasePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="pasg_EmployeeStockPurchasePlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_NumberOfEquityIncentivePlans" xlink:label="pasg_NumberOfEquityIncentivePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_NumberOfEquityIncentivePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:label="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:label="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:label="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:label="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:label="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:label="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:label="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:label="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased" xlink:label="pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Share-Based Compensation - Share-based compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ShareBasedCompensationArrangementExpensesDueToModifications" xlink:label="pasg_ShareBasedCompensationArrangementExpensesDueToModifications" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="pasg_ShareBasedCompensationArrangementExpensesDueToModifications" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="41205 - Disclosure - Share-Based Compensation - Restricted Stock Units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Income Taxes - Net operating losses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_StateTaxAuthorityMember" xlink:label="pasg_StateTaxAuthorityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="pasg_StateTaxAuthorityMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_LocalTaxAuthoritiesMember" xlink:label="pasg_LocalTaxAuthoritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="pasg_LocalTaxAuthoritiesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_TaxCreditCarryForwardSubjectToExpiration" xlink:label="pasg_TaxCreditCarryForwardSubjectToExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="pasg_TaxCreditCarryForwardSubjectToExpiration" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_OperatingLossCarryforwardSubjectToExpiration" xlink:label="pasg_OperatingLossCarryforwardSubjectToExpiration" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="pasg_OperatingLossCarryforwardSubjectToExpiration" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>22
<FILENAME>pasg-20221231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/6/2023 10:28:39 AM-->
<!--Modified on: 3/6/2023 10:28:39 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well Known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_PrepaidResearchAndDevelopmentAssetCurrent" xlink:label="pasg_PrepaidResearchAndDevelopmentAssetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_PrepaidResearchAndDevelopmentAssetCurrent" xlink:to="pasg_PrepaidResearchAndDevelopmentAssetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_PrepaidResearchAndDevelopmentAssetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of asset related to consideration paid in advance for current portion of prepaid research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_PrepaidResearchAndDevelopmentAssetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Research And Development Asset, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_PrepaidResearchAndDevelopmentAssetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total, property plant and equipment net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right of use assets - operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying balance as of the balance sheet of accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses and Other Current Liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities - noncurrent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Rent Credit, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies (note 10)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $0.0001 par value: 300,000,000 shares authorized; 54,614,690 shares issued and outstanding at December 31, 2022 and 54,244,996 shares issued and outstanding at December 31, 2021</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paidin capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at Beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Operations and Comprehensive Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development in Process</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired inprocess research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Per share information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share of common stock, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share of common stock, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding, basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average common shares outstanding, diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain (loss) on marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at Beginning of period (in shares)</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:label="pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:to="pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity impact of the value of stock vesting of common stock previously subject to repurchase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value Vesting Of Common Stock Previously Subject To Repurchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of early exercise option awards</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:label="pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:to="pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares that have been vesting of common stock previously subject to repurchase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Shares Vesting Of Common Stock Previously Subject To Repurchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of early exercise option awards (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options and vesting of restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options and vesting of restricted stock units (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of shares in connection with employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of shares in connection with employee stock purchase plan (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of common stock, net of issuance costs (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_StockIssuanceCosts" xlink:label="pasg_StockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_StockIssuanceCosts" xlink:to="pasg_StockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_StockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of stock issuance incurred.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_StockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_StockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statements of Cash Flows</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of Debt Discount (Premium)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of premium and discount on marketable securities, net</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_IncreaseDecreaseInDeferredRent" xlink:label="pasg_IncreaseDecreaseInDeferredRent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_IncreaseDecreaseInDeferredRent" xlink:to="pasg_IncreaseDecreaseInDeferredRent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of increase (decrease) in deferred rent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Deferred Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred rent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets, and other assets</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:label="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:to="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of increase (decrease) in prepaid research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) In Prepaid Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid research and development</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:to="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of increase (decrease) during the period in the carrying value of right of use assets and operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Right of Use Assets and Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right of use assets and operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable, Trade</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:to="pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and amount of increase (decrease) in current liabilities classified as other.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Accrued Expenses And Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by (used in) operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows provided by (used in) investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale and Maturity of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales or maturities of marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of technology licenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Machinery and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows provided by (used in) financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of common stock, net of offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from the issuance of common stock under employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_PaymentsForInsurancePremiumFinancing" xlink:label="pasg_PaymentsForInsurancePremiumFinancing" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_PaymentsForInsurancePremiumFinancing" xlink:to="pasg_PaymentsForInsurancePremiumFinancing_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_PaymentsForInsurancePremiumFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow from the payments for insurance premium financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_PaymentsForInsurancePremiumFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Insurance Premium Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pasg_PaymentsForInsurancePremiumFinancing_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for insurance premium financing</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by (used in) financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase (decrease) in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of noncash investing and financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosure of noncash investing and financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Unrealized Gain (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain (loss) on marketable securities</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_PropertyAndEquipmentInDeferredRent" xlink:label="pasg_PropertyAndEquipmentInDeferredRent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_PropertyAndEquipmentInDeferredRent" xlink:to="pasg_PropertyAndEquipmentInDeferredRent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_PropertyAndEquipmentInDeferredRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of property and equipment in deferred rent during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_PropertyAndEquipmentInDeferredRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property And Equipment In Deferred Rent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_PropertyAndEquipmentInDeferredRent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment in deferred rent</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" xlink:to="pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment in accounts payable and accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property And Equipment In Accounts Payable And Accrued Expenses And Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment in accounts payable and accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_VestingOfEarlyExerciseOptionAwards" xlink:label="pasg_VestingOfEarlyExerciseOptionAwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_VestingOfEarlyExerciseOptionAwards" xlink:to="pasg_VestingOfEarlyExerciseOptionAwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_VestingOfEarlyExerciseOptionAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of vesting of early exercise option awards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_VestingOfEarlyExerciseOptionAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting Of Early Exercise Option Awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_VestingOfEarlyExerciseOptionAwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting of early exercise option awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right of use assets recognized upon the adoption of Topic 842</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" xlink:label="pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" xlink:to="pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of lease liabilities recognized upon adoption of standard.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liability Recognized Upon Adoption of Standard</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities recognized upon the adoption of Topic 842</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of Operations</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_RisksAndLiquidityAbstract" xlink:label="pasg_RisksAndLiquidityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_RisksAndLiquidityAbstract" xlink:to="pasg_RisksAndLiquidityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_RisksAndLiquidityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_RisksAndLiquidityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risks and Liquidity</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_RisksAndLiquidityTextBlock" xlink:label="pasg_RisksAndLiquidityTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_RisksAndLiquidityTextBlock" xlink:to="pasg_RisksAndLiquidityTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_RisksAndLiquidityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of information pertaining to risk and liquidity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_RisksAndLiquidityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risks And Liquidity [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_RisksAndLiquidityTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risks and Liquidity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, and Marketable Securities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses and Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:to="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of information pertaining to accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses And Other Current Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses and Other Current Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring and Related Activities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_BasisOfPresentationPolicyTextBlock" xlink:label="pasg_BasisOfPresentationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_BasisOfPresentationPolicyTextBlock" xlink:to="pasg_BasisOfPresentationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_BasisOfPresentationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for basis of presentation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_BasisOfPresentationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis Of Presentation [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_BasisOfPresentationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of credit risk</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_SegmentPolicyPolicyTextBlock" xlink:label="pasg_SegmentPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_SegmentPolicyPolicyTextBlock" xlink:to="pasg_SegmentPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_SegmentPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for segment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_SegmentPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_SegmentPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Information</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">In Process Research and Development, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquired In-Process Research and Development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss Per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Adopted and Issued Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of antidilutive securities excluded from computation of earnings per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of details regarding the Company's portfolio of cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of details regarding the Company's portfolio of marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments Classified by Contractual Maturity Date [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual Final Maturities of Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of assets measured at fair value on a recurring basis</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of information pertaining to accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Accrued Liabilities And Other Current Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of accrued liabilities and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Cost [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of operating lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future minimum rental payments for operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of share-based compensation expense category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock option activity plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of weighted average assumptions applied to options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonvested Restricted Stock Shares Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of activity related to restricted stock unit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of deferred tax assets and liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of effective income tax rate reconciliation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Operating Loss Carryforwards [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_NumberOfLeadClinicalProductCandidate" xlink:label="pasg_NumberOfLeadClinicalProductCandidate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_NumberOfLeadClinicalProductCandidate" xlink:to="pasg_NumberOfLeadClinicalProductCandidate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_NumberOfLeadClinicalProductCandidate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of lead clinical product candidates.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_NumberOfLeadClinicalProductCandidate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Lead Clinical Product Candidate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_NumberOfLeadClinicalProductCandidate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of lead clinical product candidates</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_RisksAndLiquidityTable" xlink:label="pasg_RisksAndLiquidityTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_RisksAndLiquidityTable" xlink:to="pasg_RisksAndLiquidityTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_RisksAndLiquidityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of information pertaining to risk and liquidity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_RisksAndLiquidityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risks And Liquidity [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Follow-on public offering</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_RisksAndLiquidityLineItems" xlink:label="pasg_RisksAndLiquidityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_RisksAndLiquidityLineItems" xlink:to="pasg_RisksAndLiquidityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_RisksAndLiquidityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_RisksAndLiquidityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risks And Liquidity [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net proceeds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer hardware and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Office equipment</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_LaboratoryEquipmentMember" xlink:label="pasg_LaboratoryEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_LaboratoryEquipmentMember" xlink:to="pasg_LaboratoryEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_LaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Laboratory equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_LaboratoryEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Laboratory equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and fixtures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:label="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:to="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to stock options (including shares subject to repurchase).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options (including shares subject to repurchase)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested restricted stock units</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockMember" xlink:to="us-gaap_EmployeeStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee stock purchase plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounting Standards Update 2016-02</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of segments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Useful life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset Impairment Charges</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Asset impairment charges</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of antidilutive securities excluded from computation of earnings per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Lease Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Cash and Cash Equivalents [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DemandDepositsMember" xlink:label="us-gaap_DemandDepositsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DemandDepositsMember" xlink:to="us-gaap_DemandDepositsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DemandDepositsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash accounts in banking institutions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial paper</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, cash equivalents and marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost or Amortized cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CertificatesOfDepositMember" xlink:to="us-gaap_CertificatesOfDepositMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CertificatesOfDepositMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Certificates of deposit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate debt securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. government securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="us-gaap_ForeignGovernmentDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-U.S. government securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gains</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized losses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments, Debt and Equity Securities [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due within one year, Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due after one year through five years, Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total, Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due within one year, Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due after one year through five years, Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total, Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 2</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recurring</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ComputerHardwareAndSoftwareMember" xlink:label="pasg_ComputerHardwareAndSoftwareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ComputerHardwareAndSoftwareMember" xlink:to="pasg_ComputerHardwareAndSoftwareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ComputerHardwareAndSoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Computer Hardware and Software.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ComputerHardwareAndSoftwareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer hardware and software.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction in progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation and related benefits</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_AccruedResearchAndDevelopmentExpense" xlink:label="pasg_AccruedResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_AccruedResearchAndDevelopmentExpense" xlink:to="pasg_AccruedResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_AccruedResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The carrying balance as of the balance sheet of accrued research and development expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_AccruedResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Research And Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_AccruedResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent" xlink:label="pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent" xlink:to="pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs of property and equipment Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Property and Equipment, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Restructuring and Related Costs [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance Sheet Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_AccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:to="pasg_AccruedExpensesAndOtherCurrentLiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Primary financial statement caption encompassing accrued expenses and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Expenses and Other Current Liabilities [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Cost and Reserve [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_PercentReductionToOurWorkforce" xlink:label="pasg_PercentReductionToOurWorkforce" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_PercentReductionToOurWorkforce" xlink:to="pasg_PercentReductionToOurWorkforce_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_PercentReductionToOurWorkforce_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percent of percent reduction to our workforce.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_PercentReductionToOurWorkforce_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent Reduction to Our Workforce</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pasg_PercentReductionToOurWorkforce_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent reduction to workforce</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Severance and termination-related expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="us-gaap_RestructuringReserveCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restructuring Reserve, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringReserveCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unpaid severance and termination-related expenses recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_OperatingLeasesForOfficeSpaceMember" xlink:label="pasg_OperatingLeasesForOfficeSpaceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_OperatingLeasesForOfficeSpaceMember" xlink:to="pasg_OperatingLeasesForOfficeSpaceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_OperatingLeasesForOfficeSpaceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the operating lease agreement for office space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_OperatingLeasesForOfficeSpaceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases For Office Space</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_OperatingLeasesForLaboratorySpaceMember" xlink:label="pasg_OperatingLeasesForLaboratorySpaceMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_OperatingLeasesForLaboratorySpaceMember" xlink:to="pasg_OperatingLeasesForLaboratorySpaceMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_OperatingLeasesForLaboratorySpaceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the operating lease agreement for laboratory space.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_OperatingLeasesForLaboratorySpaceMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases For Laboratory Space</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="us-gaap_OtherCurrentAssetsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsMember" xlink:to="us-gaap_OtherCurrentAssetsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Lease, Description [Line Items]</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:label="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:to="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of extensions available under the new lease arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Lease Agreement, Operating Lease, Number Of Extensions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of extension terms</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:label="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:to="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the renewal term under new lease agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Lease Agreement, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Extended term of new lease agreement</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_TenantImprovementAllowanceReceivable" xlink:label="pasg_TenantImprovementAllowanceReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_TenantImprovementAllowanceReceivable" xlink:to="pasg_TenantImprovementAllowanceReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_TenantImprovementAllowanceReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of tenant improvement allowance receivable from the landlord under operating leases.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_TenantImprovementAllowanceReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tenant Improvement Allowance Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_TenantImprovementAllowanceReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tenant improvement allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TenantImprovements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tenant Improvements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TenantImprovements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tenant improvements</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_TenantImprovementAllowancesLiability" xlink:label="pasg_TenantImprovementAllowancesLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_TenantImprovementAllowancesLiability" xlink:to="pasg_TenantImprovementAllowancesLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_TenantImprovementAllowancesLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of liability for tenant improvement allowances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_TenantImprovementAllowancesLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tenant Improvement Allowances Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_TenantImprovementAllowancesLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tenant improvement allowances liability</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_LesseeOperatingLeaseIncrementalBorrowingRatePercentage" xlink:label="pasg_LesseeOperatingLeaseIncrementalBorrowingRatePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_LesseeOperatingLeaseIncrementalBorrowingRatePercentage" xlink:to="pasg_LesseeOperatingLeaseIncrementalBorrowingRatePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_LesseeOperatingLeaseIncrementalBorrowingRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental borrowing rate for lessee under operating lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_LesseeOperatingLeaseIncrementalBorrowingRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Incremental Borrowing Rate Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_LesseeOperatingLeaseIncrementalBorrowingRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental borrowing rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Payments, Due after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee Operating Lease Liability Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total Undiscounted lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: imputed interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="us-gaap_OperatingLeasePaymentsUse" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePaymentsUse" xlink:to="us-gaap_OperatingLeasePaymentsUse_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments, Use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for amounts included in the measurement of operating cash flows from operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average discount rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining lease term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:label="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:to="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to amended and restated research, collaboration and license agreement with Penn.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amended and restated agreement with Penn</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CatalentMarylandInc.Member" xlink:label="pasg_CatalentMarylandInc.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CatalentMarylandInc.Member" xlink:to="pasg_CatalentMarylandInc.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CatalentMarylandInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Catalent Maryland, Inc. (Catalent) (formerly Paragon Bioservices, Inc.).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CatalentMarylandInc.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Catalent Maryland, Inc. (Catalent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementAnnualFeePayable" xlink:label="pasg_CollaborationAgreementAnnualFeePayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementAnnualFeePayable" xlink:to="pasg_CollaborationAgreementAnnualFeePayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementAnnualFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of annual fee payable during the period under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementAnnualFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Annual Fee Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementAnnualFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual fee payable</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementQuarterlyFeePayable" xlink:label="pasg_CollaborationAgreementQuarterlyFeePayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementQuarterlyFeePayable" xlink:to="pasg_CollaborationAgreementQuarterlyFeePayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementQuarterlyFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement Quarterly Fee Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementQuarterlyFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement Quarterly Fee Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementQuarterlyFeePayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quarterly fee payable</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram" xlink:label="pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram" xlink:to="pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of remaining options available to the Company to commence additional licensed programs for rare, monogenic CNS indications.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Remaining Options Available To Commence Additional License Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of CNS indications</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementUpfrontPaymentMade" xlink:label="pasg_CollaborationAgreementUpfrontPaymentMade" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementUpfrontPaymentMade" xlink:to="pasg_CollaborationAgreementUpfrontPaymentMade_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementUpfrontPaymentMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of upfront payment made during the period under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementUpfrontPaymentMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Upfront Payment Made</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementUpfrontPaymentMade_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payments</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation" xlink:label="pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation" xlink:to="pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of upfront fee payable upon clinical candidate designation under the collaboration agreement if the company were to exercise the options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Upfront Fee Payable Upon Clinical Candidate Designation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront fee payable upon clinical candidate designation</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementUpfrontFee" xlink:label="pasg_CollaborationAgreementUpfrontFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementUpfrontFee" xlink:to="pasg_CollaborationAgreementUpfrontFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementUpfrontFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of upfront fee due.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementUpfrontFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement Upfront Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementUpfrontFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront fee due</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_DevelopmentMilestonePaymentsPayable" xlink:label="pasg_DevelopmentMilestonePaymentsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_DevelopmentMilestonePaymentsPayable" xlink:to="pasg_DevelopmentMilestonePaymentsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_DevelopmentMilestonePaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of payable on development milestone payment on collaboration and license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_DevelopmentMilestonePaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development Milestone Payments Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_DevelopmentMilestonePaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Development milestone payment</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementTieredTransactionFeePayablePercent" xlink:label="pasg_CollaborationAgreementTieredTransactionFeePayablePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementTieredTransactionFeePayablePercent" xlink:to="pasg_CollaborationAgreementTieredTransactionFeePayablePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementTieredTransactionFeePayablePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of tired transaction fee payable under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementTieredTransactionFeePayablePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Tiered Transaction Fee Payable, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementTieredTransactionFeePayablePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration agreement, tiered transaction fee percent</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_PaymentsForTechnologyLicenseFee" xlink:label="pasg_PaymentsForTechnologyLicenseFee" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_PaymentsForTechnologyLicenseFee" xlink:to="pasg_PaymentsForTechnologyLicenseFee_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_PaymentsForTechnologyLicenseFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of cash paid for technology license fee during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_PaymentsForTechnologyLicenseFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Technology License Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_PaymentsForTechnologyLicenseFee_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for technology license fee</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_AdditionalTechnologyLicenseFeePaid" xlink:label="pasg_AdditionalTechnologyLicenseFeePaid" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_AdditionalTechnologyLicenseFeePaid" xlink:to="pasg_AdditionalTechnologyLicenseFeePaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_AdditionalTechnologyLicenseFeePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Technology License Fee Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_AdditionalTechnologyLicenseFeePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Technology License Fee Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_AdditionalTechnologyLicenseFeePaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional technology license fee paid</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementAnnualFeePayableTerm" xlink:label="pasg_CollaborationAgreementAnnualFeePayableTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementAnnualFeePayableTerm" xlink:to="pasg_CollaborationAgreementAnnualFeePayableTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementAnnualFeePayableTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the term of annual fee payable during the period under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementAnnualFeePayableTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement Annual Fee Payable Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementAnnualFeePayableTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual fee payable, term</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable" xlink:label="pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable" xlink:to="pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period for which the annual fee is payable for the use of clean room suite under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Period For Which Annual Fee is Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for which annual fee is payable</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_TermOfManufacturingAndSupplyAgreement" xlink:label="pasg_TermOfManufacturingAndSupplyAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_TermOfManufacturingAndSupplyAgreement" xlink:to="pasg_TermOfManufacturingAndSupplyAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_TermOfManufacturingAndSupplyAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the term of manufacturing and supply agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_TermOfManufacturingAndSupplyAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Of Manufacturing And Supply Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_TermOfManufacturingAndSupplyAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of manufacturing and supply agreement</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm" xlink:label="pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm" xlink:to="pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the additional extension term of manufacturing and supply agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Manufacturing And Supply Agreement, Additional Extension Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional extension term of manufacturing and supply agreement</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementPaymentMadeOnOptionExercise" xlink:label="pasg_CollaborationAgreementPaymentMadeOnOptionExercise" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementPaymentMadeOnOptionExercise" xlink:to="pasg_CollaborationAgreementPaymentMadeOnOptionExercise_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementPaymentMadeOnOptionExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount paid on option exercise under the collaboration agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementPaymentMadeOnOptionExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Payment Made On Option Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementPaymentMadeOnOptionExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment made on option exercise</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase Commitment, Remaining Minimum Amount Committed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum amount agreed to purchase in batches of drug product</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:to="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of payable per product candidate  for rare monogenic disorders upon achievement of specific development milestone payment on collaboration and license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Amount Payable Per Product Candidate for Rare Monogenic Disorders, Upon Achievement Of Specific Development Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount payable per product candidate for rare, monogenic disorders</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone" xlink:to="pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of payable per product candidate for large CNS indications upon achievement of specific development milestone payment on collaboration and license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement, Amount Payable Per Product Candidate for Large CNS Indications, Upon Achievement Of Specific Development Milestone</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount payable per product candidate arising from the exploratory program for large CNS indications</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementSalesMilestonePaymentsPayable" xlink:label="pasg_CollaborationAgreementSalesMilestonePaymentsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CollaborationAgreementSalesMilestonePaymentsPayable" xlink:to="pasg_CollaborationAgreementSalesMilestonePaymentsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CollaborationAgreementSalesMilestonePaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of payable on sales milestone payment on collaboration and license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CollaborationAgreementSalesMilestonePaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration Agreement Sales Milestone Payments Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CollaborationAgreementSalesMilestonePaymentsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales milestone payments</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_SalesAgreementWithCowenAndCompanyLlcMember" xlink:label="pasg_SalesAgreementWithCowenAndCompanyLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_SalesAgreementWithCowenAndCompanyLlcMember" xlink:to="pasg_SalesAgreementWithCowenAndCompanyLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_SalesAgreementWithCowenAndCompanyLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Sales Agreement, with Cowen and Company LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_SalesAgreementWithCowenAndCompanyLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales Agreement, with Cowen and Company, LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EquityIncentivePlan2020Member" xlink:label="pasg_EquityIncentivePlan2020Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_EquityIncentivePlan2020Member" xlink:to="pasg_EquityIncentivePlan2020Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_EquityIncentivePlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2020 Equity Incentive Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_EquityIncentivePlan2020Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Incentive Plan 2020</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EquityInducementPlan2021Member" xlink:label="pasg_EquityInducementPlan2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_EquityInducementPlan2021Member" xlink:to="pasg_EquityInducementPlan2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_EquityInducementPlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2021 Equity Inducement plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_EquityInducementPlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Inducement Plan 2021</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EmployeeStockPurchasePlanMember" xlink:label="pasg_EmployeeStockPurchasePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_EmployeeStockPurchasePlanMember" xlink:to="pasg_EmployeeStockPurchasePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Employee Stock Purchase Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_EmployeeStockPurchasePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_NumberOfEquityIncentivePlans" xlink:label="pasg_NumberOfEquityIncentivePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_NumberOfEquityIncentivePlans" xlink:to="pasg_NumberOfEquityIncentivePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_NumberOfEquityIncentivePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of equity incentive plans.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_NumberOfEquityIncentivePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Equity Incentive Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_NumberOfEquityIncentivePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of equity incentive plans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares available for future grant</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:label="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:to="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the period till which there is automatic annual increase in rights granted under the share based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Payment Arrangement, Period Till Which Automatic Increase In Rights Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period till which there is automatic increase in rights granted under the Plan</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:label="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:to="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of outstanding common shares to be taken as automatic annual increase in rights granted under the share based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Payment Arrangement, Percentage Of Outstanding Common Shares As Automatic Increase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percent of the total number of shares of the Company's common stock outstanding</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:to="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Duration from date of grant (issuance of an option) to when option auto expires.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement By Share-based Payment Award Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:label="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:to="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional number of common shares reserved for future issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Additional Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional number of common shares reserved for future issuance</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:label="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:to="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the period till which there is automatic annual increase in rights granted under the employee stock purchase plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan, Period Till Which Automatic Increase In Rights Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period till which there is automatic increase in rights granted under ESPP</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:label="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:to="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of total number of shares of the Company's common stock outstanding equal to which shares may be issued under Employee Stock Purchase Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan Issuance, Percentage Of Common Stock Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of common stock outstanding</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:label="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:to="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The stock purchase price percentage on the lower of the fair market value of the Company's common stock on the first or last day of the respective offering period under the ESPP.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan, Stock Purchase Price Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of stock purchase price</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:label="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:to="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the maximum contribution percentage on eligible compensation by eligible employees under Employee Stock Purchase Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan, Maximum Employee Contribution Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of maximum employee contribution</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:label="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:to="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum amount of common stock that a participant may accrue rights to purchase for each calendar year in which such right is outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan, Maximum Amount Of Common Stock That Can Be Purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of common stock that can be purchased</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased" xlink:label="pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased" xlink:to="pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares that can be purchased.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Stock Purchase Plan Number Of Shares That Can Be Purchased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares purchased</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ShareBasedCompensationArrangementExpensesDueToModifications" xlink:label="pasg_ShareBasedCompensationArrangementExpensesDueToModifications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ShareBasedCompensationArrangementExpensesDueToModifications" xlink:to="pasg_ShareBasedCompensationArrangementExpensesDueToModifications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ShareBasedCompensationArrangementExpensesDueToModifications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of share based compensation arrangement expenses due to modifications.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ShareBasedCompensationArrangementExpensesDueToModifications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement, Expenses Due To Modifications</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_ShareBasedCompensationArrangementExpensesDueToModifications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation expense due to modifications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Ending of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and Exercisable at December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested or expected to vest at December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average exercise price per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Ending of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding, Beginning of period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and Exercisable at December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested or expected to vest at December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average remaining contractual term (years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and Exercisable at December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested or expected to vest at December 31, 2022</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise" xlink:to="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options (or share units) unvested and exercisable under early exercise during the current period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Unvested, Exercisable Under Early Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options unvested and exercisable during the period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value of options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of options outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation expense related to unvested stock option awards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average period for recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested balance, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested balance, Beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested balance, Weighted average grant date fair value, Ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unvested balance, Weighted average grant date fair value, Beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted, Weighted average grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested, Weighted average grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited, Weighted average grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total unrecognized expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average remaining contractual term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, in Process Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credits</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement" xlink:label="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement" xlink:to="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from collaboration and license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Collaboration and License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaboration and license agreement</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Capitalized Research and Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:label="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:to="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities and other.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities and Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="pasg_DeferredTaxAssetsOperatingLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="pasg_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total gross deferred tax assets before valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:to="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax liability attributable to taxable temporary differences from operating lease right of use assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Operating Lease Right of Use Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right of use assets - operating leases (deferred rent for December 31, 2021)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance increased</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal tax benefit at statutory rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State tax, net of federal benefit</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:to="pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Permanent Differences, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Permanent differences</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development and orphan tax credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective income tax rate reconciliation, total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_StateTaxAuthorityMember" xlink:label="pasg_StateTaxAuthorityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_StateTaxAuthorityMember" xlink:to="pasg_StateTaxAuthorityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_StateTaxAuthorityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to state tax authorities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_StateTaxAuthorityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_LocalTaxAuthoritiesMember" xlink:label="pasg_LocalTaxAuthoritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_LocalTaxAuthoritiesMember" xlink:to="pasg_LocalTaxAuthoritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_LocalTaxAuthoritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to local tax authorities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_LocalTaxAuthoritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research tax credits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carryforward, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research tax credits</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_TaxCreditCarryForwardSubjectToExpiration" xlink:label="pasg_TaxCreditCarryForwardSubjectToExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_TaxCreditCarryForwardSubjectToExpiration" xlink:to="pasg_TaxCreditCarryForwardSubjectToExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_TaxCreditCarryForwardSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of the tax credit carry-forward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_TaxCreditCarryForwardSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Credit Carry Forward Subject to Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="pasg_TaxCreditCarryForwardSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax credit carry forward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Examination, Penalties and Interest Accrued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued interest or penalties related to uncertain tax positions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Examination, Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax examination, penalties and interest expense</label>
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_OperatingLossCarryforwardSubjectToExpiration" xlink:label="pasg_OperatingLossCarryforwardSubjectToExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pasg_OperatingLossCarryforwardSubjectToExpiration" xlink:to="pasg_OperatingLossCarryforwardSubjectToExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="pasg_OperatingLossCarryforwardSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of operating loss carryforward subject to expiry, before tax effects, available to reduce future taxable income under enacted tax laws.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="pasg_OperatingLossCarryforwardSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforward Subject to Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="pasg_OperatingLossCarryforwardSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards subject to expiration</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>23
<FILENAME>pasg-20221231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/6/2023 10:28:39 AM-->
<!--Modified on: 3/6/2023 10:28:39 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.passagebio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#StatementBalanceSheets" roleURI="http://www.passagebio.com/role/StatementBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#StatementBalanceSheetsParenthetical" roleURI="http://www.passagebio.com/role/StatementBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#StatementStatementsOfStockholdersEquityParenthetical" roleURI="http://www.passagebio.com/role/StatementStatementsOfStockholdersEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.passagebio.com/role/StatementStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureNatureOfOperations" roleURI="http://www.passagebio.com/role/DisclosureNatureOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureRisksAndLiquidity" roleURI="http://www.passagebio.com/role/DisclosureRisksAndLiquidity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureCashCashEquivalentsAndMarketableSecurities" roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureFairValueOfFinancialInstruments" roleURI="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilities" roleURI="http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureSeverance" roleURI="http://www.passagebio.com/role/DisclosureSeverance" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureLeases" roleURI="http://www.passagebio.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.passagebio.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureCommonStock" roleURI="http://www.passagebio.com/role/DisclosureCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureShareBasedCompensation" roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureIncomeTaxes" roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureSubsequentEvents" roleURI="http://www.passagebio.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureCashCashEquivalentsAndMarketableSecuritiesTables" roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsTables" roleURI="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" roleURI="http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureLeasesTables" roleURI="http://www.passagebio.com/role/DisclosureLeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureShareBasedCompensationTables" roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureNatureOfOperationsDetails" roleURI="http://www.passagebio.com/role/DisclosureNatureOfOperationsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureRisksAndLiquidityDetails" roleURI="http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails" roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails" roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails" roleURI="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsDetails" roleURI="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" roleURI="http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureSeveranceDetails" roleURI="http://www.passagebio.com/role/DisclosureSeveranceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureLeasesDetails" roleURI="http://www.passagebio.com/role/DisclosureLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureLeasesOperatingLeaseCostDetails" roleURI="http://www.passagebio.com/role/DisclosureLeasesOperatingLeaseCostDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails" roleURI="http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureCommonStockDetails" roleURI="http://www.passagebio.com/role/DisclosureCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails" roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureShareBasedCompensationStockOptionActivityDetails" roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails" roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureShareBasedCompensationRestrictedStockUnitsDetails" roleURI="http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureIncomeTaxesEffectiveTaxRateDetails" roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="pasg-20221231.xsd#DisclosureIncomeTaxesNetOperatingLossesDetails" roleURI="http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <presentationLink xlink:role="http://www.passagebio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638136953178304590" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638136953178304590" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638136953178304590" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_638136953178304590" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638136953178304590" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638136953178304590" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638136953178304590" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638136953178304590" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638136953178304590" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638136953178304590" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638136953178314599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638136953178314599" order="6" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638136953178314599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638136953178314599" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638136953178314599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638136953178314599" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638136953178314599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638136953178314599" order="9" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638136953178314599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638136953178314599" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638136953178314599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638136953178314599" order="11" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638136953178314599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638136953178314599" order="12" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638136953178314599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638136953178314599" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638136953178314599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638136953178314599" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638136953178314599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638136953178314599" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638136953178314599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638136953178314599" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638136953178324579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638136953178324579" order="17" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638136953178324579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638136953178324579" order="18" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638136953178324579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638136953178324579" order="19" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638136953178324579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638136953178324579" order="20" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638136953178324579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638136953178324579" order="21" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638136953178324579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638136953178324579" order="22" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638136953178324579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638136953178324579" order="23" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638136953178334599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638136953178334599" order="24" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638136953178334599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638136953178334599" order="25" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638136953178334599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_638136953178334599" order="26" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638136953178334599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638136953178334599" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638136953178334599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638136953178334599" order="28" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638136953178334599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_638136953178334599" order="29" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638136953178334599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638136953178334599" order="30" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638136953178334599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638136953178334599" order="31" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638136953178344579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638136953178344579" order="32" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638136953178344579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638136953178344579" order="33" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638136953178344579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638136953178344579" order="34" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638136953178344579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638136953178344579" order="35" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638136953178344579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_638136953178344579" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638136953178344579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_638136953178344579" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638136953178354577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_638136953178354577" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Balance Sheets" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638136953178354577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638136953178354577" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638136953178354577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638136953178354577" xlink:to="us-gaap_AssetsCurrentAbstract_638136953178354577" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638136953178354577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638136953178354577" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638136953178354577" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_638136953178354577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638136953178354577" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_638136953178354577" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638136953178354577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638136953178354577" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638136953178354577" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_PrepaidResearchAndDevelopmentAssetCurrent" xlink:label="pasg_PrepaidResearchAndDevelopmentAssetCurrent_638136953178354577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638136953178354577" xlink:to="pasg_PrepaidResearchAndDevelopmentAssetCurrent_638136953178354577" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638136953178354577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638136953178354577" xlink:to="us-gaap_AssetsCurrent_638136953178354577" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638136953178354577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638136953178354577" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638136953178354577" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638136953178364589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638136953178354577" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638136953178364589" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638136953178364589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638136953178354577" xlink:to="us-gaap_OtherAssetsNoncurrent_638136953178364589" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638136953178364589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638136953178354577" xlink:to="us-gaap_Assets_638136953178364589" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638136953178364589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638136953178364589" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638136953178364589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638136953178364589" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638136953178364589" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638136953178364589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638136953178364589" xlink:to="us-gaap_AccountsPayableCurrent_638136953178364589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilities_638136953178364589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638136953178364589" xlink:to="pasg_AccruedExpensesAndOtherCurrentLiabilities_638136953178364589" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638136953178364589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638136953178364589" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638136953178364589" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638136953178364589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638136953178364589" xlink:to="us-gaap_LiabilitiesCurrent_638136953178364589" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638136953178364589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638136953178364589" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638136953178364589" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_638136953178364589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638136953178364589" xlink:to="us-gaap_DeferredRentCreditNoncurrent_638136953178364589" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638136953178374578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638136953178364589" xlink:to="us-gaap_Liabilities_638136953178374578" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638136953178374578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies_638136953178374578" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638136953178374578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_638136953178374578" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638136953178374578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638136953178374578" xlink:to="us-gaap_CommonStockValue_638136953178374578" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638136953178374578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638136953178374578" xlink:to="us-gaap_AdditionalPaidInCapital_638136953178374578" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638136953178374578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638136953178374578" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638136953178374578" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638136953178374578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638136953178374578" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638136953178374578" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638136953178374578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638136953178374578" xlink:to="us-gaap_StockholdersEquity_638136953178374578" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638136953178384577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638136953178374578" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638136953178384577" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Balance Sheets (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638136953178384577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638136953178384577" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638136953178384577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638136953178384577" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638136953178384577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638136953178384577" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638136953178384577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638136953178384577" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Statements of Operations and Comprehensive Loss" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638136953178384577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638136953178384577" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638136953178384577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638136953178384577" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_638136953178384577" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638136953178384577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638136953178384577" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638136953178384577" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638136953178394588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638136953178384577" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638136953178394588" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638136953178394588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638136953178384577" xlink:to="us-gaap_OperatingIncomeLoss_638136953178394588" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet_638136953178394588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeNet_638136953178394588" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638136953178394588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_638136953178394588" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_638136953178394588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_638136953178394588" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638136953178394588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638136953178394588" xlink:to="us-gaap_EarningsPerShareBasic_638136953178394588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638136953178394588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638136953178394588" xlink:to="us-gaap_EarningsPerShareDiluted_638136953178394588" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638136953178394588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638136953178394588" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638136953178394588" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638136953178394588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638136953178394588" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638136953178394588" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638136953178394588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638136953178394588" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_6381369531783945881" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638136953178394588" xlink:to="us-gaap_NetIncomeLoss_6381369531783945881" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_638136953178394588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_638136953178394588" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_638136953178394588" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638136953178404577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638136953178404577" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - Statements of Stockholders' Equity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638136953178404577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638136953178404577" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638136953178404577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638136953178404577" xlink:to="us-gaap_StatementEquityComponentsAxis_638136953178404577" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638136953178404577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638136953178404577" xlink:to="us-gaap_CommonStockMember_638136953178404577" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638136953178404577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638136953178404577" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638136953178404577" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638136953178404577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638136953178404577" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638136953178404577" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638136953178404577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638136953178404577" xlink:to="us-gaap_RetainedEarningsMember_638136953178404577" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638136953178404577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638136953178404577" xlink:to="us-gaap_EquityComponentDomain_638136953178404577" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638136953178404577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638136953178404577" xlink:to="us-gaap_StatementLineItems_638136953178404577" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638136953178404577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638136953178404577" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638136953178404577" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638136953178414587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638136953178404577" xlink:to="us-gaap_StockholdersEquity_638136953178414587" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638136953178414587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638136953178404577" xlink:to="us-gaap_SharesOutstanding_638136953178414587" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:label="pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase_638136953178414587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638136953178404577" xlink:to="pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase_638136953178414587" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase" xlink:label="pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase_638136953178414587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638136953178404577" xlink:to="pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase_638136953178414587" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638136953178414587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638136953178404577" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_638136953178414587" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_638136953178414587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638136953178404577" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_638136953178414587" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638136953178414587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638136953178404577" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638136953178414587" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638136953178414587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638136953178404577" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638136953178414587" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638136953178414587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638136953178404577" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638136953178414587" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638136953178414587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638136953178404577" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638136953178414587" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_638136953178424579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638136953178404577" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_638136953178424579" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638136953178424579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638136953178404577" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638136953178424579" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638136953178424579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638136953178404577" xlink:to="us-gaap_NetIncomeLoss_638136953178424579" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638136953178424579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638136953178404577" xlink:to="us-gaap_StockholdersEquity_638136953178424579" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638136953178424579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638136953178404577" xlink:to="us-gaap_SharesOutstanding_638136953178424579" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/StatementStatementsOfStockholdersEquityParenthetical" xlink:type="extended" xlink:title="00305 - Statement - Statements of Stockholders' Equity (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_StockIssuanceCosts" xlink:label="pasg_StockIssuanceCosts_638136953178434596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="pasg_StockIssuanceCosts_638136953178434596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Statements of Cash Flows" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638136953178434596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638136953178434596" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638136953178434596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638136953178434596" xlink:to="us-gaap_NetIncomeLoss_638136953178434596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638136953178434596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638136953178434596" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638136953178434596" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638136953178434596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638136953178434596" xlink:to="us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_638136953178434596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638136953178434596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638136953178434596" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638136953178434596" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638136953178434596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638136953178434596" xlink:to="us-gaap_ShareBasedCompensation_638136953178434596" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638136953178434596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638136953178434596" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638136953178434596" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_IncreaseDecreaseInDeferredRent" xlink:label="pasg_IncreaseDecreaseInDeferredRent_638136953178434596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638136953178434596" xlink:to="pasg_IncreaseDecreaseInDeferredRent_638136953178434596" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638136953178434596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638136953178434596" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638136953178434596" order="6" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638136953178444589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638136953178434596" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638136953178444589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment" xlink:label="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_638136953178444589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638136953178434596" xlink:to="pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment_638136953178444589" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities" xlink:label="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities_638136953178444589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638136953178434596" xlink:to="pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities_638136953178444589" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_638136953178444589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638136953178434596" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_638136953178444589" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_638136953178444589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638136953178434596" xlink:to="pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities_638136953178444589" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638136953178444589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638136953178434596" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638136953178444589" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638136953178444589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638136953178444589" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_638136953178444589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638136953178444589" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_638136953178444589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638136953178444589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638136953178444589" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638136953178444589" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_638136953178444589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638136953178444589" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_638136953178444589" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMachineryAndEquipment" xlink:label="us-gaap_PaymentsToAcquireMachineryAndEquipment_638136953178454580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638136953178444589" xlink:to="us-gaap_PaymentsToAcquireMachineryAndEquipment_638136953178454580" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638136953178454580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638136953178444589" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638136953178454580" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638136953178454580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638136953178454580" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638136953178454580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638136953178454580" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638136953178454580" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638136953178454580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638136953178454580" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638136953178454580" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638136953178454580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638136953178454580" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638136953178454580" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_638136953178454580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638136953178454580" xlink:to="us-gaap_ProceedsFromStockPlans_638136953178454580" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_PaymentsForInsurancePremiumFinancing" xlink:label="pasg_PaymentsForInsurancePremiumFinancing_638136953178454580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638136953178454580" xlink:to="pasg_PaymentsForInsurancePremiumFinancing_638136953178454580" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638136953178464582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638136953178454580" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638136953178464582" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638136953178464582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638136953178464582" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638136953178464582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638136953178464582" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381369531784645821" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381369531784645821" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638136953178464582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638136953178464582" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_638136953178464582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638136953178464582" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_638136953178464582" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_PropertyAndEquipmentInDeferredRent" xlink:label="pasg_PropertyAndEquipmentInDeferredRent_638136953178474580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638136953178464582" xlink:to="pasg_PropertyAndEquipmentInDeferredRent_638136953178474580" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities_638136953178474580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638136953178464582" xlink:to="pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities_638136953178474580" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_VestingOfEarlyExerciseOptionAwards" xlink:label="pasg_VestingOfEarlyExerciseOptionAwards_638136953178474580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638136953178464582" xlink:to="pasg_VestingOfEarlyExerciseOptionAwards_638136953178474580" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638136953178474580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638136953178464582" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638136953178474580" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard" xlink:label="pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard_638136953178474580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638136953178464582" xlink:to="pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard_638136953178474580" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureNatureOfOperations" xlink:type="extended" xlink:title="10101 - Disclosure - Nature of Operations" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_637184925736553018" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638136953178484589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_637184925736553018" xlink:to="us-gaap_NatureOfOperations_638136953178484589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureRisksAndLiquidity" xlink:type="extended" xlink:title="10201 - Disclosure - Risks and Liquidity" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_RisksAndLiquidityAbstract" xlink:label="pasg_RisksAndLiquidityAbstract_637184925736553018" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_RisksAndLiquidityTextBlock" xlink:label="pasg_RisksAndLiquidityTextBlock_638136953178484589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_RisksAndLiquidityAbstract_637184925736553018" xlink:to="pasg_RisksAndLiquidityTextBlock_638136953178484589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10301 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637184925736553018" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638136953178484589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637184925736553018" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638136953178484589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecurities" xlink:type="extended" xlink:title="10401 - Disclosure - Cash, cash equivalents and marketable securities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:label="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_638136953178484589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_638136953178484589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstruments" xlink:type="extended" xlink:title="10501 - Disclosure - Fair Value of Financial Instruments" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_637184925736553018" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638136953178494590" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_637184925736553018" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638136953178494590" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="10601 - Disclosure - Property and Equipment, net" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638136953178494590" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638136953178494590" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities" xlink:type="extended" xlink:title="10701 - Disclosure - Accrued Expenses and Other Current Liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637184925736553018" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_638136953178494590" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637184925736553018" xlink:to="pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock_638136953178494590" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureSeverance" xlink:type="extended" xlink:title="10801 - Disclosure - Severance" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_638136953178494590" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_638136953178494590" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureLeases" xlink:type="extended" xlink:title="10901 - Disclosure - Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_638136953178504588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_3" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_638136953178504588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11001 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637184925736709226" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638136953178504588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637184925736709226" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638136953178504588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureCommonStock" xlink:type="extended" xlink:title="11101 - Disclosure - Common Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_637184925736709226" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638136953178504588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_637184925736709226" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638136953178504588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureShareBasedCompensation" xlink:type="extended" xlink:title="11201 - Disclosure - Share-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637185648042126439" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638136953178504588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637185648042126439" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638136953178504588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11301 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637456100088567206" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638136953178514589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637456100088567206" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638136953178514589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11401 - Disclosure - Subsequent Events" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638136953178514589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638136953178514589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20302 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_BasisOfPresentationPolicyTextBlock" xlink:label="pasg_BasisOfPresentationPolicyTextBlock_638136953178514589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pasg_BasisOfPresentationPolicyTextBlock_638136953178514589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638136953178514589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638136953178514589" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_638136953178514589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_638136953178514589" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638136953178514589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638136953178514589" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_SegmentPolicyPolicyTextBlock" xlink:label="pasg_SegmentPolicyPolicyTextBlock_638136953178514589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pasg_SegmentPolicyPolicyTextBlock_638136953178514589" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638136953178514589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638136953178514589" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy_638136953178524589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy_638136953178524589" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638136953178524589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638136953178524589" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638136953178524589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638136953178524589" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638136953178524589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638136953178524589" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_638136953178524589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_638136953178524589" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638136953178524589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638136953178524589" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638136953178524589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638136953178524589" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638136953178524589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638136953178524589" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30303 - Disclosure - Summary of Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637184925736709226" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638136953178534695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637184925736709226" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638136953178534695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesTables" xlink:type="extended" xlink:title="30403 - Disclosure - Cash, cash equivalents and marketable securities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_638136953178534695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_638136953178534695" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_638136953178534695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_638136953178534695" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_638136953178534695" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_638136953178534695" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsTables" xlink:type="extended" xlink:title="30503 - Disclosure - Fair Value of Financial Instruments (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_637184925736709226" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_638136953178544601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_637184925736709226" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_638136953178544601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="30603 - Disclosure - Property and Equipment, net (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_1" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:label="pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_638136953178544601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_1" xlink:to="pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_638136953178544601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="extended" xlink:title="30703 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637184925736709226" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_638136953178544601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637184925736709226" xlink:to="pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_638136953178544601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="30903 - Disclosure - Leases (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638136953178544601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_LeaseCostTableTextBlock_638136953178544601" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638136953178554595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638136953178554595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureShareBasedCompensationTables" xlink:type="extended" xlink:title="31203 - Disclosure - Share-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638136953178554595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638136953178554595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638136953178554595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638136953178554595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638136953178554595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638136953178554595" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_638136953178554595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_638136953178554595" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31303 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637456100089115743" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638136953178554595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637456100089115743" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638136953178554595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638136953178554595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637456100089115743" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638136953178554595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_638136953178564591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637456100089115743" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_638136953178564591" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureNatureOfOperationsDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Nature of Operations (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_NumberOfLeadClinicalProductCandidate" xlink:label="pasg_NumberOfLeadClinicalProductCandidate_638136953178564591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1" xlink:to="pasg_NumberOfLeadClinicalProductCandidate_638136953178564591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Risks and Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_RisksAndLiquidityAbstract" xlink:label="pasg_RisksAndLiquidityAbstract_637184925736709226" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_RisksAndLiquidityTable" xlink:label="pasg_RisksAndLiquidityTable_638136953178564591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_RisksAndLiquidityAbstract_637184925736709226" xlink:to="pasg_RisksAndLiquidityTable_638136953178564591" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638136953178564591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_RisksAndLiquidityTable_638136953178564591" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638136953178564591" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638136953178564591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638136953178564591" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638136953178564591" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638136953178564591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638136953178564591" xlink:to="us-gaap_OverAllotmentOptionMember_638136953178564591" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_RisksAndLiquidityLineItems" xlink:label="pasg_RisksAndLiquidityLineItems_638136953178564591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_RisksAndLiquidityTable_638136953178564591" xlink:to="pasg_RisksAndLiquidityLineItems_638136953178564591" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638136953178564591" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_RisksAndLiquidityLineItems_638136953178564591" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638136953178564591" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638136953178574587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_RisksAndLiquidityLineItems_638136953178564591" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638136953178574587" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638136953178574587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_RisksAndLiquidityLineItems_638136953178564591" xlink:to="us-gaap_SharePrice_638136953178574587" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638136953178574587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_RisksAndLiquidityLineItems_638136953178564591" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638136953178574587" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Summary of Significant Accounting Policies (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637184925736709226" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638136953178574587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637184925736709226" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638136953178574587" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638136953178574587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638136953178574587" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638136953178574587" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638136953178574587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638136953178574587" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638136953178574587" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_638136953178574587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638136953178574587" xlink:to="us-gaap_ComputerEquipmentMember_638136953178574587" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_638136953178574587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638136953178574587" xlink:to="us-gaap_OfficeEquipmentMember_638136953178574587" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_LaboratoryEquipmentMember" xlink:label="pasg_LaboratoryEquipmentMember_638136953178574587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638136953178574587" xlink:to="pasg_LaboratoryEquipmentMember_638136953178574587" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638136953178574587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638136953178574587" xlink:to="us-gaap_FurnitureAndFixturesMember_638136953178574587" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638136953178574587" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638136953178574587" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638136953178574587" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638136953178584586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638136953178574587" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638136953178584586" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember" xlink:label="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_638136953178584586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638136953178584586" xlink:to="pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_638136953178584586" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638136953178584586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638136953178584586" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638136953178584586" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember" xlink:label="us-gaap_EmployeeStockMember_638136953178584586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638136953178584586" xlink:to="us-gaap_EmployeeStockMember_638136953178584586" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638136953178584586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638136953178574587" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638136953178584586" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_638136953178584586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638136953178584586" xlink:to="us-gaap_TypeOfAdoptionMember_638136953178584586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_638136953178584586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_638136953178584586" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_638136953178584586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638136953178584586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638136953178574587" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638136953178584586" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638136953178584586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638136953178584586" xlink:to="us-gaap_NumberOfOperatingSegments_638136953178584586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638136953178584586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638136953178584586" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638136953178584586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges_638136953178594582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638136953178584586" xlink:to="us-gaap_AssetImpairmentCharges_638136953178594582" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638136953178594582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638136953178584586" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638136953178594582" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638136953178594582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638136953178584586" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638136953178594582" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638136953178594582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638136953178584586" xlink:to="us-gaap_OperatingLeaseLiability_638136953178594582" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Cash, cash equivalents and marketable securities - Portfolio of Cash and Cash Equivalents (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_638136953178594582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_638136953178594582" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_638136953178594582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable_638136953178594582" xlink:to="us-gaap_CashAndCashEquivalentsAxis_638136953178594582" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638136953178594582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_638136953178594582" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638136953178594582" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DemandDepositsMember" xlink:label="us-gaap_DemandDepositsMember_638136953178594582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638136953178594582" xlink:to="us-gaap_DemandDepositsMember_638136953178594582" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638136953178604588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638136953178594582" xlink:to="us-gaap_MoneyMarketFundsMember_638136953178604588" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_638136953178604588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638136953178594582" xlink:to="us-gaap_CommercialPaperMember_638136953178604588" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_638136953178604588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable_638136953178594582" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_638136953178604588" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_638136953178604588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems_638136953178604588" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_638136953178604588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_638136953178604588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_638136953178604588" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_638136953178604588" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638136953178604588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_638136953178604588" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638136953178604588" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Cash, cash equivalents and marketable securities - Portfolio of Marketable Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:label="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTable_638136953178604588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTable_638136953178604588" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638136953178604588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable_638136953178604588" xlink:to="us-gaap_FinancialInstrumentAxis_638136953178604588" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638136953178604588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638136953178604588" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638136953178604588" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember_638136953178604588" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638136953178604588" xlink:to="us-gaap_CertificatesOfDepositMember_638136953178604588" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_638136953178614586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638136953178604588" xlink:to="us-gaap_CommercialPaperMember_638136953178614586" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_638136953178614586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638136953178604588" xlink:to="us-gaap_CorporateDebtSecuritiesMember_638136953178614586" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_638136953178614586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638136953178604588" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember_638136953178614586" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember_638136953178614586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638136953178604588" xlink:to="us-gaap_ForeignGovernmentDebtSecuritiesMember_638136953178614586" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems" xlink:label="us-gaap_CashAndCashEquivalentsLineItems_638136953178614586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTable_638136953178604588" xlink:to="us-gaap_CashAndCashEquivalentsLineItems_638136953178614586" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_638136953178614586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsLineItems_638136953178614586" xlink:to="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_638136953178614586" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_638136953178614586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_638136953178614586" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_638136953178614586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638136953178614586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_638136953178614586" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638136953178614586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638136953178614586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_638136953178614586" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638136953178614586" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638136953178614586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_638136953178614586" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638136953178614586" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40403 - Disclosure - Cash, cash equivalents and marketable securities (Contractual Final Maturities of Marketable Securities) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_638136953178624582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_638136953178624582" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_638136953178624582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_638136953178624582" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_638136953178624582" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_638136953178624582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_638136953178624582" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_638136953178624582" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_638136953178624582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_638136953178624582" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_638136953178624582" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_638136953178624582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_638136953178624582" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_638136953178624582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_638136953178624582" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_638136953178624582" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_638136953178624582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_638136953178624582" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_638136953178624582" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_638136953178704584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_638136953178624582" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_638136953178704584" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Fair Value of Financial Instruments (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_637402475098741011" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638136953178714601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_637402475098741011" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638136953178714601" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638136953178714601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638136953178714601" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638136953178714601" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638136953178714601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638136953178714601" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638136953178714601" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638136953178714601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638136953178714601" xlink:to="us-gaap_FairValueInputsLevel1Member_638136953178714601" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_638136953178714601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638136953178714601" xlink:to="us-gaap_FairValueInputsLevel2Member_638136953178714601" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638136953178714601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638136953178714601" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638136953178714601" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638136953178714601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638136953178714601" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638136953178714601" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_638136953178714601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638136953178714601" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_638136953178714601" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_638136953178714601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638136953178714601" xlink:to="us-gaap_CashAndCashEquivalentsAxis_638136953178714601" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638136953178714601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_638136953178714601" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638136953178714601" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638136953178714601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638136953178714601" xlink:to="us-gaap_MoneyMarketFundsMember_638136953178714601" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_638136953178714601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638136953178714601" xlink:to="us-gaap_CommercialPaperMember_638136953178714601" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638136953178714601" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638136953178714601" xlink:to="us-gaap_FinancialInstrumentAxis_638136953178714601" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638136953178724582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638136953178714601" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638136953178724582" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="us-gaap_CertificatesOfDepositMember_638136953178724582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638136953178724582" xlink:to="us-gaap_CertificatesOfDepositMember_638136953178724582" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember_638136953178724582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638136953178724582" xlink:to="us-gaap_CommercialPaperMember_638136953178724582" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_638136953178724582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638136953178724582" xlink:to="us-gaap_CorporateDebtSecuritiesMember_638136953178724582" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentDebtSecuritiesMember_638136953178724582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638136953178724582" xlink:to="us-gaap_USGovernmentDebtSecuritiesMember_638136953178724582" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="us-gaap_ForeignGovernmentDebtSecuritiesMember_638136953178724582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638136953178724582" xlink:to="us-gaap_ForeignGovernmentDebtSecuritiesMember_638136953178724582" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638136953178724582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638136953178714601" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638136953178724582" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638136953178724582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638136953178724582" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638136953178724582" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638136953178724582" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638136953178724582" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638136953178724582" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure_638136953178734581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638136953178724582" xlink:to="us-gaap_AssetsFairValueDisclosure_638136953178734581" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Property and Equipment, net (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638136953178734581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_2" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638136953178734581" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638136953178734581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638136953178734581" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638136953178734581" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638136953178734581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638136953178734581" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638136953178734581" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_LaboratoryEquipmentMember" xlink:label="pasg_LaboratoryEquipmentMember_638136953178734581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638136953178734581" xlink:to="pasg_LaboratoryEquipmentMember_638136953178734581" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_638136953178734581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638136953178734581" xlink:to="us-gaap_OfficeEquipmentMember_638136953178734581" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ComputerHardwareAndSoftwareMember" xlink:label="pasg_ComputerHardwareAndSoftwareMember_638136953178744603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638136953178734581" xlink:to="pasg_ComputerHardwareAndSoftwareMember_638136953178744603" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638136953178744603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638136953178734581" xlink:to="us-gaap_FurnitureAndFixturesMember_638136953178744603" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdsAndLeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_638136953178744603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638136953178734581" xlink:to="us-gaap_LeaseholdsAndLeaseholdImprovementsMember_638136953178744603" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_638136953178744603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638136953178734581" xlink:to="us-gaap_ConstructionInProgressMember_638136953178744603" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638136953178744603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638136953178734581" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638136953178744603" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638136953178744603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638136953178744603" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638136953178744603" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638136953178744603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638136953178744603" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638136953178744603" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638136953178744603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638136953178744603" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638136953178744603" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638136953178744603" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638136953178744603" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638136953178744603" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637184925736709226" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_638136953178754614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637184925736709226" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_638136953178754614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638136953178754614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637184925736709226" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638136953178754614" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_AccruedResearchAndDevelopmentExpense" xlink:label="pasg_AccruedResearchAndDevelopmentExpense_638136953178754614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637184925736709226" xlink:to="pasg_AccruedResearchAndDevelopmentExpense_638136953178754614" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent" xlink:label="pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent_638136953178754614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637184925736709226" xlink:to="pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent_638136953178754614" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638136953178754614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637184925736709226" xlink:to="us-gaap_OtherLiabilitiesCurrent_638136953178754614" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilities_638136953178754614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract_637184925736709226" xlink:to="pasg_AccruedExpensesAndOtherCurrentLiabilities_638136953178754614" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureSeveranceDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Severance (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="us-gaap_RestructuringAndRelatedActivitiesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638136953178754614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringAndRelatedActivitiesAbstract_1" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638136953178754614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638136953178754614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638136953178754614" xlink:to="us-gaap_IncomeStatementLocationAxis_638136953178754614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638136953178754614" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638136953178754614" xlink:to="us-gaap_IncomeStatementLocationDomain_638136953178754614" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638136953178764593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638136953178754614" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638136953178764593" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638136953178764593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638136953178754614" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638136953178764593" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_638136953178764593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638136953178754614" xlink:to="us-gaap_BalanceSheetLocationAxis_638136953178764593" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_638136953178764593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_638136953178764593" xlink:to="us-gaap_BalanceSheetLocationDomain_638136953178764593" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_AccruedExpensesAndOtherCurrentLiabilitiesMember" xlink:label="pasg_AccruedExpensesAndOtherCurrentLiabilitiesMember_638136953178764593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_638136953178764593" xlink:to="pasg_AccruedExpensesAndOtherCurrentLiabilitiesMember_638136953178764593" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems_638136953178764593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_638136953178754614" xlink:to="us-gaap_RestructuringCostAndReserveLineItems_638136953178764593" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_PercentReductionToOurWorkforce" xlink:label="pasg_PercentReductionToOurWorkforce_638136953178764593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638136953178764593" xlink:to="pasg_PercentReductionToOurWorkforce_638136953178764593" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1_638136953178764593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638136953178764593" xlink:to="us-gaap_SeveranceCosts1_638136953178764593" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent_638136953178764593" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems_638136953178764593" xlink:to="us-gaap_RestructuringReserveCurrent_638136953178764593" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureLeasesDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638136953178774575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638136953178774575" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638136953178774575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638136953178774575" xlink:to="srt_RangeAxis_638136953178774575" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638136953178774575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638136953178774575" xlink:to="srt_RangeMember_638136953178774575" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638136953178774575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638136953178774575" xlink:to="srt_MaximumMember_638136953178774575" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638136953178774575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638136953178774575" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638136953178774575" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638136953178774575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638136953178774575" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638136953178774575" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_OperatingLeasesForOfficeSpaceMember" xlink:label="pasg_OperatingLeasesForOfficeSpaceMember_638136953178774575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638136953178774575" xlink:to="pasg_OperatingLeasesForOfficeSpaceMember_638136953178774575" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_OperatingLeasesForLaboratorySpaceMember" xlink:label="pasg_OperatingLeasesForLaboratorySpaceMember_638136953178774575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638136953178774575" xlink:to="pasg_OperatingLeasesForLaboratorySpaceMember_638136953178774575" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638136953178774575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638136953178774575" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638136953178774575" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_638136953178774575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638136953178774575" xlink:to="us-gaap_TypeOfAdoptionMember_638136953178774575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_638136953178774575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember_638136953178774575" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_638136953178774575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_638136953178774575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638136953178774575" xlink:to="us-gaap_BalanceSheetLocationAxis_638136953178774575" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_638136953178774575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis_638136953178774575" xlink:to="us-gaap_BalanceSheetLocationDomain_638136953178774575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="us-gaap_OtherCurrentAssetsMember_638136953178784578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain_638136953178774575" xlink:to="us-gaap_OtherCurrentAssetsMember_638136953178784578" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_638136953178784578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638136953178774575" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_638136953178784578" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions" xlink:label="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions_638136953178784578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638136953178784578" xlink:to="pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions_638136953178784578" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_NewLeaseAgreementOperatingLeaseRenewalTerm" xlink:label="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm_638136953178784578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638136953178784578" xlink:to="pasg_NewLeaseAgreementOperatingLeaseRenewalTerm_638136953178784578" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_TenantImprovementAllowanceReceivable" xlink:label="pasg_TenantImprovementAllowanceReceivable_638136953178784578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638136953178784578" xlink:to="pasg_TenantImprovementAllowanceReceivable_638136953178784578" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent_638136953178784578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638136953178784578" xlink:to="us-gaap_DeferredRentCreditNoncurrent_638136953178784578" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements_638136953178784578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638136953178784578" xlink:to="us-gaap_TenantImprovements_638136953178784578" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_TenantImprovementAllowancesLiability" xlink:label="pasg_TenantImprovementAllowancesLiability_638136953178784578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638136953178784578" xlink:to="pasg_TenantImprovementAllowancesLiability_638136953178784578" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_LesseeOperatingLeaseIncrementalBorrowingRatePercentage" xlink:label="pasg_LesseeOperatingLeaseIncrementalBorrowingRatePercentage_638136953178784578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638136953178784578" xlink:to="pasg_LesseeOperatingLeaseIncrementalBorrowingRatePercentage_638136953178784578" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638136953178794576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638136953178784578" xlink:to="us-gaap_OperatingLeaseLiability_638136953178794576" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638136953178794576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638136953178784578" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638136953178794576" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638136953178794576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems_638136953178784578" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638136953178794576" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638136953178794576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638136953178794576" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638136953178794576" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638136953178794576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638136953178794576" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638136953178794576" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638136953178794576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638136953178794576" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638136953178794576" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638136953178794576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638136953178794576" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638136953178794576" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638136953178794576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638136953178794576" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638136953178794576" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638136953178794576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638136953178794576" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638136953178794576" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638136953178804577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638136953178794576" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638136953178804577" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638136953178804577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638136953178794576" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638136953178804577" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638136953178804577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638136953178794576" xlink:to="us-gaap_OperatingLeaseLiability_638136953178804577" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureLeasesOperatingLeaseCostDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Leases - Operating lease cost (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638136953178804577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_OperatingLeaseCost_638136953178804577" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="us-gaap_OperatingLeasePaymentsUse_638136953178804577" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_OperatingLeasePaymentsUse_638136953178804577" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638136953178814589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638136953178814589" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638136953178814589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638136953178814589" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Commitments and Contingencies - Collaboration Agreements (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637184925736709226" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638136953178814589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637184925736709226" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638136953178814589" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638136953178814589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638136953178814589" xlink:to="us-gaap_TypeOfArrangementAxis_638136953178814589" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638136953178814589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638136953178814589" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638136953178814589" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember" xlink:label="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_638136953178814589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638136953178814589" xlink:to="pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_638136953178814589" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638136953178814589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638136953178814589" xlink:to="dei_LegalEntityAxis_638136953178814589" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638136953178814589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638136953178814589" xlink:to="dei_EntityDomain_638136953178814589" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CatalentMarylandInc.Member" xlink:label="pasg_CatalentMarylandInc.Member_638136953178814589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638136953178814589" xlink:to="pasg_CatalentMarylandInc.Member_638136953178814589" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638136953178814589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638136953178814589" xlink:to="srt_RangeAxis_638136953178814589" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638136953178814589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638136953178814589" xlink:to="srt_RangeMember_638136953178814589" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638136953178824586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638136953178814589" xlink:to="srt_MinimumMember_638136953178824586" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638136953178824586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638136953178814589" xlink:to="srt_MaximumMember_638136953178824586" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638136953178824586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_638136953178814589" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638136953178824586" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementAnnualFeePayable" xlink:label="pasg_CollaborationAgreementAnnualFeePayable_638136953178824586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638136953178824586" xlink:to="pasg_CollaborationAgreementAnnualFeePayable_638136953178824586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementQuarterlyFeePayable" xlink:label="pasg_CollaborationAgreementQuarterlyFeePayable_638136953178824586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638136953178824586" xlink:to="pasg_CollaborationAgreementQuarterlyFeePayable_638136953178824586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram" xlink:label="pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram_638136953178824586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638136953178824586" xlink:to="pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram_638136953178824586" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementUpfrontPaymentMade" xlink:label="pasg_CollaborationAgreementUpfrontPaymentMade_638136953178824586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638136953178824586" xlink:to="pasg_CollaborationAgreementUpfrontPaymentMade_638136953178824586" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation" xlink:label="pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation_638136953178824586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638136953178824586" xlink:to="pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation_638136953178824586" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementUpfrontFee" xlink:label="pasg_CollaborationAgreementUpfrontFee_638136953178824586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638136953178824586" xlink:to="pasg_CollaborationAgreementUpfrontFee_638136953178824586" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_DevelopmentMilestonePaymentsPayable" xlink:label="pasg_DevelopmentMilestonePaymentsPayable_638136953178824586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638136953178824586" xlink:to="pasg_DevelopmentMilestonePaymentsPayable_638136953178824586" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementTieredTransactionFeePayablePercent" xlink:label="pasg_CollaborationAgreementTieredTransactionFeePayablePercent_638136953178834637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638136953178824586" xlink:to="pasg_CollaborationAgreementTieredTransactionFeePayablePercent_638136953178834637" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_PaymentsForTechnologyLicenseFee" xlink:label="pasg_PaymentsForTechnologyLicenseFee_638136953178834637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638136953178824586" xlink:to="pasg_PaymentsForTechnologyLicenseFee_638136953178834637" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_AdditionalTechnologyLicenseFeePaid" xlink:label="pasg_AdditionalTechnologyLicenseFeePaid_638136953178834637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638136953178824586" xlink:to="pasg_AdditionalTechnologyLicenseFeePaid_638136953178834637" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementAnnualFeePayableTerm" xlink:label="pasg_CollaborationAgreementAnnualFeePayableTerm_638136953178834637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638136953178824586" xlink:to="pasg_CollaborationAgreementAnnualFeePayableTerm_638136953178834637" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable" xlink:label="pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable_638136953178834637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638136953178824586" xlink:to="pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable_638136953178834637" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_TermOfManufacturingAndSupplyAgreement" xlink:label="pasg_TermOfManufacturingAndSupplyAgreement_638136953178834637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638136953178824586" xlink:to="pasg_TermOfManufacturingAndSupplyAgreement_638136953178834637" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm" xlink:label="pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm_638136953178834637" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638136953178824586" xlink:to="pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm_638136953178834637" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementPaymentMadeOnOptionExercise" xlink:label="pasg_CollaborationAgreementPaymentMadeOnOptionExercise_638136953178844598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638136953178824586" xlink:to="pasg_CollaborationAgreementPaymentMadeOnOptionExercise_638136953178844598" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted" xlink:label="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_638136953178844598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638136953178824586" xlink:to="us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted_638136953178844598" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone_638136953178844598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638136953178824586" xlink:to="pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone_638136953178844598" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone" xlink:label="pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone_638136953178844598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638136953178824586" xlink:to="pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone_638136953178844598" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CollaborationAgreementSalesMilestonePaymentsPayable" xlink:label="pasg_CollaborationAgreementSalesMilestonePaymentsPayable_638136953178844598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_638136953178824586" xlink:to="pasg_CollaborationAgreementSalesMilestonePaymentsPayable_638136953178844598" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureCommonStockDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract_637184925736709226" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638136953178844598" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract_637184925736709226" xlink:to="us-gaap_StatementTable_638136953178844598" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638136953178854596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638136953178844598" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638136953178854596" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638136953178854596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638136953178854596" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638136953178854596" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638136953178854596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638136953178854596" xlink:to="us-gaap_OverAllotmentOptionMember_638136953178854596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638136953178854596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638136953178844598" xlink:to="srt_RangeAxis_638136953178854596" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638136953178854596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638136953178854596" xlink:to="srt_RangeMember_638136953178854596" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638136953178854596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638136953178854596" xlink:to="srt_MaximumMember_638136953178854596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638136953178854596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638136953178844598" xlink:to="us-gaap_TypeOfArrangementAxis_638136953178854596" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638136953178854596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638136953178854596" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638136953178854596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_SalesAgreementWithCowenAndCompanyLlcMember" xlink:label="pasg_SalesAgreementWithCowenAndCompanyLlcMember_638136953178854596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638136953178854596" xlink:to="pasg_SalesAgreementWithCowenAndCompanyLlcMember_638136953178854596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638136953178854596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638136953178844598" xlink:to="us-gaap_StatementLineItems_638136953178854596" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638136953178854596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638136953178854596" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638136953178854596" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638136953178854596" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638136953178854596" xlink:to="us-gaap_SharePrice_638136953178854596" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638136953178864578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638136953178854596" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638136953178864578" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638136953178864578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638136953178854596" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638136953178864578" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Share-Based Compensation - Equity Incentive Plan &amp; ESPP (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637185648042438838" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638136953178864578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637185648042438838" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638136953178864578" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638136953178864578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638136953178864578" xlink:to="us-gaap_PlanNameAxis_638136953178864578" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638136953178864578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638136953178864578" xlink:to="us-gaap_PlanNameDomain_638136953178864578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EquityIncentivePlan2020Member" xlink:label="pasg_EquityIncentivePlan2020Member_638136953178864578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638136953178864578" xlink:to="pasg_EquityIncentivePlan2020Member_638136953178864578" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EquityInducementPlan2021Member" xlink:label="pasg_EquityInducementPlan2021Member_638136953178864578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638136953178864578" xlink:to="pasg_EquityInducementPlan2021Member_638136953178864578" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EmployeeStockPurchasePlanMember" xlink:label="pasg_EmployeeStockPurchasePlanMember_638136953178864578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638136953178864578" xlink:to="pasg_EmployeeStockPurchasePlanMember_638136953178864578" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178864578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638136953178864578" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178864578" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_NumberOfEquityIncentivePlans" xlink:label="pasg_NumberOfEquityIncentivePlans_638136953178864578" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178864578" xlink:to="pasg_NumberOfEquityIncentivePlans_638136953178864578" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638136953178874586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178864578" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_638136953178874586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638136953178874586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178864578" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638136953178874586" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:label="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted_638136953178874586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178864578" xlink:to="pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted_638136953178874586" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease" xlink:label="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease_638136953178874586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178864578" xlink:to="pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease_638136953178874586" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm_638136953178874586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178864578" xlink:to="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm_638136953178874586" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638136953178874586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178864578" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638136953178874586" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:label="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_638136953178874586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178864578" xlink:to="pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_638136953178874586" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted" xlink:label="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted_638136953178874586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178864578" xlink:to="pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted_638136953178874586" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding" xlink:label="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding_638136953178874586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178864578" xlink:to="pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding_638136953178874586" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage" xlink:label="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage_638136953178874586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178864578" xlink:to="pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage_638136953178874586" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage" xlink:label="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage_638136953178874586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178864578" xlink:to="pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage_638136953178874586" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased" xlink:label="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased_638136953178884579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178864578" xlink:to="pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased_638136953178884579" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased" xlink:label="pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased_638136953178884579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178864578" xlink:to="pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased_638136953178884579" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638136953178884579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178864578" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638136953178884579" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Share-Based Compensation - Share-based compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637185648042595071" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638136953178884579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637185648042595071" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638136953178884579" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638136953178884579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638136953178884579" xlink:to="us-gaap_IncomeStatementLocationAxis_638136953178884579" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638136953178884579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638136953178884579" xlink:to="us-gaap_IncomeStatementLocationDomain_638136953178884579" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638136953178884579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638136953178884579" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638136953178884579" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638136953178884579" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638136953178884579" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638136953178884579" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178894585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638136953178884579" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178894585" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638136953178894585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178894585" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638136953178894585" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ShareBasedCompensationArrangementExpensesDueToModifications" xlink:label="pasg_ShareBasedCompensationArrangementExpensesDueToModifications_638136953178894585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178894585" xlink:to="pasg_ShareBasedCompensationArrangementExpensesDueToModifications_638136953178894585" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638136953178894585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638136953178894585" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638136953178894585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638136953178894585" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638136953178894585" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_638136953178894585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638136953178894585" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_638136953178894585" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638136953178894585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638136953178894585" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638136953178894585" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638136953178894585" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638136953178894585" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638136953178894585" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6381369531788945851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638136953178894585" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6381369531788945851" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638136953178904589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638136953178894585" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_638136953178904589" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638136953178904589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638136953178894585" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_638136953178904589" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638136953178904589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638136953178904589" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638136953178904589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638136953178904589" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638136953178904589" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638136953178904589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638136953178904589" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638136953178904589" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638136953178904589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638136953178904589" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638136953178904589" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638136953178904589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638136953178904589" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638136953178904589" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6381369531789045891" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638136953178904589" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6381369531789045891" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638136953178904589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638136953178904589" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_638136953178904589" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638136953178904589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638136953178904589" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_638136953178904589" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638136953178904589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638136953178904589" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638136953178914576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638136953178904589" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638136953178914576" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638136953178914576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638136953178904589" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_638136953178914576" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638136953178914576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638136953178904589" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_638136953178914576" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise" xlink:label="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise_638136953178914576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise_638136953178914576" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638136953178914576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638136953178914576" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638136953178914576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638136953178914576" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638136953178914576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638136953178914576" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638136953178914576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_638136953178914576" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638136953178924575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638136953178924575" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Share-Based Compensation - Assumptions Used in Determining Fair Value &amp; Early exercise of Stock Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637185648042751263" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638136953178924575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637185648042751263" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638136953178924575" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638136953178924575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638136953178924575" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638136953178924575" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638136953178924575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638136953178924575" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638136953178924575" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638136953178924575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638136953178924575" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638136953178924575" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638136953178924575" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638136953178924575" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638136953178924575" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails" xlink:type="extended" xlink:title="41205 - Disclosure - Share-Based Compensation - Restricted Stock Units (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638136953178934592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638136953178934592" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638136953178934592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638136953178934592" xlink:to="us-gaap_AwardTypeAxis_638136953178934592" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638136953178934592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638136953178934592" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638136953178934592" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638136953178934592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638136953178934592" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638136953178934592" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178934592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638136953178934592" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178934592" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638136953178934592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178934592" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638136953178934592" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638136953178934592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638136953178934592" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638136953178934592" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638136953178934592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638136953178934592" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638136953178934592" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638136953178934592" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638136953178934592" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638136953178934592" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638136953178944595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638136953178934592" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_638136953178944595" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638136953178944595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward_638136953178934592" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_638136953178944595" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638136953178944595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178934592" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638136953178944595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638136953178944595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638136953178944595" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_638136953178944595" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638136953178944595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638136953178944595" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638136953178944595" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638136953178944595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638136953178944595" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_638136953178944595" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638136953178944595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638136953178944595" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_638136953178944595" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6381369531789445951" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_638136953178944595" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6381369531789445951" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638136953178944595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178934592" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_638136953178944595" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638136953178944595" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178934592" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638136953178944595" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_638136953178954581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638136953178934592" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_638136953178954581" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Income Taxes (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638136953178954581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638136953178954581" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638136953178954581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_638136953178954581" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement" xlink:label="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_638136953178954581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" xlink:to="pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement_638136953178954581" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_638136953178954581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" xlink:to="pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment_638136953178954581" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638136953178954581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638136953178954581" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther" xlink:label="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_638136953178954581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" xlink:to="pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther_638136953178954581" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="pasg_DeferredTaxAssetsOperatingLeaseLiabilities_638136953178954581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" xlink:to="pasg_DeferredTaxAssetsOperatingLeaseLiabilities_638136953178954581" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638136953178954581" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" xlink:to="us-gaap_DeferredTaxAssetsGross_638136953178954581" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638136953178964580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGross_638136953178954581" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638136953178964580" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638136953178964580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" xlink:to="us-gaap_DeferredTaxAssetsNet_638136953178964580" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_638136953178964580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_638136953178964580" order="10" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets" xlink:label="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_638136953178964580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638136953178964580" xlink:to="pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets_638136953178964580" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638136953178964580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638136953178964580" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_638136953178964580" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_638136953178964580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract_638136953178964580" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_638136953178964580" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638136953178964580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638136953178964580" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638136953178964580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_637456100089125718" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638136953178964580" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Income Taxes - Effective tax rate (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637456100089205502" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638136953178964580" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637456100089205502" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638136953178964580" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638136953178974589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637456100089205502" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638136953178974589" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent" xlink:label="pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638136953178974589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637456100089205502" xlink:to="pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent_638136953178974589" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638136953178974589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637456100089205502" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_638136953178974589" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638136953178974589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637456100089205502" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638136953178974589" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638136953178974589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637456100089205502" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638136953178974589" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Income Taxes - Net operating losses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637456100089245391" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638136953178974589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637456100089245391" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638136953178974589" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638136953178974589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638136953178974589" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638136953178974589" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638136953178974589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638136953178974589" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638136953178974589" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember_638136953178974589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638136953178974589" xlink:to="us-gaap_DomesticCountryMember_638136953178974589" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_StateTaxAuthorityMember" xlink:label="pasg_StateTaxAuthorityMember_638136953178974589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638136953178974589" xlink:to="pasg_StateTaxAuthorityMember_638136953178974589" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_LocalTaxAuthoritiesMember" xlink:label="pasg_LocalTaxAuthoritiesMember_638136953178984586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638136953178974589" xlink:to="pasg_LocalTaxAuthoritiesMember_638136953178984586" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_638136953178984586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638136953178974589" xlink:to="us-gaap_TaxCreditCarryforwardAxis_638136953178984586" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_638136953178984586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis_638136953178984586" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_638136953178984586" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember_638136953178984586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain_638136953178984586" xlink:to="us-gaap_ResearchMember_638136953178984586" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638136953178984586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638136953178974589" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638136953178984586" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_638136953178984586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638136953178984586" xlink:to="us-gaap_OperatingLossCarryforwards_638136953178984586" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount_638136953178984586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638136953178984586" xlink:to="us-gaap_TaxCreditCarryforwardAmount_638136953178984586" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_TaxCreditCarryForwardSubjectToExpiration" xlink:label="pasg_TaxCreditCarryForwardSubjectToExpiration_638136953178984586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638136953178984586" xlink:to="pasg_TaxCreditCarryForwardSubjectToExpiration_638136953178984586" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_638136953178984586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638136953178984586" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_638136953178984586" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_638136953178984586" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638136953178984586" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_638136953178984586" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="pasg-20221231.xsd#pasg_OperatingLossCarryforwardSubjectToExpiration" xlink:label="pasg_OperatingLossCarryforwardSubjectToExpiration_638136953178994576" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638136953178984586" xlink:to="pasg_OperatingLossCarryforwardSubjectToExpiration_638136953178994576" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209784248176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 02, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PASSAGE BIO,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-2729751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Commerce Square<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2005 Market Street, 39th&#160;Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Philadelphia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">866-0311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PASG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well Known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,617,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001787297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia, PA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209784381696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 34,601<span></span>
</td>
<td class="nump">$ 128,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">155,009<span></span>
</td>
<td class="nump">186,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">926<span></span>
</td>
<td class="nump">1,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_PrepaidResearchAndDevelopmentAssetCurrent', window );">Prepaid research and development</a></td>
<td class="nump">6,508<span></span>
</td>
<td class="nump">7,567<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">197,044<span></span>
</td>
<td class="nump">325,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">22,515<span></span>
</td>
<td class="nump">23,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets - operating leases</a></td>
<td class="nump">19,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4,267<span></span>
</td>
<td class="nump">6,204<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">243,549<span></span>
</td>
<td class="nump">355,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,065<span></span>
</td>
<td class="nump">9,448<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">11,011<span></span>
</td>
<td class="nump">20,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">3,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">18,351<span></span>
</td>
<td class="nump">29,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - noncurrent</a></td>
<td class="nump">23,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,921<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">42,183<span></span>
</td>
<td class="nump">36,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (note 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value: 300,000,000 shares authorized; 54,614,690 shares issued and outstanding at December 31, 2022 and 54,244,996 shares issued and outstanding at December 31, 2021</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paidin capital</a></td>
<td class="nump">694,733<span></span>
</td>
<td class="nump">675,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(966)<span></span>
</td>
<td class="num">(413)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(492,406)<span></span>
</td>
<td class="num">(356,281)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">201,366<span></span>
</td>
<td class="nump">318,657<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 243,549<span></span>
</td>
<td class="nump">$ 355,076<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying balance as of the balance sheet of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_PrepaidResearchAndDevelopmentAssetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for current portion of prepaid research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_PrepaidResearchAndDevelopmentAssetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209787728128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">54,614,690<span></span>
</td>
<td class="nump">54,244,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">54,614,690<span></span>
</td>
<td class="nump">54,244,996<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209781171968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">$ 86,053<span></span>
</td>
<td class="nump">$ 117,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired inprocess research and development</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">49,341<span></span>
</td>
<td class="nump">60,056<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(138,394)<span></span>
</td>
<td class="num">(185,729)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income, net</a></td>
<td class="nump">2,269<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (136,125)<span></span>
</td>
<td class="num">$ (185,386)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic</a></td>
<td class="num">$ (2.50)<span></span>
</td>
<td class="num">$ (3.48)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted</a></td>
<td class="num">$ (2.50)<span></span>
</td>
<td class="num">$ (3.48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="nump">54,429,023<span></span>
</td>
<td class="nump">53,343,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="nump">54,429,023<span></span>
</td>
<td class="nump">53,343,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (136,125)<span></span>
</td>
<td class="num">$ (185,386)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(553)<span></span>
</td>
<td class="num">(401)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (136,678)<span></span>
</td>
<td class="num">$ (185,787)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209785383344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Beginning of period at Dec. 31, 2020</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 475,617<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
<td class="num">$ (170,895)<span></span>
</td>
<td class="nump">$ 304,714<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at Beginning of period (in shares) at Dec. 31, 2020</a></td>
<td class="nump">45,614,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase', window );">Vesting of early exercise option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase', window );">Vesting of early exercise option awards (in shares)</a></td>
<td class="nump">302,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options and vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and vesting of restricted stock units (in shares)</a></td>
<td class="nump">186,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of shares in connection with employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of shares in connection with employee stock purchase plan (in shares)</a></td>
<td class="nump">91,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of issuance costs</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">165,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock, net of issuance costs (in shares)</a></td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(401)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,691<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(185,386)<span></span>
</td>
<td class="num">(185,386)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2021</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">675,346<span></span>
</td>
<td class="num">(413)<span></span>
</td>
<td class="num">(356,281)<span></span>
</td>
<td class="nump">318,657<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2021</a></td>
<td class="nump">54,244,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercise of stock options and vesting of restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercise of stock options and vesting of restricted stock units (in shares)</a></td>
<td class="nump">165,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of shares in connection with employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of shares in connection with employee stock purchase plan (in shares)</a></td>
<td class="nump">204,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(553)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(136,125)<span></span>
</td>
<td class="num">(136,125)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2022</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 694,733<span></span>
</td>
<td class="num">$ (966)<span></span>
</td>
<td class="num">$ (492,406)<span></span>
</td>
<td class="nump">$ 201,366<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2022</a></td>
<td class="nump">54,614,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been vesting of common stock previously subject to repurchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock vesting of common stock previously subject to repurchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209788379040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Stockholders' Equity (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statements of Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_StockIssuanceCosts', window );">Issuance cost</a></td>
<td class="nump">$ 669<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_StockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of stock issuance incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_StockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209784360672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (136,125)<span></span>
</td>
<td class="num">$ (185,386)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Acquired inprocess research and development</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,679<span></span>
</td>
<td class="nump">1,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Sharebased compensation</a></td>
<td class="nump">18,954<span></span>
</td>
<td class="nump">32,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of premium and discount on marketable securities, net</a></td>
<td class="nump">773<span></span>
</td>
<td class="nump">2,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets, and other assets</a></td>
<td class="nump">2,737<span></span>
</td>
<td class="nump">1,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment', window );">Prepaid research and development</a></td>
<td class="nump">1,059<span></span>
</td>
<td class="nump">3,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities', window );">Right of use assets and operating lease liabilities</a></td>
<td class="nump">463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Accounts payable</a></td>
<td class="num">(5,412)<span></span>
</td>
<td class="nump">2,201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(7,338)<span></span>
</td>
<td class="nump">3,983<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(118,210)<span></span>
</td>
<td class="num">(126,879)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows provided by (used in) investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(157,835)<span></span>
</td>
<td class="num">(202,546)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales or maturities of marketable securities</a></td>
<td class="nump">188,308<span></span>
</td>
<td class="nump">182,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchases of technology licenses</a></td>
<td class="num">(3,000)<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMachineryAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,274)<span></span>
</td>
<td class="num">(17,642)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">25,199<span></span>
</td>
<td class="num">(45,814)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by (used in) financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(338)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from the issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">304<span></span>
</td>
<td class="nump">887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_PaymentsForInsurancePremiumFinancing', window );">Payments for insurance premium financing</a></td>
<td class="num">(1,786)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="num">(1,353)<span></span>
</td>
<td class="nump">166,656<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(94,364)<span></span>
</td>
<td class="num">(6,037)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">128,965<span></span>
</td>
<td class="nump">135,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">34,601<span></span>
</td>
<td class="nump">128,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain (loss) on marketable securities</a></td>
<td class="num">(553)<span></span>
</td>
<td class="num">(401)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_PropertyAndEquipmentInDeferredRent', window );">Property and equipment in deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities', window );">Property and equipment in accounts payable and accrued expenses and other current liabilities</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">2,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_VestingOfEarlyExerciseOptionAwards', window );">Vesting of early exercise option awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets recognized upon the adoption of Topic 842</a></td>
<td class="num">(20,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard', window );">Operating lease liabilities recognized upon the adoption of Topic 842</a></td>
<td class="nump">$ 27,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in deferred rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) in prepaid research and development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase (decrease) during the period in the carrying value of right of use assets and operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of lease liabilities recognized upon adoption of standard.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_PaymentsForInsurancePremiumFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the payments for insurance premium financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_PaymentsForInsurancePremiumFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property and equipment in accounts payable and accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_PropertyAndEquipmentInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property and equipment in deferred rent during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_PropertyAndEquipmentInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_VestingOfEarlyExerciseOptionAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of vesting of early exercise option awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_VestingOfEarlyExerciseOptionAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMachineryAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for acquisition of machinery and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMachineryAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209788499040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1. Nature of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Passage Bio,&#160;Inc., or the Company, a Delaware corporation incorporated in July&#160;2017, is a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system, or CNS disorders, with limited or no approved treatment options. The Company has a strategic research collaboration with the Trustees of the University of Pennsylvania&#8217;s, or Penn, Gene Therapy Program, or GTP. Under this collaboration, GTP conducts discovery and preclinical activities enabling Investigational New Drug, or IND, applications and the Company conducts all clinical development, manufacturing, regulatory strategy, and commercialization activities under the agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Through this collaboration, the Company has assembled a portfolio of genetic medicine product candidates, including two lead clinical product candidates: PBGM01 for the treatment of GM1 gangliosidosis, or GM1, and PBFT02 for the treatment of frontotemporal dementia, or FTD. The Company also has a collaboration agreement and a development services and clinical supply agreement with Catalent Maryland,&#160;Inc., or Catalent, for clinical scale manufacturing requirements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209788524976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_RisksAndLiquidityAbstract', window );"><strong>Risks and Liquidity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_RisksAndLiquidityTextBlock', window );">Risks and Liquidity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2. Risks and Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has incurred recurring losses and negative cash flows from operations since inception and had an accumulated deficit of $492.4 million as of December&#160;31, 2022. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. Substantial additional capital will be needed by the Company to fund its operations and to develop its product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2021, the Company closed a follow-on public offering in which the Company issued and sold 8,050,000 shares of its common stock at a public offering price of $22.00 per share for net proceeds of $165.8 million&#160;after deducting underwriting discounts, commissions and other offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company&#8217;s operations have consisted primarily of conducting preclinical studies, developing licensed technology,  conducting clinical trials and manufacturing clinical supply to support clinical trials. The Company faces risks associated with early-stage biotechnology companies whose product candidates are in development. Product candidates currently under development will require significant additional research and development efforts and establishing manufacturing capacity and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital for the Company to complete its research and development, achieve its research and development objectives, defend its intellectual property rights, and recruit and retain skilled personnel, and key members of management. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company plans to seek additional funding through public or private equity offerings, debt financings, other collaborations, strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding or prospects of funding are unfavorable, the Company could be required to further delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In March 2022 and November 2022, the Company reduced its workforce and prioritized research and development programs to reduce operating expenses and to extend its cash runway.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In accordance with Accounting Standards Update, or ASU, No. 2014-15<i style="font-style:italic;">, Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern</i>, the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#8217;s ability to continue as a going concern </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">within one year after the date that the financial statements are issued. As of the issuance date of these financial statements, the Company expects that its cash, cash equivalents and marketable debt securities will be sufficient to fund its forecasted operating expenses and capital expenditure requirements for at least the next twelve months from the issuance date of these financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_RisksAndLiquidityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_RisksAndLiquidityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_RisksAndLiquidityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information pertaining to risk and liquidity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_RisksAndLiquidityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209788544784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.&#160;Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates promulgated by the Financial Accounting Standards Board, or FASB. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.3pt;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="letter-spacing:0.3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying financial statements in the period they are determined to be necessary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash, cash equivalents, and marketable securities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment Information</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly-liquid investments that have maturities of three&#160;months or less when acquired to be cash equivalents. Cash equivalents as of December&#160;31,&#160;2022 consisted of money market funds and commercial paper. Cash consists of cash deposits at banking institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Marketable securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company classifies its marketable securities as available-for-sale, which include commercial paper, certificates of deposit, corporate debt securities, and United States, or U.S., government debt securities with original maturities of greater than three&#160;months. These securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other comprehensive income (loss) within stockholders&#8217; equity. Gains or losses on marketable securities sold are recognized as a component of other income, net in the statement of operations and comprehensive loss on the specific identification method. All marketable securities are available for use, as needed, to fund operations and therefore, the Company classifies all marketable securities as current assets within the balance sheet.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and equipment consists of laboratory equipment, office equipment, computer hardware and software, furniture and leasehold improvements and are recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset by asset basis, which generally consists of three years for computer hardware and software, five years for office equipment, five years for laboratory equipment and seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. If circumstances require a long-lived asset to be tested for possible impairment, recoverability is measured by comparison of the carrying amount of the assets to estimated future undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset exceeds its estimated future cash flows, then impairment expense is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. For the years ended December 31, 2022, and 2021, no impairment expenses were recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company measures share-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company&#8217;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or stock option awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company uses the Black-Scholes option pricing model to value its stock option awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Estimating the fair value of stock option awards requires the input of assumptions, including, the expected term of stock options and stock price volatility. The Company accounts for forfeitures for stock option awards as they occur. The assumptions used in estimating the fair value of share-based awards represent management's estimate and involve inherent uncertainties and the application of management's judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The expected term of the stock options is estimated using the "simplified method," as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For stock price volatility, the Company uses a composite of comparable public company data as a basis for its expected volatility to calculate the fair value of option grants. The selection of comparable public company data requires the application of management&#8217;s judgement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for forfeitures for stock option awards as they occur.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred and consist primarily of expenses incurred with Penn, contract research organizations, contract manufacturing organizations, internal analytical and testing activities, and employee-related expenses, including salaries, benefits, and share-based compensation. Management makes estimates of the Company&#8217;s external accrued research and development expenses, which primarily relates to contract research organizations and contract manufacturing organizations, as of each balance sheet date in the Company&#8217;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at that time. The Company determines the estimates by reviewing contracts, vendor agreements and change orders, and through discussions with our internal clinical personnel and external service providers as to the progress to completion of services and the agreed-upon fee to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Acquired In-Process Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Fees paid to obtain research and development technology licenses are recognized as acquired in-process research and development expense if the research and development technology licensed has not reached technological feasibility and has no alternative future use. For the years ended December 31, 2022, and 2021, all fees paid to obtain technology licenses were recognized as acquired in-process research and development expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Income taxes are accounted for under the asset-and-liability method as required by FASB ASC Topic 740, <i style="font-style:italic;">Income Taxes</i> (ASC 740). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. Under ASC 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">FASB ASC Subtopic 740-10, Accounting for Uncertainty of Income Taxes, (ASC 740-10) defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company&#8217;s policy on statement of operations classification of interest and penalties related to income tax obligations is to include such items as part of total interest income, net.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:36.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,411,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,416,998</p></td></tr><tr><td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,229,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 290,500</p></td></tr><tr><td style="vertical-align:bottom;width:60.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,753</p></td></tr><tr><td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,667,236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,741,251</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Adopted Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In February 2016, the FASB issued ASU No. 2016-02, <i style="font-style:italic;">Leases (Topic 842)</i>, or ASU 2016-02, which requires a lessee to record a right-of-use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. The Company adopted ASU 2016-02 on January 1, 2022 using the modified retrospective transition method and elected the following transition practical expedients: (i) to not reassess lease identification, lease classification and initial indirect costs related to those leases entered into prior to the adoption of Topic 842; and (ii) to not separate lease and non-lease components for the Company&#8217;s operating lease portfolio. The Company recorded an operating lease right-of-use asset and lease liability of $20.4 million and $27.3 million respectively, related to the adoption of the Topic 842. See note 9 for further details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2016, the FASB issued ASU No.&#160;2016-13, <i style="font-style:italic;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</i>, or ASU 2016-13, which replaces the incurred loss impairment methodology under current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 was subsequently updated by ASU No.&#160;2019-04, <i style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments</i>, to clarify that entities should include recoveries when estimating the allowance for credit losses. This guidance is effective for the Company starting in fiscal year 2023. The Company does not expect that the adoption of ASU 2016-13 will have a material impact on its financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209788366784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents and marketable securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash, cash equivalents and marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash, cash equivalents and marketable securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4.&#160;Cash, cash equivalents and marketable securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides details regarding the Company&#8217;s portfolio of cash and cash equivalents:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Cash accounts in banking institutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,532</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,532</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,578</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,491</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,601</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Cash accounts in banking institutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,549</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,416</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 128,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 128,965</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table provides details regarding the Company&#8217;s portfolio of marketable securities:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.72120285%;padding-left:0pt;padding-right:0pt;width:101.44%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,197</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (92)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,111</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 58,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (72)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 58,512</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 67,206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (786)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 66,421</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (35)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,965</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 155,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (985)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 155,009</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,296</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,503</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (418)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145,169</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,996</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,988</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Non-U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,849</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,852</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 187,221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (431)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 186,808</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">S</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The contractual maturities of our marketable securities as of December&#160;31,&#160;2022, are as follows:<b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:19.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:20.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due within one year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 144,583</p></td><td style="vertical-align:middle;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 143,779</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due after one year through five years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,392</p></td><td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,230</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 155,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 155,009</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209788427472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5.&#160;Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Fair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments be made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company&#8217;s financial instruments, including prepaid expense and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. The Company follows the provisions of FASB ASC Topic 820, <i style="font-style:italic;">Fair Value Measurement</i>, for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:31.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 1: </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:31.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 2: </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:31.5pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 3: </i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following fair value hierarchy table presents information about the Company&#8217;s assets measured at fair value on a recurring basis. Included within cash and cash equivalents on the balance sheet, but excluded from the fair value hierarchy table, are cash deposits held at financial institutions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">markets for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58,512</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 155,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 157,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 145,169</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,988</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Non-U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,852</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 186,808</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 186,808</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209788336336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6. Property and Equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and Equipment, net, consist of the following: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:101.08%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:18.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:middle;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:middle;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,972</p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,916</p></td></tr><tr><td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office equipment</p></td><td style="vertical-align:middle;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 601</p></td><td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 621</p></td></tr><tr><td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer hardware and software</p></td><td style="vertical-align:middle;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,090</p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,028</p></td></tr><tr><td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:middle;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,208</p></td><td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,487</p></td></tr><tr><td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:middle;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,506</p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,409</p></td></tr><tr><td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:middle;width:3.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,291</p></td><td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 822</p></td></tr><tr><td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total property and equipment</p></td><td style="vertical-align:middle;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,668</p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,283</p></td></tr><tr><td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,153)</p></td><td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,477)</p></td></tr><tr><td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:18.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,515</p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,806</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Depreciation expense was $3.7 million and $1.5 million for the years ended December 31, 2022 and 2021, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209789285648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7.&#160;Accrued Expenses and Other Current Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Accrued expenses and other current liabilities consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5409012%;padding-left:0pt;padding-right:0pt;width:101.08%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 602</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 877</p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,446</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,014</p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,498</p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 161</p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 500</p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,011</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,050</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of information pertaining to accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209781937952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Severance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Severance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Severance</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8. Severance </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In March 2022 and November 2022, the Company announced workforce reductions and that it has prioritized certain research and development programs to reduce operating expenses and to extend its cash runway. <span style="background:#ffffff;">In connection with these announcements, the Company reduced headcount by approximately&#160;</span>13% and 23% in March 2022 and November 2022, respectively. <span style="background:#ffffff;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In&#160;accordance with ASC 420,<i style="font-style:italic;">&#160;Exit and Disposal Activities,</i>&#160;the Company recorded severance and termination-related costs of $3.8 million in general and administrative expenses and $2.3 million in research and development expenses for the year ended December 31, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, $2.1 million of severance and termination-related costs were unpaid and recognized in the balance sheet within Accrued expenses and other current liabilities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209788371376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9. Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On January 1, 2022, the Company adopted ASU No. 2016-02, <i style="font-style:italic;">Leases</i>, using a modified retrospective approach and recorded operating lease right-of-use, or ROU, assets and operating lease liabilities of $20.4 million and $27.3 million, respectively, related to the Company&#8217;s Lease Agreement and Laboratory Lease Agreement, or collectively, the Leases, which are each defined below. The Company elected the package of practical expedients available under ASU No. 2016-</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">02 and as such, did not reassess any of the Company&#8217;s existing or expired contracts or any other agreements that were previously concluded to not contain a lease for the following practical expedient guidance: (1) whether the arrangement is or contains a lease, (2) lease classification and (3) whether previously capitalized costs continue to qualify as initial direct costs. In addition, the Company applied the accounting policy election to not separate lease and non-lease components and the accounting policy election to not apply the recognition requirement under ASU No. 2016-02 to leases with a term of twelve months or less.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company was not required to record a cumulative effect adjustment upon adoption as the Company did not capitalize any material initial direct costs nor were any contracts reassessed leading to changes in the terms or contractual payments of historical arrangements that would impact expense recognition, however, the Company eliminated $3.2 million of deferred rent liabilities and $3.8 million of tenant improvement allowances as of January 1, 2022 related to the Leases as these liabilities are reflected in the operating lease ROU assets. The Company used incremental borrowing rates, or IBRs, of 9.0% and 10.0% to discount the operating lease liabilities for the Lease Agreement and the Laboratory Lease Agreement, respectively. The Company&#8217;s IBRs were quoted by an unrelated third-party lender and reflect a collateralized borrowing with similar terms and amounts as the Leases. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is party to a lease agreement for office space, or the Lease Agreement, in Philadelphia, Pennsylvania. The Lease Agreement commenced in February 2021 and is expected to expire in December 2031. The Company has an option to extend the term of the Lease Agreement by up to two five-year terms. This option to extend was not recognized as part of the Company's measurement of the ROU asset and operating lease liability as of December&#160;31,&#160;2022. The landlord provided the Company with a tenant improvement allowance of $2.8 million, for which the related expenditures were paid directly by the landlord.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company is also party to a lease agreement for laboratory space, or the Laboratory Lease Agreement, in Hopewell, New Jersey. The laboratory is initially focused on state-of-the-art analytical capabilities, assay development and validation, and clinical product testing to support both viral vector manufacturing and clinical development. The Laboratory Lease Agreement commenced in March 2021 and is expected to expire in February 2036. The Company has an option to extend the term of the Laboratory Lease Agreement by up to two five-year terms. This option to extend was not recognized as part of the Company's measurement of the ROU asset and operating lease liability as of December&#160;31,&#160;2022. The landlord provided the Company with a tenant improvement allowance of $1.3 million in connection with the Laboratory Lease Agreement, for which the related expenditures were paid by the Company and will be reimbursed by the landlord. As of December&#160;31,&#160;2022, $0.1 million of reimbursements were unpaid by the landlord and recorded within other current assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes the Company&#8217;s operating leases:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:65.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:24.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ in thousands)</b></p></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:middle;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:middle;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,316</p></td></tr><tr><td style="vertical-align:middle;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of operating cash flows from operating leases</p></td><td style="vertical-align:middle;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:24.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,853</p></td></tr><tr><td style="vertical-align:middle;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate</p></td><td style="vertical-align:middle;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9.7%</p></td></tr><tr><td style="vertical-align:middle;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (years)</p></td><td style="vertical-align:middle;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:24.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">12.2</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes future minimum lease payments under the Company&#8217;s operating lease agreements:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,455</p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,553</p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,654</p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,757</p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,864</p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,679</p></td></tr><tr><td style="vertical-align:middle;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:middle;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,962</p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20,855)</p></td></tr><tr><td style="vertical-align:middle;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liabilities</p></td><td style="vertical-align:middle;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,107</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209788363200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10.&#160;Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Amended and Restated Research, Collaboration and License Arrangement with Penn</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The Company has a research, collaboration and licensing agreement with Penn, as amended, or the Penn Agreement, for research and development collaborations and exclusive license rights to patents for certain products and technologies. Under the Penn Agreement, the Company has obligations to fund certain research relating to the preclinical development of selected products</span> <span style="font-weight:normal;">in research programs as well as the exploratory research program in non-rare and/or non-monogenic, or large CNS indications, currently TLE. In addition, the Company will fund discovery research conducted by Penn through August 3, 2026 and will receive exclusive rights, subject to certain limitations, to technologies resulting from the discovery research for the Company&#8217;s products developed with GTP, such as novel capsids, toxicity reduction technologies and delivery and formulation improvements. This funding commitment for the discovery research is </span><span style="font-weight:normal;">$5.0</span><span style="font-weight:normal;"> million annually, paid in quarterly increments of </span><span style="font-weight:normal;">$1.3</span><span style="font-weight:normal;"> million through June 2026. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">The Penn Agreement includes an exploratory research program focused on discovering targets and novel gene therapy candidates for large CNS indications, currently focused on TLE, and can be expanded to other large CNS diseases upon mutual agreement. The initial term of the exploratory research program is until August 2024, which term can be extended by mutual agreement. During such term, the Company will have an exclusive right of first negotiation to include additional targets to the exploratory research program within the agreed upon large CNS indications. Under the exploratory research program, the Company will have the right to further develop and commercialize any gene therapy product candidates specific for those selected targets within TLE (and any future large CNS diseases that are mutually agreed upon) that may arise from the exploratory research programs on substantially the same terms of the current Penn Agreement.   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Under the Penn Agreement, the Company has eight remaining options available to commence additional licensed programs for CNS indications and has until August 3, 2026, to exercise these options.&#160;If the Company were to exercise any of these options, it would owe Penn a non-refundable upfront fee of $1.0&#160;million per product indication, with $0.5 million due upfront and another $0.5 million fee owed upon a further developmental milestone. The Company has the obligation to fund certain research relating to the preclinical development of each licensed program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Penn Agreement requires that the Company make payments of up to (i) $16.5&#160;million per product candidate for rare, monogenic disorders in the aggregate and (ii) $39.0 million per product candidate in the aggregate arising from the exploratory program for large CNS indications, currently for TLE. Each payment will be due upon the achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and no development milestone payments for subsequent indications. In addition, on a product-by-product basis, the Company is obligated to make up to $55.0&#160;million in sales milestone payments on each licensed product based on annual sales of the licensed product in excess of defined thresholds. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Upon successful commercialization of a product using the licensed technology, the Company is obligated to pay to Penn, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits on annual worldwide net sales of such licensed product. In addition, the Company is obligated to pay to Penn a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Penn Agreement. The agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i)&#160;the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such licensed product in such country, and (ii)&#160;the expiration of the royalty period. In addition, the Company will pay a tiered transaction fee of 1-2% of the net proceeds upon certain change of control events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:0.25pt;">During the year ended December 31, 2022, the Company made payments under the Penn Agreement of </span><span style="letter-spacing:0.25pt;">$3.0</span><span style="letter-spacing:0.25pt;"> million related to the achievement of development milestones</span> <span style="letter-spacing:0.25pt;">for dosing our first patients in PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease, </span>which were recognized as in-process research and development expense<span style="letter-spacing:0.25pt;">. During the year ended December 31, 2021, the Company made payments under the Penn Agreement of </span>$1.5 million related to the achievement of a development milestone, $1.5 million related to option exercises under the Penn Agreement, and a $5.0 million payment related to the August 2021 amendment, which were recognized as in-process research and development expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;background:#ffffff;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Catalent Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2019, the Company entered into a collaboration agreement, or the Collaboration Agreement, with Catalent. As part of the Collaboration Agreement, the Company will pay an annual fee for five&#160;years ending in 2025 for the use of the Clean Room&#160;Suite.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2020, the Company entered into a development services and clinical supply agreement, or the Manufacturing and Supply Agreement, with Catalent to secure clinical scale manufacturing capacity for batches of active pharmaceutical ingredients for the Company&#8217;s gene therapy product candidates. The Manufacturing and Supply Agreement confirms the terms contemplated by the Collaboration Agreement. The Collaboration Agreement continues to be in effect pursuant to its terms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the terms of the Manufacturing and Supply Agreement, Catalent has agreed to manufacture batches of drug product for the Company&#8217;s gene therapy product candidates at the Clean Room&#160;Suite&#160;at a Catalent facility provided for in the Collaboration Agreement. The Manufacturing and Supply Agreement provides for a term of five&#160;years which period may be extended once, at the Company&#8217;s option, for an additional five-year period. The Manufacturing and Supply Agreement also includes minimum annual purchase commitments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has the right to terminate the Manufacturing and Supply Agreement for convenience or other reasons specified in the Manufacturing and Supply Agreement upon prior written notice. If the Company terminates the Manufacturing and Supply Agreement, it will be obligated to pay an early termination fee to Catalent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under both the Collaboration Agreement and the Manufacturing and Supply Agreement, the Company has an annual minimum commitment of $10.6 million per&#160;year owed to Catalent for five&#160;years from the validation of the Clean Room, subject to certain inflationary adjustments. For the years ended December 31, 2022 and 2021, the Company paid amounts in excess of the minimum commitment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employment Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has entered into employment agreements with key personnel providing for compensation and, in certain circumstances, severance and acceleration of vesting in stock-based compensation awards, as described in the respective employment agreements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209788381568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Common Stock.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11. Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2021, the Company closed a follow-on public offering in which the Company issued and sold 8,050,000 shares of its common stock, which included shares sold pursuant to an option granted to the underwriters to purchase additional shares, at a public offering price of $22.00 per share for net proceeds of $165.8 million&#160;after deducting underwriting discounts, commissions and other offering expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On March 5, 2021, the Company entered into a Sales Agreement, or the Sales Agreement, with Cowen and Company, LLC, or Cowen, pursuant to which the Company may, but are not obligated to, offer and sell, from time to time, shares of the Company&#8217;s common stock with an aggregate offering price up to $125.0 million through Cowen, as sales agent. No sales of common stock have been made pursuant to this Sales Agreement to date.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209788294704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12. Share-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Equity Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company has three equity incentive plans: the 2018 Equity Incentive Plan, as amended, or the 2018 Plan, the 2020 Equity Incentive Plan, or the Incentive Plan, and the 2021 Equity Inducement Plan, or the Inducement Plan. New awards can only be granted under the Incentive Plan and the Inducement Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The total number of shares authorized under the Incentive Plan as of December&#160;31,&#160;2022 was 10,370,926. Additionally, any awards previously issued under our 2018 Plan which were forfeited become available for issuance under the Incentive Plan. As of December&#160;31,&#160;2022, 3,880,210 shares were available for future grants under our Incentive Plan. The number of shares of the Company&#8217;s common stock that may be issued pursuant to rights granted under the Incentive Plan shall automatically increase on January&#160;1st of each&#160;year, commencing on January&#160;1, 2021 and continue for <span style="-sec-ix-hidden:Hidden_pyhlfNmlOEC4x3JdtR4JSQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten&#160;years</span></span>, in an amount equal to five&#160;percent of the total number of shares of the Company&#8217;s common stock outstanding on December&#160;31st of the preceding calendar&#160;year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such&#160;year. As a result, the number of shares reserved for issuance under the Incentive Plan increased by 2,730,735 and 2,712,249 shares in January 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Incentive Plan provides for the granting of common stock, incentive stock options, nonqualified stock options, restricted stock awards, and/or stock appreciation rights to employees, directors, and other persons, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options awarded to date under the Incentive Plan vest based on a requisite service period, generally over four-year periods, and have a term of ten years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Inducement Plan was approved by the Company&#8217;s board of directors in July 2021. The total number of shares authorized under the Inducement Plan as of December&#160;31,&#160;2022 was 2,000,000, as a result of an increase to the shares authorized for issuance in February 2022. Of this amount, 384,167 shares were available for future grants as of December&#160;31,&#160;2022. The Inducement Plan provides for the granting of nonqualified stock options and restricted stock awards to employees hired by the Company, as determined by the Company&#8217;s board of directors. The Company&#8217;s stock options awarded to date under the Inducement Plan vest based on requisite service period and have a term of ten years. The Company&#8217;s restricted stock units awarded to date under the Inducement Plan vest based on requisite service period and have a term based on each award agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company recorded share-based compensation expense in the following expense categories in its accompanying statements of operations for the period presented:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:52.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,432</p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,676</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,259</p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,691</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December&#160;31,&#160;2022, the Company modified certain awards and recognized $0.4 million related to the modifications, all of which was recognized in general &amp; administrative expense. The terms of such modifications included, on an awards-by-award basis, acceleration of the vesting period and extensions of the post-employment period to exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">During the year ended December&#160;31,&#160;2021, the Company modified certain awards and recognized $7.4 million related to the modifications, $6.1 million of which was recognized in research and development expense and $1.3 million was recognized in general and administrative expense. The terms of such modifications included, on an awards-by-award basis, acceleration of the vesting period and extensions of the post-employment period to exercise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes stock option activity for the&#160;year ended December&#160;31,&#160;2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise&#160;price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per&#160;share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">term&#160;(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at January&#160;1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,416,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,609,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (126,056)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,488,993)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,411,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and Exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,074,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested or expected to vest at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,411,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The weighted-average grant date fair value of options granted was $2.33 and $12.75 for the&#160;years ended December&#160;31, 2022 and 2021, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of options exercised was $0.2 and $1.3 million and during the year ended December 31, 2022 and 2021, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value of options outstanding as of December 31, 2022 was $0.1 million and the aggregate intrinsic value of options exercisable as of December 31, 2022 was de minimus. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, the total unrecognized compensation expense related to unvested stock option awards was $24.1&#160;million, which the Company expects to recognize over a weighted-average period of 2.4&#160;years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The 2018 Plan and 2020 Plan provide certain holders of stock options an election to early exercise prior to vesting. The Company has the right to repurchase early exercised options without transferring any appreciation in the value of the underlying shares to the employee if the employee terminates employment before the end of the original vesting period. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The repurchase price is the lesser of the original exercise price or the then fair value of the Company&#8217;s common stock. As of December&#160;31,&#160;2022, 113,932 options to purchase common stock are unvested, but exercisable, under early exercise provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The fair value of each option was estimated on the date of grant using the weighted average assumptions in the table below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:50.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 92.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 99.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk&#8209;free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted Stock Units </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company issues restricted stock units, or RSUs, to employees that vest over periods as determined by the board of directors. Any unvested shares are forfeited upon termination of services. The fair value price of the RSUs is equal to the fair market value of the Company&#8217;s common stock on the date of grant. Compensation expense is recognized on a straight-line basis over the vesting period of the RSUs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The following table summarizes activity related to RSU awards during the year ended December&#160;31,&#160;2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:23.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted average </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">grant date fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested balance at January 1, 2022</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 290,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.78</p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,171,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.97</p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,167)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.06</p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (193,667)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.87</p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,229,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.98</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of December&#160;31,&#160;2022, the total unrecognized expense related to all RSUs was $2.8 million, which the Company expects to recognize over a weighted-average period of 1.8 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employee Stock Purchase Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s 2020 Employee Stock Purchase Plan, or the ESPP, became effective on February 28, 2020. The ESPP authorizes the issuance of up to 1,435,619 shares of the Company&#8217;s common stock. Of this amount, 1,119,914 were available for future grants as of December&#160;31,&#160;2022. The number of shares of the Company&#8217;s common stock that may be issued pursuant to rights granted under the ESPP shall automatically increase on January 1st of each year and continuing for ten years, in an amount equal to one percent of the total number of shares of the Company&#8217;s common stock outstanding on December 31st of the preceding calendar year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such year. As a result, on January 1, 2023, the number of shares reserved for issuance under the ESPP increased by 546,147 shares, resulting in a total of 1,981,766 shares authorized for issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Under the ESPP, eligible employees can purchase the Company&#8217;s common stock through accumulated payroll deductions at such times as are established by the compensation committee. Eligible employees may purchase the Company&#8217;s common stock at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first day of the offering period or on the last day of the offering period. The offering periods under the ESPP have a duration of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">six months, with periods ending in May and November of each calendar year. Eligible employees may contribute up to 15% of their eligible compensation. Under the ESPP, a participant may not accrue rights to purchase more than $25,000 worth of the Company&#8217;s common stock for each calendar year in which such right is outstanding or purchase more than 4,000 shares of the Company&#8217;s common stock in any single offering period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In accordance with the guidance in ASC 718-50,<i style="font-style:italic;">&#160;Compensation&#160;&#8211; Stock Compensation</i>, the ability to purchase shares of the Company&#8217;s common stock at 85% of the lower of the price on the first day of the offering period or the last day of the offering period (i.e. the purchase date) represents an option and<b style="font-weight:bold;">, </b>therefore, the ESPP is a compensatory plan under this guidance. Accordingly, share-based compensation expense is determined based on the option&#8217;s grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the withholding period. The Company recognized share-based compensation expense of $0.2 million and $0.4 million during the years ended December&#160;31, 2022 and 2021, respectively, related to the ESPP.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209788398512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">13. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">(in thousands) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,351</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,244</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Collaboration and license agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,504</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,976</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,012</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51,806</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,245</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,922</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,654</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">      Total gross deferred tax assets before valuation allowance</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 188,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 136,276</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (179,843)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (135,053)</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">      Net deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,223</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;">Right of use assets - operating leases </span><i style="font-style:italic;">(deferred rent for December 31, 2021)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,609)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (876)</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (813)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (347)</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">      Total deferred tax liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,422)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,223)</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">      Net deferred taxes</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more-likely-than-not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company&#8217;s net deferred tax assets as of December&#160;31, 2022 and 2021. The valuation allowance increased by $44.8 million and $72.1 million during the&#160;years ended December&#160;31, 2022 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">A reconciliation of the federal income tax rate to the Company&#8217;s effective tax rate is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development and orphan tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (38.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes carryforwards of federal, state and local net operating losses, or NOL, and research and development and orphan drug tax credits:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">(in thousands) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 199,233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 126,551</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 199,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">126,547</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 180,859</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">116,301</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22,244</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For federal income tax purposes, $0.3 million of NOL carryforwards expire in 2037. The remaining federal NOL carryforwards were generated subsequent to January 1, 2018, and therefore, are able to be carried forward indefinitely. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For state income tax purposes, NOL carryforwards begin expiring in 2037, and expire through 2042. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For local income tax purposes related to the city of Philadelphia, NOL carryforwards begin expiring in 2023, and expire through 2042. NOL carryforwards generated prior to 2023 expire after 3 years, whereas NOL carryforwards generated in 2023 expire after 20 years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company also had federal research and development and orphan drug tax credit carryforwards of $32.1 million that will begin to expire in 2038, unless previously utilized. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50&#160;percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception. Certain state NOL carryforwards may also be limited, including Pennsylvania, which limits NOL utilization as a&#160;percentage of apportioned taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company will recognize interest and penalties related to uncertain tax positions as a component of interest income, net. As of December 31, 2022, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#8217;s statement of operations. Tax years from 2019 and after remain subject to examination by the taxing jurisdictions. The NOL and tax credit carryforwards remain subject to review until utilized.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209784347072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14.&#160;Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">None.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209779931424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_BasisOfPresentationPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates promulgated by the Financial Accounting Standards Board, or FASB. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;letter-spacing:0.3pt;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"><span style="letter-spacing:0.3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying financial statements in the period they are determined to be necessary.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Management believes that the carrying amounts of the Company&#8217;s financial instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of credit risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash, cash equivalents, and marketable securities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_SegmentPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Segment Information</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash and cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly-liquid investments that have maturities of three&#160;months or less when acquired to be cash equivalents. Cash equivalents as of December&#160;31,&#160;2022 consisted of money market funds and commercial paper. Cash consists of cash deposits at banking institutions.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Marketable securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company classifies its marketable securities as available-for-sale, which include commercial paper, certificates of deposit, corporate debt securities, and United States, or U.S., government debt securities with original maturities of greater than three&#160;months. These securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other comprehensive income (loss) within stockholders&#8217; equity. Gains or losses on marketable securities sold are recognized as a component of other income, net in the statement of operations and comprehensive loss on the specific identification method. All marketable securities are available for use, as needed, to fund operations and therefore, the Company classifies all marketable securities as current assets within the balance sheet.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Property and equipment consists of laboratory equipment, office equipment, computer hardware and software, furniture and leasehold improvements and are recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset by asset basis, which generally consists of three years for computer hardware and software, five years for office equipment, five years for laboratory equipment and seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. If circumstances require a long-lived asset to be tested for possible impairment, recoverability is measured by comparison of the carrying amount of the assets to estimated future undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset exceeds its estimated future cash flows, then impairment expense is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. For the years ended December 31, 2022, and 2021, no impairment expenses were recognized.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company measures share-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company&#8217;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or stock option awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company uses the Black-Scholes option pricing model to value its stock option awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Estimating the fair value of stock option awards requires the input of assumptions, including, the expected term of stock options and stock price volatility. The Company accounts for forfeitures for stock option awards as they occur. The assumptions used in estimating the fair value of share-based awards represent management's estimate and involve inherent uncertainties and the application of management's judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The expected term of the stock options is estimated using the "simplified method," as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For stock price volatility, the Company uses a composite of comparable public company data as a basis for its expected volatility to calculate the fair value of option grants. The selection of comparable public company data requires the application of management&#8217;s judgement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for forfeitures for stock option awards as they occur.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are expensed as incurred and consist primarily of expenses incurred with Penn, contract research organizations, contract manufacturing organizations, internal analytical and testing activities, and employee-related expenses, including salaries, benefits, and share-based compensation. Management makes estimates of the Company&#8217;s external accrued research and development expenses, which primarily relates to contract research organizations and contract manufacturing organizations, as of each balance sheet date in the Company&#8217;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at that time. The Company determines the estimates by reviewing contracts, vendor agreements and change orders, and through discussions with our internal clinical personnel and external service providers as to the progress to completion of services and the agreed-upon fee to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">Acquired In-Process Research and Development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Acquired In-Process Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Fees paid to obtain research and development technology licenses are recognized as acquired in-process research and development expense if the research and development technology licensed has not reached technological feasibility and has no alternative future use. For the years ended December 31, 2022, and 2021, all fees paid to obtain technology licenses were recognized as acquired in-process research and development expense.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Income taxes are accounted for under the asset-and-liability method as required by FASB ASC Topic 740, <i style="font-style:italic;">Income Taxes</i> (ASC 740). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. Under ASC 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">FASB ASC Subtopic 740-10, Accounting for Uncertainty of Income Taxes, (ASC 740-10) defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company&#8217;s policy on statement of operations classification of interest and penalties related to income tax obligations is to include such items as part of total interest income, net.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:36.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,411,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,416,998</p></td></tr><tr><td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,229,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 290,500</p></td></tr><tr><td style="vertical-align:bottom;width:60.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,753</p></td></tr><tr><td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,667,236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,741,251</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Adopted Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">In February 2016, the FASB issued ASU No. 2016-02, <i style="font-style:italic;">Leases (Topic 842)</i>, or ASU 2016-02, which requires a lessee to record a right-of-use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. The Company adopted ASU 2016-02 on January 1, 2022 using the modified retrospective transition method and elected the following transition practical expedients: (i) to not reassess lease identification, lease classification and initial indirect costs related to those leases entered into prior to the adoption of Topic 842; and (ii) to not separate lease and non-lease components for the Company&#8217;s operating lease portfolio. The Company recorded an operating lease right-of-use asset and lease liability of $20.4 million and $27.3 million respectively, related to the adoption of the Topic 842. See note 9 for further details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2016, the FASB issued ASU No.&#160;2016-13, <i style="font-style:italic;">Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments</i>, or ASU 2016-13, which replaces the incurred loss impairment methodology under current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 was subsequently updated by ASU No.&#160;2019-04, <i style="font-style:italic;">Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments</i>, to clarify that entities should include recoveries when estimating the allowance for credit losses. This guidance is effective for the Company starting in fiscal year 2023. The Company does not expect that the adoption of ASU 2016-13 will have a material impact on its financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_BasisOfPresentationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_BasisOfPresentationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_SegmentPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_SegmentPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209788392656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:36.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,411,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,416,998</p></td></tr><tr><td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Unvested restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,229,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 290,500</p></td></tr><tr><td style="vertical-align:bottom;width:60.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee stock purchase plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,753</p></td></tr><tr><td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,667,236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,741,251</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209784214912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, cash equivalents and marketable securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract', window );"><strong>Cash, cash equivalents and marketable securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of details regarding the Company's portfolio of cash and cash equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Cash accounts in banking institutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,532</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,532</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,578</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,491</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 34,601</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Cash accounts in banking institutions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,549</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,416</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 128,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 128,965</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of details regarding the Company's portfolio of marketable securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.72120285%;padding-left:0pt;padding-right:0pt;width:101.44%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,197</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (92)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,111</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 58,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (72)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 58,512</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 67,206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (786)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 66,421</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (35)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,965</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 155,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (985)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 155,009</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,296</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,503</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145,577</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (418)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145,169</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,996</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,988</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Non-U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,849</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,852</p></td></tr><tr><td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 187,221</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (431)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 186,808</p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Contractual Final Maturities of Marketable Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:19.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:20.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized Cost</b></p></td><td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:middle;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due within one year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 144,583</p></td><td style="vertical-align:middle;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 143,779</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Due after one year through five years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:19.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,392</p></td><td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,230</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 155,975</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 155,009</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209787393728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value of Financial Instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of assets measured at fair value on a recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair value measurement at</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">reporting date using</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">markets for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">identical</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level&#160;3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,491</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,111</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 58,512</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 66,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 155,009</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 24,578</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 157,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Certificates of deposit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,296</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 145,169</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,988</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Non-U.S. government securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,852</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 186,808</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total financial assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 84,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 186,808</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209789600528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of property and equipment, net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:101.08%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:18.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:middle;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Laboratory equipment</p></td><td style="vertical-align:middle;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,972</p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,916</p></td></tr><tr><td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office equipment</p></td><td style="vertical-align:middle;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 601</p></td><td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 621</p></td></tr><tr><td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Computer hardware and software</p></td><td style="vertical-align:middle;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,090</p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,028</p></td></tr><tr><td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and fixtures</p></td><td style="vertical-align:middle;width:3.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,208</p></td><td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,487</p></td></tr><tr><td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:middle;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,506</p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,409</p></td></tr><tr><td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Construction in progress</p></td><td style="vertical-align:middle;width:3.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,291</p></td><td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 822</p></td></tr><tr><td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total property and equipment</p></td><td style="vertical-align:middle;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,668</p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,283</p></td></tr><tr><td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,153)</p></td><td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,477)</p></td></tr><tr><td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:18.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,515</p></td><td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,806</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209781937952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock', window );">Schedule of accrued liabilities and other current liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5409012%;padding-left:0pt;padding-right:0pt;width:101.08%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 602</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 877</p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Compensation and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,446</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,014</p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,498</p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Property and equipment </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 85</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 161</p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 500</p></td></tr><tr><td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,011</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 20,050</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209789582272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of operating lease cost</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:65.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:24.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">($ in thousands)</b></p></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:middle;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost</p></td><td style="vertical-align:middle;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,316</p></td></tr><tr><td style="vertical-align:middle;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement of operating cash flows from operating leases</p></td><td style="vertical-align:middle;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:24.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,853</p></td></tr><tr><td style="vertical-align:middle;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate</p></td><td style="vertical-align:middle;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9.7%</p></td></tr><tr><td style="vertical-align:middle;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term (years)</p></td><td style="vertical-align:middle;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:24.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">12.2</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum rental payments for operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,455</p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,553</p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,654</p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,757</p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,864</p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 29,679</p></td></tr><tr><td style="vertical-align:middle;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted lease payments</p></td><td style="vertical-align:middle;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 47,962</p></td></tr><tr><td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20,855)</p></td></tr><tr><td style="vertical-align:middle;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease liabilities</p></td><td style="vertical-align:middle;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,107</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209784248032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of share-based compensation expense category</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:52.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,432</p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,676</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,259</p></td></tr><tr><td style="vertical-align:bottom;width:43.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18,954</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,691</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">exercise&#160;price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">per&#160;share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">term&#160;(years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at January&#160;1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,416,998</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,609,441</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.09</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (126,056)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,488,993)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,411,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested and Exercisable at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,074,955</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Vested or expected to vest at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11,411,390</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions applied to options</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:50.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 92.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 99.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk&#8209;free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Summary of activity related to restricted stock unit</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:23.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted average </b></p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number&#160;of&#160;shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:23.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">grant date fair value</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested balance at January 1, 2022</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 290,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14.78</p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,171,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.97</p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (39,167)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15.06</p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (193,667)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.87</p></td></tr><tr><td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested balance at December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,229,166</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2.98</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209784357760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">(in thousands) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 64,547</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 42,351</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,244</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Collaboration and license agreement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,504</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,976</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 65,012</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 51,806</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,312</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,245</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,922</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,654</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,900</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">      Total gross deferred tax assets before valuation allowance</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 188,265</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 136,276</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (179,843)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (135,053)</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">      Net deferred tax assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,422</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,223</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;">Right of use assets - operating leases </span><i style="font-style:italic;">(deferred rent for December 31, 2021)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (7,609)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (876)</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (813)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (347)</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">      Total deferred tax liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (8,422)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,223)</p></td></tr><tr><td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">      Net deferred taxes</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development and orphan tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (32.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (38.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> -</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Schedule of net operating loss carryforwards</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"><b style="font-weight:bold;">(in thousands) </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 199,233</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 126,551</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 199,230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">126,547</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 180,859</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">116,301</p></td></tr><tr><td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 32,068</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22,244</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209788398512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>item</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_NumberOfLeadClinicalProductCandidate', window );">Number of lead clinical product candidates</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NumberOfLeadClinicalProductCandidate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of lead clinical product candidates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NumberOfLeadClinicalProductCandidate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209785391392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Risks and Liquidity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_RisksAndLiquidityLineItems', window );"><strong>Risks And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (492,406)<span></span>
</td>
<td class="num">$ (356,281)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Follow-on public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_RisksAndLiquidityLineItems', window );"><strong>Risks And Liquidity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="nump">$ 22.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds</a></td>
<td class="nump">$ 165,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_RisksAndLiquidityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_RisksAndLiquidityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209787581616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount of antidilutive securities excluded from computation of earnings per share | shares</a></td>
<td class="nump">12,667,236<span></span>
</td>
<td class="nump">9,741,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 19,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 27,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember', window );">Stock options (including shares subject to repurchase)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount of antidilutive securities excluded from computation of earnings per share | shares</a></td>
<td class="nump">11,411,390<span></span>
</td>
<td class="nump">9,416,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount of antidilutive securities excluded from computation of earnings per share | shares</a></td>
<td class="nump">1,229,166<span></span>
</td>
<td class="nump">290,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Amount of antidilutive securities excluded from computation of earnings per share | shares</a></td>
<td class="nump">26,680<span></span>
</td>
<td class="nump">33,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209781347744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, cash equivalents and marketable securities - Portfolio of Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cost or Amortized cost</a></td>
<td class="nump">$ 34,601<span></span>
</td>
<td class="nump">$ 128,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair value</a></td>
<td class="nump">34,601<span></span>
</td>
<td class="nump">128,965<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_DemandDepositsMember', window );">Cash accounts in banking institutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cost or Amortized cost</a></td>
<td class="nump">7,532<span></span>
</td>
<td class="nump">44,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair value</a></td>
<td class="nump">7,532<span></span>
</td>
<td class="nump">44,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cost or Amortized cost</a></td>
<td class="nump">24,578<span></span>
</td>
<td class="nump">84,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair value</a></td>
<td class="nump">24,578<span></span>
</td>
<td class="nump">$ 84,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cost or Amortized cost</a></td>
<td class="nump">2,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Fair value</a></td>
<td class="nump">$ 2,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_DemandDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_DemandDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209781881600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, cash equivalents and marketable securities - Portfolio of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">$ 155,975<span></span>
</td>
<td class="nump">$ 187,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(985)<span></span>
</td>
<td class="num">(431)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">155,009<span></span>
</td>
<td class="nump">186,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">28,197<span></span>
</td>
<td class="nump">5,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(92)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">28,111<span></span>
</td>
<td class="nump">5,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">58,572<span></span>
</td>
<td class="nump">26,503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(72)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">58,512<span></span>
</td>
<td class="nump">26,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">67,206<span></span>
</td>
<td class="nump">145,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(786)<span></span>
</td>
<td class="num">(418)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">66,421<span></span>
</td>
<td class="nump">145,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">1,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">$ 1,965<span></span>
</td>
<td class="nump">1,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,849<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,852<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209781208000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, cash equivalents and marketable securities (Contractual Final Maturities of Marketable Securities) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due within one year, Amortized Cost</a></td>
<td class="nump">$ 144,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, Amortized Cost</a></td>
<td class="nump">11,392<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total, Amortized Cost</a></td>
<td class="nump">155,975<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year, Fair Value</a></td>
<td class="nump">143,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, Fair Value</a></td>
<td class="nump">11,230<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total, Fair Value</a></td>
<td class="nump">$ 155,009<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209781588528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 34,601<span></span>
</td>
<td class="nump">$ 128,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">155,009<span></span>
</td>
<td class="nump">186,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">28,111<span></span>
</td>
<td class="nump">5,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">58,512<span></span>
</td>
<td class="nump">26,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">66,421<span></span>
</td>
<td class="nump">145,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">1,965<span></span>
</td>
<td class="nump">1,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">24,578<span></span>
</td>
<td class="nump">84,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">24,578<span></span>
</td>
<td class="nump">84,416<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">24,578<span></span>
</td>
<td class="nump">84,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">24,578<span></span>
</td>
<td class="nump">84,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">2,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">155,009<span></span>
</td>
<td class="nump">186,808<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">157,500<span></span>
</td>
<td class="nump">186,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">28,111<span></span>
</td>
<td class="nump">5,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">58,512<span></span>
</td>
<td class="nump">26,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">66,421<span></span>
</td>
<td class="nump">145,169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring | U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">1,965<span></span>
</td>
<td class="nump">1,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring | Non-U.S. government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,852<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 2,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209785376416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 27,668<span></span>
</td>
<td class="nump">$ 26,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(5,153)<span></span>
</td>
<td class="num">(2,477)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total, property plant and equipment net</a></td>
<td class="nump">22,515<span></span>
</td>
<td class="nump">23,806<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">3,679<span></span>
</td>
<td class="nump">1,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">9,972<span></span>
</td>
<td class="nump">8,916<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">601<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_ComputerHardwareAndSoftwareMember', window );">Computer hardware and software.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,090<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">1,208<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">13,506<span></span>
</td>
<td class="nump">13,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 1,291<span></span>
</td>
<td class="nump">$ 822<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_ComputerHardwareAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_ComputerHardwareAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdsAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209781842080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">$ 602<span></span>
</td>
<td class="nump">$ 877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation and related benefits</a></td>
<td class="nump">8,446<span></span>
</td>
<td class="nump">10,014<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_AccruedResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,878<span></span>
</td>
<td class="nump">8,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent', window );">Property and equipment</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 11,011<span></span>
</td>
<td class="nump">$ 20,050<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying balance as of the balance sheet of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs of property and equipment Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AccruedResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying balance as of the balance sheet of accrued research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AccruedResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209784157472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Severance (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Severance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_PercentReductionToOurWorkforce', window );">Percent reduction to workforce</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pasg_AccruedExpensesAndOtherCurrentLiabilitiesMember', window );">Accrued expenses and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Severance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Unpaid severance and termination-related expenses recognized</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Severance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and termination-related expenses</a></td>
<td class="nump">3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Severance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and termination-related expenses</a></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_PercentReductionToOurWorkforce">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percent of percent reduction to our workforce.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_PercentReductionToOurWorkforce</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pasg_AccruedExpensesAndOtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pasg_AccruedExpensesAndOtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209781476688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="nump">$ 6,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_TenantImprovementAllowancesLiability', window );">Tenant improvement allowances liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">$ 27,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">19,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Future minimum lease payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">3,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">3,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">3,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">3,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">3,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">29,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total Undiscounted lease payments</a></td>
<td class="nump">47,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(20,855)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total Lease Liabilities</a></td>
<td class="nump">27,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvements</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Future minimum lease payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total Lease Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_OperatingLeasesForOfficeSpaceMember', window );">Operating Leases For Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_LesseeOperatingLeaseIncrementalBorrowingRatePercentage', window );">Incremental borrowing rate</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_OperatingLeasesForLaboratorySpaceMember', window );">Operating Leases For Laboratory Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_LesseeOperatingLeaseIncrementalBorrowingRatePercentage', window );">Incremental borrowing rate</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Operating Leases For Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions', window );">Number of extension terms | item</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_NewLeaseAgreementOperatingLeaseRenewalTerm', window );">Extended term of new lease agreement</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_TenantImprovementAllowanceReceivable', window );">Tenant improvement allowance</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Operating Leases For Laboratory Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_TenantImprovementAllowanceReceivable', window );">Tenant improvement allowance</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_LesseeOperatingLeaseIncrementalBorrowingRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental borrowing rate for lessee under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_LesseeOperatingLeaseIncrementalBorrowingRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of extensions available under the new lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NewLeaseAgreementOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the renewal term under new lease agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NewLeaseAgreementOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_TenantImprovementAllowanceReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tenant improvement allowance receivable from the landlord under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_TenantImprovementAllowanceReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_TenantImprovementAllowancesLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability for tenant improvement allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_TenantImprovementAllowancesLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 25<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123408481&amp;loc=SL77919140-209958<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123415192&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_OperatingLeasesForOfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_OperatingLeasesForOfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_OperatingLeasesForLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pasg_OperatingLeasesForLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209784036528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Operating lease cost (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 3,316<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePaymentsUse', window );">Cash paid for amounts included in the measurement of operating cash flows from operating leases</a></td>
<td class="nump">$ 2,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">9.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">12 years 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePaymentsUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePaymentsUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209781602400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Collaboration Agreements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 03, 2020 </div>
<div>USD ($) </div>
<div>Option</div>
</th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_DevelopmentMilestonePaymentsPayable', window );">Development milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=pasg_CatalentMarylandInc.Member', window );">Catalent Maryland, Inc. (Catalent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementAnnualFeePayableTerm', window );">Annual fee payable, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable', window );">Period for which annual fee is payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_TermOfManufacturingAndSupplyAgreement', window );">Term of manufacturing and supply agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm', window );">Additional extension term of manufacturing and supply agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted', window );">Minimum amount agreed to purchase in batches of drug product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember', window );">Amended and restated agreement with Penn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementAnnualFeePayable', window );">Annual fee payable</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementQuarterlyFeePayable', window );">Quarterly fee payable</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram', window );">Number of CNS indications | Option</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementUpfrontPaymentMade', window );">Upfront payments</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation', window );">Upfront fee payable upon clinical candidate designation</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementUpfrontFee', window );">Upfront fee due</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_PaymentsForTechnologyLicenseFee', window );">Payments for technology license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_AdditionalTechnologyLicenseFeePaid', window );">Additional technology license fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementPaymentMadeOnOptionExercise', window );">Payment made on option exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone', window );">Amount payable per product candidate arising from the exploratory program for large CNS indications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementSalesMilestonePaymentsPayable', window );">Sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember', window );">Amended and restated agreement with Penn | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementTieredTransactionFeePayablePercent', window );">Collaboration agreement, tiered transaction fee percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember', window );">Amended and restated agreement with Penn | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementTieredTransactionFeePayablePercent', window );">Collaboration agreement, tiered transaction fee percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone', window );">Amount payable per product candidate for rare, monogenic disorders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_AdditionalTechnologyLicenseFeePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Technology License Fee Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_AdditionalTechnologyLicenseFeePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payable per product candidate for large CNS indications upon achievement of specific development milestone payment on collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payable per product candidate  for rare monogenic disorders upon achievement of specific development milestone payment on collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementAnnualFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of annual fee payable during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementAnnualFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementAnnualFeePayableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the term of annual fee payable during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementAnnualFeePayableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementPaymentMadeOnOptionExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount paid on option exercise under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementPaymentMadeOnOptionExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period for which the annual fee is payable for the use of clean room suite under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementQuarterlyFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Quarterly Fee Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementQuarterlyFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementSalesMilestonePaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payable on sales milestone payment on collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementSalesMilestonePaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementTieredTransactionFeePayablePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of tired transaction fee payable under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementTieredTransactionFeePayablePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront fee payable upon clinical candidate designation under the collaboration agreement if the company were to exercise the options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CollaborationAgreementUpfrontPaymentMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of upfront payment made during the period under the collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CollaborationAgreementUpfrontPaymentMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_DevelopmentMilestonePaymentsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payable on development milestone payment on collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_DevelopmentMilestonePaymentsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the additional extension term of manufacturing and supply agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of remaining options available to the Company to commence additional licensed programs for rare, monogenic CNS indications.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_PaymentsForTechnologyLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for technology license fee during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_PaymentsForTechnologyLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_TermOfManufacturingAndSupplyAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the term of manufacturing and supply agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_TermOfManufacturingAndSupplyAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pasg_CatalentMarylandInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pasg_CatalentMarylandInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209785475392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 05, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,806<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pasg_SalesAgreementWithCowenAndCompanyLlcMember', window );">Sales Agreement, with Cowen and Company, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Sales Agreement, with Cowen and Company, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock, net of issuance costs</a></td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Follow-on public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 165,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pasg_SalesAgreementWithCowenAndCompanyLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pasg_SalesAgreementWithCowenAndCompanyLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209787452656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Equity Incentive Plan &amp; ESPP (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>plan </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_NumberOfEquityIncentivePlans', window );">Number of equity incentive plans | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased', window );">Number of shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,954,000<span></span>
</td>
<td class="nump">$ 32,691,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pasg_EquityIncentivePlan2020Member', window );">Equity Incentive Plan 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,370,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,880,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted', window );">Period till which there is automatic increase in rights granted under the Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease', window );">Percent of the total number of shares of the Company's common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm', window );">Term of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance', window );">Additional number of common shares reserved for future issuance</a></td>
<td class="nump">2,730,735<span></span>
</td>
<td class="nump">2,712,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pasg_EquityInducementPlan2021Member', window );">Equity Inducement Plan 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm', window );">Term of award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pasg_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized</a></td>
<td class="nump">1,981,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,435,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,119,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance', window );">Additional number of common shares reserved for future issuance</a></td>
<td class="nump">546,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted', window );">Period till which there is automatic increase in rights granted under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding', window );">Percentage of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage', window );">Percentage of stock purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage', window );">Percentage of maximum employee contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased', window );">Maximum amount of common stock that can be purchased | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of total number of shares of the Company's common stock outstanding equal to which shares may be issued under Employee Stock Purchase Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of common stock that a participant may accrue rights to purchase for each calendar year in which such right is outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum contribution percentage on eligible compensation by eligible employees under Employee Stock Purchase Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that can be purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period till which there is automatic annual increase in rights granted under the employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The stock purchase price percentage on the lower of the fair market value of the Company's common stock on the first or last day of the respective offering period under the ESPP.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_NumberOfEquityIncentivePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of equity incentive plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_NumberOfEquityIncentivePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Duration from date of grant (issuance of an option) to when option auto expires.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of outstanding common shares to be taken as automatic annual increase in rights granted under the share based payment arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period till which there is automatic annual increase in rights granted under the share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pasg_EquityIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pasg_EquityIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pasg_EquityInducementPlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pasg_EquityInducementPlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pasg_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pasg_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209781319504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Share-based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 18,954<span></span>
</td>
<td class="nump">$ 32,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ShareBasedCompensationArrangementExpensesDueToModifications', window );">Share-based compensation expense due to modifications</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">8,278<span></span>
</td>
<td class="nump">15,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ShareBasedCompensationArrangementExpensesDueToModifications', window );">Share-based compensation expense due to modifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 10,676<span></span>
</td>
<td class="nump">17,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ShareBasedCompensationArrangementExpensesDueToModifications', window );">Share-based compensation expense due to modifications</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ShareBasedCompensationArrangementExpensesDueToModifications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of share based compensation arrangement expenses due to modifications.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ShareBasedCompensationArrangementExpensesDueToModifications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209781878224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Beginning of period</a></td>
<td class="nump">9,416,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">6,609,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="num">(126,056)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(4,488,993)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, Ending of period</a></td>
<td class="nump">11,411,390<span></span>
</td>
<td class="nump">9,416,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested and Exercisable at December 31, 2022</a></td>
<td class="nump">6,074,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested or expected to vest at December 31, 2022</a></td>
<td class="nump">11,411,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Beginning of period</a></td>
<td class="nump">$ 13.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">3.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">1.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">10.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, Ending of period</a></td>
<td class="nump">9.01<span></span>
</td>
<td class="nump">$ 13.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Vested and Exercisable at December 31, 2022</a></td>
<td class="nump">11.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested or expected to vest at December 31, 2022</a></td>
<td class="nump">$ 9.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted average remaining contractual term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and Exercisable at December 31, 2022</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested or expected to vest at December 31, 2022</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise', window );">Number of share options unvested and exercisable during the period</a></td>
<td class="nump">113,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted</a></td>
<td class="nump">$ 2.33<span></span>
</td>
<td class="nump">$ 12.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value of options outstanding</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense related to unvested stock option awards</a></td>
<td class="nump">$ 24.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) unvested and exercisable under early exercise during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209789223248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Assumptions Used in Determining Fair Value &amp; Early exercise of Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">92.50%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209784278208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Restricted Stock Units (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward', window );"><strong>Number of shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance, Beginning</a></td>
<td class="nump">290,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">1,171,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested</a></td>
<td class="num">(39,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited</a></td>
<td class="num">(193,667)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance, Ending</a></td>
<td class="nump">1,229,166<span></span>
</td>
<td class="nump">290,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted average grant date fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested balance, Weighted average grant date fair value, Beginning</a></td>
<td class="nump">$ 2.98<span></span>
</td>
<td class="nump">$ 14.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted average grant date fair value</a></td>
<td class="nump">1.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Weighted average grant date fair value</a></td>
<td class="nump">15.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, Weighted average grant date fair value</a></td>
<td class="nump">11.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested balance, Weighted average grant date fair value, Ending</a></td>
<td class="nump">$ 2.98<span></span>
</td>
<td class="nump">$ 14.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total unrecognized expense</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted-average remaining contractual term</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209784255760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 64,547<span></span>
</td>
<td class="nump">$ 42,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credits</a></td>
<td class="nump">32,068<span></span>
</td>
<td class="nump">22,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement', window );">Collaboration and license agreement</a></td>
<td class="nump">4,504<span></span>
</td>
<td class="nump">3,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">65,012<span></span>
</td>
<td class="nump">51,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">11,312<span></span>
</td>
<td class="nump">11,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther', window );">Accrued expenses and other</a></td>
<td class="nump">1,922<span></span>
</td>
<td class="nump">4,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets before valuation allowance</a></td>
<td class="nump">188,265<span></span>
</td>
<td class="nump">136,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(179,843)<span></span>
</td>
<td class="num">(135,053)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">8,422<span></span>
</td>
<td class="nump">1,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets', window );">Right of use assets - operating leases (deferred rent for December 31, 2021)</a></td>
<td class="num">(7,609)<span></span>
</td>
<td class="num">(876)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(813)<span></span>
</td>
<td class="num">(347)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Total deferred tax liabilities</a></td>
<td class="num">(8,422)<span></span>
</td>
<td class="num">(1,223)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance increased</a></td>
<td class="nump">$ 44,800<span></span>
</td>
<td class="nump">$ 72,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities and other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from operating lease right of use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209781623120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Effective tax rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax benefit at statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefit</a></td>
<td class="num">(7.50%)<span></span>
</td>
<td class="num">(11.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent', window );">Permanent differences</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development and orphan tax credits</a></td>
<td class="num">(6.90%)<span></span>
</td>
<td class="num">(7.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">32.90%<span></span>
</td>
<td class="nump">38.90%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate reconciliation, total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140209785460032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Net operating losses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_TaxCreditCarryForwardSubjectToExpiration', window );">Tax credit carry forward</a></td>
<td class="nump">$ 32,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued interest or penalties related to uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Income tax examination, penalties and interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Research tax credits</a></td>
<td class="nump">32,068<span></span>
</td>
<td class="nump">$ 22,244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">199,233<span></span>
</td>
<td class="nump">126,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_pasg_OperatingLossCarryforwardSubjectToExpiration', window );">Net operating loss carryforwards subject to expiration</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=pasg_StateTaxAuthorityMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">199,230<span></span>
</td>
<td class="nump">126,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=pasg_LocalTaxAuthoritiesMember', window );">Local</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 180,859<span></span>
</td>
<td class="nump">$ 116,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_OperatingLossCarryforwardSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward subject to expiry, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_OperatingLossCarryforwardSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pasg_TaxCreditCarryForwardSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carry-forward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pasg_TaxCreditCarryForwardSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pasg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=pasg_StateTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=pasg_StateTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=pasg_LocalTaxAuthoritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=pasg_LocalTaxAuthoritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>pasg-20221231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pasg="http://www.passagebio.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pasg-20221231.xsd" xlink:type="simple"/>
    <context id="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_d5OcH9P0YU6Mqog4XpwvoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_wDFfPO_ZNUKxeG-q7TC3Rg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_yIzi3o8bAE2L3dxvXEqkRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_5_2021_To_3_5_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_SalesAgreementWithCowenAndCompanyLlcMember_LbBLENbq1kqwVJ5FMdSo8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:SalesAgreementWithCowenAndCompanyLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-05</startDate>
            <endDate>2021-03-05</endDate>
        </period>
    </context>
    <context id="Duration_3_5_2021_To_3_5_2021_us-gaap_TypeOfArrangementAxis_pasg_SalesAgreementWithCowenAndCompanyLlcMember_c83rb3pHbUyDv5vHPbSVOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:SalesAgreementWithCowenAndCompanyLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-05</startDate>
            <endDate>2021-03-05</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_illNEQwEHECIcckfPCTJRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PyRd_9rL4UqO5RO9ulICug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WTd6dzj7eEa_9Sk21SavjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7fu6Hq9yz0WPODQu1__Srw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mej-DQ41G0WhXJ-3c4uH-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rW0i_NK93UyCd57P6lJiTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_hM0jUdnMX0SstDzHGw84NQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_68O7F9-naUyJ7hFnufywEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7dx_D0t8AkeU7CcwmPSrnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_H3Kyaw9iDUKSzbJyfoPBBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TWUY5elwAUOM2vM1WL0RyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mB93yuXxFkmHu4pFLjXgug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hYpnLKF0Pkq_6zN2_OqwkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_XMou09J0cEirXcLwXtLPDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_ffSkQEILP0GGYx3Q6UsjsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2023_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_X3oAMRpPCkuZ5fd72D8-YA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityInducementPlan2021Member_R6lRMEzvCkuXk7SlC-tL4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityInducementPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_Ba8ei5M0iU212FOvifvfgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_IVEx45mF9UGGotpVBJv3wA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2SJMJY-9JE2TYYv1hxxQlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_pasg_AccruedExpensesAndOtherCurrentLiabilitiesMember_GPYjhSt04kqGmR--V5LGEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pasg:AccruedExpensesAndOtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_z_YtRBUDn0S9xCBNBKE8ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pasg:CatalentMarylandInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_oMHqSuMuOEyeN1Ln42FsEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_CJboIsPRPU2JiJLp82d18Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_c2lmnbj2xk-05fdWrtq5pA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_LaboratoryEquipmentMember_BrSr9bR8aE62mOH4GDhAjQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_2Hsg8LNvXEucBUm5ld8Thw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_618eVrMiP0KqpawEGChP-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_bJ5zjvxB5EGnQcqTp7xFSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_Wqhrge7I_kKR4RChMkdtEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_LaboratoryEquipmentMember_VlmbuSYC6USj3OTDddchPQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_ComputerHardwareAndSoftwareMember_JzsV16LRG0WCbPoDdOU4QA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_OVQG01q9_Eid2wbn4B4PpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_wweEz0CjaU-LuKc41hE1fg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdsAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_yGDjvEYReEuRzXheeim-wQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_S84Lz4H_jE-dgwqZQM7UOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_LaboratoryEquipmentMember_15fk6eyMukOdrAYC2-ThJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_ComputerHardwareAndSoftwareMember_kCoolnyGaUy4-vQysBpBNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_VKjaYfeOdEmdzPqOICqhlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Dy2fqtwSE0iMjVYx7LAqaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ft0vm0rTlEWzwuGEbsW4BQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_pasg_StateTaxAuthorityMember_csXMoMs05E-EaQFBpJ-dDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:StateTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_pasg_LocalTaxAuthoritiesMember_Ig7yZu-Op0CHDDSoRCT99A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:LocalTaxAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_mgIQoET8g0GzCQSgrV4mEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_pasg_StateTaxAuthorityMember_Af3k6h92bkmtwN0ci3mBEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:StateTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_pasg_LocalTaxAuthoritiesMember_NABkP1gdZkiCPP5SKrlohA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pasg:LocalTaxAuthoritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_7zow5ahakk-p3Zr2YBVVfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5iXkDh6_nUWdtcuegYMTbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_YnP14VvzNEuqjHFsfp6GYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_4GJmz4SaeUW8G0iqOGx50A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_62A9Ji97c0e2uu5ff0EtfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ycWO8dyX_kC6uG93WKsSqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KknMkl4yeUm7mwrKVSBAMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember__Gr_-HqIS0e2m0hxthuJSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_BcQOcPP9S029dfsVqpuUWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_hKzkHH1vOE64CgLe9E8cBg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_PZny6jRjkUiFZ51MD_j8yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_9DDLbzIViEiYZ2wdZ2ebDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_EX8q_EtFJkmb7GR4fiSkgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_nU963VORek-l98BVpjXc2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_nzjfVFDIVUWSs3XTC4bDsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_xNnhYs_8xE25HkrTLSUCDg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_8rQIwJjX7U-HUdBs0mHPHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_U1C9pEJYU0mSIYjsXdwWXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_GIzjQ4m1DEOd0Y5zdqwlEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_SOu6oV8f4Uqc6G1TRruyZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_bskf0Lik9k62JRNH0Ahm_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_UcKqbx4Po0Ou91dnkxKM6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_tfIA7SpRCEeYVQ2vDETw2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_RLg8-oaulEugO9P5aol4lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember__szE3cOXwEaiDH4szkcG3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_oE0pMTTA8kyy9iM_moGuCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_zS-Tm2J2FUOYlB6qItnUOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_EKMTAzZhuUyVq0LA3FdSVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_mPnRzJMdn0WpI85X-EalUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_X6XgFKAqdUq2v933qg7wzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ddNrvr493EuYOz1vw-xceg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_m3qLi4_cEU60Ts_xTIoBAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qnM-OR-gAECiFX_LbmMPfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_btpJFa9_VkSBS3ixhn_iWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_C-o2Zgq5lkazNtHRBvQ8_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_pH7TkCz-oUyHvehAdIIrKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_zQffUCmMdE-_aOBnQ2S_vA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_LZ4JlGCAxUyPUIGpj_JLDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pasg:StockOptionsIncludingSharesSubjectToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_IwGipl1FgE6Gk4DlC1uLiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_LFuw3TMIekuZBYlTISw11g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_qOjzooIZXUyOJbcVJeTNvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">pasg:StockOptionsIncludingSharesSubjectToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_fzK4cBH8fkuhwpQHwW1AZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_rKbIo3RACkur9OAM8iqIbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_gplgcbUrjEqXbb7bUxMbbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_aTuBNIMD5UOPhj-XOY8Bqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_weqi7Po-uUOAVerAuobXvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_1_2022_1hJs1cU8B0yEBX43Mau-lg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <instant>2022-01-01</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForLaboratorySpaceMember_m3JiXizoFEGM-jTR8nDJpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tKy1_NMOUEmEHV1J-B4fuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FatF9mHr8kyTws1l1ujYjA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_lvXskTRyzEmHGgFZuscuXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember__jemGaqshkeAAlBd2h-gkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityInducementPlan2021Member_NN2gJkl_wkeCgwEIqLXLgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityInducementPlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_mGa3yEM8z06MhUJxjwJeqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_11_30_2022_mVsYEdTSSEuJbQ89GBbHMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="As_Of_3_31_2022_NhtNZVP74Ei9hd55TAwTew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_68a1wKllOU-ygbrbsjHfXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForOfficeSpaceMember_PnKu318m2kKf0m31ftbUUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForOfficeSpaceMember_ZrafZiQhmUuODBwDYCS8rQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForOfficeSpaceMember_Y66Drnyc1kO-defDYISTag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForLaboratorySpaceMember_olTE_Yzm10uPm2K7m0faAg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pasg:OperatingLeasesForLaboratorySpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_28_2020_To_2_28_2020_iDWURz96TU6yNVnGevdtWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <startDate>2020-02-28</startDate>
            <endDate>2020-02-28</endDate>
        </period>
    </context>
    <context id="As_Of_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_2wbIkeBld021QObVHUyCCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-28</instant>
        </period>
    </context>
    <context id="Duration_2_28_2020_To_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7S0-ZkqLP02l2ZtnRMvqNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-28</startDate>
            <endDate>2020-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_e7qXKu9B8kaes7yJbBslkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_paHmp6CcHEeXKfzN77VxdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_V-j15wJiN0KMnb4hw5k1nA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pasg:EquityIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="Duration_8_3_2020_To_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_X9L4Qp3mCEKi6Z_BUccfKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-03</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_0J6NHzFpyUuN4ppDeH9zaQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_Qg9ksmS5wkuN_RKSudErVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2020_To_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_4KZiWVNG9E22l6ySZmuTUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pasg:CatalentMarylandInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2019_To_6_30_2019_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_2O0jJDglI0ukihnR8RMuWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pasg:CatalentMarylandInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_Tz7eti2M40mA4VxFf-_HGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-03</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_z13QfKfPmkK_8C2JId34Bw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_HuyYaPjrf0-kSgqt367TIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_doDUoWoF-U6E9lX1OVWkNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_KS_iGfGyu0moP1TAVBgiKQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pasg:AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ZNLZ2q08tUyXeYUCJO4M5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_3_2_2023_niqzyjJXOUWALoPppfBlmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <instant>2023-03-02</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001787297</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_item_wlhC8WlTVEmcZqQ79zgOUA">
        <measure>pasg:item</measure>
    </unit>
    <unit id="Unit_Standard_plan_r3kCEt0dLUCKcJ9iz91x7Q">
        <measure>pasg:plan</measure>
    </unit>
    <unit id="Unit_Standard_Option_5y2HNcjXj0iaLv1FEhwgXQ">
        <measure>pasg:Option</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_lMTtBbJKdUumSSlUVKw17A">
        <measure>pasg:segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      id="Hidden_xRI4qzn6Jku67ugFgR2TuA"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      id="Hidden_85ZD75uU2k692pkPXiFulA"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tc_UOFjn3LqRU-nQ769eKzmFg_2_1">0001787297</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tc_4VlxRFwzT0CbX4siJvq-cA_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tc_L6naryoywkaZxcXlK6MX-Q_4_1">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tc_ZjAwFKZyMUC0CVz14hQfyQ_5_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tc_9KuL6NmsW0aL558Cvv4cgg_6_1">false</dei:AmendmentFlag>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="INF"
      id="Hidden_vIrVM0Yz5kWZ5uqDROhiig"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">54614690</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="INF"
      id="Hidden_a4vZEQ-8k0exEPYJXuhf1w"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">54244996</us-gaap:CommonStockSharesIssued>
    <pasg:ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_mGa3yEM8z06MhUJxjwJeqA"
      id="Hidden_pyhlfNmlOEC4x3JdtR4JSQ">P10Y</pasg:ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Narr_svA_oXBkX0uORtQctT-N4Q">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tc_hfsDcjT3d0m1ii1q1gQlZg_1_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Narr_q5QVpqYYFUqhlbxjCgHOcw">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tc_BGKRrgVehUS1Dc5UgupSew_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Narr_3F89XQ3n2UyHGRo1fcz4uw">001-39231</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Narr_HGpg_gBiMU-feCw5-NE1MA">PASSAGE BIO,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tc_KmJIA0-VR0C-Jy6Wwl6krQ_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tc_K6Gz2t5Kfk6WpUeWAeaFxA_1_2">82-2729751</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tc_e-9Zx5VON0GMiiNJbfzW4A_1_0">One Commerce Square</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tc_q_fTBI8KeUGzgnB2GkyVxw_2_0">2005 Market Street, 39th&#160;Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Narr_63A7M2GSCkSyID9i2e5_1A">Philadelphia</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Narr_NqdwauVFwkqmBZP7y_2LEA">PA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tc_HJFhxUzYtEqYeS1V8iOzCQ_3_2">19103</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Narr_-2qvSztQqka4eAyNfHFp5g">267</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Narr_LxsjsT1LFEqHoBYaPQhRtg">866-0311</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tc_qJvNqP1JU0KDJxKo_9SwUg_2_0">Common stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tc_yF2V23I8cUKMulEw_dAB8g_2_2">PASG</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Narr_f8FfTjngAUqA3xNcFZXztA">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Narr_Xv2-QFL37Uyir2pFE33WtA">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Narr_WiaCZcU5HUCV4fuwSZgp2A">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Narr_8AIC-SndAEuEeTyttfnVAA">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Narr_VdxHmJTjD0KKpj1KubsOhQ">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tc_IsjK74jxLU-A50-BBh0BPw_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tc_Hv5weFZwnEeXulSdmjzj0A_2_5">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tc_c9tpE5nbEUiH5E8YhJQA7w_3_5">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Narr_xnGZP97E_ky4WvMkjconMg">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Narr_IKkYcF2NCkGTcF8_L-EFyg">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Narr_nRlf7I08qE6kjQIUWgCOEw">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2022_ZNLZ2q08tUyXeYUCJO4M5w"
      decimals="-5"
      id="Narr_Vpw37YnP2kmPk1jQFmE37A"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">100600000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_3_2_2023_niqzyjJXOUWALoPppfBlmA"
      decimals="INF"
      id="Narr_xDVEqLPqTkiqqPps6emsnw"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">54617523</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Narr_OT4_kkL8X0KlKDF3pdd59g">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Narr_fCYHzQ_EFEO8LagdrWmI8g">Philadelphia, PA</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Narr_VpsdHOL3QEGXsDtEuR2HDA">185</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_HPY0ICBa0USWsKZ9nAfRlA_5_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">34601000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_1Hj15ki3LkGHz_tFknFrpA_5_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">128965000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_LCgJA8knc0OnwGLOMTWqPQ_6_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">155009000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_T8iutxzID0SHzrg5TRHrtQ_6_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">186808000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_lfZvKvaoB0KeJDC43G8VHA_7_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">926000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_1LTFKmw-7UOGebbao0I_NQ_7_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1726000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <pasg:PrepaidResearchAndDevelopmentAssetCurrent
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_27YVteqGFE-feVZ8r_MCcw_8_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">6508000</pasg:PrepaidResearchAndDevelopmentAssetCurrent>
    <pasg:PrepaidResearchAndDevelopmentAssetCurrent
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_RyHrDgmKkk-93jDcJ0XT9w_8_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">7567000</pasg:PrepaidResearchAndDevelopmentAssetCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_pg6zsPXSaEKv4HZBcjl5XQ_9_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">197044000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_-oQ6RTOq_EWbGPAB7oO5yw_9_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">325066000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_utlk5-DoiEiiFhZ_Op0NKA_10_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">22515000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_vEBfSSV_gU60XMuVRSWRhw_10_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">23806000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_sfXFqL7220S6wlFjz4Hqfw_11_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">19723000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_zYKYkODp_0qxdz30huDUMw_12_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">4267000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_Ptpdv6nkukC-I2Cdws6oQg_12_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">6204000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_ZnubataPNEaa5JXofTztjg_13_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">243549000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_FRA5lpmJIUqr0NncEUPHjA_13_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">355076000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_TwLuRbnhDki4WcFwS5DSFg_16_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">4065000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_Li-oqSQ3xk2rbz_AUjF2VA_16_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">9448000</us-gaap:AccountsPayableCurrent>
    <pasg:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_Y1i74yuu2EiImkxlyKN8QQ_17_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">11011000</pasg:AccruedExpensesAndOtherCurrentLiabilities>
    <pasg:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_tvGOj8pGGkCcUimeA2nfuw_17_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">20050000</pasg:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_oZJqeUSJm0e1W9F3q0bZnQ_18_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">3275000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_Zt2zfpGdKkqj18SBidFuJQ_19_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">18351000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_zgObEMyz70OLFwwRWMmXpg_19_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">29498000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_FTO6emVzaESL2rUD1r-y3Q_20_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">23832000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_xswjchEA0UeC2U8wB_Vp-w_21_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">6921000</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_keN984gHR0iEvAC5ya8aQA_22_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">42183000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_j1-wZlF0lUqDpUXp0c2uVQ_22_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">36419000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="INF"
      id="Narr_mjCIo7Wtg0ySi8D0YZIaMA"
      unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="INF"
      id="Narr_ToR_PorVa0GasJXTsv-_LQ"
      unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="INF"
      id="Narr_eK7Bh-S3AkmeaB4rmY0Plg"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="INF"
      id="Narr_V59K88fHq0uzwm4AMRbGNg"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="INF"
      id="Narr_RgXCIiwx1k-Q4fqTRg8hgQ"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">54614690</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="INF"
      id="Narr_9LY3TFlj2UuTA4V7T2TtcQ"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">54244996</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_ILnX5nlG00C54dCbWGmXMg_27_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">5000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_kyGIdJhlokiH3GIP0gj-fw_27_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">5000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_sKP5BWKYP0SXdElruaikQA_28_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">694733000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_Hedi-rwQJ0i7A0WHYPuqJg_28_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">675346000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_m8L839fEJESFf7pKLVEKow_29_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-966000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_y3d1Nx-PxkieJJsjYFE_LQ_29_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-413000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_1lnSQY7BFka-Aad1LuQswA_30_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-492406000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_MgRpPwK4xEKCCRAHO6WZdA_30_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-356281000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc__sCO_FL0FkGtiXunJrrrXg_31_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">201366000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_pzgO3Ek4S0-kSxWzT4CHmg_31_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">318657000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_owgZT1-ZikqESFTku-BD1Q_32_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">243549000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_ghxKc58_3Em40vcSAJZjyg_32_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">355076000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_AMsP-CLk6kGqHAW6LpMTFg_4_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">86053000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_GFDsoO0150KFG9bpvQtM4w_4_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">117673000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_KHfc8TEmY0aB1xbPxMsWeA_5_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">3000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_AlGH-p4O2U2wnQpqYOjASg_5_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">8000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_rDgXiYDSNEm3Auxyvd8-mQ_6_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">49341000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_jhZHrZc4-kGbpPqQz28kHg_6_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">60056000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_oXRP6GAay0-G7nCQpIxMgQ_7_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-138394000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_skDytPjYHEu25ohdFVjxcA_7_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-185729000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_IsWVduXUw0SA5oj0E2On-g_8_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">2269000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_36xk3PMgF0auDLnvr0lwew_8_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">343000</us-gaap:InvestmentIncomeNet>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc__z1vlNn7o0m-yQ0fuMeGyA_9_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-136125000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_Dae8OrLPMEmcOgk_fOa_wQ_9_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-185386000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="2"
      id="Tc_MdQCTgzeEUC11o__Gyr-0w_11_3"
      unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">-2.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="2"
      id="Tc_MdQCTgzeEUC11o__Gyr-0w_11_3_2"
      unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">-2.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="2"
      id="Tc_V3M6KmIH5UCiFT0bPgn8oQ_11_6"
      unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">-3.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="2"
      id="Tc_V3M6KmIH5UCiFT0bPgn8oQ_11_6_2"
      unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">-3.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="0"
      id="Tc_pRQJ54HPd06bJ3i_3rmZfA_12_3"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">54429023</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="0"
      id="Tc_pRQJ54HPd06bJ3i_3rmZfA_12_3_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">54429023</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="0"
      id="Tc_XH6KunGTMEyzZPRJtL2WDw_12_6"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">53343959</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="0"
      id="Tc_XH6KunGTMEyzZPRJtL2WDw_12_6_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">53343959</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_ZW-DV_R2TE-MsaZav67Ymg_14_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-136125000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_HLwDO37Gw0y34z4Euv61kQ_14_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-185386000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_4vs3WWQAxkaMajJiTCmHaQ_15_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-553000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_PRP9H0Bc1UOEy6o9Jaur_Q_15_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-401000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_grx9SwOEyUWGJgn8Xkqdhw_16_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-136678000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_u9K4N4OzN0uN80NBukto4g_16_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-185787000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hYpnLKF0Pkq_6zN2_OqwkA"
      decimals="INF"
      id="Tc_251biwtk4EShZ_RefLZcSQ_6_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">45614807</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hYpnLKF0Pkq_6zN2_OqwkA"
      decimals="-3"
      id="Tc_0aajLq00q0-h2mOmthireg_6_5"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7dx_D0t8AkeU7CcwmPSrnA"
      decimals="-3"
      id="Tc_5e94sseTJk6ifjCwAvsSgQ_6_7"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">475617000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_H3Kyaw9iDUKSzbJyfoPBBQ"
      decimals="-3"
      id="Tc_kaBajKQOD020jRkYyg0p9A_6_10"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_68O7F9-naUyJ7hFnufywEw"
      decimals="-3"
      id="Tc_Y_M8Y1GZR0mw1-WZ88lZdg_6_13"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-170895000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_62A9Ji97c0e2uu5ff0EtfA"
      decimals="-3"
      id="Tc_klfpxG3Mqka7IKcOd2uXZg_6_16"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">304714000</us-gaap:StockholdersEquity>
    <pasg:StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FatF9mHr8kyTws1l1ujYjA"
      decimals="INF"
      id="Tc_KRxPjggpekCogikmuEjOFg_7_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">302277</pasg:StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase>
    <pasg:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tKy1_NMOUEmEHV1J-B4fuA"
      decimals="-3"
      id="Tc_ktLvd9jGqUODmXGmAMLpJg_7_7"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">45000</pasg:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase>
    <pasg:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_So198YRpwEmhDuEoekpLcg_7_16"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">45000</pasg:StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FatF9mHr8kyTws1l1ujYjA"
      decimals="INF"
      id="Tc_DPztbNsOgEqx9T0QvR9Q-g_8_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">186787</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tKy1_NMOUEmEHV1J-B4fuA"
      decimals="-3"
      id="Tc_kDOYbD3GckiodUnQ9Ou7qg_8_7"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">301000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_wV4UiP_A1UGguqplIngdkQ_8_16"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">301000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FatF9mHr8kyTws1l1ujYjA"
      decimals="INF"
      id="Tc_MZFOMtINskWuR4Mee6x5ZQ_9_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">91125</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tKy1_NMOUEmEHV1J-B4fuA"
      decimals="-3"
      id="Tc_J_2zdg1d-UiQQgQmgnD3cQ_9_7"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">887000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_w1F7vPbzyE2E9D6EMu0JTA_9_16"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">887000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <pasg:StockIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Narr_3jInUu3E1UK_nUvuqctT1w"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">669000</pasg:StockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FatF9mHr8kyTws1l1ujYjA"
      decimals="INF"
      id="Tc_VDH_ES3UdkmnwbOh1dUo1A_10_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">8050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FatF9mHr8kyTws1l1ujYjA"
      decimals="-3"
      id="Tc_6eShocZ0o0akEWlXrwp0eA_10_5"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tKy1_NMOUEmEHV1J-B4fuA"
      decimals="-3"
      id="Tc_QFAw2C1510GPVdNLnRbUyQ_10_7"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">165805000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_Nj9OPQH--06PL0OagbWoKw_10_16"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">165806000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ft0vm0rTlEWzwuGEbsW4BQ"
      decimals="-3"
      id="Tc_knPoybHxlEm0-zRCh070Jg_11_10"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-401000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_5xUkRq7_wE65AYIR9mT9Mg_11_16"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-401000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_tKy1_NMOUEmEHV1J-B4fuA"
      decimals="-3"
      id="Tc_bR1kvDqN2kW7v1f85ZlTBQ_12_7"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">32691000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_va_mT1FW4UafeOdezV1PkQ_12_16"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">32691000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_YnP14VvzNEuqjHFsfp6GYw"
      decimals="-3"
      id="Tc_Nwj7s8Cap0qKeODR2r8flg_13_13"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-185386000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_7IlfHzJ-Z02RbnNtimXHJA_13_16"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-185386000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mB93yuXxFkmHu4pFLjXgug"
      decimals="INF"
      id="Tc_wZxFeUZ7Tk-yBC6c-CAzVQ_14_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">54244996</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mB93yuXxFkmHu4pFLjXgug"
      decimals="-3"
      id="Tc_Iv9QTvrpg0yDj2GvJ6yz3w_14_5"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rW0i_NK93UyCd57P6lJiTg"
      decimals="-3"
      id="Tc_vednNFSTcUqz9Jxi_wcERw_14_7"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">675346000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_hM0jUdnMX0SstDzHGw84NQ"
      decimals="-3"
      id="Tc_GmMPuvpSyUu_ea0JBPqE5w_14_10"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-413000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mej-DQ41G0WhXJ-3c4uH-w"
      decimals="-3"
      id="Tc_SuO2sLIjyUO_tetZqVd9cg_14_13"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-356281000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_TenSbsOSvkaMPKUVEeMO9A_14_16"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">318657000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mB93yuXxFkmHu4pFLjXgug"
      decimals="INF"
      id="Tc_vQoW6vZdpUGq3j868bAARA_6_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">54244996</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_mB93yuXxFkmHu4pFLjXgug"
      decimals="-3"
      id="Tc_E2p3CzLub0yL6qswoG2Luw_6_5"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_rW0i_NK93UyCd57P6lJiTg"
      decimals="-3"
      id="Tc_LjfmAL1AuEGD1-tE10WIYg_6_7"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">675346000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_hM0jUdnMX0SstDzHGw84NQ"
      decimals="-3"
      id="Tc_g-BNLsULiE-Z1U0ZufVfAw_6_10"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-413000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_mej-DQ41G0WhXJ-3c4uH-w"
      decimals="-3"
      id="Tc_cNJR0KyVUkit2tUtvWYjZg_6_13"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-356281000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_eG4YwDCO0kKJfR5QDd4Stw_6_16"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">318657000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_illNEQwEHECIcckfPCTJRg"
      decimals="INF"
      id="Tc_S12byrm9iUq0YErQS0vcmA_7_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">165223</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_weqi7Po-uUOAVerAuobXvg"
      decimals="-3"
      id="Tc_4JF--l_6E0qmVMK42TnbQw_7_7"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">129000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_D56gJbPiN0utoj5-ii9PBg_7_16"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">129000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_illNEQwEHECIcckfPCTJRg"
      decimals="INF"
      id="Tc_cBuGnUMwx0eHwufBUbFVsQ_8_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">204471</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_weqi7Po-uUOAVerAuobXvg"
      decimals="-3"
      id="Tc_1Uxs_NbC7E6uwbwxrlIhLA_8_7"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">304000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_kO1MqX_mUkiJwDvhx2PqgQ_8_16"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">304000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_Dy2fqtwSE0iMjVYx7LAqaQ"
      decimals="-3"
      id="Tc_soVRS36uik270ThjPxbDJA_9_10"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-553000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_vmaZIXL5zUKJ3iS9nNwg_g_9_16"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-553000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_weqi7Po-uUOAVerAuobXvg"
      decimals="-3"
      id="Tc_3gqXsVWK-U2L3kpQEUYwTg_10_7"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">18954000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_P_SeW_S8U0q29z812R5iFw_10_16"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">18954000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_5iXkDh6_nUWdtcuegYMTbQ"
      decimals="-3"
      id="Tc_6lMIM0F4QU6jGCweW0TZXw_11_13"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-136125000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_lpLTVu0AYkSlScTkp0lkIw_11_16"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-136125000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TWUY5elwAUOM2vM1WL0RyA"
      decimals="INF"
      id="Tc_GjVlQzQIM0yRSn9j1fNBYA_12_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">54614690</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TWUY5elwAUOM2vM1WL0RyA"
      decimals="-3"
      id="Tc_tV_4D1poPkukaA8czDwybw_12_5"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WTd6dzj7eEa_9Sk21SavjA"
      decimals="-3"
      id="Tc_JUOqItYe4kiV6Z9JeGEkuw_12_7"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">694733000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_7fu6Hq9yz0WPODQu1__Srw"
      decimals="-3"
      id="Tc_P1hsndcT_kaMn3mvFAy_xw_12_10"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-966000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_PyRd_9rL4UqO5RO9ulICug"
      decimals="-3"
      id="Tc_NQ4Q-DhKEkCjoIQL8xiTpA_12_13"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-492406000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_kVVNneGhPUyweIbOJuDtbA_12_16"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">201366000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_sM0rynFA-U-QnAwUoeWdFA_5_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-136125000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_ZuIdxImy1EGSF5G5KH9H9Q_5_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-185386000</us-gaap:NetIncomeLoss>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_fRVHCOyibkez4H7d-2CbfA_7_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">3000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_inpf-oYSCE-P76XI9g3OTw_7_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">8000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_qlzSMntx_EquKeKgTmV1Vg_8_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">3679000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_8X2gVXRsuEKElUQK5YbhbQ_8_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1543000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_8jJ92_F2Bkexk_QkD6erJQ_9_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">18954000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_rq0sMd_40Ee2SHle_aIZ4Q_9_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">32691000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_g9YWezi7Q0Swvgp3tLN9CQ_10_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">773000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_eWLTfelOsUKFdwD-gYiUYA_10_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">2778000</us-gaap:AmortizationOfDebtDiscountPremium>
    <pasg:IncreaseDecreaseInDeferredRent
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_yr1-b2AYTUuxrqpSyCYZmw_11_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">2075000</pasg:IncreaseDecreaseInDeferredRent>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_xKT85bZiVU2m0mBAMci36w_13_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-2737000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_801rSOCfpkSGZVbi7phOog_13_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-1842000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_4TAwyYx6bU66WRlRnLQpxw_14_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-1059000</pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment>
    <pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_LLffgBXHKEWV8D2d_07JAg_14_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-3394000</pasg:IncreaseDecreaseInPrepaidResearchAndDevelopment>
    <pasg:IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc__eu-y0xDv069C06FMczVxA_15_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-463000</pasg:IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_maRXptlYskGz2Hv49WLWYg_16_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-5412000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_V4t-hWszW0SWYB86Sjyvww_16_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">2201000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <pasg:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_DtlLvj0dOUKD08VpG_RHcg_17_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-7338000</pasg:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
    <pasg:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_9Eq-dDIQVUudWksqmQjJJQ_17_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">3983000</pasg:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_Z6DsLYekYEuZFCiTPNrV5Q_18_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-118210000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_7h1eq61qik-UoPyWxv5CzA_18_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-126879000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_HeMM2aW5CkuHlPDIiLSVCg_20_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">157835000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_4bFOXPDy8EaW8bNhQjFfvg_20_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">202546000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_hDcHo-b1LUi5CHID9lh2dQ_21_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">188308000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_2rBlriRJikiKcMoEbUA_DQ_21_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">182374000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_vsL2F_0dUEWYuiTthOD2Kw_22_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">3000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_3iPIuobWo0SbJhIa1AZr9A_22_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">8000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_-eeQ0xzwo0O6qpalJRIdjQ_23_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">2274000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:PaymentsToAcquireMachineryAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_V01F791h40i05sm_ro6pXg_23_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">17642000</us-gaap:PaymentsToAcquireMachineryAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_c_xGx3Y2wESkfkKdRopoaA_24_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">25199000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_hbMKa3bymEGAQuKCwrncvA_24_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-45814000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_Pz1dSpu2BEKjSMRP1WlYYQ_26_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">165806000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_OpRhlMjlDEupL-IOW3aayQ_27_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">338000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_-2BnF55xqkSWCqvK1fCizQ_28_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">129000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_mqAB4C6dQEGjz1hV1r6KFQ_28_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">301000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_rgu3iJAFRESGVlPeM_u0jQ_29_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">304000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_rJVZ9ynZcEKDfzeRZbyEjw_29_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">887000</us-gaap:ProceedsFromStockPlans>
    <pasg:PaymentsForInsurancePremiumFinancing
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_BDDjjHNEjEyKv-Zwb1ealg_30_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1786000</pasg:PaymentsForInsurancePremiumFinancing>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_Jtpw2ib9AEiV6LvXF5PKpA_31_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-1353000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_X77nbYJafUmboBSFD04P0A_31_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">166656000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_pY0Kdqx320aedCbbRRTSSw_32_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-94364000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_gol8hjxs6UeSIuygmxJMAg_32_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-6037000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_jcD1a0m2rkCauTYG0B0ELQ_33_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">128965000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_62A9Ji97c0e2uu5ff0EtfA"
      decimals="-3"
      id="Tc_YNecIB_zAkGBCu5KzXx_QA_33_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">135002000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_hb9smLyYhUyPq16bSCb6lw_34_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">34601000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_NINg7Td4sUW8amcM8P5Qkw_34_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">128965000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_SGHPc_ofREeOEk6EhoIjow_36_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-553000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_8LXcnulEcEG82QLpx-pOXA_36_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-401000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <pasg:PropertyAndEquipmentInDeferredRent
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_yukRypLR8k2ZEZRn14uzXA_37_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">2769000</pasg:PropertyAndEquipmentInDeferredRent>
    <pasg:PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_yUEVg2wRxk-BP6QqFAPZcQ_38_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">114000</pasg:PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities>
    <pasg:PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_8s3llENqpkGw2VvBTn5Ccw_38_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">2143000</pasg:PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities>
    <pasg:VestingOfEarlyExerciseOptionAwards
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_-ObitvjlB0-N4Wp-S_9doA_39_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">45000</pasg:VestingOfEarlyExerciseOptionAwards>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_mQUYu3IZYUa_VnzKJV5Thg_40_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">20375000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <pasg:OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_ZpKy3aYX0EaG2LDT29DoaA_41_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">27296000</pasg:OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard>
    <us-gaap:NatureOfOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_U1u25cc8oUmpLmuzPktZXw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;1. Nature of Operations&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Passage Bio,&#160;Inc., or the Company, a Delaware corporation incorporated in July&#160;2017, is a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system, or CNS disorders, with limited or no approved treatment options. The Company has a strategic research collaboration with the Trustees of the University of Pennsylvania&#x2019;s, or Penn, Gene Therapy Program, or GTP. Under this collaboration, GTP conducts discovery and preclinical activities enabling Investigational New Drug, or IND, applications and the Company conducts all clinical development, manufacturing, regulatory strategy, and commercialization activities under the agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Through this collaboration, the Company has assembled a portfolio of genetic medicine product candidates, including two lead clinical product candidates: PBGM01 for the treatment of GM1 gangliosidosis, or GM1, and PBFT02 for the treatment of frontotemporal dementia, or FTD. The Company also has a collaboration agreement and a development services and clinical supply agreement with Catalent Maryland,&#160;Inc., or Catalent, for clinical scale manufacturing requirements.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <pasg:NumberOfLeadClinicalProductCandidate
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="INF"
      id="Narr_OhsuLSTrG0Kqzf433wx61g"
      unitRef="Unit_Standard_item_wlhC8WlTVEmcZqQ79zgOUA">2</pasg:NumberOfLeadClinicalProductCandidate>
    <pasg:RisksAndLiquidityTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_98T5PQzQ7E6tpblSKk9Jhw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;2. Risks and Liquidity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has incurred recurring losses and negative cash flows from operations since inception and had an accumulated deficit of $492.4 million as of December&#160;31, 2022. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of its product candidates currently in development. Substantial additional capital will be needed by the Company to fund its operations and to develop its product candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In January&#160;2021, the Company closed a follow-on public offering in which the Company issued and sold 8,050,000 shares of its common stock at a public offering price of $22.00 per share for net proceeds of $165.8 million&#160;after deducting underwriting discounts, commissions and other offering expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company&#x2019;s operations have consisted primarily of conducting preclinical studies, developing licensed technology,  conducting clinical trials and manufacturing clinical supply to support clinical trials. The Company faces risks associated with early-stage biotechnology companies whose product candidates are in development. Product candidates currently under development will require significant additional research and development efforts and establishing manufacturing capacity and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital for the Company to complete its research and development, achieve its research and development objectives, defend its intellectual property rights, and recruit and retain skilled personnel, and key members of management. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company plans to seek additional funding through public or private equity offerings, debt financings, other collaborations, strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#x2019;s stockholders. If the Company is unable to obtain funding or prospects of funding are unfavorable, the Company could be required to further delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In March 2022 and November 2022, the Company reduced its workforce and prioritized research and development programs to reduce operating expenses and to extend its cash runway.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In accordance with Accounting Standards Update, or ASU, No. 2014-15&lt;i style="font-style:italic;"&gt;, Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern&lt;/i&gt;, the Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;within one year after the date that the financial statements are issued. As of the issuance date of these financial statements, the Company expects that its cash, cash equivalents and marketable debt securities will be sufficient to fund its forecasted operating expenses and capital expenditure requirements for at least the next twelve months from the issuance date of these financial statements.&lt;/p&gt;</pasg:RisksAndLiquidityTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-5"
      id="Narr_9XnLlxWqfkq3bOOkn5F0Rw"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">-492400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_VKjaYfeOdEmdzPqOICqhlQ"
      decimals="INF"
      id="Narr_AvguchULykS1qWstKH09hg"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">8050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_XMou09J0cEirXcLwXtLPDg"
      decimals="INF"
      id="Narr_1ljSHZjiX0igplLr_oCC2A"
      unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">22.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_VKjaYfeOdEmdzPqOICqhlQ"
      decimals="-5"
      id="Narr_pQ9pyVN9k0OEFddlSt-1EQ"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">165800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_ta73gUbMwUmn0Wbo0MunWg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;3.&#160;Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates promulgated by the Financial Accounting Standards Board, or FASB. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;letter-spacing:0.3pt;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"&gt;&lt;span style="letter-spacing:0.3pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying financial statements in the period they are determined to be necessary.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of credit risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash, cash equivalents, and marketable securities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segment Information&lt;/span&gt; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly-liquid investments that have maturities of three&#160;months or less when acquired to be cash equivalents. Cash equivalents as of December&#160;31,&#160;2022 consisted of money market funds and commercial paper. Cash consists of cash deposits at banking institutions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Marketable securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company classifies its marketable securities as available-for-sale, which include commercial paper, certificates of deposit, corporate debt securities, and United States, or U.S., government debt securities with original maturities of greater than three&#160;months. These securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other comprehensive income (loss) within stockholders&#x2019; equity. Gains or losses on marketable securities sold are recognized as a component of other income, net in the statement of operations and comprehensive loss on the specific identification method. All marketable securities are available for use, as needed, to fund operations and therefore, the Company classifies all marketable securities as current assets within the balance sheet.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment, net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment consists of laboratory equipment, office equipment, computer hardware and software, furniture and leasehold improvements and are recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset by asset basis, which generally consists of three years for computer hardware and software, five years for office equipment, five years for laboratory equipment and seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. If circumstances require a long-lived asset to be tested for possible impairment, recoverability is measured by comparison of the carrying amount of the assets to estimated future undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset exceeds its estimated future cash flows, then impairment expense is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. For the years ended December 31, 2022, and 2021, no impairment expenses were recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Share-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures share-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company&#x2019;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or stock option awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company uses the Black-Scholes option pricing model to value its stock option awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Estimating the fair value of stock option awards requires the input of assumptions, including, the expected term of stock options and stock price volatility. The Company accounts for forfeitures for stock option awards as they occur. The assumptions used in estimating the fair value of share-based awards represent management's estimate and involve inherent uncertainties and the application of management's judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The expected term of the stock options is estimated using the "simplified method," as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;For stock price volatility, the Company uses a composite of comparable public company data as a basis for its expected volatility to calculate the fair value of option grants. The selection of comparable public company data requires the application of management&#x2019;s judgement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for forfeitures for stock option awards as they occur.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred and consist primarily of expenses incurred with Penn, contract research organizations, contract manufacturing organizations, internal analytical and testing activities, and employee-related expenses, including salaries, benefits, and share-based compensation. Management makes estimates of the Company&#x2019;s external accrued research and development expenses, which primarily relates to contract research organizations and contract manufacturing organizations, as of each balance sheet date in the Company&#x2019;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at that time. The Company determines the estimates by reviewing contracts, vendor agreements and change orders, and through discussions with our internal clinical personnel and external service providers as to the progress to completion of services and the agreed-upon fee to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Acquired In-Process Research and Development&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Fees paid to obtain research and development technology licenses are recognized as acquired in-process research and development expense if the research and development technology licensed has not reached technological feasibility and has no alternative future use. For the years ended December 31, 2022, and 2021, all fees paid to obtain technology licenses were recognized as acquired in-process research and development expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes are accounted for under the asset-and-liability method as required by FASB ASC Topic 740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt; (ASC 740). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. Under ASC 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;FASB ASC Subtopic 740-10, Accounting for Uncertainty of Income Taxes, (ASC 740-10) defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company&#x2019;s policy on statement of operations classification of interest and penalties related to income tax obligations is to include such items as part of total interest income, net.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss Per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:36.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,411,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,416,998&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,229,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 290,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee stock purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33,753&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,667,236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,741,251&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently Adopted Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;i style="font-style:italic;"&gt;Leases (Topic 842)&lt;/i&gt;, or ASU 2016-02, which requires a lessee to record a right-of-use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. The Company adopted ASU 2016-02 on January 1, 2022 using the modified retrospective transition method and elected the following transition practical expedients: (i) to not reassess lease identification, lease classification and initial indirect costs related to those leases entered into prior to the adoption of Topic 842; and (ii) to not separate lease and non-lease components for the Company&#x2019;s operating lease portfolio. The Company recorded an operating lease right-of-use asset and lease liability of $20.4 million and $27.3 million respectively, related to the adoption of the Topic 842. See note 9 for further details.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In June&#160;2016, the FASB issued ASU No.&#160;2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/i&gt;, or ASU 2016-13, which replaces the incurred loss impairment methodology under current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 was subsequently updated by ASU No.&#160;2019-04, &lt;i style="font-style:italic;"&gt;Codification Improvements to Topic 326, Financial Instruments&#x2014;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments&lt;/i&gt;, to clarify that entities should include recoveries when estimating the allowance for credit losses. This guidance is effective for the Company starting in fiscal year 2023. The Company does not expect that the adoption of ASU 2016-13 will have a material impact on its financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <pasg:BasisOfPresentationPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_fD5SItEXykeJAnxp8CsKkg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates promulgated by the Financial Accounting Standards Board, or FASB. &lt;/p&gt;</pasg:BasisOfPresentationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_-qmI60vS50qlL6W7YRchTA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;letter-spacing:0.3pt;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:12.5pt;margin:0pt;"&gt;&lt;span style="letter-spacing:0.3pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Estimates and assumptions are periodically reviewed and the effects of the revisions are reflected in the accompanying financial statements in the period they are determined to be necessary.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_wJAjO7L_M0aFYsw_D79LuA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Management believes that the carrying amounts of the Company&#x2019;s financial instruments, including cash equivalents, prepaid expenses, and accounts payable, approximate fair value due to the short-term nature of those instruments. &lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_ylzk2Hng7Em5w5yLx6kklA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of credit risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash, cash equivalents, and marketable securities.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <pasg:SegmentPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_morfPzgBTkiQBYbst2yfpQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;"&gt;Segment Information&lt;/span&gt; &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment.&lt;/p&gt;</pasg:SegmentPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="INF"
      id="Narr_c_iM5uf6yUS3gGyr9v_mYw"
      unitRef="Unit_Standard_segment_lMTtBbJKdUumSSlUVKw17A">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_MmZ-8UmVOUmbcsVamFcaew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly-liquid investments that have maturities of three&#160;months or less when acquired to be cash equivalents. Cash equivalents as of December&#160;31,&#160;2022 consisted of money market funds and commercial paper. Cash consists of cash deposits at banking institutions.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_32KxGYtDAEeMuvnUZbVSdg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Marketable securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company classifies its marketable securities as available-for-sale, which include commercial paper, certificates of deposit, corporate debt securities, and United States, or U.S., government debt securities with original maturities of greater than three&#160;months. These securities are carried at fair market value, with unrealized gains and losses reported in comprehensive loss and accumulated other comprehensive income (loss) within stockholders&#x2019; equity. Gains or losses on marketable securities sold are recognized as a component of other income, net in the statement of operations and comprehensive loss on the specific identification method. All marketable securities are available for use, as needed, to fund operations and therefore, the Company classifies all marketable securities as current assets within the balance sheet.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_7jzVn-XFfEKtWtN27mw4lw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment, net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment consists of laboratory equipment, office equipment, computer hardware and software, furniture and leasehold improvements and are recorded at cost. Maintenance and repairs that do not improve or extend the lives of the respective assets are expensed as incurred. Property and equipment are depreciated on a straight-line basis over their estimated useful lives. The Company estimates useful life on an asset by asset basis, which generally consists of three years for computer hardware and software, five years for office equipment, five years for laboratory equipment and seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviews long-lived assets, such as property and equipment, for impairment when events or changes in circumstances indicate the carrying amount of the assets may not be recoverable. If circumstances require a long-lived asset to be tested for possible impairment, recoverability is measured by comparison of the carrying amount of the assets to estimated future undiscounted cash flows that the assets are expected to generate. If the carrying amount of an asset exceeds its estimated future cash flows, then impairment expense is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the asset. For the years ended December 31, 2022, and 2021, no impairment expenses were recognized.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_c2lmnbj2xk-05fdWrtq5pA"
      id="Narr_Mbqdy00C40OyHwJPrZU6yw">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_oMHqSuMuOEyeN1Ln42FsEQ"
      id="Narr_5WJpsaV7jEKmVwCggG-cSw">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_LaboratoryEquipmentMember_BrSr9bR8aE62mOH4GDhAjQ"
      id="Narr_TUTF97CVkE6Y1M0QXBN99Q">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_CJboIsPRPU2JiJLp82d18Q"
      id="Narr_2NjPsTCIU0-wyDKhq6W2kw">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Narr_ZanLbkojKUe6z-1QAp5pTQ"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Narr_v1bF3y2dYE6O0h0nWtVyUg"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_n2Z8zHSMYkGxniV7twWn-A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Share-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures share-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company&#x2019;s share-based compensation consists of restricted stock units, or RSUs, and options to purchase common stock, or stock option awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company uses the Black-Scholes option pricing model to value its stock option awards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Estimating the fair value of stock option awards requires the input of assumptions, including, the expected term of stock options and stock price volatility. The Company accounts for forfeitures for stock option awards as they occur. The assumptions used in estimating the fair value of share-based awards represent management's estimate and involve inherent uncertainties and the application of management's judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The expected term of the stock options is estimated using the "simplified method," as the Company has limited historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;For stock price volatility, the Company uses a composite of comparable public company data as a basis for its expected volatility to calculate the fair value of option grants. The selection of comparable public company data requires the application of management&#x2019;s judgement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for forfeitures for stock option awards as they occur.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_kD9ZjBRoHkuGRwwlqm22nQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Research and development costs are expensed as incurred and consist primarily of expenses incurred with Penn, contract research organizations, contract manufacturing organizations, internal analytical and testing activities, and employee-related expenses, including salaries, benefits, and share-based compensation. Management makes estimates of the Company&#x2019;s external accrued research and development expenses, which primarily relates to contract research organizations and contract manufacturing organizations, as of each balance sheet date in the Company&#x2019;s financial statements based on an estimate of progress to completion of specific tasks using facts and circumstances known to the Company at that time. The Company determines the estimates by reviewing contracts, vendor agreements and change orders, and through discussions with our internal clinical personnel and external service providers as to the progress to completion of services and the agreed-upon fee to be paid for such services. If the actual timing of the performance of services or the level of effort varies from the estimate, the Company will adjust the accrual and related expenses accordingly. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:InProcessResearchAndDevelopmentPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_x7mdNRn74k6zxYkQ6OEB3Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Acquired In-Process Research and Development&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Fees paid to obtain research and development technology licenses are recognized as acquired in-process research and development expense if the research and development technology licensed has not reached technological feasibility and has no alternative future use. For the years ended December 31, 2022, and 2021, all fees paid to obtain technology licenses were recognized as acquired in-process research and development expense.&lt;/p&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_GMBudi1t6UqEZ_OMj9hsWg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes are accounted for under the asset-and-liability method as required by FASB ASC Topic 740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt; (ASC 740). Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period corresponding to the enactment date. Under ASC 740, a valuation allowance is required when it is more likely than not all or some portion of the deferred tax assets will not be realized through generating sufficient future taxable income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;FASB ASC Subtopic 740-10, Accounting for Uncertainty of Income Taxes, (ASC 740-10) defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC 740-10, the Company&#x2019;s policy on statement of operations classification of interest and penalties related to income tax obligations is to include such items as part of total interest income, net.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_Qsup5OwXfEe9NkC1tBliCA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss Per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as stock options, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:36.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,411,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,416,998&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,229,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 290,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee stock purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33,753&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,667,236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,741,251&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_e57BDM_QUEaJlGnUL32Q8Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:36.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,411,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,416,998&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Unvested restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,229,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 290,500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee stock purchase plan&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33,753&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,667,236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,741,251&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_LZ4JlGCAxUyPUIGpj_JLDQ"
      decimals="0"
      id="Tc_aytSNXWX7kCftzrM2PVYAw_3_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">11411390</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember_qOjzooIZXUyOJbcVJeTNvA"
      decimals="0"
      id="Tc_CeKuHjNIOEGGrrVRd4HcXA_3_4"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">9416998</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_pH7TkCz-oUyHvehAdIIrKA"
      decimals="0"
      id="Tc_YWPFrhL_gEK_1vwUc5uSMw_4_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">1229166</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_IwGipl1FgE6Gk4DlC1uLiw"
      decimals="0"
      id="Tc_iBnx5gSpc02AlYFiYVSvrg_4_4"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">290500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_zQffUCmMdE-_aOBnQ2S_vA"
      decimals="0"
      id="Tc_KTOtm09Ss0eMg8mr4o5G-A_5_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">26680</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockMember_LFuw3TMIekuZBYlTISw11g"
      decimals="0"
      id="Tc_V0qqje0I9UakCiLoBql2Wg_5_4"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">33753</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="0"
      id="Tc_b0gVByDShkahgdkuDD9BGw_6_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">12667236</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="0"
      id="Tc_Oq4qDl0zsU24W3mJn2EIkw_6_4"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">9741251</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_KD7LTCma_U2YKGcwdV4F5Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently Adopted Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;i style="font-style:italic;"&gt;Leases (Topic 842)&lt;/i&gt;, or ASU 2016-02, which requires a lessee to record a right-of-use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. The Company adopted ASU 2016-02 on January 1, 2022 using the modified retrospective transition method and elected the following transition practical expedients: (i) to not reassess lease identification, lease classification and initial indirect costs related to those leases entered into prior to the adoption of Topic 842; and (ii) to not separate lease and non-lease components for the Company&#x2019;s operating lease portfolio. The Company recorded an operating lease right-of-use asset and lease liability of $20.4 million and $27.3 million respectively, related to the adoption of the Topic 842. See note 9 for further details.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In June&#160;2016, the FASB issued ASU No.&#160;2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial Instruments&lt;/i&gt;, or ASU 2016-13, which replaces the incurred loss impairment methodology under current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 was subsequently updated by ASU No.&#160;2019-04, &lt;i style="font-style:italic;"&gt;Codification Improvements to Topic 326, Financial Instruments&#x2014;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments&lt;/i&gt;, to clarify that entities should include recoveries when estimating the allowance for credit losses. This guidance is effective for the Company starting in fiscal year 2023. The Company does not expect that the adoption of ASU 2016-13 will have a material impact on its financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_7zow5ahakk-p3Zr2YBVVfQ"
      decimals="-5"
      id="Narr_xvhPYp-37ECvxaxTDXLx6Q"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">20400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_7zow5ahakk-p3Zr2YBVVfQ"
      decimals="-5"
      id="Narr_QJctGMnvWUG2kULLxhDjmg"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">27300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_mIv3l6maP0OclDp8N2HPpQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;4.&#160;Cash, cash equivalents and marketable securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides details regarding the Company&#x2019;s portfolio of cash and cash equivalents:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost or&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Cash accounts in banking institutions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,532&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,532&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,578&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,578&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,491&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,491&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,601&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Cash accounts in banking institutions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,549&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,416&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 128,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 128,965&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table provides details regarding the Company&#x2019;s portfolio of marketable securities:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.72120285%;padding-left:0pt;padding-right:0pt;width:101.44%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,197&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (92)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,111&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 58,572&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (72)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 58,512&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 67,206&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (786)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 66,421&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (35)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,965&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 155,975&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (985)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 155,009&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,296&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,503&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,503&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 145,577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (418)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 145,169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,996&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,988&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Non-U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,849&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,852&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 187,221&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (431)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 186,808&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"&gt;S&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The contractual maturities of our marketable securities as of December&#160;31,&#160;2022, are as follows:&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Due within one year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 144,583&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 143,779&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Due after one year through five years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,392&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,230&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 155,975&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 155,009&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_NybnG4rtg0WByutnnM3CAQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost or&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Cash accounts in banking institutions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,532&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,532&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,578&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,578&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,491&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,491&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 34,601&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Cash accounts in banking institutions&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,549&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,416&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.02%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 128,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 128,965&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_BcQOcPP9S029dfsVqpuUWQ"
      decimals="-3"
      id="Tc_j1S7DEKQ5UCQYSLiMB28Kg_4_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">7532000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_BcQOcPP9S029dfsVqpuUWQ"
      decimals="-3"
      id="Tc_x_XjrmXGlUmUTaphmAvokQ_4_12"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">7532000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember__Gr_-HqIS0e2m0hxthuJSA"
      decimals="-3"
      id="Tc_MZ8s_4vtJEiwDoF7B3Ci7Q_5_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">24578000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember__Gr_-HqIS0e2m0hxthuJSA"
      decimals="-3"
      id="Tc_M1cgavEpRUO-eLtBXMB_Cw_5_12"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">24578000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_hKzkHH1vOE64CgLe9E8cBg"
      decimals="-3"
      id="Tc_g8zELqeh20-h6pShLL3jnA_6_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">2491000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_hKzkHH1vOE64CgLe9E8cBg"
      decimals="-3"
      id="Tc_K9TEgG2ON0qVpRBjcBlLpw_6_12"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">2491000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_MtJnt5H_6kuKXyIb4Ib9PQ_7_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">34601000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_8jp9xSvYLUWnUV4sgRTn-A_7_12"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">34601000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_EX8q_EtFJkmb7GR4fiSkgA"
      decimals="-3"
      id="Tc_z8e3aEERN0uXggFVZ9tx3w_10_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">44549000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_DemandDepositsMember_EX8q_EtFJkmb7GR4fiSkgA"
      decimals="-3"
      id="Tc_f9XgmqzDM0WzR--Vh-obJg_10_12"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">44549000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_9DDLbzIViEiYZ2wdZ2ebDw"
      decimals="-3"
      id="Tc_y8dzZfqws02CVojW39r8aA_11_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">84416000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_9DDLbzIViEiYZ2wdZ2ebDw"
      decimals="-3"
      id="Tc_Lkwth17FYEi5a9VCS_5gdw_11_12"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">84416000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_iR73GAoxekCGSLQhCtDvgA_13_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">128965000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_dv1X8PnAVkKltqp2vQVQCg_13_12"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">128965000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_wiTq37h5eUajusVvIauYPw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.72120285%;padding-left:0pt;padding-right:0pt;width:101.44%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized gains&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized losses&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,197&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (92)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,111&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 58,572&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (72)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 58,512&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 67,206&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (786)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 66,421&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (35)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,965&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 155,975&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (985)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 155,009&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,296&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,503&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,503&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 145,577&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (418)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 145,169&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,996&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,988&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;"&gt;Non-U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,849&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,852&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 187,221&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (431)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 186,808&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_EKMTAzZhuUyVq0LA3FdSVQ"
      decimals="-3"
      id="Tc_f5ApiKLXCkS589lm4NO1Mw_3_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">28197000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_EKMTAzZhuUyVq0LA3FdSVQ"
      decimals="-3"
      id="Tc_n84NtLyz6U-CIeZFdCoR9Q_3_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_EKMTAzZhuUyVq0LA3FdSVQ"
      decimals="-3"
      id="Tc_ejs2Te4LK0y14bINq7-sRQ_3_9"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">92000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_EKMTAzZhuUyVq0LA3FdSVQ"
      decimals="-3"
      id="Tc_NEBJ9QBQ-0i8AVvMlvYTUg_3_12"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">28111000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_zS-Tm2J2FUOYlB6qItnUOQ"
      decimals="-3"
      id="Tc_UbDAllr-VEyjye3_ccVpJw_4_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">58572000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_zS-Tm2J2FUOYlB6qItnUOQ"
      decimals="-3"
      id="Tc_B9kpDVdUV02HId1YgWP9VA_4_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_zS-Tm2J2FUOYlB6qItnUOQ"
      decimals="-3"
      id="Tc_uZGv75UHYUK3Ue2gpdT68w_4_9"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">72000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_zS-Tm2J2FUOYlB6qItnUOQ"
      decimals="-3"
      id="Tc_yMzLz0DOJUmXFflcGhdn8Q_4_12"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">58512000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_oE0pMTTA8kyy9iM_moGuCg"
      decimals="-3"
      id="Tc_PCAiKSvq1UO_cE66jb4Xng_5_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">67206000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_oE0pMTTA8kyy9iM_moGuCg"
      decimals="-3"
      id="Tc_Lw-YSHq2KUuYAe8-EgKY_w_5_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_oE0pMTTA8kyy9iM_moGuCg"
      decimals="-3"
      id="Tc_XHUEVZEgdk2mFEMJy8pCiw_5_9"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">786000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_oE0pMTTA8kyy9iM_moGuCg"
      decimals="-3"
      id="Tc_FpPUkZCAN0OceqTHMFjv9w_5_12"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">66421000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_RLg8-oaulEugO9P5aol4lg"
      decimals="-3"
      id="Tc_OgVG0WhGj0yz06X0q2INSg_6_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">2000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_RLg8-oaulEugO9P5aol4lg"
      decimals="-3"
      id="Tc__cRyAvslW0S1Sfy3GlHgnA_6_9"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">35000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_RLg8-oaulEugO9P5aol4lg"
      decimals="-3"
      id="Tc_Kf-GWWYjtkyIja4B6BPpeA_6_12"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1965000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_0QQsonojWUOVVQqtdZakfQ_7_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">155975000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_VTarH4hhzUWvFmwuR1Hmuw_7_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_BC7Xmlb1BUOuAAOCyMfhoA_7_9"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">985000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_WlA-AHpVxUu0erZxemC3wA_7_12"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">155009000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_tfIA7SpRCEeYVQ2vDETw2g"
      decimals="-3"
      id="Tc_W9enkDyaNEWg-EprXaaosg_10_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">5296000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_tfIA7SpRCEeYVQ2vDETw2g"
      decimals="-3"
      id="Tc_AKoobUylWEy5uymWzHa69A_10_12"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">5296000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ddNrvr493EuYOz1vw-xceg"
      decimals="-3"
      id="Tc_Sj0ja5jS3Eui5BQBG7iJ-A_11_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">26503000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ddNrvr493EuYOz1vw-xceg"
      decimals="-3"
      id="Tc_CyCAbCbL0UWgWPFAOvL44A_11_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ddNrvr493EuYOz1vw-xceg"
      decimals="-3"
      id="Tc_8SjOmzQba0qzu68XzBzUVQ_11_9"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_ddNrvr493EuYOz1vw-xceg"
      decimals="-3"
      id="Tc_7v9VbWbGakK_efoGuAM5_g_11_12"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">26503000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_X6XgFKAqdUq2v933qg7wzw"
      decimals="-3"
      id="Tc_MjKrOGwMj0CPkdAhmOPyaw_12_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">145577000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_X6XgFKAqdUq2v933qg7wzw"
      decimals="-3"
      id="Tc_ztvGhmmmeUWCWjXnD1yrSQ_12_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_X6XgFKAqdUq2v933qg7wzw"
      decimals="-3"
      id="Tc_-uPDoyP3w0ilhJE_ZdraUw_12_9"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">418000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_X6XgFKAqdUq2v933qg7wzw"
      decimals="-3"
      id="Tc_JEgPGRJhLk2L_Nn95pSKeA_12_12"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">145169000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember__szE3cOXwEaiDH4szkcG3A"
      decimals="-3"
      id="Tc__3dXEAezK0msy-qVgejpwg_13_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1996000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember__szE3cOXwEaiDH4szkcG3A"
      decimals="-3"
      id="Tc_lnhIXn--skCNrR37mPAZIg_13_9"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember__szE3cOXwEaiDH4szkcG3A"
      decimals="-3"
      id="Tc_Fvz6JpFnREuo_d-d7eyFBw_13_12"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1988000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_mPnRzJMdn0WpI85X-EalUg"
      decimals="-3"
      id="Tc_mLxw9KmRb0W4qhZpAluzIg_14_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">7849000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_mPnRzJMdn0WpI85X-EalUg"
      decimals="-3"
      id="Tc_q2dyb9t85065YHWtTw94oA_14_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_mPnRzJMdn0WpI85X-EalUg"
      decimals="-3"
      id="Tc_NOPoraitbUaZSje-YPUgag_14_9"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_mPnRzJMdn0WpI85X-EalUg"
      decimals="-3"
      id="Tc_NGy59yYsb0KpnrvDKyWHpQ_14_12"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">7852000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_Bvsu1y5lsEa22O9-t46wBQ_15_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">187221000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_0mryIhWpRE61FYTxXbjeJQ_15_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_K018q8VZ_Uy37BuF8odH5A_15_9"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">431000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_ATVft1Iy00SlTKnL8xYgzQ_15_12"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">186808000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_6uA5CPm8wkWKmaipgliggQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:20.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Due within one year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 144,583&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:20.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 143,779&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Due after one year through five years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:19.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,392&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:20.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,230&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:19.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 155,975&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 155,009&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_QOxh7SHx706e05C5Kk6DWA_2_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">144583000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_B4CqORyxn0abHMeiz-MI5A_2_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">143779000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_nfqRO73sukC47pO5ipHjDg_3_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">11392000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_hhccZZEwa0yQnwZbNzR-TA_3_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">11230000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_dhL9Pw-_PkOQkErtxxcS0Q_4_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">155975000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_Zr2DQSYybUSnLVl2tB5sKQ_4_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">155009000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_LgSmn0pbcEOpnf3jW_Ofxg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;5.&#160;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Fair value is the price that could be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Fair value determination in accordance with applicable accounting guidance requires that a number of significant judgments be made. Additionally, fair value is used on a nonrecurring basis to evaluate assets for impairment or as required for disclosure purposes by applicable accounting guidance on disclosures about fair value of financial instruments. Depending on the nature of the assets and liabilities, various valuation techniques and assumptions are used when estimating fair value. The carrying amounts of certain of the Company&#x2019;s financial instruments, including prepaid expense and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. The Company follows the provisions of FASB ASC Topic 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt;, for financial assets and liabilities measured on a recurring basis. The guidance requires fair value measurements be classified and disclosed in one of the following three categories:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:31.5pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level 1: &lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:31.5pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level 2: &lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:31.5pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:13.5pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level 3: &lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following fair value hierarchy table presents information about the Company&#x2019;s assets measured at fair value on a recurring basis. Included within cash and cash equivalents on the balance sheet, but excluded from the fair value hierarchy table, are cash deposits held at financial institutions:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value measurement at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;reporting date using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;markets for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,578&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,491&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,578&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,491&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 58,512&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 66,421&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 155,009&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,578&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 157,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,503&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 145,169&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,988&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Non-U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,852&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 186,808&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 186,808&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_iUaF-uwpHEypyhFaJ6oGDA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair value measurement at&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:35.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;reporting date using&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted prices&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;in active&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;markets for&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;other&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;identical&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level&#160;3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,578&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,491&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,578&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,491&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,111&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 58,512&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 66,421&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 155,009&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 24,578&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 157,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b style="font-weight:bold;"&gt;Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total cash equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Certificates of deposit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,296&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Commercial paper&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,503&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 145,169&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,988&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"&gt;Non-U.S. government securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,852&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total marketable securities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 186,808&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total financial assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 84,416&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 186,808&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ycWO8dyX_kC6uG93WKsSqA"
      decimals="-3"
      id="Tc_eDSu8yUnvk-nu3-5o6uXuQ_12_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">24578000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CommercialPaperMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_KknMkl4yeUm7mwrKVSBAMQ"
      decimals="-3"
      id="Tc_46K-I3OYckqrtl8Ao0uS5w_13_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">2491000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qnM-OR-gAECiFX_LbmMPfQ"
      decimals="-3"
      id="Tc_tTi6iSCJhUierBogPd2W8w_14_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">24578000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_m3qLi4_cEU60Ts_xTIoBAA"
      decimals="-3"
      id="Tc_1c9c51HbnkWMxPpjMcsN-w_14_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">2491000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_8rQIwJjX7U-HUdBs0mHPHQ"
      decimals="-3"
      id="Tc_R5lgOQwEyUiZOq6A3SO5YA_17_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">28111000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_xNnhYs_8xE25HkrTLSUCDg"
      decimals="-3"
      id="Tc_V1dkllVHzkeauuJh53aa8g_18_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">58512000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_nzjfVFDIVUWSs3XTC4bDsA"
      decimals="-3"
      id="Tc_272w1uFGS0CtUd-jX-7roA_19_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">66421000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_nU963VORek-l98BVpjXc2Q"
      decimals="-3"
      id="Tc_LCZu8JetN0ijvTY0zSc6iQ_20_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1965000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_m3qLi4_cEU60Ts_xTIoBAA"
      decimals="-3"
      id="Tc_IYeIkFuLZ0W0IzYS6hRRAg_21_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">155009000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qnM-OR-gAECiFX_LbmMPfQ"
      decimals="-3"
      id="Tc_31LPwCJlX0e4KyMuBOGuvA_23_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">24578000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_m3qLi4_cEU60Ts_xTIoBAA"
      decimals="-3"
      id="Tc_ZryHmRaRYU66FbJJLlQ-Sw_23_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">157500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_PZny6jRjkUiFZ51MD_j8yw"
      decimals="-3"
      id="Tc_1s_6vCMbwkqjICQc1hzUZQ_28_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">84416000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_C-o2Zgq5lkazNtHRBvQ8_Q"
      decimals="-3"
      id="Tc_DVI3_UVK6063lRiLGbvpzA_30_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">84416000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember_UcKqbx4Po0Ou91dnkxKM6Q"
      decimals="-3"
      id="Tc_RGCU4sMm7k6cF2BvGlPSng_33_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">5296000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember_bskf0Lik9k62JRNH0Ahm_w"
      decimals="-3"
      id="Tc_t6XO8GkLR02rlu-d5-EZ0g_34_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">26503000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_SOu6oV8f4Uqc6G1TRruyZA"
      decimals="-3"
      id="Tc_TrJNhvLVRkywL3Dgb5X6iQ_35_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">145169000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentDebtSecuritiesMember_U1C9pEJYU0mSIYjsXdwWXA"
      decimals="-3"
      id="Tc_u2Qqvhnj5UC-zOF6iqznAg_36_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1988000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember_GIzjQ4m1DEOd0Y5zdqwlEA"
      decimals="-3"
      id="Tc_HRl_l1f8dkm9IVh6KzTNIQ_37_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">7852000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_btpJFa9_VkSBS3ixhn_iWw"
      decimals="-3"
      id="Tc_CzfrLgJVAEOkApuO1iNpgQ_38_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">186808000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_C-o2Zgq5lkazNtHRBvQ8_Q"
      decimals="-3"
      id="Tc_CwoIpAHBnk2uE6Xz7LANAw_40_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">84416000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_btpJFa9_VkSBS3ixhn_iWw"
      decimals="-3"
      id="Tc_JttsclLO70SL4U3Zw9bGhA_40_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">186808000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_H5VwR4SJZEetSkMMxfipSA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;6. Property and Equipment, net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment, net, consist of the following: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:101.08%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,972&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,916&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 621&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer hardware and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,208&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,487&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,409&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,291&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 822&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,668&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,283&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,153)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,477)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,515&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,806&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Depreciation expense was $3.7 million and $1.5 million for the years ended December 31, 2022 and 2021, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <pasg:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_iPoshBSLa0-S1o7FGZFjVA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:101.08%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.19%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,972&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,916&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 601&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 621&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer hardware and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,090&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,028&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,208&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.19%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,487&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,506&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,409&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,291&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 822&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total property and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,668&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.19%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,283&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:53.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,153)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,477)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:53.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:18.72%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,515&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,806&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</pasg:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_LaboratoryEquipmentMember_VlmbuSYC6USj3OTDddchPQ"
      decimals="-3"
      id="Tc_LkIoyMQOhECC3W3-gAMFfA_2_2"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">9972000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_LaboratoryEquipmentMember_15fk6eyMukOdrAYC2-ThJg"
      decimals="-3"
      id="Tc_Do0af7RS5EWzMgOJQE4DIA_2_5"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">8916000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_2Hsg8LNvXEucBUm5ld8Thw"
      decimals="-3"
      id="Tc_uBDYQFRN-UyNmIdLCl6m8A_3_2"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">601000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_OVQG01q9_Eid2wbn4B4PpQ"
      decimals="-3"
      id="Tc_oxgt5YuQcky5e_QPu4CI8Q_3_5"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">621000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_ComputerHardwareAndSoftwareMember_JzsV16LRG0WCbPoDdOU4QA"
      decimals="-3"
      id="Tc_8eurQUJ5rUGxZxvMjUvL8A_4_2"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1090000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_ComputerHardwareAndSoftwareMember_kCoolnyGaUy4-vQysBpBNw"
      decimals="-3"
      id="Tc_QyC9gmG2JkGOgifbIdRTFg_4_5"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1028000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_bJ5zjvxB5EGnQcqTp7xFSg"
      decimals="-3"
      id="Tc_TL4JzvAHTkyKbsaTnzLQ2Q_5_2"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1208000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_yGDjvEYReEuRzXheeim-wQ"
      decimals="-3"
      id="Tc_8Z6XTGU_90aP_LHwiZy-0w_5_5"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1487000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_618eVrMiP0KqpawEGChP-A"
      decimals="-3"
      id="Tc_3sIJSGqYtU2QdGPe-UgahA_6_2"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">13506000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdsAndLeaseholdImprovementsMember_wweEz0CjaU-LuKc41hE1fg"
      decimals="-3"
      id="Tc_eTtrlHjCpkmXa3qjrO-xow_6_5"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">13409000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_Wqhrge7I_kKR4RChMkdtEQ"
      decimals="-3"
      id="Tc_St74M15f906lixs__H6IDg_7_2"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1291000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_S84Lz4H_jE-dgwqZQM7UOA"
      decimals="-3"
      id="Tc_oyWUL7pDQkOFRLHuTQue0w_7_5"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">822000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_l4hR0prNkEWbRtdyEKBlig_8_2"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">27668000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_dMO6Te7Nlk68PW3N5bKfaQ_8_5"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">26283000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_dNNdvqDAgEaix3CB5dNM3Q_9_2"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">5153000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_AHST5i2wiE6RlaoPbPOEzw_9_5"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">2477000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_2whFKk2R30WLlb6MqoJYow_10_2"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">22515000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_ZUWJfVtFxEmd6j1-XbcbkQ_10_5"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">23806000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-5"
      id="Narr_tV8hzmBa-kiOpWPJyTYV6w"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">3700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-5"
      id="Narr_ZIGQQrkb0EOpTi-CtdBejw"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1500000</us-gaap:DepreciationDepletionAndAmortization>
    <pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_GFFe2Tu5Uk6bIdA2CY0Jfg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;7.&#160;Accrued Expenses and Other Current Liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5409012%;padding-left:0pt;padding-right:0pt;width:101.08%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 602&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 877&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Compensation and related benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,446&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,878&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,498&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 161&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,011&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,050&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock>
    <pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_i-PYfKwuX0KYtfhAT31HSQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.5409012%;padding-left:0pt;padding-right:0pt;width:101.08%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Professional fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 602&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 877&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Compensation and related benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,446&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,014&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,878&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,498&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Property and equipment &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 85&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 161&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 500&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:57.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,011&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 20,050&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_XMgUOhzDQEuvYYM8ByuPKw_2_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">602000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_PHzQa-XX3EeDkHEjIJ5B7g_2_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">877000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_xh4tAa4HKUG5QhFIIljhQw_3_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">8446000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_8g-epVlfBkCN1MdCMglthw_3_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">10014000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <pasg:AccruedResearchAndDevelopmentExpense
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_fvkXn0BM2ESaYPhlgzVToQ_4_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1878000</pasg:AccruedResearchAndDevelopmentExpense>
    <pasg:AccruedResearchAndDevelopmentExpense
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_npvwdHZzXUSOfnQdh-4ZGQ_4_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">8498000</pasg:AccruedResearchAndDevelopmentExpense>
    <pasg:AccruedLiabilitiesPropertyAndEquipmentCurrent
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_B3246E0feEOynBBthLJfeA_5_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">85000</pasg:AccruedLiabilitiesPropertyAndEquipmentCurrent>
    <pasg:AccruedLiabilitiesPropertyAndEquipmentCurrent
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_CCvY-BpGq0-VwB6zFeHXPQ_5_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">161000</pasg:AccruedLiabilitiesPropertyAndEquipmentCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_62z7ldT1x0-3rQ7OqH3DLg_6_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">500000</us-gaap:OtherLiabilitiesCurrent>
    <pasg:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_2mrd6B2cGkyrUvFKH4jBfQ_7_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">11011000</pasg:AccruedExpensesAndOtherCurrentLiabilities>
    <pasg:AccruedExpensesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_HyTZjnNsB0WXnBDyWvRVAA_7_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">20050000</pasg:AccruedExpensesAndOtherCurrentLiabilities>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_I8l8WvPvkU24jIpMLf85SQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8. Severance &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In March 2022 and November 2022, the Company announced workforce reductions and that it has prioritized certain research and development programs to reduce operating expenses and to extend its cash runway. &lt;span style="background:#ffffff;"&gt;In connection with these announcements, the Company reduced headcount by approximately&#160;&lt;/span&gt;13% and 23% in March 2022 and November 2022, respectively. &lt;span style="background:#ffffff;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In&#160;accordance with ASC 420,&lt;i style="font-style:italic;"&gt;&#160;Exit and Disposal Activities,&lt;/i&gt;&#160;the Company recorded severance and termination-related costs of $3.8 million in general and administrative expenses and $2.3 million in research and development expenses for the year ended December 31, 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, $2.1 million of severance and termination-related costs were unpaid and recognized in the balance sheet within Accrued expenses and other current liabilities.&lt;/p&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <pasg:PercentReductionToOurWorkforce
      contextRef="As_Of_3_31_2022_NhtNZVP74Ei9hd55TAwTew"
      decimals="2"
      id="Narr_AqJfC837TEqYrhjTEONmoQ"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.13</pasg:PercentReductionToOurWorkforce>
    <pasg:PercentReductionToOurWorkforce
      contextRef="As_Of_11_30_2022_mVsYEdTSSEuJbQ89GBbHMg"
      decimals="2"
      id="Narr_nNazXiUaokqIKJBMaC-I8A"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.23</pasg:PercentReductionToOurWorkforce>
    <us-gaap:SeveranceCosts1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_rKbIo3RACkur9OAM8iqIbA"
      decimals="-5"
      id="Narr_KisDaDMivES6uxyjBoO9CQ"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">3800000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_fzK4cBH8fkuhwpQHwW1AZA"
      decimals="-5"
      id="Narr_Zfb4cYvwqEi3Bw8f7MhT_A"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">2300000</us-gaap:SeveranceCosts1>
    <us-gaap:RestructuringReserveCurrent
      contextRef="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_pasg_AccruedExpensesAndOtherCurrentLiabilitiesMember_GPYjhSt04kqGmR--V5LGEg"
      decimals="-5"
      id="Narr_gETmUQHnlk6WiltVVlzF0g"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">2100000</us-gaap:RestructuringReserveCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_Wtcup82kPkqjbg-zc2CZeg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;9. Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;On January 1, 2022, the Company adopted ASU No. 2016-02, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;, using a modified retrospective approach and recorded operating lease right-of-use, or ROU, assets and operating lease liabilities of $20.4 million and $27.3 million, respectively, related to the Company&#x2019;s Lease Agreement and Laboratory Lease Agreement, or collectively, the Leases, which are each defined below. The Company elected the package of practical expedients available under ASU No. 2016-&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;02 and as such, did not reassess any of the Company&#x2019;s existing or expired contracts or any other agreements that were previously concluded to not contain a lease for the following practical expedient guidance: (1) whether the arrangement is or contains a lease, (2) lease classification and (3) whether previously capitalized costs continue to qualify as initial direct costs. In addition, the Company applied the accounting policy election to not separate lease and non-lease components and the accounting policy election to not apply the recognition requirement under ASU No. 2016-02 to leases with a term of twelve months or less.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company was not required to record a cumulative effect adjustment upon adoption as the Company did not capitalize any material initial direct costs nor were any contracts reassessed leading to changes in the terms or contractual payments of historical arrangements that would impact expense recognition, however, the Company eliminated $3.2 million of deferred rent liabilities and $3.8 million of tenant improvement allowances as of January 1, 2022 related to the Leases as these liabilities are reflected in the operating lease ROU assets. The Company used incremental borrowing rates, or IBRs, of 9.0% and 10.0% to discount the operating lease liabilities for the Lease Agreement and the Laboratory Lease Agreement, respectively. The Company&#x2019;s IBRs were quoted by an unrelated third-party lender and reflect a collateralized borrowing with similar terms and amounts as the Leases. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is party to a lease agreement for office space, or the Lease Agreement, in Philadelphia, Pennsylvania. The Lease Agreement commenced in February 2021 and is expected to expire in December 2031. The Company has an option to extend the term of the Lease Agreement by up to two five-year terms. This option to extend was not recognized as part of the Company's measurement of the ROU asset and operating lease liability as of December&#160;31,&#160;2022. The landlord provided the Company with a tenant improvement allowance of $2.8 million, for which the related expenditures were paid directly by the landlord.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company is also party to a lease agreement for laboratory space, or the Laboratory Lease Agreement, in Hopewell, New Jersey. The laboratory is initially focused on state-of-the-art analytical capabilities, assay development and validation, and clinical product testing to support both viral vector manufacturing and clinical development. The Laboratory Lease Agreement commenced in March 2021 and is expected to expire in February 2036. The Company has an option to extend the term of the Laboratory Lease Agreement by up to two five-year terms. This option to extend was not recognized as part of the Company's measurement of the ROU asset and operating lease liability as of December&#160;31,&#160;2022. The landlord provided the Company with a tenant improvement allowance of $1.3 million in connection with the Laboratory Lease Agreement, for which the related expenditures were paid by the Company and will be reimbursed by the landlord. As of December&#160;31,&#160;2022, $0.1 million of reimbursements were unpaid by the landlord and recorded within other current assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the Company&#x2019;s operating leases:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:65.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:24.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;($ in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,316&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement of operating cash flows from operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:24.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,853&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;9.7%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average remaining lease term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:24.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;12.2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes future minimum lease payments under the Company&#x2019;s operating lease agreements:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,455&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,553&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,654&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,757&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,864&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,679&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,962&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (20,855)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,107&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_7zow5ahakk-p3Zr2YBVVfQ"
      decimals="-5"
      id="Narr_d_RHFoWfME-d8ZXcT0_jHQ"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">20400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_1_1_2022_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_7zow5ahakk-p3Zr2YBVVfQ"
      decimals="-5"
      id="Narr_ok3sEn6xzUa5hp4JGVHTDg"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">27300000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DeferredRentCreditNoncurrent
      contextRef="As_Of_1_1_2022_1hJs1cU8B0yEBX43Mau-lg"
      decimals="-5"
      id="Narr_b8OFlYMMxkefmhT1raInnQ"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">3200000</us-gaap:DeferredRentCreditNoncurrent>
    <pasg:TenantImprovementAllowancesLiability
      contextRef="As_Of_1_1_2022_1hJs1cU8B0yEBX43Mau-lg"
      decimals="-5"
      id="Narr_b1w_xlW-ykqQG_SrytZ_SA"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">3800000</pasg:TenantImprovementAllowancesLiability>
    <pasg:LesseeOperatingLeaseIncrementalBorrowingRatePercentage
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForOfficeSpaceMember_Y66Drnyc1kO-defDYISTag"
      decimals="3"
      id="Narr_xL2yH2wVa0iHo9ccDJ7pWw"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.090</pasg:LesseeOperatingLeaseIncrementalBorrowingRatePercentage>
    <pasg:LesseeOperatingLeaseIncrementalBorrowingRatePercentage
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForLaboratorySpaceMember_olTE_Yzm10uPm2K7m0faAg"
      decimals="3"
      id="Narr_KBAhqGKweEiexf-WLTDWkQ"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.100</pasg:LesseeOperatingLeaseIncrementalBorrowingRatePercentage>
    <pasg:NewLeaseAgreementOperatingLeaseNumberOfExtensions
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForOfficeSpaceMember_ZrafZiQhmUuODBwDYCS8rQ"
      decimals="INF"
      id="Narr_7_zH39opJ0WtvlgZkgf1Eg"
      unitRef="Unit_Standard_item_wlhC8WlTVEmcZqQ79zgOUA">2</pasg:NewLeaseAgreementOperatingLeaseNumberOfExtensions>
    <pasg:NewLeaseAgreementOperatingLeaseRenewalTerm
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForOfficeSpaceMember_PnKu318m2kKf0m31ftbUUQ"
      id="Narr_D3sX_VUaKkSc8u5e3jiYwQ">P5Y</pasg:NewLeaseAgreementOperatingLeaseRenewalTerm>
    <pasg:TenantImprovementAllowanceReceivable
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForOfficeSpaceMember_ZrafZiQhmUuODBwDYCS8rQ"
      decimals="-5"
      id="Narr_d_cubb5Xr0yJkcEKQud8cw"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">2800000</pasg:TenantImprovementAllowanceReceivable>
    <pasg:NewLeaseAgreementOperatingLeaseNumberOfExtensions
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForOfficeSpaceMember_ZrafZiQhmUuODBwDYCS8rQ"
      decimals="INF"
      id="Narr_Uiv-1vR5aEi7Gu8WXtGZiw"
      unitRef="Unit_Standard_item_wlhC8WlTVEmcZqQ79zgOUA">2</pasg:NewLeaseAgreementOperatingLeaseNumberOfExtensions>
    <pasg:NewLeaseAgreementOperatingLeaseRenewalTerm
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForOfficeSpaceMember_PnKu318m2kKf0m31ftbUUQ"
      id="Narr_iBbCNnvgzUK7Nq8di5bShA">P5Y</pasg:NewLeaseAgreementOperatingLeaseRenewalTerm>
    <pasg:TenantImprovementAllowanceReceivable
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_pasg_OperatingLeasesForLaboratorySpaceMember_m3JiXizoFEGM-jTR8nDJpA"
      decimals="-5"
      id="Narr_n31UX1_bC02UyVGwxkiXVA"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1300000</pasg:TenantImprovementAllowanceReceivable>
    <us-gaap:TenantImprovements
      contextRef="As_Of_12_31_2022_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_d5OcH9P0YU6Mqog4XpwvoA"
      decimals="-5"
      id="Narr_Pr_qyl7XAk2jCQvEwFGZPA"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">100000</us-gaap:TenantImprovements>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_R6fYZkeoeUadv-Iveokqjg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:65.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:24.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;($ in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:29.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,316&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement of operating cash flows from operating leases&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:24.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,853&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;9.7%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average remaining lease term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:24.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;12.2&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_W56INVoRIkOOcjDEFs1ilw_3_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">3316000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_OyEY4lkKVEq4NF1tcSAI0Q_4_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">2853000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="3"
      id="Tc_kSXqbHpuVUS5IH9evC5z9A_5_3"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.097</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      id="Tc_1MNgGBP2K0GzSrl_iv30gw_6_3">P12Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Group_06Xd6Q3vcEafb_zt3okNdA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,455&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,553&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,654&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,757&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,864&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 29,679&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total undiscounted lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 47,962&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (20,855)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:65.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:24.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,107&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_AP1F5YgQFE2J5LTrK4rq0w_2_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">3455000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_E3bEK__Y90q5d2zKFhxMiw_3_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">3553000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_m-ZjksSYA0-qZDPt4Ey7aA_4_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">3654000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_xEQ0IEnxyEumx9-eg3P7zg_5_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">3757000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_z8L5-_W21k-fQFKxP6qjhA_6_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">3864000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_TVU4oZkbKUGAvKYtkBkxVw_7_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">29679000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_nH4HfXpNz0uVE0efGd0ETw_8_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">47962000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_pxHT7HfLQU2isiIKlL9YyA_9_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">20855000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_yQZQcj-aJU2YAcH9917idg_10_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">27107000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_BMTiodvaZkyr0EfkBcYzPA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;10.&#160;Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Amended and Restated Research, Collaboration and License Arrangement with Penn&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;The Company has a research, collaboration and licensing agreement with Penn, as amended, or the Penn Agreement, for research and development collaborations and exclusive license rights to patents for certain products and technologies. Under the Penn Agreement, the Company has obligations to fund certain research relating to the preclinical development of selected products&lt;/span&gt; &lt;span style="font-weight:normal;"&gt;in research programs as well as the exploratory research program in non-rare and/or non-monogenic, or large CNS indications, currently TLE. In addition, the Company will fund discovery research conducted by Penn through August 3, 2026 and will receive exclusive rights, subject to certain limitations, to technologies resulting from the discovery research for the Company&#x2019;s products developed with GTP, such as novel capsids, toxicity reduction technologies and delivery and formulation improvements. This funding commitment for the discovery research is &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$5.0&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; million annually, paid in quarterly increments of &lt;/span&gt;&lt;span style="font-weight:normal;"&gt;$1.3&lt;/span&gt;&lt;span style="font-weight:normal;"&gt; million through June 2026. &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Penn Agreement includes an exploratory research program focused on discovering targets and novel gene therapy candidates for large CNS indications, currently focused on TLE, and can be expanded to other large CNS diseases upon mutual agreement. The initial term of the exploratory research program is until August 2024, which term can be extended by mutual agreement. During such term, the Company will have an exclusive right of first negotiation to include additional targets to the exploratory research program within the agreed upon large CNS indications. Under the exploratory research program, the Company will have the right to further develop and commercialize any gene therapy product candidates specific for those selected targets within TLE (and any future large CNS diseases that are mutually agreed upon) that may arise from the exploratory research programs on substantially the same terms of the current Penn Agreement.   &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Under the Penn Agreement, the Company has eight remaining options available to commence additional licensed programs for CNS indications and has until August 3, 2026, to exercise these options.&#160;If the Company were to exercise any of these options, it would owe Penn a non-refundable upfront fee of $1.0&#160;million per product indication, with $0.5 million due upfront and another $0.5 million fee owed upon a further developmental milestone. The Company has the obligation to fund certain research relating to the preclinical development of each licensed program.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Penn Agreement requires that the Company make payments of up to (i) $16.5&#160;million per product candidate for rare, monogenic disorders in the aggregate and (ii) $39.0 million per product candidate in the aggregate arising from the exploratory program for large CNS indications, currently for TLE. Each payment will be due upon the achievement of specific development milestone events by such licensed product for a first indication, reduced development milestone payments for the second and third indications and no development milestone payments for subsequent indications. In addition, on a product-by-product basis, the Company is obligated to make up to $55.0&#160;million in sales milestone payments on each licensed product based on annual sales of the licensed product in excess of defined thresholds. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Upon successful commercialization of a product using the licensed technology, the Company is obligated to pay to Penn, on a licensed product-by-licensed product and country-by-country basis, tiered royalties (subject to customary reductions) in the mid-single digits on annual worldwide net sales of such licensed product. In addition, the Company is obligated to pay to Penn a percentage of sublicensing income, ranging from the mid-single digits to low double digits, for sublicenses under the Penn Agreement. The agreement will expire on a licensed product-by-licensed product and country-by-country basis upon the later of (i)&#160;the expiration of the last valid claim of the licensed patent rights that covers the exploitation of such licensed product in such country, and (ii)&#160;the expiration of the royalty period. In addition, the Company will pay a tiered transaction fee of 1-2% of the net proceeds upon certain change of control events.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="letter-spacing:0.25pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="letter-spacing:0.25pt;"&gt;During the year ended December 31, 2022, the Company made payments under the Penn Agreement of &lt;/span&gt;&lt;span style="letter-spacing:0.25pt;"&gt;$3.0&lt;/span&gt;&lt;span style="letter-spacing:0.25pt;"&gt; million related to the achievement of development milestones&lt;/span&gt; &lt;span style="letter-spacing:0.25pt;"&gt;for dosing our first patients in PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease, &lt;/span&gt;which were recognized as in-process research and development expense&lt;span style="letter-spacing:0.25pt;"&gt;. During the year ended December 31, 2021, the Company made payments under the Penn Agreement of &lt;/span&gt;$1.5 million related to the achievement of a development milestone, $1.5 million related to option exercises under the Penn Agreement, and a $5.0 million payment related to the August 2021 amendment, which were recognized as in-process research and development expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffffff;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Catalent Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In June&#160;2019, the Company entered into a collaboration agreement, or the Collaboration Agreement, with Catalent. As part of the Collaboration Agreement, the Company will pay an annual fee for five&#160;years ending in 2025 for the use of the Clean Room&#160;Suite.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In April&#160;2020, the Company entered into a development services and clinical supply agreement, or the Manufacturing and Supply Agreement, with Catalent to secure clinical scale manufacturing capacity for batches of active pharmaceutical ingredients for the Company&#x2019;s gene therapy product candidates. The Manufacturing and Supply Agreement confirms the terms contemplated by the Collaboration Agreement. The Collaboration Agreement continues to be in effect pursuant to its terms.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the terms of the Manufacturing and Supply Agreement, Catalent has agreed to manufacture batches of drug product for the Company&#x2019;s gene therapy product candidates at the Clean Room&#160;Suite&#160;at a Catalent facility provided for in the Collaboration Agreement. The Manufacturing and Supply Agreement provides for a term of five&#160;years which period may be extended once, at the Company&#x2019;s option, for an additional five-year period. The Manufacturing and Supply Agreement also includes minimum annual purchase commitments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has the right to terminate the Manufacturing and Supply Agreement for convenience or other reasons specified in the Manufacturing and Supply Agreement upon prior written notice. If the Company terminates the Manufacturing and Supply Agreement, it will be obligated to pay an early termination fee to Catalent.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;Under both the Collaboration Agreement and the Manufacturing and Supply Agreement, the Company has an annual minimum commitment of $10.6 million per&#160;year owed to Catalent for five&#160;years from the validation of the Clean Room, subject to certain inflationary adjustments. For the years ended December 31, 2022 and 2021, the Company paid amounts in excess of the minimum commitment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Employment Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has entered into employment agreements with key personnel providing for compensation and, in certain circumstances, severance and acceleration of vesting in stock-based compensation awards, as described in the respective employment agreements.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <pasg:CollaborationAgreementAnnualFeePayable
      contextRef="As_Of_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_Tz7eti2M40mA4VxFf-_HGA"
      decimals="-5"
      id="Narr_ehFkMrpSBkOC4iXShODsiA"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">5000000.0</pasg:CollaborationAgreementAnnualFeePayable>
    <pasg:CollaborationAgreementQuarterlyFeePayable
      contextRef="As_Of_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_Tz7eti2M40mA4VxFf-_HGA"
      decimals="-5"
      id="Narr_eyjlbewMr0mlgfGWQfRwkA"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1300000</pasg:CollaborationAgreementQuarterlyFeePayable>
    <pasg:NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram
      contextRef="As_Of_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_Tz7eti2M40mA4VxFf-_HGA"
      decimals="INF"
      id="Narr_RZcIS2w8UkCD_RBrsiyjsQ"
      unitRef="Unit_Standard_Option_5y2HNcjXj0iaLv1FEhwgXQ">8</pasg:NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram>
    <pasg:CollaborationAgreementUpfrontPaymentMade
      contextRef="Duration_8_3_2020_To_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_X9L4Qp3mCEKi6Z_BUccfKQ"
      decimals="-5"
      id="Narr_OR81fHPjuU-sUkHtlPlE3A"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1000000.0</pasg:CollaborationAgreementUpfrontPaymentMade>
    <pasg:CollaborationAgreementUpfrontFee
      contextRef="As_Of_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_Tz7eti2M40mA4VxFf-_HGA"
      decimals="-5"
      id="Narr__1EyRSVWnkyAntz3fEei7w"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">500000</pasg:CollaborationAgreementUpfrontFee>
    <pasg:CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation
      contextRef="As_Of_8_3_2020_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_Tz7eti2M40mA4VxFf-_HGA"
      decimals="-5"
      id="Narr_NsaZwmt0f0uQatzw1Hnq4Q"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">500000</pasg:CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation>
    <pasg:CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone
      contextRef="As_Of_12_31_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_z13QfKfPmkK_8C2JId34Bw"
      decimals="-5"
      id="Narr_SsqKqqKSL0Gyd8JYjp9Wwg"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">16500000</pasg:CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone>
    <pasg:CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone
      contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_HuyYaPjrf0-kSgqt367TIw"
      decimals="-5"
      id="Narr__3Eth1hgrkeMUMMIHeOVZw"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">39000000.0</pasg:CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone>
    <pasg:DevelopmentMilestonePaymentsPayable
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Narr_4PCJqVVmmEOL7MqaQqxulg"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">0</pasg:DevelopmentMilestonePaymentsPayable>
    <pasg:CollaborationAgreementSalesMilestonePaymentsPayable
      contextRef="As_Of_12_31_2022_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_HuyYaPjrf0-kSgqt367TIw"
      decimals="-5"
      id="Narr__0dROtyb0UK76faZzwFjhg"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">55000000.0</pasg:CollaborationAgreementSalesMilestonePaymentsPayable>
    <pasg:CollaborationAgreementTieredTransactionFeePayablePercent
      contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_0J6NHzFpyUuN4ppDeH9zaQ"
      decimals="2"
      id="Narr_VPouL4DUiUu3MVVVIgzBiA"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.01</pasg:CollaborationAgreementTieredTransactionFeePayablePercent>
    <pasg:CollaborationAgreementTieredTransactionFeePayablePercent
      contextRef="Duration_8_1_2021_To_8_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_Qg9ksmS5wkuN_RKSudErVA"
      decimals="2"
      id="Narr_XK4Ay03tsUGTfdqGCGVTWA"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.02</pasg:CollaborationAgreementTieredTransactionFeePayablePercent>
    <pasg:AdditionalTechnologyLicenseFeePaid
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_doDUoWoF-U6E9lX1OVWkNg"
      decimals="-5"
      id="Narr_Z-l113Bn0kWYHl9sEkBw-g"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">3000000.0</pasg:AdditionalTechnologyLicenseFeePaid>
    <pasg:AdditionalTechnologyLicenseFeePaid
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_KS_iGfGyu0moP1TAVBgiKQ"
      decimals="-5"
      id="Narr_IwkTdeYZukqir4twS1ggaw"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1500000</pasg:AdditionalTechnologyLicenseFeePaid>
    <pasg:CollaborationAgreementPaymentMadeOnOptionExercise
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_KS_iGfGyu0moP1TAVBgiKQ"
      decimals="-5"
      id="Narr_o1k0q1nbD0y37dNt2EK2eg"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1500000</pasg:CollaborationAgreementPaymentMadeOnOptionExercise>
    <pasg:PaymentsForTechnologyLicenseFee
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember_KS_iGfGyu0moP1TAVBgiKQ"
      decimals="-5"
      id="Narr_BDBeSKjE8k-GxWBPd6_nmQ"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">5000000.0</pasg:PaymentsForTechnologyLicenseFee>
    <pasg:CollaborationAgreementAnnualFeePayableTerm
      contextRef="Duration_6_1_2019_To_6_30_2019_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_2O0jJDglI0ukihnR8RMuWw"
      id="Narr_YouqQGfHsE2JbQsPSfseFg">P5Y</pasg:CollaborationAgreementAnnualFeePayableTerm>
    <pasg:TermOfManufacturingAndSupplyAgreement
      contextRef="Duration_4_1_2020_To_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_4KZiWVNG9E22l6ySZmuTUg"
      id="Narr_iHen0SSp1ECX5JYTYlQHAw">P5Y</pasg:TermOfManufacturingAndSupplyAgreement>
    <pasg:ManufacturingAndSupplyAgreementAdditionalExtensionTerm
      contextRef="Duration_4_1_2020_To_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_4KZiWVNG9E22l6ySZmuTUg"
      id="Narr_XlIfJfQaFUmj9MSlWrJHyw">P5Y</pasg:ManufacturingAndSupplyAgreementAdditionalExtensionTerm>
    <us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted
      contextRef="As_Of_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_z_YtRBUDn0S9xCBNBKE8ew"
      decimals="-5"
      id="Narr__BhDroaTo0yLV8-vKo6dCA"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">10600000</us-gaap:PurchaseCommitmentRemainingMinimumAmountCommitted>
    <pasg:CollaborationAgreementPeriodForWhichAnnualFeeIsPayable
      contextRef="Duration_4_1_2020_To_4_30_2020_dei_LegalEntityAxis_pasg_CatalentMarylandInc.Member_4KZiWVNG9E22l6ySZmuTUg"
      id="Narr_XMOreELbC0SftSQs7TFprg">P5Y</pasg:CollaborationAgreementPeriodForWhichAnnualFeeIsPayable>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_uclua8HSn0uyCVmrDUUf-g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11. Common Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In January&#160;2021, the Company closed a follow-on public offering in which the Company issued and sold 8,050,000 shares of its common stock, which included shares sold pursuant to an option granted to the underwriters to purchase additional shares, at a public offering price of $22.00 per share for net proceeds of $165.8 million&#160;after deducting underwriting discounts, commissions and other offering expenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;On March 5, 2021, the Company entered into a Sales Agreement, or the Sales Agreement, with Cowen and Company, LLC, or Cowen, pursuant to which the Company may, but are not obligated to, offer and sell, from time to time, shares of the Company&#x2019;s common stock with an aggregate offering price up to $125.0 million through Cowen, as sales agent. No sales of common stock have been made pursuant to this Sales Agreement to date.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_VKjaYfeOdEmdzPqOICqhlQ"
      decimals="INF"
      id="Narr_TCly6uDhs0qcgembMJJLFw"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">8050000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_XMou09J0cEirXcLwXtLPDg"
      decimals="2"
      id="Narr_rgQgFgfM9km5LQfsw6RlNg"
      unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">22.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2021_To_1_31_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_VKjaYfeOdEmdzPqOICqhlQ"
      decimals="-5"
      id="Narr_utguEKI6_ky5dRTWVkSjNQ"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">165800000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_3_5_2021_To_3_5_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_pasg_SalesAgreementWithCowenAndCompanyLlcMember_LbBLENbq1kqwVJ5FMdSo8g"
      decimals="-5"
      id="Narr_1zHh8dG4OU2P25UHPxducA"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">125000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_3_5_2021_To_3_5_2021_us-gaap_TypeOfArrangementAxis_pasg_SalesAgreementWithCowenAndCompanyLlcMember_c83rb3pHbUyDv5vHPbSVOA"
      decimals="INF"
      id="Narr_CzdGKh_02kSOcoRsMCHEoQ"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_Px5Gp_v24kK0TdUmUMMyMg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;12. Share-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Equity Incentive Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has three equity incentive plans: the 2018 Equity Incentive Plan, as amended, or the 2018 Plan, the 2020 Equity Incentive Plan, or the Incentive Plan, and the 2021 Equity Inducement Plan, or the Inducement Plan. New awards can only be granted under the Incentive Plan and the Inducement Plan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The total number of shares authorized under the Incentive Plan as of December&#160;31,&#160;2022 was 10,370,926. Additionally, any awards previously issued under our 2018 Plan which were forfeited become available for issuance under the Incentive Plan. As of December&#160;31,&#160;2022, 3,880,210 shares were available for future grants under our Incentive Plan. The number of shares of the Company&#x2019;s common stock that may be issued pursuant to rights granted under the Incentive Plan shall automatically increase on January&#160;1st of each&#160;year, commencing on January&#160;1, 2021 and continue for &lt;span style="-sec-ix-hidden:Hidden_pyhlfNmlOEC4x3JdtR4JSQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;ten&#160;years&lt;/span&gt;&lt;/span&gt;, in an amount equal to five&#160;percent of the total number of shares of the Company&#x2019;s common stock outstanding on December&#160;31st of the preceding calendar&#160;year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such&#160;year. As a result, the number of shares reserved for issuance under the Incentive Plan increased by 2,730,735 and 2,712,249 shares in January 2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Incentive Plan provides for the granting of common stock, incentive stock options, nonqualified stock options, restricted stock awards, and/or stock appreciation rights to employees, directors, and other persons, as determined by the Company&#x2019;s board of directors. The Company&#x2019;s stock options awarded to date under the Incentive Plan vest based on a requisite service period, generally over four-year periods, and have a term of ten years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Inducement Plan was approved by the Company&#x2019;s board of directors in July 2021. The total number of shares authorized under the Inducement Plan as of December&#160;31,&#160;2022 was 2,000,000, as a result of an increase to the shares authorized for issuance in February 2022. Of this amount, 384,167 shares were available for future grants as of December&#160;31,&#160;2022. The Inducement Plan provides for the granting of nonqualified stock options and restricted stock awards to employees hired by the Company, as determined by the Company&#x2019;s board of directors. The Company&#x2019;s stock options awarded to date under the Inducement Plan vest based on requisite service period and have a term of ten years. The Company&#x2019;s restricted stock units awarded to date under the Inducement Plan vest based on requisite service period and have a term based on each award agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company measures share-based awards at their grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the awards. The Company recorded share-based compensation expense in the following expense categories in its accompanying statements of operations for the period presented:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:52.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,278&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,432&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,676&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,259&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,954&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,691&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December&#160;31,&#160;2022, the Company modified certain awards and recognized $0.4 million related to the modifications, all of which was recognized in general &amp;amp; administrative expense. The terms of such modifications included, on an awards-by-award basis, acceleration of the vesting period and extensions of the post-employment period to exercise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December&#160;31,&#160;2021, the Company modified certain awards and recognized $7.4 million related to the modifications, $6.1 million of which was recognized in research and development expense and $1.3 million was recognized in general and administrative expense. The terms of such modifications included, on an awards-by-award basis, acceleration of the vesting period and extensions of the post-employment period to exercise.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes stock option activity for the&#160;year ended December&#160;31,&#160;2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&#160;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;per&#160;share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;term&#160;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at January&#160;1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,416,998&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,609,441&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (126,056)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,488,993)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,411,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and Exercisable at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,074,955&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested or expected to vest at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,411,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted-average grant date fair value of options granted was $2.33 and $12.75 for the&#160;years ended December&#160;31, 2022 and 2021, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value of options exercised was $0.2 and $1.3 million and during the year ended December 31, 2022 and 2021, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value of options outstanding as of December 31, 2022 was $0.1 million and the aggregate intrinsic value of options exercisable as of December 31, 2022 was de minimus. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2022, the total unrecognized compensation expense related to unvested stock option awards was $24.1&#160;million, which the Company expects to recognize over a weighted-average period of 2.4&#160;years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The 2018 Plan and 2020 Plan provide certain holders of stock options an election to early exercise prior to vesting. The Company has the right to repurchase early exercised options without transferring any appreciation in the value of the underlying shares to the employee if the employee terminates employment before the end of the original vesting period. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The repurchase price is the lesser of the original exercise price or the then fair value of the Company&#x2019;s common stock. As of December&#160;31,&#160;2022, 113,932 options to purchase common stock are unvested, but exercisable, under early exercise provisions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of each option was estimated on the date of grant using the weighted average assumptions in the table below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:50.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 92.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 99.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk&#x2011;free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Restricted Stock Units &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The Company issues restricted stock units, or RSUs, to employees that vest over periods as determined by the board of directors. Any unvested shares are forfeited upon termination of services. The fair value price of the RSUs is equal to the fair market value of the Company&#x2019;s common stock on the date of grant. Compensation expense is recognized on a straight-line basis over the vesting period of the RSUs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;The following table summarizes activity related to RSU awards during the year ended December&#160;31,&#160;2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted average &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;grant date fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested balance at January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 290,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.78&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,171,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.97&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39,167)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15.06&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (193,667)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested balance at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,229,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.98&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;As of December&#160;31,&#160;2022, the total unrecognized expense related to all RSUs was $2.8 million, which the Company expects to recognize over a weighted-average period of 1.8 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Employee Stock Purchase Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s 2020 Employee Stock Purchase Plan, or the ESPP, became effective on February 28, 2020. The ESPP authorizes the issuance of up to 1,435,619 shares of the Company&#x2019;s common stock. Of this amount, 1,119,914 were available for future grants as of December&#160;31,&#160;2022. The number of shares of the Company&#x2019;s common stock that may be issued pursuant to rights granted under the ESPP shall automatically increase on January 1st of each year and continuing for ten years, in an amount equal to one percent of the total number of shares of the Company&#x2019;s common stock outstanding on December 31st of the preceding calendar year, subject to the discretion of the board of directors or compensation committee to determine a lesser number of shares shall be added for such year. As a result, on January 1, 2023, the number of shares reserved for issuance under the ESPP increased by 546,147 shares, resulting in a total of 1,981,766 shares authorized for issuance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Under the ESPP, eligible employees can purchase the Company&#x2019;s common stock through accumulated payroll deductions at such times as are established by the compensation committee. Eligible employees may purchase the Company&#x2019;s common stock at 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first day of the offering period or on the last day of the offering period. The offering periods under the ESPP have a duration of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;six months, with periods ending in May and November of each calendar year. Eligible employees may contribute up to 15% of their eligible compensation. Under the ESPP, a participant may not accrue rights to purchase more than $25,000 worth of the Company&#x2019;s common stock for each calendar year in which such right is outstanding or purchase more than 4,000 shares of the Company&#x2019;s common stock in any single offering period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In accordance with the guidance in ASC 718-50,&lt;i style="font-style:italic;"&gt;&#160;Compensation&#160;&#x2013; Stock Compensation&lt;/i&gt;, the ability to purchase shares of the Company&#x2019;s common stock at 85% of the lower of the price on the first day of the offering period or the last day of the offering period (i.e. the purchase date) represents an option and&lt;b style="font-weight:bold;"&gt;, &lt;/b&gt;therefore, the ESPP is a compensatory plan under this guidance. Accordingly, share-based compensation expense is determined based on the option&#x2019;s grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the withholding period. The Company recognized share-based compensation expense of $0.2 million and $0.4 million during the years ended December&#160;31, 2022 and 2021, respectively, related to the ESPP.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <pasg:NumberOfEquityIncentivePlans
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="INF"
      id="Narr_SsahnBf9DEayudufeUx5tw"
      unitRef="Unit_Standard_plan_r3kCEt0dLUCKcJ9iz91x7Q">3</pasg:NumberOfEquityIncentivePlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_Ba8ei5M0iU212FOvifvfgw"
      decimals="INF"
      id="Narr_SeSGWSOaK0mOijwDlB0fyQ"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">10370926</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_Ba8ei5M0iU212FOvifvfgw"
      decimals="INF"
      id="Narr_HXpuufEUp0K4BsOEiKQdHQ"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">3880210</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <pasg:ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_mGa3yEM8z06MhUJxjwJeqA"
      decimals="2"
      id="Narr_craZfrqLnEOeYtgT9nrvjA"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.05</pasg:ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease>
    <pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance
      contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_e7qXKu9B8kaes7yJbBslkQ"
      decimals="INF"
      id="Narr_hq9NrCVz-E2Y_iKh3Rnsbg"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">2730735</pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance>
    <pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance
      contextRef="Duration_1_1_2022_To_1_1_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_V-j15wJiN0KMnb4hw5k1nA"
      decimals="INF"
      id="Narr_UwNMdgXcWU2YG5NHvyANZA"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">2712249</pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_mGa3yEM8z06MhUJxjwJeqA"
      id="Narr_lz8XU_HMwEqdxVIXdj4Wwg">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityIncentivePlan2020Member_mGa3yEM8z06MhUJxjwJeqA"
      id="Narr_pfl24w71v0S_sltoKc2Qog">P10Y</pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityInducementPlan2021Member_R6lRMEzvCkuXk7SlC-tL4A"
      decimals="INF"
      id="Narr_ZaqasPb7AEaZrRX_UwFmsg"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityInducementPlan2021Member_R6lRMEzvCkuXk7SlC-tL4A"
      decimals="INF"
      id="Narr_KBV_7DrwHUKUZtsGomPkCQ"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">384167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_pasg_EquityInducementPlan2021Member_NN2gJkl_wkeCgwEIqLXLgQ"
      id="Narr_J3ouHxHqFk2Mvu3OPG9NOg">P10Y</pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_M6yI82Xr-0ax2ISSqjQVJA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:52.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,278&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15,432&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,676&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,259&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:43.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:22.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 18,954&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:21.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,691&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_fzK4cBH8fkuhwpQHwW1AZA"
      decimals="-3"
      id="Tc_4XuPDVcmA0ijodk1SGBz9A_3_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">8278000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_lvXskTRyzEmHGgFZuscuXw"
      decimals="-3"
      id="Tc_xwwqN8VhdkSZeWaPl8iZvw_3_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">15432000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_rKbIo3RACkur9OAM8iqIbA"
      decimals="-3"
      id="Tc_V4oyNyFYu0mTVth77HOgrA_4_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">10676000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember__jemGaqshkeAAlBd2h-gkA"
      decimals="-3"
      id="Tc_Snl2YtOvS0CuCnnvw9TcFw_4_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">17259000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-3"
      id="Tc_RUHjXr5FCEKKellQpWiOvA_5_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">18954000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-3"
      id="Tc_-lvP35Xnj0uKlgr3rYU_iQ_5_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">32691000</us-gaap:AllocatedShareBasedCompensationExpense>
    <pasg:ShareBasedCompensationArrangementExpensesDueToModifications
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-5"
      id="Narr_AtuPxgju70aRArOx6ukmUA"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">400000</pasg:ShareBasedCompensationArrangementExpensesDueToModifications>
    <pasg:ShareBasedCompensationArrangementExpensesDueToModifications
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-5"
      id="Narr_Kq4mnNpEA0CQF4pvKjKjgw"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">7400000</pasg:ShareBasedCompensationArrangementExpensesDueToModifications>
    <pasg:ShareBasedCompensationArrangementExpensesDueToModifications
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_lvXskTRyzEmHGgFZuscuXw"
      decimals="-5"
      id="Narr_BqS4D2ewnk2xl0LgTIWJaA"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">6100000</pasg:ShareBasedCompensationArrangementExpensesDueToModifications>
    <pasg:ShareBasedCompensationArrangementExpensesDueToModifications
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember__jemGaqshkeAAlBd2h-gkA"
      decimals="-5"
      id="Narr_nLPfaTlQ3U2aqx_HYEpEug"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1300000</pasg:ShareBasedCompensationArrangementExpensesDueToModifications>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_ztPmsFEAr0qGsskacFcLEA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;exercise&#160;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;per&#160;share&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;term&#160;(years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at January&#160;1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,416,998&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.72&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,609,441&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.09&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (126,056)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,488,993)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,411,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and Exercisable at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,074,955&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:53.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested or expected to vest at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11,411,390&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.74%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="INF"
      id="Tc_XAfIjZze40CosK4oKZpCHA_6_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">9416998</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="2"
      id="Tc_sHKP1DNLaE6nQ9LJQ7uOrw_6_5"
      unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">13.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      id="Tc_unacRbmoZ0-fxZAb95R05g_6_7">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="INF"
      id="Tc_mZjeIJbF9USwrLyQX48aLw_7_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">6609441</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="2"
      id="Tc_XxYR2EgW3UWX9iCWOR20mQ_7_5"
      unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">3.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="INF"
      id="Tc_0pwo0nae8U2eFvf2DCYp5w_8_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">126056</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="2"
      id="Tc_juiyUM_WgUyFWREDL5wMGw_8_5"
      unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">1.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="INF"
      id="Tc_TACj1n5l8EiS2kfvPfA3AA_9_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">4488993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="2"
      id="Tc__qBo21SNVEyBKyTVhNZkIw_9_5"
      unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">10.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="INF"
      id="Tc_85DQiiJgHU6OFA8rIAAdFg_10_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">11411390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="2"
      id="Tc_OjXyJYdDHU22M_jw6gK0Gg_10_5"
      unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">9.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tc_oEYMLD_DTU6SjeBPbp7O9Q_10_7">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="INF"
      id="Tc_Ou-z9EXWVU2dOeTABLe-tQ_11_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">6074955</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="2"
      id="Tc_BbhSdzFd_UKnlkVnnMlnjg_11_5"
      unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">11.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tc_OvHaHqEG6kaazHfUE641bQ_11_7">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="INF"
      id="Tc_KeS39jA2fEaePk5b1Kvy-A_12_2"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">11411390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="2"
      id="Tc_ROMDk_bh5ker5I2gImSBAw_12_5"
      unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">9.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tc_kT6Rq2wXLkSb_zhlxlH-rg_12_7">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="2"
      id="Narr_1mvaf2FcSEyxyOshakaRAA"
      unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">2.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="2"
      id="Narr_Ed2a4gGk20ixiBv5mb8gcg"
      unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">12.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-5"
      id="Narr_I74GuAer-UewKnJ_WI4ghg"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-5"
      id="Narr_UVFYyJLlpUeVAtlNlhye0w"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-5"
      id="Narr_0JD0lW9RZEOc6zQfSCCziw"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-5"
      id="Narr_b5ai8tpYrkOV1cvyrda67A"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">24100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Narr_ba0siOFpckStYsfvTw9Lig">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="INF"
      id="Narr_io2Mh3xjpkm-hFKRErrVBQ"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">113932</pasg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_GvkbGCOHYEeM2Eyc7fJaug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:94.58%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:50.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:23.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 92.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 99.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk&#x2011;free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:45.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="3"
      id="Tc_7UAxGOP0ikyx80vfObTVIQ_3_2"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.925</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="3"
      id="Tc_E12zrwyIq0-4nfglR_J5tw_3_5"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="3"
      id="Tc_MxO_Nwxp10aNIkKOxtcYyQ_4_2"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="3"
      id="Tc_itmot3my0k22IkL6NZmktA_4_5"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tc_A8QyVPtMDECHMPMs9XXPxg_5_2">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      id="Tc_CXZ-GIYg9km7njj0ceO6KA_5_5">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="3"
      id="Tc_COt_l1E9zUaqXJHzPlB7rQ_6_2"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="3"
      id="Tc_nIc79rLcQkOJbny6ZoDaXA_6_5"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_mXTzMamlnEujgvfSNJp2IQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted average &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&#160;shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:23.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;grant date fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested balance at January 1, 2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 290,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 14.78&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,171,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.97&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Vested&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (39,167)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 15.06&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (193,667)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.87&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:50.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Unvested balance at December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,229,166&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2.98&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_IVEx45mF9UGGotpVBJv3wA"
      decimals="INF"
      id="Tc_83ucZiz-10qeShpifXafiw_3_3"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">290500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_IVEx45mF9UGGotpVBJv3wA"
      decimals="2"
      id="Tc_lS71s2WlhEqdY8nuDr93hQ_3_6"
      unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">14.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2SJMJY-9JE2TYYv1hxxQlA"
      decimals="INF"
      id="Tc_zxtPg80W0U6fgSJddPCY1w_4_3"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">1171500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2SJMJY-9JE2TYYv1hxxQlA"
      decimals="2"
      id="Tc_EG3K-mCC3UeLghdvvxIXMQ_4_6"
      unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">1.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2SJMJY-9JE2TYYv1hxxQlA"
      decimals="INF"
      id="Tc_xFAv4KpbpEqcupbFJn7MdQ_5_3"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">39167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2SJMJY-9JE2TYYv1hxxQlA"
      decimals="2"
      id="Tc_vqH3hqNzaUSYcohbLgeiiw_5_6"
      unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">15.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2SJMJY-9JE2TYYv1hxxQlA"
      decimals="INF"
      id="Tc_15JDK8BssU6D4pt5uIdB7Q_6_3"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">193667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2SJMJY-9JE2TYYv1hxxQlA"
      decimals="2"
      id="Tc_xXhw9-ChKkuWvXlfJA7-lw_6_6"
      unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">11.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_4GJmz4SaeUW8G0iqOGx50A"
      decimals="INF"
      id="Tc_5tXoDGSiakK8gFlJpk8-IQ_7_3"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">1229166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_4GJmz4SaeUW8G0iqOGx50A"
      decimals="2"
      id="Tc_QlRufJuQW0-FJn9vNa3Aag_7_6"
      unitRef="Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA">2.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_4GJmz4SaeUW8G0iqOGx50A"
      decimals="-5"
      id="Narr_L-H5cnxvqEKr2A1dqyqPBw"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">2800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2SJMJY-9JE2TYYv1hxxQlA"
      id="Narr_yYI8L9oLCkSQHTbDxy6wNg">P1Y9M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_2wbIkeBld021QObVHUyCCQ"
      decimals="INF"
      id="Narr_YzWP21vpt0e4ohn_D8Lb_g"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">1435619</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_ffSkQEILP0GGYx3Q6UsjsQ"
      decimals="INF"
      id="Narr_H9FySbUpjEGSHH-OzpuP0A"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">1119914</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <pasg:EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted
      contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7S0-ZkqLP02l2ZtnRMvqNw"
      id="Narr_6Buyu_AEt0aybnqJNC_biw">P10Y</pasg:EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted>
    <pasg:EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding
      contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7S0-ZkqLP02l2ZtnRMvqNw"
      decimals="2"
      id="Narr_tfNStqdlLUW1LjMZuWaNGw"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.01</pasg:EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding>
    <pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance
      contextRef="Duration_1_1_2023_To_1_1_2023_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_paHmp6CcHEeXKfzN77VxdQ"
      decimals="INF"
      id="Narr_1YJLBvnWEkarTQWA02DW5A"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">546147</pasg:CommonStockAdditionalCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_1_1_2023_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_X3oAMRpPCkuZ5fd72D8-YA"
      decimals="INF"
      id="Narr_-GTHgua29E-Ee7EMKX2DHQ"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">1981766</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <pasg:EmployeeStockPurchasePlanStockPurchasePricePercentage
      contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7S0-ZkqLP02l2ZtnRMvqNw"
      decimals="2"
      id="Narr_RnciF8S6UkKiU3a1hD9yAA"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.85</pasg:EmployeeStockPurchasePlanStockPurchasePricePercentage>
    <pasg:EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage
      contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7S0-ZkqLP02l2ZtnRMvqNw"
      decimals="2"
      id="Narr_gxnzaM8GrkeJx0Gs0yyPaQ"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.15</pasg:EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage>
    <pasg:EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased
      contextRef="As_Of_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_2wbIkeBld021QObVHUyCCQ"
      decimals="0"
      id="Narr_5SKeR088_ES4s9jKEoSMPA"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">25000</pasg:EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased>
    <pasg:EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased
      contextRef="Duration_2_28_2020_To_2_28_2020_iDWURz96TU6yNVnGevdtWQ"
      decimals="INF"
      id="Narr_PhUBHAAdWEOw4-5-h9tWPA"
      unitRef="Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw">4000</pasg:EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased>
    <pasg:EmployeeStockPurchasePlanStockPurchasePricePercentage
      contextRef="Duration_2_28_2020_To_2_28_2020_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_7S0-ZkqLP02l2ZtnRMvqNw"
      decimals="INF"
      id="Narr_nzgqZsdHfk2v0h0MoZlhNw"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.85</pasg:EmployeeStockPurchasePlanStockPurchasePricePercentage>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_gplgcbUrjEqXbb7bUxMbbA"
      decimals="-5"
      id="Narr_rHDZH-Nfgku34E_dYjYcEg"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_pasg_EmployeeStockPurchasePlanMember_aTuBNIMD5UOPhj-XOY8Bqg"
      decimals="-5"
      id="Narr_qbc-Yco5yEaUA00MnaCUMA"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_Rw3yMP-Urk6dPHv9iwQ0gw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;13. Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands) &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 64,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,351&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,068&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,244&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Collaboration and license agreement&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,504&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,012&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51,806&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,312&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,245&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued expenses and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,922&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,654&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;      Total gross deferred tax assets before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 188,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 136,276&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (179,843)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (135,053)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;      Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,422&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,223&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;"&gt;Right of use assets - operating leases &lt;/span&gt;&lt;i style="font-style:italic;"&gt;(deferred rent for December 31, 2021)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,609)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (876)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (813)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (347)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;      Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,422)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,223)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;      Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;In assessing the need for a valuation allowance, management must determine that there will be sufficient taxable income to allow for the realization of deferred tax assets. Based upon the historical and anticipated future losses, management has determined that the deferred tax assets do not meet the more-likely-than-not threshold for realizability. Accordingly, a full valuation allowance has been recorded against the Company&#x2019;s net deferred tax assets as of December&#160;31, 2022 and 2021. The valuation allowance increased by $44.8 million and $72.1 million during the&#160;years ended December&#160;31, 2022 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;A reconciliation of the federal income tax rate to the Company&#x2019;s effective tax rate is as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal tax benefit at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State tax, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development and orphan tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (38.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes carryforwards of federal, state and local net operating losses, or NOL, and research and development and orphan drug tax credits:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands) &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 199,233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 126,551&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 199,230&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;126,547&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Local&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 180,859&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;116,301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,068&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;22,244&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;For federal income tax purposes, $0.3 million of NOL carryforwards expire in 2037. The remaining federal NOL carryforwards were generated subsequent to January 1, 2018, and therefore, are able to be carried forward indefinitely. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;For state income tax purposes, NOL carryforwards begin expiring in 2037, and expire through 2042. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;For local income tax purposes related to the city of Philadelphia, NOL carryforwards begin expiring in 2023, and expire through 2042. NOL carryforwards generated prior to 2023 expire after 3 years, whereas NOL carryforwards generated in 2023 expire after 20 years. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, the Company also had federal research and development and orphan drug tax credit carryforwards of $32.1 million that will begin to expire in 2038, unless previously utilized. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50&#160;percent, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future&#160;years. The Company has not done an analysis to determine whether or not ownership changes have occurred since inception. Certain state NOL carryforwards may also be limited, including Pennsylvania, which limits NOL utilization as a&#160;percentage of apportioned taxable income.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company will recognize interest and penalties related to uncertain tax positions as a component of interest income, net. As of December 31, 2022, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company&#x2019;s statement of operations. Tax years from 2019 and after remain subject to examination by the taxing jurisdictions. The NOL and tax credit carryforwards remain subject to review until utilized.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_RMCqefDzWkq7n9G5t_wk5A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands) &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 64,547&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 42,351&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,068&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22,244&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Collaboration and license agreement&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,504&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,976&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Capitalized research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 65,012&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 51,806&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,312&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,245&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accrued expenses and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,922&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,654&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,900&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;      Total gross deferred tax assets before valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 188,265&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 136,276&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (179,843)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (135,053)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;      Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,422&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,223&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"&gt;&lt;span style="font-size:10pt;"&gt;Right of use assets - operating leases &lt;/span&gt;&lt;i style="font-style:italic;"&gt;(deferred rent for December 31, 2021)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (7,609)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (876)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (813)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (347)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;      Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (8,422)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,223)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:63.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;      Net deferred taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_pYQGT4O8hkeSO1yxZramig_4_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">64547000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_Zww8h2R0Q0CGDXg4p5_Rrw_4_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">42351000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_nm7HjtYpsk-GtgHQ-G9tcA_5_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">32068000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_gvHTsxIiI0y2uZKaVQtc-w_5_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">22244000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <pasg:DeferredTaxAssetsCollaborationAndLicenseAgreement
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_5WUjxOfFhESdD8P8OlwWgw_6_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">4504000</pasg:DeferredTaxAssetsCollaborationAndLicenseAgreement>
    <pasg:DeferredTaxAssetsCollaborationAndLicenseAgreement
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_BsSnKSrVeU2GkluucqI2-w_6_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">3976000</pasg:DeferredTaxAssetsCollaborationAndLicenseAgreement>
    <pasg:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_nj7YsQgDs0eF1X57kh09Sg_7_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">65012000</pasg:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <pasg:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_HjrwA8l5Gk2dJh6BFtaujQ_7_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">51806000</pasg:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_l9C0364JBEelNcfYIt89YQ_8_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">11312000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_fAhGoWBehk6v320r7DrWOA_8_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">11245000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <pasg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_EzU7MlXs_EypwdLyu-46AQ_9_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1922000</pasg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther>
    <pasg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_yaEPa4ALqk2j4ke0MA12xw_9_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">4654000</pasg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther>
    <pasg:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_bqp1b91oXk6YDqCrsBKm5A_10_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">8900000</pasg:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_4c1D2_cV7kKL_OkUVgrIwQ_11_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">188265000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_Dx931cizYEKES94IDej1Tw_11_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">136276000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc__8RXCIenME69fVYOov2UKw_12_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">179843000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_f3sw_8UXmEqVUWUMvo319w_12_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">135053000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_vxfrxQ69lkWW3y_Satqg3Q_13_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">8422000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_FtogY2c4bEebAmJN5m6XZw_13_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1223000</us-gaap:DeferredTaxAssetsNet>
    <pasg:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_iItmoUO870mKXNub51_cDg_15_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">7609000</pasg:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <pasg:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_fEJC1K_4v0u6cKmIz3TkHA_15_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">876000</pasg:DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_Bk1qbe5cQUm5NEiCO3ptTQ_16_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">813000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_DmkZ3_t2w0WAarD4MDlIJw_16_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">347000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_t0eeJD7onka3LZmlUqwqKA_17_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">8422000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_NL0lBaHX_kGp3up-5IEDcA_17_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">1223000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-3"
      id="Tc_h78TLZKA90y-EILg_Be_sw_18_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ"
      decimals="-3"
      id="Tc_iw81rVK8bkmeGl7lb6Q9bA_18_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-5"
      id="Narr_r2YwEMLht0O6x7rtRS1CGg"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">44800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="-5"
      id="Narr_kQfu37Af6Eq9uigTLeWdCA"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">72100000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_L3cMDrlxtUSWCHMxNkwshg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:34.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal tax benefit at statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State tax, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Permanent differences&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development and orphan tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.9&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (32.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (38.9)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:59.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; -&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="3"
      id="Tc_i4bWzcnCmU-8x2k3KQ5KWQ_4_2"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="3"
      id="Tc_2SSiEw84ZU-abQ0qDJuzwQ_4_4"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="3"
      id="Tc_bcDaA_DjFkO6wD3un5VXGg_5_2"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.075</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="3"
      id="Tc_LabfdxvF0k-f4jWRw0jB3w_5_4"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.119</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <pasg:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="3"
      id="Tc_ylU-0FJv3k6oQREfWHT0mw_6_2"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.025</pasg:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <pasg:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="3"
      id="Tc_ki3_EcvgoEGFN3hjwTbcFg_6_4"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.011</pasg:EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="3"
      id="Tc__mUoIXsC6Em4rWl5aHw94g_7_2"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.069</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="3"
      id="Tc_dc3T59JWKkmFpgHIEb_r3g_7_4"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.071</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="3"
      id="Tc_BKALwpjjzEuig4R7Y90D9Q_8_2"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.329</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="3"
      id="Tc_Q22mW0MBGkGAXd2LPQnIRw_8_4"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0.389</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="3"
      id="Tc_TWOE8d7eJEiPGxPuKjC54g_9_2"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA"
      decimals="3"
      id="Tc_IXBbaU5zPEadhuZ1xJT4cw_9_4"
      unitRef="Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb_RYfx5ess60KteVD9yGIF-w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands) &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 199,233&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 126,551&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 199,230&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;126,547&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Local&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 180,859&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;116,301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:60.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 32,068&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:13.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;22,244&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_68a1wKllOU-ygbrbsjHfXA"
      decimals="-3"
      id="Tc_m9uSToTGuECxftoX3v_FTw_3_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">199233000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_mgIQoET8g0GzCQSgrV4mEg"
      decimals="-3"
      id="Tc_rdHNVxZ0JkC8yPWP6NSh7A_3_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">126551000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_pasg_StateTaxAuthorityMember_csXMoMs05E-EaQFBpJ-dDw"
      decimals="-3"
      id="Tc_-vx4c3rPqE2UmNjJD990SQ_4_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">199230000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_pasg_StateTaxAuthorityMember_Af3k6h92bkmtwN0ci3mBEg"
      decimals="-3"
      id="Tc_-7mwZXcLVE6sbxyH2M0-_A_4_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">126547000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_pasg_LocalTaxAuthoritiesMember_Ig7yZu-Op0CHDDSoRCT99A"
      decimals="-3"
      id="Tc_v5xorGLuMUmebr9u9Yh7ew_5_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">180859000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_us-gaap_IncomeTaxAuthorityAxis_pasg_LocalTaxAuthoritiesMember_NABkP1gdZkiCPP5SKrlohA"
      decimals="-3"
      id="Tc_WWy71905Qk2M3MZBV4G-vg_5_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">116301000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2022_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_wDFfPO_ZNUKxeG-q7TC3Rg"
      decimals="-3"
      id="Tc_3-_ws7zo2ki0ZPft85Ha7A_6_3"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">32068000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="As_Of_12_31_2021_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember_yIzi3o8bAE2L3dxvXEqkRg"
      decimals="-3"
      id="Tc_HJ55MAq1WUWT9AQnhGzG6Q_6_6"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">22244000</us-gaap:TaxCreditCarryforwardAmount>
    <pasg:OperatingLossCarryforwardSubjectToExpiration
      contextRef="As_Of_12_31_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_68a1wKllOU-ygbrbsjHfXA"
      decimals="-5"
      id="Narr_gWlkp9KlU0K9rc9nQevgJQ"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">300000</pasg:OperatingLossCarryforwardSubjectToExpiration>
    <pasg:TaxCreditCarryForwardSubjectToExpiration
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-5"
      id="Narr_qt-Mz9p3fUaDM1jMeWPlVQ"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">32100000</pasg:TaxCreditCarryForwardSubjectToExpiration>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag"
      decimals="-5"
      id="Narr_yoSj5eHEMEG9srXfZjicWA"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      decimals="-5"
      id="Narr_f725_u3bOUOHQ1hPnoZQLQ"
      unitRef="Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw"
      id="Tb__96y-SsoJUezcIcnVs8v6Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;14.&#160;Subsequent Events&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;None.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>77
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MRY_.0.@V8+;3A=R1C%XM]'Z15.SI8OWK+RB&[US>O9"Q(U^#WM? 9WV](;(
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MV-]UC-'G=,LRYF0&;'<;;\,4A]""Z1 ,HABO9NH^'GH)?$HO(1VUQ0G8T25
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M%1+R^-Z#6L.>2O'P^1G]<VL\&O.0"+AFY;<BD_G"BBV2P2K9E/*6[7Z%WJ!
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M\V[*[!:2->V@]L DCGWM8XZ3.7 E@-]7C,GGA=I@F/67_P)02P,$%     @
M6#EF5L%)A2^V!@  M3   !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6RU
M6VUOVS80_BN$5VPM4-<B]=XE!AI;POIA0]&TW6=&9F(ADNA*=)SLUX^4%<N2
M:#K:+OF06/;=<\=[>!3Y6+G8\?*^6C,FT&.>%=7E9"W$YN-L5B5KEM/J ]^P
M0GYRR\N<"GE9WLVJ3<GHJG;*LQFQ+&^6T[28S"_J][Z4\PN^%5E:L"\EJK9Y
M3LNG*Y;QW>4$3Y[?^)K>K85Z8S:_V- [=LW$]\V74E[-#BBK-&=%E?("E>SV
M<O()?XR)KQQJBQ\IVU5'KY$:R@WG]^KB\^IR8JF,6,82H2"H_// %BS+%)+,
MXV<#.CG$5(['KY_1XWKP<C WM&(+GOV=KL3Z<A),T(K=TFTFOO+='ZP9D*OP
M$IY5]6^TV]OZX00EVTKPO'&6&>1IL?]+'YM"'#E@^X0#:1Q(ST%61N]@-PYV
MS\'Q3C@XC8/3CV"=<' ;!_>E8_ :!Z^N_;Y8=:675-#Y1<EWJ%36$DV]J.FJ
MO66!TT+-K&M1RD]3Z2?FUX(*)F>*J!"_1=>")_=KGJU86?V&HI_;5#RA*?I^
MO41OW[Q#;U!:H&]KOJUHL:HN9D(FH&!F21/L:A^,G BVX'DN9U.EHFB\%V;O
M3ZM5JF8CS="&IJNIS"6AFU303(.U/(.5)-M\F\FQKQ 7:U:BA.>R-=>J9QZ8
M'*>\9NAMQJOJG08^>CF\G.9ID@H-2&P&^<8'0YM)=@\4DP/%I,9Q3N!<T8P6
M"4-4H"MVEQ9%6MPILC>L3/E*O;UDR0=DX_>(6,32T;H/X-<!U%KU,'<N9@_'
MU&DL?-?#?M=L.32;8M*UB70VOA6$;M<N'MK9EN/C-K-.M>Q#M>S_4ZVW<M95
M:UJRZMV+*K</YAW719;%":Q>91;&K-3]Y6.UH0F[G,A96K'R@4WFO_Z"/>MW
MW>2'!(L@P6(@L ZUSH%:IT:W3ZYUQZL;JU<W'6<.X( 7D&!+2+ ($BP& NOP
MZAYX=8TM^X-5HNE21LOL";%'5B9IQ1#?[+<O.UKJ[U=&X+%4NYI>[ZU_D/$B
M2+#8F'R'%N] BP=!R_&2JJ/(&R1F6X3X_?73F,O8/H,$BR#!8B"P#J'^@5#?
M2&ATX.]VOX=KB*R0W ZBAY9N&5J4::)V/WN[;9$*;?\9 X[M/U\S4W"O 2$#
M1I!@L3G[#F'!@;#@-0D[UYG!(&,<>'[0[TQCCF,[$Q(L@@2+@< Z1(<'HD,C
MT9^K:EOO6A71-6'JI);PHF@.\+M4K!'+-QE_8JSA>+,MD[4\E*.-W/'J^#7&
M'-N<X6"R!/V9LH0,&$&"Q>;L.YQAJSUZ6Z_,VKD.;1(XSCO$F/1V)0MSGF-;
M%!0M D6+H="ZC!^)+=C(^#7-:K:3(R'D/2J84&^FS],AX97^;MF@'Q]Y<9]*
M/%R4/3>P^AM1<Z*C28)$BT^-P3O1<*T0@LU*R(CRG^TL,EP1+->2/WU"C"F-
M[BU(M @4+89"ZY+;ZC;8+-Q\+TI&L_0?N8>YHY*\O7:'),\Y+>^9H#>2_(HE
MVS(5*=/W%Z34L0!%6^*ADC1U^MO;"#1F?"YFEZE6AL%&-6!^K=IJJKX/6-6R
M*RLJ6M_OV*-ZS;34@(HR#5IGLTV\L']8  T:@:+%9X?0):?54K!93/E+KH:J
M<[0D@,HEH&A+4+0(#^60*0Y<._!Z(O0+#+M$M.H)-LLG1T(TDZ>UDX(]UC+E
M#78*@TW?4%CQ?-=VO'X3#.VF#K;["X_&RG8]$N!^P31ZCCPVNJ=VTZTX@<WJ
MQ,EZ&21[?>V&)W'7(8X3AEZ_A) "P!(4+0)%BZ'0NMRV.@8.0)1[#'FB7X"B
M+4'1(E"T& JM2V^K7F"S?/$*PJ(YXNB9,#S_8Q+V%TI0^0(4+3XS@.[WRJV
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M]ET1A6PN-J\:'*X>WD?Y8-_"&%S_B*_NFK=*.C?-2RX_,PGJ0$&XUN R>)]
MZ93->R/-%RUJ^^K%H]!:E/;CEC,0Y,8 ?E\+H5^^F!L<WMZY_3]02P,$%
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MSW _%IJS+PD=&=X*0/A*BK[">H H *DI^(>2\\Q4)S%BE%+<CAUZ*9$ )1
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MH"P O^=2FD-@)^A^=<O?4$L#!!0    ( %@Y9E:2)+WN @,  (T&   9
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M_@B2>4 9F>!!*U\!MZY3CZ/H1I-S^WKM3*BB?H^#\GB4?VZJ/ZR$2AJ2EJ
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MR4DD,U&V!L.)RIJT28+G:I5DI<G-AI C_H!BXTK5>TXPJUQO@A(X9]U 5GM
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MV$JPC>*% 0U5P.O0KG[3'D%4F"D-SUE1[5:PN%PSC3H'T2NS+97\SUFZ&A>
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M[M^4$_AE@R]T[^'2JJPV6SSVJW:51;4]/RC(E*#HK$I=$V2L_J".%1196&
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M+IQ[!T:2Y9YR-IZ_<<C1Z4*3W+2>PC?FZ!".A]PC3YV/K%C%T5WNQ:O)9+C
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M-0H2+[_PD@=D_?RKJH6K:[?FCRNC46K0 +PO'# P/M "[>_LKOX?4$L#!!0
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MZ-G$=WW_ -ZP\W_8X V?[W^?VRUHT ]JA'2I*IK V$*E*) +L"9O7GF1^_8
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MML@\Y8S_;7H+;?^B+R3/^0!%J)_AD;.;%X2V%_5EC)>FMWCW8W=&_A3\[$7
MYW8<]F7X%^;-.+)CMX_P+\^;.XK>YH:Z[BL2G(T:#U_6O*ED%4E$S75;[G6S
M7;%\U=:(/[>WE3:*:<ZX(@5D:.H.SD.+R+9Z;0=:5$W%.!,:Z\^FFV/!#])L
MP/5,X&_KU< <T/T+8?(W4$L#!!0    ( %@Y9E8L!%O>_ (  $('   9
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M7!KLN<TPQT<.E W ^4Q*LS9L@N[9G/T#4$L#!!0    ( %@Y9E8OQ2^^N@(
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M[\KJCY>U(4!=5<F2>\*JGJ$R^4BJG)[MQ7'8[UW&;_U_UHR'1?[/#G2'1=O
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M> G1CUN\]0%7!OA^S9AL!;5 =X]<_@-02P,$%     @ 6#EF5F;AT<&B!
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M;9TR>$2EV:!N:)+BXER?( +J>G'2#"EU:1@2W- %6PH3@9$)6^L490<(6TL
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M6E72L[R -/^%%V7X#>9K0@6*8:6@UME0Y4=>E+9%1[(T+_:63*K2,6]&ZFL
MN Y0]U>,R5U'3U!]7WA_ 5!+ P04    " !8.696M%96WS(&  "J+   &0
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M=+[9&+LYD3PKMXK.N90\*0]7E"QHK@>HWR/.Y?9$WV"W/7GR+U!+ P04
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M5T=LX#I /9\R)M\O]"&N.+0'?P%02P,$%     @ 6#EF5CI6"?%'!0  I1X
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MJ<XC<UNH+P;@.D#-YXS)W4 ?2OTW2/(74$L#!!0    ( %@Y9E;$[GJVAP,
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MU51$?2!0%Q2O[!;Y@2N]X;:W!> <A*F@WZ\X5T\%TT![+)/\ E!+ P04
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M@(?C/?L7[YV\/#*#5ZI\X)DMEL%Y !GFK"[MK=I]Q=;/U/&EJC3^";MV;Q1
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M$ F8LTRM#H&+^'X$=Y+%/\'7=7%[K<--Y1-X?T,DIJGXH$;<W]V ]^\^@'?
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M'V"M'Z!=0%@[E;$]H  '7B<';Z$48"T5H%TK6'N5L3VDX TZ:L$^QZD<:KT
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MC0&^7PFA7V_, .V_%Q;_ %!+ P04    " !8.696"$Y" !L#  ")"0  &0
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MQ0JT6Y"TVV=&.EM:)=$CZ=C]]SM*BF1;,KL:ZI=8E'@O[R'OR OG.R&_J 1
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M-;??VBHGG[2$VSATU9_*TC305<>=\P3KG2>TF*&FO69EJ&\"XK?CJJV#(:"
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M?_V7MKFGE2[J8SYK?X5//P%02P$"% ,4    " !8.696!T%-8H$   "Q
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M %@Y9E;AZU0>[@   "L"   1              "  :\   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( %@Y9E:97)PC$ 8  )PG   3
M  "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ 6#EF5LD
MS4.=!P  ,S,  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( %@Y9E8@0H*1C04  $ 7   8
M  " @> /  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " !8
M.6961K8?P6\"   =!P  &               @(&C%0  >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ 6#EF5@;*1^=,!   ]P\  !@
M         ("!2!@  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( %@Y9E;!284OM@8  +4P   8              " @<H<  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " !8.6964^=:_"D"  "Y!
M&               @(&V(P  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ 6#EF5FV]M?Z\!P  R2,  !@              ("!%28  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( %@Y9E8W/Q;3'@0
M "X)   8              " @0<N  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    " !8.696-W+ U"P'  !J$0  &               @(%;
M,@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ 6#EF5AEU
M=67<$   $C   !D              ("!O3D  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    " !8.696=8]#]IT$   $$@  &0
M    @('02@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M %@Y9E:AN=A,G@8  %07   9              " @:1/  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ 6#EF5O<4&UL] P  $ @  !D
M             ("!>58  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    " !8.696-E=@D[L"  #V!@  &0              @('M60  >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( %@Y9E:2)+WN @,
M (T&   9              " @=]<  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ 6#EF5FF(76BN!P  V10  !D              ("!
M&&   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " !8.696
MM*&H3\D*   [(   &0              @(']9P  >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( %@Y9E;FTRD6>P,  ,T'   9
M      " @?UR  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ 6#EF5C4R#AAH#   82H  !D              ("!KW8  'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " !8.696<.?W'$0)  !"&0
M&0              @(%.@P  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( %@Y9E84<P0S]0$  )X$   9              " @<F,  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ 6#EF5G5-P%S2
M$0  <S<  !D              ("!]8X  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    " !8.696KA?0^+\"  !%!@  &0
M@('^H   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( %@Y
M9E:-%)A-D@0  !$2   9              " @?2C  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ 6#EF5OO^J9_F P  3A   !D
M         ("!O:@  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    " !8.696+ 1;WOP"  !"!P  &0              @(':K   >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( %@Y9E8OQ2^^N@(  (D&
M   9              " @0VP  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ 6#EF5KRH_&<Q P  ! @  !D              ("!_K(
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " !8.696C+([
MBZ\$  !3#@  &0              @(%FM@  >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( %@Y9E9FX='!H@0  %\-   9
M  " @4R[  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
M6#EF5F!]IG\; @  H 0  !D              ("!)<   'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    " !8.696;SXZ4B,#  !K#   &0
M            @(%WP@  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( %@Y9E:T5E;?,@8  *HL   9              " @='%  !X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ 6#EF5H#E;Z1I P
MP \  !D              ("!.LP  'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    " !8.696.E8)\4<%  "E'@  &0              @(':
MSP  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( %@Y9E;.
M S?_[P(  (((   9              " @5C5  !X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ 6#EF5K6R"OEW!@  S38  !D
M     ("!?M@  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %@Y9E92Y%\CK (  *0&   9              "
M@8SQ  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ 6#EF
M5FK2+^SN!P  <44  !D              ("!;_0  'AL+W=O<FMS:&5E=',O
M<VAE970T,RYX;6Q02P$"% ,4    " !8.696@F_.FG8#  !)#P  &0
M        @(&4_   >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0
M   ( %@Y9E9'P+8^3P<  -(Z   9              " @4$  0!X;"]W;W)K
M<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ 6#EF5H?O,G%D P  3PX
M !D              ("!QP<! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"% ,4    " !8.696$7H,IWT%  #K&@  &0              @(%B"P$
M>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    ( %@Y9E9#XZ&'
M$@,  &8(   9              " @181 0!X;"]W;W)K<VAE971S+W-H965T
M-#@N>&UL4$L! A0#%     @ 6#EF5J[:Z(E!!   #1,  !D
M ("!7Q0! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    " !8
M.696)"S;UWH$  !J$   &0              @('7& $ >&PO=V]R:W-H965T
M<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( %@Y9E8(3D( &P,  (D)   9
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M 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !8.696BC%V7\\!   S'P
M&@              @ 'N+0$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    " !8.696,N&!X<<!   2'P  $P              @ 'U+P$
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     /  \ %L0  #M,0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>134</ContextCount>
  <ElementCount>307</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/StatementBalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity</Role>
      <ShortName>Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/StatementStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureNatureOfOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Risks and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureRisksAndLiquidity</Role>
      <ShortName>Risks and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Cash, cash equivalents and marketable securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecurities</Role>
      <ShortName>Cash, cash equivalents and marketable securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Severance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureSeverance</Role>
      <ShortName>Severance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>20302 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Cash, cash equivalents and marketable securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesTables</Role>
      <ShortName>Cash, cash equivalents and marketable securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecurities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstruments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureLeases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Nature of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureNatureOfOperationsDetails</Role>
      <ShortName>Nature of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureNatureOfOperations</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Risks and Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails</Role>
      <ShortName>Risks and Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureRisksAndLiquidity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Cash, cash equivalents and marketable securities - Portfolio of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails</Role>
      <ShortName>Cash, cash equivalents and marketable securities - Portfolio of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Cash, cash equivalents and marketable securities - Portfolio of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails</Role>
      <ShortName>Cash, cash equivalents and marketable securities - Portfolio of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40403 - Disclosure - Cash, cash equivalents and marketable securities (Contractual Final Maturities of Marketable Securities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails</Role>
      <ShortName>Cash, cash equivalents and marketable securities (Contractual Final Maturities of Marketable Securities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails</Role>
      <ShortName>Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Property and Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Severance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureSeveranceDetails</Role>
      <ShortName>Severance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureSeverance</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureLeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureLeasesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Leases - Operating lease cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureLeasesOperatingLeaseCostDetails</Role>
      <ShortName>Leases - Operating lease cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Commitments and Contingencies - Collaboration Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails</Role>
      <ShortName>Commitments and Contingencies - Collaboration Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureCommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureCommonStock</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Share-Based Compensation - Equity Incentive Plan &amp; ESPP (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails</Role>
      <ShortName>Share-Based Compensation - Equity Incentive Plan &amp; ESPP (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Share-Based Compensation - Share-based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Share-based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Share-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41204 - Disclosure - Share-Based Compensation - Assumptions Used in Determining Fair Value &amp; Early exercise of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails</Role>
      <ShortName>Share-Based Compensation - Assumptions Used in Determining Fair Value &amp; Early exercise of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41205 - Disclosure - Share-Based Compensation - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails</Role>
      <ShortName>Share-Based Compensation - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureIncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.passagebio.com/role/DisclosureIncomeTaxesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41302 - Disclosure - Income Taxes - Effective tax rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Effective tax rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="pasg-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41303 - Disclosure - Income Taxes - Net operating losses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails</Role>
      <ShortName>Income Taxes - Net operating losses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, pasg:ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding -  pasg-20221231x10k.htm 9</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies -  pasg-20221231x10k.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="pasg-20221231x10k.htm">pasg-20221231x10k.htm</File>
    <File>pasg-20221231.xsd</File>
    <File>pasg-20221231_cal.xml</File>
    <File>pasg-20221231_def.xml</File>
    <File>pasg-20221231_lab.xml</File>
    <File>pasg-20221231_pre.xml</File>
    <File>pasg-20221231xex10d24.htm</File>
    <File>pasg-20221231xex10d26.htm</File>
    <File>pasg-20221231xex23d1.htm</File>
    <File>pasg-20221231xex31d1.htm</File>
    <File>pasg-20221231xex31d2.htm</File>
    <File>pasg-20221231xex32d1.htm</File>
    <File>pasg-20221231xex32d2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>pasg-20221231x10k006.jpg</File>
    <File>pasg-20221231x10k007.jpg</File>
    <File>pasg-20221231x10k008.jpg</File>
    <File>pasg-20221231x10k009.jpg</File>
    <File>pasg-20221231x10k010.jpg</File>
    <File>pasg-20221231x10k011.jpg</File>
    <File>pasg-20221231x10k012.jpg</File>
    <File>pasg-20221231x10k013.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="459">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pasg-20221231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 459,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 134,
   "dts": {
    "calculationLink": {
     "local": [
      "pasg-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "pasg-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "pasg-20221231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pasg-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pasg-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "pasg-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 457,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 4,
    "http://www.passagebio.com/20221231": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 10
   },
   "keyCustom": 68,
   "keyStandard": 239,
   "memberCustom": 14,
   "memberStandard": 30,
   "nsprefix": "pasg",
   "nsuri": "http://www.passagebio.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Cash, cash equivalents and marketable securities",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecurities",
     "shortName": "Cash, cash equivalents and marketable securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Fair Value of Financial Instruments",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstruments",
     "shortName": "Fair Value of Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Property and Equipment, net",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Accrued Expenses and Other Current Liabilities",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Severance",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.passagebio.com/role/DisclosureSeverance",
     "shortName": "Severance",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.passagebio.com/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.passagebio.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Common Stock",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.passagebio.com/role/DisclosureCommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Share-Based Compensation",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.passagebio.com/role/DisclosureShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.passagebio.com/role/StatementBalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.passagebio.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.passagebio.com/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pasg:BasisOfPresentationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20302 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "22",
     "role": "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pasg:BasisOfPresentationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Cash, cash equivalents and marketable securities (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesTables",
     "shortName": "Cash, cash equivalents and marketable securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pasg:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Property and Equipment, net (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pasg:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.passagebio.com/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - Share-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.passagebio.com/role/DisclosureShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.passagebio.com/role/StatementBalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_Icv-dqMzpkWpwPT-S8J1IA",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31303 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.passagebio.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pasg:NumberOfLeadClinicalProductCandidate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_wlhC8WlTVEmcZqQ79zgOUA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Nature of Operations (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.passagebio.com/role/DisclosureNatureOfOperationsDetails",
     "shortName": "Nature of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pasg:NumberOfLeadClinicalProductCandidate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_item_wlhC8WlTVEmcZqQ79zgOUA",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Risks and Liquidity (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails",
     "shortName": "Risks and Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "pasg:SegmentPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_lMTtBbJKdUumSSlUVKw17A",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "pasg:SegmentPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_lMTtBbJKdUumSSlUVKw17A",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Cash, cash equivalents and marketable securities - Portfolio of Cash and Cash Equivalents (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails",
     "shortName": "Cash, cash equivalents and marketable securities - Portfolio of Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40402 - Disclosure - Cash, cash equivalents and marketable securities - Portfolio of Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails",
     "shortName": "Cash, cash equivalents and marketable securities - Portfolio of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40403 - Disclosure - Cash, cash equivalents and marketable securities (Contractual Final Maturities of Marketable Securities) (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails",
     "shortName": "Cash, cash equivalents and marketable securities (Contractual Final Maturities of Marketable Securities) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Fair Value of Financial Instruments (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails",
     "shortName": "Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_qnM-OR-gAECiFX_LbmMPfQ",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pasg:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Property and Equipment, net (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pasg:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Accrued Expenses and Other Current Liabilities (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued Expenses and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "pasg:ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "pasg:AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_11_30_2022_mVsYEdTSSEuJbQ89GBbHMg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "pasg:PercentReductionToOurWorkforce",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - Severance (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.passagebio.com/role/DisclosureSeveranceDetails",
     "shortName": "Severance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_11_30_2022_mVsYEdTSSEuJbQ89GBbHMg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "pasg:PercentReductionToOurWorkforce",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_1_1_2022_1hJs1cU8B0yEBX43Mau-lg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredRentCreditNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Leases (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.passagebio.com/role/DisclosureLeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_1_1_2022_1hJs1cU8B0yEBX43Mau-lg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredRentCreditNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - Leases - Operating lease cost (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.passagebio.com/role/DisclosureLeasesOperatingLeaseCostDetails",
     "shortName": "Leases - Operating lease cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pasg:DevelopmentMilestonePaymentsPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Commitments and Contingencies - Collaboration Agreements (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails",
     "shortName": "Commitments and Contingencies - Collaboration Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pasg:DevelopmentMilestonePaymentsPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Common Stock (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.passagebio.com/role/DisclosureCommonStockDetails",
     "shortName": "Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_3_5_2021_To_3_5_2021_us-gaap_TypeOfArrangementAxis_pasg_SalesAgreementWithCowenAndCompanyLlcMember_c83rb3pHbUyDv5vHPbSVOA",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pasg:NumberOfEquityIncentivePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_plan_r3kCEt0dLUCKcJ9iz91x7Q",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Share-Based Compensation - Equity Incentive Plan & ESPP (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails",
     "shortName": "Share-Based Compensation - Equity Incentive Plan & ESPP (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pasg:NumberOfEquityIncentivePlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_plan_r3kCEt0dLUCKcJ9iz91x7Q",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41202 - Disclosure - Share-Based Compensation - Share-based compensation expense (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails",
     "shortName": "Share-Based Compensation - Share-based compensation expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": "-5",
      "lang": null,
      "name": "pasg:ShareBasedCompensationArrangementExpensesDueToModifications",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2021__q3TBLgQZUa86xXUkhV4PQ",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41203 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails",
     "shortName": "Share-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41204 - Disclosure - Share-Based Compensation - Assumptions Used in Determining Fair Value & Early exercise of Stock Options (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails",
     "shortName": "Share-Based Compensation - Assumptions Used in Determining Fair Value & Early exercise of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41205 - Disclosure - Share-Based Compensation - Restricted Stock Units (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails",
     "shortName": "Share-Based Compensation - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_2SJMJY-9JE2TYYv1hxxQlA",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_IX1f7nEwj0ibkE15bpuVaw",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hYpnLKF0Pkq_6zN2_OqwkA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity",
     "shortName": "Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hYpnLKF0Pkq_6zN2_OqwkA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41302 - Disclosure - Income Taxes - Effective tax rate (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails",
     "shortName": "Income Taxes - Effective tax rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_u4aJSvjN9UCD1Zay5RExvA",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "pasg:TaxCreditCarryForwardSubjectToExpiration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41303 - Disclosure - Income Taxes - Net operating losses (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails",
     "shortName": "Income Taxes - Net operating losses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_x765JqpCcUmsWmKBqTD5Ag",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "pasg:TaxCreditCarryForwardSubjectToExpiration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pasg:StockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - Statements of Stockholders' Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquityParenthetical",
     "shortName": "Statements of Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_n8R9rnmNf0q8kUyWD59spA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "pasg:StockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.passagebio.com/role/StatementStatementsOfCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_igQSE08ufkKu9FiKIPvVZw",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Nature of Operations",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.passagebio.com/role/DisclosureNatureOfOperations",
     "shortName": "Nature of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pasg:RisksAndLiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Risks and Liquidity",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.passagebio.com/role/DisclosureRisksAndLiquidity",
     "shortName": "Risks and Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pasg-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_qyK7UvcoxUmr44ratPbRMw",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pasg:RisksAndLiquidityTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 46,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.passagebio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "pasg_AccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying balance as of the balance sheet of accrued expenses and other current liabilities.",
        "label": "Accrued Expenses and Other Current Liabilities.",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails",
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information pertaining to accrued expenses and other current liabilities.",
        "label": "Accrued Expenses And Other Current Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesDisclosureTextBlock",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pasg_AccruedExpensesAndOtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing accrued expenses and other current liabilities.",
        "label": "Accrued Expenses and Other Current Liabilities [Member]",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedExpensesAndOtherCurrentLiabilitiesMember",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSeveranceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_AccruedLiabilitiesPropertyAndEquipmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "pasg_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs of property and equipment Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Property and Equipment, Current",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "AccruedLiabilitiesPropertyAndEquipmentCurrent",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_AccruedResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "pasg_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying balance as of the balance sheet of accrued research and development expense.",
        "label": "Accrued Research And Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpense",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_AdditionalTechnologyLicenseFeePaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Technology License Fee Paid",
        "label": "Additional Technology License Fee Paid",
        "terseLabel": "Additional technology license fee paid"
       }
      }
     },
     "localname": "AdditionalTechnologyLicenseFeePaid",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to amended and restated research, collaboration and license agreement with Penn.",
        "label": "Amended and restated agreement with Penn"
       }
      }
     },
     "localname": "AmendedAndRestatedResearchCollaborationAndLicenseAgreementWithPennMember",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_BasisOfPresentationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of presentation.",
        "label": "Basis Of Presentation [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfPresentationPolicyTextBlock",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pasg_CashCashEquivalentsAndMarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Cash, cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesAbstract",
     "nsuri": "http://www.passagebio.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pasg_CatalentMarylandInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Catalent Maryland, Inc. (Catalent) (formerly Paragon Bioservices, Inc.).",
        "label": "Catalent Maryland, Inc. (Catalent)"
       }
      }
     },
     "localname": "CatalentMarylandInc.Member",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payable per product candidate for large CNS indications upon achievement of specific development milestone payment on collaboration and license agreement.",
        "label": "Collaboration Agreement, Amount Payable Per Product Candidate for Large CNS Indications, Upon Achievement Of Specific Development Milestone",
        "terseLabel": "Amount payable per product candidate arising from the exploratory program for large CNS indications"
       }
      }
     },
     "localname": "CollaborationAgreementAmountPayablePerProductCandidateForLargeCnsIndicationsUponAchievementOfSpecificDevelopmentMilestone",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payable per product candidate  for rare monogenic disorders upon achievement of specific development milestone payment on collaboration and license agreement.",
        "label": "Collaboration Agreement, Amount Payable Per Product Candidate for Rare Monogenic Disorders, Upon Achievement Of Specific Development Milestone",
        "terseLabel": "Amount payable per product candidate for rare, monogenic disorders"
       }
      }
     },
     "localname": "CollaborationAgreementAmountPayablePerProductCandidateForRareMonogenicDisordersUponAchievementOfSpecificDevelopmentMilestone",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_CollaborationAgreementAnnualFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of annual fee payable during the period under the collaboration agreement.",
        "label": "Collaboration Agreement, Annual Fee Payable",
        "terseLabel": "Annual fee payable"
       }
      }
     },
     "localname": "CollaborationAgreementAnnualFeePayable",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_CollaborationAgreementAnnualFeePayableTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the term of annual fee payable during the period under the collaboration agreement.",
        "label": "Collaboration Agreement Annual Fee Payable Term",
        "terseLabel": "Annual fee payable, term"
       }
      }
     },
     "localname": "CollaborationAgreementAnnualFeePayableTerm",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pasg_CollaborationAgreementPaymentMadeOnOptionExercise": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount paid on option exercise under the collaboration agreement.",
        "label": "Collaboration Agreement, Payment Made On Option Exercise",
        "terseLabel": "Payment made on option exercise"
       }
      }
     },
     "localname": "CollaborationAgreementPaymentMadeOnOptionExercise",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_CollaborationAgreementPeriodForWhichAnnualFeeIsPayable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period for which the annual fee is payable for the use of clean room suite under the collaboration agreement.",
        "label": "Collaboration Agreement, Period For Which Annual Fee is Payable",
        "terseLabel": "Period for which annual fee is payable"
       }
      }
     },
     "localname": "CollaborationAgreementPeriodForWhichAnnualFeeIsPayable",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pasg_CollaborationAgreementQuarterlyFeePayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement Quarterly Fee Payable",
        "label": "Collaboration Agreement Quarterly Fee Payable",
        "terseLabel": "Quarterly fee payable"
       }
      }
     },
     "localname": "CollaborationAgreementQuarterlyFeePayable",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_CollaborationAgreementSalesMilestonePaymentsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payable on sales milestone payment on collaboration and license agreement.",
        "label": "Collaboration Agreement Sales Milestone Payments Payable",
        "terseLabel": "Sales milestone payments"
       }
      }
     },
     "localname": "CollaborationAgreementSalesMilestonePaymentsPayable",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_CollaborationAgreementTieredTransactionFeePayablePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of tired transaction fee payable under the collaboration agreement.",
        "label": "Collaboration Agreement, Tiered Transaction Fee Payable, Percent",
        "terseLabel": "Collaboration agreement, tiered transaction fee percent"
       }
      }
     },
     "localname": "CollaborationAgreementTieredTransactionFeePayablePercent",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pasg_CollaborationAgreementUpfrontFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront fee due.",
        "label": "Collaboration Agreement Upfront Fee",
        "terseLabel": "Upfront fee due"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontFee",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront fee payable upon clinical candidate designation under the collaboration agreement if the company were to exercise the options.",
        "label": "Collaboration Agreement, Upfront Fee Payable Upon Clinical Candidate Designation",
        "terseLabel": "Upfront fee payable upon clinical candidate designation"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontFeePayableUponClinicalCandidateDesignation",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_CollaborationAgreementUpfrontPaymentMade": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of upfront payment made during the period under the collaboration agreement.",
        "label": "Collaboration Agreement, Upfront Payment Made",
        "terseLabel": "Upfront payments"
       }
      }
     },
     "localname": "CollaborationAgreementUpfrontPaymentMade",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_CommonStockAdditionalCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional number of common shares reserved for future issuance.",
        "label": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "terseLabel": "Additional number of common shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockAdditionalCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pasg_ComputerHardwareAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Computer Hardware and Software.",
        "label": "Computer hardware and software."
       }
      }
     },
     "localname": "ComputerHardwareAndSoftwareMember",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalized research and development costs.",
        "label": "Deferred Tax Assets, Capitalized Research and Development",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_DeferredTaxAssetsCollaborationAndLicenseAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from collaboration and license agreement.",
        "label": "Deferred Tax Assets, Collaboration and License Agreement",
        "terseLabel": "Collaboration and license agreement"
       }
      }
     },
     "localname": "DeferredTaxAssetsCollaborationAndLicenseAgreement",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities and other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities and Other",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilitiesAndOther",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from operating lease right of use assets.",
        "label": "Deferred Tax Liabilities, Operating Lease Right of Use Assets",
        "negatedLabel": "Right of use assets - operating leases (deferred rent for December 31, 2021)"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_DevelopmentMilestonePaymentsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of payable on development milestone payment on collaboration and license agreement.",
        "label": "Development Milestone Payments Payable",
        "terseLabel": "Development milestone payment"
       }
      }
     },
     "localname": "DevelopmentMilestonePaymentsPayable",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent differences.",
        "label": "Effective Income Tax Rate Reconciliation, Permanent Differences, Percent",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentDifferencesPercent",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pasg_EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of total number of shares of the Company's common stock outstanding equal to which shares may be issued under Employee Stock Purchase Plan.",
        "label": "Employee Stock Purchase Plan Issuance, Percentage Of Common Stock Outstanding",
        "terseLabel": "Percentage of common stock outstanding"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanIssuancePercentageOfCommonStockOutstanding",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pasg_EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum amount of common stock that a participant may accrue rights to purchase for each calendar year in which such right is outstanding.",
        "label": "Employee Stock Purchase Plan, Maximum Amount Of Common Stock That Can Be Purchased",
        "terseLabel": "Maximum amount of common stock that can be purchased"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumAmountOfCommonStockThatCanBePurchased",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum contribution percentage on eligible compensation by eligible employees under Employee Stock Purchase Plan.",
        "label": "Employee Stock Purchase Plan, Maximum Employee Contribution Percentage",
        "terseLabel": "Percentage of maximum employee contribution"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMaximumEmployeeContributionPercentage",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pasg_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Employee Stock Purchase Plan.",
        "label": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that can be purchased.",
        "label": "Employee Stock Purchase Plan Number Of Shares That Can Be Purchased",
        "terseLabel": "Number of shares purchased"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanNumberOfSharesThatCanBePurchased",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pasg_EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period till which there is automatic annual increase in rights granted under the employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan, Period Till Which Automatic Increase In Rights Granted",
        "terseLabel": "Period till which there is automatic increase in rights granted under ESPP"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanPeriodTillWhichAutomaticIncreaseInRightsGranted",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pasg_EmployeeStockPurchasePlanStockPurchasePricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The stock purchase price percentage on the lower of the fair market value of the Company's common stock on the first or last day of the respective offering period under the ESPP.",
        "label": "Employee Stock Purchase Plan, Stock Purchase Price Percentage",
        "terseLabel": "Percentage of stock purchase price"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanStockPurchasePricePercentage",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pasg_EquityIncentivePlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2020 Equity Incentive Plan.",
        "label": "Equity Incentive Plan 2020"
       }
      }
     },
     "localname": "EquityIncentivePlan2020Member",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_EquityInducementPlan2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2021 Equity Inducement plan.",
        "label": "Equity Inducement Plan 2021"
       }
      }
     },
     "localname": "EquityInducementPlan2021Member",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase Decrease In Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_IncreaseDecreaseInDeferredRent": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) in deferred rent.",
        "label": "Increase (Decrease) In Deferred Rent",
        "terseLabel": "Deferred rent"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRent",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_IncreaseDecreaseInPrepaidResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) in prepaid research and development.",
        "label": "Increase (Decrease) In Prepaid Research and Development",
        "negatedLabel": "Prepaid research and development"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidResearchAndDevelopment",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase (decrease) during the period in the carrying value of right of use assets and operating lease liabilities.",
        "label": "Increase (Decrease) in Right of Use Assets and Operating Lease Liabilities",
        "negatedLabel": "Right of use assets and operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInRightOfUseAssetsAndOperatingLeaseLiabilities",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Laboratory equipment.",
        "label": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_LesseeOperatingLeaseIncrementalBorrowingRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental borrowing rate for lessee under operating lease.",
        "label": "Lessee, Operating Lease, Incremental Borrowing Rate Percentage",
        "terseLabel": "Incremental borrowing rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseIncrementalBorrowingRatePercentage",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pasg_LocalTaxAuthoritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to local tax authorities.",
        "label": "Local"
       }
      }
     },
     "localname": "LocalTaxAuthoritiesMember",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_ManufacturingAndSupplyAgreementAdditionalExtensionTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the additional extension term of manufacturing and supply agreement.",
        "label": "Manufacturing And Supply Agreement, Additional Extension Term",
        "terseLabel": "Additional extension term of manufacturing and supply agreement"
       }
      }
     },
     "localname": "ManufacturingAndSupplyAgreementAdditionalExtensionTerm",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pasg_NewLeaseAgreementOperatingLeaseNumberOfExtensions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of extensions available under the new lease arrangement.",
        "label": "New Lease Agreement, Operating Lease, Number Of Extensions",
        "terseLabel": "Number of extension terms"
       }
      }
     },
     "localname": "NewLeaseAgreementOperatingLeaseNumberOfExtensions",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pasg_NewLeaseAgreementOperatingLeaseRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the renewal term under new lease agreement.",
        "label": "New Lease Agreement, Operating Lease, Renewal Term",
        "terseLabel": "Extended term of new lease agreement"
       }
      }
     },
     "localname": "NewLeaseAgreementOperatingLeaseRenewalTerm",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pasg_NumberOfEquityIncentivePlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of equity incentive plans.",
        "label": "Number Of Equity Incentive Plans",
        "terseLabel": "Number of equity incentive plans"
       }
      }
     },
     "localname": "NumberOfEquityIncentivePlans",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pasg_NumberOfLeadClinicalProductCandidate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of lead clinical product candidates.",
        "label": "Number of Lead Clinical Product Candidate",
        "terseLabel": "Number of lead clinical product candidates"
       }
      }
     },
     "localname": "NumberOfLeadClinicalProductCandidate",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureNatureOfOperationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pasg_NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of remaining options available to the Company to commence additional licensed programs for rare, monogenic CNS indications.",
        "label": "Number Of Remaining Options Available To Commence Additional License Program",
        "terseLabel": "Number of CNS indications"
       }
      }
     },
     "localname": "NumberOfRemainingOptionsAvailableToCommenceAdditionalLicenseProgram",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pasg_OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of lease liabilities recognized upon adoption of standard.",
        "label": "Operating Lease Liability Recognized Upon Adoption of Standard",
        "terseLabel": "Operating lease liabilities recognized upon the adoption of Topic 842"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityRecognizedUponAdoptionOfStandard",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_OperatingLeasesForLaboratorySpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the operating lease agreement for laboratory space.",
        "label": "Operating Leases For Laboratory Space"
       }
      }
     },
     "localname": "OperatingLeasesForLaboratorySpaceMember",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_OperatingLeasesForOfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the operating lease agreement for office space.",
        "label": "Operating Leases For Office Space"
       }
      }
     },
     "localname": "OperatingLeasesForOfficeSpaceMember",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_OperatingLossCarryforwardSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward subject to expiry, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforward Subject to Expiration",
        "verboseLabel": "Net operating loss carryforwards subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardSubjectToExpiration",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_PaymentsForInsurancePremiumFinancing": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the payments for insurance premium financing.",
        "label": "Payments for Insurance Premium Financing",
        "negatedLabel": "Payments for insurance premium financing"
       }
      }
     },
     "localname": "PaymentsForInsurancePremiumFinancing",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_PaymentsForTechnologyLicenseFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for technology license fee during the current period.",
        "label": "Payments for Technology License Fee",
        "terseLabel": "Payments for technology license fee"
       }
      }
     },
     "localname": "PaymentsForTechnologyLicenseFee",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_PercentReductionToOurWorkforce": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percent of percent reduction to our workforce.",
        "label": "Percent Reduction to Our Workforce",
        "verboseLabel": "Percent reduction to workforce"
       }
      }
     },
     "localname": "PercentReductionToOurWorkforce",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSeveranceDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pasg_PrepaidResearchAndDevelopmentAssetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for current portion of prepaid research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Research And Development Asset, Current",
        "terseLabel": "Prepaid research and development"
       }
      }
     },
     "localname": "PrepaidResearchAndDevelopmentAssetCurrent",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property and equipment in accounts payable and accrued expenses and other current liabilities.",
        "label": "Property And Equipment In Accounts Payable And Accrued Expenses And Other Current Liabilities",
        "terseLabel": "Property and equipment in accounts payable and accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "PropertyAndEquipmentInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_PropertyAndEquipmentInDeferredRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property and equipment in deferred rent during the period.",
        "label": "Property And Equipment In Deferred Rent",
        "terseLabel": "Property and equipment in deferred rent"
       }
      }
     },
     "localname": "PropertyAndEquipmentInDeferredRent",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_RisksAndLiquidityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Risks and Liquidity"
       }
      }
     },
     "localname": "RisksAndLiquidityAbstract",
     "nsuri": "http://www.passagebio.com/20221231",
     "xbrltype": "stringItemType"
    },
    "pasg_RisksAndLiquidityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Risks And Liquidity [Line Items]"
       }
      }
     },
     "localname": "RisksAndLiquidityLineItems",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pasg_RisksAndLiquidityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information pertaining to risk and liquidity.",
        "label": "Risks And Liquidity [Table]"
       }
      }
     },
     "localname": "RisksAndLiquidityTable",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pasg_RisksAndLiquidityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of information pertaining to risk and liquidity.",
        "label": "Risks And Liquidity [Text Block]",
        "terseLabel": "Risks and Liquidity"
       }
      }
     },
     "localname": "RisksAndLiquidityTextBlock",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureRisksAndLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pasg_SalesAgreementWithCowenAndCompanyLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Sales Agreement, with Cowen and Company LLC.",
        "label": "Sales Agreement, with Cowen and Company, LLC"
       }
      }
     },
     "localname": "SalesAgreementWithCowenAndCompanyLlcMember",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to accrued expenses and other current liabilities.",
        "label": "Schedule Of Accrued Liabilities And Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued liabilities and other current liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pasg_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]",
        "terseLabel": "Schedule of property and equipment, net"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pasg_SegmentPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment.",
        "label": "Segment Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentPolicyPolicyTextBlock",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) unvested and exercisable under early exercise during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Unvested, Exercisable Under Early Exercise",
        "terseLabel": "Number of share options unvested and exercisable during the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedExercisableUnderEarlyExercise",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pasg_ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duration from date of grant (issuance of an option) to when option auto expires.",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award Term",
        "terseLabel": "Term of award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTerm",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pasg_ShareBasedCompensationArrangementExpensesDueToModifications": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of share based compensation arrangement expenses due to modifications.",
        "label": "Share Based Compensation Arrangement, Expenses Due To Modifications",
        "terseLabel": "Share-based compensation expense due to modifications"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementExpensesDueToModifications",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of outstanding common shares to be taken as automatic annual increase in rights granted under the share based payment arrangement",
        "label": "Share Based Payment Arrangement, Percentage Of Outstanding Common Shares As Automatic Increase",
        "terseLabel": "Percent of the total number of shares of the Company's common stock outstanding"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementPercentageOfOutstandingCommonSharesAsAutomaticIncrease",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pasg_ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period till which there is automatic annual increase in rights granted under the share based payment arrangement.",
        "label": "Share Based Payment Arrangement, Period Till Which Automatic Increase In Rights Granted",
        "terseLabel": "Period till which there is automatic increase in rights granted under the Plan"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementPeriodTillWhichAutomaticIncreaseInRightsGranted",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pasg_StateTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to state tax authorities.",
        "label": "State"
       }
      }
     },
     "localname": "StateTaxAuthorityMember",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_StockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of stock issuance incurred.",
        "label": "Stock Issuance Costs",
        "terseLabel": "Issuance cost"
       }
      }
     },
     "localname": "StockIssuanceCosts",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been vesting of common stock previously subject to repurchase.",
        "label": "Stock Issued During Period Shares Vesting Of Common Stock Previously Subject To Repurchase",
        "terseLabel": "Vesting of early exercise option awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesVestingOfCommonStockPreviouslySubjectToRepurchase",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "pasg_StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock vesting of common stock previously subject to repurchase.",
        "label": "Stock Issued During Period Value Vesting Of Common Stock Previously Subject To Repurchase",
        "terseLabel": "Vesting of early exercise option awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueVestingOfCommonStockPreviouslySubjectToRepurchase",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_StockOptionsIncludingSharesSubjectToRepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to stock options (including shares subject to repurchase).",
        "label": "Stock options (including shares subject to repurchase)"
       }
      }
     },
     "localname": "StockOptionsIncludingSharesSubjectToRepurchaseMember",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pasg_TaxCreditCarryForwardSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carry-forward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carry Forward Subject to Expiration",
        "terseLabel": "Tax credit carry forward"
       }
      }
     },
     "localname": "TaxCreditCarryForwardSubjectToExpiration",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_TenantImprovementAllowanceReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of tenant improvement allowance receivable from the landlord under operating leases.",
        "label": "Tenant Improvement Allowance Receivable",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantImprovementAllowanceReceivable",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_TenantImprovementAllowancesLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability for tenant improvement allowances.",
        "label": "Tenant Improvement Allowances Liability",
        "terseLabel": "Tenant improvement allowances liability"
       }
      }
     },
     "localname": "TenantImprovementAllowancesLiability",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pasg_TermOfManufacturingAndSupplyAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the term of manufacturing and supply agreement.",
        "label": "Term Of Manufacturing And Supply Agreement",
        "terseLabel": "Term of manufacturing and supply agreement"
       }
      }
     },
     "localname": "TermOfManufacturingAndSupplyAgreement",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pasg_VestingOfEarlyExerciseOptionAwards": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of vesting of early exercise option awards.",
        "label": "Vesting Of Early Exercise Option Awards",
        "terseLabel": "Vesting of early exercise option awards"
       }
      }
     },
     "localname": "VestingOfEarlyExerciseOptionAwards",
     "nsuri": "http://www.passagebio.com/20221231",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r261",
      "r428",
      "r442",
      "r459",
      "r460",
      "r468",
      "r472",
      "r477",
      "r512",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails",
      "http://www.passagebio.com/role/DisclosureCommonStockDetails",
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r261",
      "r428",
      "r442",
      "r459",
      "r460",
      "r468",
      "r472",
      "r477",
      "r512",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r254",
      "r261",
      "r291",
      "r292",
      "r293",
      "r404",
      "r428",
      "r442",
      "r459",
      "r460",
      "r468",
      "r472",
      "r477",
      "r506",
      "r512",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails",
      "http://www.passagebio.com/role/DisclosureCommonStockDetails",
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r227",
      "r254",
      "r261",
      "r291",
      "r292",
      "r293",
      "r404",
      "r428",
      "r442",
      "r459",
      "r460",
      "r468",
      "r472",
      "r477",
      "r506",
      "r512",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails",
      "http://www.passagebio.com/role/DisclosureCommonStockDetails",
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails",
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r8",
      "r476"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "pasg_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r55",
      "r123"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r126",
      "r439",
      "r450",
      "r454"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r14",
      "r17",
      "r83",
      "r395",
      "r445",
      "r446",
      "r492",
      "r493",
      "r494",
      "r496",
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r3",
      "r476"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paidin capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r300",
      "r301",
      "r302",
      "r496",
      "r497",
      "r498",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r148",
      "r149",
      "r150",
      "r151",
      "r160",
      "r185",
      "r186",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r300",
      "r301",
      "r302",
      "r319",
      "r320",
      "r321",
      "r322",
      "r329",
      "r330",
      "r331",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r430",
      "r431",
      "r432",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails",
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r73",
      "r74",
      "r263"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r24",
      "r31",
      "r95",
      "r238"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of premium and discount on marketable securities, net"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Amount of antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails",
      "http://www.passagebio.com/role/DisclosureCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r31",
      "r53"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r96",
      "r104",
      "r125",
      "r143",
      "r179",
      "r181",
      "r183",
      "r194",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r332",
      "r334",
      "r357",
      "r476",
      "r510",
      "r511",
      "r552"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r119",
      "r127",
      "r143",
      "r194",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r332",
      "r334",
      "r357",
      "r476",
      "r510",
      "r511",
      "r552"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r188",
      "r206"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r48",
      "r190",
      "r437"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years, Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r500",
      "r501",
      "r562"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total, Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "auth_ref": [
      "r500",
      "r501",
      "r561"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost",
        "totalLabel": "Total, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r48",
      "r189",
      "r436"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year, Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesContractualFinalMaturitiesOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r45",
      "r187",
      "r206",
      "r433"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable securities",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r44",
      "r206"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails",
      "http://www.passagebio.com/role/DisclosureSeveranceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r84",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails",
      "http://www.passagebio.com/role/DisclosureSeveranceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r33",
      "r121",
      "r461"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash, cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails",
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Cash, cash equivalents and marketable securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r28",
      "r33",
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r28",
      "r94"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r488"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cost or Amortized cost"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails",
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r12",
      "r99",
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (note 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies."
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r58",
      "r222",
      "r223",
      "r455",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r496",
      "r497",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r2",
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r2",
      "r476"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value: 300,000,000 shares authorized; 54,614,690 shares issued and outstanding at December 31, 2022 and 54,244,996 shares issued and outstanding at December 31, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets:"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r18",
      "r131",
      "r133",
      "r138",
      "r434",
      "r440"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer hardware and software"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r103",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of credit risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r469",
      "r471",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r307",
      "r308"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r112",
      "r490",
      "r551"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.",
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Deferred rent",
        "verboseLabel": "Deferred rent"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails",
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r313"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total gross deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r82",
      "r544"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "verboseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r543"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r543"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r82",
      "r544"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r82",
      "r544"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r314"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r82",
      "r544"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DemandDepositsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts that may or may not bear interest and that depositor is entitled to withdraw at anytime without prior notice. Checking and negotiable order of withdrawal (NOW) accounts are the most common forms of demand deposits.",
        "label": "Cash accounts in banking institutions"
       }
      }
     },
     "localname": "DemandDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r31",
      "r178"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r265",
      "r296",
      "r297",
      "r299",
      "r304",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Per share information:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r139",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r161",
      "r163",
      "r165",
      "r166",
      "r167",
      "r169",
      "r347",
      "r348",
      "r435",
      "r441",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share of common stock, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r139",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r163",
      "r165",
      "r166",
      "r167",
      "r169",
      "r347",
      "r348",
      "r435",
      "r441",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share of common stock, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r37",
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r309"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective income tax rate reconciliation, total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r144",
      "r309",
      "r324"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "negatedLabel": "Federal tax benefit at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r541",
      "r545"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r541",
      "r545"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "negatedLabel": "Research and development and orphan tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r541",
      "r545"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "negatedLabel": "State tax, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r10"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "pasg_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Compensation and related benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r540"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r540"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense related to unvested stock option awards"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock."
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r60",
      "r115",
      "r135",
      "r136",
      "r137",
      "r145",
      "r146",
      "r147",
      "r149",
      "r157",
      "r159",
      "r170",
      "r198",
      "r253",
      "r300",
      "r301",
      "r302",
      "r321",
      "r322",
      "r346",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r395",
      "r445",
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r350",
      "r351",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r90",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of assets measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r237",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r351",
      "r401",
      "r402",
      "r403",
      "r466",
      "r467",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r353",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r237",
      "r255",
      "r260",
      "r351",
      "r401",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r237",
      "r255",
      "r260",
      "r351",
      "r402",
      "r466",
      "r467",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r237",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r401",
      "r402",
      "r403",
      "r466",
      "r467",
      "r469",
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r354",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r92",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r191",
      "r192",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r207",
      "r208",
      "r209",
      "r239",
      "r251",
      "r336",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r465",
      "r502",
      "r503",
      "r504",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r513",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Non-U.S. government securities"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSeveranceDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentPolicy": {
     "auth_ref": [
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.",
        "label": "In Process Research and Development, Policy [Policy Text Block]",
        "terseLabel": "Acquired In-Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Operations and Comprehensive Loss"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r210",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSeveranceDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSeveranceDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r144",
      "r310",
      "r311",
      "r317",
      "r323",
      "r325",
      "r326",
      "r327",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "terseLabel": "Accrued interest or penalties related to uncertain tax positions"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r542"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Income tax examination, penalties and interest expense"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r134",
      "r305",
      "r306",
      "r311",
      "r312",
      "r316",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets, and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r23",
      "r24"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Contractual Final Maturities of Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of operating lease cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdsAndLeaseholdImprovementsMember": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset held by lessee under finance lease and addition or improvement to asset held under lease arrangement.",
        "label": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdsAndLeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of future minimum rental payments for operating leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.passagebio.com/role/DisclosureLeasesDetailss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total Undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "verboseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r388"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureLeasesDetailss": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r9",
      "r143",
      "r194",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r333",
      "r334",
      "r335",
      "r357",
      "r463",
      "r510",
      "r552",
      "r553"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r7",
      "r98",
      "r107",
      "r476",
      "r495",
      "r505",
      "r548"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r120",
      "r143",
      "r194",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r333",
      "r334",
      "r335",
      "r357",
      "r476",
      "r510",
      "r552",
      "r553"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r21"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r171",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Operations"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureNatureOfOperations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows provided by (used in) financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r140"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows provided by (used in) investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r28",
      "r29",
      "r32"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows used in operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r19",
      "r32",
      "r100",
      "r111",
      "r118",
      "r130",
      "r132",
      "r137",
      "r143",
      "r148",
      "r152",
      "r153",
      "r154",
      "r155",
      "r158",
      "r159",
      "r164",
      "r179",
      "r180",
      "r182",
      "r184",
      "r194",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r348",
      "r357",
      "r464",
      "r510"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows",
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss",
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted and Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Summary of activity related to restricted stock unit"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.",
        "label": "Office equipment"
       }
      }
     },
     "localname": "OfficeEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r179",
      "r180",
      "r182",
      "r184",
      "r464"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r383",
      "r475"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesOperatingLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureLeasesDetailss": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liability",
        "verboseLabel": "Total Lease Liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails",
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities - noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePaymentsUse": {
     "auth_ref": [
      "r381",
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments, Use",
        "terseLabel": "Cash paid for amounts included in the measurement of operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePaymentsUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesOperatingLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets",
        "verboseLabel": "Right of use assets - operating leases"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails",
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r387",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesOperatingLeaseCostDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r386",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesOperatingLeaseCostDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r124"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r128",
      "r129",
      "r193"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "terseLabel": "Unrealized gain (loss) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss",
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r84",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r476"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "pasg_AccruedExpensesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Follow-on public offering"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommonStockDetails",
      "http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Purchases of technology licenses"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMachineryAndEquipment": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for acquisition of machinery and equipment.",
        "label": "Payments to Acquire Machinery and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquireMachineryAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r491"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r26"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommonStockDetails",
      "http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of offering costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sales or maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r26",
      "r72"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from the issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails",
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r57",
      "r456",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r54",
      "r122"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r56",
      "r108",
      "r438",
      "r476"
     ],
     "calculation": {
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total, property plant and equipment net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r56",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails",
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted": {
     "auth_ref": [
      "r0",
      "r97",
      "r105"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations.",
        "label": "Purchase Commitment, Remaining Minimum Amount Committed",
        "terseLabel": "Minimum amount agreed to purchase in batches of drug product"
       }
      }
     },
     "localname": "PurchaseCommitmentRemainingMinimumAmountCommitted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired inprocess research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows",
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSeveranceDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research tax credits"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Unvested restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails",
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r211",
      "r213",
      "r216",
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Severance"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSeverance"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Severance"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSeveranceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserveCurrent": {
     "auth_ref": [
      "r489",
      "r507",
      "r508"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.",
        "label": "Restructuring Reserve, Current",
        "terseLabel": "Unpaid severance and termination-related expenses recognized"
       }
      }
     },
     "localname": "RestructuringReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSeveranceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r4",
      "r61",
      "r106",
      "r449",
      "r454",
      "r476"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails",
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r115",
      "r145",
      "r146",
      "r147",
      "r149",
      "r157",
      "r159",
      "r198",
      "r300",
      "r301",
      "r302",
      "r321",
      "r322",
      "r346",
      "r445",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r385",
      "r475"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "negatedLabel": "Right of use assets recognized upon the adoption of Topic 842"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommonStockDetails",
      "http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of details regarding the Company's portfolio of marketable securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfCashAndCashEquivalentsDetails",
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of details regarding the Company's portfolio of cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of effective income tax rate reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of share-based compensation expense category"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r215",
      "r217",
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSeveranceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r262",
      "r264",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r64",
      "r65",
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity plan"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of weighted average assumptions applied to options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "verboseLabel": "Severance and termination-related expenses"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSeveranceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Sharebased compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited, Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted, Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested balance, Ending",
        "periodStartLabel": "Unvested balance, Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested balance, Weighted average grant date fair value, Ending",
        "terseLabel": "Unvested balance, Weighted average grant date fair value, Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted-average remaining contractual term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested, Weighted average grant date fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationEquityIncentivePlanEsppDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted average remaining contractual term (years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Vested and Exercisable at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested and Exercisable at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, Ending of period",
        "periodStartLabel": "Outstanding, Beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r270",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, Ending of period",
        "periodStartLabel": "Outstanding, Beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price per share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested or expected to vest at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested or expected to vest at December 31, 2022"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r269",
      "r288",
      "r289",
      "r290",
      "r291",
      "r294",
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommonStockDetails",
      "http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationAssumptionsUsedInDeterminingFairValueEarlyExerciseOfStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and Exercisable at December 31, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfSharesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted average grant date fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationRestrictedStockUnitsDetails",
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested or expected to vest at December 31, 2022"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at end of period (in shares)",
        "periodStartLabel": "Balance at Beginning of period (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r36",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r13",
      "r60",
      "r115",
      "r135",
      "r136",
      "r137",
      "r145",
      "r146",
      "r147",
      "r149",
      "r157",
      "r159",
      "r170",
      "r198",
      "r253",
      "r300",
      "r301",
      "r302",
      "r321",
      "r322",
      "r346",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r395",
      "r445",
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommonStockDetails",
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statements of Stockholders' Equity"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r170",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommonStockDetails",
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r1",
      "r2",
      "r60",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of shares in connection with employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r60",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued",
        "verboseLabel": "Sale of common stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommonStockDetails",
      "http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails",
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r1",
      "r2",
      "r60",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options and vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r1",
      "r2",
      "r60",
      "r61",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r1",
      "r2",
      "r60",
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of shares in connection with employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r1",
      "r2",
      "r60",
      "r61"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Sale of common stock, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommonStockDetails",
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r1",
      "r2",
      "r61",
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Exercise of stock options and vesting of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r2",
      "r5",
      "r6",
      "r42",
      "r476",
      "r495",
      "r505",
      "r548"
     ],
     "calculation": {
      "http://www.passagebio.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at Beginning of period",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets",
      "http://www.passagebio.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r62",
      "r142",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events."
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r396",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommonStockDetails",
      "http://www.passagebio.com/role/DisclosureRisksAndLiquidityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]",
        "terseLabel": "Schedule of net operating loss carryforwards"
       }
      }
     },
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of noncash investing and financing activities:",
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Research tax credits"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesNetOperatingLossesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r110"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "terseLabel": "Tenant improvements"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r191",
      "r192",
      "r239",
      "r251",
      "r336",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r502",
      "r503",
      "r504",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r116",
      "r117",
      "r148",
      "r149",
      "r150",
      "r151",
      "r160",
      "r185",
      "r186",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r300",
      "r301",
      "r302",
      "r319",
      "r320",
      "r321",
      "r322",
      "r329",
      "r330",
      "r331",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r372",
      "r373",
      "r375",
      "r376",
      "r377",
      "r378",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r430",
      "r431",
      "r432",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureLeasesDetails",
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCommitmentsAndContingenciesCollaborationAgreementsDetails",
      "http://www.passagebio.com/role/DisclosureCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by the United States government.",
        "label": "U.S. government securities"
       }
      }
     },
     "localname": "USGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureCashCashEquivalentsAndMarketableSecuritiesPortfolioOfMarketableSecuritiesDetails",
      "http://www.passagebio.com/role/DisclosureFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r39",
      "r40",
      "r41",
      "r172",
      "r173",
      "r175",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Valuation allowance increased"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/DisclosureIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r162",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r161",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.passagebio.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r478": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r479": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r481": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r482": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r483": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r484": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r485": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r486": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r487": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(17))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001558370-23-002833-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-002833-xbrl.zip
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MN8;R5,>D.['1G2PIZ;:\I&E/'H/IBW.JN)K-[S+;59-R5,:V%>5@],*[7=W
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M-<>EU+MZU7@5M_!1NUC3K6L/0?6O[,6D.27BYO.G[IG/7JB75;=3C7>@XM<
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M6:<]MFLF*9]95]ECE^W99)]2, 59J%"$ I ^\NNW 5$2*1$D>(B$J'G(Q)*
M1G_=C4:C<7W^Y7WB6*^8<4+=+WO=_<Z>A5V;#HG[\F7/YRW$;4+V?OGYG__X
M_*]6Z_>SAQMK2&U_@EW/LAE&'AY:;\0;6T]T.D6N=8L9(XYCG3$R?,&6U>WL
M]_8[^P.KU0IHG"$.=:AK26*]_>[BE_. 'G5/K'[[L-WK]/I X*1W=-(_MDYO
M%P5O@;\122WI$/?/$_'/,S1I 5"7?]D;>][TI-U^>WO;?W]FSCYE+U"]TV_/
M"^[-2IZ\<Q(I_=:?E^VV?[^]>;3'>():Q.4><NUE+4$FKE[W^/BX+7^%HIR<
M<%G_AMK(DZ)/Y<M2EA"?6O-B+?%5J]MK];O[[WPXYVN-K13P\"M)*+^ #7*V
MK,^,.O@!CRR)[\3[F.(O>YQ,IHX@*+\;,SSZLC=%_ 48[/6ZO1E[_W[T0.7"
MFLZ0(P@^CC'V^)XE*'Y[N(ZP +4Y>L'/A.[;=-(61=JJ^NW2&%O\P>]&=U/,
MI+[XJ3L\IY,IPV/L<O**;RC/PW46XIN!=([X^,JA;T6Y#]$IS.@%X;9#N<^P
MH"K^N_S+)Z_($4V!<&X1^Q-[Z-G!C]CV&?$(YO>4>2/J$'HWBOOY KX@3@:0
MF^2A%@&=4]=CR/9\Y%P1%SFWR M^J5%BN9DJ4817B+#_(L?'=R/!@VL3Y%R#
M?V-RE"LB!UW*)8*Y9Q3<B/<!\A;2GXJ&OF*O (@TBB4R?VK;S,?#R_<I^#TL
M;.;.&V-V[C,&C=X0]$R<HK:9O8T2 =Y@&&/GE'.QOTIA4\P5YJU4UJXA))W@
M)_1>B+\X*IMA\G(TPK8'(S=\>H QLARFE50#$#9R;-^1(<0-L!PP+NCE#J/"
M\L#O'G:'>+CXEGB",L3#G8[5LA8DX.^ BA60D>P!@PZU(Q0=$?U2%A6QX)0#
MJS+@'"'^+*-.F(J\(#05D7ZOC1V/S[^1VI":"+[XXY3S$.\.>L:.G,I$?FQ7
MRY/T,;.VOU+7GCD;!8NQ9?\X[!]U^X?'!_WNIT^'G<%A=Q "$=+\*8OB0<R>
MMP-_KAE#-*P/2K2Y/YE(:BT".IW7'S$Z69=DT!C- X"R(68P[=RS? Y\T:EH
M$SE[UALF+V-/_C)EA,+@__%EKU>]VF8AN?LB7=N#X.EN](UC"4ZEOJ0Z6Z7&
MS$ "=?:2U%FQ!N?1RSTX)&\EA%$H,*G*-NDO,XY ?7U3>^,,ZGFB\XR4V29M
MI3,>J&=@JGKN&9XB,H^LYX&UCM(T:IJJRB3VXKID/J ;'B?7HUKQS9S;!\PQ
M"&8,[%[@5^Q0Z40DT_%JS59YNS5; E:=47.IW'[U;O<59ADB#7-%V2.*9F.>
MO5 N)]DQ9Z.RW591)FC31V61Z!,)ZY5\GW>.&/N Z%$FP!1&H56W&::0'ZKI
MXWXH9P8 'SUJ_SFF#O#,!5#O0Z'[]&H5X]#F?+U@5&_=P<%QOV83U55*V$0U
M<9D^:7\0:3$7#R\1<Z%C\5/;]B="_AB&Y1&QB6J(2J]HGIXU=;:N[)Q@35=^
M",8LKQ]>1YWE4L5J*DR![T9/Z%T5K&2CTB"S* -YMH"V!AL9#LF,I7N(VJ_=
M<S0EGN OWA;B2S=)YQD0&A^-TLF$NE(4B8'G2K$&:5,+VA;%E.GAHWG*RQ-]
MI0$RW:M&EPOF:#[2E[O2ZD6ET0-I],Q1KV:GS =2)]BJ6,L0&V)@>/@ /)_#
M_XF7JN"D*DW0;69\IO?DD B2<WKK!9N@3TU4&XZ$%#EY[>U+<3EY[<I&JS%)
M*2N)^6* 39_K*@:5Y#Z;7*D!BB\ U,#]"V#!U'<]?H\^Q#I"RAI+;.$&Z30#
MP)SN^7-[91==>5OKLNSU#ZM!N>^NM[;O;MF$14?6LA$+N4,KTHPEVZE\;KZ:
M2TK)PR76J+@G0L/+_)>"WTB9J%GV!T>=XYK[G88"PKTM'8WI(^2U^XJY)SK$
M JU"<S$ES=-?ND+6E:@+S'15+H;SU$X84[(9JM0%9OK\\E?L A '1K[3X82X
MA'L"UBL.PG2%6E-JF:=B776M*SH/U-3^VZIY&U'"[JA3^R^?L&#%Z6F,W*<Q
MH_[+^,SGQ,6<P[CU3%PI[]^ ?0B'[D8CY2)NN<TTR:XJD4VJ]VG5OC\@3@I!
MW[I\MQU?G'Z?"^3:O6?4EA+@ZHT#N2DVW[SRBR%U"E>W):E6R+^Y#".'_(V'
M_Z&.P/PK(JX0Y)V[W/-WR@ATK9<+^.B^W&. ,3S#(\JP>CJTL?;,L\*,4Y5J
M)9,SP*HHMQ ZB:^51ABDI!$$/6M&L/J=I2O[)<'%>(S8'AX&^RFC7X1*SO0(
M5L!$^N\"S_X/GV=>"-P1#'(O6)RCG)VK3-BB6B43U6<U!,_@BE\)&,?9QS<N
M7'-P7%UX:P@\D];A]0E$N])@<'!\4+>3J<7 5E(L1:1G^J1=CO!XR*] ['(7
MQ)WDD%^^8V83OG1&ZT?PDNN99TL%-;EN&OEDL'46(4XGJGQ+?.%=U+T:N.G)
MGGOT$<0E$L@UY[ZX&D $_4JU)U39!>5GA6_\/"ELSG,X$*<N-RIJ]/_8>KM@
M#;EDL.']G:H#HX'E7E%V[7*?"5[O&9X0?[(00-R^%)UZ#59U,1D$JCY([/UF
MS"IF:U$%9A4Q!*(R.1@<=KK?9Q7%I+<M(<43#7*)<3?%I<06B77-LZF"&E4'
M&=GED'&AJ>8I!O0J>?6@O%;P(_Y209W9APZ=73";4F2RA0[&'A,7L\@EB/H>
M)J;R+MA*?D&8/Z-9Q7;M>C N$[#]Q.OG4NOMHEUHR2!U1E.W22CDM%A.S1OS
MQA PSTB,C7EUI5?/:8YUS(7.=Q0@9YY)%53HRO2Z;-'4<R/7.HJ5:QDEC-B#
M#]HFDX7B[EE-8>EH;8^J?)MT3.<('[1X8FBHVI>I5SDJB\/!P=%14RRE!$&8
M?JO".K3@RKOYV=?8&PVU#4:'V$X:4&[!9(R6,^\&UAZ?$J]&U!N0$DDTV"Q*
M$X?6"D$5P4KXI+R>[L,U=D_5J>@#S1[JC1N#RL>-TPEE'OE;RO%N).Z\% \;
MB#$Q6-I2#!&I]1IL"\5D$%C$)U,CB<<Q8E@^ 2=VZ\)H)O$IS""^\ [H/@/P
M0.%'IBK\ D\9MHD$ '\[6&K&'8;-6Z%^G:H[8 RYQ1"8QK&IIM&($V&?0-9U
MWT=<NLE5(K)Y"JUCJGT6//'?2,M(QSM7:];4:/FG8S;YA&-8>XJ3-8/.H-.S
M6M:2#?@@N/C)LL61&KQD1M[/,5FT9_%%@U!EP9(XC+-DREIR9?T0\/5CU4]M
MK=QO'[W5/AB@1!##/8AFB/)1KLQD:GX"887!Y9VYOS+H%LM#9^*T6=JAOE)H
MF^=Y\II&TO,)Y8G&^-/R>:$+M[PIBXO0_FYQV423;<_30>T&IWJJ1-.F5-5W
MPVPRH3?FIK)*'W#6#*#ZA0.H'T(L6I)':\FD,J3ZT9B8*FI+2]8?(7QW\'SW
MY04XI=SQ5K$FC')42^9/1QYF=RX.YJ=7Y!7_#R:UT1Y=4$!:;40[_9$!)U<V
M86+Z[K ,\1EX,[8NZ-^(-R8NH!90RS1&->'O%EB2S$R\(#:W)$L?'(S%'M'R
M%2(LZ6F08D2;U-5*ZUC)TMEB7ZX:P,JRL53ZW\VMB*#TW?DF)UL+'N]&P4E?
MY%R[W&.^/":1;<9TT.FNSI@$?4LV(&8[BR:L4!OU37;D%K:%!)9\JSJ.NKP1
MSY[J(]&N;V 73U-:^KNGNCBW;FS84*)LZ]1>"*8Q]^LM,=XS.L7,BQQ=_(J]
M;,[Y<-TYS^G*!-:"\D^6B[W:G/*<)W'ID+<"6'6N,;%*?6^ ZNR=4?*NZL$E
MD8^:_C&8?MVI<!W%*QX++5\26DMTU5\M$(] +@=E[1NRTO9;00Y\9@3>VB<
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M^TG3Q,_MF4;AGV?$\<__!U!+ P04    " !8.696B*C5D:PE   37 ( %0
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M\-7JL[J#%<XMZK !#X@I,+VKGAKXO-[H@7:K,?* 5XW.J#NH?>G:+BZPW@2
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MQDUAEM=3S>Y3GX::C0-AI3 5XV+"I#6J@.YK-J_8"U2^,,+']P]?:@JV:/M
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M-^;GRYQ$9VRTP$/A&8K\@)<".<=Q,(F6;SA9,MQF: A1'N[DP892SL6EB1S
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M32"M,#IN.XMH4JAX'%0'#=''EDK>H1N"#J?^BQ6O/'>2YV7HP7\N_[;S7YR
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M"9XLO4)DRUS#$0IU!O6%OO*_=,2FH[[S1*)Z$^AF1$7'^:&,0OX1,Q[&3#3
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MV&:2D:<]>9<AP_>(H.$"IAJNSV<W[.> P@_+T%MNHCCU_]YT-%6S*_+0[6(
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M181J#?!FJ.K:%REL]3+!8<G\UHZ8LXU.\@\I]R[NGAQ5QL<2[I8,<E@"WPH
MU-7Z;UQ0:.R /-3;E97C6]T:<5!K"-W7<6L?L< 7Q=-8P/+[%,K*KWI#=X?N
MR$.ZJR&TZB//9PSOK,(H=9'Q@<#D=L%2%;D\T"T?N;[=PO\S.USS=0__A8)A
MF@?Z?I20P\4 \U1.#'4G@QA$AF@SVO4)+$ABVSBN[9L3]S2A+,)@9G1!7V@0
M<83+RJ,V(HA>3^2(T4']@S**;=T0(T(7Z0<42>0\^,@I<<DK[^)+*FQ:Q=(=
M%);>N#1)ZC5O#'[=OLC#OY,)JM=3-#HBAH!N\O>_NT$R-D3E^?AP8!K3+%TV
MFXA9!G =GK79R.X--;TUAX;FZ#&@6=':6VGS64-H%7GXQ2R,,3RZTK8J;#DQ
MO(V1W-&8SR/THK.]%_(@U52[4I2KN0OBD-65O*\3Y_0)8T X!WP1/+8-OM"4
MW$2)9 ,KX?R%OBZ+<R L#PC9CRZ53CCJQ7</,L@#OJ]A9 3H2@,Q)/16I7]\
MO)*2(ZFRQ <7D]OGGL+*8+ G2R_:PML/D+-?)\F./P.AL)N=/0/WF7J[@-ZN
MEDPFSP]VL*!9[IY>OKG!SJ/>%8L_6 3=B=-QMZM#"&Z]4#P&(^0P-9YQ*QL2
MQKD@AKH1E>V]8I^)!,<V9:&DDQ(D%XN @Q!),'[#Z"CC(K\_\I,&UI$3N;D=
MV=SEL0Q"*^9VJ^:FN;FWS-R)M>2N-&W]V3/N ?JHJDED-HC9Q2CU:*A#819(
MUTD1$V&E/+>)$)<F-XY'4\</$A+3M1-[_"729\HAW0GW_\10)8K3%<LG(WZW
M!-6!3PG-7Y@.8*.K*'YPY.-R+'5E8>H'/L?+CB#4F^QL8&F8X11I6R^:LX"N
M@:H92<ER$<Y647R6.)4CK*0J!D)\0V#!3HBW07-.]CI\H8EX .,\<)+$7_G4
M^[2'=S"@LM?."3X[\.AANK]P4JJ%= -)(D<Y$P:K[H?UIX<8W8RHU7^+J6!.
M2N[D:4\D_B07@( $:$#-JN%D\\!-_L)(, HPW*J]X6"WY,<R22A_*TAZ=/PS
M=>"*J'<;WH.4V9.M7Z(PSO_)"P1IH=DHC)!CW'C&K:T\8HP+8CP<45D#A3LR
M ;*=B4((/BF3Q4"#D@C-^;#;L+1NSU?<N%!DD\E!G)2LP-@OHDI*2!Q2FI17
MI#-94Z'(BI5W/+XF=+4+;OQ5<T)G@!Q2H#-EJ+)@0W]:Z.LY&%"M;TPQ<KO
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M&R>P+??OP(+TH^JTHGG9)@:O5:4D2+7#BA\T=6)]U^,;])NR12NE9'=T(R-
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M>B831(4W60T K?-,\P;D*NGT$Y+W$OW7";G$857I.V>D9=<ZW[0:H>!/-'E
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MHI':S1Q#_0;P.II_)C<N9ZX6A152.N\*2$E5I!FY 9AZ9-;II4[E)38EZ;#
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M->P)1VX]\E19$)0#PF2)4-V.\Z2ZC"E3-)^ :GY;6LR%H17O/!\DQ$HIT)?
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M38U##7HZ;IOE$-XE"M]M^O"N!&G]IG&#R[S-,'G\^AC">.4#^"IM[YX 3F1
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MO$*O>>7F)1Z8"W$W<$)>KA:XM,@U+O=3\P<W4AOQ^?-"H6DV\JU,)K3FX[,
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M)&Y@@1#^5ZN6WPAB^(Q1"<MT;:D3/OL)ZR:DK ,SM;Q)ZC,6A7!2$.J!?0@
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M-#9MS4M'=R1RY(;A?24MJ_$#"WZY4 ^/C/$@&&/L5;4-X=4%,UEH;VJ9&J@
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MJFK:ZF_VP'0U9?57-(-RQ]5?\<00GO3:[R--,E9_@^Z-$-YST.H5>=,+52#
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M:F*+J:PG Q;'RG%9F6R)D(G%3L@^Z9"NKIQXMM#RK2<LRS,XK%#<,"P&/MG
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M)4..O=V/8!53%,28,!/X(<\GHX^C_@_0@O_[XPQ+?ZSK_? &Q)LZTJ3YJ6H
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MZN1 ,X<295<U29=LBQZ;ZQ^%0-12B'<A'S%9[&*!F(Z'F,@;D8QA#\PIN&S
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MB-204I8_OVRF% &UQ:-.%+I:;U:H*-*2RV?CH:&@Y^%KT/WP %K_$^>K:5>
MR6SH7;FEN1/*!J_N;K^N@L>4V'"C'U0 LVOIY#!:L]CY)^Y"0H%,OJW\O/Q'
M?BY^+RMBX_@[_L?#/WH ,Y#;_O6YSUC# XI2T4@T7YIG#D^DC).(BM[7-+//
M,;>K1?'R9/3\JZ:8>0->+\7<;):KM?*B..MS%TN4/^U+E/L2Y4Z5*'D<'O7M
MWBTI7+].)MSW#!VQ+X&X>#80.VM]Q9DOS6+_\0^*+Y@NO#3-\ <?R<',PO/G
ME^0#)!UP903KY F&L@*79 3\P?W'7L5?*;?PF\#FS?G0!$KRS('KOY$+=T57
M:&K<<4*Q!T*X=%<Z10-."523UG_XXHM.Q>XA:X_?/!M UG*8N)G5U6(#[U@Q
MI0:TW2RF=+^EX&U=ICQF(QQWV0DEG9.U:TTGU$SWCP#$IQ@ <4?]SK[C$T<W
MS>N$KV71B>.I /-$+>VELA*7PG[KT;/0Y *#Q\ +V]780V[(:;@H7?/L:193
M;?:^K^*_S0;L)469*TCC"H"L7F91K(I9XXHQ_BIIT)B+O!A><E6CNWQ&$S/'
M)98;=&",Q$IXNI* 3T*C9J;J\$MJ@+/XW:\?@KZY+Q5&\O9@.0-N>66/BV:1
M'-AG7S5>Y/M>%2]Z!$EWD9,;^99;"J_K14;OQ-__%=5X V0(N5I95JUP?RV
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MOW<.L-TQ<M[(V/?\B=/.XX9<H2(:S5%AZ"H$GTFE5[<2'6$<W?0(]R!?S.Y
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M<8OL,7/_D*A8JS!8>$7%[;CC<-"<>1I@7:;TD@7#^%R%';QXZ[I5I/:6ZNI
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MY::"8E3"S1:!W2@4'LJ@YB%\=3#(X^2="3H)VP"_O!#MZ#0(PIG;;-RXIAY
MA^IWR7CSK-2O!]\X>I!(GT\J_*,.J!\BH#F^=88\",,[IM4QEXG.[RQ?,NT%
M,_X,XZQY" "XY?'RO?,4]G%OT:+X")"=$-EC:-B)KY74O\2/[DO2+ZN:=%P$
MQE\K*/LM1.*+#IH8M-C];E%VEB;&1!&"% OPL80NW5(JX2"OK7-1@0R5W ("
M"9XT?W49^?XD[BSL-7R>:\IYW;4FJ_O[)JM]D]6N-EG=IH5ZJ"'^+CLG3/?@
MN8LTF8HV'QRIW:Y7A8'C( 51326-"/HE.MCZXC=C^VM+5RG0V94-49/-VT>/
M51_4BWF:,BOW3:!)!!*AW%1FO"[]XS(4GW7$#@Z4E3OI!'82]%9"$*3L-U[!
M4[E,IS4':@&?Z."-+4RZ3FOX/SUK5J(JNCP RNB#KV(DMPD%J>H/\W:TN#Z&
M*^0;<M$=/90 ) .MIR&$4J36Q*^1L9\FE\!A'23<%(;OVG%8)=">76@Y"G)+
M?;P9OJ(..3JA8M$?>B%#<!I0[GS+!/?&N3_&:;_)X8S;"]J!^\I2CZYJD:JI
M375FLAN!!^,=#-:=<#PNL0UNY- F$0H1=^LNR!PKR>0%)E!2OCV>_G8%O.WV
M+32X*#AB83?5*45=48AJ0-S$]&#63LF,+ZI+I4U:W"[+?#1EA#\!T92[/1Y:
M4B%F</[59M;UPCWY3+C%,578H?+/7&#+G@V,X:#J$$.R=J,*CW;=%9ZXM!<:
M8$7C:"]R[^7QW2#$GR5S\#OO--Z $*"V@MADT_GH$I0YX(=HE(@,?$*K=<AT
MUM!_3'9-EGI-$9IVVI"1@ES#[C9OWBHIT4ND[<0A?Y->U%CQS072_KPNPGZI
MR2;*'IX6#(075->;7PY]^O*'SVPE']T;_7C]=O)E,<T532UYTP7B;5W C4N$
MQ-(>C0>A@<253LZI<8.CASS,8VIR)#0E(7=<)BF$*TO?6B$7N]?,:4C!?,ZI
M"6XEU12GC;.OJ[&:>9)-Q*D62BX)LODJ9'A]GA2I7-K74U@O9&==_8W92%X_
M^P>>_'>OG&O37'YN]S]-V<UF3)$#<B!"1EO+BIQC%I$KKN>13^5I"@9Q-<&X
MIE+(IRW2+B79)!>/'1D,DGALPYB&"^1JFJ::"O^R-E3;-^A2):3?BZG/NCM7
M(.3H_$*\"C<?V9C7D,:Y6K0VX0!V.&4@68O]'#P9<E$ :_0(TI24YVCPH[/,
MEW29TLLC"O'-F^.W[T;8)RPMRH,TG=-&H^-^DWJBS'BCZ<A*"9KN07%[1VD>
MC21*42?LPHTZ\+35BK5-N4V5WQ7OANS6!7)KJW:R*)JYHX7$K8\.C@[&W])&
M?R>A]BM.OC_]#\@P3QS99?*!Z>QX-?[!1^4ZF^TX.3PZ&,VR#06,U2Q1_D7T
M-*]PT# #,9C_WKQ+.>19%&!,\-RAB; #*@^"&$*F<'5[CJ,W94A=5PLR83(<
MZ:#$5?X)C6S*='I:+,*XVY?/!K1G63F+0B&AYW#\YG6NX;L/:[789E?50,T]
MB0 D.3Y27".:P8/O2S,U<QO3L<?[3Q =\O:!'>]JRLZJNF%=W&JMIVK&H_O\
M_2L)VLGK)D]&W&Y]+KH;G,[H%JP#)O$?V_D@6QX=/.X=58(64E_QZ\0G"V/'
M)"V.',$X>2O.M%,<&1)[)HNSY42S\>.3C!^45<Z"13+9>+8;%R^QS;2X5AK(
M4)*9B;UOR<XYMK%YN\QTW90SL ! ^;*>TZ'<! \UW@E7]9)COS]0,MN<=V1]
M8CXEA.2&YEE6-%<CFN3P03+#&2->F$UX)S?UVMTH=5>SS^2U[E+PJRGQ 6X
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MY1X[M/2:<N2@P6\G\X??,>8[3C[FY.MS*S :+SI]EBL0UM@O>PV6C8DI,T2
M/U.MUN#R$Y",=4=&K;?1)=DKCI+*>=#@%??1!4TPN"T3C/ MK6"APJ):7J#I
MQZMYD6T(1D-XIA$ ZPU@6W$+!U;D9;PRG +?PLG F?:<N^?TY22.;+1\0I\(
M&5FG;5T+^5B7BD<7=U6>544@YVK]]1>Y$$(YS9F@+;F+:>I.*WTZ(J$-AMV"
MF^X?8B9;F1R6! I[GAZ,$U]_JO,S-&QC04@/.S^SJ3-6LGY\4Y,A3/$FX=/%
MG$F\HI@V*)EGB]-@S^_09M\I>QMMO.P\*Q:\\234'5X>;N]UJSX#)2>K(%VC
M$B2M<IQ]0J3+P!DM'7I.J&,F4&7RB!G_@399<5ZM'876+,=^$B((1^0GJE[6
MT:B=C+9S_(81%0],&/>N31<MYRNF-0#"1<:@R>P3O=&_966J0L.(B5Y[-FHG
M#YKO0MEWG75($UM%S'98@$MF)6_<Y,"B<7&3)6LM,R*MR9DJF_+:"XQ+UJ[G
MR&<5TN#+[C!GBV6A&)8O/* D4\/]V&#07M6,DP55[D6V$5;(R;)PR:PL^443
M+TWRIB!/FZS2\<JUT#+J_)<WQZE**?DGP\7/532'UO<RKSDIK;DLW7U_+WD#
M?5A#3%?) .AURTR,^5<FX/X")!)=!/]SFMD[R[ZH,H;^6#YM2Y7O@4<PG/,;
M:$-%OT/4YX#N;W0*3T'"51FH4;8!;)#;%P.<=1&Y(U;([^UY7FH&6"6-).^(
MIG9'U\,[Q;O4=;X.;NS94Y47A:EV^"E+R=[V7M91L8@E;&Q=FTB?VEWW9Y8S
M,#VS6KKJ2\_FP9N=_G8I9>+.\DS>8J.\]Z;A.1LG.:^^6H&J3R&8O'Q^S#RX
M9W7&2^2WY\_3Y/T[_)>94J#%?4*F]F/XA %?O?G[ 6SCU!9AGKQHR9CF&3KA
MEV8_H[O5*_B7L^#2N.OQ[#QC*-&)R'@G;R$HSKH>JH\JE!@G;]^ET9?Q-"8U
MLE=9_C*I^<?[U/P^-;\K?.%?DN+J X[&S;<RMM=D$Z&==#;GTY#NUIYFJ)D*
MN*]>EYS1L!8#_W>5DE&+[/,/_'Y2B\87T.UEDF59[V/3.8KJ[.JR;",_PW"N
MP?(B!>*S[^6O]2?\VCGMER?/V1,[>OKNEY<G!T=_((_BM_.\-GI >LW1J_>_
MWEG/FYX?^48G*Z9("<1-\(^S5A-2S,8Y$CK;&;NZ+/$UA<N.Q:LP9NY^+*V=
MZ^%#02R,,4RFU"G"A2++N8BU-/UVV92SNE)@C#Y$01XOQ9**&3;9FC0A?_:L
M!86ORJSETY9=;2/;&B?// \7I"PY6<?I;T >%A9!R,LPJQ,SC])&/LN;#APX
ME!9=5(*I+DIN:.*8-&/EE]0NC5&9U=D%,B'S#=T<.CN6ZZ3HN66P5#%E?[Y=
M\"#8FPGD!HRC(DDD[::,OX#N%#T0# UB)+H64CMT:$@':M%X4G,>ZU6SF7H%
M3&C)+BN+<Q6]0]- IQ2S;:<6(^= &Z,!;()L?P-4FWA__K7X8M.I*)DR-9K,
MM,RIY 8*6DKBLBE'EPP;Q40YTL8\:<;! ZX>485,,@C#8@;8V$BD(I21PN L
M:Q$7TO'9V:#E>@6:CJX8N6'0[#GX;UEBY!T4LQ8);=YI-,IIN"X%>=BJ%.BR
M-5USG4F$ NVBD*3)YRB>OO\UO;[<*9#W*3^6A/*!_ 9KG5;V6./D'5V9::V5
MH?*3X_)=;$2<G"L1IF*ZGN,$YX2V'--@QJ*O)76UD(T.^0]%[FS2B&A3<CVG
MBVRY5*JO%\N\/I,R@%+;->T9**A4AA@/Y[(*+"9+;\:;MO0:C_0H6/K,OL^D
M<(J/-!FI<YXK=KJ-_4TR9YP(E0Z.2L2UO)*KLV%W>6D+%UXF5(FV7CEWO-$.
M<9P%R,*M5'=V,-ZET1TGQW3NH"<>YH*S&IK/SDLE]^1D<HGSI\'Y$:J;F9F
MN'M>GF5G[**MYT4]&\'SDT+HB+Z]V+ &-5*7FIOA X(5&>F/*A:1)>=97>0"
MZ9OE(ZR==7%:T&55R "+!">BM.= +;/I-GK8!:5,TZQY^SM!^6QA3(M\3@^E
M+J4X&]N.1T<I!8?:%]V[S*S- U+]6YJ!&X@>JS$"@E'D>Y@91)0Q:02<H0/G
M'L8(LAZ;:XP'_*Z.I,_UAN<^1H?I^'F8=G5OW4KUGC4SR$M8Y$K.?4?]4G 5
MSU&(M(G.G)-:L9<F=73V>>0D64)7A<_ I%C3MLO76ONP.A.L2IT!)$VNK9IP
ML'1XLRR 9.DPMQ(<ZF*</>,3Q)%_TN]FQ8R7F+J^6CV%(Z5"P.P[DH^CM QQ
MF4(5@GZ^[>H3$47+#_$+(#>TR%9-_K/]\/0+S* ERA[[WQA&B)]AM,@V5;O^
M^;3XE,_"[(QEF&32US7];V8/K!][+'^[MYZ%?_RLAR:OD4]33;UQ%HZ>]VG(
M/EQ6S#T</(2FJSS\[^CHT=/N<\4?ZNS/VS[OY2&V)I&VIEE DD'37M>RW7_N
M[?<O]6S;$UQ;#?\E3;%("*0,'C?7GSXE/B#P^-S(R8<^W#A/-$.;5623E8<$
M'Z4M+B=" RJ;=>0DDN\FGZ<C0*(7-#9@[]6<3.6L"^Z0QNRJL5X=UULZ RV<
MY<(D ETF+Q3*;A\BS+X79Z0F'%O1M6O5TQX\@;['Q,56YML^33^-C\UW#V;C
M'MN9O<G;FSP@:QSN;*>,G0]R/I8L,N >$P;%G!@V29GC%^/US( (AQ!:,W5:
MT7"2:U:W9V'LNC<4_SF&XN&#JPW%,SK\"O(YZ;&_BE&H=M\<O.L0#/I]-]XE
M\^#S6UO<E*SD+&N?=E P=XNL66:J+KKFZGZ<\V!\-@4F\5?)'9FW]');8OWO
M,F%#N8/O.#$N.S'-:NREX2SRWL9^?QM[L+>QWVG+/A\ Q^VHG?UGB'5'XD]]
MJI8%-*:*H^.W,$-I:=NI"^$N104&CAT"0R[$^)H@6=U40L""X=UGFO99,ZXJ
M[)E 2S<]_:) GG)8>GH"<6$M\DE-4D1IK"5[B%; /3+*%*OYII$2R(Y:M;Y9
M&48#6=#$0)D_@N79AX&?Z_<%/4#_H"_/LIW+?[W>JB +T[-WR;:-&P70TX^T
MKQ+RY_-+*M;?:ZR2T;U1LD,#)L/T^MD_NL0>W#.#5&M$+.Z92;Q2FJ5>'26[
M2,"GUO;15(O6+NGSFISW/-.SAD^9 1VS0-:62RLSB*&MI6X; AA6\YQ^OUGE
M:?2T=35I&R^=Q5N'G]9SD </_$<ZYKY:%8[I/3ME.'T(Z15?_6&IBY_L8=9[
MF/6.41=_66@J.1S:O9$\LQ+U708!9+7CE.4:H9QGKOW:*[ES"&3M5Y9OU](\
MRHN+/&ALYHM0>#4@NVE_Y60=ZWVNM3^&$W5T#"[H[0#<28Z/_W&8G!< %YW3
MS0%:0MN^:+UFVAY+C_3\UV,*Y*;53.%.WPQZ(X\/C)F.DT.Q<=53 $)G%6"<
MIP)'TO? <:HOH@V5F>@6T,6L]AKVT\LF[#H4VIF&\YE^1+47[<;6K6;@OPZ$
MYYO#DBSQ)Y*4'D_F^9KUMY9@168U=$$BR8+[!PQG>BBX3>X8"#X:"DO*F*7^
M0<JJ'+DL)#(9@N+1Q@->;*IDRYS,?4^+3BXP, N\"]^!(D5#\4<F7U%?*E"\
MU$>4)+',F9.Y#?BJN5\"'CFW9S,Q(..G5YS5 &9+O3P+<$)& G[P09\P6"_!
M$X2I[^D<&!PP.Z_ ?*/9C&)JWY0V2)/1Q?8.,^@B7++1BULN/?\TS?-9/M.%
MEEQKN6R;1'BV8AB072KP6WK?A]PX=_R/>?OH,12!V:]M8'#.N#-3=\U#;M(/
MVCMVS4;?"H'6BW9WXOBY[I&CUI_E9&W[90(D"U-S#OX52!UEVI>,W3&C $86
MAT0]GF"$P1_1#@S6OM6$PCW 8/>!W4[?9$Y(.F1.\YIEXL1XNU9B-?!R3'7^
MID"V@;W5M^/8-4,+-SH"F/N!@<]R*]H6><-JWEFC=:H)#=^%Q(C\3#2"' LV
M@,J>+39B?/!4H@G%YR@TM;VF.EC<Z>EB;?!I44\!JS,0D86::(H0HSV Z&E+
M*=0' NLNC2KO/88G53';"0W;-*=]<5HP:$A%PE:M=7K1SGYU\@[3=G1P=/!U
M^[5VD*/BLQC==NI)MW.W@4'/]=S3DOB';*@/9MU_!CM:<ND%U#'7S?M7M^U'
MP;;7LBV;#F]::,N,:,OT)>*_FRAG.*4[,X,W4 X]//K>#.T/O[#BZ)<AT\R2
M8O9__O3__W7Q\<DC&J2?#N__22+HK\&+C:/P%(9]ZF0WPL-*B8FS3:2(:.ZV
M.VPOUU'5A"V<$$XHNP"/KQ[R:YT7&6=17>"#R(D/<GR/*;*DL_%BGJ.)856=
MMLV4 QB;[>2'+%%^O2A3.MLT!@+],0U^KQKT$=FUH#RDAABT*>F1(SV4W ')
M?CA$]Z31Z[Q:J%-JT6^W!AB8G- %"9R-B+6ZIT"Y!'-('9@E'<EN!'WB8HC@
M+@OQT@/-$T[>,LN))9 A$ H/':.2<5ND[]QDSKG.*RL/X31JR\SDS _)?K+I
MM%VRAZ I;#]W4IX53Z@_YC\XWZ50]X5<@#.*+W[4;E/Q16;!E,[S3U6384!F
M2&O'C-$[LLGO6-KVZ&"?MMVG;3\W;7OTX*<O2US].?HP]V^K6_Y -.>V.A\/
M[K#O\34>XPJ-]7?)2?6IF/+YJ"+HWTRYY!8>V</'3QX?/%*/K/.'HT>'7\]5
MNQ[98/+D8#2CH/O5FW?2QUU 3&'M1UA\-D_99ADT)VW"3*-,X J$U(+"<AFA
M%-BI&7P,Z[?65!Z@5?2OB":2G9(H>.KF3I@CL\ZU)""9A+%B^-G/*JN$]AWT
M)VK)PD1R)-*^/1.&K@$7B'.,2!<@E:Y]Q_!G4E9P4S9;.$F%^')!;1LW6^3M
MQVJZ67OADU \)"M!!-Q<+V<H$W/=#&,O!09EXY', R?"R 5>+)2EUJ>TV%^%
MKPSUY]RE47@@!;&F2C,55%78D&%<+4^H@#E-/C'@(VS;)OM*<Z/AMEL"EO/U
M&&D6.?=)(:E]8)!/R6>-G\7D9.!.IE$:&Q=Z_OX5WO0Y+>0GVD3]KQ8T@#+^
M&IS0]<&=&EV4*QU%T[3H"@4#FY,>C#UI%X/0/%:TFK(IDDA!FDL23J4N)[<,
M@EP5K\Y4<V22C%_DN2]?W63"]8U0IL)3RQOQL4SW!3.2:@/E4WJOA\+$0=N\
M2>B@H1.PL[4@9417(6_,7P=U.+K6HP/_Y?^X)-G-[6D0KO7GQ98]W:Q=<K@&
M$7*Q#<A'_L1=]0^"V9),\J#!@O)[]A'&<I*O+U#]>HYO'#Y@_>W'8ZA#,/NW
M[NIX82<^1)1PRL-W>H6;L) B#X2%?22IY$:YNL?)"Q\XSKB@($E6[,E'!VG"
MC9B:\752H-F*7J+.E"  &Y8,#O-*G-$^;]9!J<M7N59&=2@I8V&I6$?<]];Z
MC6@U6RTH0FS:4RE9=LF9-?+^#U[;MRGSOZ5#48B+>/F"K6:6!P>D)U&1\)T,
MM%#VGM /<IH&^E5-7C9HL"]1I$NR3U59*2D3+]VP>H<MH_N!US&"R)7C7>JF
M)@(%O,:\A#59X/*CP0ZR<N.1W%4=G6M]13-\VC9LN\( /#E(L%.U2B_F%0\&
MI=Y<GW1DY*[R55JIS#[%7";!^2!OKYX6IT(B^BQV*H2KBS_)51IWE$U [P\7
MIV;B$KT$/W1G=.7:KK+"A_>'7X_?T?7@_I&[ES,L'1OWZ+$<KWRNIMH+R7O6
M:4QX2+NY6%R'.^?>RD_((J%_6G)$LPK#R^6<8E(SV55\RM/ERWQ:5ZMF8\?B
MJ"@EU8-G=-DE,:/V7FC?CI><F^NN2MJ-YOM&]>:M:R-8%-_?QC!M5=,NZ7NT
MO;:!G6?YDJN.6OZD:<'9Y;*LWF5'6UM<J%N+G,-BXYQD6N]T)<!76B@+=J"@
M!C>1(=N&&A"RQH%[:7+R<Y*2W24"UJ+O/U$[XNC\0=.3A_OTY#X]^4<D[PT0
M+W<*Q/-;)'D1P'98NT=@C((?O1905 J#W222-D>$;%0=!M_3:MHJUYM2BOI4
MD/!DNN#!D(??$AUJP,.=(4#;D;1Q9P?9':\SIJP)X42\.@)J6;*^J$8BW20)
MH;RAQ:)D_RJ7(\$L4I--R^)A#;QZ%7R26$?7:@QG4B)#A62Q@VA?,L=39&]9
MX8>+G: ?(\?-RS=C\4GP[FAO126*GMLDIZZ9;V3F056::-:0H:!(G1]*G^:'
M^^/[GPX/_O+GGPX>/ST\T'0:W05,D/?.ENI6B3G^\7I.,VMJ"+Q3](I?.,[$
M;[6G?.]:U0K+96ZS:L,13GK54=VRP3D<'_K!.;QB<&XR)74!7QW1TZHJA%=3
MB#:][ISDXDU&C5/502)>%)\?'9B<\XVBFI/*I*>0':25);)N(?&SRX%.'2%U
M+ZIU*#S?6I:S)K9)L+C+T4,6:Q%"5_F3EJ+2T_7HN<C]G&,',5N7[C_>( VO
M5B@_TR'>CZ0MKG$P#8OX\D\@(0RLO@653.'1>PO'3_V!I=7">1&N9S\9$G((
MPMSIM2,U]\ 4PJ/.]$Y'>D A$@'O35PO:&DW K,H_N5N@'XKO%BC4$7'!,40
MM3L@]F0C89E]Z+FRAR?O.7_'*8-GS]^+1+U$8(67Y-.43YQFHW$HUV3^H-<-
MN&HUR>HH9.>+OCQY\]RN[HZX-CXMV/Y+77AXT7()UJ!?<.*LE-KMMJY6?%8<
M_O0 AU.[NI[!2&E>6CJFCI\]T^?M$ A/JS,X%\BU\%)@X,S8*?<*?6S>>!TO
MI<^=TN/!1@1SZ^PP9!1+%63G? *,CW$5G :5&3^A$PIO12-,OPPF[O"[8E]H
M8[I4L$B-^0T(2OF"1D%:>E\_?_M,59!$IY#\=JX=>H52OD!/IA2$XVA&T>-1
M@$IR.(V3X\7"GYLFL2250!T7R,VMI>'E%*,JC.)(/LJ3AG;/ <!CU50'6=,E
MWFRYKR^0L<VD0S0D,3^-[V473?WC3C8,./,"D_<?R05LRY_2RJ<H#3*A^BTR
M;]M;8,77V2$W_3AI.(D.@X_J(5!VX&UU6?VW?WTO):EYOI!B,:!CD[R6<0#6
M.M5^)&[ H8,?P39LDB2C*EJA2K5$.VDQ3E[:1QC]A^I;-<$^P>J <96=%ZK)
MD5&9PMK35F!%TA[%\,ZZSX//L".9H$ORB<?M&;J4@)?A@WU6&3 @EBP-#O27
M)W2@BW#9#BSL'1_BB")'1)U= !L8I(X=YMT1*MRJ5/05^K#?^W5W?"Z>\VG)
MWF8<?O%PAX+1&GY%"L1BNN@C*PHX5&QPP'#9E?_5%K4";TUL4R J=TP\\\J.
MDMYHW]^=>NA- E#&Z(7ZA8$*GPR[<ZI/.( [UMG[>N*&8C\X507?1$0M7__Z
MW"]8:!TZC5?469^='+/!<!H=TZJ%;D;>J)*@D$%K_1U>3).TUFG,L;S+LSE;
M?R+1&I)YX<)+Y28C2=F3GTF[:[3()HC!);4WRLA78NG+I*]Z&:3\(!44A1Q9
MXC5U3 ZIF\^STO]_3&ILB[;EE:*6"M ;%OD86<OA>HNVY26ZEGY!?2-IRKLC
MC?>9JG<\95TYNU#([DH1NV\R']O;[[98U]_8X7^?-[2CR?ZH@$;#G777ROCM
M&IC&S#-RMD'LZ#0RH(WDFI>=3D@BV,IIQ25Y+WT6UO-K'236!V.>O8GQWK.)
M?'7RSJ SDG["NCE^<_"0M^7Q&V%I8CM>EMDR=\(=_/>_MM =/UM77L!9<TY?
MW9FX%",>BOT]>U+5IS\=\;N,].5X_]["#.P<SOPK/(:.UXB11C#9Q\M-M2:+
M3F=]\D;Q11^FBYSA.Y*KTR&^7@+AS8>4B5JTXU[T"=.^MB 9ID$Y+DYI3N<9
M9.[I=?XM69>@6T^94#(X(*?D?ZPT!X0,#=G1:FVH'W+(H$7##"]5)&IXD6<?
M2_HY=<IW\C6[11K<8[U98:O1HRMB5DI!X KUR2JH3>FC\_N.D[?(PTTSE6KD
MG0:I0&1'9S32BE5R+>^ S(LNVJ1==[215'#..3_BZK5K[6Z[RS"-HSU,8P_3
MV%68QG7,W:RBJ1(2C*(DMX6#<#H[5=,.>YZ+3YI/Z%M?F$OZ*]*L787(SRB0
MZGUN2$O%!2Z6FX7M$KG9OE0<;%F0=;*B%A?F>!+@9/X0F[ '8L+<GW$--HX_
M:J.$FD7W^^X%'O^WZ),&GW// (*FC3NEW#"B'WC*@2TGHE%HB,WJ(5\3@&-W
M6U1QD"<[%"5/J4N4+?+;ZGJQWMTZ<COD@9&]-G$\!R^(!R%]>'"07%3U8@86
M*+[7FGTSOL(EXJ$96I@I * -4JV1\:[S%: R^:<5 -D^"R3I6 K :ZG1Z6-J
MI=G+9"YSE"^+9AFZ4,$";!A;N\F9D^8\+^58DI//@QS<51J,C&R%=1[B]KG/
M+ '6GZ??G>!UT3AZKJ!5GQFTZ8VF=3%AM+"<O30H*WKA\,V5GD.@YO?@*4=7
MP:L L5Q,*AXU%#.FQ8S=F?>_'KMOV?'OG@QYA'*&4:K:QMWEJ[J[MS$[0%-U
M.." ;7!H*1"3#/+?%?3VD@NB#3ZKRE&UHB7+7A;_;40N$F2%@R7N&S/()$R*
M4JNY6.'8\C3P])2Y\<VQ\K&,_A+W4J=)1,-<7XA_#DEX+[)IKG5DG0E6:E[,
MP./2;1#!:BX:%ZE@I[0UV)8@^KZV713&3=]T_FYAKO^NP5<WYOU6B8CK1;$:
M4+J4!&K.03C;K/*ID"M:5&I3E(8M.\+@N#895D5-"/3ODH SFO-4<_#:T20&
M.UH':@^[ZR#Y)=]4G,?"Q:IZ?5HMBBHU/CV.A-W3#\?3G)+A,J5#!V(/21Z-
M)CDO#9(AR)-:Q++#D0)61J0-OJUEN<7*?/%IM< ((-4]N#KO=$(F0UNP?\'N
MNG5S[@V7,7,&_*?=Y2R3#N9(*)O&<J8&^1JP7 %&R:5? VM\\N:%1*4J2\1'
M_TP\#:F0+VA(W.VD>;E=B0?7PC!3])M[P4=DAK[EM-PX"_@V3(C>W=S?JY"N
M-D[RBK:Z*8WC]T!;:>E6I&A/VQ@LS0N@5P($0HRLW**_%%,[8[G'ASP;GU F
M7S4SKCRMV"R29V^?@=!4@(4H!X7IY-9X!#OOP5 VSZ-&A_D:$9  8VVG2?<8
M3-Z\6,D2?):MV9E.V1E!9_5TW7O;^%95?48.Y[\]H.S9\[>_"4PM!'W'7RKS
M?+8[D)!;VBLE.4ZRX:$V7Y ']J\O_G;TY#Z-PA*];IEY7]I>!257[OQ*41!
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M5;GX@NXAUYQ_@P_>?XSGU@9HW[)MX$E=HD2-*,O 6R_SL\JP!]P$(9RX03;
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MM0?":((XASEB'>659.GYKE'H8 2NW?*YP8O%]=;JO38"10UOQV#=]N);=N6
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M*@FG&EO,QG. ' ;#D2@V6TJ(KF5-"4N-R,4*V,[0C9-G'H#= .IL4IT>C^"
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M+3<T MH)/^N5GCK#LC29O8Q[(D:B*>#!DHI*EZMG\#'N6U4LUMDF7AA5@J@
MX;8_,1K51>@"$,Q+^?*HF&(Z/UJ3%9M2A6VFCV(UA+F;>QWZ$MKCI8>BK: *
M#'9\5S0:FM8/"X<R*/<!2A6"IR["+B^-GN))Q1O$:%(]D4Q*:>Z]N)?9TR(=
M5<+AC&:#4G.:0M10$Y_E%2M1'JT,1)AV91%V8;U\$$[]EU#0HEZ H>._!*&9
M_W"I(8SG>3"0^Y@3_4QV\DE_'8ZV+S;[&DJZWE1M'M":P:18WC8D*.18E%)\
M5VR9D4:<&;GG!@S=9DN-YH.]4S*@^J&?R/%@&+7@C4 !S8^8BG(W^'_SP_$;
M^6.Y]:5O;(3G=#!R>8@8;Z)8!N__!>$I/!1JOH[^A^+RZI)OXB>JR>),>\G>
MLF$Z^U84RLQGZ#Z?N]]UR3599??';.Z7_SJ0^"#7$E_\]%<A!? T/?R59R[%
M<@'?B9OF,73"?VF\\E>TIVM)9RGRH!)(\M6KNP.AXLA56;5G GA=[-I\8.7.
M?#UTJ5CQ38.:V9MB@XY)X$,6(W$^L>H$_-OAKA0=45Y3R1L/HU^>7E[>U4NJ
M>6*OOB*XBU0%Z;MTVCC'J7^ER.>_O'SU[)DLE12F>,GX#@ GH)KV 9"Y;)7[
M\I+SFP_",YYK9NK:/Z-W^._EYAWEPG ( YC)FWVY+C'",F'?S] .=V%&QX$=
M$Q%G7(FF"!4'.X]^NA"4,-"PU();W\?\A/^E:?)-R4745D:W.>BF./@PT$:2
MUA]J'M!1QE;@/V6H4<I?;^2_H8^WR;L]?W;UKJ0.$$CPT4/BOVT+%VV(;-=
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MCX-!D5\=-JPDU1;^S2B"DHM?^K<1(I/PFUR<\F3=LJCN%-F6]+"RT]PB4%2
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MB#I!8%H8)$\BU>6IC%B$B%FJ- 1(*;L5K7-M$(:"[BI2YY*'5,?/)I*]-8$
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MD25V#FU]XMF?P'AA-8@ZGG+=KNJ\'SQ!ADZR&9IVAI5*2Q&34LTFGZ@C<'N
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M15-)SPR3JVI6)JW4%%U8Q0^!1+!T_#%M:EH0)#EINA4Q,R*^1R60._*,I+6
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M&E*IHS>:\0GM#RJ6*48NE K_A"KW06!I4M^>0BH_R3M]G28.F]SES$T*8RV
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MC,[[*G$^Q"]S=%YDH* #J*MO_^/9/+_S^A0(Z<Y24K%#\@17.R.ID9!0S_C
MG/W9?-TVN;/RLDM0E=.FJD]&M#4+(";W"DLCJ<MX1YDV\<(Q$7,F'W<L(FFE
M::3_&I]]=Q:<G;)08W1C&R&)):Q):+FP_4WM%5:O^,M!:)NL4>AM3KX*81O&
M/#>];IQMM%WD;#Y/8(1?G!F"+UF)PW)JL]_56&_;% Q6Q(T84"T+RKG(+\CC
M#@@1]'G<?59>R#4X#N*T2B]A1U,%&U:)2BRP1-<<7L7Z2I[A?J1L:>)Y3\9N
M[K(D#NQ#KAQ&,TOD@X_>")Y8W])0V)6SKF+R17HZV(06R/EG%M[1V0>W3Q
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M#00.&&7^:JSW\KY"1)G.KC_4A&=$3#:%!IHK4/MZH1Y1S/1I\S!YUW6.07R
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M?UP*39="TU,M- T""CMU"593:(M2U?BTPWI2V"?/G6_8LN<7O;AW &]A- ,
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MS6).'*BM0C[L2DC:H?]$HIO*N>TC+/%ED<,E"DM')$FV>F]Y.0RFZ[W*!\\
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MZT@$DE%N*G<#;:5M0RH#@,@@UJ9$ZZ'C%6R#9<"*',:(M\_(I6-4*32G!$7
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M[QI_?]0B7MZ-_-8N=X\/;@@FYLC?:)6G5L[XWU[.K(0D_O$#J89!.92IK7F
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M49;;L$?!?=\A <$.$:6)6@8VD/[)09[ /1I+<!3>]9O#MLEX_8Q^5MJ=+",
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MDHX4S51;ME*Q2K;TN)E1S;>1K_I&51!<6Q!WQCB[BS1&\7E )+@G.JV;>C)
MWB=O/39RDXZ:CYAS.^ )FS^@-_/BRWTJW^R([K&>--N>533O]2ULYO#@3=S.
M>IV"?93WT%Y/:1?NHWZ%:\4,#XX7E&\:[7MLELVJ<>[:V"0GYEF(RA*#IQ*
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MF;MO%8Q:].P\SV:CM^$]I],+Y\143HBUL>E2.HO)"J26#NP3T_/..81XAB@
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M /4C\0R2-4A64%(F!K H"X8023G)B#A)YXIC_ A&P1@D:9 D+TD*-E5Q\>-
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M]?QF@[PVAA@S= =:;D/IX)7PE&*D@C?*#-*J@+6BN><5+V=]&IM;W<SS-CW
M+5%>\Z3/RA$ >L&ZS3X]H/R(2K*!C;])(2OI<LGKX0<#HO?P(<P8=[_SX;2C
M)5"O^Q!(A[Y9'2-2XC0"=D+#Y5VZ:UGI"P/W>G /^]Q,BK>B)"-[,'Z@4D[8
MFXLIBH7+ 8T9)87P@H=$D_->%OTALOP$(#SV,3JO:1E6T^RBC$$UF;K-_:EP
M:S$)$.A*)7EQN_[TE1JA/</$P$@2R0-PB+U%X,R-XHP\9TW_;3(U-15XN7$?
M;':)4&L2:PP&?)I ;R>'?)ISS)4?P[LD@,WR]I9-L\'0<YN]M[.SQYBZJWE6
MLR.*C?(N@U=H 9[\[8MG]!6Q8<A0)")X]Q'%/X]-S:+C/]@XL(]1!&V94O!.
M<3V#1L1)GS/Q>(=I(W@4(2/ ",OTG*7BGK.%W2)\D^YOK_<C)TH$.,XF"5,)
MS&@19C8)-XCSZ'=G"G/;G9B.8<';F,;T<CVE=-H$L+DU9?\B.<=*H[Y(/\#Q
M7&06XIE,\9;;R(L%IY(B;"DMZS6"K7*-[\HG:V<?S E$6W5H^Q H:*S3""M@
MJYI]C"0E!F#J'X%>9IO>2I--U[P*'4U-!.S.OR-IN)#3*#&D.R4MN+D&26NZ
M>8MPO?U]M5@Z071N*43Y)PTFO\6O5LLZ'.[=O40307]_]=-;_"&0$5WK+H^@
MBN;L>#IEF"/M/1M]G__ 8LN8W.ZNGZ9K=2=G;F/3.?]][;X40?"3IFA*RDEP
MP,"]KZZ5W0S/^&YW>V__<.2\MKE4YD)NG[J7ZEM[4]&'] D[, (F*=LO%\><
MS\*YF[E[WXY_&T#DR\(=#RIR@1!.L[&;GH:(.-M$^JUQQG06IED_Q5"_SR^N
M&@%V?9K! ))+TCFO3DHH&)3-<>EF.-^0:>(UX!,3U(1Z["^>:7QTD:5%;=&8
M-\8V^>YP%B,AQ(_AI!9;4<G#Q"F[>O3=T<Z.6Y&%K$AJP-?=1ONTA>PX&0+@
M;P(2)%T7I)2(-J%&'=A4!&+T[Y43S:SB!'/-UZB06=TL:B/==(N\H8RM$)QP
M?J="G*P$B8LSREF%$K&"DKQLTC:^3:^%^\9W02?BI9\FC/M-JHD2)@B3A+%(
M8&E C?YKUI5Q.(BS%L$HIH.R#K&YU-E"#6H@HM!C'*^[>;I 3;NA0'<0Q$\0
MQ)22QE[H LD>+JMIN31.P&M6C\_$4C@-CLLKHBQ!F<9/95J19>O^CPLTT+M/
M,,&0=HIWCZI26VPJLK"7XF_XM#0?#,]])/%XSX=CXS9Y070 G'>G%G__!&^"
M]D4<AF,R'!-_3/B(!%N#,MI44NAL#%0W79;&\*-"" A8-NT/9N7!$5>8'W_\
M5H5^E<)H^:+_$70V0>.3U4NT:A )I[I2XD3\[OU9?U*>.[-G5==:A')* !DY
MC?AG_YIGVOM!GWD34&->^8XB]4.,&:4ET#Y%/)R@X0090.:.EV^#JN%""*7#
MA/A=U-Q5-'1F#/)DY:GMU_7ELE&BQ<6DSK,=YX68!A=Y#7N#XG?L(?8('(>3
M4,;5JH?60N0S_)K(C-+)^:K) L,>;"H-"LR5_B";#BT=UX7 8%5.SDL4"L/0
M0ZR."HV;5#CARD66C,;.A.."YWFBWDZ*>E_2 4$NMD<O4,SG@_4A4/_OE3L.
M8(^NKXLP8$1U@\"8_<[&,&-H^^"&WOF\O)0<4W<VV@9$%8WI(NN$*C:$*&R8
M_%[\2 Y-?Y$ZUTPAB+_*J?,9/ @7YT _KJ-BC%#IZ<[5E'KV9B%$RY%+9R5-
MKP_MCD.5-;,"<I2H:<5G*.-)T?+PEIN]H%U:6&7>69+/2HRY2J>F0+VWG4#S
M:I:Y31Y&T4I/SO95#BCJ1ML)(PT8BZOE(V";P\4H<.O*/K[PL2%J6>[0D$8+
M$@=F#R49UNI#2@H2W)O35EE4;><9D:6]@P[=50>;LS?HJJ*S 1=6*M(T-MCW
M=!_W+JG]17_+!YVB@Y?H#DL)%IO< YM\HR"@UK4_RB*>@Z&(9RCB>:A%/-1J
M)I"YL 2@->ML?I&%YBFOV_ENO8$^X5+Q)K0ZM.I$#<.XO\*]-J%"70*IA#*[
MT=OJ+TPRW&FB<@XD_IOG>I&4\B75FW)3?,UM2$:!I!37)V?H6ADIN2=#Q3&E
M#N.O[$9?,?F[3<FJ=MHR)$E;=2U7V(.P4[*<MC5*D7[A]/<.[5PHRZA/__KK
MT&9[O94])(-+4GI7K:>(#Y57H'R>JB%D&ZXWY>W&?7F"T/L<:*;:7'BP/7J[
MS"94U$/,P5=[$'ZHW@^* XV8_&5I-ZNS03>*/V*S3EE.WOAJ=H3N^#F(W[$"
M-/"D&W5/<F7A!1D]7^@P/)@2.A1J9Q^=_U5CB$ZYKQ9L#-<6%+8B/PO5= C
M8.N;C%L6M Y)]19U0TOVVG]KO"9><\@!8P>DMN?,!W--?]6XXD#'9)[F"^[7
M_9>3 -IX'B0G^QMR8YRHIQ=N%$H)[RDRR-9F"&2#/6^:MT,[O^^X-@3Q4H'@
MAFVZJC&55:XA:^G=IS,#BG<:\!U=7J]NNC.)7NJSE9/JNF%GI3$) *?<W+R2
MEA^$KSQSTZ9<Z[-SU&%5WL<GCCD&3G!?A0;1ILNF1Z;<__Y(>^ V')X$^983
M38I1F7!&YV5,* "A^2([3^>SI_15^3Q:Y"O!/@B<\[/<'<@<Q<K35;/>^ 46
MJ!3=OS6A8Z>" ;4T/6N8@)_5+X+Y\\Q(^F]8*RDZ>O[+L]^2FY^21/&X6Z?C
MJ0KI30:ME2Y<^Q<REKY2V=U2:>XTY[2<-!5*=MF9W'C2W0<SCO1YCX^%7+<#
MZA*91_1UT0H3#Z'O/4$=GRV?#)CE+SX*OH>D['=/]@_XTF!-X=?1?M!=G]H[
M0^,QG5#4$(.Q\2+,G)ZN?4>?Z<@1*<4>G)7$?.B,AX54(&FKT<;E(%5&.U#+
MD3;U2F9VU+;HKJ1Z@</O9A7%G?;V_&%I?877BSE\N"G;Z3<GB0@&D5$/&JEL
MZMGH252P(A@0]60!\6+S%A7K3]HDVIM0C-5?LDFN ZV"=$Q# B, +(H,7IYG
MI$=3'JZ$%'1DI"3#.K=UZ+5K'<60HFYO<6-"]1G=TY<I09,KE(T4D_I0HJZQ
M =FGJ\H7<VZN8#7+<2?:_F6!)JK)N8C6SMY.PC_"S.R[=7N4C+0N0\4'#:]K
MX.XXIRNX.:X*W7,QI:C[Y:D[14ZWT:K?_&;9?"]0=\G\P@, 8)L@4+$*3)7M
M6]2CJ.W-DD*U%C_+W'ZFE[U6N>/Z:.5^)IT"3W?S%]PX$8?#$H>OZ3E: =O#
MW)3]MZ-F;[B=/SH&-1G@LU3 ?IP'DD]E9O[K[O^<QT9MH!R&121R3&D MT[.
M-(%<LTJ4*: *T:H-#BO3/&B(.B 9L7]3:SZ5@=GQ,K-IF>IS[7.7 S]EXRWT
M&P#@(4LL59D;0/ D-SU8RT!I[:S6DP;42!]\H29<K&I2)?H* &+(L%BE<<M,
M(1K'?,RL]UVA+5$]_GDI73L= _XO9'./3N=D_<"VA,D %!B]@S)N-*:<!YD%
MFU=,>K)8<F_N_&"Z5_@^[-,[2R&4X5*SF,@I_4+Z@P563SO=N $F%(!I0U-=
M$MS'U*^)Z%!:DM!:S MLC8MZ _1$@.:UQ$J^1*;;C<)#NK/;+Z1N8B-K9]^K
M,&>*MT0GN0YQ3MK<?3DYMQ9UWL#-/[4/IV!_JUP!P0K!\0(6G-:/NV>-\\*L
M'>^$ ? "QEMS"2A0!O(8J?Z"F=P#']?!\7AL29?#(>DR)%WN-^GR1<&RUYW
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M@<5U&NP&+<HI*)PCA92H%EVK/I2*'%Y3/DQZ_:P$=-1[43W'26'?,S%[ J$
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M/#O@02=17=R-XYY 6TFKZ5R8 <I5XR[AS-;Z$31(N]I.,VNHRQM-5P)!.4.
M5Z #FT;Z9:31A$"LZ\ZP856Z 5&%E4=DYLI"35>%6CXW'43;$V-QSACG?HC?
M?L&]MS?<>\.]]X7WWL[.[.C)DW3Z/MT;'[\_V-_=?7]\E!V\W\V.GNSO[8ZG
MXZP;OSWXW2FAM^DL:];/ V#?^^.=W9TGA_=_^1U<<_EA]",>_LB,_ZXBLHVI
MI1WTWQ?HO_U!_PWZ[XOS5].CP\/9Y/TT.\R<W7]R_#[=WW'Z[^3P*,V.3@[V
MCV.[__7IFW<O7[J_GWQU0W_C8>C1?A@6:[>7+VE]@K8^_)T*KF9EY6Q&B@NZ
MY7Q&5!0O_HTT_)ML_G4G$LGZP=[VH9[TO "2]H];\KN;*/?#+_5L?@^@[6$]
M?.<PK\N(%R9QG^ >H;>&V^UW)HAC:_8EVGVKT6MG"I\S3M],OGQCARFPS=R^
MZW3M_;D3;B99&-M<C462%:$5N,61V?VG ?2-;,<'X/OIF.;H9*,:3533"+72
M+UQL*M,)*#SU>N&60.'T7I^^_44!^6I$27V46Q(<QPJQ_+K*44E5^C8\!/%3
MH/YI*]4-Z%[NE%O,;.JO0E/HQ/)--G'7U_ULX6GM0\*RO(P@K9CPEP0,'T6Z
M]PY&$=$B"H)I!KW4;20 @E$00$.B!^2U1Y!S.PF7W/TF?%8>+I\66$5FNJGC
M!X%/$+& <59D,VX@+R\+^M)XU>#/@#!&2P_W0!'<#NIZFPKQ^@*PVF-@&Y<?
M?-DG.<7$6)DQ!E,TMNX:4(+ @T_*.#O##..0F(@.A=OSQMHCKEA6]R6ESX$[
M@US :S1KKN]'1O_T%<S4+,:Y";2#404D<X.-G(U1,*0+:L"+=2*%D)0&V\CJ
MP%6' .I )30_R9FFE\UYR(T4*(FE(G+J!4-Y?9IS(_\DK<]'4UFC6F-!6JW.
M.I&2>TSO9.JUERGA_?<\1"G/2@2S&']>Z<]><Q4YU59&7PJ3C@C3.!LX]EDG
MM!E66;0.3+4Z$W0OQ<>B[TFM-*,S%5N^C#+4;%HTRXWHUX&P3NJ DPBW1-$P
M^'FZ=!8#- F[Y4N#NP&K3=/!^9IFV8(Z?"_<#MS744+=$:P: M]_J\CV;))$
MIL9]'#&4(]W;PG!45T+:4J;]QJS57WAM>LQ72X(H34EBZ^),G,YF^9RA /6[
MMTI:>L6Z?86ENOIM?43*$@>!AW)3+F5Q.+.C\30=[TW?'^]FT_<'N^.C]\<'
MXYWWZ<YT_^1H]SB;''0#;D_>9LS;\+.J/L#JOM\]/CAZLGO_ ;<G7^J3_;]O
M,G0J9=/_;TB'?W%8[& (BPUAL2\,BTWV#W=GLYT3IZY.]MX?S-*]]\?[Z<'[
MD_W9='R4'>SOG!QWM-31[SX]6".NOB)8-G==G!+57EZ7LY_O7UD=79<=Z%+U
MALGPY2?3P3YXA8P=,=UE;T(SVBO?:G4WA4?Y59KV_Y0KYQ)*UVTZ%1]@/B\O
M83I/XXFF9J(;#._-&%?.WSG+R'1FU*#H^Q9\1DK %(['>3 1&4/X4LRK)QRT
MV;S.N+ R%Y?^9V#3[NYL_6-[]);@/KFLS'Y;(/,5\#ZO-\[<@^N[+U\ZJW]K
M7I8?A'U,9R#TO%1M($W+>$:@)R(0JFCE"0)2@":Y'"YOYH*^LK?SU%+!:Y"J
M,SUIL3,C!X;K NV%!&<F#HN!,.,6XN 1T::A B G%&FM/9BO0X&??FJ:.9\N
M'Z-U-7/"XJRO_([JZ,;1"^QI_Z__^]4%^INSR__K;^.O9C)(X4<:R$5J:@A%
MDZ'SLT= #IP0=!Q3G;G%*R<K0?N5<EM"@"&\)Q9!+H6LG!<J"+K/_OD6&TGW
MJ),51#R9R@%1*PH<S&<$>4U4CQYX"F.0)ZUAI9O7\15/%[?@S\CK.(JI@Y$V
MO@LA0'-C"^1[,BBB8N$ VXQ!RF>=R6.8>/X4)(1$0,-A!VHC'X/I^B+SW8NI
M"!SA.A,P$ )_P*RC:A2S8EG:A'[V:(UX&EF!^["61M2:C&2%."6TO!X@ ,86
M&YT[.6*&H7$:0!.:;'+.FVPPQ:BL=D5\;R%<0V88*1#B2*5R:^=,3D*Y-;B.
MN"XWM]2?[Q!ZRS*/%OE'P14V/ !;,:[W#P/%NS^$7X"#"3M"&^]<VK,J9:J0
M7]Z]3JBEF)O,GU=RV_T]Q1'X,Y_7"):D*+(5]'7"9^C(,NTT5SUQ*3)S^G+@
MB1"^ )[.X19!@3K/ESQ+.]31JVJ)8.MSEJ/1,UHW&NJKY\\2L^-N1VJWU'[Q
M-0B3"[]6RM LVE7+GUZKR.+C[H0H!1%]WLD*U1ES/V^^1-X+,R80CPMFI52N
M(!+P2N!FA2G/;)Y*;EUGB_&<\%VG6;:D7FYW?>9E[Z'H2A^'"SW&J\06!1Z#
MD;C;T2[4/V.W@O[I/O;'T>N??OE]9]>@<<O1P;A^^7UW=)869VZ8=3XM"7@#
MHO*[X->^_NGG=SM[_=]U%X$3<'?3N9FBEYFAF1FD[.=WSP5]Q VQI1U[#IZ?
M.84/Z1AS?!7<:R9^IPW'B5]VM]/+)2 $!>?8OZO=S0!%[;[NO!J^HO5,&NAX
M6JM_O-G9[Y_O/YR442,\BRLOS^^_[1S0QQ=NOR9.3*##)VY75A_*Z=J]IER>
MKVE)?O_MN:EVOP0,))U-'V_UVH&6"6,Y_6WGD*_RQ;JD1^'1N(JQF,Y\K_R.
MG?[V5A"<"V==((\PU1?0$WY=$6QV4X;C)Q,))UDK GF9E'=5!F4?]D[W_+?2
M+<B+I3M<RYIG^>ZW%P^J<.4.H$TOV<*<E!4619I]0,4JZ:R=W2.3:F3<68^A
MS@T1SYVB=":DVXNW.2.Y E:&&1I$8IP\EWBVZ;]'E2F#KC ^HE1=,ON@)]D-
MG3U,Y,Z'C\XF;C3GYY^MO7X1N%*)E??V!F&;G<K(_Z-/K]'#JBI)#!T;,9^G
M1:&?!:X.1? YRAX.!($+5 2#B1^(+KBL:Z&&=O;GOTH%76<52897XQ3T>"7X
M.^45[4RFB8E0Q;4LE9(8,V>U2M#7XO#^ZB\=4'#I/LP(D;0-2M+X"R(CSEB!
M?KU &QNCE"IQ6TC)2(:8:%JH(IB^8Q.7L/7<O2$KP8+VW>[^D^U=%BTEN,+3
MOML]/MP^\)Q7HL'X<^B) 9@R!J[]6%(,SG2]>_0(ABT'KE,FO)K;(\[.=KZD
MHKVW)RM#BB>=3%:+%?MJ4\I_DN+\[N!D+PR-I[6L\@5JJH5'@O9![=EBVJ_R
MI?N,0&KE 4!(I,SGAHVG;SMW%$5\B:;:8.*X!:T$93?QH"!L'MH6N>@!/'*#
M$L7?:\*5)HQVEBK$4(&2'=+H]VV&RUEE%S05O@G$H@3#8_L:(T@.0MM'8U4%
MYS?_3T@L%H1&0P2,F@H7Y"7W:TG)=>]?.H:8*3?F64HW ?TP&#4!]"/:)Y%1
MO3F[R4-FB/3F]P8L+CU(4&QT#Y+\M5<A)G.L&<4-*%E<(" 8[L9&9PX:*)P(
M."8GG'!!=><2#=)4\FF^>QD=JW^\)/UAY;JKU=TFOWX:U2!$:'YP!-B3A!$E
M0D0M4$^L]?Q9,BJ"T,OGP (B?ODP$'7<!4X(+]4?W4.#FL ?U@1IPZ))>IVE
MTJVNL*VRI=_9 OJ]/3"4CA;ZB6LU\]V@3OTI*6DE 6&@-PMJTP/Z1BR92QCT
M<L<Q2@T6(\:E6JZJ6M"..(>OAJ;3I'^X+\T9GHG:4O@XH!/#JQ$K.*I*:-=4
M/D@*2&P9#-P] ->K$"+Z<W7-Q91)!=LT&S<:0Z/[1W&L?/F MG&PZA40("HG
MB9R@VJ)_!U;W@%+MK6T*+@A<+L4-*NV=@0/EO+=BHG&(RU \8/0AW ,ZKFQ1
M!,HHYF^&6Z(38E*I:039MWFA(.1,YF4@_0#Y32A=BNAG$,R]\'@PQ^[K(MPB
M;W2$3INK(J?R9W/=&.F*K"OA49-%#OP'C%"E,R$D\BPLF&V<979TWR&EW)ZQ
M_B X0:>))A CI(H4M=I?%T0[U=+4UUU3/7<  28"NI!T+B;-=D3@^\J++6<Z
ML1K%]L#:Y8S%XT1(/CD<$G-#8NZA,G@ZD\EW[+.]#_#/%4% I*/=?69RH#N+
MG$?*P5 0D"#2^68D/<7D%\2T\Y]LLU'@(R-7Q8#4FA>H "Y[<UY$M2J<L).A
M]\_R0K$G>@:N(:.]ASF!NZ$UN+%[AZ$E/$#8#\XZ]BDZ-E.91S!4!L'QVST^
MV7X2'+_@9;"EJ.5\G_CH1#!&^&I;&:\Q7.GM==9+VIBG,<TW!>O)<\FK&J2M
M<^"J0'(.;Y5BHIMY_814=4@IA\SQ*&2Z[JY + SI-[Z'1Z?*6?95U^HJC/9-
MN9*[\BO$S%.ED+02!9!"-EHB:K^$[,9%QCPWXCUC^&%%DY [X23!1KW3LLHI
M8/#1&>Q$R246D[)Z4O:C\2DTA7,5>ZR.(X2P*EDI_!&HB]N#M$@NGCC''TY]
M@1^\I43BY&76&[TG%AVN<0NCLP_RVI9<JOE<H<4+XE*\(I:=@XFRV*HHELC\
M@_CWHBQ*YY/E$]J/N=OS+*$4H[!Z2J&P*0BGL+>/H]-TR3 FA%.3]:/@*J??
M:/74.PN\@4]"]3. WCD$I3NH45H#HJ2K2G"K.C0LJ-FY-BV=%F(+4+0)[/OE
ME?57XA&D#GG[%5ZX*.%N.:U:YU-ZXT?N[@\W:#0"%E0DDP7R%0EFX8B!/P2<
M6M+#(F6O5E7?"HJC8HB<$33\[G![QP<^4Q/+P)0 "F2BH'*6)/8!.&S%1:?[
M:GO?/TCWAGE)W<[8 \ _=D^!/P2D.X6]UHV8/U\*+T%ZX7Q(XV$RNQ7A)%FW
M3 [L- BXYKJ-((Y6%%=@"?+W]A/U 2EF3$8&O#!*6RG8.U2!CD^@ESB>Q:@3
MY:5,+N5#DF'Q:=#IV1E(B!H"F7(/X[>ZQ?.[(*O\W<[V81RI7F8ABA8FP>T,
M^0+94>[PX4P61P_PE!#7QALO@::]),9D->*,P@"./-*]C2\%ULJUY7LX9>_W
MWN_%J'K^+[OO]_9NM0SM:LK+ENR(/1+B'PNPF%L!9=BK[_,?G*@^N6IMO3?-
M]T4*9'"OUDRI!'@5_&YBT;_/\?#]$W.B^I\K24OS;4%-\2K&JEZK9$BA7J5/
MG3+EB 9T#<O 8H6@-P0#JR6[W_N@[=$+E(O(JOD0$@!-Z$LT: [(^]M%6*BC
M6\>+$(?<J=*=B2/-J:0UX5HK-AO#0!(Q_*<;GAKQ,4BY5UE,I>8-] 'VD%/2
MJKS)HP+C;+PJ4=R;CHZ,?VN\WM*I".6XQ([D$N>P&<DBR]]WAT[AQK*'%C:*
M4/>,"C'OM&_AW-N$1:,H5D0S,@^U+YU/@R_ZXT1 ;9!=*@ABWYT7=+7=4?CX
MCR71BOMP9&]XRR^M(?CRTPE)U_YU=LN&_V-CC_:IO1+8L,[J".T>:-[Q=_G1
M<\CG5)!4E6LA+_W>FA#$&9)6YO*N?]#SO<BG6YC$'";#6<[;*?OE'.3Y%$PR
ME('PN]=[2EH">,W,]187OYRJB_#@<3"@D7 'JE&5%F>1VNF.F(@'+T?3<C7V
MOTSTL/@XXFJ#8=L=.>D4C%:N1UE=$]NF:RH:V>[6WO^H:&.UEMIK1$K)<RD(
M3\&,&]3*N2B?WFML]_W^U[JL^N\GW_*ZJ48D=GB0#T/?#!@0&JAJ<2K<9YF&
MI!WW)7X;HN;MU>OO6G=*UYROH_I*,1_I!)K7L^4:E4>V*I'"^[7$T=Y.YA7N
MHE*.I91F@IN&:QQ9I/GRZCZ/=YTOM> *\A2=/48Q;HM[>=VT]T=BW*+AU-B#
ML%L/-'U##_2#;+@<P-UJW6$\9\(0SE7A6RKTH4(H<DDX[8+[K\C.RB8/^R_9
M(F/4ZE9XHMNK_3.V,:Z]\X-7>M4#DW@B5'1%XR<?-3(D.\D+MIPCL>D186]*
M\*U.7=;JN^K,81JSRSCZGNW<M:;(>V?'T@5UV6<%_:!_AG'?:WMU_62ZPVP9
M$6<'%X9>V9(VM?7AH\RP/!DR+$.&Y:%D6#BITI.>X'.M,1?H)>%\YPRK*BDI
MHE$'1NHNKE2DI\^_P;K,3XA3/^L$8W^/V+'PF[?,KN=5W6UV97U*+/M9VE .
MY$Y<FI>%AKAV3[B<*6Y?:$6Q0[Q7_-9X84,\F"UX[A:1^2"-N)ZC6$OPJ(K)
M-CU'/T#UAJC)URMHT\.I\@5!(_]HU#TOJ22=C&_UJBE22"U05.#P;W=_4D4#
M&_,7[E_3(!&(ORR74N2$,GZZ@U'',0=+9E6ZVQ7%"%F8//WA#?[P%G^@(+#W
M#U+O*NF0$(UD6\V/,-A24@O9]]Q>['VK/W;8/(*[$R9U1]SH3H).EU4^]]''
MG3XYLK$+Y9Z,B_F$W+(K8M>?5 DX>FD(]2[AZ52W$E/B35+@P#=KVHQQVDS.
MV85-N;>D0P1W!J[6S+)H7F,0LDE__?B)J2V?9DJ.I\9_*WHM4B!T>0+<XVWY
ML@#]0ZJ,B2SB7,+8ALD/S]SBA_% -QRW&_#QZ15%ACTA+"L\,17PI+PGY(T3
M4P-?!3=A^@NF?62<WD0FO#@03P'?K13*TJ]F=M.GU>HL"NK=8'\5UZ9]7G4_
MF7=6_)@-JZMU<#FX%%!\O%@M5&\L!4'#9CPH_.VFX6?74BSCS)W30@"L(QW1
MFSGR),6( *73?SFWD3,Q$36#]Y.P"7F!@._-=D&:KHJ+K,@IP>&K D&<#/=&
M?*;,<T3?X*&D[*@28W19Y0T8%YVAY%2*YCT^=9B)K3?LA*7@\E+40A^K,1ZS
M#=OW1B%QQ;&!A7N5[/D6ZQNND <-9_%4:;72B33:3JCZH/0!9>.NDUMR7K]
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M53UGNI(U!@5843!WU<@'".G!J;H\Y$'1%-!DU":_O5G8^LM*=O=D^ZCDXNN
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M'6#><$\Z5 ,HXD =*M>G&<YW"<IC8G?;4%<1CQ.:RYI]%ZKJ*P]T[6U8LGL
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MAV?N6XGC^:BD399(6X'?N V!K/WEJYM8E6L=3 >>&VYRHFW_>XANE=BO/S>
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MV:Y-^&RWEZ^G[N-ZC5O,H.#!TSO*<&$J=F/A"QRQ0*-:[ 6.5* B3(-T<M9
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MZO.VO=/',=0ULZQB4RVXH%1MY6@*%8-3VUMM:(QM+ :CE,+$6[K"3U+MB-A
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MVFB$7?(A_:)<(FP.NU[AMA'/19B/#30'-=^ OV 3%)6#1#'-0$9VX-JD\/1
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M4\V)IF(V)RVDQ6H6?AI^>4!L=5)(=LL6-]PM0"6K;5?IO%E=3"\)UC.=\A<
MC0^%\VE.CG4UV_XL/SJ0BV$GX1@ #?D!5Z*K=SY7R$F<346&$S:G@>PU\'-#
M"?"Y*Q6']+Q4(K0&"Q0W72&;;4$^B4V9"51O22#690>'S&TW@0<QMJFMD U
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M5,B07$,2ZQR[E<2&8I(P]-O[1L53A[MV2]-0_1PI,0?R:6^:0_K#,ST#Y]?
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M0E>Z7-3MK%KC.!D8Y:&N=Z)"Q1EZ0M<&63"7"[-1Y20)SZU,*B/7<C4X],3
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M/*$3&I.R6&*<(>>%MAF/QD?GVIR,,L5^CVR4\^S:WI36.599VDOX3.KUR-3
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MX3*-N),1ZII[[E6=M@:O)'O*"!QVT4.-E>TE<IXERGB)N/7?MG'>=HFH\V"
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M<HCC\%EOL&PUMBXFJ($6(M@556RWYR_-7BEUH?!7%P8FPF_').^^29Q>']O
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M5 4$FQ+!9#3B^Y1\K7!6I]/-UWH_6N$0;"F)5E)3IK4Q,4](W74_&TWJLQM
MHY"\:-#1@?)"F&59T&CMJ3L449(9A$8T%8PER?>@T;]P$/W]B.V%:Z$?IL=8
MI>*W#1(/^B,>K:&ZU])!Y:W*#DXW/B>;QDZ7L3(R+MZXY!.'UBF=#TXK>F!S
MIYXU04>MX@VQ3([CS1!2AME8"2]FG&!;*:V^BIG2M)OZ]8<(>T^P;2L$S:H)
M[]1FF;K?$@R@PH3JV"FFR^KNK8<TL4ME!?X?.YW]^\ 9Z20,V=5_G#[GJ++A
M_ENV/8:".-7)H71HM Y9%1!PME/0TW'Q2.838@[@M'+>%HZ<J;H1<C55M >C
M0B KH'&B#JY37NFC$D'>I41\0F'?3"+*\\A4J<V8%)%IYB*S1?FE_"(L?_V)
M?UXBKKV]-[BEN1FYTO-V)$N!I2)1*YFH")UBO\1"!18+>P_;+;G>4$_:*U$C
MVUQ&]/D]$_1LWJ2;D52I-,9L1V[278J=KX:%)V;&F (TK,+TZR1]_:#QWGGY
MQ\RQO.1=VJZ=R6E.X1?@E_?K4070SB]0WP@[.]?5;/Q=O';MQ-WCK(F+R%J-
MX?24O1I<7<6;H;LQ&E,]QZ0T8I[7=8GE<ER%\3-TSY>AZV1@?"U%-TJ'HS\T
M^\JRN\-$]'CEJUOG (7C/S0]\;[I0E)AZH?FM-\W8:# Q'RZW!]=R' \XM/E
M#NE"PIGYA+D_POB*[#[I@FIH^IKL#@GC"\Q%Z?+!T*-W+<J;;<(Y\E\O8\R=
M.?/YR(Z<)<GS0A;3E4K<WCV+O*G$OC>+O&,C_$"5\2X\]Z7FQTO->X#TXAGQ
M']R//OX-\&=:_\6)?S.MX4.N^X=<C[<E/A#[V5KE+&5:(!/%WZQ-YQ\ZC\L>
M/P2'L'"!K !\CO!AB ]#?!ARE[OT?;7*SX0A_IGCHY!]CM# E!45.$&?)WP<
MXN.0;XA#SJPPK";3E@M9'?M:P\<91YC$27^PV&2FB9R/.7S,X7 '2D1 &4 F
M*_M<X:,.'W7<"G7<<9GS#ZH4W-Q2][7)%='(]V&>F8-G,1?Y3'1AH/)]& ?E
M'EN<\S=*H#U;_Y;ORSN?@S,WK9GEW9RZ:>BH1@!*MF:-0(E53%9;6XQ !@-6
M:Y8SP98[6_K92I Z".0.R[.[UWMJ+2P+?PR+ W(<5YCE"R&.)(:,CF9FCSVH
M%I'2A_6QNSS$<$YWTA6A^=QE$['5H"M->I%&TUW,H5C+?:  UKL%'=+KW9 &
MBTL7I% ]!#NGWL7>EK-G6^:!V-;*&J3&Q9?G#8@0&54O1]3R\RQ32 UC0^K7
MGV0P0L:"R>1%&C-8JO';2@4.0;ZSU9VC,)X=2/S@XIX5%R(/<%T81^"Y18B?
M5S<SJ3];-CJA=J)$%E-?%GCJ-N+N1"FEK&M"QO;B-9#_[H@2T OE!IFM55@F
MIC23E5(S;M:U)50"T5]_2#H<?ZOK@J\ WH3(=RXG'Z@!<VKQ,!>_AW3 _>9-
M#6'JH]P^>I_;1Q_F]I9S$YK9N2<[$.!36WXW%99KC:;J,Q$:KYY3HV2T140%
MR.]QJ#D2X9BGX.(WY?9/EY!])&<F*J\$WY&'C(7C-K^!&_+<X/VN5-(%D/K7
M*X->%[AC7M6+2@.7(3MR8$^?7T"Q-,HEN^VE5EDW!Y$$6UD.XPBUQX(Q B+W
MR%M%;K^+0^,ZWJ[[2B?\IOF"-\+T7U<-9X7X^H<TPP=A_F#UU*(8H4]W^X.D
MF.G76Q0Q;4*M 6$^'2;>:ACRP KCW)#^EC+QRN+.UT_HYM2Z,B2]&T!NHU1'
MA,^'4^]FA3_"[^Q9;^#O;P!G49W6HJZ;@+?JH%NG#SZH='<1URWW'CE\B-E2
M)106)+H4R"W&5#;S-(LNAPD$64DJ%B2BWA9W__B&]WE!K+\-/]A]_6!0UU$F
MGT6[+Z:X[E:'?:&[SO5;3+8275;S2.$@IW:8\'W:W\2G?1U,?&<T_4F>VYRJ
MC8'H^V[O+O3SAZ+A+SIW;78V-?"6A[>3RKR02E1.,&*;DL:+QCA%IU+#)(++
MD6 DD0@FD]XV'.<#S ^IW'P7K^_B?7C<>T0_?!#Y#N=IE2+;M1ZS3I?7G=ZD
M]BP5EU!W(.1+A+_KS9#OZ'TD:OU41Z_UBH/(XS=:-?F.X$\[@N^_5>]U(Y2I
MX2H>BY;FLPS7G>K]:3D][V2C*>&^(Y03T6Q3%$M"H1NKYU()K9A*\3EA2!+8
M<TP&(_#_=)+X,>X<WW<\\X.9SQ[,?(IN>(Q@YOK+8%UZXK.%+D55AR_+F% F
M\EA?0/B;#!,71+]W)B+?W/'[E6#F4VW !PAF5IFG:B4[S':ZL?8+2#=&LW@]
MV43\CJ*9X[O^NWXT\S?PB5NOZ $=M;E&S6QM=8A;BE[)DO@>.NV8^_R(C6 /
M,-39G3G7?0-B=TF,N/]5 Z)NAC9)9M#O=2F^#CJI= 6$#*@@22M:FHA'@LEH
M]'OZQ'ZB*_V,EL$CR?>W- -<\OU!,R ]FK3Y38X?=LN*+/44I2HK+P*2>N0%
M)\/?5>*_DQ?\&R'\UQGY-81/[@ZP18$MS)E\3&+936'<96(1<H0/,(3PHV'Z
M8@C_(8^N;W%!8"-\50N U0QPZ&=##2S@I_Y]@7]?\%/AOB45*85G;*'HJ.BC
M4ZX1RJ!-)U]2U)AA04.*CLCR8AU*H<7ZUPC^-8)_C? ][8?W%<8'S8I6O9J5
MAJ-)5 ):M$@)Q6D[G5JB#?!O%_S;A?NT/3XL!.^;)%(GUII3RT%%:H^&FXF\
MD@LA34!K]B\=/F"E_,M !N&%YHG"Y[\RRP,"7GJ.G0D(+&T^#-G];0("RG</
M\*P! F-6U (+5C9!0!T'5(NUK0'0.%JR>N!_?T#TZ%?J ^ _9N%>YN!6]M!.
M'AYP-5;3AN1TP8ZI'-=FUJMU'6Z5Q+92J5]_J##MC3C'=U!7V?A3ZT\][L8S
M/,5&A+Q$$>)*3"^BTU%"X 24'AN.>[V5:&T!8V*W9L!E:P- X:$L>+P#N)(I
MIA3:N6  D@ =!.("R.MP $O[-:2;%00-"$B617BLB(H.CU&/0#L=)TX2Z:V1
MBWA+%)IMADB88ZEL)G-BN=A8])[/GBP2BE[?_;V+!.^H!BL7G=W;9Z68BY6*
M\4C>3 $MU 7+LE(:]HL180)9B0A[\QY/$>$O;_3'I?<Q-KK;RSVM2Q5YU@6]
ME"'7Y,D:$$N487I$5T*ADM'>H@WG<28]$N  DMT#T0T\F-2J[GAF'?W%NY)+
MR/,GS,^K\I4+8Y_ 3$0I2\C]9.N9J7.Q37/<SF0VXA))K=>LW&,FXX/:U8H6
M>8-./(#/5\2IJ5^)TU)[D]D_N8)X?0:22,@O&N!408&/1"T0=C3!?G)%!U!,
M9-9VEYO*PG*CZZA(A;T) 1;11W](=F2F,UE= ] &VD+DP''NK*GVLC$CZEB3
MN?^>476CIAI/ ,[9V4IW%8^CK#F*LF+"F#UI4KU'<HNUQK.Q. *%D2.\:9'/
M9M!@ %ITW 33$$V#5=;VG8:.:+0E9T"%8"G >FV &5;(B#UN9X)?;..MTR:G
M:O9':!SIWG>6T,5Z;L9);>-)'R\ZRV1%%! 8CQQ::"X@&+Z(S-H' D60B4!#
M9A7G;"*LWV::BG!^@(-F/2LJ@8DJ\T##<NV6/QU^+0!D8 D<Y  X87F]Q7WP
M,2("MM9E%]2;X4#'Q3D3*+6(D["_QN*?F:EQ\&-P\"!^^[ZE:$S@ 14PH-;6
MQT##!R]Z&#N;0?83+?T!9XP>O%69Z!<3'LKPF6B\9;F@-Z(_ )L? N)X_W?4
M24)4H +2[<_0B1 8 <AGP!JI\,[35;@(.%9V5FISNJUQ$741AXN*R=J.1%Y<
M_/D/_,>A*R?#)2._R<2FTO;N"E'+\:X1?UW$8[;?<X.*.-Z1K4HGJ:BU$#QM
M_.]__Y=[^CM73HA3957[[=RSN=8UL?I34-BW(X#02 .L%&+'\-6_67G)KG5[
MG?%DF';"^7YOK^IH?,P083KZ5\#U,]H0SVY.V57(M6>V*RDD@['QV_Z:\QGF
MONV'JH[%]C<^>2 \0T_?>RXF#8H@I,AP#(D4_-5>6(2$MMV%B'5PVM([TOR'
M#4PTI#;_IU//'&T2@GZ&R@4J1WFO48C]$=0$&$- 3D8^0I36NO4=L7_.J'W>
M:O+R[W>ZNC1874<'2%I4@X&BPH6W75VNU!/<[8%[LQ6G:EBJ)0?5@0(5DAR
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M3L$D$4H#?)*VFX&5^XP4@AY$R>ZM=A?^@ HQV46,4+(\:UC-1G!1+JLND1[
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M[KA4P'MKM[IK6SN@CJW_6M<[9RL_<>$3\ JTONNSZZJZ"Q].#\SN1[N/GN,
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M=G@\'>BT%IBRH@(_S\ ]0A0Q61F5(===Q%P_%1.5I%K)2.UFH3/*KM:Q94U
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M1(-_;,"C!?),("VJP4!1X:!4C:XUMT.L\N9$:ZH!7PQA14Y4H,(2(2B 6M;
MA[X>^!LIT_ _V\F_K0;V>?@8:[(.^$QPG6;DV<C*W5!ZV5VHFU3WJ=!$2OJ7
M1<;MR#K;:6X&S7):RA"S'%]3UB/1; XI[\AN48M,A50GR5!R%XB]"D_0R=20
M]HX$XTR(C$74#L/&-YMD4C=B_=X2CHP<CASKG>EZ968K3+Y> #U3U$%&2 TC
M0^)P9#'9!>6963 E<Y6N#5NK5EKHHY'TX4@N(6BC&AO2NC'JF:[6GB/%^EB
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M \&OP:!+"])Y\$5I@29/DE1ZMU[QU^I3;M>E@(MIG(4]B:V8_5G:TC#R5/1
MWHU^!=P#C05MA+[F;9;XLM=?X*5L-"D6+-J2H2^2+E5KZ?PKIK]^YY,4.>D\
M;H0"4CDO))LS4SJ"AR2J'4_]6(XEI?5/N)_'J:F80=S2?+$@_"QGIE=G>,I&
M(QH$L4UG/7-N-+IS27?ES5Z<4K2PY6_Y' 0?<NT=H$=ITO9(9XO%3R)U7%QN
M5/3%Q/A+D]#)G JZ):[)JEZ>K\MZKZ=+GOGBK#?K!V:69%4_*E)I80Y4S,-@
M0AIC7(@,P+IS2)&/2V:DX$5PI2-?:96N1='!^51]K-"<I(+G'E@\0"4;Z6\5
MZE[WVZ.6]9I+3]I:)9^_%U/5YOHFS?5IKO_,A!&GQ1W/-LQNL]/WNDZ#>]VV
MZ7A=T6AWN-WI.)SWYU,&WG[&F?G9-+*SVVR:K4Y+@W2!MT])%Y#BL)(\FN1U
MD/O>8?=MD?LF]_U,]VTY[8YM-)K=3J/=ZCI.J]'M6 W>;34;C;XE&HV.-YOQ
MY:/[=E?JIY^4JUY><!_%0AY7GSMRUCFI,_Q3RE289CV]CV*!A.^OY6TSU&3E
M/%^A/ O5[E#PPXIC@I=TG$52M!_*-?$>YIK/>.&I [*;>=2'- _R_'OA^6WR
M_.3YG^GY>;OGN6:SW6TW.'C^AM/L\I9PN[UVL^TV6WW1:,X"]_/C+Y=G9V<P
M2%B-AKE>I/Z8#4VP7@JF0^U*V<PX%)C&NR(R[[18R?J<9UCQT#N)XE&TK3G'
M<SU^;W45OM,J\S2;Z?0(NJ8:$J5-WI5*_VZ:-C%I=E:TNUQ!E"V/ZUWL9^3P
M9.#TQK:_6YA16&2_(L#!!2[<MRZOH\>0R?7EQEO0NS$:RI4)>4A*GL?1S7BZ
M2\Y<F!'>(S>YS5>?/@DA:5U<;2SOAJF"FC!'L93<?'%Z4B1PFI;!/'#+DP62
M:1YOW\>=S>1V8O<G\\ZL>:UGN\%]&8(=&H)I"'[F$.Q:3L>S6NUNHRWLKF,V
M81K6['2ZC4[/=BW3X9;ES@S!<D@S)RX5-QL48:((--MRG+:Q?0+--._<9V4Z
M%I1K3FY_HVZ?O/XSO'Z#O#YY_>=Z?=-I\([C='O-ON@Z36YU>;_#NUPX':?3
M:75LQYSW^E8>@S/^7&QY'?7SS:S?RHAHU]? ]UMW^OZB^FQ2?]G4>=QT(0*X
M+/6[G"1\FDVR^I+O:ESRGW +[E"QF=T,:0RAJ<,J!I$F#2(TB#QS$.F8CB=$
MK]EMM4R<.G2,;KO7:73;IC ;O;YMM_G\3GVFG?O;+Z7<&>3!<L]Z&7,-]FDT
M[3L'D6*XF*G_S-AP>3MEOJ"BV-DD&)28)AHN*C1<M&BXH.'BF<.%8?!FVQ%F
MUS%:C:XCVFZWU^HWN_V&:+K]CMMTG?;\<.&<%QO433>V?2\$CACY652)!L.%
M<^=P,:E^:6->A@+(D:$0@08#&@PJ,QC0028T&#QW,.@9G4[3:?>[3J-I=)VV
MU>IV[$ZOV[ Z#=<P3;/5F%UVD"O__^[:9J/5LK1<^/_W[77_QNG- !Q BF/5
M)"]HXBTOW('P-!BZ&G<.70]&'!?RW=I9?CH@2!EQ5\:ROWO$OD#/ZR*%VRQ=
MP=XJ'1[6H1;P<92E1WW_1GCEKEJX&]6I9K<3RF]KYQ%OLYO7/*O2MW>^02N\
M=UL?68G977!>F:]OU^G6-CG^ZDQMQAH6>I-%)_@<82[Q@EUG%KM6F>(V<>L;
M#RB\E!!CP>Y?9>Q4[DR3I%;,*U.(AB=JDPZ)6.Z")45D2^U#GMH_+;1=Y-HN
M/ ])HLAL- KD=]S&[!U/>3U/P-VA#@>#LJ9]SM*]SY7]<.7['DL*89;KA)'<
M6<&;[%T$LX:QS/K$+&ZYJ[>+C7 @OT]*S)/.)]_+\R9_LKG\9-_ZA3Y"G0\K
M=Z2%>0EN,)3D+@'3ATO]>TG/4-^AWJQI5[:UZLH%OJH_H]NN:A?&_ 5RVL2S
M-"HNJ#F3O++:C1J5]=VC/J-N-@MCFV3$CVY8$@6^QXI)Y[HW#'S.D8RY?F4P
MZWWW_=B+V>%/#][V6X8I\-.3$>_=6/&AYK7JK?;=K2MW5 54,[6,];7P3'LN
MF*4\7U:[4;?,:IO2.Y&XL3]2L6Q+&<#]OK'>;JY_L\WG"+S($%9B^(UZH^)N
M!5'#*HS JK<WL..JED: @TNKXE;@%SNO_!;55^036NLW!QV4WZQ77/<K!A9@
M2L71-"LH[1U,D%;DGBKOG0" (S'Z/R^L%T_W5(95;6M%3^4=KLQ8LSCTDX'P
M5E7@+S!YQX7(6>4M><+%@JF*G*,]0D'W=Y&A[WF!F 'M*REJ%A.OMLZEEGD
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M^U?&6IT$?HCZ56>YC1>$<(UB/V!F'MDP"=[JB?1:B'!1^-8)-$^ +X*)WSB
M*P>XQ^>>;L-$FWCNY3Y,M(FG9G"'N(8UBC0]?]JTZL0^$/M [$,%Y^;$/E3/
M,HE](/9A)>P#I:(1G;$LG6'UC5;;ZVV1SO@H>")N,13&(QB*:#@4L2O8Q;<,
M3^0^YW$:BCAA-78^\ /NB6 T\#D[#_C?_(!]K)]3WME.D2C5:W5-4"=%UNB$
M)]?%,FG6/0@LZ@06B86K JXDSDUO2$.<6P71#W%NU<-(Q+D1C-(11L$[5YYT
MICLHJ2+99?=ML]-L;)'L>N_'2<KD-DPR?B>-V#/YKWF2B\ED,O,-_ 0EL[,S
M]O&< G8H8(<"=O8F8&=_QB$Z=?=IWD=#3[!WO70]2'29;>1VR0-L!(FN;@-0
MT]C\:3AGH2>&H3H"![<>F 2&WP<L<;M.SX^%BUN#RBM1'TH0\=IV)M ;3*YZ
MP\SJ8<DU[52I-YA<YWZ0U1FJ]F<X(4!)@'+3O?0PY;U P/^>__VG'^&?HGPW
M$#P^ZD7I("^G!I_3:'AD8QG%>XR7&Z!P+6>4,F/Z%\&FW5$]1%9;_OO/?Y2K
M/Z7 :M!X47ST@R'_O"G)E2<;6+)]KD2M%PO^M<;[\.HC'ESS<9++V>K4[9=O
M>E'LP2]&42UL"(;\:^,E*WV6[7N[-8?\IE9JLUP=M4#TTZ/\L>):K#(@\HM1
MXB-N.HI%  #JN\#29\J5J@&#.K+,>G,TDT7AF/568TW*FMJ6U(H]50V 8@5>
M?[C\?+((:CX,'B_1)M59BF '83H/^^ZUUMFF7M2"TN@GIB+UBF82\%$BCHH/
M99&Q9?-6Q?)=5:^B9T@U\BR-B@M*A_+*C*I+73&_9[XSZ3W%:U @QL[.-%=X
MU@1,-;4[;,(RS#8[_9:!*6 F,?1?$ [7+<(#QF&:J9XYD _UH? $/1"_YC&4
M4\Q:Z>2(G9H(5Z_1=WL^3M$I^C$%FO41"C_1"1%2%&\%P./:>*7J-3^%Z.HG
MCH[XAD)TJP>"*$27,)*.& G>V:3 ")T"(]H=1[%5+;N=LU7VI@(C<'JVF(5"
MNFDV&&);7)3>@.JB9AX>4SS$'L=#F&T*B-B'880"(B@@HJJ]=#U LD5 4G,@
MZ6P62 Y'0306@EW@Z?;L/(.Z8^95&4_&$SQY&R]J,FW5I!H:#BZ$G@D]$WJN
MP+C<II6MG84'SPB+6H /-G1\PQTQ4 HOR/R;:2:.RO^>^@=G^13PMW'F"O9S
M%'C)T$\'%!VU6T-[]9I]MQ$&+0UJB'TTZR2T^$?,*C&KQ*SN[ Q.TUY*/8AZ
M4$5ZT'HXD ZM3>BT-K%H]X^-;?]Q$H5)%J2@@/FC('_EH<3B$HJ;G7+R%8O"
MR<^VN3P-\2O':O_I!TD4'K!/]7?U W8^@/_V-D*&&/X]9OC7N%_($I)WZDV'
M$"'-VW3R.AHZ@'WHF&LZXMS0XXQSS8@_35V6EFMTD^V: 3%W&J7MFINV@=LU
M.YV^TV[RK:[578P 1$>QD)<$!XD.V GN3=*+8K69'M[^T7=%F(AYF(U;T3:6
MA]"7<.DR!BPE1%)$#OT10AO&"8:JPY5S$8;)./C.0Y^7<'6=%OHJO[ET]5I=
MDWD&'62FTP3H.+L"09FY^[L@K #M[=&Z7O641]!3Z]ER]9J?-C[03QP= 0UM
M?% ]V$,;'Q LT@06X3O-9=@YHN6(EKN/EK.=EE6BY3J*EC/;G4ZOM;&]&J:'
MI?T6U9DY.2EM=IIY@$>I(5VV2A9O"<8N?2IC1U"8"+M]Q;=$V.F$7'^+OHMA
M3\238R<)FQ(VK:CR")8295=UG$*4704A#5%VU0,^1-D1+-($%N$[+:+L*H"-
MM*3L3,-I-CJ6:1@-J],\3(?0J&W#:7N-+C)V-;.Q';;.*MBZR1S3(KJNBCUM
M!_)GJM?HFD!;F<;3L"S3)M2J 6HM4O,P:0]<Z:,[R6[UD5V'I7,.8<<&%@*E
M>HI$8$9SB0CXZ"[2IJ'0CN,>8NL(%FG$UMF4_EHA?%1)TJZY'=+.+DB[=\)5
MI%V'2+LJ]C0B[787NU::M-MQI$H,'4'1'5$>P4\]12+8HKE$!'$JN+1'.$AS
MB0@F$4QZ,F/G%$0<02!BX,H,G&':+=/JE!@X.V?@-D7 ?10\$7.TFYGO'+<$
M1?9+-!+7(@C8"1^.LH1]O@Y%?, ^?CPA.FR+N+)=^T!840>LJ'/&Z8ZCP*D[
MV_UCGPCG$1U6+8DTI,-NKZ4;QJXQ9*N1<-O@9L-J)&Q$/)H.2B,>33=I"%]M
ME$=K$&K::P8-F;/Y[>),/&B]8QZFPQ[N%F<:+;-S(VXZ'6]C+!J^EIU^RS H
M["ST,E<%F)T'/"06;*M!86U">CH@/144UH9>2R!NXT%A64 18031*J\\ G-Z
MBD2817.)"-\0DZ67THC)TDV:78-)ARGO!0+^]_SO/_T(_Q0EN8'@\5$O2@?Y
MZVKP.8V&1S:^MG JQLL-R&DYHY09T[_(<CGY!$E66_[[SW^4JS]=VZBY41#%
M1S\8\L^;DEP#Q4Y84G%7HM:+!?]:XWUX]1$/KODXR>5L=>KVRS>]*/;@%Z.H
M%C8$ []J-UZRTF=LD+G6'/*;6JG-<CNI!:*?'N6/%==B6:GB8I3XF)EW%(N
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MS7._6-&U JT0U_AV#%$9?(N%4H=E*9Y:B)U=G0072 1L'<0T]1PTSYM&XFG
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MB7#:V6C)U)[7O:6$Z:[,IQ<L ]HU)\H/'3M90V7+N!J0E^5A9:]+KZV/]\W
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MSK#NEM)]>?X\6E9,1#FT+&:*=<'+) )Y3>B>NKV;T)T;PJL)TDC-,Y.XW&O
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M&+/Y/4FZLC$N$(J:QC4X#^AYL9@C8ZJQA-XR#SOT \^>=MG;(PQ6T/V=.B7
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MT-$4'(-^=#BVYGNA\4$*:-%_4T3FH-T<8RHOB@>R8#CU]M].P%+E=8"WF?'
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M)-.@8FUBOF;T;P;W;,(#+9M([T/RYWB Q(800D.@L]X8:5Q(+QX(&B08A"'
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M\$ X'JBL[F#3I,8\:&?=V4B:LY=5F^GU-GH[L.Z10V8\ 6D];J2P\&KK:#<
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MEBB [!LC]13G8*DG(RQ%HR)Q#]"M]:'/U:6\3]+5=X3T\DP43(%#/@D/<$5
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M/5G*U8]-I>[CC%^,F2\JFV\B3N\/:T&J1A$UW"0-FOP[1=Q!3/^Z,JU!^"Q
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M&;;!-N\\0]LM<S 2L^E2P3IAVY*KX%TD]!$(68=]0+RR*(<@/B5&>^<T]&*
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MV.&:=%M'OS'4?/:T>>G;S[ZQ=\=MOA:;9' ;&Y^GR=H*E*!8GQR;.V?FT]?
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M('@)MTD,58"2@#W?MM?]EK9;Y>6)XXGKYB74D(O+0#D(@!-R[/1WGG%$%F0
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MT1N] QK]OY&VWG,&,Q!Y\PP)\&,G?,3WIL BJL2UJ]ES/T W<7TS,;;%!B0
M]0WZ5OQR;B\<?'S+K,G=.)I:!K(94LG)4-\F#Z]](%*V=.\"C,GW*!B,/RS*
M<R4!)GJE[ EM*WZRBQS9AJG%9<&]:NEAX66G96A37:B/<H9OI.8ER'^9[U)\
MLHR(F\B/VO#G[%F27&*T7IGM>[)@[DU1].##HEGNWHACPYF4+N?VZ9^5R;3$
M2X\),[QC[WVZS31R_UA'A0QS>IQ>B;C@K$N\;MSY'-T3^Z]3)%+))QX:9T$P
MRIO?T?WLE6^<F&F6;G)>K_I&2+UQ9%#0@CY!>-GSG2)30;>P657IT\\&?G<'
MU$40[N'>X5NAD*]?(924N=YMP<I,EFXO'SGJ^O2TUT6QU-UAB;*7N)_6L>">
M"]$HBV[RID59=EZ/-=/P?>><[#<G^ Y+1>"R@X9+E"/I;65O#W-%OSN1KS!8
M-LNC>LU)?S$RA/_KKJQ^NZ?IZ;[\5&STE%&W"/?N-9$!XPQSEY<N*9?1B90?
M.<?3*Y>7PHH$6846"1=>#AD9QUH_3]A05>OWG]$R!A[49\^N2T_2>WDH[%S]
M6"&<.D0PZ)"73C.9SDZ9.:(J5*<52^P>C&&[ZARX2NN:N-JJ.2X:E$R9+,IH
M(^L0X6V>9:/'S)+MQS716-%:XF;'P7DGV<4%KA2(D(&%N\?S=UO:&VVE=3].
MFP\9V[R>]26,WM\9?;UG 3;.</^V)'+A2/;PY\L+#,DB(B9/OO(>377Y0I@^
M3<7 FHY;'5*[E'H',Z (\Y7%,=3E[V^U3[=9SL-N])2$&*RS63D?SA3FR]K4
M#OLP^"#Q 3ZF!DHGS^N):]#LHPIRSK+=J-(<?K'1'&]O<"S1Y;Y^<S1/Z9?#
M2.Y$JW?H 4%=?-18>1*/GSB'@,,B\Z2-8I=DS6=,P%T5GF/S ?1(F+SBZ3[L
M*ZJ(W1+P16Z>)Y:QFT4(#$*O>P_V)2?9J,2JGV_M1R6?,H*J>NW4^M,@[B,.
M.4HR0 Y9/)\IWCRD9.>".]Z=H^6@]9;Z=(V:EFH37.<R&)2*C<83V1&V5Z>C
MK++3PTY4'JCS<SY&32..$4,([&%Q-!FZ<J;5=PDY@3QDFWUJ>&X@::"5NOB1
M5<6CNG<<3I%?5IZO/HB?1$-1%9K,#]TR"<HOTY_<M%9\5_*:VO?UZ<8W'E(/
MO5EK,+,]PA9'-Q[Y,602X+BN&O]3^*@#0];[TV;*'$-9KCZRY]8251]X&6Q^
M]1-*^.US(4_:C1PZCM&INB'$N^VAGJ34.':%8K2%O,= 6FMK<%FC4+30/8U3
M0I%2#;%GCR;>]5/T04#QR2=O'X>#*(^'L^:RFGZ@*SM(8="V]/@@)O#!W7(&
M2H)?G^]1]R>5AD4S[F<.)4Q.$L<%T4-3UJL8IQU_A_B&WG3=4^^M&]@?^F"Z
MD&/[< WA\_HJ'<-3<-Q0PX.;K\-AA1^:OT:<*0UP\;<Z5J#&YT"9Y@UYGP13
M[UI7T[F$2\>,64>KC[I7Q7\UOOL L+#D4ET&U+Z8]V;B!\=#2D'](6QCAM1O
ME4BK>PDM\%F$R%R5C#+1A_F>"BS/FDIV-DB8"EM''6EE'*C/]LG6.+R@+IK'
M;:D]37,DT/AJVEG)DV=DVH0-><6#E*G*X\.V-78D2$ C/2YNUT>:&'EG;785
MVI]!5/.\AYWKQZZ9]V7H-\''K8H8@O<Q:FL9D*\I>IJ6KGXT\K"*5RM__,*Y
MP]K:;+7KC.G7_?P$]EPZ)1G'RW?S86OC>,#QE*>O0]@RR/=P]_IAI]( V?#(
MRV(?>/LDO*NZ*8XSUIQP;;CD),,(%%[SRE^8*DT8EL%XCU8_D70RDH^,JBM6
MY96\&7! ("7@P,FH$\/=$2(^[$!T>*X[<E\X[^?+#P7+ZM/U#K ]#7AYYG,T
MP-68U5-R '!GVO=UO0KM>/Q]=\=@#>OGE::Q:ZI9_($Z@@YLS_>EO"@M"V_;
M?R*^4\#\:CM?)-.U<XU\R0#W6L%U55?VQB."&*"IR85:@7Q&B=')J*-&3K?7
MP%KA^9*[E94M4BN:G*[MY4U1B50QULWV7%?DQL$(1HU>61AP[GL7,1CIO%-/
M=*>"Y\+)1X"40-<[L/&9<EH4,7,J\%Q6# %\GS4%T*+!R-_FI#70N([A[PT7
M^/:WNT,9<#?B)P0=(R#CLWO0F*K64[R1ZT3+M] P9"$\R)_9)$)8;\4X28,C
M*BK2_]9+.>;& ]CS2B\CKR<]?*;=DYRD[#L+<W"D( $?!=_!\'00$L"-(7(\
MJT:N'5AF(%(JD8"&;+BYSI;:QL-%/R9EWSGRLNRHZ/8^?"@)H'A.7I8EKYG3
M$ /]R=\R6,/PZ[ ;^EL&E3ER:&5MA"SHR_S^E+R@OH<$/$?<1^+8&8@*J@79
MA!R%?RLM2I 6#<!.LXQ#"51!Y%7A^5,D0)#!CGZJ0T*__<+&* ["]JI/?\Z.
MA01PI8&NVR@>U*'BG27B'M!O:;#>8$+&AA:%NDY?$IS"XAT80-"K4WF@3R*$
M)'B@\ [07S-<XEYE?<=R7ANA &)Q\@5=1K0">0$:C*<F"I%_R_%A1S?5#=25
MKAUG6ATA2#/4D8"MU3XDCAE&E%$E2$-^2<NI_I4ZX3=:C_]'ZK]3^RNW_Q7V
M<?_!$8;^ GOW0N[T7I#:59#";5]YT/NYTT#<(TIV <GT_3L5VOU3*B!$#O.Q
M*<)J+PQW"$EVL8L5N9'M"B!5"A:RJ_>IFZBGZ+6IL!V.@^+M4:'HU7;0LZE6
M_A$3?,*3+VM;1Q'V(D#?%#0N ]>&TJ5N_8"_,R5(-=2U;TWE($=YR.' -\C)
M_S4&SN5%GW6F41AN$,H FTI^10("(KY'-G2O<*M$[SDHGAI+,.&NSU@IF$*Y
MCF3F4_P-'MX>_1O^#4E8;*B\3_*NLA>$(-5>-[+U]0<Z=Q[_ 31]OPNR*.Y3
M/XIX"DVV;)F)SYME@C78L<(J+B12%Z0"(S:!1$5#$2,],!P#"7B=-F^+%&0I
M1+D.6^=3@?P[\>Z[NV @ Y" G5.PWRN2E>6CMJDP&8YS_$$$^8T(V&DUQOHV
MU^$$2A(PG_D-Y7>2(GC/'66\ZKA'OG/Z]))7R<%S#M %J:]4U4T5!^$R-TSO
M29;SP/J0$[E$IL24\?D.F_2\B+5KT(5RT:U%V%(,D1%I#T8HSB3 %XW+8KL3
MCMDM 3U:A8;=%23Y#KR?I2C^_8G;6GX++&IDQ4 >C IOV*%W6>W62HO YPMH
M_'X2<(#0CN^>$WT_PEJ6F&U;P@?=L;;[6$VX/?&.(# ^G1*^"9<NT,:/APNP
MS6,/8*T$4>&*K.PY=W(V&/BB&]@;;Y0=UG*.IPWWYG5LRGVP_@DO..9YCV \
ME@])+\":QQ$/[:HL#+?1Y9]I<)IH\;B:^OBZV4$7>O%]WAEW%6%>H=4)4NCT
M 0,;EHZ9SD;AQWT;:5^+5V&]IT[?"'!Q'8EIU<.1@/I=GSI7:[B]?493@G+J
MAM@%>:%&"1T93\-SSN4Q@US[O'M.]CV[DW1 2YVW%)<_GR$=7B'*7 JYW\OA
M\^I,O_>3<Y H<::T$UKFGY5&(0V<O;<0;XC)):8T79/+WA'ZRQ):<*:7,\%/
M&)U7#Q,=Z(>=N\XJG,V10Z(2NHW$9UY/#T,K[D)BYXUFZUKL*/B/'VLV$^ /
MJ'FUI7>'8-%;CQT31LQOG)BJD^H8,,Q_LL-UT(R-:A'^,7!!#W._=YXS:T.V
M>S?I:"62OBIVW++G]KK<UEJ_1=!EIX^:A\]P96&G= JCWN7))M).Y';"++F.
MG%L^WAIWORALR3[]HX.D(%*DKS&:ET/ TNEU@9RG"(L'A^=M_7B\ZT; ,BPX
M9UXXYV;7.P_/KA&4.+.C6-K5O*A5<TM6'* @DVVU$;5\>$[6@B!K&6;/%9RX
ML=^<#D-C<_3QW0\SV/1S]=3RKLFN]*RAW;:ZFZ_R&6KL')F\[.J"-+J%[VUZ
MW,GMB4A/GE'8*GFT1_6$Y3&-DWQF=)6*#BDC(5B+;-0A(8X*I:]G.Q?6.=YB
MBO2]+G^MR*RVT95N2@L[[MP D7QO[.O8EU,$I1TV-IHISAW;B7@6H?8BN/?,
M5-7,H3CDR4\4D0Q&KQ@:V@^B#N*#=,M>=[H+K->P#\^4%-=KZ!T*X!TH#^1P
M;CB1'5U5?*/URJ9L,[;?Q5X6=EABF,]P4,TIFSOIE@-71\HJLSH3PLVNK2N
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M!!"0</+Y3_E7BE;R(^4=W<=%(Y+9EKU,E'VE4[RBZ1@NQ_(.6IQ.+"KJJ?O
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MJU-QSBX-!6A<.GF:]SP\%!S2C1F^C5PGL0 X8,2 [CV!N8X\J"ASKBSJ\_E
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MU"3"'MRCISJGP6B]9%:"\V9&M_\6F750L^/N2Z8?]NO^R/O#!IE)'H,3"_$
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MJ"Z>VTB"O9>8O;&R89/JKQ9[IY&NAY6@/&YF=:[)FDH\=_)NZ+H[K#>=D\W
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M;;?%BN8MRR=++,V1)G<(0R+)T.XU.9Y?@F"2 K<>1B[4*#QF7F3=W#;=MT>
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M3B?N1ICAN'A\<[-RT(\^N1;%)A41L8[6/@]%_^(?CZY=@;"$(%Z&*83ES*F
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MF4.7J^O*)W:4JO1Y2<Z;Q+J6BA2OU=9=I_D!B95@7:)[=$T5': U457&#E$
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MJ8+?7]@#R?E336I?B/Y:");^PW/H333MM7?N-6T]9@<0^S)*K.(61!VG'',
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M4%PE7CQ0_=YF_5@PB7M/&E+;#_H,LO2] D1A>P9O!]%LY2/V0@W/.C,GK[4
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M&_437H@Z?J_J[NS)8G+7X6::6M\M%U = 1?6;*LIPV;G<[RMJ2J=G=ELS*5
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M!#812]#B>]65(@V5;XI'DCVZ: L@'ACRRF IBB'H%7\J4[[EH*.\%V/"SW"
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M^3L.FYZPEBDCUCBH7MQIY%YSS^/";-[/1WYB'Y?68I_DZO4(*[(X.3T^CEJ
M[9 NP&+K],?7WAPQ9&C>(QI/['LI&"YC;6NE&$/%=.VVPK)ACN$J-8:6L#5E
M9[+CPKJ= =7+$&2;TVWOJ42=S%4FQX0@KF71]"4Z8;Y0@AE_>?+"*J#[RG)Q
M:R1?8>]_:G0445*WRT%#W2\WC4C)IXL<76%8ZEG,>D^MW7,W%VW=SJA$A[H"
M+7S*1>UI*3=X;::=ZUU96G2/%^=48QB6!=@%/EA<C,5<[="GJZMG\[)9G&\T
M* @Q,9:YT$M</&Y"5R] PJ?FH]S[3<S'_&1S6MQS&U?.>VYZUAA-WTB(JWYG
M^+ZD16KKUS>E#;8(4;+-#/;ZJ =5HT=\$X+0DHVX%LX\BV9']@7#][0)#U)&
M.C]N?GBYD-?=G5-@UU]?/7OXU_9%JW_;%UW[T[[H)[][:,9GB/EK/#52)NGB
M>R^^]5Z?FC;MX#3N&YU6K_)*R^[B%",B&=C[R$KAXT!'T(J11]M[+VBK&M=#
M.XQCX!=%KYUX8\ZF)F[Q"D0T,#V_?\*IW/*]^6BU=I#6#LL] K$%7C8JAG-Z
M61N.'"F>"1AWEA:^)W<IJ_@HTO^)!$#_4)ZVWV?'Y7I7:RS%UIS$*,;0_YG0
MU#&THVA^FA?,Y5<?G/6=YLI4?>B,]'#:4J!$$VBCCKT4">Z4-N?,L#=C\)<V
MVN6M>M,OY T4O$G=T%+UOG& *$#"&,,_X2YLO#HW^?RILEBTTUY+I:K><"MH
M,%C>4K'@V!HQ%PT*#[B*CM*NLE+??1XC94M*1IHHM]3$@8=9KB@J".)<&P=H
M@N( $;#'I#KB40YI4JM+(ZJ5V$XX^2&<"NTR:OSPQ"-)8&)"IS2)DE?I5=?0
M\GNEW"'#>J\$1&Y0 Y>9%/BJL8E6HP5ED^[YBHO]FFX8O)RANLCK^6VI>:#F
M5QOGGD6W:5Z'-VO<32_)2$';*8=P:NP #D",X0BM,3J*>KMY]G8X&8^9M$37
M[>PZT[[N3N^KN<U\T(\WSZ&T/AX:RJF1SJ!'[A8MF92W[L3VJ"B67%D%G7PO
MIEX*BU620".:ZZ;!7AJBE&CK[>69PM*K\JIQ70.>M&EN>F"5#:P0TBE4N*,I
MP8'HRPW+WI+RJZ+K1-9>R4N*2979YD]-?LY4?TSUZP(([%/YI-RHM:JUO4 D
MU'E"9P*<4EG2\.BS @<XV8"W-D6@69"J8!0LR/!Q*:H)ME@3/5;*PF+#(T"V
M<]IDJ#?@+V^8RUXYYR6OAQ*N>G=S1/*'=?4!TVF9IZ,$YEY]P8!IQFX8-U=M
MI<(\EKFKRQE3ZF<RR2!V<C=T*P@'@/#C ,C/6-ZN U64IZ$U:^"&>\C1:;0O
M]2=$-PZPDIX#OSC \L1NPUA-H= G56$7,Q#E8BKOHW@,Z/O62BP>A,,^(>#(
MK]A;;0?W43J[*@K/U7;%8CNT.=#/4#WSX4I<I 2;5C'FH-O1OD#,325^Z(5G
M> ]D4GQ^@5^UK4C#"8U&<4^?4\Z/YQU'%2;/XJT'6> #[$&G23,.4$$/[\E0
M*K?I4HGG&=QRM",>@=O(FYMT&FN^VFZYLC= 8#ZE1(>GVZK4K/7WH4;E(]#:
MV:*BW&-A<W= .>P3; XX0& 8%P9[T+P\T:3T%-._9';E_JBE)'"<R#"A"\+N
M %_ESC1=FZ,"W06K*B-[[\865<1#&@4A&M6,@15,=;:ET)-/L0>2C8VB*Q@:
M7[ET'(!V50REBF@'\6N3/;[8FX6HT'^V1SU&V+\]H&T30^3',:UA3^W.C$7)
M;(8N9L4G4>' -0/$R"N\96-H[00\+^7#?DCW 7^7TL@] "H]]=-!5W*&\&)N
MUNP6.+@@#IW-J* (_)00!\Y/KR<03LUKUP(''IN/Q=WT']<_HWA<^K1N"/*,
M(7_P-/966.><E%%+JG*,BB*BY"/U!<48(_A:PV,20;PQ<3&P.-DS*@(\>]YH
M'AEK#UQ6]I6%B"U,SC/[Z5TJA[0J+E%0?16EFJ$!7:L<L ,!_?0O)2FQH5Z.
M-@MFTS&?Q8%U'CVOT%]H:N4823C7.KV" QR'HXRE08O,*$.%Z.&/92"BPH/S
M>YM:TTY^4DNO9[M2(-\F?_XXP[HYL., Z3:E>F +J 4.\!$]%# DQ^+JOCA(
M5WT2<XB8S,O/NOB,(2+MP[*@;L>>]PWA $<%VX\R@ZEO'$O1&M]#4-*]4B0+
M49U(WL=R; ,AS:?2T\<?T2;,>%,G%/- 49Q3%F_U954*P^U ;S1JE8 3-&?J
MCH600UO85[!&>0)+T8U7/NVY9T_$O5S5$ZN5/KW<V9Q8U]W/<U\XT=WC?Q2_
MV81H%L8![.!OG-\*YIAS@.9&W\?A +'7DPTO"@.8E:+RE)^+,&SL+!NI'@<T
M@VVG)*9Y62=K0,$*\AS<AVQB4>X\ Q)0C$<M#L#L)X0\SEZD=)QH:SV3A:=T
M>NU4_6C-[1<KT9*>H]IVG8K/5Z]TPZ)J=*9A-:>$V.L&;=A 1@CZ&A2C[<]X
M+N&G%M;%SC2^BQC==;C&,LS0=CZBFY0KJ[<'%H"T"6 >X2U\??ST%)_' 6(,
MQ^;+P&VQ5_VDD0&EUDN*MS>J91BQ;LZ?'MWK7LD;T O?I/1\_D)[Q*\(]*GW
MGOCC>M4*B&TN!E6# \ IL73_E*9WB43%/LB]^ H]Z$1@,3)HO=^3^CU\E_[-
M/NX_DH9\F620*3SR5W $[;5!W@+_*6V:%8A?1O[#IP'^=SZ+/FZI7WJT4XFM
M:;BXXU"Z.N[T4<55FA5Q4M/W7C<LSFG-V/"V'XW4.9P,+6@\\<HA?G^U=7S7
M@)3I6\W=VE!518*OU4.Z#CJZYFB]3'1(^_5=F,3FT&#AU%UK5SK^\%;5F[4"
M9*R,5SO?^7ZCL#@P\8D-XZR?V#M*-=EYK#NV6[10^72QVG _.V+9_UOQ&[_.
M^_6RZS6=@@GUZ%Y?3^\\D4]4J6QO&SR3-_+,M99XRBKWAY=/?1OZ;^:O,XC/
M+!.F9F$TQH]$66T.>@&1FEL.XJW:H!VJ9\%/,S/V5P(10G%<=ZX1F__L,/N4
MON2X!:6F:&*H&)8L*/CQ9FK,IS@'HF ]F/BFR;>&@(Q!7 @B,E2O(F_1B&4P
M8O[<$*L_6704*[=J'ZW#I2>YZC4B2RRVHR6D]W:*X&$(V\&O> B#1A,.PHQW
MA[0O=OH;SM[<NYV3PG_C7.O]U-=#)I6/*B:^[\,)0%*>2IPHG5+BR 90IJU!
MTLM5[-S2_JY)/E.44988Q5M31J$1(M:8-\<=[/O NCY2I:LVT)_PGT,S6PS'
MPI_;,M6OJ9#Z>O72RT=>8]IS:&>5]F8EBU-BV-#37M+E67L4/&\:L\$;(\BG
MCY!A%J=/[CF@Y@ZG:*<X7+"\HAOC4^A1:@>W&$W5K!^1HG0DARAV]'E,+)!\
M0D]I%6Z,LKBH]JFHO '2^RG3KW3&^N88J1;WNCZS=BS5VJ%X;'J7:X3K3:!)
MC]JGLIK91*"(J^X<8YW])IQ*,ET-7.%JE^0RZQ_(V4%S\^K+\T5]@WMDN]T6
M/XD5"^XOO=BO;M.EY] ,AI2)=*Z^>8==/-TP%< X3SH5+E:-'GJ)'CU-P:HM
MET7ZAG.%3CEQD)#47K$E:'E.?X>K%*%XTLZ?6X/67))US#SG[EU/%A8B:#MU
M=/A1MLOVVD5BGCYM5/.Q0+_<XVKK4V#TES7@776-60B!.O@61/RM_]KY%;3E
M7518"XS&MHEC6%AJ6J*XE ;\M*C]3JJ7RNOF0/^MA9X+:KRAZ SIYD$!+T*G
M<0#UQ>(&7I3>L0(O#L"I=@;Z?I:L/.0V3[F!^F$KYU_\R1(X4U7^]GET0&0F
M@>%Z5F/VR9V_^!UD5MS'WT(5S8"06H/U*%YLG2W\C*C#3_'/&^[C;[$"2O"W
MH&5[:O4 K?/(2#[8JXL?O[Q7\$OT$P>!I;W@75C>X*U.):'*R>(=PS8EL=$&
M1:?%0Z/HHO&&6*OXT\!\5\Z+TI]&MZ:K%"@<9PAVP30/U1<NU&2T(R$TF\I>
MS[;,<8"E L17M-.C^NO*$TT."]XJR5:E%2?**@]LN%[<ZV)B^4AQ=+/I#OH%
M"OXT>:FZ\W(MFA-%:%09951J8B9\<Y1U@\RM_M%06>/Z Y&.K^TO@JX%JSV_
MLYUM]B@Z1?;;B#O;J%((TC#0;<=7)>9X4[VWO&Q;A<#K]F%QV?3B0)#3X ^_
MT2VN=Q"MI8:ZT>.WDZ\X:*8#!B&T-\*OW5.]\CXSX!(V!Z^GXE"\%S3 2.#)
MECH>1+U](3>:X.'#>%TOTE 5-HVVUZC$ ?1SC7/A'TAS-\\4?+[&N5H4"D]8
M_:Q]Z </H\?CJ1$EO*V118BZC[VP!6%*LK'75=NAAW<"^"#S1?@Q3J)/EFC<
MM>TILLS' =Y*0P\90&B\2/PT?+$(H8ZEM'W>I^-X:_N\QV%K)\$<SP(EYY+N
MV0T0'6AO F^O])*!%K_XX2\_(%X*NS@;@9P^,]8H7"WBT;+MI-I@7U'V<L)(
MQD: U@,Q#_%KK+$N#B#$]^=6/;?Q3:1?_!.OA1!:[ _&)LJJLIJ))F*,5DGH
M\=FT5K7WC9'O\:M+^I%,G=,'O?("P5[=RY& ,X%(Y#S:%G@-,DR QF.D@ HH
MUDCOSPP#3@0$VR!_Y%KUSVP2SN3!*/_,*_"/7&92NV0UR/RQ6^D@;6KH!&PX
M=0?U^:^WT_NM@8H]?YW#-3 )]H=,AOS0J-%0 (F?UIC;9(JO>TT,I?#=>.8,
M9D/* "H#M5E=MB<(SI0??V82\._VYY_&GHY@]XEA* [P1U9C_\CE0^):/7.6
MOS#Z=_[RF -\8_CMUQ1UC]OJAS':66B?@X6P]N]2Z2]$N$HJ;MF^*&8@,O@8
M+%HB'::U'-/PL@K^O_*H_YN]80JM@(4O1:<W$?@]),LL53)(&(),7[Q$FQS7
MC/G9+S:*ME_G;9Z/J N-_6:BZFWMR7K]4>'0]\]QS?;(UT]"OA.G ,ZN_]\3
M[3S1;8<C398H^9I'2Q-+TJ%&5LR&*I?%X];OWFQX_%>$7AP'6,Q]6ZDI2"Y?
M=*G55Y/%U=:!\(Y"S<(-0AKS5"7]4UT@GZ*R+F0!1&WGBQW/GM(R7W3\46$I
M+-!YDTH7EG0)4M^EL3_XQ^8;:,-VO"&^2]&J;248*G0J3V7NU/3<K#&)9./P
M?7F-DEJ04R=SYD<*5DS8[:7T'X6QEI P=F;/49;S:_U4J=<[;#AC+2*E+'H"
M*2@SW[V5!1P7P;9303O@'=%RU6,4]4_L:/7:_HGC3ZC6 1[C_H7.%VG]?ICJ
M]':.MEPS,:QMRD>X_27_G3=^P\G4Y1>SS=)S@8=T@PP8A5*4<&$!36C/DDE%
M8Q*DK(L_7C^VUX C[&$-()@:X").G?87!%#/@T$5\M7O)K(J_?-ZW=/1FW5A
MZN%M#D*(DU3-*Z\2FSD^7A&,KMTQAM!(;AQ!+J$C.\<IDF7DW/O$;F!Y;3[=
MP7R'"?\_#3_H;\/_Y6@FXJZ&B.)@+W.65XZ5FY6[_%,CB^#;-T9?^U,&!*%3
MJ,F\VI[6C%<Z_51=HNS\_'IZ]1.M=E2?X_8]NSO7?-.L)@SQ=CHA#I"MB8["
M 2!"H%-K<]VQM>'L?>;7!A*?]L>BFR#+?IPAZ_:')EC2T6?.]DA?XPPC\]N.
M[OGLC,^";M"T?XG5>Z\Z=GV5L=6<\!')13SVYK)K[P_@1??D9U/L&,,\*8:?
M;@K:O!?.3H6,2>&,-.D6EAPL-VH?R&^,%YSTSRSAM2MG]^*IS@Y+E'65]CUE
MI#3L%8,\A4ENIZB#8=]41R0?$:88[X'^>.)!$**-5D?T.BC-\2N0+@6N!UZ]
MB'#SQL\@=VLLO6$,9%T%I8LEV86C9_VVWL!*,9./B2)<$Y[DP%^Z'!KBQ8.L
MH MTR.F5BP-<]@1C'&/1^N9X:_,S2P<(S5F' R#<:KE_#&X:P4Z/1&O3&NG'
M(*W?4(,7)'-XBZ2%;1('8,G^PV-8X[>!CSH@@_G^?2M;?_IH H^^WNHCH&=7
M&Q[C\9P\#"L#ML;7)*? #?-Z+AHN7&3CDQ$I8E6RKY+S0K@TP6Z Q<:=N5/%
M>5.P@))9(*+"'TR^6##2MRCPWM;8)/<G]*6>,OTVM.HW=S NAE R/]X\KTX0
MW8Q-TLA6.*K[.*&>DLO.0)99HO2+\G/ZGYI\G23-72;* )[;779KAT "FZ;K
M*&!$9;_24%N^5\PJ2Z/&8\Y;249%B.I[=&DBG!%7& $(1?6B$XM(HS2 N#HL
M78DU8,A<$L6>O\#F9#)<80(FQ-RIS9A6B1EYJO/9ZH'XH.,D$=P#^^JU]#VB
M'WW9PMV9U%G'HB>J*RH=V'5,OL_($*''[]FQA_]YSHA=',D0A=C2EIXVKI!Y
MN'&6_A7F6,"I6K4Z]2*%45[MNZ&RO"XQTXW(^7CE".8?;_69N8[I][O>@%[]
MM]J^,ZK)[ULS_&C2BR"]""@=I+?01)J(%!4$A A(C12E!0A%.J$)" A*D8XT
MZ;TFH?<JG20(@I2$9H0 @_\[Z\[,G9DU]\/<#_O#_O">L\[>SRYGO6?MI[3A
MXB8(YWV6$4T;[52PP[Y2$K77?O1UU,V]+:U]DX_E+4 BIF1XE<@^S)EX)RCN
M8O*/24U(J[H(SB.*YR8TX/H264$0Q%$93KCM-R30G.RIN9'IPWKY4P2R%D$*
M*@M0?$RR)\?F'W-BM7D-FN]=*SQI'"SG!8<E)O\)C4Q.O5==Y$GW=A9N+:J+
MN=T%8QB(=D\HQ7L93,F%T.J[9OF\ZW0A]C_-?V65F:9'DZ+@[]KS5D,R_CV=
M)E8PU-LH:I4]3G-"G*8XDPLY.H4XK"_4!QZ^>.@G)9AYQRL>]YD64!5N=P7P
M#GYV)+96[Y?8+G"IBCWM*(0$/L?Y)KSYLN!2YWQD1!/_6[FPF-7VLWX+1NH>
MHQ+)?L*'T,)W-JG8:#0=3*Z:"=_5LRK;.)6!4.,^O]._Y&TDY^:^5V4R\IK1
MU)K-4OC9.T=R0/@8@+QT%[2?-)3PUXA/2O/(_I-:^9":&,$$IQ!*\%JGD8;?
MK\N%GYTV>!39N#;Y/="K%//ZIF=G8T!TX\YR)%$H4:)OJ&_ .'R%"H3+B(8^
M"72>^F5)XF?B<A1K;7:GY:G%.PW?Q@<NO]_U*?:!\_]E9>@2YF#1')'#AA]4
MCZC8/=84LTS_Y.2 6AH'NB[^Z.A;4SZ=25J)L1UI$5#D<<SP?U3E.'T%<#9B
MMP9;@F)Y="?)X:I/D"F0QPNF%ET-3'&9XHRXV(O5ON:8)%&.,.5&M*8EX$SF
M7V9^^OKOL3Z8_J?Q/9N!]I>+J:?:Q!+DG_Q2L[A55CJ$6SKX21T/&ZWW67^%
MX722)0H.=*YZF2),S^0C B\A>3FG&P9E*22H8J/B4 FTWQ=_+JI^-KOE*9MP
M.Y%U1D384: 1P)F:=4A'=CG!/I91"'ULQ&6QW:2<%";'ZGT%J,>#1^ZYOAWW
M8/JVA.2,J!UOA:"%GA-&VN/7O7)8+_*#;T-*X-STDYA)J*HMCL5F7BY;PD-9
MOW!:C&^Z\/VC+9>C.QYI]("GM]XN4$II\#Q^_>^.-"?&&J&YO^!8>A6>_#(S
MFV._3"M;=6[]+"\MF[Z)7G1,R+G[DL,^M.I+E :4,SGKF!+@_M<&I?]RDC+L
M_ZV5DPUWM\KG8JS-D9Z6'^;E#$3=U';6!Q! ^0,9Q!>9^I?+!@-L*BT_18<N
M1:%V.#_X>.PJ^_1>?Z1DO;65><U4P01RIM^Z67_I=9-4WI]_[BOH/2TGYGR,
MG,_K33J-P27/5A*,SW1BNJC=@<\O;VINCEX44Z[(?>P0O+"!>T;X/U_Y%K62
MFQZJEO0_0KDZ.YB-$()KBCD)B3[K["IP;@RFQD<<%<=Q?:[]=,ZI>0?9M6@
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MP:.^H1P=*-*NLHW_7>H"WJKOD@N'K/^MQCE?/QJ\2@$L<YB6P#3KK;$M(BD
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MYZ)&>3X:WYX3+=_;H0,6!A6OH!D,$:M?_,GE=M7K,L(=)\;C3GYUJ""5':X
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MSK7K%UU.LIRNWDP\1W#S)AFP<TU7W T,)\UN_L/U2;CVU5MI\TTVKH0@M]#
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MF3H^K$[.K^5'4^NW5ACQQ,<Y&6S:U1N:(54-83!8FVS0UH,9;L)X$JI@$XT
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MU2Y]_N<.?F=$44 ;.#@DC1QA&=H(7-INXFVM<=LV@VI40W-'.H6RR>4=B-N
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MI/G(P81A)6HB#-:RQ(<POJ1H0 ,NZ*;!& %_I(^.^?EV^^+'4T@V5><?/]S
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MD:Y,3>YL_C19?^1D))0IN5:!T*.,.A/U6[C&<Z#F5.3?&4T_*;N8'K  C_3
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M>X3Z.P8C_<M*K(%5)SQS'0%E\C)K[7T:T5>$3,4N^:P'<W&(O>E7'Z2[93!
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MF!=N5E]9#[]]?+I?^W.-\*8@0N%@OC<M/]Q9]4V/<Z86V:1DDEQ%//6T&O,
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M2-9BSX]H#F_J>9X &X];Q0GCY"Q&QG7<.FFX?HJ,R+Z/L\R^CO,407X$\(/
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MA.S+!.2EP(;PYN;XQ0J(=YWC<G43D^<5CAI-MI>*)'M]5&L*[&50UR1'9[U
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M>+5ACN&%P#&N\ <%343N%]CB!T..Q9RAN^F0\AW.L=ELS/C_ %!+ P04
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MV;[6)WEV1H0MT;&%Q4]N26G\O!&_+L*.M 'JJ O@2%L:VE*:;B5"\HXJ\=K
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M' ':VZ$@1FAX&*;(]/8=H[+?[SMJ2=::-%=>?=;:*J]\'Y\\Q;;U90[!V^M
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MJ*/CL761>O;IK6$Q!^*#U5PETVF);HQ-@BZC(9<UZ%^QNU/X,<1/V5\3.2^
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MN;+(G\'7O7X$NK*\O,H^'[$+MN\;MU1%7T0Q=C1='\*HY&L(Y^Z$!RH_'&B
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M).UIQF,KNLUW3:H1V"@1')N)J1.( NI3L&;!&2K*>_:$TMFO_6R-]#M5!H7
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MAKB],4Y^_)^HV- P/, GB;+'M32QXX'^2N:C&ZBY,#RPYVG) -LB7]C%DNO
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M5HED;BO<8NF/A5ZS GT%B_35#T?94;F_57*SO^?NQ:S_38.K"3=&!/T%XU(
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MNA4=B3I< ))@I:H<)RL<'?"OW]#< %I _9=,\YBLKA9I3/@J'WG%>FEV4E^
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M=S+04L&([NF9TNLQ8MCA<[?-:5<![=Q(MLB<&*W1(!I=<]*#YQ/J]PRD^$>
M"V@#7<B9F5L";;YW'86D(XOL%RU9)1:.7L$+CCMYBPD6WCMGPE\-^2/P$EE-
M\5<Y32K:+,* ;#+\3[5%9OA]3P%H+*<-!\X_CH)&A15!<G5G)82:TYH(.T'6
MJUHL'@Z<Z^K3\%0?XJU:1-X<!%[EM_DUJE&3S"<!H >O]A_@XURD7HX6FZ4-
MI+EX&'6L4CWQ*KQ8U^[5R6.%\NA?.B.(Z)[#4&W&!W#[D&EC!B0Z8V56,'_B
M!$,T?VQLD"_RQDHVB]%I.2'23Z,--E.6/8<N1*HCNP\J8$*E,GL"B#D@R"5[
M0=Y)?RV$_MGSYK'7:24XVPA?*?M+Z;E'T57=(6JFY_C]UX<%*Q]B4HX@9NCO
M2-< %T(JY&[-NFD8^%RFPDY?BM6<11'=H\5TQP%J)TLC2L'3NL^S7)SQA)$P
MMR&SWN X7^H8I'.GG;<F2#=R>(G/&8]Z,\,&<!)2;21-DZ*[!XG5OBM0PDF]
M6:;V?,I#*S%]#UWSU:#*88C\W9<K!ZZ^PU;0#8#0N/>'_E;/#6!_$.+"EN3N
MDS<O_ZFP_TZ%B[^K>N4^IQ/Y<4#$:BK5OMQ**97";P/C2\^ED3R$#6TN0CO!
MT1F4'_K[T7%?6 <+RW<[EF5SU!# DV@]L":+.FIGD>L+_C,+V;4CP0H]@W:[
M6Z65XTMX?Q)@,ICG;IQWJ0S5F.N.@;I.2>D?K;HO#O.H$?&"! ^KN;W-GM7A
M@A!U[#2[N^I;/M7>@4+10:6;EZ[-I393-P ;*%8LQPA(]^@\Z*5@>'6UTG?"
M5O:X,5\I/TT.  "P=4_3BZ%#.<L)K;WO0/PFGY679)JF7'+:6V+KPK6TR!H$
M_C&[TP]RYOERD1CG>"_MS]<>H]CGR:_J >;+1P+^-NEYJ-L2I(C!*8#.[D$.
M779WJ6GG@!'5CD W#AQF_%@<L\-N@$<EHB.N:9",>_C%V+TGWSS33ZKFNET>
MRPN"N"&3]*]Q,;2H4@%TVNA3C&,V&#&4< P6*19TWD*P?J\=[Q:DN52@4'!E
M&W.C<Y#7J[_Z(4D$,LM;Z+LH#$*/29R_VZZLG8$LU.36/L5=O^/E?ABACO]#
M,6?F-82UR55[^VZ&-VOHJ]H),[R2;K+7M+DVI.0?.2, 4H$.)N373//0#\K(
MHZT,B_H)^+[:$K *U ZM>#8H31[AZQLSXF@X!;_4A3Z611%M1#I?-;)VY^UN
M5ZI"LHR&<)IPF1;,WW".O;C\(7";1:=G5?[*7])6(O/E K\6<N?,G))[Q3)6
MNU]KN&/F-B!/*K;3Z\JY?!!N[9"5(0$M..U4CG062X5\SJSUV6,;SE&?,A+;
MXF9A']*/,K1%Q=Y3/B35?24646O:$]F-E49OI%-SYN>YA;O1@I4)K]<#/[ZV
M:Z>65,>OY _2R#5GN"^D"THTG9CS2F2LBHNC2FR4X39M(NCU@9M9(S$7/%R=
M9]LW@/L3E$DO;<Y<G:02?CF3LT36R;A$_7[ <Z'SP>)2#?-N5S8%,[=;Y$,Q
MKRTS<V1=2[HT*!C:\I*.,.L;OW_;R>T:PM,":S)HHJ86N3ZSLYK*!LC(J:4,
M$R0SNW^*THE8I_E-5C#Q>*SI4AF3[.Z(TE[J3-+.7@).G%A,"MX Q/'#MFE,
M;"L&2J#, ;_-1,L5,_$DE7A%LFN(%5:^,^I[W99?8;2#/OZCUW3/AC=(,PTS
M/D2=U*!_(Q37V\E>);/;VI";GRYK5JO?%1%V,+[WN).N79<_E%R8Q%1@,=:3
MRS,_,C](3%^@GB#3M&#"*@\H#R#O?$AS-Y4*2DT4Y7A:,"I+*@<F*KL!L+&$
M>]I!PJ@<3T5W;%X)3"6& 0H<<W47>D*ETIKZ,ES,0W7Y?I-VZX6Q^ M%">JN
MO0_4H@9XX "S?:E'F1NJF*KX%EB<I./=E3;<4ZF\7S;2K8W?EN#_^3\*. #<
MS&Z>_T ;'>&?BV],;S%#P%]#GI!8C(XV\?9;A<R5M6&KRE^"!--E<0<*<87%
MS4]E(F\=IU S8NKQ+*_NM[)G[9$[UF?EB_F]2;-:]EZ6E#7WY?!QR=LJ49P_
M#W%?T/-[I.@M1^VPA5E/Z7[_%#/Q@GF>-C8,D"W((RK[FX#@/0']$&-LH])V
M[,NP"K#5O0@F+JB9_[.^MU\YH]LT;Y%%^7^1]UY137CM^F 04!#IO2,@*%4Z
M4D6EB8" ]":=T#NAAB*]@P*"]%X" @F]2"]*#44ZA!IJ(BU"@.%WSEIGSO?-
M_/\S9\WE7.R;7.SL]WW>\CQ[)?N%L ]<:O'WY[3_P0GYTU?MCDSEZ7V3.&1(
M]?F%MO)K>&P0%6!.,86>^37O(VJ+9$4]V)13M>]U[A2!1+S$%XH:Y8(?55[O
M\7S.T48]=:\9%"E0Y;%4I/G4Q-L9=N7"V54& @\WGZ6+!=K5"//,4.&8(,\A
MG,*,H+@>(4HG>H7=LJ9UG60Z,B6% \?A=ANT8']3%[D=2C/D%,*^HP4_Q9S)
M*MT"3%O2I4%3RM:Q5 9?,ML./)O7GII%L>E+YP?#)PVP;]"DD3(65N+93W(+
MK"R8!_(LW-V!CD_ZR.M+^G^;\[E\&>$E:]E@\\XG=8--'CB5 /D/(&LID?2(
MF \I1R\K#@\MH*^2WR07<!XFO(K/+;O7#I$'CN/+=G9XD-0XG3J6PG=:&!2[
M$QV[G\8=3)!U=7ZN,V&WDX[0S[CK7XJ=*:Z^/(X50>*%7GD'Y@=J:17*OEOT
M>ER-A.TT"BT:XLG^9_FD!NUPB!BU;FMCY)9^?M;SM6#+PHQ7\#*#634B0QJA
M3\0/DXL6$WE_'8.!X_>-[?W%BYQ:9ZNX*JC@RF7 ++'1_@-5HH.<TE!]KU<2
M?XW=Z&0>S7JQ0G/C:-H0C/O95W[M]([%P-:$B*V<]OHE4UGX2 $U+=]!/Q4/
M/G&JPD[^ QC/I_>5@/?/ 4PXNNR3!VPM$D+SQH-NGE<S,:]/YK[9ML/ #JSW
M&V.>K(6;W4PE'A\(@P)WYW _J+8W<,&=FWQDOIO[+O^003DTIMQEMNL'W=G-
MZ?LYZ^'Y/ZLSCZ'[T;6ZVMYQ[LQ"J<H9"9LI+UF&V!4>NU4RQ=,,<@8Y2+<Q
M!F"P;9GLS4DUP^^?8Q/\?G6QG&;*<&6=YC*APY2FH$K#[1(^ M,\1\*BQL(5
M33F#B<N@\G9B]"?0"4)W.[M4U=%W/7T"(A; "TV8-7Q4T[L]O/:11#R,Q/,E
M2W*K:=9"G(4CH.F!6[12&\[9@)!>55^[V-4=^W0,_#B'%0NR<+58;S/8,94V
M.#%,F)[M-D*J# !TW128?9I*#*;N>N,M '=/L(I>QQC.#]WGG%:?+2K6=&7N
M(UFT JD]&F[?L-=*2]E_R5+O%8#K(Y#PI6M!83QGLP9[N4-?4=001K^9)6FE
M6GSUAP<P>B:[_QD3A-9Y@TD#E@^77M?,[FM\?AU@46'4 1MM(&_Q'5@*46;[
M0^PFI7SXS,IJW=[[%D"NX/%QUCL;(O&Z81**K#D2H&$?P?FP9)@YL".)2Y=/
MZI1%=\1NOZ68*DYGXYZLW%P^FM!@=)W93=XT(%,8;BLK--5>UB,/DP@)M"M7
M=K;SKE@8Y&^'#_J5(R5HTL<L\,;)4M\\M(Y_MM2A1&H4NW@.05%EV5:!/;GJ
M2HU_&X*!SZ9%'3,9CN!NYG)+PKC"-E'+PYM,=Y[MJ21_5?XP_R/.Q,.8ZC7'
M+\W/!^RTH&\_N.#"91U[L<I7QO92KI%C9268@#XC2)]126.V>ZEJB::C-\48
MV%<B@SU,*^2)AIS+-QT9H:OWO]70#\Q1.]'\KM5ZQ&:RXF-[LEP;!ZBO''J)
MTE]16IR6*K@<99+YI,X,LB&M5RKU3;0OQK^QF_Z]W!!S_BSUY>/#E#!2?_0Q
M&=;?]/6/&^ZYP,=6OAZM+-97>B5E:M0Y",YL&[*AMT<<CX2ER"?FJNP7BHU6
M4FS*N_/8C_":DV1]6B-9"_()_TGU:$4\U4=6A4H%+['X4I*IU#WL^6-N151W
M#)K>:2W7?BN5;C-=3FL>A_=4ML)HEC:'RSZE]*6N-8_$4]F7LHIJB@!NHT@B
MQ@#[%<F/B9P>:CQL[U7WDWG\G]YC=%1Q*B0W[F4B3WRE5*"\R:.<8*-=4_ Y
M_JZXE6F]).OX1M&N@1HX)/_E-$*H67;'8K44 4H32@?T*88A'$\4)&45%1R+
M#7Z/3"W.+W9S>(,*=;G1]R"3+PG?&7 8M-<Q1*,30I7D>>Z*N^+[6.J7NDP
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MR=!A&_R&P^&:$;!^ZX[3B:.,'5]'JIGI+8#:XE(_SMF;)EFU$>[ZFN].4#'
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M'4$9&W(Y-JA#&>."P>L&JR>;>BE?)7[4MEI0/N=K8:-P'R"1FJ-%_UR3*T)
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M0#?0A.9#MVD\H[WVRQ>5<DF$B04)776=.1M/;P%(5?/-(.-<^W&Q$_G0OA7
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MCQD3PW1&7>-7D<6?8J4/%LCQMI(WDN4\VC=>0&2ES]/1*\5SK3:UYYP9QQ7
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MSB^M6&@ZP!!QK%?+CX+#$E3I:R?1@]IEH9\5.%()P7W#6:TZ<?V'UFCG;Y4
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M9>0ZHG2KM/U7OK[Y+WGFF?E8Q[]S2;<?[\(HM4+CYR$LAJ5>QJUS]B)13@^
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MP>P%SZ)74YAK#%%!L,.Z72"K'<6R/X"&Y R8*O(/ZCA&!:S "1*X9<Y&Z3X
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M=H[T$VBG54>$Q(Z1.X"G)CO$J5;V3!#[CV%]2+:/P&'\M=4U!W]9AF6(\M*
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M>P"CUHNI$W_RIWVE#C89 A,7^5.S?=HAN_N4O<=S0Q)GGS#1N^8I,9 %GW'
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M#!J9>P;YOPL@V<:^? +=*:X1^7DN%K6KKJQZ'@W)O-*9_L*I/^%B9(^1IX,
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MF:HCQ4P_+YN6V95;!DIVYF*VF"(79@DSS772^YDZIN_/J0,4=5ZD0%P=KMX
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MTPJV/:C<YE?])>CG9EU3'>&EC"?O8W2@ZA6I[R+-!-CJE'_)1BNK[*@\9Y1
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M#%Q@XR[4P7']QL&1-M!TJ.^-7<-D-8/02\. _+W91DA][,CSFF#S,S89X]J
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M9 X+T7*Y$H#/,F.? \JI9_/@RH*VZU,"4:!28@J_/W.R3W;2N7'7="Y)MK7
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M978*?-=ZA-_O(QSA^"KD74?LL7Z*[Y=#_N@97WK:O9O8-K<?%FW"&#_?Q3C
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MD !D1G*(NU.)B5V+9M2YKS!Z/$VA[6W\[ 7::YB#R1$<N(GQ3;12&27*U?L
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M[->8AC<_!H;'"/B.9.@A=F$#_7^?PZ/A8>>^MN:(QIX8$>E$QU8+HX44!WO
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M5/L?N@K,80FU/"_,WV;$Y1)JY2MJ1?; 5]N!QH/=?3;L3';.,;G:V=PJ8V)
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MZH*^4F+GX436*P 8  ! %]G0W8?_B@A:8)L=KQ\ @TG>#P"3EP^ R5(96N.
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M1SZ!KXSR31\[''8RE[2&NV[>\&![>5)4TL5\C$*F!5=QLV+M;&]D>I<*T5%
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M3YW<Z%=T9%1T=J0M&/_]1VT=R_RT#:VQZRAS71/="4O41ZY56":4I6FEQKO
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M4[,3XXR**O/VKOB7_AD__V]TG?L/LM%]<!F N/[FE[[Z94#\0O3L 9"C<_P
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MO>+.06 :>KCSY_W(W;CF??D#@/UV]?J%1&>=6;!NY&]?3X@?YZ%UBG3"%,Z
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MK)G']+6HF*#*B\>%L\%"(R_WH-<24WJO::M'HNO!G%YE%()6'*L\8AZCNK-
M;L\(Q6G'YS4I4_._+E*\H),L4*O4=P),9.\_+AC]YG@E<9Z;$'CD0:46M9XV
M;N4HFB'%82K ZL@OU;1 $P-ZN_)+S#(OZ85'H8$QZU")>JUT!2M.>G8-T$S
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M;+2O)+1D"^"&7PD-NI^IDCZAH'9* \6X7*4 KKR'-Y-Z_L#G8U@JAK<K$8?
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MBV8]^?6O)OI?2L],_TLMFE_HT_\[+L%_13B'@1RW@*G/[/N;6O&:+9._"VO
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MR;Y@9KZ:P#C[BVC@_[Z8X&RNAMVS3[?H;@RWBKR%UDU)L/D7S _G23:UI,3
MB5[0=F?HAG4]%ZMS3 %<EOQS!C1)]=,;*?7&QL7VP:A,ZZ/ E)/5D*:&R7,_
M=3@[CF*IJ4;1$'G<\T\XH,5MFO>-+(<@L8E"5DJ'<:.</\L;TKX'][_9B4$X
M7KMGWE\5NJB;6[\UF@MKT7T>F]\R:?CJQ_<2<],?.OY?6AQ=RJZ0R]+F<1)\
MUKK5Y_DCE2 VDZ>VM.JP\/%[V .@T.8!<)0B]?<[IH]ZQ6;+6ST [/RGZQX
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M1CZQZ?K@*L$-=IXI;C<U/S!#)\Z+?_UI?GH4,['DWY6*C-I.1XQE^A3NB7C
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M!G7WMW/H68WWK;[7C'YCI'FV;IZ-!RVH$.[/L!DSVF6&WOX*D:NZ!T(V9C;
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M/TKK"N-X_^$3KJI^X\6<)58[]6W!R1V,:'SN\1;P*_BE !&-R4^A2BTD7ES
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M#Y0N]VS+82_'&SM,(G5I;^!P0['Y'!R^HRT=G;*F%NPQHHC+.U<3ZTV'E&X
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ME<)O^<T+5PX<RG'JCNZ^F5-JCI"S%&%IYM[SEI6>%ZD?J[%=#;S,7SJZG!3
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M\L?-\(UAF]U!4 L!D)B_@"[S*0IHR!',RCKMKB( 6,=P> 2\P;\UC4K>$$,
MF&(-T1 &<[/9:2W24H^EW8!1T*UFC6M?HA:U_?;!P9R4GOUO+$@&ZAW35Z\U
M9KL_OP8>$)Y_EFI#%>03\K*$3.[!4F,#OF,8LCSJNH<=_&,Y9\TF$@ 6=6XU
M(>V#\3>%']EZ(?R:M(H7RV18TO2*"GY0.(RZQ=7:;R^E/4]R].C_N+T9(%"
M351N((H#E7=%O<5INW.K>O0,:U*:IHL]]3&&>"VG)6; '+"QJ 9W8\R%D^?1
M11/CLVJ,_=X%8T)HC8+<%W;]S$Z>[)?=P.Q-SX74VA,,DZI#-W/*1IYYI"[]
MO"5H7LM6%#G.QX2J.X+=PX+1D9"W+ !343?AC&=?)Q^7US^N?JQ!RJ3QQ?.
MA/0;PYT^O5##[<YN":1J$S^COVGO@:AQ  ]9S'>I57O(4LZLNBD!P)M4GOBA
M%IR,)ZO#2%8'XQ[A^7;8X3EUY[7.$BWMV5K4^:@@HP%A"M&35.3;X.<X(<QV
M6QZ>S<>! %#9R4GV=%5XHYN34F3_-.LI]%MYA_=3OZ1# ZQ<>AEO_;7,N$?J
MLOI-(.RFJZF/P]K/&1FA_:5@\F%!%3J'O)!2P NRH:K.>@9!W4+5Y#<+6Q/^
M9Z,'HXNZ_>(R0V$<E2,:+PRB;)GZ>!=[4QH-;.,@+?8[<O>(VW-UZZF" ]>H
M*[7#J[*CW44 OE)DDQJU3D:##==$X@1$()OFPDI,!$#5NQI')!$#;O?C:GJ.
M*5B5FSQNCKXLYRBX>QU/O^ O&XL5/%L%_>C?D3S!GZ\^[;@L(OOR(QBOM<ES
MI,+!B)Z=X&].<LE%C>W7-8B;1>K6[F[EO@)^XEFM^=9UAZ?8_X;2!<?%4)IY
M8"E =#-BKXD)_X.#=:>C3JHXS[[VH[3N*XKQAZ6JHBL%#8'K0QYIERSL3FR*
MHPR.=-M=6=J@=Z@6SKW^,#64<4M-_JS.8-7:#'G*C"HE ,:_K'W53DN:]C1P
M0%9- E<ZD/^B<]^:-K24\0'$U>%U(J]-^MDE3D!-OUEOV%!%-4GQ):5>6Y.]
MR 3?.NI1>(F1O07;CL1$FY>B9U6%8R9KBBRC E7<LEWG"\=P3&X'B!/+WU8K
MU!EQ$*W=4:N:BZH:;2KWV*;,KLI@W=8G+^.IN,/<K],>J( &7[9OO#W@6NEL
M->+JT3/6*\VPU7OAK5^P$MFN9+L/R:$7UA=39R;;&28OS9"8_TFK:8)AR9>U
M1\%PV0O@9I'"]HB6COT.XJCA6F/*3-FQV>=[+H;:VNO;LI?U]+[MB+1&KF\J
MCF[]6-M[&+^YN846U6:M=(:;RQ:2Q  [ZUEMT9^=<.RD']SR.2^O&4@AS/I)
M;&[U H[+7G^!)>]B9'$C^UK*CK87/W(#?7B"N>)H;U!D*OC0S\_T39[,XOI.
M.$4=JVQU!H*N^X2<LA WH\2)V(J*,H2+1+>0_GUO<AXOJXQG\<FWO#Z$?N]N
M#Y3.+2JT=N&[\TDUH[_Q3JZ9\>1T0=& FE@AF0XW:>N5-[9-#5H:)T:!+D1$
M=?V_KRQ$S>1F^H4)T2@JG=>KOXH=245C%&Z2L O8I5.(*[.=?'U'\^P\[5T;
ML@:MLS0BFE7<@<R6X>E:?\NIE=#Z "2RP$E(?SWX: ,2RCE^.+NWS7AVRHDR
MN)G]C*VP#'RJ.(D/) +J)FO<37P_T>.F^31M$R$F19D*@]*/.N9:F] *>\PU
M5P8O J!?%$_O^)<;!/Z5@(,HOT@_]MK)^6/P];<T75P7M57H+M^HHOA?(>CA
M ;$1(A^T_ 45]9T:SY"_\G3("_4->K:G(4@B2$Z/N&#RJZ#E5^GAOT'SVE^J
M4%:$B6!3]X\+=$ +_")G[N EA^DGVL>7>@@ ,^1Q4K76NU\G5)8/D\^( ]3:
M[W<WC8!.<U[QE!&'NPF:XOR1FW<+,O^#^HAL-W^%]E>O3](_S@5^+SKY]:I^
M.ZUPU/8F$B,>P601_>/4W+]7\/RE=_??JXC]/O]1;0SY2['Q:"G6YLQ351>;
M>>:AH/M;>L\W6.1C8PL?*SFYOMMK0V;3S9?AU1,+\+.=%S119>^[SBWSI +A
M)>+HGGL!?$\=C;>V2H0M(_J$2B[61[XP(Y]ZH'0)7NH>@LA857M"1C)'?;E]
MKO\=)1-F!W%+V#9U]*?KIN:X>8H5K7C]RQI5@V/,=UONAH[Z'I1+O%OQ-Z1G
MGY[.\$$D,V_Y58OC\W*J3-05W?>O/.C\J?K"[76?G[-9K5G\,+ E2(R(H@.P
M"O] T8(-$9-M)_I+=9Z92H%T$RE%FA*'72\'@6P"+JV**8Z=BF)L..+%T.,_
M,G^?J+E53+^:TXD@4])\+"JJ*F!?+A,CY26CS\SW2O$Q=@36ZKO39_'R<D*H
MG3#?!8R40'SX"GQ/Y%VC$ '04E*!N;B(CV6 2V7F]Z'7UZ5J;E<6UQ>1+SL^
M/6]<RQ$_BU,=?;[#5X8>O^Z,-,%G)3VDHI9C>2A* #1>Q7LN-5U3I%P#,\@K
MY:PG><&<J6132QH9!SV0[R(EI-9H<J>NG#_/#N6,MF_Y:&_E?@GMQGG!==;7
MKFKC@_7W.Y;?7+)]<#X_^@B *5D3D0\?FTA6FL)G61JY@B8,#&4-PBT96Z$4
MIEW<HY*1CMN5,QI9META-^LHJ18Q+X K/)@)U[ T"I< .4Q!S\,A.!,:Z'"T
M&/5<^2@[_M6M[>&% \61>3!Y$W&=O 57&+:DT:Q:T-4-U>NCM9X?\KB^4*H*
M[B,7'"I]Z;U)YG5NF7X+3*;(2!T:Q.#(&FVR9S&RS>?8IZE7'_^Y1)AU6RQ?
M1F6#SHM^:W[M<5122[>_!/*6_L'68F! /-[\D8:&EO_I$0' 7=V<%I( OK3O
MGQ.W9>[85IL9F0(VJUUR[&Z C"L-/B'"T2">FK >I6'^;_'7@^5\F1=B@PNB
M<^.TE8S3KBIRVX&I NXHPF'3R8XRF/.=K)JWBORXN8-[.P<HE@/<,9/*V#-4
MWT6X[X%/)6VW/]_'<LF"&0&S(F^!Z'8UW7IW"\,& P>XU\;,X>8@)%'9F;O&
M*H +I?V. *!./TNI5T$51E\Y 3.9:P8XPQW!5('P1ZM,.<)2-,%R(1V.&YSC
M)"C#\  R#*1U(B'MJYIU\5J":%^>>6^1BXW[^.?&IV0V<]0:A\7B&A6#'J?^
ME)1V11O% VJ7ZREH>'0& #+GBY&9T;VC?+2YCX0%=8EH"R*4D.8;+RL?+;5M
M,_:KRA[8(OMGK3_]'F.G:TB0Y%#C[14032,#W[352J2"Q>3+(O'KB\\^TIX#
MHQ1.6$[\WN_*K)NT9(:+K2"TE_&F, GG>Y6E!]8&K+G()[BDM:3!DLY0^UGX
M<HA'%P%0@;-SJ>='1WKMNDKD%_,E6I]D<K__X1=BT4X 7)+ZF'#;0BOP8M:U
MZ[$LJVW\]LS,EX-!++A3;#XZ!=@^R[I55 _)F5TSM&"IBY>,A%%,,/-\T%ZG
M_&8X$_6YE?.1X]KLI2"BH9)Z3C.T&B/DA7+7&:3?%PV837<+=<62=X'JK7&%
M<3F,HBW=!8./%#@*3BQ.%:%=)QNZJ()AN]%,W2Q!=6D97N:\NHGN&I7B$ECO
MQFBN91'."^N9[G+J';U/SART"[&[WPNZ> ,I[GYJ@A.*BH?OL#J4@$(>EGZK
M.=,5 YEL2J2]"2(?B"=-0UV^TF\[?7MU(!C$7E.2.O.34F+\@NCWM.GH>]"A
MBBJN \V%V36H^,2S 2(3T"<N =<.4/@- D!\D?HM9Q4^ ]7@QQK(^?W(V\]Y
M0,?1K5!-X<V'.W.AJLJI;EV2!XQA,%>X"/7JD5]\D9?A7DNYENNU1*.QJ/@+
MK[\8B,0H,JVD776M9"TV(;E5*SE77]WI19)QN *A6'>P0Q0S=X^D()6=$,SQ
MZ-N57*]:_>\4[E7S P]GM>!>FCJBFBKT8P'-B[/7%,4=P%?@ E^AWSFXD/O8
MIWN+P_L[C.,#UC=H>\D[_?8@X4U5#/GS#7S^*2!4VEO)CF"#&'4)=[K87$\R
M]_-71#?!FIJT#Z/BN&MO-QLPDV96E5953!_Z^Z1/(WONUN *8SP*[\Q(WJHS
MYM0*[Q7[862H477I44[JD?SHY#0_LCM+Z:N#V-J$2O;"J-[J4#]MUVCB]4O<
M-P)'.YGIO275+$;0 Q*:9QHVMA%#9"GQI,;!^3( 3WZF]@ X:OMMXVV,5S+:
M",Y.V<:COT.?Y7WB8:BY=,T;>/Q2[1)MJ8H^]]VL=(Z1T3I/Q9=:4@OQ\?AM
MK/6Z_& :;!$LN-)X:X?L%4[DL.<4=%6-/]A3*L)?;@BA[9MK=EVT;&)[2:Q,
MZ4L9I[3&T'!E3S^E P?3Z+8G.4X%S6SU2CJL)+KUT?:MQ1D[BNY*>NJN9]?)
M=^(+%X=_GG ^''R0%7\ABE;63W?XO[-$Z3GV@P4<4QT.5WA^!!G;/[477MK]
MX+ZA<FN,_2>9QE 1F 7KCK]&3;:>Q#BAV'V6:RV9-B'ENHMK ]:YJ+I]F>=1
MK/PT LN'9@<8#+@ZNSX;YH-<Z;&*57<GK628SE077VSTIA><-#K/M)OU0HG^
MF[QIQN<V'J-2<5;7JHU3#5NB)TAM"%H^-0?VVV!%\\W6&8*XT\!5$#IC"4IG
MP;';Y49?8Y[15"IZ+?5/\#K//%=V[B0A$UL^= QV%JC,\SR-%)+2XC^5FC/)
MS*I^>%M7G?R#);G:#WK]5[S>F^CBR0P@D1.BDUD;+L(#!0B :N<'O>!QIPKF
M1VZA<L'+BEGGIB*TR;$EK1TS'!6C'AVQ15L?X_<R16O?:Y2_]P\FWY\/5I/L
M6P%3J;Z>*U96?;U_&EEWG(1>,UVWW]K<8B]EZF9#U%7=>]V;4FB(@@4SHI A
MMR0N-'YXK*G'9?S,/$/YP4\>E>YQ%I>)R ]P?=5' G9DXCN%Z G<]?"'PZR:
MLK!)YF)<F71\!8F7>TC2;C_6^1L!L/+X5YN[3@* M63[\#W6N@BG@]AW%+JV
M,1-8!)-(LT_L8=789)*17ZH'XID9.YL.* B [ZV_.L3T6SM89QH77-I='>2\
ME(063_+)5[N0QI=0J;=:4NPM!_O;\)EX5A?0"1W1T7S?(0 ZUD,)@#"5G>VS
M>TV8VW_T-VOEQA[A,\!8)@@V G4XGFM[)+(K#RW>X=PE0LUST&-V)$YJ"K)_
M\U<3O'D"('J0 +A<S7E&00N9\R$ YCU;B)3D+T. 4+$!_@3 8QB."H13X9B4
MV, OXI4.&GGPQI Y(D3A@<//X#Q5U3$BV/OF55&VF_-IN)?91*$FH?C02R",
M/&2G=B[C+*[>6UZ3FP"P<;:,Q7\BC@O!B8E (6OT1"G"?W4<FGR>DC;5U*58
MW0;I$<&1@A:\P9A)-^)RRN#'DT'QTFJ_2XVD) "H(N=G3T(A<Y;_:*[UFQK\
MG1 5IXG'9*-8Z+$- ?"J$Q>S_KOFU@2:G(T6B72(AI'#U(6(LG?Z+T#<9[[!
ML,_ ' 3 KY(Q$FH"@.8A9!S8&5LN@/_1DY)Y=ON@&31U^!^D;?H_*^W*[QI%
M07Y[+9R8KD8BKLTSQ)-RXKFASDE>D)<$P/6361H"X%83AHD B)V&M#H3[>?>
MFS0L!P@[K4*V6<C&1Z0:Y)$IVW5X4"?;N;-^!W33;\.*@8A3CV,D.04N..<2
MI]X!J=E6J^J3 ]5 W@>ZOB4 $L!8HAWS-/PN' A519QTAA(!\/]0UL.@Z#P"
MP'&507H&''_XB2?YN7OUR[ ._X/"^!34)+-'/_5J@KOS7O&F5>CAE^@?K]@X
M\XI93KIF?BRO7:V+6)KZCV<8:R?TPS?_3#$3_,O!1<%?T\56RZ[_.N<0^$=!
MA.*?!1(#%[S^>71Q</%?V6+G3?^'M0+X5<8OF>L#TXCIU*GY5J&M>(<[:6BU
M>-%8_[562=95]YCX!C/7=CFY&IR"JZ<-7PK;1. "8\V(2S2\AN:;%<O=XNI<
M,Q;9=&849ZB)=X@D7WWY"'P]>&,+8[&&T*:LHV)X9J6D>#"!_!@ '#GH$7JY
M=W<8W++[@#?IT&=_VGE+.(-6:I&4(33(0DTN7*?=K^$);#C>)?R:,THS&?(V
MJ2KS8OGXN/EJ(7E-I!V?\\*'U]TRS=VX]3:);9(U"&60+)9=7@\]K89F74NS
M#VN'WR0Z(MLN1N]/G[W6Q&2:EQJS89>P1!?&NS=W=!9H#EDIR&M\A=2;5M/X
M57TY:G/1'0]"6F/Z@P^*'^G4.&\^"ZSI>(3H<$R',9X5':"R @12Q]@4<*MD
MJ"_5*\ T&KUQG2^G/.'LQ@.M3_*JU2>1N>B QY[Y3K#1K1M[RP@AFYH(,??:
M7??%NXIUR9(?=HJ,J^JR[+R]#$E:.5@0G>'[QZC$'^4?C)]=EM,4D+_YG+?<
MMYENFL1,DW)A)!O:?_7A">RC[]Y#GAXX%']1/+_S5/* >F-YWI6D=8Y=N<5"
MW/6*Z6I"]8WN0#3K&&!D^]-V;:Q5(J! [L+4I56P>NO'Q42;TK;=.W>D]@?'
M5QKM16H?'HDG49)BCF6]3N RQ,45,W4 VO65W)6"6*YD#E:"Z;$0K9W+LQ$X
MA>QI)?:<?)[P*OLHWV\/.&O).D3;_;:C%&5\K)MG1(?D!6XEFN2^\Y2FY$C,
MONO"]TZNYR;9D1MTF[-5L@\GB=V<@]%A\1  ]GR+W*:X)ES<W,%$HYTCS<D]
M-/I\;!-_[7FR8B_\5:P^RO6\(\MH8::]J,F:7]L2^G G4EVBUY_1Z@%8A8U:
MHX?^9@^-[*>W$A-:0HI'DXT3QRZ^C[54;HH7"C*%Q*@I/_H:L7OYMZ8^[_<T
M50 !*8&8"C1_*XC9I[N>=XZ=LGT'&V><5;'#WK?OA62Q^V3U8)&J+N7<P@5Y
MY, L!8YIEKJ18\6"PYU$T]*A3&.TNTKLS"AO0TS+T\/0,^#9SE6=. M7<Z<B
M&&S16@:AXZVD0F=X*?V?K:*6(#2>_1$&LI4)^"N8T?!\^S[R2=\\!^<+D5QL
M^&W+"R3;?;[>K4WL08,L42Q1R$9F##ZOS$RAO'@:.:8ARR9UOM#EPA&Z,26+
MA+Y37CY;T=4.F9"V$"C,*I,9WBI+VSSTP>LH*7Y_;VE]T2HA4NBLXX,]7ZXK
M?4GZ8'XJTXV9M]@%H%OLMJ&;IHIG,<U>7,"0,_#2:U4!NYP'_V,:6@ER_BOO
MMR <?Z^0 ##3QH<:5&B]HU3AL^OCBOSU"=#_=]+O?8BM4C]FI&B M[12]WG4
M@*C#7TK=[A14O_']2]KO2E8?<Y:H'?$S_>)?3J>_C#AR2T^[$P!"VOC@FS0.
M$0\'DTB%Z#YG2IPS_$N(+4=M+&L9<3Q2%!%X<=A$0%S5GNK7I]WY@K\4OKV!
MV/?TXRK 2PZC]F5<Q$<)<86*N1YHXU=S$7P$P!,"8"L)$-.)ER=B]A<0P=3T
M?P?=TC6?_AG9 QC^?C3]"Z?_YO6+%68S<5$%3@V&2WXI_Z7EVK__;<1N?\CL
MKBR..(G2$\CJ#<DUVPS8K5]A*1Y8.^B4.A<?IVS2BDH\&&'61$,/!@XT?GL?
M\W@!>]<\++A/O1(;'=\FG>QI'%!H+%]]N4JU>>**[-S\ -+2K+K-^?PV>,#:
M]"97?0V\-FS3:<O4R9O#-&QW;.[U%T\>P+R$YUTW14I,2GMXE,0GEQ(/:-6$
M4$>QUR%2;HL_;O[EYI/OBKK!F;[K<!_Z]8-EOP"6[4AYV\RU:CP+Y/*DO:;P
ML[IO8<;+MO>2Z>[WGG?_%J?Z@,WPJ[YFQLW_&F>;J!>9EW=*8U.\-DUS&ND?
MF1N_=Z0$99=-?;"JKW5'H_M"DL;&D>B [LC%T:*^>9-+34,TTN4;+J3B2*8\
MM7?[B.<NC0,!KTZE?5V1"*8^CI^N&TW?S':V')!=X&I(!!7-RL03U[TB5U'P
M8?(">,EQ;7NS3@3>[K@<A+]_I;"LAJ.F [B7?#BVLV&2UI:B@D[L#>Z^\"!P
MV*.9<\9UJ+Z^)5ZC-(R#TB1.!RSEQ^Q,83352:U14CDO[$L !,=Y\A[E32Y9
M!?7A688:;P98(7 *^1;MI,GD>ZD\MV,T7Y^/9;/_J2XF#N*<ZO,S;+,+HO01
M.7R/L0W&J?"]E^=";5)L47Z#5]&JL VEK#9 C2]U]YO%&H L.5_M8G4W?.;;
M7>E3BXM,G :XK#B46$,:G;Q<[_K3.J[,AJ==E">;F^;4B=2IKMRQ*$+JSCC(
M=L!R;U3T\52]?!D.H (PQ@#W_0[RYM9.65P>78V(T$&82OIOYLSDQEK4[\!M
MWQ4AY1<6MI>V?*DW*J1?99_E*%ZG#MO.!H4B[E480<K);V_3!LSJ(?@:6TKT
M[B/JN5#N[#]CLU<G]"RB@S59+X9F ?9YK[+9CE:#JIVBV]LXW/:NFP\)=QRK
M+?:CP-+1^;>TP/9,=<9"GGY \_+\;RU2M2*#QK9MM2\J8E:F.+E5QXH7F_A7
MHX9;32L<1RNO<2H8^II'(YC7HPS)*M)V*RQ\CD1TC"&8#_9-UHZP2DXN4TM7
MH9,ST:1/ZU[WUE@A,L=#)?OFT5TG\W3^ K!R_-PR].4!_2=Y]5S)^CW*D,6[
M7ETSIIB@3\N8W!2_-H6"XT[/KEYEZX#97,YHCA^0'\0;PMWO1?P$7S6Z4WO^
M95"ON,C6Y.+9'9Q ,5I!@:OZX\][C]R8=R>70(F<T2 ;O6/P%!MFRW[P":CZ
M5O3P(=YM[^FOZ<X%NH5@GZBU3=A5:F:^" AWCI@QW0WZU"=B(WWXQQT..D\@
M547X\4.P]-&I?%\=Z];\G9^BCZ'7['/ZMHBF^R8PBBAGH&C4X,82ON<T)!68
MGZ^B@Y\L/WTB17Q(COE*'6OL0<?%^XTW$$F7EJY]8"-S"N]QH29J68VHI])E
MJ/NCB)^N5XVXJDA?7N[J!=>Y)N_/[V1XGC(XIO/?J6).7'!-W%_&9([W'QNY
M=]9DJCSGI+5OH?2-;MY=EK-6-'T)$0:QP%WS)J?-^ESIDG/"69'V3/TU3!F(
MI)$<"C=_L3ZBMTKX3QU'?6W_:[Z;80+^[VEQCB+!('$9G.N"T"^W=Y''(SO+
MY>.YQ::_Y[M9&/^7I+AB,%IS^$?B]X;S?YPGU$#?G4S/AN%9L;D&I?%/&\N&
MMER>QG^\K4[+9W.#XPHY&P<P-\]E\WH3/&EBB6E+:$F9+58C(W8XBOXZ1HGM
MZ9"UB7C[9J. 8R/'CAJ.AW2+DW;*/#MM7))U,V'UPE"[&T^[7$NRC^F+'O@Y
M18>0-4WHA/:&K/1AP])K(?C')-!A=*7I]$+M1^O>&+$\PTOO'Z&9\F<*5/R2
M?'A:R^R@F3DA.7SO-QN*&'Z*GKOS\Z&_U_)UCGAK/$T*SV:T]UFBS6%.R$8.
MI")GCQJW-QVU002PN7!3^[C**10/MCB?,SQQ8F3FM6_NFJAY8-C-I"%O=>:(
M@OY2M:6W89N=+TE"7:T\%"]@&]<[P10!"D6S%@2 O<64TKNM]K+J/7.C?-=;
MKZME5D@5@.5#E?Z7*3KD%*1^S&I70N6$-JV,,L%?\P!/1JO>&TUF,0QTNE)0
MW7*[J:^S078^X96/X:8U^LRQ^43QM=M7!V\6LSTS=;8X4ZFAM6O7.3L:G0B
MT-GY7P@"KGUZ FII',7&8CI5L%F'!K*S$P&1YHC.0_N BF^X7'XR'OHV J#U
M.I82_[4)RTSD),A^ZQ>?"D:^K&KT/"KFO)2T:)P*I!?\YI 04O6ESV,#FD@
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M?^MK9X7XEK/:*[R?GJ@5RLW%V@0]QVQO\2T?#+WXI#C]B&W1>Y+9K5HV/[1
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M_UXB]DVWC#^<8I4O'=)A0E:6E; P=U6J64.=/UZV<HX\ -:^-3P KDENG1\
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M:F6J28L9DOCB4UV>:-+?ITO,"L6>P/I-6$]X@F<]&H7@IFFE504@WDQZI29
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MJ]QVP*J(Y/5T08\4/=&^LH #IOH;9U<?\B4EN!5EW_#0V"*^1M'3T>O[]@<
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M=N#GT#7]<KD1%*-,=VRA=<Z=^#TC)/M.&CWQQ/-B9OH9/D* YLY*8&%<AK7
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M/UD[FZ&\W TW'1SKVAQC1H9[K^8;T=0LAQGK=E"RNUY5AL_"?8Y#VZW6LO^
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M\B6*'<I!2HH;@ N7*2@O4YQU P3.<5)1_%L"_!^)XL(Y1FJ:2[1T].<%ZE@
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ML:HI0+QW!MB2A79UVI#?2YT!PMS)*!#_J/W4Q"VH)'98<,.LF:PS#<+CT\X
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MBWNL61$>2;!'H__0@L#_"[/BYA*-$'-IP?I'8#KAV7[9_/GVL DD0O2A(Q%
M_/D6@G8^ T2^;SB]Y' &H%X\+6I3S4\L>TP&]41.EON1$K\A,!B),\!]SC-
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MQGXO':A(1FCO;^<B#1Z.39IO$2NLXDO(/Y0R+3<J"B#EZH0[Y7EY*8_'O-=
M6RQOF39?/(OJP"5\VNAQ@H .@MH( EVS MRVD/0'(WMBT<L15OORWKOWJAX;
MT@Q9)K#YKZB6C[<(!RX-AUH?QI.>G=/C=A+6M!0]IUGD$F!:FWZ%"P3Y$_F@
MHWTEH1C.UK5Q+D4J@2\DF-43G]2FV,5:I;G([G_D&J77\V-=I_FA>,AF7&H,
M)]$4!Y,Q2MZHD^.#Z8%QJ*,[ZS1)#]7"QS<$\Y,XA<\NC>,^QIJ^5MM[G_2!
MIEA56PG5HG^BII,'N;#1,YFK/"+W4XV+W!?]-+G&R"/;7S3 [4!N3R2\1;<
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MACC5)VUI._24/:E#JE%=YJ37[A/M[OZPARVCL+!8X8C;G7ON)<;V-7C@TIP
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MNZB6QZ;Z@38E6S<@7QI2/1^*=F_;%[Q1Z(-?P;NW3_NX4Z,A6=T+XE5XWY1
MR9E-ZW6T?O0=6Y_KC^,DOW_%V4NT#2PF)GTIT;OMYT=BEHRA=:.]K"7TA2&)
MF_U: ,$<ICGN,);R!*RVYHW\T-U0Q,YR'FUXJTG!7D^-@P!JO*^ ]"%WB 7:
MXS<C-I0NIG3XO39*5S$XM'1*VJNTP? *X#."F(EYF.]DGRH@VK<Y(:CAX@I_
M#M6C\D(_OF2C'5]>9_D7AV!XY\JPK EE(^7&3PF?[+Q_=?'F_Q-RD\847T[6
M<PH';HJXGP'R8DYN+"*/MXM/S%QSKWQ'2$.<7<8D#URT=K.631OC/ UQ_?#P
MVJW[*[J(AM::C(KMK66KYZE2']]X7OKI+15D3'C!+Y[53=B8TH7_B%"4 US]
M\?+:!;5M)8K9.B_S@BU0/QSA4)0*<FQSQ:L._)YFGE%;1W-.I).OI,7?$*'3
MR6YG?H9N+>C)%6TB>I0:E='#6/N=P 7"+2&\8[4N("-=.H:'#==]&?A;EKWV
MX%'G8B,J\X>U3UMB<+#J3B35[J)1894Q[W"SUPN<HLHA4FZOC(P*H:\EO X1
M;2 (Q*N45#QPP;!%FR/?V'V^FM.XDXL8^"XZFEZQ<R3D8UK!?@(^JG=T ;&T
M:&!V9F[NV*/J%"OJLG+<'A\B&>_.;5I&7,,D*.U7'GVMW>$(LB&JEKJ.]OA!
M??):NW1OW''*41>U]!,4UQEKNT]@[L[QLJL:E\WS%VZ(W(:_:./6 ^\:ST3C
MX@Y5URL+"33=F<TNS'X5=@/']R]M\M[5KC<>N?[XTO%^16N8>Y8KXKOG[!]I
MGS';YK7##:^UX2CHU3W_%DD"9=<QC"22>_W[1RG:KVN/8\%*9NZI22B>JPK+
M*_OE0*;]#7@T/_5(BW#^JX#S=3Y\>:W) 1RVR5,[KZW:TIS<J/QNW2A$!J1
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MFFP1D=^ZE:F"9F G2P=?!STBL/Y1*:E^_?KZVP^?WR5?6MY5@'/AV;81F#,
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M2FC14/ONRAX+=1+RG8KT[;?,?TO#M<[\ZBA09#(.9AT9&6N.\#E,W?H5.-M
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ME))G0.TUC?*NJAYOE5^+IK@5)W[6%_YABC-4*[]EA[HZ_;NC%#TV?K=W-'?
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MU">2187[FC(V,GIID1O"B4]<OB60)4CHRT-I>YTS^9$E<F_.&BHU/LUNEX@
MF.ZF]'&=R[+3 #:S.%[0.I <O7<I-O!&A6'$[LDDVO%>'(:R1?2C\5FBZ("$
M1=5H\ZF2Y'J%[QI#91T%&Y\!YT/'9;0 ^ZUIN[3,8'7YWP;D4"Z1[+(I,@.2
M@][*0Y;C=Z]]]=&XCM\S'NWD5*MC^LDA7?(W-;-_'NN</'2@JP=ZFM94C=X[
MBH*@Q(@FE#>8$,1/MD &QK&.IZSUT_1N*]L4;6C HZ2*C?^VP>\OX77[[)\U
M.=(_:G(N@4:#6WHWIS3SRV[H\D86_(+ VW[HJKA%]S3\J4\/DB,^<<!#58IX
MB2:=J-"];33YVCUH=$NM)/HQ/G)SI+)R6*ZBZ.& [$GE)V)0E->/UG,O4-T=
MANK'>H"@E+V2E[Z]CW8>R1R:$#1/OESD>/ST)19UVSRR/<C)0'V!,F^]+$K\
MA"H0>;P&287SDUAFC"^T/.DN@LD2C]!8XVA#-B3CDBL8?K\B6Z)1@-@&Q^:%
M%W[SR(:XK05!2#-GY A6N)[-'X%;,9^WJDZZF@GF#1$<;VF1UHM;&I[%)C]\
M$3^YHA:ON<FTQZL+HQ)0G0AN63C8E;:/.%*"FWSX3410Q/);$/^UE)X^]0')
M3JST:I/VY_8@YM^UW'WH3&< 9ZLG^_=EVJFA[ 'O:-OH4U^;(X[\Y-5B/2Q1
M!@"')4:H_IV=V' ,B(L&JHKWS'$.(+--N+[[,+SF(8-/L'NA,J'($G"IX]:Z
MPD'MK$-SU%RXT$152+6H5'6%NY?CZ($A[LOVV!.Q%SVTYU8?W?9;^:[-K,2+
M6KE(J-T;O%=31<S,\.*+6A19?%;WTO%E6SIPKZM6RY1G,F6_#^_&:@[Y%.SZ
M<(64=_J*U[6A5 MC99&KZSLW/J6X*[-IZ%E]F@E+4\"P="?8<<Q=OWE:I1C)
M#&^C T=A('=WB=1Q]LG.</>?;A6O!E8=K/74@LR,!C:2^%?OIAB',A%:-=B!
MH-?36"$GQ%&8BB,*&F@6?GM KOG<I,Z+DA#MXV)'M?<?U1*+<WW2J$-Z2L"T
M0PXQZ$[\,9=$4OX-1BB,]G92TK#G/+)T)"7;>57T46P-2QHW?$JK5]T+8@X-
M\)?SEE5UOM<EDT+\J+)D:&J8Q<XJ5<J/KTHE<MX:_'D3M]J0Y601+2Y4J+2B
M8#7KW<G$IV)WUBO34)&IQY!\#R86!3IV=4IC (;FK'^\)",A<?F;YHW!-\C4
MN&='_7EML=M%)"._THG%H] -O;0]?(?Q5<6XH"\C"PJ]GQ['V).#3;1<VT]1
M4^"R)L[X0&<?5)B9-MY_?^T ^ADJ?CN41>Y(YTJ-A^',NW.JP%E7\%CJC"BR
M=&+9G"9.>B!:YIX?>U9$AW;,=4/=_*EOQ.V>[<LS'Y8>F:CWL0R .6AGH4;X
M;TG*^3AV>'<;W]$O]Q,#SUQ\;Z!R-HCC$#BB-&5]=,K2!$BS\CJKX/_AC:J]
MW9,WPL>&+$+AO5B6QE.4DYD8P\81RE%UWJ/)=* <!GYK;?GEE%=&MT2U G"1
MRZ!3!87(XN0"?[3N^D5A?Y R-=!5)71@5S"))O!^GA8-;N>DB$S0@74EC^^P
M@R%X_U.:JL3O#J-5GRFZ"N]GYP&[IRLW&".#0VGA6! "9WB19,HB-",?T@?E
M;AE'1BA!8L$\,X/>"X(_\ 9;4.%<U^$/LI%-PDCM)!N=/%)K2T *DO!MI5$.
MYE@%$95FJ)SBU(3$N*(D(=NA57>LU,2;K<6>(&X$^9+S>,G+$;]&16+[7.Z2
MF55@_%$CB2=GE@0,Q.+M;K^CIE9(QY_N(9K$.*S;;]AB2VK6L="@[N3I-:9R
ME<\L)<"MI.V':?C3<28Q"&[[V*$BB;2>C]+,0T?=/^B798/'4NZ$^B..TR0[
M/Z6H*:4_2 Q(BO9HW*JF ZS[./= ,(8<"Y/ XO0I4H? "T'$'1I/$B(,L.<<
MRUS8)'43M>C =Q<L'4@H8(@^QSJ&R.HFZM,!EE^=C+$V.3A.-OG038?!P5O#
M2H]*>[<S;(BE^2HJS;[SS!]6K+R9\ C"UQW$YEVX%!V87OIC'O!'I2E.B@TD
M"DQ297R+69?M+U+[V-ANVCEX>CBFS+8+=CS,"#64!(1>!2M<5X NW^S_RV,G
M9C3YZ$!2'A%%C1[WH\6F_"KV_R5#//)G_LC%$P3IVW:1RBY3_G?;!9*?$3H&
M8 RM]X&/H53?ZMCT_)XD_J.%X_CPKQ:._S+^&N8$T66P'=,(#"<UC8^\SH*^
MT6\<H -WJBZ,=VCOWXTZ=.GLH<EOJM,S+'C0&&8[D=@;IRE% K78G*1FJQ_
M"V372OOGDUQUZUQ+;B1>_*HW]_8.:U*(]3[JE$836*?PO-:BD=;AJ'7D>#C-
MX!V:#KB!-V$^2UMSH$I.2H(Q@C:*6" M, ^'7[74'DCY+2R>3!L0"H^<BU(1
ME<0*J8;<J+5W?#M?>=.3P]G$_;''N'NZ]F-YI*+>)&O7:9#:D?O5S$F]^RJ<
MLEBC<\?T"PT+2C)JL5W'(U>?73UESW+":$;"L<JU1_,(XO,<T8[6P=@*N;Y;
M2_EY_A;-\;O"C3*(T2_@S;BI8 W+/\*IM%"'YKE^"A,NR*3-1JS1^(+NX'W7
M]+HNWJA6P9B/1[,R-<( +S!/O0]^[<"I^D8A$L)KQLA+.-':R//]Q%WJ&WFQ
M8^</E%\8'*@!/<6*4BR(F8.&P[TMR[]^(L#*+,Y0?$2N,EVE:N7AO>,WJM>_
MZ)L$S"CUDJ20/Q?]LI>.MA/UK_G;5R<<@W=[=9W5 BT5?0,[H">JI\%/X?M(
M1CH8N+CSGF^)XY$BC8J4G2/]2>HQ3-("(L=%&Q:85P.D(T@FQ*)FL'#%X4KT
MOF4"--KHN9WGJ9[Z)V)W@?VE(K<VQ2M]-__U!.O_[K#X2S4X@/J7@K'Y'STH
M"H6_>E"6-_\[!<_[G[E0BS*+.)(K[3JB [)]H)SF_J?$4L@D;FE$_<EL</!S
M,#L"IAG":EA,BK]5/O@L/?MCW+8=UW>3BN3X1^;C'"JVYW*2VJ&]S[;HP#@S
MWOMB6F;"C&?8'N3%$D>28^Z4R^/V&IWL!FP&W_JMT!IN8:(6R-3,]M-:6#5-
MI8% B20R&PXH3OH>O@;W"//=&+<66SS+8DJ<)\<F:AC[W@)>\=BF) :K,QLS
MOO8D!OWSVD<Z,%!8M,"Z2P=^>^UO;NA]\8;#B<FIV&X&S%F\YW;ZWN"5\5>2
M'> J_=HU8:24QRX1Z^$L042%9U</GP[RNV:@^&ZLX"HF(>RCFWWD]9]ZC_2G
M.BV!#?#$:9JQ%]Z3&KP*?H$R(Z IT0$0:D ['<AB78>,S]RH&&;$WK4(3-5%
MTZFQWJQ>"0N^]</B"0;''>X;B.U%;:'8Z,#G:H9LQA1#]H L]JO_V%<J*!%+
M:.V&<1@,]-YI[S8I5:&[Q'E@JJU_FE DW'_4*^X)/!G?R$W4[P3QD)8[IH0@
MW%#6R7HE+W</#S!.H,$3W%-EN%&]TNIQ<67)*P;3W_Y<-8KH^>P*HF67A.NE
MM&UBJ<K-6J+=3A]E*R[/#1@%!QL0"V_+QAGL3SP8:#]4\5JTHN)_[7W_0^+\
M"_'6HQY<R6VY<V*N=Z^DYRBPUW$\R0KY[BOBNC&Q#2;UU7K&4I@)\\:DVKWM
MI$/*5;7J=.#(Z<&Y%!Z]$_"1@8RG>II/.)F3OKENFIB_TGYG_1ESN4WB>L=L
M,*R8>6.:\!B#O$KRQ.G'VI+>$CV;O$@Y>%0;^-C"C24%:Z@-';A%2,Z,SUGV
MB^2)CBA]$&,P\^#ELT=/M]]XM -!WU5O9#[66H3(0;MQ%!LQZD?%NO3#/MWG
M<Q<\\2)FWB.>\.['<CA/9X^J[M,O#YH;'M_?[2::+P:Z,4_!U^=OOZ4#B6<8
M<F6"DPH2@9W*6\8$>(9L2:O%\R^)GB389TH,Y!)3HRN*&FQ&=;FC<S0^%@\(
MR$9=%9N<?29D;]IDVU!D2>1L%XH?.]T4^?CMF$N TDB"_7AC6;%+8GOAE<:
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M$MU3L[\[?KZ?[>FG@J:92R@-TGDZ()[:'D\6T*<E3&#>9R;/00Z"9Y^0RNB
M'4,!#Z@% %LNORQ!6)L(I1F+X]'4Z!W('A/J,8J#^@D\.Z IS?!*- />LP0!
MVA-V'D$IYNU\VJ%N.B Y48H89?!9ON0=*HR)X?@.#*=SQX!_:LC3HJ^2:7]:
M^&QI(3S-/,,+2C16U18RL*N.Z1('+H3=Z 8]L!&F U468>)#V8/(%L11BQLI
M%Q0L+S[SW/\MM&C_1.)!O>M2S%,+Q;WLKOU0I';Y\(/*^O*HU?,G)Y;X5CQ5
M.?5C/WP)BG7N^_LM]=<ND.6MOW2*6)E-[H$_?WG7/0QW1/7_,YOZ6\#^C\!J
MT_Z71MD_M^67P,ZA[;._[JLXN^2WF.>,L4C45^SRY+[:/]'FD! 2\Z) Q:X3
M>.**-XE&"VN*4F[7#S\<I*G E FQ,0RT<$B_3G1\SNRR/<#TO!>I:";-_"5>
M/N3@!<@3S%>P$-J)X6+I.&R;LS<ZPFR!B_2E_P:VE[ !N:?[@I53Z8&;L%W,
MCV -EFT[8@D=B&L4T@WRQ[.9\$RTGPD9M"CK6ZTH*'U@NN^#T?.'<&00_.9X
M@^][9_Z1\<Q49S]'9+D)5Q>?:?YG+?$Y]3@UBQY(!7\;*@)TN%%BW#7%<JZ-
MQITXOB BO-BG%*)H_N1JHWN'.DZM2V \:^5,YB;3)E46_H0$WDXCM>*=L@G)
MO;$IV#M#IRJ';D*J!MRO51&,\QOZJQ@[[#/'6QV%E FL.N9F+GP8>\PG/C*3
MNY$V% 5B5UI-RL$ZV;:H6VO,O7X]OW%H@S>Y S#C%]'.XGP\B)C=\5DC<\O0
M@<WW+GO[&LU)%D0A8U(2^2$T>\>X?,3-KHJ04?+Q767N=^?U"VRO:W1?\Y33
M@8J#G"5!-_^=$>;]1NIN]X/S5(2XFAQQU3SM?*\P5(]O;N8XN6?>^'AG7]**
MC7LV;="Q3976D#T*DR<.=^2][1:^2/"W?+(K1RR.4/!\]*0X/V8KB],UNVC4
M6F/E)3^7E?'#]2POS\?57V,2=JR<Q<5'$];,I8#<TSR5<^B*S+*L!>3A+95Z
MW1*1@U_T#6QK W=_NO>T"E].Y3\*(VKU5JCM \R>.#$/>>GIPIV60'P^A3"A
MZ:)DHD<)*$HO_6W^<W'5W*PE/\_";M[=,&9$7IOM;:$W%U>WSW<\>=0H#+M#
ME,O/FXKU[ CXZ-SK^:XZ[EW-\+L89TQ\B=&1SRN?@I*4EP5?A %:G (]0% /
MV=Z++/??Q5D("VFGTT:CD1I6:8>CBH($29;K$W>>ST"&M@:2QA<7O9?=)1X,
MI\T>#VZ6.0P\\8) H1":;H,\K<&6P6(/ "Y_;!46X@;-P+,-3.:OY*2>#EB3
M#B4QR(W$13R(&LW Y*0& *$P2 =*$"4*2/ >9F]0BGF9DW2JFI*)#49\9P#V
M@$K1#A[-@)+I%.QZ()SQ!X.0,A3!#Q36:R"8+VKWYG8L:89(GFY 1<&,WY'X
MFRU3GWJGZH6L+M_)D#\5F7&4+]("6'W<I"$]H,D*C9[QJ"RQD6_#LD)-M 8.
M? B\N\ENYEIH8]TZY^ #R'U_L]?'4M;_?Z" [2%*[/ U@H;>521]J8T;UXLR
MD>FJ;'DCDI,R+^R'"@4S.%.,:GXT[,'T*,QB!A&;FBE=Z\L_[E&(6RBIX$]E
M?_.IROS.IP-/IC>_J5J,(WEA\OFD]);V2@VCNP,KBF,69L[>:HNRDIY2?*-W
M#\F$UWHKK7LVCQ"VXPM@?,06%PB/PZ"ZI[]20XPE-O[AD&W(Y;B1%OQ0#9=,
M64Y9!ZR<YV(!0([PSE'O4]G7>);4@]<(:-UN&DPW&DF_67='MMB-<IJWXZV[
M8B"NQ@M^5&'"A*MJDIS\0;SC]H=#+.,UJ#/4 L1LE"M#?3%(BWXGA'-15'TH
MCQ3H@L)CN2Z&RFW)<R"%EKB6+MI:21>6K*;?B#%&*GSW7W81$3];^ ;(2MLV
M=FU'<_F QOB;V?VS6HL7,7NWWZ25UKUW*6'?%%\Y7%8?>DRA+-Z5ZZ[AZ4PG
MYI43 RDOO/_1QXM60KBOD<Z8M"''4#-3;Z>1[ MPP<:!E9\KJUSN5Z?\7GT,
M,3AUZD:<AO3F>_0A\'0Q=AV:UDL-903Z3;XL-@@O8KH(PD.3(RG,MUJBP^O/
MN#L\EKF@F.*+81,[?[5<CNV:GD*.NG=I'0UD3$RGA2$.(*9%,+\*C/-;/$S4
M?72@69,.N(!YX,-H5J5X;M+[5J/!M>(MO;(X#4D5+H40);<7JYTJ=E.-.:A>
M).GD/"4=&8G^^2")#ESIA&0- 6:W_,R.N^>]X#5[;R7SZ""+%R1CZ@0U'R[N
M;-&WP&]S4=D"LY?^O;O4>2?-X^T#D82XE17<TP'@I*_3#0%[N4Z6(X<5F?;.
M!OZNNEO0CJAXVB5B;\2FN]&]$3DEH6C"@QI"7K%RUVSVX@WKPS<,+(ZLUP!U
M*ZU,'=*C"$<1%\0Q%RSW%EN&D&F?9'K;:W?PK6-L$>A^V<ZOXG[7 PB=)4#@
M[3^:*_U6FAF$(8$(H;63450 \PD3#O\.6G<&\=*!GY!:QE9@!Q J!Z/8>9C(
M-W^G$HT,% A18"B%JF7DMBB#6.OF!142I?%ZJ014JTFIR_9>WG":0=FKS5CE
MP-WU3N9CEXO; M[<-V6QT(6M9,,GT>PPW:+&UP\<9U363F;(OHN!@LVH;;$Q
M,LB:W4MBE-&9M#W)8%9BAA?M>GZK,'*7WY.QNP>OH%1(.61STG(+DDM=&[?"
MW!)P\.V#O"\OHC-T;J8)W"L_"#[;UBJ\ATFQ@?=AN3TU3SE/G?<\1+KMX59\
MZH/5C>)[;@Z^YC)67=_TIEZA;%)NQ*,.F"7SX;<=TV\JM)BEAUV-5 QB7 OL
M-8&\74YZBI<7A2+T1BCBN E9L%F]T5TY&1_#N12-R4/FD=J4Y66Y[Q9\XFQ6
MA\&.-G+R@1?>QP;<>;71GXQY46'Q!21$T2'K4#1'%,D9\AV:^VF=(SZCBD72
M@4C.>_4CRQ=6S!/:IC6G2,Q*J]C#F]@(U8?1CT%M&EXZ&!^]]'.];YW7[[:5
MS>1(?YY]L]/S)(/%2Y<7!ZEXF$X$&_3[]/*2=/!N-@*#%9,:^8+JF2+5#5P&
MP8G7ON&>!YUO!P)+>&>03!6@2/!8K6>$NAWQ+)AOS"7 [>+A=YVX!1GU2 E=
MV&Y"C6S,S'X&'_F?IFA'-U46(1GHR@L+CGC.-F,U@UIB3TQ8RH[Y2$40U_CV
M0)__L;SA>AN[@WY.46J@Z;&$'GBD:/+N%K$5APFCZ)-U2;7+G6"VQK-+(WI6
MOE7U!-Z,0>?:-S9FSZWR+)A>':M(;A([TL<R:<-BI4OP>"XC)U%;SF>Z>Z%G
M9]8XU/5BC8BKT$W2A>D2QXXB_,0:Q]CD,OX"__B/(\U/K=^\53L\?G7U['6.
M"U&+%3S5\5<^6!E9E%?>.:KK?M+-*<FI)6'T:<=9*N!O"^]&LMH25CK"^9]6
MO/+NCGX;*'%>[S-LFO4YQZ$'8:>T]@/YQSMY*^ L4!8:U^2%MM:6 ,OE6GOI
M WGX)N8K[^LL@,?)D)?G!9B#M4I_1 %_EX3X;Q,39SAY*G&0:M$R1!:\BPYP
M*;$K;,\;HT.OL[,/Y_;PE"&5#MX>"N'LZV.I^;B/<S^-=QJ[7P_L!(Z7*&0F
M6YET?D$L@ [ #U6O,!%U3M/D]*/1A$"&P.@\FX'J0$687TSU\YU2(RHU#,^P
MU&3*VN)L'@)2<LWK;0#0^R *H&4P<R*^I*"1\F.@&<\V8]?M5)*G70%TIVUG
MY.:RJ4051K7G:\+GW'6!NY_%1S&;?&AO4^;W0MW209='C%P+Q&NJ7[A#WVDM
MM/:%-A<69+&>OC+X-27.S3UZ+$3V54O-,[OC.O&I<9?:.=\N#NC["=V94/0+
M]VEY=2LROB@&AHUS8: X'EEUH$(94I[?]DH6;W B_G*&V:6ALP7 ?>#2O@9(
M"QU8EUU$;"WSTX*ENQ%NR%VEWDCT-O,GVN4&H__ZIA2SV:^(] D<CUS7@9_X
MI?X+$(MJ&/][H,[>W1/HHPQLM!D";V8L,.^F_)F/8*S)"'KDM1;H#J)9%CV[
M36&FS3$(1D(/!,W[=\F'>I@K1OVN/S&U59.OC^)0"#6ZCKS<,)3OKC R<%<R
M12T:VL>M;G:?2=J[T^63[K>KTH4*B5$_[.B )S,=.(Z<8<RRPYARX)/TY,_>
M/1GP*N<<Y QI>1H; 3\%O6E*P$309$G5-_H]A\WQ$S_3[ -;:C_M)@Z=VTTV
M8:GTR']&\8UZKWF!5"$US?F3>IH1;Z112[>O>Q8/:B9GUW-N:Q(QD11WG*=P
M)S[#%W',>B'SW%"%E>ORJQ//S:O#7NH=OQR1N^[/-M60WBXJ/:#.F]U;M%S[
M3-#F-=,-V>%N]RO?+\<@GVB52A;__):[6NIZP^8N'6#7)Z0_AI!,-C6:[%'C
MS[6VV@/D(DM&H4F&%<.*W05K%>1/;7WW+C])/+'0M">H(V_.B#61%4%RTQ-3
M+E7F2<&<R1I?Q.]O7CJME&^C0M:B<),0>#IPD(1N4YT/J6"WLX[7K1TKA#CW
M&S^J$WORRM=,;^H[44L4Z8"/%3*KL0HTMNQ8PGV,>%NC;Q?W"?A1*<U8\H>>
M(2!.F!)A C<?N8G<#T5<(W)#X5]TWH\[E^D_L32ZM2'TE:U.-BDI\XGKY%\Z
M< 4(U90,^5C$3YM!]*9;Y:_LSG]6FZOR*QK M^QN0O=HX1]_M05]^"_\%4V[
MGH2C ]3@2A,JJ^ O OO78O.?(-M1^@MD_S6<"8D7,50,8C-%)_)]BAN?,DP[
M)2#':R@6]#B*TDE]"1<GZ9M2LRE*>"0'[ 2A--*SQ.A@AD^!<VU#^]>JZIVJ
MC7L)CFP77T8+&V0'%>09??C&(;VY<>>E=IZ- >;,PT*VLD\)%XOOW-PX&O 4
M(SI,D&]>BPA0?DU,Q?U(P)G$V!PBQ7L6N&Q$EPBU-#)7E-548]U/)*[UQ/:F
MY+L4QS>?J-O,XNPS?7) LET.Q/SH^#>5=JF%,TY,F6;N#N/*54_.-Z.D_Y-C
MVJ!L;I!-&5?.PZ!B*^&T^+A@C3O>>;DB9_[L?T2U<)*D+U(R)1E =W\"3#U0
MM /_G?UQQC(H.D#-9I 1.417#2F=UB$ WKSFL\<.08()NKV[%\'<B-'6T[3(
M.+1V =.AS\VE08TBI-LE\K(FS[V]7/TOU=0$C^J6^S_]G(#Q$/A(T4];<,HZ
M\DE=-L=RV6SYW"+?N:7U-K$DT[@Q/MR,R-'/!_$Y@[^R.'+G9^2C0=L*\53Q
M:M1M#>DOC?]1!-]D6OIU3PPO#EO-0DG3;T>0^5?1F\PV,S8BY$>(KER8!1TH
M@R_3 2U%)LJLH-2OBH8)Y5@JS;CZ'L,/-M%[LM)K>/T2. S1+"H9B!CS:BOO
M\*UUO5F.O'S2<JV>/YMB1NQ\ON(SIJD._7C=%9-F4FZYJ&JD>XBK-LQL)"^"
M2=_,V/7ZR_=U5[[YB!O;Z.?1OLTB6F9(N[V4K[Y4.K#8+XTM9X>Y9L&8B<BP
MK2"_6P,T-6C' /G>)ZL&O0=YBS*.R:9BMNQES'/  RW>!<@!3$>C,*E&,AH/
MBA3LC?->SA"TR@TW+R\/_9S\,%;G3/5SA2?'XPQYBPG#9SK3C"Z?L.&&%1!Z
MHT'K5K_Z1R#]B(6$>RO>$#[P;!6)3$,SEJS_9,TX%<- V00'3IWU:Q/4/51A
M#6&#=C4^!/%3GG,#]9#*V ^NG%RP@\2XIUE0O^844:ETLX\IZX;RE3?M3QYJ
M?G1>:/5;4%$'7!31=8/!4<)P-!_P"I$.G.IL1FXS_WJF7B&$I>V6'40E_VK@
M)=30#N%5[:LC<562L379$Q83;UM@IM0RN"3E6C5ATXQROD\&7*X4;6U]E?0:
MV7.N:DV&-FVG63\S4,<@0=,Y"*Z?#YQ7X5Q.ASU!/>*GHP1>R?F+!2&3;(3N
M9DHRK@+!<.=2_=VH#G])OO/ND#4Z$ R[S:'4<_;V,\&P="-'[!!5D80DZY$L
MIE$M/1<Z;10"TT7DMMP[)M1\:WP2;^^7XT_"E,!:B9XT5D^"3@?H",4HVWG\
M^:<=S+;"1 LJ^^M[ZU1FB<T"\'0>8MT>S@ =5*P\PX<L*=$HUU 2F*WME>6K
MJ"T'?@$K(U^3]T&]XV7'P_4,)> =4$X::S1!OI5VB+"=ZE>P7.3CD&\U<8W_
MRJO@1<&B^SNS@GNM.%![/"?%G2")Q*\=,5+?4]I>.[5Z_US-^*,G^0D]B$NA
M)? ?#*VDC)CM5Q>B ^Z,#?B@^%/GLT??E?1B+7D=-'U'JA90_6*M>)&'@_I#
M/#=TX99^_Z/WQ.>5-.PY87KR)+B6;%F4"Y\81.:-^[*(OZ@K>^.+^MH;V:A,
M2G"8T6 SH;[S6>.#^K7XU:)3"ZT6^&P'6WY\S7';MS<\CANM^EH<%CAKL9A9
M66Q)"M1O');/77<KS@I\/=OAVQ%U-WZ:"16_!29)Y3]7HLK-R3;R0 ?O#<Z$
MKNR]]%.%20M;6@F?PG',&@H]N1SWB!T("LR2#7$*@ Z,08SY%F1?'_]P?D7(
MX'12AXK2+)(7[>3:^PRN]+%LF*+"#'WR0V V:D_C-OO/1N,Z8^F\=]_L3.N,
M^%D>"]__T>"I-22SY<YITC 8;"44P76'U\+IT!?6&-_I..FN>GVRC)/F&5*[
M#Y'3E,@?D5=75^:N,*-/O@:YGSB<(]7W\_S:;;5(M7L.-8I,<WNG5Q;!$>[M
ML?G!@F >$PFN\<7!I26Q0$/WM+E3_FU7BOQ=0YYR?@V82?O^@?K)N^=F1P!?
MACLN,*7/<[ZL[-.PS<K^E!V+1P+9VAS8C'TA CM'1-N\S&7 ]]',SIHB:2VM
M;:)G*X9ZQN]IHV0I[@AWP2L/C+Q]8U O3]J^.FL"FT];R*;&45@\9R;9VOHT
MB_8M2GMTY^3UD=G;"%=LG^/O;,_E7I$X<D[D<P_P!,U)\<.A0?!QS5-UA!'T
M.VC(.+9%^86Q\FO?U,/"(3_<<G@D#HJ&I^WY-GH2D.$5* [X^-3)4,-!F<U/
M]H2@W'B1Y-K+I1U+;F6L!TUJ4+G_".E(!K]"[EY8BP)M'P'M*:ON[6M$4!L1
ML[V-4HC1<XB%40;A&_6L=SYCM29X%=CV'!VD74_'Q5/#9>E !L+@\(XNXB(#
MT?,I&1=;060.*SJ@2GO!O1H%^/@C5_CQUB8,L<WJ8VUWC?@P8SK)J;_+JV1)
M&>U,5A=Z3@?.GCSD']&2_4+;]B![@,-]TF!3IB@I.ELY'A_$UVTS,*[[<FSI
M:*2M7'V1N[J]KR(3L0I-UH$](,R'4\!%+JH9#6'?(NUR;);&[XU?<=D;@&"[
M/-ZN>[F?;(LBVTVKG5-AYNV%"FU7D8IFA 1.I-XKJ_Q$=&\(VT[RX4@6H //
M@CR4G-W29+BNS$IH/TTB=;'$L)+/P0Z3 C-XD <7>JDQVH,[8T5!KY[+*3N^
M.YXB^BSQG%/X-+BUR-7]X11H_X)I:[%J%SQA5"\;E[Q3Z,;QMNM!7(SA<@\
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M@M:6VBD>CZL/'ST*.(.C_!=#K?[I]+SSM',KVHWY0.[?SM@'0]Z&:M)&@XX
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M@BF3"2L-?AV-)P6<]Q4IIP%[NA U/T<"M'\^8Q /4Q4)&%>:"6!$;^'=CVH
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M=\J,O:$'_"J #['E!-YU@0[TW5/T)M!2LW0WD@7H:Q/@]]@1<L_W_YDI!B(
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M^WUE 96YR"R->E/+\*+C(O6OZWMRP"PJ)-H"Y+<'L00=.L%2^4P"(V!!.9V
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M]5EN.X&RAN$MARL/$BK;Z_4^WRHM97CF(I9&%5PV%X.HK*XCB/=H#*B(8N;
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M] I1PX.*UUMGYVF) 0F%7KGBL9+[,/\0<8>6)\E/6#(K><5O\:89#EYSH_;
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MQ@/H+%_#%"["Z!P):JGYMCV$P[X$P4Q\#-"D=EB_IC8L;D"8AXUG99HM7-Q
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MH9*_H7:@R^^@(_4X\+Q@H9I76&$F^!OQ$6A 01*KME6N,*^-9JAI?T\ N3@
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M(0:TKG6YM>TDUU;=)*?*>]Z52P.6ZK/ U,7.E))G7C(&VG->MP]&?T SY&?
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MR2%:EQQ9H948WUDL]*HQ(B,]:I\E(/"128KLX/+Y1C$[Z+(5"9Q%GCB"1U3
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M$"@_(6#AZIW?;9JZS534VH+FU5)1FP,L8DK[O?PQM%\H@@V2N&554U7@?EH
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M:!!AR 6@T^'=LF!8I9G:I:,!G<V-Q )UQ!+34,RTS-#9#[;WH^5M*-34K*.
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M50[QX%\A,X 7HGR:'3]!)O?D =(1=U#POW( G\*1CMB20OGT L0\^TG@>TN
M;,*9UX_Z41PF7*V(V%6Z:K:5@FI"%R?17XO1$W%D!"S>Q[[(/;OD'X+"X@1,
M5:% N_:9UL,9^F@9H]LEGI$391OWUSJBAP;F+6Q-$Q38]=UI,, ZVE?)_+PZ
M23#B-%+? N2%A XSCHS ZQSS5N"55R;N5XV>J\'"3+-1VPV0=2#7V#WMD3+9
M]W62L8[^$C#%!\<$4%U2!0/%4HWQ@_0IP%Z27P9^IGQPK42B,BW3/Z+$F2*Q
MY1!?=HX^DTY^A3[3X:_GOV"S\CB(#==^, <3#WE?4_G.,J\SP-;R.?5;5I=
MM-C$XFI084;4Z(3,!+ZKB:.FP8:Q0"3-MI%=:F)CV34:1-A>$C,:J08!S=@+
M0IXUX(S:94,)>=Z&NHX0V/VJ,1[V7P$_PP>_R-_QXLB<HKF85H;$-^'S$7XB
MZ7,"#Q*!3#/>&SYTP?6S H+W\"):=3&=S0)_0;#'OF2??2:^'RV]9^Q3C$[@
M)T$2HXGP(XE(<P9F/@TXP. 87KB"*(]2'?'TN,]I'G0E SG;P'(X^&F^;D;
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M1S0.3>U'#3JB*'",G0L-= K;N^($'%?LB\H_%7]REPJ-L4<=\4DQVGI_?Z]
M$R>I__84C7C=B0'^J'M:P+)E"I21QA@Z4#8F#'R-DD)L]-SJH-F8J*W40;.Q
M"V1B"I!<G0/FC&NM"M>5T]:B<)B'@4/<)"1=9,3IHH/]9KGHV9R9J26E+',A
M\2%SV2X3=IF):&6JX6@M588@:,I"(-2' (2(I/CH[-MA#[EX&<FV>K(IGTMF
M8#5#=#)[K0@(2@V/L0$]\ 0'=,*&<\F8 NHRA!NH?[HJ%96>8QZ''%&?4Y"[
M;*0*P-%63OJGV5<B*KH-S)VI'&F4U5Y\)F^%(F[Z<%;),ELINH"CN9PFN5*,
M7_*'7A[%FC^2TY[1%_Y66(3?LG4UY@GXG JVJ'H9EPK'=M'!@\66*)#FLP)Z
MG)GQAZH^7),+@#D6NH(3UR0/<)R]:SUL/+R]'.*+DF%C^;!6V'@:Q_/H[OQ\
ML5ATL1MV@W"RM:_QP0D[;P89$64B[)R)>]P,>I)FD.'%YV/*!/8YE^;-H GN
ME&90$O/+[/_[G8P&_?YM=^Z.J^9BG (.!BEH#IF*,24>5W,^3ZF'7>+-IQ0C
MCI&W[!3ZN_#D"-Z33R0L>8&3I6BMTI;2ML.S)$YXUC$/%Q3'7S4#G 4 *L-?
M!]K4!%0A470O]+-GS%A @9+(">:DLXX^ Q>\A/#$(N<H ][(3];Q<!*E1"QP
MF,.YPTSEP%$ VI?X1H!_P-*PCS(ESZY_ S1,NQ08<0^KHZJ;,>#4QW<"R/6+
MS%C4[3(TP\^FL0Y3@D/V%A.I+!I4F($5U)%+Q*'MH;#M7%I=JU;Y8 K57V,G
MF $3U\AU!)Q<NR2 ^I)YBMB__TC<B0 GFLM^RT+-R52<%$B8(ZRY*?Z?$R0A
MH*7Q1GY_)"&-7.H(;4_DQ'91O:&Q=3^9>J ,<<!'GNW+9R9R\=F-'H=0[QLM
M0:_-YPISH,-BLC!\M%8'MPT *G.S9;DR,G<F#R25)17GZ@< 61E*#WC] *^Y
MZPA"HXRB<1C,5LG+[F;R\J[<9?:Q?!4XV1)_CJD1N'OE+;H O"T3S6 T9.8B
M9);'.+'<A22W+2SS@UT>L9DU4;\_XL#Y]D.'3YO  8Z[:;E-D>5E,!5%UN'
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MQ#J5G<E;.^&0< Q-(5:8D21E!?Q3"@ 7'/^KD\J^D V/,N07CDDKL#X01[E
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M/=#YZ&"Q@]ON'(?[AEKEC2'/9#IK_]B7F;#L3$S9I<ZX^C%RG\!?*XP<_GA
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MG0T6BS3U#DOYWHYY[-_#'0;^):%7[YCL0X_^KC"V9I[4+YP(D\N8IY[PT<3
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MLU]14U)N<Y;P&2+ G3H[$.Q$Q,X#WFLY#_A).,?"#![$/;;9D>=)L,5H[CC
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M<_?A\M<@ZB#;H1R"9)V\2_&#KR@6+UD0?NOU?K3W^C&%[T)B #J@IP.M"DM
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M?RN=_V\5?*)E<I=^-P<ZF<&?49ZEA_\/4$L#!!0    ( %@Y9E9[*)MJ1 ,
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M2+'<C(.' ,L\6<^U]G@00.88Y!(H39>'\2:'G FZ*)'RR)SAJG*L>,2IY&@
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M D@D<AW+=\?L26H@42NMPIS(@'!:&+-U2C<P"I7NT4"VL9^48[5<0(NR)]O
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M=3' TZ(2*:)W!YA(%L&>7?Z];(!686WVM@^Q[30S/X^6WN2_&*K?&J8716+
MMEE WWM,H6NA/BT_?3H:6&SXBMM7<-N_D@P1RQ&R_QXMR^;]%<"O OB WR@,
MQ3)3Z$P#X,$3Z%EE5]S4H^<NF/^C1";W;7A PL\+B3%%^A AI-<PX,:7QVU!
MW7NXZ C'0Y%1/]M;!XKJZ^;6B6)KZ/Y3:DX6U*BZ%!+C&<$CMX)%]4[H]4SW
M@:FK,;O<5M4GVO*;[_!?4$L! A0#%     @ 6#EF5D7*2X:)$@  ^L8  !$
M             ( !     '!A<V<M,C R,C$R,S$N>'-D4$L! A0#%     @
M6#EF5C6&RDML#P   ^(  !4              ( !N!(  '!A<V<M,C R,C$R
M,S%?8V%L+GAM;%!+ 0(4 Q0    ( %@Y9E:(J-61K"4  !-< @ 5
M      "  5<B  !P87-G+3(P,C(Q,C,Q7V1E9BYX;6Q02P$"% ,4    " !8
M.696DS4Q5,MN  #-6 < %0              @ $V2   <&%S9RTR,#(R,3(S
M,5]L86(N>&UL4$L! A0#%     @ 6#EF5C!-C__G10  J1\% !4
M     ( !-+<  '!A<V<M,C R,C$R,S%?<')E+GAM;%!+ 0(4 Q0    ( %@Y
M9E89U@^M\>8# .\L(@ 5              "  4[]  !P87-G+3(P,C(Q,C,Q
M>#$P:RYH=&U02P$"% ,4    " !8.696G5BVG(ZU  #] 0$ &
M    @ %RY 0 <&%S9RTR,#(R,3(S,7@Q,&LP,#8N:G!G4$L! A0#%     @
M6#EF5LL2&7A=I@  &=D  !@              ( !-IH% '!A<V<M,C R,C$R
M,S%X,3!K,# W+FIP9U!+ 0(4 Q0    ( %@Y9E9;,H3MLG<  #:M   8
M          "  <E !@!P87-G+3(P,C(Q,C,Q>#$P:S P."YJ<&=02P$"% ,4
M    " !8.696<E!.PF,5  ":%@  &               @ &QN 8 <&%S9RTR
M,#(R,3(S,7@Q,&LP,#DN:G!G4$L! A0#%     @ 6#EF5F>3K&L,W0  -O\
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M,3!D,C0N:'1M4$L! A0#%     @ 6#EF5BM4:8\S%0  V88  !D
M     ( !=:\* '!A<V<M,C R,C$R,S%X97@Q,&0R-BYH=&U02P$"% ,4
M" !8.696>RB;:D0#  "Q"   &               @ '?Q H <&%S9RTR,#(R
M,3(S,7AE>#(S9#$N:'1M4$L! A0#%     @ 6#EF5EKF+GYN"0  0#P  !@
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M '!A<V<M,C R,C$R,S%X97@S,F0R+FAT;5!+!08     %0 5 *H%  ##Y@H
"   !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
